@prefix ns1: <https://1145.am/db/> .
@prefix org: <http://www.w3.org/ns/org#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://1145.am/db/2164966/Wideopenwest> a org:Organization ;
    ns1:basedInLowRaw "Nasdaq" ;
    ns1:buyer <https://1145.am/db/2164966/Knology_Acquisition> ;
    ns1:description "Acquisition" ;
    ns1:documentDate "2012-06-15T11:19:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Proxy firms urge Knology shareholders to approve WOW aquisition" ;
    ns1:documentURL <https://www.streamtvinsider.com/cable/proxy-firms-urge-knology-shareholders-to-approve-wow-aquisition> ;
    ns1:foundName "WideOpenWest" ;
    ns1:name "WideOpenWest" ;
    ns1:sameAsMedium <https://1145.am/db/2157667/Wideopenwest>,
        <https://1145.am/db/2161031/Wideopenwest>,
        <https://1145.am/db/2165332/Wideopenwest>,
        <https://1145.am/db/2174276/Wideopenwest>,
        <https://1145.am/db/2602590/Wideopenwest>,
        <https://1145.am/db/2603828/Wideopenwest>,
        <https://1145.am/db/2609961/Wideopenwest>,
        <https://1145.am/db/2621340/Wideopenwest>,
        <https://1145.am/db/417992/Wideopenwest>,
        <https://1145.am/db/582163/Wideopenwest_Inc> ;
    ns1:sourceName "StreamTV Insider" .

<https://1145.am/db/2176546/Cisco> a org:Organization ;
    ns1:buyer <https://1145.am/db/2176546/Nds_Acquisition> ;
    ns1:description "networking" ;
    ns1:documentDate "2012-04-04T15:23:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "James Murdoch steps down from BSkyB; Hulu Plus lands on Android tablets" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/james-murdoch-steps-down-from-bskyb-hulu-plus-lands-android-tablets> ;
    ns1:foundName "Cisco" ;
    ns1:name "Cisco" ;
    ns1:sameAsHigh <https://1145.am/db/1696201/Cisco>,
        <https://1145.am/db/1697078/Cisco>,
        <https://1145.am/db/1701907/Cisco>,
        <https://1145.am/db/1708036/Cisco>,
        <https://1145.am/db/1717977/Cisco>,
        <https://1145.am/db/1738152/Cisco>,
        <https://1145.am/db/1766185/Cisco>,
        <https://1145.am/db/1835330/Cisco>,
        <https://1145.am/db/1836417/Cisco>,
        <https://1145.am/db/1837563/Cisco>,
        <https://1145.am/db/1897659/Cisco>,
        <https://1145.am/db/2121547/Cisco>,
        <https://1145.am/db/2131916/Cisco>,
        <https://1145.am/db/2157150/Cisco>,
        <https://1145.am/db/2162803/Cisco>,
        <https://1145.am/db/2164203/Cisco>,
        <https://1145.am/db/2166974/Cisco>,
        <https://1145.am/db/2167172/Cisco_Systems>,
        <https://1145.am/db/2169876/Cisco>,
        <https://1145.am/db/2174781/Cisco>,
        <https://1145.am/db/2174824/Cisco_Systems>,
        <https://1145.am/db/2175327/Cisco>,
        <https://1145.am/db/2404118/Cisco>,
        <https://1145.am/db/2598857/Cisco>,
        <https://1145.am/db/2600159/Cisco>,
        <https://1145.am/db/2601836/Cisco>,
        <https://1145.am/db/2603577/Cisco>,
        <https://1145.am/db/2604048/Cisco_Systems>,
        <https://1145.am/db/2608260/Cisco>,
        <https://1145.am/db/2610767/Cisco_Systems>,
        <https://1145.am/db/2615295/Cisco>,
        <https://1145.am/db/2616303/Cisco>,
        <https://1145.am/db/2617515/Cisco_Systems>,
        <https://1145.am/db/2634430/Cisco>,
        <https://1145.am/db/2640421/Cisco_Systems>,
        <https://1145.am/db/2643485/Cisco_Systems>,
        <https://1145.am/db/2646055/Cisco>,
        <https://1145.am/db/2659244/Cisco_Systems>,
        <https://1145.am/db/2660938/Cisco>,
        <https://1145.am/db/2666737/Cisco>,
        <https://1145.am/db/2668684/Cisco_Systems>,
        <https://1145.am/db/2669154/Cisco>,
        <https://1145.am/db/2681174/Cisco>,
        <https://1145.am/db/2683381/Cisco_Systems>,
        <https://1145.am/db/2685036/Cisco> ;
    ns1:sameAsMedium <https://1145.am/db/1027690/Cisco>,
        <https://1145.am/db/1028774/Cisco>,
        <https://1145.am/db/1256453/Cisco>,
        <https://1145.am/db/1700191/Cisco>,
        <https://1145.am/db/1700963/Cisco>,
        <https://1145.am/db/1702017/Cisco>,
        <https://1145.am/db/1704548/Cisco>,
        <https://1145.am/db/1710590/Cisco>,
        <https://1145.am/db/1717967/Cisco>,
        <https://1145.am/db/1717993/Cisco>,
        <https://1145.am/db/1724559/Cisco>,
        <https://1145.am/db/1727419/Cisco>,
        <https://1145.am/db/1733739/Cisco>,
        <https://1145.am/db/1742704/Cisco>,
        <https://1145.am/db/1743362/Cisco>,
        <https://1145.am/db/1752792/Cisco>,
        <https://1145.am/db/1753887/Cisco>,
        <https://1145.am/db/1762081/Cisco>,
        <https://1145.am/db/1767815/Cisco>,
        <https://1145.am/db/1771378/Cisco>,
        <https://1145.am/db/1783231/Cisco>,
        <https://1145.am/db/1784917/Cisco>,
        <https://1145.am/db/1794453/Cisco>,
        <https://1145.am/db/1795721/Cisco>,
        <https://1145.am/db/1799582/Cisco>,
        <https://1145.am/db/1806956/Cisco>,
        <https://1145.am/db/1809700/Cisco>,
        <https://1145.am/db/1810827/Cisco>,
        <https://1145.am/db/1814119/Cisco>,
        <https://1145.am/db/1814224/Cisco>,
        <https://1145.am/db/1815435/Cisco>,
        <https://1145.am/db/1815500/Cisco>,
        <https://1145.am/db/1819033/Cisco>,
        <https://1145.am/db/1821893/Cisco>,
        <https://1145.am/db/1822505/Cisco>,
        <https://1145.am/db/1822639/Cisco>,
        <https://1145.am/db/1826832/Cisco>,
        <https://1145.am/db/1828458/Cisco>,
        <https://1145.am/db/1830084/Cisco>,
        <https://1145.am/db/1830952/Cisco>,
        <https://1145.am/db/1831852/Cisco>,
        <https://1145.am/db/1834671/Cisco>,
        <https://1145.am/db/1836953/Cisco>,
        <https://1145.am/db/1838070/Cisco>,
        <https://1145.am/db/1838216/Cisco>,
        <https://1145.am/db/1842440/Cisco>,
        <https://1145.am/db/1846654/Cisco>,
        <https://1145.am/db/1857825/Cisco>,
        <https://1145.am/db/1867943/Cisco>,
        <https://1145.am/db/1872388/Cisco>,
        <https://1145.am/db/1876483/Cisco>,
        <https://1145.am/db/1877473/Cisco>,
        <https://1145.am/db/1905954/Cisco>,
        <https://1145.am/db/1906341/Cisco>,
        <https://1145.am/db/1913543/Cisco>,
        <https://1145.am/db/2045709/Cisco>,
        <https://1145.am/db/2122478/Cisco>,
        <https://1145.am/db/2157044/Cisco>,
        <https://1145.am/db/2157342/Cisco>,
        <https://1145.am/db/2157512/Cisco>,
        <https://1145.am/db/2157628/Cisco>,
        <https://1145.am/db/2159181/Cisco>,
        <https://1145.am/db/2159845/Cisco>,
        <https://1145.am/db/2160873/Cisco>,
        <https://1145.am/db/2161318/Cisco>,
        <https://1145.am/db/2162767/Cisco>,
        <https://1145.am/db/2162792/Cisco>,
        <https://1145.am/db/2162802/Cisco>,
        <https://1145.am/db/2166984/Cisco>,
        <https://1145.am/db/2169483/Cisco>,
        <https://1145.am/db/2173942/Cisco>,
        <https://1145.am/db/2173994/Cisco>,
        <https://1145.am/db/2176378/Cisco>,
        <https://1145.am/db/2406325/Cisco>,
        <https://1145.am/db/2598885/Cisco>,
        <https://1145.am/db/2598895/Cisco>,
        <https://1145.am/db/2598977/Cisco>,
        <https://1145.am/db/2599080/Cisco>,
        <https://1145.am/db/2599960/Cisco>,
        <https://1145.am/db/2600308/Cisco>,
        <https://1145.am/db/2600954/Cisco>,
        <https://1145.am/db/2600989/Cisco>,
        <https://1145.am/db/2602447/Cisco>,
        <https://1145.am/db/2603184/Cisco>,
        <https://1145.am/db/2603247/Cisco>,
        <https://1145.am/db/2603662/Cisco>,
        <https://1145.am/db/2603672/Cisco>,
        <https://1145.am/db/2604434/Cisco>,
        <https://1145.am/db/2604771/Cisco>,
        <https://1145.am/db/2604935/Cisco>,
        <https://1145.am/db/2605255/Cisco>,
        <https://1145.am/db/2605659/Cisco>,
        <https://1145.am/db/2605983/Cisco>,
        <https://1145.am/db/2607197/Cisco>,
        <https://1145.am/db/2607581/Cisco>,
        <https://1145.am/db/2607645/Cisco>,
        <https://1145.am/db/2607648/Cisco>,
        <https://1145.am/db/2608818/Cisco>,
        <https://1145.am/db/2609061/Cisco>,
        <https://1145.am/db/2609364/Cisco>,
        <https://1145.am/db/2609629/Cisco>,
        <https://1145.am/db/2610101/Cisco>,
        <https://1145.am/db/2611248/Cisco>,
        <https://1145.am/db/2612021/Cisco>,
        <https://1145.am/db/2612342/Cisco>,
        <https://1145.am/db/2613058/Cisco>,
        <https://1145.am/db/2613511/Cisco>,
        <https://1145.am/db/2613523/Cisco>,
        <https://1145.am/db/2613706/Cisco>,
        <https://1145.am/db/2613721/Cisco>,
        <https://1145.am/db/2613863/Cisco>,
        <https://1145.am/db/2614353/Cisco>,
        <https://1145.am/db/2614409/Cisco>,
        <https://1145.am/db/2614456/Cisco>,
        <https://1145.am/db/2614569/Cisco>,
        <https://1145.am/db/2615174/Cisco>,
        <https://1145.am/db/2615806/Cisco>,
        <https://1145.am/db/2616219/Cisco>,
        <https://1145.am/db/2616548/Cisco>,
        <https://1145.am/db/2616680/Cisco>,
        <https://1145.am/db/2616748/Cisco>,
        <https://1145.am/db/2617245/Cisco>,
        <https://1145.am/db/2617604/Cisco>,
        <https://1145.am/db/2617779/Cisco>,
        <https://1145.am/db/2618170/Cisco>,
        <https://1145.am/db/2618416/Cisco>,
        <https://1145.am/db/2618625/Cisco>,
        <https://1145.am/db/2618833/Cisco>,
        <https://1145.am/db/2619519/Cisco>,
        <https://1145.am/db/2619621/Cisco>,
        <https://1145.am/db/2619945/Cisco>,
        <https://1145.am/db/2620707/Cisco>,
        <https://1145.am/db/2624098/Cisco>,
        <https://1145.am/db/2628002/Cisco>,
        <https://1145.am/db/2628475/Cisco>,
        <https://1145.am/db/2634790/Cisco>,
        <https://1145.am/db/2637729/Cisco>,
        <https://1145.am/db/2640046/Cisco>,
        <https://1145.am/db/2640659/Cisco>,
        <https://1145.am/db/2641810/Cisco>,
        <https://1145.am/db/2641999/Cisco>,
        <https://1145.am/db/2643723/Cisco>,
        <https://1145.am/db/2644389/Cisco>,
        <https://1145.am/db/2644576/Cisco>,
        <https://1145.am/db/2649253/Cisco>,
        <https://1145.am/db/2651712/Cisco>,
        <https://1145.am/db/2651992/Cisco>,
        <https://1145.am/db/2652389/Cisco>,
        <https://1145.am/db/2655699/Cisco>,
        <https://1145.am/db/2656110/Cisco>,
        <https://1145.am/db/2657684/Cisco>,
        <https://1145.am/db/2660246/Cisco>,
        <https://1145.am/db/2660927/Cisco>,
        <https://1145.am/db/2661491/Cisco>,
        <https://1145.am/db/2662802/Cisco>,
        <https://1145.am/db/2665662/Cisco>,
        <https://1145.am/db/2668413/Cisco>,
        <https://1145.am/db/2670616/Cisco>,
        <https://1145.am/db/2671617/Cisco>,
        <https://1145.am/db/2675037/Cisco>,
        <https://1145.am/db/2678680/Cisco>,
        <https://1145.am/db/2681760/Cisco>,
        <https://1145.am/db/2681771/Cisco>,
        <https://1145.am/db/2682553/Cisco>,
        <https://1145.am/db/2683016/Cisco>,
        <https://1145.am/db/2683019/Cisco>,
        <https://1145.am/db/2683584/Cisco>,
        <https://1145.am/db/731124/Cisco>,
        <https://1145.am/db/734617/Cisco>,
        <https://1145.am/db/833076/Cisco> ;
    ns1:sourceName "StreamTV Insider" .

<https://1145.am/db/2176546/Ihs_Screen_Digest> a org:Organization ;
    ns1:buyer <https://1145.am/db/2176546/Nds_Acquisition> ;
    ns1:documentDate "2012-04-04T15:23:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "James Murdoch steps down from BSkyB; Hulu Plus lands on Android tablets" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/james-murdoch-steps-down-from-bskyb-hulu-plus-lands-android-tablets> ;
    ns1:foundName "IHS Screen Digest" ;
    ns1:name "IHS Screen Digest" ;
    ns1:sourceName "StreamTV Insider" .

<https://1145.am/db/2176546/Investment_Hiro_Media_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-04T15:23:44+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Israeli video advertising management and optimization technology firm HIRO Media, has landed an additional $ 5 million in funding from investors, which will be used to open an office in New York." ;
    ns1:documentTitle "James Murdoch steps down from BSkyB; Hulu Plus lands on Android tablets" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/james-murdoch-steps-down-from-bskyb-hulu-plus-lands-android-tablets> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "StreamTV Insider" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2176546/Hiro_Media> ;
    ns1:valueRaw "$ 5 million" ;
    ns1:whereGeoName "State of Israel" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/294640/about.rdf> ;
    ns1:whereRaw "Israel" .

<https://1145.am/db/2178025/Prosiebensat_1_Media_Ag> a org:Organization ;
    ns1:basedInHighGeoName "Federal Republic of Germany" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:basedInHighRaw "Germany" ;
    ns1:buyer <https://1145.am/db/2178025/Joint_Venture_Affectiva_Prosiebensat_1_Media_Ag_Rtl_Television_Stopped> ;
    ns1:description "commercial broadcasters" ;
    ns1:documentDate "2012-08-08T14:37:37+00:00"^^xsd:dateTime ;
    ns1:documentTitle "HBO not talking with Netflix; Affectiva raises an 'emotional' $12 million" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/hbo-not-talking-netflix-affectiva-raises-emotional-12-million> ;
    ns1:foundName "ProSiebenSat 1 Media AG" ;
    ns1:industry "broadcasters" ;
    ns1:name "ProSiebenSat 1 Media AG" ;
    ns1:protagonist <https://1145.am/db/2178025/Joint_Venture_Prosiebensat_1_Media_Ag_Stopped> ;
    ns1:sameAsHigh <https://1145.am/db/141892/Prosiebensat1_Media>,
        <https://1145.am/db/141930/Prosiebensat1_Media>,
        <https://1145.am/db/1469953/Prosiebensat1_Media>,
        <https://1145.am/db/1487264/Prosiebensat1>,
        <https://1145.am/db/1504218/Prosiebensat1>,
        <https://1145.am/db/1584826/Prosiebensat1_Media_De_Deutschland>,
        <https://1145.am/db/1657836/Prosiebensat1>,
        <https://1145.am/db/1661001/Prosiebensat1>,
        <https://1145.am/db/1677803/Prosiebensat1>,
        <https://1145.am/db/1849600/Prosiebensat1>,
        <https://1145.am/db/1951817/Prosiebensat1>,
        <https://1145.am/db/2015716/Prosiebensat1>,
        <https://1145.am/db/2017891/Prosiebensat1>,
        <https://1145.am/db/203465/Prosiebensat>,
        <https://1145.am/db/235620/Prosiebensat1_Media>,
        <https://1145.am/db/326722/Prosiebensat1_Media>,
        <https://1145.am/db/622368/Prosiebensat1_Group>,
        <https://1145.am/db/76144/Prosiebensat1>,
        <https://1145.am/db/76848/Prosiebensat1>,
        <https://1145.am/db/85758/Prosiebensat1_Media>,
        <https://1145.am/db/920449/Prosiebensat1>,
        <https://1145.am/db/92916/Prosiebensat1_Media>,
        <https://1145.am/db/94152/Prosiebensat1_Media>,
        <https://1145.am/db/94376/Prosiebensat1_Media> ;
    ns1:sourceName "StreamTV Insider" .

<https://1145.am/db/2178025/Rtl_Television> a org:Organization ;
    ns1:basedInHighGeoName "Federal Republic of Germany" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:basedInHighRaw "Germany" ;
    ns1:buyer <https://1145.am/db/2178025/Joint_Venture_Affectiva_Prosiebensat_1_Media_Ag_Rtl_Television_Stopped> ;
    ns1:documentDate "2012-08-08T14:37:37+00:00"^^xsd:dateTime ;
    ns1:documentTitle "HBO not talking with Netflix; Affectiva raises an 'emotional' $12 million" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/hbo-not-talking-netflix-affectiva-raises-emotional-12-million> ;
    ns1:foundName "RTL Television" ;
    ns1:industry "broadcasters" ;
    ns1:investor <https://1145.am/db/2178025/Investment_Affectiva_Rtl_Television_Completed> ;
    ns1:name "RTL Television" ;
    ns1:sameAsHigh <https://1145.am/db/1388884/Rtl_Group>,
        <https://1145.am/db/1903549/RTL>,
        <https://1145.am/db/1903549/The_Rtl_Group>,
        <https://1145.am/db/2171389/RTL>,
        <https://1145.am/db/2665872/RTL>,
        <https://1145.am/db/269794/RTL>,
        <https://1145.am/db/269889/RTL>,
        <https://1145.am/db/286857/RTL>,
        <https://1145.am/db/334871/RTL> ;
    ns1:sourceName "StreamTV Insider" .

<https://1145.am/db/2242523/Investment_Sunlink_Health_Systems_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-20T01:09:02+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SunLink Health Systems Announces $ 9.975 Million Financing for Improvements at Trace Regional Hospital in Houston, MS, and for Partial Debt Refinancing.",
        "SunLink Health Systems, Inc. (NYSE: MKT: SSY) today announced that it closed a $ 9,975,000 loan for its Trace Regional Hospital in Houston, MS." ;
    ns1:documentTitle "SunLink Health Systems Announces $9.975 Million Financing for Improvements at Trace Regional Hospital in Houston, MS, and for Partial Debt Refinancing" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/sunlink-health-systems-announces-9-975-million-financing-for-improvements-at-trace> ;
    ns1:foundName "loan" ;
    ns1:name "loan" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2242523/Sunlink_Health_Systems>,
        <https://1145.am/db/2242523/Trace_Regional_Hospital> ;
    ns1:targetName "Trace Regional Hospital" ;
    ns1:valueRaw "$ 9,975,000",
        "$ 9.975 Million",
        "Approximately $ 1,475,000",
        "approximately $ 8,500,000" ;
    ns1:whereGeoName "Houston",
        "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4430529/about.rdf>,
        <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "Houston, MS",
        "United States" .

<https://1145.am/db/2273820/Anthem_Blue_Cross_And_Blue_Shield> a org:Organization ;
    ns1:basedInHighGeoName "Connecticut" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4831725/about.rdf> ;
    ns1:basedInHighRaw "Connecticut" ;
    ns1:documentDate "2012-03-13T19:10:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anthem Donates $150,000 to GCC Foundation's Building Campaign" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/anthem-donates-150-000-to-gcc-foundation-s-building-campaign> ;
    ns1:foundName "Anthem Blue Cross and Blue Shield in Connecticut" ;
    ns1:industry "health care" ;
    ns1:investor <https://1145.am/db/2273820/Investment_Anthem_Blue_Cross_And_Blue_Shield_Gateway_Community_College_Foundation_Completed> ;
    ns1:name "Anthem Blue Cross and Blue Shield" ;
    ns1:sameAsHigh <https://1145.am/db/2198013/Anthem>,
        <https://1145.am/db/2198049/Anthem>,
        <https://1145.am/db/2198077/Anthem>,
        <https://1145.am/db/2213170/Anthem>,
        <https://1145.am/db/2226157/Anthem>,
        <https://1145.am/db/2231141/Anthem_Blue_Cross_Of_California>,
        <https://1145.am/db/2253145/Anthem>,
        <https://1145.am/db/2253170/Anthem>,
        <https://1145.am/db/2257177/Anthem_Blue_Cross_And_Blue_Shield_In_Colorado>,
        <https://1145.am/db/2260786/Blue_Shield>,
        <https://1145.am/db/2262543/Blue_Shield>,
        <https://1145.am/db/2263952/Anthem_Blue_Cross_And_Blue_Shield_Of_Colorado>,
        <https://1145.am/db/2263998/Anthem_Blue_Cross_And_Blue_Shield_In_Maine>,
        <https://1145.am/db/2264287/Anthem>,
        <https://1145.am/db/2265938/Anthem_Blue_Cross_And_Blue_Shield_In_Missouri>,
        <https://1145.am/db/2268414/Anthem_Blue_Cross_And_Blue_Shield>,
        <https://1145.am/db/2269586/Blue_Shield>,
        <https://1145.am/db/2272244/Anthem>,
        <https://1145.am/db/455988/Anthem_Blue_Cross_And_Blue_Shield_In_Ohio> ;
    ns1:sameAsMedium <https://1145.am/db/458330/Anthem_Blue_Cross_And_Blue_Shield>,
        <https://1145.am/db/830914/Anthem_Blue_Cross_And_Blue_Shield>,
        <https://1145.am/db/831414/Anthem_Blue_Cross_And_Blue_Shield> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2276474/The_Blues_Companies> a org:Organization ;
    ns1:basedInHighGeoName "Idaho",
        "Montana" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5596512/about.rdf>,
        <https://sws.geonames.org/5667009/about.rdf> ;
    ns1:basedInHighRaw "Montana and Idaho" ;
    ns1:basedInLowRaw "Montana" ;
    ns1:buyer <https://1145.am/db/2276474/Insurance_Coordinators_Of_Montana_Acquisition>,
        <https://1145.am/db/2276474/Peak_1_Administration_Acquisition> ;
    ns1:description "health products and employee-benefit administration services" ;
    ns1:documentDate "2012-04-15T00:22:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Molina sues over Missouri Medicaid contract; Cigna hires first chief nursing officer;" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/molina-sues-over-missouri-medicaid-contract-cigna-hires-first-chief-nursing-officer> ;
    ns1:foundName "Blues companies",
        "The Blues companies" ;
    ns1:industry "health products and employee-benefit administration services" ;
    ns1:name "Blues companies",
        "The Blues companies" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2287956/Agilent> a org:Organization ;
    ns1:basedInLowRaw "Denmark" ;
    ns1:buyer <https://1145.am/db/2287956/Dako_Acquisition> ;
    ns1:documentDate "2012-06-22T15:17:51+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Agilent closes $2.2B Dako deal" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/agilent-closes-2-2b-dako-deal> ;
    ns1:foundName "Agilent" ;
    ns1:industry "life science" ;
    ns1:name "Agilent" ;
    ns1:sameAsHigh <https://1145.am/db/1134944/Agile>,
        <https://1145.am/db/1247406/Agilent_Technologies_Inc>,
        <https://1145.am/db/1248505/Agilent_Technologies_Inc>,
        <https://1145.am/db/1933144/Agilent_Technologies_Inc>,
        <https://1145.am/db/2286147/Agilent>,
        <https://1145.am/db/2358357/Agilent> ;
    ns1:sameAsMedium <https://1145.am/db/2291601/Agilent>,
        <https://1145.am/db/2299524/Agilent>,
        <https://1145.am/db/2321361/Agilent>,
        <https://1145.am/db/2324866/Agilent>,
        <https://1145.am/db/2359363/Agilent>,
        <https://1145.am/db/2370599/Agilent>,
        <https://1145.am/db/2537302/Agilent>,
        <https://1145.am/db/631526/Agilent>,
        <https://1145.am/db/636207/Agilent> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2287956/Genomic_Health> a org:Organization ;
    ns1:documentDate "2012-06-22T15:17:51+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Agilent closes $2.2B Dako deal" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/agilent-closes-2-2b-dako-deal> ;
    ns1:foundName "Genomic Health" ;
    ns1:investor <https://1145.am/db/2287956/Investment_Genomic_Health_Qiagen_Completed> ;
    ns1:name "Genomic Health" ;
    ns1:sameAsMedium <https://1145.am/db/1249145/Genomic_Health>,
        <https://1145.am/db/2151956/Genomic_Health>,
        <https://1145.am/db/2155212/Genomic_Health>,
        <https://1145.am/db/2279538/Genomic_Health>,
        <https://1145.am/db/413764/Genomic_Health_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2287956/Qiagen> a org:Organization ;
    ns1:description "companion diagnostics" ;
    ns1:documentDate "2012-06-22T15:17:51+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Agilent closes $2.2B Dako deal" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/agilent-closes-2-2b-dako-deal> ;
    ns1:foundName "Qiagen" ;
    ns1:industry "pharmaceuticals" ;
    ns1:investor <https://1145.am/db/2287956/Investment_Genomic_Health_Qiagen_Completed>,
        <https://1145.am/db/2287956/Investment_Qiagen_Completed> ;
    ns1:name "Qiagen" ;
    ns1:sameAsHigh <https://1145.am/db/1048113/Qiagen_Nv>,
        <https://1145.am/db/1048637/Qiagen_Nv>,
        <https://1145.am/db/1051026/Qiagen_Nv>,
        <https://1145.am/db/112703/Qiagen>,
        <https://1145.am/db/1627597/Qiagen>,
        <https://1145.am/db/176790/Qiagen>,
        <https://1145.am/db/192294/Qiagen>,
        <https://1145.am/db/2151978/Qiagen>,
        <https://1145.am/db/2155071/Qiagen>,
        <https://1145.am/db/2295416/Qiagen>,
        <https://1145.am/db/2299031/Qiagen>,
        <https://1145.am/db/2299524/Qiagen>,
        <https://1145.am/db/2299628/Qiagen>,
        <https://1145.am/db/2300221/Qiagen>,
        <https://1145.am/db/2305804/Qiagen>,
        <https://1145.am/db/2309580/Qiagen>,
        <https://1145.am/db/2314564/Qiagen>,
        <https://1145.am/db/231490/Qiagen>,
        <https://1145.am/db/2318979/Qiagen>,
        <https://1145.am/db/2319698/Qiagen>,
        <https://1145.am/db/2319701/Qiagen>,
        <https://1145.am/db/2327447/Qiagen>,
        <https://1145.am/db/2335126/Qiagen_Nv>,
        <https://1145.am/db/2335129/Qiagen>,
        <https://1145.am/db/2342651/Qiagen>,
        <https://1145.am/db/2353494/Qiagen>,
        <https://1145.am/db/2360851/Qiagen_Nv>,
        <https://1145.am/db/244512/Qiagen>,
        <https://1145.am/db/2594575/Qiagen> ;
    ns1:sameAsMedium <https://1145.am/db/1405799/Qiagen_Nv>,
        <https://1145.am/db/1626352/Qiagen>,
        <https://1145.am/db/1627755/Qiagen>,
        <https://1145.am/db/2152010/Qiagen>,
        <https://1145.am/db/2286455/Qiagen>,
        <https://1145.am/db/2291838/Qiagen>,
        <https://1145.am/db/2292294/Qiagen>,
        <https://1145.am/db/2292316/Qiagen>,
        <https://1145.am/db/2296346/Qiagen>,
        <https://1145.am/db/2296788/Qiagen>,
        <https://1145.am/db/2301132/Qiagen>,
        <https://1145.am/db/2307597/Qiagen>,
        <https://1145.am/db/2308094/Qiagen>,
        <https://1145.am/db/2313051/Qiagen>,
        <https://1145.am/db/2321123/Qiagen>,
        <https://1145.am/db/2325215/Qiagen>,
        <https://1145.am/db/2327444/Qiagen>,
        <https://1145.am/db/2327991/Qiagen>,
        <https://1145.am/db/2327995/Qiagen_Nv> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2287956/Roche> a org:Organization ;
    ns1:basedInHighGeoName "Indiana" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4921868/about.rdf> ;
    ns1:basedInHighRaw "Indiana" ;
    ns1:buyer <https://1145.am/db/2287956/Illumina_Acquisition> ;
    ns1:documentDate "2012-06-22T15:17:51+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Agilent closes $2.2B Dako deal" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/agilent-closes-2-2b-dako-deal> ;
    ns1:foundName "Roche" ;
    ns1:investor <https://1145.am/db/2287956/Illumina_Acquisition> ;
    ns1:name "Roche" ;
    ns1:sameAsMedium <https://1145.am/db/1322436/Roche>,
        <https://1145.am/db/1334866/Roche>,
        <https://1145.am/db/1570526/Roche>,
        <https://1145.am/db/1767410/Roche>,
        <https://1145.am/db/1998785/Roche>,
        <https://1145.am/db/2061027/Roche>,
        <https://1145.am/db/2152005/Roche>,
        <https://1145.am/db/2152475/Roche>,
        <https://1145.am/db/2152787/Roche>,
        <https://1145.am/db/2154526/Roche>,
        <https://1145.am/db/2154736/Roche>,
        <https://1145.am/db/2187676/Roche>,
        <https://1145.am/db/2223188/Roche>,
        <https://1145.am/db/2232759/Roche>,
        <https://1145.am/db/2244622/Roche>,
        <https://1145.am/db/2254658/Roche>,
        <https://1145.am/db/2279060/Roche>,
        <https://1145.am/db/2279266/Roche>,
        <https://1145.am/db/2280847/Roche>,
        <https://1145.am/db/2281213/Roche>,
        <https://1145.am/db/2286404/Roche>,
        <https://1145.am/db/2286671/Roche>,
        <https://1145.am/db/2286719/Roche>,
        <https://1145.am/db/2287064/Roche>,
        <https://1145.am/db/2287171/Roche>,
        <https://1145.am/db/2288237/Roche>,
        <https://1145.am/db/2289977/Roche>,
        <https://1145.am/db/2290009/Roche>,
        <https://1145.am/db/2290817/Roche>,
        <https://1145.am/db/2292337/Roche>,
        <https://1145.am/db/2292593/Roche>,
        <https://1145.am/db/2292608/Roche>,
        <https://1145.am/db/2294783/Roche>,
        <https://1145.am/db/2295842/Roche>,
        <https://1145.am/db/2295853/Roche>,
        <https://1145.am/db/2295854/Roche>,
        <https://1145.am/db/2295907/Roche>,
        <https://1145.am/db/2296164/Roche>,
        <https://1145.am/db/2296171/Roche>,
        <https://1145.am/db/2296180/Roche>,
        <https://1145.am/db/2296371/Roche>,
        <https://1145.am/db/2296600/Roche>,
        <https://1145.am/db/2297072/Roche>,
        <https://1145.am/db/2297131/Roche>,
        <https://1145.am/db/2297300/Roche>,
        <https://1145.am/db/2297593/Roche>,
        <https://1145.am/db/2297619/Roche>,
        <https://1145.am/db/2298070/Roche>,
        <https://1145.am/db/2298237/Roche>,
        <https://1145.am/db/2298297/Roche>,
        <https://1145.am/db/2298766/Roche>,
        <https://1145.am/db/2299175/Roche>,
        <https://1145.am/db/2299764/Roche>,
        <https://1145.am/db/2299784/Roche>,
        <https://1145.am/db/2299867/Roche>,
        <https://1145.am/db/2300140/Roche>,
        <https://1145.am/db/2300897/Roche>,
        <https://1145.am/db/2303352/Roche>,
        <https://1145.am/db/2303385/Roche>,
        <https://1145.am/db/2303398/Roche>,
        <https://1145.am/db/2303402/Roche>,
        <https://1145.am/db/2303873/Roche>,
        <https://1145.am/db/2303880/Roche>,
        <https://1145.am/db/2305192/Roche>,
        <https://1145.am/db/2305545/Roche>,
        <https://1145.am/db/2305578/Roche_Ag>,
        <https://1145.am/db/2305582/Roche>,
        <https://1145.am/db/2306401/Roche>,
        <https://1145.am/db/2306858/Roche>,
        <https://1145.am/db/2307022/Roche>,
        <https://1145.am/db/2308972/Roche>,
        <https://1145.am/db/2309816/Roche>,
        <https://1145.am/db/2309846/Roche>,
        <https://1145.am/db/2309947/Roche>,
        <https://1145.am/db/2309962/Roche>,
        <https://1145.am/db/2309988/Roche>,
        <https://1145.am/db/2309993/Roche>,
        <https://1145.am/db/2310005/Roche>,
        <https://1145.am/db/2310015/Roche>,
        <https://1145.am/db/2310906/Roche>,
        <https://1145.am/db/2311026/Roche>,
        <https://1145.am/db/2311682/Roche>,
        <https://1145.am/db/2312193/Roche>,
        <https://1145.am/db/2312481/Roche>,
        <https://1145.am/db/2313073/Roche>,
        <https://1145.am/db/2313320/Roche>,
        <https://1145.am/db/2313324/Roche>,
        <https://1145.am/db/2313872/Roche>,
        <https://1145.am/db/2314398/Roche>,
        <https://1145.am/db/2319577/Roche>,
        <https://1145.am/db/2320592/Roche>,
        <https://1145.am/db/2320930/Roche>,
        <https://1145.am/db/2321676/Roche>,
        <https://1145.am/db/2321701/Roche>,
        <https://1145.am/db/2323214/Roche>,
        <https://1145.am/db/2323221/Roche>,
        <https://1145.am/db/2324237/Roche>,
        <https://1145.am/db/2330483/Roche>,
        <https://1145.am/db/2330486/Roche>,
        <https://1145.am/db/2331558/Roche>,
        <https://1145.am/db/2335338/Roche>,
        <https://1145.am/db/2336767/Roche>,
        <https://1145.am/db/2337234/Roche>,
        <https://1145.am/db/2338682/Roche>,
        <https://1145.am/db/2340363/Roche>,
        <https://1145.am/db/2340626/Roche_Ag>,
        <https://1145.am/db/2341621/Roche>,
        <https://1145.am/db/2341630/Roche>,
        <https://1145.am/db/2342211/Roche>,
        <https://1145.am/db/2342417/Roche>,
        <https://1145.am/db/2343658/Roche>,
        <https://1145.am/db/2344272/Roche>,
        <https://1145.am/db/2344534/Roche>,
        <https://1145.am/db/2344754/Roche>,
        <https://1145.am/db/2344807/Roche>,
        <https://1145.am/db/2345550/Roche>,
        <https://1145.am/db/2346072/Roche>,
        <https://1145.am/db/2346076/Roche>,
        <https://1145.am/db/2346819/Roche>,
        <https://1145.am/db/2346852/Roche>,
        <https://1145.am/db/2348776/Roche>,
        <https://1145.am/db/2349537/Roche>,
        <https://1145.am/db/2352841/Roche>,
        <https://1145.am/db/2352976/Roche>,
        <https://1145.am/db/2352978/Roche>,
        <https://1145.am/db/2352993/Roche>,
        <https://1145.am/db/2353986/Roche>,
        <https://1145.am/db/2353992/Roche>,
        <https://1145.am/db/2356012/Roche>,
        <https://1145.am/db/2356014/Roche>,
        <https://1145.am/db/2357054/Roche>,
        <https://1145.am/db/2358186/Roche>,
        <https://1145.am/db/2359957/Roche>,
        <https://1145.am/db/2359959/Roche>,
        <https://1145.am/db/2359963/Roche>,
        <https://1145.am/db/2359965/Roche>,
        <https://1145.am/db/2360246/Roche>,
        <https://1145.am/db/2360248/Roche>,
        <https://1145.am/db/2360249/Roche>,
        <https://1145.am/db/2360539/Roche>,
        <https://1145.am/db/2360982/Roche>,
        <https://1145.am/db/2360997/Roche>,
        <https://1145.am/db/2360999/Roche>,
        <https://1145.am/db/2361632/Roche>,
        <https://1145.am/db/2361994/Roche>,
        <https://1145.am/db/2361998/Roche>,
        <https://1145.am/db/2362001/Roche>,
        <https://1145.am/db/2362065/Roche>,
        <https://1145.am/db/2362113/Roche>,
        <https://1145.am/db/2362305/Roche>,
        <https://1145.am/db/2362730/Roche>,
        <https://1145.am/db/2363726/Roche>,
        <https://1145.am/db/2364074/Roche>,
        <https://1145.am/db/2365305/Roche>,
        <https://1145.am/db/2366649/Roche>,
        <https://1145.am/db/2366853/Roche>,
        <https://1145.am/db/2366885/Roche>,
        <https://1145.am/db/2368653/Roche>,
        <https://1145.am/db/2369197/Roche>,
        <https://1145.am/db/2369199/Roche>,
        <https://1145.am/db/2371046/Roche>,
        <https://1145.am/db/2371047/Roche>,
        <https://1145.am/db/2371314/Roche>,
        <https://1145.am/db/2537591/Roche>,
        <https://1145.am/db/2538424/Roche>,
        <https://1145.am/db/2538826/Roche>,
        <https://1145.am/db/2539298/Roche>,
        <https://1145.am/db/2540755/Roche>,
        <https://1145.am/db/2541555/Roche>,
        <https://1145.am/db/2541672/Roche>,
        <https://1145.am/db/2543605/Roche>,
        <https://1145.am/db/2544409/Roche>,
        <https://1145.am/db/2545574/Roche>,
        <https://1145.am/db/2545742/Roche>,
        <https://1145.am/db/2545952/Roche>,
        <https://1145.am/db/2546646/Roche>,
        <https://1145.am/db/2547098/Roche>,
        <https://1145.am/db/2547770/Roche>,
        <https://1145.am/db/2547998/Roche>,
        <https://1145.am/db/2548696/Roche>,
        <https://1145.am/db/2549102/Roche>,
        <https://1145.am/db/2549670/Roche>,
        <https://1145.am/db/2551122/Roche>,
        <https://1145.am/db/2551716/Roche>,
        <https://1145.am/db/2553276/Roche>,
        <https://1145.am/db/2553947/Roche>,
        <https://1145.am/db/2558080/Roche>,
        <https://1145.am/db/2558313/Roche>,
        <https://1145.am/db/2559230/Roche>,
        <https://1145.am/db/2559655/Roche>,
        <https://1145.am/db/2560865/Roche>,
        <https://1145.am/db/2563029/Roche>,
        <https://1145.am/db/2565142/Roche>,
        <https://1145.am/db/2565794/Roche>,
        <https://1145.am/db/2567367/Roche>,
        <https://1145.am/db/2571045/Roche>,
        <https://1145.am/db/2571613/Roche>,
        <https://1145.am/db/2572452/Roche>,
        <https://1145.am/db/2573339/Roche>,
        <https://1145.am/db/2573395/Roche>,
        <https://1145.am/db/2573397/Roche>,
        <https://1145.am/db/2574245/Roche>,
        <https://1145.am/db/2574281/Roche>,
        <https://1145.am/db/2575289/Roche>,
        <https://1145.am/db/2578312/Roche>,
        <https://1145.am/db/2578313/Roche>,
        <https://1145.am/db/2579314/Roche>,
        <https://1145.am/db/2579320/Roche>,
        <https://1145.am/db/2580384/Roche>,
        <https://1145.am/db/2581493/Roche>,
        <https://1145.am/db/2582270/Roche>,
        <https://1145.am/db/2582355/Roche>,
        <https://1145.am/db/2582468/Roche>,
        <https://1145.am/db/2584101/Roche>,
        <https://1145.am/db/2587653/Roche>,
        <https://1145.am/db/2587657/Roche>,
        <https://1145.am/db/2592126/Roche>,
        <https://1145.am/db/2592803/Roche>,
        <https://1145.am/db/2593007/Roche>,
        <https://1145.am/db/2593713/Roche>,
        <https://1145.am/db/2593760/Roche>,
        <https://1145.am/db/2594870/Roche>,
        <https://1145.am/db/2595237/Roche>,
        <https://1145.am/db/2596333/Roche>,
        <https://1145.am/db/2597109/Roche>,
        <https://1145.am/db/2597648/Roche>,
        <https://1145.am/db/2597732/Roche>,
        <https://1145.am/db/2598072/Roche>,
        <https://1145.am/db/271528/Roche>,
        <https://1145.am/db/304559/Roche>,
        <https://1145.am/db/304740/Roche>,
        <https://1145.am/db/320219/Roche>,
        <https://1145.am/db/595011/Roche>,
        <https://1145.am/db/652831/Roche> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288282/Investment_Mdxhealth_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-02T19:37:58+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> MDxHealth has raised €10,000,000 ($ 12.6 million) through a private placement of new shares, to scale up a U.S. - based sales and marketing team, and to operate and grow the company's U.S. - based CLIA-registered commercial laboratory." ;
    ns1:documentTitle "Biomarker companies raise funding to scale up sales and marketing, validate diagnostics; NIH plans to fund blood cancer biomarker research;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/biomarker-companies-raise-funding-to-scale-up-sales-and-marketing-validate> ;
    ns1:foundName "raised" ;
    ns1:name "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2288282/Mdxhealth> ;
    ns1:valueRaw "$ 12.6 million",
        "€10,000,000" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "U.S." .

<https://1145.am/db/2288282/Investment_Nexdx_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-02T19:37:58+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> NexDx has raised $ 2.6 million to fund the development of its molecular diagnostic test for rheumatoid arthritis and move it into analytical and clinical validation." ;
    ns1:documentTitle "Biomarker companies raise funding to scale up sales and marketing, validate diagnostics; NIH plans to fund blood cancer biomarker research;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/biomarker-companies-raise-funding-to-scale-up-sales-and-marketing-validate> ;
    ns1:foundName "raised" ;
    ns1:name "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "stopped" ;
    ns1:target <https://1145.am/db/2288282/Nexdx> ;
    ns1:valueRaw "$ 2.6 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "U.S." .

<https://1145.am/db/2288282/Seed_Investment_Geneassess_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-02T19:37:58+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> GeneAssess has raised half a million dollars in seed funding to fund the validation of its lead biomarker as a diagnostic for breast cancer and a predictive biomarker in other cancers." ;
    ns1:documentTitle "Biomarker companies raise funding to scale up sales and marketing, validate diagnostics; NIH plans to fund blood cancer biomarker research;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/biomarker-companies-raise-funding-to-scale-up-sales-and-marketing-validate> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2288282/Geneassess> ;
    ns1:targetDetails "seed" ;
    ns1:valueRaw "half a million dollars" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "U.S." .

<https://1145.am/db/2288613/Asklepios> a org:Organization ;
    ns1:basedInLowRaw "Greece" ;
    ns1:buyer <https://1145.am/db/2288613/Rhoen_Share_Stake_Investment> ;
    ns1:documentDate "2012-07-13T12:25:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: B. Braun moves to block Fresenius' bid for Rhoen" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/report-b-braun-moves-to-block-fresenius-bid-for-rhoen> ;
    ns1:foundName "Asklepios" ;
    ns1:industry "hospital operator" ;
    ns1:investor <https://1145.am/db/2288613/Rhoen_Share_Stake_Investment> ;
    ns1:name "Asklepios" ;
    ns1:sameAsMedium <https://1145.am/db/2286937/Asklepios> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288613/B_Braun> a org:Organization ;
    ns1:basedInHighGeoName "Federal Republic of Germany" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:basedInHighRaw "Germany" ;
    ns1:buyer <https://1145.am/db/2288613/Rhoen_Share_Stake_Investment> ;
    ns1:description "Devicemaker",
        "bidding battle" ;
    ns1:documentDate "2012-07-13T12:25:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: B. Braun moves to block Fresenius' bid for Rhoen" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/report-b-braun-moves-to-block-fresenius-bid-for-rhoen> ;
    ns1:foundName "Braun",
        "Devicemaker B. Braun" ;
    ns1:industry "Devicemaker" ;
    ns1:investor <https://1145.am/db/2288613/Rhoen_Share_Stake_Investment> ;
    ns1:name "B. Braun",
        "Braun" ;
    ns1:sameAsHigh <https://1145.am/db/2288626/B_Braun> ;
    ns1:sameAsMedium <https://1145.am/db/1519521/B_Braun_Se>,
        <https://1145.am/db/1519536/B_Braun_Se> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288613/Fresenius_Sana> a org:Organization ;
    ns1:basedInLowRaw "German" ;
    ns1:buyer <https://1145.am/db/2288613/Rhoen_Share_Stake_Investment> ;
    ns1:description "bidding battle" ;
    ns1:documentDate "2012-07-13T12:25:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: B. Braun moves to block Fresenius' bid for Rhoen" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/report-b-braun-moves-to-block-fresenius-bid-for-rhoen> ;
    ns1:foundName "Fresenius",
        "Fresenius, Sana" ;
    ns1:industry "hospital operator" ;
    ns1:investor <https://1145.am/db/2288613/Rhoen_Share_Stake_Investment> ;
    ns1:name "Fresenius",
        "Fresenius, Sana" ;
    ns1:sameAsHigh <https://1145.am/db/1068641/Fresenius_Kabi>,
        <https://1145.am/db/1114809/Fresenius_Medical_Care>,
        <https://1145.am/db/1381518/Fresenius>,
        <https://1145.am/db/1432314/Fresenius>,
        <https://1145.am/db/1622788/Fresenius_Medical_Care_North_America>,
        <https://1145.am/db/1670638/Fresenius>,
        <https://1145.am/db/1677487/Fresenius_Medical_Care>,
        <https://1145.am/db/1677821/Fresenius_Medical_Care>,
        <https://1145.am/db/2154697/Fresenius_Medical_Care>,
        <https://1145.am/db/2183315/Fresenius_Health_Partners>,
        <https://1145.am/db/2217811/Fresenius>,
        <https://1145.am/db/2227737/Fresenius_Medical_Care>,
        <https://1145.am/db/2289965/Fresenius_Medical_Care>,
        <https://1145.am/db/2295261/Fresenius_Medical_Care>,
        <https://1145.am/db/2298798/Fresenius_Medical_Care>,
        <https://1145.am/db/2547383/Fresenius>,
        <https://1145.am/db/2554324/Fresenius>,
        <https://1145.am/db/2561353/Fresenius_Kabi>,
        <https://1145.am/db/2593398/Fresenius_Kabi>,
        <https://1145.am/db/438453/Fresenius_Medical_Care>,
        <https://1145.am/db/852654/Fresenius>,
        <https://1145.am/db/938062/Fresenius>,
        <https://1145.am/db/938366/Fresenius_Kabi>,
        <https://1145.am/db/940939/Fresenius_Kabi>,
        <https://1145.am/db/956563/Fresenius_Medical_Care> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288633/Ge> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:documentDate "2012-07-16T15:25:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "GE invests in ultrasound-disinfecting device; Cambridge looks at how to speed up device marketing;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/ge-invests-ultrasound-disinfecting-device-cambridge-looks-at-how-to-speed-up-device> ;
    ns1:foundName "> GE",
        "GE" ;
    ns1:industry "medical device" ;
    ns1:investor <https://1145.am/db/2288633/Investment_Ge_Nanosonic_Has_Not_Happened> ;
    ns1:name "GE" ;
    ns1:sameAsHigh <https://1145.am/db/1165515/Ge_Healthcare>,
        <https://1145.am/db/1541663/Ge_Healthcare_Holding_Llc>,
        <https://1145.am/db/1544276/Ge_Healthcare_Holding_Llc>,
        <https://1145.am/db/2206326/Ge_Healthcare>,
        <https://1145.am/db/2221736/Ge_Healthcare>,
        <https://1145.am/db/2252116/Ge_Healthcare_Performance_Solutions>,
        <https://1145.am/db/2252181/Ge_Healthcare_Performance_Solutions>,
        <https://1145.am/db/2296936/Ge_Healthcare>,
        <https://1145.am/db/2298659/Ge_Healthcare>,
        <https://1145.am/db/2312054/Ge_Healthcare>,
        <https://1145.am/db/2333983/Ge_Healthcare>,
        <https://1145.am/db/2342728/Ge_Healthcare>,
        <https://1145.am/db/2342730/Ge_Healthcare>,
        <https://1145.am/db/2546580/Ge_Healthcare> ;
    ns1:sameAsMedium <https://1145.am/db/1715197/Ge>,
        <https://1145.am/db/1770173/Ge>,
        <https://1145.am/db/1854301/Ge>,
        <https://1145.am/db/1862378/Ge>,
        <https://1145.am/db/1870685/Ge>,
        <https://1145.am/db/1874655/Ge>,
        <https://1145.am/db/1884994/Ge>,
        <https://1145.am/db/2013430/Ge>,
        <https://1145.am/db/2167707/Ge>,
        <https://1145.am/db/2172059/Ge>,
        <https://1145.am/db/2204344/Ge>,
        <https://1145.am/db/2221158/Ge>,
        <https://1145.am/db/2264087/Ge>,
        <https://1145.am/db/2289588/Ge>,
        <https://1145.am/db/2295938/Ge>,
        <https://1145.am/db/2296600/Ge>,
        <https://1145.am/db/2306391/Ge>,
        <https://1145.am/db/2356683/Ge>,
        <https://1145.am/db/2366049/Ge>,
        <https://1145.am/db/2438781/Ge>,
        <https://1145.am/db/2438801/Ge>,
        <https://1145.am/db/495687/Ge>,
        <https://1145.am/db/572109/Ge>,
        <https://1145.am/db/581496/Ge>,
        <https://1145.am/db/708834/Ge>,
        <https://1145.am/db/710146/Ge> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288633/Investment_One_Lambda_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-16T15:25:44+00:00"^^xsd:dateTime ;
    ns1:documentExtract "@ DamianFierce: Thermo Fisher is dropping $ 925M on One Lambda, looking to beef up its diagnostics offerings." ;
    ns1:documentTitle "GE invests in ultrasound-disinfecting device; Cambridge looks at how to speed up device marketing;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/ge-invests-ultrasound-disinfecting-device-cambridge-looks-at-how-to-speed-up-device> ;
    ns1:foundName "dropping" ;
    ns1:name "dropping" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2288633/One_Lambda> ;
    ns1:valueRaw "$ 925M" .

<https://1145.am/db/2288967/Series_A_Investment_Histogenics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-23T23:30:45+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Histogenics-a tissue engineering company-has nailed down $ 49 million in new Series A financing intended to bring its two signature products to the regulatory finish line." ;
    ns1:documentTitle "Histogenics reels in $49M Series A for tissue engineering implants" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/histogenics-reels-49m-series-a-for-tissue-engineering-implants> ;
    ns1:foundName "acquisition",
        "financing" ;
    ns1:name "acquisition",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2288967/Histogenics>,
        <https://1145.am/db/2288967/Prochon_Biotech> ;
    ns1:targetDetails "Series A" ;
    ns1:targetName "Prochon BioTech" ;
    ns1:valueRaw "$ 49 million" ;
    ns1:whenRaw "May 2011" ;
    ns1:whereGeoName "State of Israel" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/294640/about.rdf> ;
    ns1:whereRaw "Israel" .

<https://1145.am/db/2297119/Asahi_Kasei> a org:Organization ;
    ns1:basedInHighGeoName "Japan" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1861060/about.rdf> ;
    ns1:basedInHighRaw "Japan" ;
    ns1:buyer <https://1145.am/db/2297119/Zoll_Medical_Acquisition> ;
    ns1:documentDate "2012-03-12T11:53:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Asahi Kasei scoops up Zoll for $2.2B, reflecting Japanese companies' hunger for growth" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/asahi-kasei-scoops-up-zoll-for-2-2b-reflecting-japanese-companies-hunger-for-growth> ;
    ns1:foundName "Asahi Kasei" ;
    ns1:industry "Health Care" ;
    ns1:name "Asahi Kasei" ;
    ns1:sameAsHigh <https://1145.am/db/2344236/Asahi_Kasei_Of_Japan>,
        <https://1145.am/db/2553889/Asahi_Kasei_Medical>,
        <https://1145.am/db/986224/Asahi_Kasei_Medical> ;
    ns1:sameAsMedium <https://1145.am/db/1488480/Asahi_Kasei>,
        <https://1145.am/db/1510562/Asahi_Kasei>,
        <https://1145.am/db/1556504/Asahi_Kasei>,
        <https://1145.am/db/1557431/Asahi_Kasei>,
        <https://1145.am/db/1559063/Asahi_Kasei>,
        <https://1145.am/db/2011189/Asahi_Kasei>,
        <https://1145.am/db/2068430/Asahi_Kasei>,
        <https://1145.am/db/2298576/Asahi_Kasei>,
        <https://1145.am/db/560096/Asahi_Kasei> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2297604/Safeguard_Scientifics> a org:Organization ;
    ns1:basedInLowRaw "Cambridge, MA" ;
    ns1:description "Investing" ;
    ns1:documentDate "2012-04-02T14:10:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "2 molecular diagnostics companies grab major money" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/2-molecular-diagnostics-companies-grab-major-money> ;
    ns1:foundName "Safeguard Scientifics" ;
    ns1:investor <https://1145.am/db/2297604/Series_B_Investment_Good_Start_Genetics_Orbimed_Advisors_Sv_Life_Sciences_Safeguard_Scientifics_Completed> ;
    ns1:name "Safeguard Scientifics" ;
    ns1:sameAsHigh <https://1145.am/db/1232627/Safeguard_Scientifics>,
        <https://1145.am/db/2317455/Safeguard_Scientifics_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1383287/Safeguard_Scientifics>,
        <https://1145.am/db/1801934/Safeguard_Scientifics>,
        <https://1145.am/db/1843216/Safeguard_Scientifics>,
        <https://1145.am/db/1855887/Safeguard_Scientifics>,
        <https://1145.am/db/1873156/Safeguard_Scientifics>,
        <https://1145.am/db/1914893/Safeguard_Scientifics>,
        <https://1145.am/db/2147446/Safeguard_Scientifics>,
        <https://1145.am/db/2182583/Safeguard_Scientifics>,
        <https://1145.am/db/2290453/Safeguard_Scientifics>,
        <https://1145.am/db/2291872/Safeguard_Scientifics>,
        <https://1145.am/db/2292039/Safeguard_Scientifics>,
        <https://1145.am/db/2295945/Safeguard_Scientifics>,
        <https://1145.am/db/2298535/Safeguard_Scientifics>,
        <https://1145.am/db/2304598/Safeguard_Scientifics>,
        <https://1145.am/db/2304605/Safeguard_Scientifics_Inc>,
        <https://1145.am/db/2305443/Safeguard_Scientifics>,
        <https://1145.am/db/2305609/Safeguard_Scientifics>,
        <https://1145.am/db/2307837/Safeguard_Scientifics>,
        <https://1145.am/db/2316302/Safeguard_Scientifics>,
        <https://1145.am/db/2319506/Safeguard_Scientifics>,
        <https://1145.am/db/2322984/Safeguard_Scientifics>,
        <https://1145.am/db/2323003/Safeguard_Scientifics>,
        <https://1145.am/db/2323336/Safeguard_Scientifics>,
        <https://1145.am/db/2325237/Safeguard_Scientifics>,
        <https://1145.am/db/2354706/Safeguard_Scientifics>,
        <https://1145.am/db/2359125/Safeguard_Scientifics>,
        <https://1145.am/db/2436408/Safeguard_Scientifics_Inc>,
        <https://1145.am/db/2447203/Safeguard_Scientifics_Inc>,
        <https://1145.am/db/2576460/Safeguard_Scientifics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2298082/Bioanalítica_Inversiones_Sl> a org:Organization ;
    ns1:basedInLowRaw "Spain" ;
    ns1:documentDate "2012-04-16T15:41:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Diagnostics startups Vivia, Molecular Detection raise millions" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/diagnostics-startups-vivia-molecular-detection-raise-millions> ;
    ns1:foundName "Bioanalítica Inversiones SL" ;
    ns1:investor <https://1145.am/db/2298082/Investment_Bioanalítica_Inversiones_Sl_Vivia_Has_Not_Happened> ;
    ns1:name "Bioanalítica Inversiones SL" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2298082/Series_B_Investment_Molecular_Detection_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-16T15:41:11+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Meanwhile, Molecular Detection in Wayne, PA, raised $ 1.9 million in what it calls Series B recapitalization financing." ;
    ns1:documentTitle "Diagnostics startups Vivia, Molecular Detection raise millions" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/diagnostics-startups-vivia-molecular-detection-raise-millions> ;
    ns1:foundName "raised",
        "recapitalization" ;
    ns1:name "raised",
        "recapitalization" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2298082/Molecular_Detection> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 1.9 million" ;
    ns1:whereGeoName "Kingdom of Spain" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2510769/about.rdf> ;
    ns1:whereRaw "Spain" .

<https://1145.am/db/2298542/Activiews> a org:Organization ;
    ns1:basedInHighGeoName "Wakefield" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4954265/about.rdf> ;
    ns1:basedInHighRaw "Wakefield, MA" ;
    ns1:documentDate "2012-04-22T14:52:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Boston Scientific completes enrollment for aortic valve trial; Diagnostics startup Aggredyne raises $3M;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/boston-scientific-completes-enrollment-for-aortic-valve-trial-diagnostics-startup> ;
    ns1:foundName "ActiViews" ;
    ns1:industry "medical" ;
    ns1:investor <https://1145.am/db/2298542/Investment_Activiews_Has_Not_Happened> ;
    ns1:name "ActiViews" ;
    ns1:sameAsHigh <https://1145.am/db/1121048/Indegene>,
        <https://1145.am/db/1166030/Conextions_Inc>,
        <https://1145.am/db/1185007/Acumed>,
        <https://1145.am/db/1185007/Exsomed>,
        <https://1145.am/db/1233331/Doceree>,
        <https://1145.am/db/2183421/Related_Optum>,
        <https://1145.am/db/2183441/Related_Optum>,
        <https://1145.am/db/2215434/HCSC>,
        <https://1145.am/db/2251888/CHS>,
        <https://1145.am/db/2283271/Alcedis>,
        <https://1145.am/db/2350256/Bioscrip>,
        <https://1145.am/db/2546137/Capsugel>,
        <https://1145.am/db/2565346/Eckuity>,
        <https://1145.am/db/293801/Biontech>,
        <https://1145.am/db/438630/Indegene>,
        <https://1145.am/db/456352/Citiustech>,
        <https://1145.am/db/458620/Citiustech>,
        <https://1145.am/db/470797/Biotricity_Inc>,
        <https://1145.am/db/721568/Biotricity_Inc>,
        <https://1145.am/db/739725/Consensys_Health> ;
    ns1:sameAsMedium <https://1145.am/db/2299955/Activiews> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2298542/Investment_Aggredyne_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-22T14:52:42+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Diagnostics startup Aggredyne has raised $ 3 million in a Series A convertible preferred stock financing round." ;
    ns1:documentTitle "Boston Scientific completes enrollment for aortic valve trial; Diagnostics startup Aggredyne raises $3M;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/boston-scientific-completes-enrollment-for-aortic-valve-trial-diagnostics-startup> ;
    ns1:foundName "financing",
        "raised" ;
    ns1:name "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2298542/Aggredyne> ;
    ns1:valueRaw "$ 3 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2298542/Investment_Delcath_Systems_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-22T14:52:42+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Delcath Systems ($ DCTH) , a specialty medical device and pharmaceutical company focused on cancer treatment, has closed a $ 20 million line of credit with Silicon Valley Bank to support growth and product development." ;
    ns1:documentTitle "Boston Scientific completes enrollment for aortic valve trial; Diagnostics startup Aggredyne raises $3M;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/boston-scientific-completes-enrollment-for-aortic-valve-trial-diagnostics-startup> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2298542/Delcath_Systems> ;
    ns1:valueRaw "$ 20 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2327795/Investment_Oxford_Nanopore_Technologies_Ltd_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-07T12:07:19+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Oxford Nanopore Technologies Ltd, a privately held company that is developing a disruptive technology for the real-time electronic analysis of single molecules, today announced that it has raised £31.4 million ($ 50.8 million) in new funding via a private placement of ordinary shares in the Company.",
        "Oxford Nanopore announces £31.4 million ($ 50.8 million) fundraising." ;
    ns1:documentTitle "Oxford Nanopore announces £31.4 million ($50.8 million) fundraising" ;
    ns1:documentURL <https://www.fiercebiotech.com/it/oxford-nanopore-announces-%C2%A331-4-million-50-8-million-fundraising> ;
    ns1:foundName "funding",
        "fundraising",
        "private placement" ;
    ns1:name "funding",
        "fundraising",
        "private placement" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2327795/Oxford_Nanopore_Technologies_Ltd> ;
    ns1:valueRaw "$ 50.8 million",
        "£31.4 million" ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "UK" .

<https://1145.am/db/2327843/Jumpstart_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Cleveland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5150529/about.rdf> ;
    ns1:basedInHighRaw "CLEVELAND" ;
    ns1:basedInLowRaw "Northeast Ohio" ;
    ns1:documentDate "2012-06-06T19:40:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "JumpStart Invests $250,000 in GenomOncology" ;
    ns1:documentURL <https://www.fiercebiotech.com/it/jumpstart-invests-250-000-genomoncology> ;
    ns1:foundName "JumpStart",
        "JumpStart Inc." ;
    ns1:investor <https://1145.am/db/2327843/Investment_Genomoncology_Jumpstart_Inc_Has_Not_Happened> ;
    ns1:name "JumpStart",
        "JumpStart Inc." ;
    ns1:sameAsMedium <https://1145.am/db/1150749/Jumpstart>,
        <https://1145.am/db/1737408/Jumpstart>,
        <https://1145.am/db/2205980/Jumpstart_Inc>,
        <https://1145.am/db/2328567/Jumpstart_Inc>,
        <https://1145.am/db/2330775/Jumpstart>,
        <https://1145.am/db/2454161/Jumpstart_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2328931/Clinical_Outcome_Assessment_Solutions> a org:Organization ;
    ns1:description "Clinical Outcome Assessment Solutions" ;
    ns1:documentDate "2012-07-09T13:50:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ERT Acquires invivodata to Establish the Industry's Most Experienced Provider of Clinical Outcome Assessment Solutions" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/ert-acquires-invivodata-to-establish-industry-s-most-experienced-provider-clinical-outcome> ;
    ns1:foundName "invivodata" ;
    ns1:name "Clinical Outcome Assessment Solutions" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2328931/Ert> a org:Organization ;
    ns1:buyer <https://1145.am/db/2328931/Clinical_Outcome_Assessment_Solutions_Acquisition> ;
    ns1:description "Health outcomes services" ;
    ns1:documentDate "2012-07-09T13:50:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ERT Acquires invivodata to Establish the Industry's Most Experienced Provider of Clinical Outcome Assessment Solutions" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/ert-acquires-invivodata-to-establish-industry-s-most-experienced-provider-clinical-outcome> ;
    ns1:foundName "ERT" ;
    ns1:industry "health outcomes services" ;
    ns1:name "ERT" ;
    ns1:sameAsMedium <https://1145.am/db/1107485/Ert>,
        <https://1145.am/db/1107529/Ert>,
        <https://1145.am/db/1127158/Ert>,
        <https://1145.am/db/1127175/Ert>,
        <https://1145.am/db/2290360/Ert>,
        <https://1145.am/db/2308030/Ert>,
        <https://1145.am/db/2308033/Ert>,
        <https://1145.am/db/2321784/Ert>,
        <https://1145.am/db/2323947/Ert>,
        <https://1145.am/db/2323956/Ert>,
        <https://1145.am/db/2328930/Ert>,
        <https://1145.am/db/2332522/Ert>,
        <https://1145.am/db/2333453/Ert>,
        <https://1145.am/db/2347857/Ert>,
        <https://1145.am/db/2353180/Ert>,
        <https://1145.am/db/2363386/Ert>,
        <https://1145.am/db/507193/Ert> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335700/Celgene> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:description "long-term investors" ;
    ns1:documentDate "2012-07-23T15:59:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $30 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-30-million-financing> ;
    ns1:foundName "Celgene" ;
    ns1:industry "Pharmaceutical" ;
    ns1:investor <https://1145.am/db/2335700/Investment_Celgene_Credit_Suisse_First_Boston_Equity_Partners_Delphi_Ventures_Hbm_Bioventures_Novo_A_S_Ptc_Therapeutics_Inc_The_Column_Group_Vulcan_Ventures_Completed> ;
    ns1:name "Celgene" ;
    ns1:sameAsHigh <https://1145.am/db/2301990/Celgene>,
        <https://1145.am/db/2302006/Celgene_Corporation>,
        <https://1145.am/db/2302012/Celgene>,
        <https://1145.am/db/2304362/Celgene_Corporation>,
        <https://1145.am/db/2304831/Celgene_Corporation>,
        <https://1145.am/db/2305030/Celgene_Corporation>,
        <https://1145.am/db/2314474/Celgene>,
        <https://1145.am/db/2323370/Celgene>,
        <https://1145.am/db/2326490/Celgene>,
        <https://1145.am/db/2335769/Celgene>,
        <https://1145.am/db/2336238/Celgene>,
        <https://1145.am/db/2337453/Celgene>,
        <https://1145.am/db/2338420/Recro_Pharma>,
        <https://1145.am/db/2339413/Celgene>,
        <https://1145.am/db/2340634/Celgene>,
        <https://1145.am/db/2344782/Celgene_Corporation>,
        <https://1145.am/db/2347663/Celgene_Corporation>,
        <https://1145.am/db/2349202/Celgene_Corporation>,
        <https://1145.am/db/2349233/Celgene_Corporation>,
        <https://1145.am/db/2350231/Celgene>,
        <https://1145.am/db/2353225/Celsus_Therapeutics>,
        <https://1145.am/db/2356187/Recro_Pharma>,
        <https://1145.am/db/2361962/Celgene_Corporation>,
        <https://1145.am/db/2361967/Celgene_Corporation>,
        <https://1145.am/db/2364468/Celgene_Corporation>,
        <https://1145.am/db/2365987/Celgene_Corporation>,
        <https://1145.am/db/2368041/Celgene>,
        <https://1145.am/db/2368299/Celgene>,
        <https://1145.am/db/2369633/Celgene>,
        <https://1145.am/db/2539561/Celgene>,
        <https://1145.am/db/2539787/Celgene>,
        <https://1145.am/db/2542218/Celgene>,
        <https://1145.am/db/2543185/Celgene>,
        <https://1145.am/db/2543220/Celgene>,
        <https://1145.am/db/2543227/Celgene>,
        <https://1145.am/db/2543236/Celgene>,
        <https://1145.am/db/2543655/Celgene>,
        <https://1145.am/db/2551883/Celgene>,
        <https://1145.am/db/2553958/Celgene>,
        <https://1145.am/db/2565844/Credence_Medsystems>,
        <https://1145.am/db/2567124/Celgene>,
        <https://1145.am/db/2577644/Celgene>,
        <https://1145.am/db/2578498/Celgene>,
        <https://1145.am/db/2584056/Celgene>,
        <https://1145.am/db/2585607/Celgene>,
        <https://1145.am/db/2592505/Celgene>,
        <https://1145.am/db/2595340/Celgene>,
        <https://1145.am/db/720103/Nobelpharma_Co_Ltd> ;
    ns1:sameAsMedium <https://1145.am/db/2152096/Celgene>,
        <https://1145.am/db/2197183/Celgene>,
        <https://1145.am/db/2291277/Celgene>,
        <https://1145.am/db/2293123/Celgene_Corporation>,
        <https://1145.am/db/2301048/Celgene>,
        <https://1145.am/db/2301271/Celgene>,
        <https://1145.am/db/2301310/Celgene>,
        <https://1145.am/db/2302687/Celgene>,
        <https://1145.am/db/2304335/Celgene>,
        <https://1145.am/db/2304340/Celgene>,
        <https://1145.am/db/2308148/Celgene_Inc>,
        <https://1145.am/db/2322317/Celgene_Corporation>,
        <https://1145.am/db/2322323/Celgene>,
        <https://1145.am/db/2323746/Celgene>,
        <https://1145.am/db/2336511/Celgene_Corporation>,
        <https://1145.am/db/2337599/Celgene_Corporation>,
        <https://1145.am/db/2339707/Celgene_Corporation>,
        <https://1145.am/db/2340963/Celgene_Corporation>,
        <https://1145.am/db/2343605/Celgene_Corporation>,
        <https://1145.am/db/2346066/Celgene>,
        <https://1145.am/db/2347566/Celgene_Corporation>,
        <https://1145.am/db/2347844/Celgene_Corporation>,
        <https://1145.am/db/2364471/Celgene>,
        <https://1145.am/db/2366680/Celgene>,
        <https://1145.am/db/2366684/Celgene_Corporation>,
        <https://1145.am/db/2366690/Celgene>,
        <https://1145.am/db/2366896/Celgene_Corporation>,
        <https://1145.am/db/2368721/Celgene>,
        <https://1145.am/db/2369311/Celgene>,
        <https://1145.am/db/2369694/Celgene_Corporation>,
        <https://1145.am/db/2538738/Celgene>,
        <https://1145.am/db/2543648/Celgene>,
        <https://1145.am/db/2558927/Celgene>,
        <https://1145.am/db/2563139/Celgene>,
        <https://1145.am/db/2563587/Celgene>,
        <https://1145.am/db/2565753/Celgene>,
        <https://1145.am/db/2566605/Celgene>,
        <https://1145.am/db/2567006/Celgene>,
        <https://1145.am/db/2571869/Celgene>,
        <https://1145.am/db/2571871/Celgene>,
        <https://1145.am/db/2583298/Celgene_Corporation>,
        <https://1145.am/db/2585603/Celgene_Corporation>,
        <https://1145.am/db/2592040/Celgene>,
        <https://1145.am/db/2593298/Celgene>,
        <https://1145.am/db/2593520/Celgene_Corporation>,
        <https://1145.am/db/2593892/Celgene_Corporation>,
        <https://1145.am/db/870410/Celgene> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335700/Credit_Suisse_First_Boston_Equity_Partners> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:documentDate "2012-07-23T15:59:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $30 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-30-million-financing> ;
    ns1:foundName "Credit Suisse First Boston Equity Partners" ;
    ns1:investor <https://1145.am/db/2335700/Investment_Celgene_Credit_Suisse_First_Boston_Equity_Partners_Delphi_Ventures_Hbm_Bioventures_Novo_A_S_Ptc_Therapeutics_Inc_The_Column_Group_Vulcan_Ventures_Completed> ;
    ns1:name "Credit Suisse First Boston Equity Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2584056/Credit_Suisse_First_Boston_Equity_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335700/Hbm_Bioventures> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:description "long-term investors" ;
    ns1:documentDate "2012-07-23T15:59:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $30 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-30-million-financing> ;
    ns1:foundName "HBM BioVentures" ;
    ns1:investor <https://1145.am/db/2335700/Investment_Celgene_Credit_Suisse_First_Boston_Equity_Partners_Delphi_Ventures_Hbm_Bioventures_Novo_A_S_Ptc_Therapeutics_Inc_The_Column_Group_Vulcan_Ventures_Completed> ;
    ns1:name "HBM BioVentures" ;
    ns1:sameAsHigh <https://1145.am/db/2305703/Pinnacle_Bioventures> ;
    ns1:sameAsMedium <https://1145.am/db/2292772/Hbm_Bioventures>,
        <https://1145.am/db/2301790/Hbm_Bioventures>,
        <https://1145.am/db/2302994/Hbm_Bioventures>,
        <https://1145.am/db/2302995/Hbm_Bioventures>,
        <https://1145.am/db/2303121/Hbm_Bioventures>,
        <https://1145.am/db/2304335/Hbm_Bioventures>,
        <https://1145.am/db/2304340/Hbm_Bioventures>,
        <https://1145.am/db/2313322/Hbm_Bioventures>,
        <https://1145.am/db/2313438/Hbm_Bioventures>,
        <https://1145.am/db/2324255/Hbm_Bioventures>,
        <https://1145.am/db/2325831/Hbm_Bioventures>,
        <https://1145.am/db/2326176/Hbm_Bioventures>,
        <https://1145.am/db/2329550/Hbm_Bioventures>,
        <https://1145.am/db/2332864/Hbm_Bioventures>,
        <https://1145.am/db/2339295/Hbm_Bioventures>,
        <https://1145.am/db/2349301/Hbm_Bioventures_Ltd>,
        <https://1145.am/db/2352382/Hbm_Bioventures>,
        <https://1145.am/db/2353607/Hbm_Bioventures>,
        <https://1145.am/db/2353610/Hbm_Bioventures>,
        <https://1145.am/db/2365748/Hbm_Bioventures>,
        <https://1145.am/db/2584056/Hbm_Bioventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335700/Vulcan_Ventures> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:documentDate "2012-07-23T15:59:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $30 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-30-million-financing> ;
    ns1:foundName "Vulcan Ventures" ;
    ns1:investor <https://1145.am/db/2335700/Investment_Celgene_Credit_Suisse_First_Boston_Equity_Partners_Delphi_Ventures_Hbm_Bioventures_Novo_A_S_Ptc_Therapeutics_Inc_The_Column_Group_Vulcan_Ventures_Completed> ;
    ns1:name "Vulcan Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2584056/Vulcan_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335701/7_Med_Health_Ventures> a org:Organization ;
    ns1:basedInLowRaw "JERUSALEM" ;
    ns1:documentDate "2012-07-23T16:25:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Chiasma Closes $38.5 Million Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/chiasma-closes-38-5-million-equity-financing-0> ;
    ns1:foundName "7 Med Health Ventures" ;
    ns1:investor <https://1145.am/db/2335701/Investment_7_Med_Health_Ventures_Arch_Venture_Partners_Abingworth_Chiasma_F3_Ventures_Fredric_Price_Mpm_Capital_Completed> ;
    ns1:name "7 Med Health Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2335714/7_Med_Health_Ventures>,
        <https://1145.am/db/2337140/7_Med_Health_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335701/Abingworth> a org:Organization ;
    ns1:basedInLowRaw "JERUSALEM" ;
    ns1:description "equity financing" ;
    ns1:documentDate "2012-07-23T16:25:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Chiasma Closes $38.5 Million Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/chiasma-closes-38-5-million-equity-financing-0> ;
    ns1:foundName "Abingworth" ;
    ns1:investor <https://1145.am/db/2335701/Investment_7_Med_Health_Ventures_Arch_Venture_Partners_Abingworth_Chiasma_F3_Ventures_Fredric_Price_Mpm_Capital_Completed> ;
    ns1:name "Abingworth" ;
    ns1:sameAsHigh <https://1145.am/db/1533327/Abingworth>,
        <https://1145.am/db/2284358/Abingworth>,
        <https://1145.am/db/2288699/Abingworth>,
        <https://1145.am/db/2319784/Abingworth>,
        <https://1145.am/db/2349233/Abingworth>,
        <https://1145.am/db/951050/Abingworth> ;
    ns1:sameAsMedium <https://1145.am/db/1533685/Abingworth>,
        <https://1145.am/db/1669813/Abingworth>,
        <https://1145.am/db/2198942/Abingworth>,
        <https://1145.am/db/2235767/Abingworth>,
        <https://1145.am/db/2281044/Abingworth>,
        <https://1145.am/db/2282263/Abingworth>,
        <https://1145.am/db/2285674/Abingworth>,
        <https://1145.am/db/2286368/Abingworth>,
        <https://1145.am/db/2286541/Abingworth>,
        <https://1145.am/db/2292721/Abingworth>,
        <https://1145.am/db/2293814/Abingworth>,
        <https://1145.am/db/2293845/Abingworth>,
        <https://1145.am/db/2294502/Abingworth>,
        <https://1145.am/db/2298306/Abingworth>,
        <https://1145.am/db/2299499/Abingworth>,
        <https://1145.am/db/2301901/Abingworth>,
        <https://1145.am/db/2303656/Abingworth>,
        <https://1145.am/db/2308925/Abingworth>,
        <https://1145.am/db/2308931/Abingworth>,
        <https://1145.am/db/2316391/Abingworth>,
        <https://1145.am/db/2316478/Abingworth>,
        <https://1145.am/db/2317934/Abingworth>,
        <https://1145.am/db/2318733/Abingworth>,
        <https://1145.am/db/2319412/Abingworth>,
        <https://1145.am/db/2322012/Abingworth>,
        <https://1145.am/db/2324936/Abingworth_Llp>,
        <https://1145.am/db/2328502/Abingworth>,
        <https://1145.am/db/2328763/Abingworth>,
        <https://1145.am/db/2328769/Abingworth>,
        <https://1145.am/db/2331750/Abingworth>,
        <https://1145.am/db/2335714/Abingworth>,
        <https://1145.am/db/2335928/Abingworth_Llp>,
        <https://1145.am/db/2337140/Abingworth>,
        <https://1145.am/db/2346293/Abingworth>,
        <https://1145.am/db/2348012/Abingworth_Llp>,
        <https://1145.am/db/2349753/Abingworth>,
        <https://1145.am/db/2352357/Abingworth>,
        <https://1145.am/db/2352361/Abingworth>,
        <https://1145.am/db/2358430/Abingworth>,
        <https://1145.am/db/2364517/Abingworth_Llp>,
        <https://1145.am/db/2368164/Abingworth>,
        <https://1145.am/db/2368251/Abingworth>,
        <https://1145.am/db/2370582/Abingworth>,
        <https://1145.am/db/2787528/Abingworth>,
        <https://1145.am/db/4142/Abingworth_Llp>,
        <https://1145.am/db/899382/Abingworth> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335701/Arch_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "JERUSALEM" ;
    ns1:documentDate "2012-07-23T16:25:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Chiasma Closes $38.5 Million Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/chiasma-closes-38-5-million-equity-financing-0> ;
    ns1:foundName "ARCH Venture Partners" ;
    ns1:investor <https://1145.am/db/2335701/Investment_7_Med_Health_Ventures_Arch_Venture_Partners_Abingworth_Chiasma_F3_Ventures_Fredric_Price_Mpm_Capital_Completed> ;
    ns1:name "ARCH Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1042080/Arch_Venture_Partners>,
        <https://1145.am/db/1105790/Arch_Venture_Partners>,
        <https://1145.am/db/1108240/Arch_Venture_Partners>,
        <https://1145.am/db/1320499/Arch_Venture_Partners>,
        <https://1145.am/db/1334395/Arch_Venture_Partners>,
        <https://1145.am/db/1376077/Arch_Venture_Partners>,
        <https://1145.am/db/1406211/Arch_Venture_Partners>,
        <https://1145.am/db/1476658/Arch_Venture_Partners>,
        <https://1145.am/db/1519613/Arch_Venture_Partners>,
        <https://1145.am/db/1519799/Arch_Venture_Partners>,
        <https://1145.am/db/1553175/Arch_Venture_Partners>,
        <https://1145.am/db/1553459/Arch_Venture_Partners>,
        <https://1145.am/db/1582111/Arch_Venture_Partners>,
        <https://1145.am/db/1619794/Arch_Venture_Partners>,
        <https://1145.am/db/1663313/Arch_Venture_Partners>,
        <https://1145.am/db/1750401/Arch_Venture_Partners>,
        <https://1145.am/db/1791220/Arch_Venture_Partners>,
        <https://1145.am/db/1799828/Arch_Venture_Partners>,
        <https://1145.am/db/1928208/Arch_Venture_Partners>,
        <https://1145.am/db/1984721/Arch_Venture_Partners>,
        <https://1145.am/db/2095032/Arch_Venture_Partners>,
        <https://1145.am/db/2151983/Arch_Venture_Partners>,
        <https://1145.am/db/2181184/Arch_Venture_Partners>,
        <https://1145.am/db/2280315/Arch_Venture_Partners>,
        <https://1145.am/db/2281905/Arch_Venture_Partners>,
        <https://1145.am/db/2282162/Arch_Venture_Partners>,
        <https://1145.am/db/2284585/Arch_Venture_Partners>,
        <https://1145.am/db/2292675/Arch_Venture_Partners>,
        <https://1145.am/db/2294815/Arch_Venture_Partners>,
        <https://1145.am/db/2296113/Arch_Venture_Partners>,
        <https://1145.am/db/2301122/Arch_Venture_Partners>,
        <https://1145.am/db/2302047/Arch_Venture_Partners>,
        <https://1145.am/db/2305524/Arch_Venture_Partners>,
        <https://1145.am/db/2306529/Arch_Venture_Partners>,
        <https://1145.am/db/2315446/Arch_Venture_Partners>,
        <https://1145.am/db/2328599/Arch_Venture_Partners>,
        <https://1145.am/db/2330075/Arch_Venture_Partners>,
        <https://1145.am/db/2330712/Arch_Venture_Partners>,
        <https://1145.am/db/2330852/Arch_Venture_Partners>,
        <https://1145.am/db/2331754/Arch_Venture_Partners>,
        <https://1145.am/db/2331868/Arch_Venture_Partners>,
        <https://1145.am/db/2335714/Arch_Venture_Partners>,
        <https://1145.am/db/2335773/Arch_Venture_Partners>,
        <https://1145.am/db/2336126/Arch_Venture_Partners>,
        <https://1145.am/db/2337140/Arch_Venture_Partners>,
        <https://1145.am/db/2339413/Arch_Venture_Partners>,
        <https://1145.am/db/2340344/Arch_Venture_Partners>,
        <https://1145.am/db/2340345/Arch_Venture_Partners>,
        <https://1145.am/db/2340348/Arch_Venture_Partners>,
        <https://1145.am/db/2341599/Arch_Venture_Partners>,
        <https://1145.am/db/2345223/Arch_Venture_Partners>,
        <https://1145.am/db/2345769/Arch_Venture_Partners>,
        <https://1145.am/db/2347368/Arch_Venture_Partners>,
        <https://1145.am/db/2347469/Arch_Venture_Partners>,
        <https://1145.am/db/2348074/Arch_Venture_Partners>,
        <https://1145.am/db/2356066/Arch_Venture_Partners>,
        <https://1145.am/db/2357253/Arch_Venture_Partners>,
        <https://1145.am/db/2357256/Arch_Venture_Partners>,
        <https://1145.am/db/2358725/Arch_Venture_Partners>,
        <https://1145.am/db/2359124/Arch_Venture_Partners>,
        <https://1145.am/db/2359447/Arch_Venture_Partners>,
        <https://1145.am/db/2359655/Arch_Venture_Partners>,
        <https://1145.am/db/2364332/Arch_Venture_Partners>,
        <https://1145.am/db/2364336/Arch_Venture_Partners>,
        <https://1145.am/db/2366536/Arch_Venture_Partners>,
        <https://1145.am/db/2366539/Arch_Venture_Partners>,
        <https://1145.am/db/2366654/Arch_Venture_Partners>,
        <https://1145.am/db/2368912/Arch_Venture_Partners>,
        <https://1145.am/db/2369000/Arch_Venture_Partners>,
        <https://1145.am/db/2369549/Arch_Venture_Partners>,
        <https://1145.am/db/2371167/Arch_Venture_Partners>,
        <https://1145.am/db/2592611/Arch_Venture_Partners>,
        <https://1145.am/db/430986/Arch_Venture_Partners>,
        <https://1145.am/db/531806/Arch_Venture_Partners>,
        <https://1145.am/db/769568/Arch_Venture_Partners>,
        <https://1145.am/db/847865/Arch_Venture_Partners>,
        <https://1145.am/db/900779/Arch_Venture_Partners>,
        <https://1145.am/db/900943/Arch_Venture_Partners>,
        <https://1145.am/db/922192/Arch_Venture_Partners>,
        <https://1145.am/db/944358/Arch_Venture_Partners>,
        <https://1145.am/db/979509/Arch_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335701/F3_Ventures> a org:Organization ;
    ns1:basedInLowRaw "JERUSALEM" ;
    ns1:documentDate "2012-07-23T16:25:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Chiasma Closes $38.5 Million Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/chiasma-closes-38-5-million-equity-financing-0> ;
    ns1:foundName "F3 Ventures" ;
    ns1:investor <https://1145.am/db/2335701/Investment_7_Med_Health_Ventures_Arch_Venture_Partners_Abingworth_Chiasma_F3_Ventures_Fredric_Price_Mpm_Capital_Completed> ;
    ns1:name "F3 Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2335714/F3_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335701/Fredric_Price> a org:Organization ;
    ns1:basedInLowRaw "JERUSALEM" ;
    ns1:description "Chiasma" ;
    ns1:documentDate "2012-07-23T16:25:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Chiasma Closes $38.5 Million Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/chiasma-closes-38-5-million-equity-financing-0> ;
    ns1:foundName "Fredric Price" ;
    ns1:industry "biopharma" ;
    ns1:investor <https://1145.am/db/2335701/Investment_7_Med_Health_Ventures_Arch_Venture_Partners_Abingworth_Chiasma_F3_Ventures_Fredric_Price_Mpm_Capital_Completed> ;
    ns1:name "Fredric Price" ;
    ns1:sameAsHigh <https://1145.am/db/2335714/Fredric_Price> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336098/Prochon_Biotech_Series_A_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2012-07-24T12:13:57+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Histogenics-a tissue engineering company-has nailed down $ 49 million in new Series A financing intended to bring its two signature products to the regulatory finish line." ;
    ns1:documentTitle "Histogenics reels in $49M Series A for tissue engineering implants" ;
    ns1:documentURL <https://www.fiercebiotech.com/regulatory/histogenics-reels-49m-series-a-for-tissue-engineering-implants> ;
    ns1:foundName "acquisition",
        "financing" ;
    ns1:name "acquisition",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2336098/Histogenics>,
        <https://1145.am/db/2336098/Prochon_Biotech> ;
    ns1:targetDetails "Series A" ;
    ns1:targetName "Prochon BioTech" ;
    ns1:valueRaw "$ 49 million" ;
    ns1:vendor <https://1145.am/db/2336098/Histogenics> ;
    ns1:whenRaw "May 2011" ;
    ns1:whereGeoName "State of Israel" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/294640/about.rdf> ;
    ns1:whereRaw "Israel" .

<https://1145.am/db/2336125/Rusnanomedinvest> a org:Organization ;
    ns1:basedInLowRaw "RUSNANO",
        "Russia" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T21:20:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CoDa Therapeutics Completes $40 Million Series B Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/coda-therapeutics-completes-40-million-series-b-equity-financing> ;
    ns1:foundName "RUSNANO",
        "RusnanoMedInvest" ;
    ns1:investor <https://1145.am/db/2336125/Series_B_Investment_Coda_Therapeutics_Rusnanomedinvest_Rusnanomedinvest_Completed> ;
    ns1:name "RUSNANO",
        "RusnanoMedInvest" ;
    ns1:participant <https://1145.am/db/2336125/Series_B_Investment_Coda_Therapeutics_Rusnanomedinvest_Rusnanomedinvest_Completed> ;
    ns1:sameAsHigh <https://1145.am/db/2361625/Rusnanomedinvest> ;
    ns1:sameAsMedium <https://1145.am/db/2297408/Rusnanomedinvest>,
        <https://1145.am/db/2339894/Rusnanomedinvest>,
        <https://1145.am/db/2347984/Rusnanomedinvest>,
        <https://1145.am/db/2356301/Rusnanomedinvest>,
        <https://1145.am/db/2357325/Rusnanomedinvest>,
        <https://1145.am/db/2358541/Rusnanomedinvest>,
        <https://1145.am/db/2360258/Rusnanomedinvest> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337971/Pfizer_Venture_Investments> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2012-07-31T14:27:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates> ;
    ns1:foundName "Pfizer Venture Investments" ;
    ns1:investor <https://1145.am/db/2337971/Series_A_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_New_Enterprise_Associates_Pfizer_Venture_Investments_Proquest_Investments_Rho_Ventures_Completed> ;
    ns1:name "Pfizer Venture Investments" ;
    ns1:sameAsMedium <https://1145.am/db/2299758/Pfizer_Venture_Investments>,
        <https://1145.am/db/2306549/Pfizer_Venture_Investments>,
        <https://1145.am/db/2318310/Pfizer_Venture_Investments>,
        <https://1145.am/db/2319442/Pfizer_Venture_Investments>,
        <https://1145.am/db/2322984/Pfizer_Venture_Investments>,
        <https://1145.am/db/2323003/Pfizer_Venture_Investments>,
        <https://1145.am/db/2336335/Pfizer_Venture_Investments>,
        <https://1145.am/db/2338527/Pfizer_Venture_Investments>,
        <https://1145.am/db/2338528/Pfizer_Venture_Investments>,
        <https://1145.am/db/2340096/Pfizer_Venture_Investments>,
        <https://1145.am/db/2346978/Pfizer_Venture_Investments>,
        <https://1145.am/db/2348066/Pfizer_Venture_Investments>,
        <https://1145.am/db/2349143/Pfizer_Venture_Investments>,
        <https://1145.am/db/2352226/Pfizer_Venture_Investments>,
        <https://1145.am/db/2354296/Pfizer_Venture_Investments>,
        <https://1145.am/db/2355043/Pfizer_Venture_Investments>,
        <https://1145.am/db/2356287/Pfizer_Venture_Investments>,
        <https://1145.am/db/2356290/Pfizer_Venture_Investments>,
        <https://1145.am/db/2359321/Pfizer_Venture_Investments>,
        <https://1145.am/db/2362862/Pfizer_Venture_Investments>,
        <https://1145.am/db/2364457/Pfizer_Venture_Investments>,
        <https://1145.am/db/2364458/Pfizer_Venture_Investments>,
        <https://1145.am/db/2367549/Pfizer_Venture_Investments>,
        <https://1145.am/db/2369000/Pfizer_Venture_Investments>,
        <https://1145.am/db/2587938/Pfizer_Venture_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337972/Nea> a org:Organization ;
    ns1:description "investment" ;
    ns1:documentDate "2012-07-31T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana grabs $27M from Pfizer, NEA and others for muscled cancer drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/mersana-grabs-27m-from-pfizer-nea-and-others-for-muscled-cancer-drugs> ;
    ns1:foundName "NEA" ;
    ns1:investor <https://1145.am/db/2337972/Series_A-1_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_Nea_Proquest_Investments_Rho_Ventures_Venture_Investments_Completed> ;
    ns1:name "NEA" ;
    ns1:sameAsHigh <https://1145.am/db/1137051/Nea>,
        <https://1145.am/db/129908/Nea>,
        <https://1145.am/db/1445426/Nea>,
        <https://1145.am/db/1503651/Negma>,
        <https://1145.am/db/1699512/Nea>,
        <https://1145.am/db/1747054/Nea>,
        <https://1145.am/db/1773703/Nea>,
        <https://1145.am/db/1790986/Nea>,
        <https://1145.am/db/1817209/Nea>,
        <https://1145.am/db/1823612/Nea>,
        <https://1145.am/db/1830084/Nea>,
        <https://1145.am/db/1830819/Nea>,
        <https://1145.am/db/1848523/Nea>,
        <https://1145.am/db/1945485/Nea>,
        <https://1145.am/db/1960888/Nea>,
        <https://1145.am/db/2348066/Nea>,
        <https://1145.am/db/526175/Nea>,
        <https://1145.am/db/591538/Nea>,
        <https://1145.am/db/641613/Nea>,
        <https://1145.am/db/700388/Nea> ;
    ns1:sameAsMedium <https://1145.am/db/1131171/Nea>,
        <https://1145.am/db/1166550/Nea>,
        <https://1145.am/db/1169121/Nea>,
        <https://1145.am/db/1174277/Nea>,
        <https://1145.am/db/1174670/Nea>,
        <https://1145.am/db/1338464/Nea>,
        <https://1145.am/db/1362581/Nea>,
        <https://1145.am/db/1442931/Nea>,
        <https://1145.am/db/1533327/Nea>,
        <https://1145.am/db/1533685/Nea>,
        <https://1145.am/db/1578326/Nea>,
        <https://1145.am/db/1694450/Nea>,
        <https://1145.am/db/1696426/Nea>,
        <https://1145.am/db/1704817/Nea>,
        <https://1145.am/db/1708920/Nea>,
        <https://1145.am/db/1709685/Nea>,
        <https://1145.am/db/1716622/Nea>,
        <https://1145.am/db/1722914/Nea>,
        <https://1145.am/db/1734259/Nea>,
        <https://1145.am/db/1735722/Nea>,
        <https://1145.am/db/1737425/Nea>,
        <https://1145.am/db/1741791/Nea>,
        <https://1145.am/db/1741884/Nea>,
        <https://1145.am/db/1741929/Nea>,
        <https://1145.am/db/1742516/Nea>,
        <https://1145.am/db/1744029/Nea>,
        <https://1145.am/db/1744900/Nea>,
        <https://1145.am/db/1746577/Nea>,
        <https://1145.am/db/1751877/Nea>,
        <https://1145.am/db/1752390/Nea>,
        <https://1145.am/db/1756163/Nea>,
        <https://1145.am/db/1761276/Nea>,
        <https://1145.am/db/1761402/Nea>,
        <https://1145.am/db/1767301/Nea>,
        <https://1145.am/db/1770553/Nea>,
        <https://1145.am/db/1770931/Nea>,
        <https://1145.am/db/1774939/Nea>,
        <https://1145.am/db/1775434/Nea>,
        <https://1145.am/db/1776201/Nea>,
        <https://1145.am/db/1776613/Nea>,
        <https://1145.am/db/1776646/Nea>,
        <https://1145.am/db/1777232/Nea>,
        <https://1145.am/db/1778132/Nea>,
        <https://1145.am/db/1788267/Nea>,
        <https://1145.am/db/1791640/Nea>,
        <https://1145.am/db/1791780/Nea>,
        <https://1145.am/db/1792401/Nea>,
        <https://1145.am/db/1795013/Nea>,
        <https://1145.am/db/1799888/Nea>,
        <https://1145.am/db/1801287/Nea>,
        <https://1145.am/db/1801621/Nea>,
        <https://1145.am/db/1801792/Nea>,
        <https://1145.am/db/1803774/Nea>,
        <https://1145.am/db/1804152/Nea>,
        <https://1145.am/db/1805468/Nea>,
        <https://1145.am/db/1807968/Nea>,
        <https://1145.am/db/1808099/Nea>,
        <https://1145.am/db/1809161/Nea>,
        <https://1145.am/db/1809853/Nea>,
        <https://1145.am/db/1811740/Nea>,
        <https://1145.am/db/1816840/Nea>,
        <https://1145.am/db/1819956/Nea>,
        <https://1145.am/db/1824137/Nea>,
        <https://1145.am/db/1827025/Nea>,
        <https://1145.am/db/1828441/Nea>,
        <https://1145.am/db/1833265/Nea>,
        <https://1145.am/db/1833278/Nea>,
        <https://1145.am/db/1833814/Nea>,
        <https://1145.am/db/1835007/Nea>,
        <https://1145.am/db/1835740/Nea>,
        <https://1145.am/db/1836989/Nea>,
        <https://1145.am/db/1840478/Nea>,
        <https://1145.am/db/1843003/Nea>,
        <https://1145.am/db/1849606/Nea>,
        <https://1145.am/db/1849884/Nea>,
        <https://1145.am/db/1850271/Nea>,
        <https://1145.am/db/1850352/Nea>,
        <https://1145.am/db/1851595/Nea>,
        <https://1145.am/db/1854587/Nea>,
        <https://1145.am/db/1856900/Nea>,
        <https://1145.am/db/1867420/Nea>,
        <https://1145.am/db/1870426/Nea>,
        <https://1145.am/db/1875184/Nea>,
        <https://1145.am/db/1876063/Nea>,
        <https://1145.am/db/1877241/Nea>,
        <https://1145.am/db/1895232/Nea>,
        <https://1145.am/db/1896326/Nea>,
        <https://1145.am/db/2009539/Nea>,
        <https://1145.am/db/2062003/Nea>,
        <https://1145.am/db/2133555/Nea>,
        <https://1145.am/db/214119/Nea>,
        <https://1145.am/db/2196875/Nea>,
        <https://1145.am/db/2298510/Nea>,
        <https://1145.am/db/2303548/Nea>,
        <https://1145.am/db/2303560/Nea>,
        <https://1145.am/db/2323138/Nea>,
        <https://1145.am/db/2331700/Nea>,
        <https://1145.am/db/2336634/Nea>,
        <https://1145.am/db/2348967/Nea>,
        <https://1145.am/db/2687902/Nea>,
        <https://1145.am/db/396154/Nea>,
        <https://1145.am/db/415557/Nea>,
        <https://1145.am/db/417606/Nea>,
        <https://1145.am/db/474783/Nea>,
        <https://1145.am/db/488687/Nea>,
        <https://1145.am/db/606235/Nea>,
        <https://1145.am/db/644429/Nea>,
        <https://1145.am/db/765986/Nea>,
        <https://1145.am/db/887690/Nea>,
        <https://1145.am/db/909436/Nea>,
        <https://1145.am/db/947292/Nea>,
        <https://1145.am/db/960286/Nea>,
        <https://1145.am/db/971811/Nea>,
        <https://1145.am/db/973579/Nea>,
        <https://1145.am/db/993478/Nea> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337972/Venture_Investments> a org:Organization ;
    ns1:description "Venture Investments" ;
    ns1:documentDate "2012-07-31T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana grabs $27M from Pfizer, NEA and others for muscled cancer drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/mersana-grabs-27m-from-pfizer-nea-and-others-for-muscled-cancer-drugs> ;
    ns1:foundName "Venture Investments" ;
    ns1:investor <https://1145.am/db/2337972/Series_A-1_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_Nea_Proquest_Investments_Rho_Ventures_Venture_Investments_Completed> ;
    ns1:name "Venture Investments" ;
    ns1:sameAsHigh <https://1145.am/db/1754484/Top_Tier_Capital_Partners>,
        <https://1145.am/db/1755860/Vs_Partners>,
        <https://1145.am/db/1767026/Target_Partners>,
        <https://1145.am/db/1789767/Group_11>,
        <https://1145.am/db/1853417/New_Markets_Venture_Partners>,
        <https://1145.am/db/1855529/Target_Partners>,
        <https://1145.am/db/1856228/Venture_Partners>,
        <https://1145.am/db/1858991/Target_Partners>,
        <https://1145.am/db/1859494/Partners_Investment>,
        <https://1145.am/db/1928828/Top_Tier_Capital_Partners>,
        <https://1145.am/db/2222905/Venture_Capitalists>,
        <https://1145.am/db/2299743/Venture_Investors>,
        <https://1145.am/db/2309506/Prospect_Venture_Partners>,
        <https://1145.am/db/2330852/Prospect_Venture_Partners>,
        <https://1145.am/db/2331868/Prospect_Venture_Partners>,
        <https://1145.am/db/2352804/Prospect_Venture_Partners>,
        <https://1145.am/db/2357333/Investinor>,
        <https://1145.am/db/2360006/Prospect_Venture_Partners>,
        <https://1145.am/db/2370798/Investinor>,
        <https://1145.am/db/396235/Top_Tier_Capital_Partners>,
        <https://1145.am/db/588551/Citi_Ventures>,
        <https://1145.am/db/704753/Target_Partners>,
        <https://1145.am/db/734448/Venture_Investments>,
        <https://1145.am/db/838181/Index_Venture_Capital>,
        <https://1145.am/db/893076/Top_Tier_Capital_Partners>,
        <https://1145.am/db/893316/Top_Tier_Capital_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2298631/Venture_Investments>,
        <https://1145.am/db/2345017/Venture_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337974/Canaan_Partners> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:documentDate "2012-07-31T14:27:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CytomX Therapeutics Expands Series B Financing; Canaan Partners Joins Syndicate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-expands-series-b-financing-canaan-partners-joins-syndicate> ;
    ns1:foundName "Canaan Partners" ;
    ns1:investor <https://1145.am/db/2337974/Series_B_Investment_Canaan_Partners_Cytomx_Therapeutics_Roche_Venture_Fund_Third_Rock_Ventures_Has_Not_Happened> ;
    ns1:name "Canaan Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1043342/Canaan_Partners>,
        <https://1145.am/db/146274/Canaan_Partners>,
        <https://1145.am/db/1695894/Canaan_Partners>,
        <https://1145.am/db/1696766/Canaan_Partners>,
        <https://1145.am/db/1697131/Canaan_Partners>,
        <https://1145.am/db/1702857/Canaan_Partners>,
        <https://1145.am/db/1711633/Canaan_Partners>,
        <https://1145.am/db/1724566/Canaan_Partners>,
        <https://1145.am/db/1734259/Canaan_Partners>,
        <https://1145.am/db/1741014/Canaan_Partners>,
        <https://1145.am/db/1741105/Canaan_Partners>,
        <https://1145.am/db/1741424/Canaan_Partners>,
        <https://1145.am/db/1749744/Canaan_Partners>,
        <https://1145.am/db/1754820/Canaan_Partners>,
        <https://1145.am/db/1768400/Canaan_Partners>,
        <https://1145.am/db/1770648/Canaan_Partners>,
        <https://1145.am/db/1791628/Canaan_Partners>,
        <https://1145.am/db/1792426/Canaan_Partners>,
        <https://1145.am/db/1793543/Canaan_Partners>,
        <https://1145.am/db/1796375/Canaan_Partners>,
        <https://1145.am/db/1814413/Canaan_Partners>,
        <https://1145.am/db/1819543/Canaan_Partners>,
        <https://1145.am/db/1827240/Canaan_Partners>,
        <https://1145.am/db/1829078/Canaan_Partners>,
        <https://1145.am/db/1829544/Canaan_Partners>,
        <https://1145.am/db/1836578/Canaan_Partners>,
        <https://1145.am/db/1842466/Canaan_Partners>,
        <https://1145.am/db/1845119/Canaan_Partners>,
        <https://1145.am/db/1852066/Canaan_Partners>,
        <https://1145.am/db/1858762/Canaan_Partners>,
        <https://1145.am/db/1863401/Canaan_Partners>,
        <https://1145.am/db/1866968/Canaan_Partners>,
        <https://1145.am/db/1894670/Canaan_Partners>,
        <https://1145.am/db/1897255/Canaan_Partners>,
        <https://1145.am/db/1900458/Canaan_Partners>,
        <https://1145.am/db/1906336/Canaan_Partners>,
        <https://1145.am/db/1907151/Canaan_Partners>,
        <https://1145.am/db/1907762/Canaan_Partners>,
        <https://1145.am/db/1910644/Canaan_Partners>,
        <https://1145.am/db/1919135/Canaan_Partners>,
        <https://1145.am/db/1920478/Canaan_Partners>,
        <https://1145.am/db/2164798/Canaan_Partners>,
        <https://1145.am/db/2164838/Canaan_Partners>,
        <https://1145.am/db/2210939/Canaan_Partners>,
        <https://1145.am/db/2238667/Canaan_Partners>,
        <https://1145.am/db/2287025/Canaan_Partners>,
        <https://1145.am/db/2287777/Canaan_Partners>,
        <https://1145.am/db/2297592/Canaan_Partners>,
        <https://1145.am/db/2298642/Canaan_Partners>,
        <https://1145.am/db/2301765/Canaan_Partners>,
        <https://1145.am/db/2304587/Canaan_Partners>,
        <https://1145.am/db/2304605/Canaan_Partners>,
        <https://1145.am/db/2306281/Canaan_Partners>,
        <https://1145.am/db/2308329/Canaan_Partners>,
        <https://1145.am/db/2309376/Canaan_Partners>,
        <https://1145.am/db/2309387/Canaan_Partners>,
        <https://1145.am/db/2313171/Canaan_Partners>,
        <https://1145.am/db/2320925/Canaan_Partners>,
        <https://1145.am/db/2322231/Canaan_Partners>,
        <https://1145.am/db/2329010/Canaan_Partners>,
        <https://1145.am/db/2329011/Canaan_Partners>,
        <https://1145.am/db/2329531/Canaan_Partners>,
        <https://1145.am/db/2332322/Canaan_Partners>,
        <https://1145.am/db/2337958/Canaan_Partners>,
        <https://1145.am/db/2346532/Canaan_Partners>,
        <https://1145.am/db/2347469/Canaan_Partners>,
        <https://1145.am/db/2351129/Canaan_Partners>,
        <https://1145.am/db/2351316/Canaan_Partners>,
        <https://1145.am/db/2351684/Canaan_Partners>,
        <https://1145.am/db/2353588/Canaan_Partners>,
        <https://1145.am/db/2353608/Canaan_Partners>,
        <https://1145.am/db/2355043/Canaan_Partners>,
        <https://1145.am/db/2355238/Canaan_Partners>,
        <https://1145.am/db/2355715/Canaan_Partners>,
        <https://1145.am/db/2358378/Canaan_Partners>,
        <https://1145.am/db/2359185/Canaan_Partners>,
        <https://1145.am/db/2360258/Canaan_Partners>,
        <https://1145.am/db/2360266/Canaan_Partners>,
        <https://1145.am/db/2360647/Canaan_Partners>,
        <https://1145.am/db/2363535/Canaan_Partners>,
        <https://1145.am/db/2365700/Canaan_Partners>,
        <https://1145.am/db/2366187/Canaan_Partners>,
        <https://1145.am/db/2366753/Canaan_Partners>,
        <https://1145.am/db/2368322/Canaan_Partners>,
        <https://1145.am/db/2368973/Canaan_Partners>,
        <https://1145.am/db/2368982/Canaan_Partners>,
        <https://1145.am/db/2370582/Canaan_Partners>,
        <https://1145.am/db/2370802/Canaan_Partners>,
        <https://1145.am/db/2370834/Canaan_Partners>,
        <https://1145.am/db/2572398/Canaan_Partners>,
        <https://1145.am/db/2583466/Canaan_Partners>,
        <https://1145.am/db/2635439/Canaan_Partners>,
        <https://1145.am/db/316299/Canaan_Partners>,
        <https://1145.am/db/319155/Canaan_Partners>,
        <https://1145.am/db/353476/Canaan_Partners>,
        <https://1145.am/db/411041/Canaan_Partners>,
        <https://1145.am/db/523179/Canaan_Partners>,
        <https://1145.am/db/564082/Canaan_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337974/Roche_Venture_Fund> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-31T14:27:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CytomX Therapeutics Expands Series B Financing; Canaan Partners Joins Syndicate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-expands-series-b-financing-canaan-partners-joins-syndicate> ;
    ns1:foundName "Roche Venture Fund",
        "the Roche Venture Fund" ;
    ns1:investor <https://1145.am/db/2337974/Series_B_Investment_Canaan_Partners_Cytomx_Therapeutics_Roche_Venture_Fund_Third_Rock_Ventures_Has_Not_Happened> ;
    ns1:name "Roche Venture Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2308834/Roche_Investments_Usa_Inc>,
        <https://1145.am/db/2313985/Roche_Venture_Fund>,
        <https://1145.am/db/2336333/Roche_Venture_Fund>,
        <https://1145.am/db/2337958/Roche_Venture_Fund>,
        <https://1145.am/db/2343301/Roche_Venture_Fund>,
        <https://1145.am/db/2346534/Roche_Venture_Fund>,
        <https://1145.am/db/2349143/Roche_Venture_Fund>,
        <https://1145.am/db/2352203/Roche_Venture_Fund>,
        <https://1145.am/db/2352204/Roche_Venture_Fund>,
        <https://1145.am/db/2352216/Roche_Venture_Fund>,
        <https://1145.am/db/2352436/Roche_Venture_Fund>,
        <https://1145.am/db/2352442/Roche_Venture_Fund>,
        <https://1145.am/db/2363396/Roche_Venture_Fund>,
        <https://1145.am/db/2367549/Roche_Venture_Fund>,
        <https://1145.am/db/829447/Roche_Venture_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2299180/Roche_($_Rhhby)_Venture_Fund>,
        <https://1145.am/db/2302731/Roche_Venture_Fund>,
        <https://1145.am/db/2306549/Roche_Venture_Fund>,
        <https://1145.am/db/2317779/Roche_Venture_Fund>,
        <https://1145.am/db/2326222/Roche_Venture_Fund>,
        <https://1145.am/db/2327441/Roche_Venture_Fund>,
        <https://1145.am/db/2327442/Roche_Venture_Fund>,
        <https://1145.am/db/2330668/Roche_Venture_Fund>,
        <https://1145.am/db/2336328/Roche_Venture_Fund>,
        <https://1145.am/db/2336335/Roche_Venture_Fund>,
        <https://1145.am/db/2355043/Roche_Venture_Fund>,
        <https://1145.am/db/2358496/Roche_Venture_Fund>,
        <https://1145.am/db/2358502/Roche_Venture_Fund>,
        <https://1145.am/db/2362533/Roche_Venture_Fund>,
        <https://1145.am/db/2362715/Roche_Venture_Fund>,
        <https://1145.am/db/2364249/Roche_Venture_Fund>,
        <https://1145.am/db/2364255/Roche_Venture_Fund>,
        <https://1145.am/db/2364283/Roche_Venture_Fund>,
        <https://1145.am/db/2365748/Roche_Venture_Fund>,
        <https://1145.am/db/2370694/Roche_Venture_Fund>,
        <https://1145.am/db/2371169/Roche_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342165/Klp_Enterprises_Llc> a org:Organization ;
    ns1:basedInHighGeoName "Medford" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4943629/about.rdf> ;
    ns1:basedInHighRaw "Medford, MA, USA" ;
    ns1:description "Business" ;
    ns1:documentDate "2012-03-05T15:05:51+00:00"^^xsd:dateTime ;
    ns1:documentTitle "4s3 Bioscience, Inc. Secures $20M in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/4s3-bioscience-inc-secures-20m-series-a-financing> ;
    ns1:foundName "KLP Enterprises, LLC" ;
    ns1:investor <https://1145.am/db/2342165/Series_A_Investment_4s3_Bioscience_Klp_Enterprises_Llc_Completed> ;
    ns1:name "KLP Enterprises, LLC" ;
    ns1:sameAsMedium <https://1145.am/db/2359404/Klp_Enterprises> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342192/Series_C_Investment_Aragon_Pharmaceuticals_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-05T21:24:31+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Aragon Pharmaceuticals Secures $ 42 Million in Series C Financing to Advance Pipeline of Therapies Targeting Hormone-Driven Cancers.",
        "SAN DIEGO, March 6, 2012 - Aragon Pharmaceuticals today announced that the company has secured $ 42 million in an oversubscribed Series C financing to advance Aragon's pipeline of therapies targeting hormone-driven cancers, including ARN-509, the company's lead compound for the treatment of castration-resistant prostate cancer (CRPC) ." ;
    ns1:documentTitle "Aragon Pharmaceuticals Secures $42 Million in Series C Financing to Advance Pipeline of Therapies Targeting Hormone-Driven Cancers" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aragon-pharmaceuticals-secures-42-million-series-c-financing-to-advance-pipeline-of> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2342192/Aragon_Pharmaceuticals> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 42 Million",
        "$ 42 million" ;
    ns1:when "2012-03-06T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "March 6, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2342365/Urogenix_Divestment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "divestment",
        "investment" ;
    ns1:documentDate "2012-08-06T12:52:45+00:00"^^xsd:dateTime ;
    ns1:documentExtract "TOKYO, Aug. 6, 2012- Astellas Pharma Inc. (\"Astellas\"; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that it decided to close Urogenix, Inc. (\"Urogenix\", Durham, NC, President: Shuuichi Tawara) , an Astellas subsidiary, which is a research facility focusing on drug discovery in the field of urology." ;
    ns1:documentTitle "Astellas to Close Urogenix, North Carolina-based Urology Research Facility" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/astellas-to-close-urogenix-north-carolina-based-urology-research-facility> ;
    ns1:foundName "close" ;
    ns1:name "close" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2342365/Urogenix> ;
    ns1:targetName "Urogenix" ;
    ns1:when "2012-08-06T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2012-Aug.6" ;
    ns1:whereGeoName "Durham County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4464374/about.rdf> ;
    ns1:whereRaw "Durham, NC" .

<https://1145.am/db/2343197/European_Union> a org:Organization ;
    ns1:basedInLowRaw "European" ;
    ns1:description "Research and Technological Development" ;
    ns1:documentDate "2012-03-07T14:41:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Exonhit is Beneficiary of a Grant from the European Union within the Responsify Consortium" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/exonhit-beneficiary-of-a-grant-from-european-union-within-responsify-consortium> ;
    ns1:foundName "European Union" ;
    ns1:investor <https://1145.am/db/2343197/Investment_European_Union_Exonhit_Completed> ;
    ns1:name "European Union" ;
    ns1:sameAsMedium <https://1145.am/db/1775669/European_Union>,
        <https://1145.am/db/1822340/European_Union>,
        <https://1145.am/db/2007265/European_Union>,
        <https://1145.am/db/2057601/European_Union>,
        <https://1145.am/db/2144771/European_Union>,
        <https://1145.am/db/2291636/European_Union>,
        <https://1145.am/db/2662065/European_Union>,
        <https://1145.am/db/2673653/European_Union>,
        <https://1145.am/db/2781292/European_Union> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343197/Responsify> a org:Organization ;
    ns1:basedInLowRaw "European Union" ;
    ns1:description "Research and Technological Development" ;
    ns1:documentDate "2012-03-07T14:41:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Exonhit is Beneficiary of a Grant from the European Union within the Responsify Consortium" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/exonhit-beneficiary-of-a-grant-from-european-union-within-responsify-consortium> ;
    ns1:foundName "RESPONSIFY" ;
    ns1:investor <https://1145.am/db/2343197/Investment_European_Union_Exonhit_Completed> ;
    ns1:name "RESPONSIFY" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343206/Domain_Associates> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:documentDate "2012-03-07T16:52:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sequent Medical Announces Closing of $26.0 Million Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sequent-medical-announces-closing-of-26-0-million-venture-financing> ;
    ns1:foundName "Domain Associates" ;
    ns1:investor <https://1145.am/db/2343206/Series_C_Investment_Delphi_Ventures_Domain_Associates_Sequent_Medical_Us_Venture_Partners_Versant_Ventures_Completed> ;
    ns1:name "Domain Associates" ;
    ns1:sameAsMedium <https://1145.am/db/1859331/Domain_Associates>,
        <https://1145.am/db/2153759/Domain_Associates>,
        <https://1145.am/db/2155032/Domain_Associates>,
        <https://1145.am/db/2155189/Domain_Associates>,
        <https://1145.am/db/2289515/Domain_Associates>,
        <https://1145.am/db/2289819/Domain_Associates>,
        <https://1145.am/db/2290405/Domain_Associates>,
        <https://1145.am/db/2294753/Domain_Associates>,
        <https://1145.am/db/2296841/Domain_Associates>,
        <https://1145.am/db/2297408/Domain_Associates>,
        <https://1145.am/db/2299776/Domain_Associates>,
        <https://1145.am/db/2300270/Domain_Associates>,
        <https://1145.am/db/2300293/Domain_Associates>,
        <https://1145.am/db/2300337/Domain_Associates>,
        <https://1145.am/db/2300455/Domain_Associates>,
        <https://1145.am/db/2302292/Domain_Associates_Llc>,
        <https://1145.am/db/2302508/Domain_Associates>,
        <https://1145.am/db/2303641/Domain_Associates>,
        <https://1145.am/db/2303642/Domain_Associates>,
        <https://1145.am/db/2303793/Domain_Associates>,
        <https://1145.am/db/2304578/Domain_Associates>,
        <https://1145.am/db/2304587/Domain_Associates>,
        <https://1145.am/db/2305524/Domain_Associates>,
        <https://1145.am/db/2305530/Domain_Associates>,
        <https://1145.am/db/2305706/Domain_Associates>,
        <https://1145.am/db/2305713/Domain_Associates>,
        <https://1145.am/db/2305729/Domain_Associates>,
        <https://1145.am/db/2306290/Domain_Associates_Llc>,
        <https://1145.am/db/2306873/Domain_Associates>,
        <https://1145.am/db/2307237/Domain_Associates>,
        <https://1145.am/db/2307644/Domain_Associates>,
        <https://1145.am/db/2309809/Domain_Associates>,
        <https://1145.am/db/2310073/Domain_Associates>,
        <https://1145.am/db/2311099/Domain_Associates>,
        <https://1145.am/db/2311221/Domain_Associates>,
        <https://1145.am/db/2312051/Domain_Associates>,
        <https://1145.am/db/2312120/Domain_Associates>,
        <https://1145.am/db/2312297/Domain_Associates>,
        <https://1145.am/db/2313171/Domain_Associates>,
        <https://1145.am/db/2316210/Domain_Associates>,
        <https://1145.am/db/2316214/Domain_Associates>,
        <https://1145.am/db/2317145/Domain_Associates>,
        <https://1145.am/db/2317951/Domain_Associates>,
        <https://1145.am/db/2318934/Domain_Associates>,
        <https://1145.am/db/2320925/Domain_Associates>,
        <https://1145.am/db/2322231/Domain_Associates>,
        <https://1145.am/db/2326423/Domain_Associates>,
        <https://1145.am/db/2326430/Domain_Associates_Llc>,
        <https://1145.am/db/2328030/Domain_Associates_Llc>,
        <https://1145.am/db/2328034/Domain_Associates_Llc>,
        <https://1145.am/db/2330075/Domain_Associates>,
        <https://1145.am/db/2330539/Domain_Associates>,
        <https://1145.am/db/2330549/Domain_Associates>,
        <https://1145.am/db/2331026/Domain_Associates>,
        <https://1145.am/db/2331047/Domain_Associates>,
        <https://1145.am/db/2331784/Domain_Associates>,
        <https://1145.am/db/2336221/Domain_Associates>,
        <https://1145.am/db/2340284/Domain_Associates>,
        <https://1145.am/db/2340634/Domain_Associates>,
        <https://1145.am/db/2341764/Domain_Associates>,
        <https://1145.am/db/2344090/Domain_Associates>,
        <https://1145.am/db/2344092/Domain_Associates>,
        <https://1145.am/db/2344100/Domain_Associates>,
        <https://1145.am/db/2344782/Domain_Associates>,
        <https://1145.am/db/2347984/Domain_Associates>,
        <https://1145.am/db/2349143/Domain_Associates>,
        <https://1145.am/db/2349753/Domain_Associates>,
        <https://1145.am/db/2350044/Domain_Associates>,
        <https://1145.am/db/2352167/Domain_Associates>,
        <https://1145.am/db/2352170/Domain_Associates>,
        <https://1145.am/db/2352808/Domain_Associates>,
        <https://1145.am/db/2354899/Domain_Associates>,
        <https://1145.am/db/2354903/Domain_Associates>,
        <https://1145.am/db/2355936/Domain_Associates>,
        <https://1145.am/db/2355938/Domain_Associates>,
        <https://1145.am/db/2356301/Domain_Associates>,
        <https://1145.am/db/2357325/Domain_Associates>,
        <https://1145.am/db/2357981/Domain_Associates>,
        <https://1145.am/db/2358541/Domain_Associates>,
        <https://1145.am/db/2358883/Domain_Associates>,
        <https://1145.am/db/2361625/Domain_Associates>,
        <https://1145.am/db/2362278/Domain_Associates>,
        <https://1145.am/db/2365700/Domain_Associates>,
        <https://1145.am/db/2366128/Domain_Associates>,
        <https://1145.am/db/2366133/Domain_Associates>,
        <https://1145.am/db/2366187/Domain_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343206/Versant_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Calif" ;
    ns1:documentDate "2012-03-07T16:52:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sequent Medical Announces Closing of $26.0 Million Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sequent-medical-announces-closing-of-26-0-million-venture-financing> ;
    ns1:foundName "Versant Ventures" ;
    ns1:investor <https://1145.am/db/2343206/Series_C_Investment_Delphi_Ventures_Domain_Associates_Sequent_Medical_Us_Venture_Partners_Versant_Ventures_Completed> ;
    ns1:name "Versant Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1540787/Versant_Ventures>,
        <https://1145.am/db/1541055/Versant_Ventures>,
        <https://1145.am/db/1571794/Versant_Ventures>,
        <https://1145.am/db/1928388/Versant_Ventures>,
        <https://1145.am/db/1975490/Versant_Ventures>,
        <https://1145.am/db/2069394/Versant_Ventures>,
        <https://1145.am/db/2110276/Versant_Ventures>,
        <https://1145.am/db/2151802/Versant_Ventures>,
        <https://1145.am/db/2154338/Versant_Ventures>,
        <https://1145.am/db/2154566/Versant_Ventures>,
        <https://1145.am/db/2281211/Versant_Ventures>,
        <https://1145.am/db/2287023/Versant_Ventures>,
        <https://1145.am/db/2288016/Versant_Ventures>,
        <https://1145.am/db/2290283/Versant_Ventures>,
        <https://1145.am/db/2291315/Versant_Ventures>,
        <https://1145.am/db/2291344/Versant_Ventures>,
        <https://1145.am/db/2293059/Versant_Ventures>,
        <https://1145.am/db/2293893/Versant_Ventures>,
        <https://1145.am/db/2294202/Versant_Ventures>,
        <https://1145.am/db/2296209/Versant_Ventures>,
        <https://1145.am/db/2298176/Versant_Ventures>,
        <https://1145.am/db/2299080/Versant_Ventures>,
        <https://1145.am/db/2299776/Versant_Ventures>,
        <https://1145.am/db/2300337/Versant_Ventures>,
        <https://1145.am/db/2303767/Versant_Ventures>,
        <https://1145.am/db/2304598/Versant_Ventures>,
        <https://1145.am/db/2304606/Versant_Ventures>,
        <https://1145.am/db/2304769/Versant_Ventures>,
        <https://1145.am/db/2305015/Versant_Ventures>,
        <https://1145.am/db/2308758/Versant_Ventures>,
        <https://1145.am/db/2310285/Versant_Ventures>,
        <https://1145.am/db/2310302/Versant_Ventures>,
        <https://1145.am/db/2311353/Versant_Ventures>,
        <https://1145.am/db/2313143/Versant_Ventures>,
        <https://1145.am/db/2317750/Versant_Ventures>,
        <https://1145.am/db/2317753/Versant_Ventures>,
        <https://1145.am/db/2318733/Versant_Ventures>,
        <https://1145.am/db/2319784/Versant_Ventures>,
        <https://1145.am/db/2322646/Versant_Ventures>,
        <https://1145.am/db/2323226/Versant_Ventures>,
        <https://1145.am/db/2324226/Versant_Ventures>,
        <https://1145.am/db/2325681/Versant_Ventures>,
        <https://1145.am/db/2326361/Versant_Ventures>,
        <https://1145.am/db/2326373/Versant_Ventures>,
        <https://1145.am/db/2326903/Versant_Ventures>,
        <https://1145.am/db/2330075/Versant_Ventures>,
        <https://1145.am/db/2330712/Versant_Ventures>,
        <https://1145.am/db/2330852/Versant_Ventures>,
        <https://1145.am/db/2331754/Versant_Ventures>,
        <https://1145.am/db/2331868/Versant_Ventures>,
        <https://1145.am/db/2335675/Versant_Ventures>,
        <https://1145.am/db/2335760/Versant_Ventures>,
        <https://1145.am/db/2339885/Versant_Ventures>,
        <https://1145.am/db/2339886/Versant_Ventures>,
        <https://1145.am/db/2342445/Versant_Ventures>,
        <https://1145.am/db/2343184/Versant_Ventures>,
        <https://1145.am/db/2343185/Versant_Ventures>,
        <https://1145.am/db/2343467/Versant_Ventures>,
        <https://1145.am/db/2343547/Versant_Ventures>,
        <https://1145.am/db/2343641/Versant_Ventures>,
        <https://1145.am/db/2343647/Versant_Ventures>,
        <https://1145.am/db/2344915/Versant_Ventures>,
        <https://1145.am/db/2344916/Versant_Ventures>,
        <https://1145.am/db/2344922/Versant_Ventures>,
        <https://1145.am/db/2344926/Versant_Ventures>,
        <https://1145.am/db/2345769/Versant_Ventures>,
        <https://1145.am/db/2347368/Versant_Ventures>,
        <https://1145.am/db/2348012/Versant_Ventures>,
        <https://1145.am/db/2348857/Versant_Ventures>,
        <https://1145.am/db/2349233/Versant_Ventures>,
        <https://1145.am/db/2349834/Versant_Ventures>,
        <https://1145.am/db/2350917/Versant_Ventures>,
        <https://1145.am/db/2351904/Versant_Ventures>,
        <https://1145.am/db/2354296/Versant_Ventures>,
        <https://1145.am/db/2360189/Versant_Ventures>,
        <https://1145.am/db/2360191/Versant_Ventures>,
        <https://1145.am/db/2360415/Versant_Ventures>,
        <https://1145.am/db/2362457/Versant_Ventures>,
        <https://1145.am/db/2362527/Versant_Ventures>,
        <https://1145.am/db/2362528/Versant_Ventures>,
        <https://1145.am/db/2362565/Versant_Ventures>,
        <https://1145.am/db/2362566/Versant_Ventures>,
        <https://1145.am/db/2364480/Versant_Ventures>,
        <https://1145.am/db/2365134/Versant_Ventures>,
        <https://1145.am/db/2365135/Versant_Ventures>,
        <https://1145.am/db/2367275/Versant_Ventures>,
        <https://1145.am/db/2368517/Versant_Ventures>,
        <https://1145.am/db/2370609/Versant_Ventures>,
        <https://1145.am/db/2370782/Versant_Ventures>,
        <https://1145.am/db/2370799/Versant_Ventures>,
        <https://1145.am/db/2371160/Versant_Ventures>,
        <https://1145.am/db/2371163/Versant_Ventures>,
        <https://1145.am/db/2541575/Versant_Ventures>,
        <https://1145.am/db/2584561/Versant_Ventures>,
        <https://1145.am/db/456081/Versant_Ventures>,
        <https://1145.am/db/488687/Versant_Ventures>,
        <https://1145.am/db/547640/Versant_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343210/Easton_Capital_Investment_Group> a org:Organization ;
    ns1:basedInLowRaw "PA" ;
    ns1:documentDate "2012-03-07T19:32:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promedior-secures-21-5-million-first-closing-of-series-d-financing-to-expand-and-advance> ;
    ns1:foundName "Easton Capital Investment Group" ;
    ns1:investor <https://1145.am/db/2343210/Series_D_Investment_Easton_Capital_Investment_Group_Fibrotec_Ventures_Forbion_Capital_Partners_Healthcare_Ventures_Morgenthaler_Ventures_Polaris_Venture_Partners_Promedior_Completed> ;
    ns1:name "Easton Capital Investment Group" ;
    ns1:sameAsMedium <https://1145.am/db/2338373/Easton_Capital_Investment_Group>,
        <https://1145.am/db/2366539/Easton_Capital_Investment_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343210/Fibrotec_Ventures> a org:Organization ;
    ns1:basedInLowRaw "MALVERN, PA" ;
    ns1:documentDate "2012-03-07T19:32:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promedior-secures-21-5-million-first-closing-of-series-d-financing-to-expand-and-advance> ;
    ns1:foundName "Fibrotec Ventures, LLC" ;
    ns1:investor <https://1145.am/db/2343210/Series_D_Investment_Easton_Capital_Investment_Group_Fibrotec_Ventures_Forbion_Capital_Partners_Healthcare_Ventures_Morgenthaler_Ventures_Polaris_Venture_Partners_Promedior_Completed> ;
    ns1:name "Fibrotec Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2338373/Fibrotec_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343210/Forbion_Capital_Partners> a org:Organization ;
    ns1:basedInLowRaw "MALVERN, PA" ;
    ns1:documentDate "2012-03-07T19:32:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promedior-secures-21-5-million-first-closing-of-series-d-financing-to-expand-and-advance> ;
    ns1:foundName "Forbion Capital Partners" ;
    ns1:investor <https://1145.am/db/2343210/Series_D_Investment_Easton_Capital_Investment_Group_Fibrotec_Ventures_Forbion_Capital_Partners_Healthcare_Ventures_Morgenthaler_Ventures_Polaris_Venture_Partners_Promedior_Completed> ;
    ns1:name "Forbion Capital Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2223193/Forbion_Capital_Partners>,
        <https://1145.am/db/2288529/Forbion_Capital_Partners>,
        <https://1145.am/db/2295207/Forbion_Capital_Partners>,
        <https://1145.am/db/2296065/Forbion_Capital_Partners>,
        <https://1145.am/db/2301966/Forbion_Capital_Partners>,
        <https://1145.am/db/2309865/Forbion_Capital_Partners>,
        <https://1145.am/db/2309872/Forbion_Capital_Partners>,
        <https://1145.am/db/2313401/Forbion_Capital_Partners>,
        <https://1145.am/db/2313410/Forbion_Capital_Partners>,
        <https://1145.am/db/2313915/Forbion_Capital_Partners>,
        <https://1145.am/db/2318829/Forbion_Capital_Partners>,
        <https://1145.am/db/2320503/Forbion_Capital_Partners>,
        <https://1145.am/db/2323586/Forbion_Capital_Partners>,
        <https://1145.am/db/2327009/Forbion_Capital_Partners>,
        <https://1145.am/db/2328040/Forbion_Capital_Partners>,
        <https://1145.am/db/2328763/Forbion_Capital_Partners>,
        <https://1145.am/db/2328769/Forbion_Capital_Partners>,
        <https://1145.am/db/2329919/Forbion_Capital_Partners>,
        <https://1145.am/db/2336126/Forbion_Capital_Partners>,
        <https://1145.am/db/2338373/Forbion_Capital_Partners>,
        <https://1145.am/db/2338987/Forbion_Capital_Partners>,
        <https://1145.am/db/2339427/Forbion_Capital_Partners>,
        <https://1145.am/db/2339428/Forbion_Capital_Partners>,
        <https://1145.am/db/2339932/Forbion_Capital_Partners>,
        <https://1145.am/db/2339933/Forbion_Capital_Partners>,
        <https://1145.am/db/2341942/Forbion_Capital_Partners>,
        <https://1145.am/db/2343202/Forbion_Capital_Partners>,
        <https://1145.am/db/2343244/Forbion_Capital_Partners>,
        <https://1145.am/db/2346397/Forbion_Capital_Partners>,
        <https://1145.am/db/2348506/Forbion_Capital_Partners>,
        <https://1145.am/db/2348523/Forbion_Capital_Partners>,
        <https://1145.am/db/2350101/Forbion_Capital_Partners>,
        <https://1145.am/db/2352566/Forbion_Capital_Partners>,
        <https://1145.am/db/2355511/Forbion_Capital_Partners>,
        <https://1145.am/db/2355512/Forbion_Capital_Partners>,
        <https://1145.am/db/2356989/Forbion_Capital_Partners>,
        <https://1145.am/db/2357941/Forbion_Capital_Partners>,
        <https://1145.am/db/2357956/Forbion_Capital_Partners>,
        <https://1145.am/db/2359960/Forbion_Capital_Partners>,
        <https://1145.am/db/2360313/Forbion_Capital_Partners>,
        <https://1145.am/db/2360317/Forbion_Capital_Partners>,
        <https://1145.am/db/2361390/Forbion_Capital_Partners>,
        <https://1145.am/db/2363593/Forbion_Capital_Partners>,
        <https://1145.am/db/2363597/Forbion_Capital_Partners>,
        <https://1145.am/db/2366539/Forbion_Capital_Partners>,
        <https://1145.am/db/2369872/Forbion_Capital_Partners>,
        <https://1145.am/db/2370054/Forbion_Capital_Partners>,
        <https://1145.am/db/2370056/Forbion_Capital_Partners>,
        <https://1145.am/db/2538923/Forbion_Capital_Partners>,
        <https://1145.am/db/2569491/Forbion_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343210/Healthcare_Ventures> a org:Organization ;
    ns1:basedInLowRaw "MALVERN" ;
    ns1:documentDate "2012-03-07T19:32:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promedior-secures-21-5-million-first-closing-of-series-d-financing-to-expand-and-advance> ;
    ns1:foundName "HealthCare Ventures" ;
    ns1:investor <https://1145.am/db/2343210/Series_D_Investment_Easton_Capital_Investment_Group_Fibrotec_Ventures_Forbion_Capital_Partners_Healthcare_Ventures_Morgenthaler_Ventures_Polaris_Venture_Partners_Promedior_Completed> ;
    ns1:name "HealthCare Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2235852/Healthcare_Ventures>,
        <https://1145.am/db/2304650/Healthcare_Ventures>,
        <https://1145.am/db/2308148/Healthcare_Ventures>,
        <https://1145.am/db/2308887/Healthcare_Ventures>,
        <https://1145.am/db/2309845/Healthcare_Ventures>,
        <https://1145.am/db/2311069/Healthcare_Ventures>,
        <https://1145.am/db/2311075/Healthcare_Ventures>,
        <https://1145.am/db/2312192/Healthcare_Ventures>,
        <https://1145.am/db/2313405/Healthcare_Ventures>,
        <https://1145.am/db/2316601/Healthcare_Ventures>,
        <https://1145.am/db/2316605/Healthcare_Ventures>,
        <https://1145.am/db/2316823/Healthcare_Ventures>,
        <https://1145.am/db/2318657/Healthcare_Ventures>,
        <https://1145.am/db/2321097/Healthcare_Ventures>,
        <https://1145.am/db/2323586/Healthcare_Ventures>,
        <https://1145.am/db/2331639/Healthcare_Ventures>,
        <https://1145.am/db/2338373/Healthcare_Ventures>,
        <https://1145.am/db/2342269/Healthcare_Ventures>,
        <https://1145.am/db/2343202/Healthcare_Ventures>,
        <https://1145.am/db/2346204/Healthcare_Ventures>,
        <https://1145.am/db/2347469/Healthcare_Ventures>,
        <https://1145.am/db/2348486/Healthcare_Ventures>,
        <https://1145.am/db/2349717/Healthcare_Ventures>,
        <https://1145.am/db/2349722/Healthcare_Ventures>,
        <https://1145.am/db/2352814/Healthcare_Ventures>,
        <https://1145.am/db/2352820/Healthcare_Ventures>,
        <https://1145.am/db/2363510/Healthcare_Ventures>,
        <https://1145.am/db/2365138/Healthcare_Ventures>,
        <https://1145.am/db/2365171/Healthcare_Ventures>,
        <https://1145.am/db/2367497/Healthcare_Ventures>,
        <https://1145.am/db/2443170/Healthcare_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343210/Morgenthaler_Ventures> a org:Organization ;
    ns1:basedInLowRaw "PA" ;
    ns1:documentDate "2012-03-07T19:32:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promedior-secures-21-5-million-first-closing-of-series-d-financing-to-expand-and-advance> ;
    ns1:foundName "Morgenthaler Ventures" ;
    ns1:investor <https://1145.am/db/2343210/Series_D_Investment_Easton_Capital_Investment_Group_Fibrotec_Ventures_Forbion_Capital_Partners_Healthcare_Ventures_Morgenthaler_Ventures_Polaris_Venture_Partners_Promedior_Completed> ;
    ns1:name "Morgenthaler Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1281079/Morgenthaler_Ventures>,
        <https://1145.am/db/1281647/Morgenthaler_Ventures>,
        <https://1145.am/db/1653506/Morgenthaler_Ventures>,
        <https://1145.am/db/1695894/Morgenthaler_Ventures>,
        <https://1145.am/db/1699268/Morgenthaler_Ventures>,
        <https://1145.am/db/1709168/Morgenthaler_Ventures>,
        <https://1145.am/db/1724566/Morgenthaler_Ventures>,
        <https://1145.am/db/1826128/Morgenthaler_Ventures>,
        <https://1145.am/db/1829487/Morgenthaler_Ventures>,
        <https://1145.am/db/1830084/Morgenthaler_Ventures>,
        <https://1145.am/db/1836989/Morgenthaler_Ventures>,
        <https://1145.am/db/1837117/Morgenthaler_Ventures>,
        <https://1145.am/db/1839836/Morgenthaler_Ventures>,
        <https://1145.am/db/1846752/Morgenthaler_Ventures>,
        <https://1145.am/db/1881748/Morgenthaler_Ventures>,
        <https://1145.am/db/1890157/Morgenthaler_Ventures>,
        <https://1145.am/db/2246579/Morgenthaler_Ventures>,
        <https://1145.am/db/2257512/Morgenthaler_Ventures>,
        <https://1145.am/db/2297408/Morgenthaler_Ventures>,
        <https://1145.am/db/2297592/Morgenthaler_Ventures>,
        <https://1145.am/db/2307644/Morgenthaler_Ventures>,
        <https://1145.am/db/2308142/Morgenthaler_Ventures>,
        <https://1145.am/db/2311069/Morgenthaler_Ventures>,
        <https://1145.am/db/2311075/Morgenthaler_Ventures>,
        <https://1145.am/db/2312192/Morgenthaler_Ventures>,
        <https://1145.am/db/2323586/Morgenthaler_Ventures>,
        <https://1145.am/db/2329524/Morgenthaler_Ventures>,
        <https://1145.am/db/2329531/Morgenthaler_Ventures>,
        <https://1145.am/db/2338251/Morgenthaler_Ventures>,
        <https://1145.am/db/2338254/Morgenthaler_Ventures>,
        <https://1145.am/db/2338373/Morgenthaler_Ventures>,
        <https://1145.am/db/2338703/Morgenthaler_Ventures>,
        <https://1145.am/db/2338704/Morgenthaler_Ventures>,
        <https://1145.am/db/2342925/Morgenthaler_Ventures>,
        <https://1145.am/db/2342937/Morgenthaler_Ventures>,
        <https://1145.am/db/2343202/Morgenthaler_Ventures>,
        <https://1145.am/db/2352207/Morgenthaler_Ventures>,
        <https://1145.am/db/2362553/Morgenthaler_Ventures>,
        <https://1145.am/db/2363510/Morgenthaler_Ventures>,
        <https://1145.am/db/2364939/Morgenthaler_Ventures>,
        <https://1145.am/db/2367204/Morgenthaler_Ventures>,
        <https://1145.am/db/2570481/Morgenthaler_Ventures>,
        <https://1145.am/db/2570483/Morgenthaler_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344196/Cancer_Prevention_And_Research_Institute_Of_Texas> a org:Organization ;
    ns1:basedInLowRaw "Texas" ;
    ns1:description "cancer" ;
    ns1:documentDate "2012-03-08T14:18:26+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bellicum Closes $20 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bellicum-closes-20-million-series-b-financing> ;
    ns1:foundName "Cancer Prevention and Research Institute of Texas" ;
    ns1:investor <https://1145.am/db/2344196/Investment_Bellicum_Pharmaceuticals_Cancer_Prevention_And_Research_Institute_Of_Texas_Completed> ;
    ns1:name "Cancer Prevention and Research Institute of Texas" ;
    ns1:sameAsHigh <https://1145.am/db/1294016/Cancer_Prevention_And_Research_Institute_Of_Texas>,
        <https://1145.am/db/572681/Cancer_Prevention_And_Research_Institute_Of_Texas> ;
    ns1:sameAsMedium <https://1145.am/db/1294786/Cancer_Prevention_And_Research_Institute_Of_Texas> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344219/Eastern_Capital_Limited> a org:Organization ;
    ns1:basedInLowRaw "ANN ARBOR, Mich." ;
    ns1:documentDate "2012-03-09T16:47:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aastrom Biosciences Completes $40 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aastrom-biosciences-completes-40-million-financing> ;
    ns1:foundName "Eastern Capital Limited" ;
    ns1:investor <https://1145.am/db/2344219/Investment_Aastrom_Biosciences_Eastern_Capital_Limited_Mlv___Co_Completed> ;
    ns1:name "Eastern Capital Limited" ;
    ns1:sameAsMedium <https://1145.am/db/2299271/Eastern_Capital>,
        <https://1145.am/db/2340305/Eastern_Capital_Limited>,
        <https://1145.am/db/2349221/Eastern_Capital>,
        <https://1145.am/db/2537321/Eastern_Capital_Limited>,
        <https://1145.am/db/592382/Eastern_Capital_Limited> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344219/Mlv___Co> a org:Organization ;
    ns1:basedInLowRaw "ANN ARBOR, Mich." ;
    ns1:documentDate "2012-03-09T16:47:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aastrom Biosciences Completes $40 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aastrom-biosciences-completes-40-million-financing> ;
    ns1:foundName "MLV & Co" ;
    ns1:investor <https://1145.am/db/2344219/Investment_Aastrom_Biosciences_Eastern_Capital_Limited_Mlv___Co_Completed> ;
    ns1:name "MLV & Co" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346307/Nicox> a org:Organization ;
    ns1:basedInHighGeoName "Republic of France" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:basedInHighRaw "France" ;
    ns1:buyer <https://1145.am/db/2346307/Altacor_Stake_Investment> ;
    ns1:description "ophthalmology" ;
    ns1:documentDate "2012-03-21T13:58:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NicOx eyes global status in eye drug game with up to $30.9M buyout of Altacor" ;
    ns1:documentURL <https://www.fiercebiotech.com/financials/nicox-eyes-global-status-eye-drug-game-up-to-30-9m-buyout-of-altacor> ;
    ns1:foundName "NicOx" ;
    ns1:industry "pharmaceutical" ;
    ns1:investor <https://1145.am/db/2346307/Altacor_Stake_Investment> ;
    ns1:name "NicOx" ;
    ns1:sameAsHigh <https://1145.am/db/1237051/Nicox_Sa>,
        <https://1145.am/db/2294967/Nicox>,
        <https://1145.am/db/2315370/Nicox>,
        <https://1145.am/db/2315373/Nicox_Sa>,
        <https://1145.am/db/2316665/Nicox>,
        <https://1145.am/db/2320333/Nicox>,
        <https://1145.am/db/2327073/Nicox_Sa>,
        <https://1145.am/db/2330216/Nicox>,
        <https://1145.am/db/2332815/Nicox>,
        <https://1145.am/db/2346308/Nicox_Sa>,
        <https://1145.am/db/2346313/Nicox>,
        <https://1145.am/db/2348791/Nicox>,
        <https://1145.am/db/2348792/Nicox_Sa>,
        <https://1145.am/db/2350001/Nicox_Sa>,
        <https://1145.am/db/2354753/Nicox_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346485/Mei_Pharma> a org:Organization ;
    ns1:basedInLowRaw "Singapore" ;
    ns1:buyer <https://1145.am/db/2346485/Pracinostat_Rights_Acquisition> ;
    ns1:description "Oncology" ;
    ns1:documentDate "2012-08-13T16:34:36+00:00"^^xsd:dateTime ;
    ns1:documentTitle "MEI Pharma to buy S*BIO's rights to HDAC inhibitor, Pracinostat" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mei-pharma-to-buy-s-bio-s-rights-to-hdac-inhibitor-pracinostat> ;
    ns1:foundName "MEI Pharma",
        "MEI Pharma, Inc." ;
    ns1:name "MEI Pharma" ;
    ns1:sameAsHigh <https://1145.am/db/2313460/Cabrellis_Pharmaceuticals>,
        <https://1145.am/db/2363564/Mei_Pharma>,
        <https://1145.am/db/2369301/Cti_Biopharma>,
        <https://1145.am/db/2594353/Mei_Pharma> ;
    ns1:sameAsMedium <https://1145.am/db/1150398/Mei_Pharma>,
        <https://1145.am/db/1152234/Mei_Pharma>,
        <https://1145.am/db/1362662/Mei_Pharma>,
        <https://1145.am/db/1680583/Mei_Pharma>,
        <https://1145.am/db/1687234/Mei_Pharma>,
        <https://1145.am/db/2023840/Mei_Pharma>,
        <https://1145.am/db/2038168/Mei_Pharma>,
        <https://1145.am/db/2039291/Mei_Pharma>,
        <https://1145.am/db/2039678/Mei_Pharma>,
        <https://1145.am/db/2052904/Mei_Pharma>,
        <https://1145.am/db/2056005/Mei_Pharma>,
        <https://1145.am/db/2056049/Mei_Pharma>,
        <https://1145.am/db/2056755/Mei_Pharma>,
        <https://1145.am/db/2061803/Mei_Pharma>,
        <https://1145.am/db/2062156/Mei_Pharma>,
        <https://1145.am/db/2062633/Mei_Pharma>,
        <https://1145.am/db/2066480/Mei_Pharma>,
        <https://1145.am/db/2067011/Mei_Pharma>,
        <https://1145.am/db/2336432/Mei_Pharma>,
        <https://1145.am/db/2347043/Mei_Pharma>,
        <https://1145.am/db/2363719/Mei_Pharma>,
        <https://1145.am/db/640920/Mei_Pharma>,
        <https://1145.am/db/661749/Mei_Pharma>,
        <https://1145.am/db/663640/Mei_Pharma>,
        <https://1145.am/db/665488/Mei_Pharma>,
        <https://1145.am/db/667249/Mei_Pharma>,
        <https://1145.am/db/675023/Mei_Pharma>,
        <https://1145.am/db/680465/Mei_Pharma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2347327/Ipo_Clovis_Oncology_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "ipo" ;
    ns1:documentDate "2012-03-23T16:13:06+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Boulder, CO - based cancer drug developer Clovis Oncology ($ CLVS) has announced plans for a $ 75 million public offering." ;
    ns1:documentTitle "Anaphore scoops up Chinese biotech; Clovis reveals $75M offering;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anaphore-scoops-up-chinese-biotech-clovis-reveals-75m-offering> ;
    ns1:foundName "public offering" ;
    ns1:name "public offering" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:valueRaw "$ 75 million" ;
    ns1:vendor <https://1145.am/db/2347327/Clovis_Oncology> ;
    ns1:whereGeoName "Boulder County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5574999/about.rdf> ;
    ns1:whereRaw "Boulder" .

<https://1145.am/db/2347327/Series_A_Investment_Enterome_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-23T16:13:06+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Paris - based Enterome, which specializes in biomarker discovery, has raised $ 6.6 million in a Series A round of funding." ;
    ns1:documentTitle "Anaphore scoops up Chinese biotech; Clovis reveals $75M offering;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anaphore-scoops-up-chinese-biotech-clovis-reveals-75m-offering> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2347327/Enterome> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 6.6 million" ;
    ns1:whereGeoName "Boulder County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5574999/about.rdf> ;
    ns1:whereRaw "Boulder" .

<https://1145.am/db/2348350/Cycad_Group> a org:Organization ;
    ns1:basedInLowRaw "LOS ANGELES" ;
    ns1:documentDate "2012-03-28T14:04:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ImaginAb Concludes $12.5m Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/imaginab-concludes-12-5m-series-a-financing> ;
    ns1:foundName "Cycad Group" ;
    ns1:investor <https://1145.am/db/2348350/Series_A_Investment_Cycad_Group_Imaginab_Merieux_Developpement_Momentum_Biosciences_Nextech_Invest_Novartis_Venture_Funds_Completed> ;
    ns1:name "Cycad Group" ;
    ns1:sameAsMedium <https://1145.am/db/2292582/Cycad_Group>,
        <https://1145.am/db/2331763/Cycad_Group>,
        <https://1145.am/db/2337294/Cycad_Group>,
        <https://1145.am/db/2337571/Cycad_Group>,
        <https://1145.am/db/2337577/Cycad_Group>,
        <https://1145.am/db/2337976/Cycad_Group>,
        <https://1145.am/db/2349437/Cycad_Group>,
        <https://1145.am/db/2365296/Cycad_Group>,
        <https://1145.am/db/2546216/Cycad_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348350/Merieux_Developpement> a org:Organization ;
    ns1:basedInLowRaw "LOS ANGELES" ;
    ns1:documentDate "2012-03-28T14:04:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ImaginAb Concludes $12.5m Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/imaginab-concludes-12-5m-series-a-financing> ;
    ns1:foundName "Merieux Developpement" ;
    ns1:investor <https://1145.am/db/2348350/Series_A_Investment_Cycad_Group_Imaginab_Merieux_Developpement_Momentum_Biosciences_Nextech_Invest_Novartis_Venture_Funds_Completed> ;
    ns1:name "Merieux Developpement" ;
    ns1:sameAsMedium <https://1145.am/db/2288936/Mérieux_Développement>,
        <https://1145.am/db/2337294/Mérieux_Développement>,
        <https://1145.am/db/2337976/Mérieux_Développement>,
        <https://1145.am/db/2344202/Merieux_Developpement>,
        <https://1145.am/db/2344205/Merieux_Developpement>,
        <https://1145.am/db/2351734/Mérieux_Développement>,
        <https://1145.am/db/2354266/Mérieux_Développement>,
        <https://1145.am/db/2354277/Mérieux_Développement>,
        <https://1145.am/db/2361809/Merieux_Developpement> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348350/Momentum_Biosciences> a org:Organization ;
    ns1:basedInLowRaw "LOS ANGELES" ;
    ns1:documentDate "2012-03-28T14:04:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ImaginAb Concludes $12.5m Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/imaginab-concludes-12-5m-series-a-financing> ;
    ns1:foundName "Momentum Biosciences" ;
    ns1:investor <https://1145.am/db/2348350/Series_A_Investment_Cycad_Group_Imaginab_Merieux_Developpement_Momentum_Biosciences_Nextech_Invest_Novartis_Venture_Funds_Completed> ;
    ns1:name "Momentum Biosciences" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348350/Novartis_Venture_Funds> a org:Organization ;
    ns1:basedInLowRaw "LOS ANGELES" ;
    ns1:documentDate "2012-03-28T14:04:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ImaginAb Concludes $12.5m Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/imaginab-concludes-12-5m-series-a-financing> ;
    ns1:foundName "Novartis Venture Funds" ;
    ns1:investor <https://1145.am/db/2348350/Series_A_Investment_Cycad_Group_Imaginab_Merieux_Developpement_Momentum_Biosciences_Nextech_Invest_Novartis_Venture_Funds_Completed> ;
    ns1:name "Novartis Venture Funds" ;
    ns1:sameAsMedium <https://1145.am/db/1340338/Novartis_Venture_Fund>,
        <https://1145.am/db/1523031/Novartis_Venture_Fund>,
        <https://1145.am/db/207823/Novartis_Venture_Fund>,
        <https://1145.am/db/2152422/Novartis_Venture_Fund>,
        <https://1145.am/db/2247240/Novartis_Venture_Funds>,
        <https://1145.am/db/2289983/Novartis_Venture_Funds>,
        <https://1145.am/db/2292300/Novartis_Venture_Funds>,
        <https://1145.am/db/2292345/Novartis_Venture_Funds>,
        <https://1145.am/db/2297795/Novartis_Venture_Funds>,
        <https://1145.am/db/2298176/Novartis_Venture_Fund>,
        <https://1145.am/db/2307682/Novartis_Venture_Fund>,
        <https://1145.am/db/2310905/Novartis_Venture_Fund>,
        <https://1145.am/db/2310907/Novartis_Venture_Fund>,
        <https://1145.am/db/2313438/Novartis_Venture_Fund>,
        <https://1145.am/db/2315943/Novartis_Venture_Fund>,
        <https://1145.am/db/2315957/Novartis_Venture_Fund>,
        <https://1145.am/db/2317737/Novartis_Venture_Fund>,
        <https://1145.am/db/2323210/Novartis_Venture_Funds>,
        <https://1145.am/db/2323228/Novartis_Venture_Fund>,
        <https://1145.am/db/2323682/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2323683/The_Novartis_Venture_Fund>,
        <https://1145.am/db/2326222/Novartis_Venture_Fund>,
        <https://1145.am/db/2327256/Novartis_Venture_Fund>,
        <https://1145.am/db/2327441/Novartis_Venture_Fund>,
        <https://1145.am/db/2327442/Novartis_Venture_Fund>,
        <https://1145.am/db/2330711/Novartis_Venture_Fund>,
        <https://1145.am/db/2331343/Novartis_Venture_Funds>,
        <https://1145.am/db/2331750/Novartis_Venture_Fund>,
        <https://1145.am/db/2331751/Novartis_Venture_Fund>,
        <https://1145.am/db/2332658/Novartis_Venture_Fund>,
        <https://1145.am/db/2332659/Novartis_Venture_Fund>,
        <https://1145.am/db/2335764/Novartis_Venture_Funds>,
        <https://1145.am/db/2336032/Novartis_Venture_Fund>,
        <https://1145.am/db/2336328/Novartis_Venture_Funds>,
        <https://1145.am/db/2337294/Novartis_Venture_Funds>,
        <https://1145.am/db/2337645/Novartis_Venture_Fund>,
        <https://1145.am/db/2338527/Novartis_Venture_Funds>,
        <https://1145.am/db/2339193/Novartis_Venture_Fund>,
        <https://1145.am/db/2339196/Novartis_Venture_Fund>,
        <https://1145.am/db/2340344/Novartis_Venture_Fund>,
        <https://1145.am/db/2340345/Novartis_Venture_Fund>,
        <https://1145.am/db/2340612/Novartis_Venture_Fund>,
        <https://1145.am/db/2340942/Novartis_Venture_Fund>,
        <https://1145.am/db/2343486/Novartis_Venture_Funds>,
        <https://1145.am/db/2343493/Novartis_Venture_Funds>,
        <https://1145.am/db/2343966/Novartis_Venture_Funds>,
        <https://1145.am/db/2344045/Novartis_Venture_Fund>,
        <https://1145.am/db/2348012/Novartis_Venture_Fund>,
        <https://1145.am/db/2348348/Novartis_Venture_Funds>,
        <https://1145.am/db/2351958/Novartis_Venture_Funds>,
        <https://1145.am/db/2351959/Novartis_Venture_Fund>,
        <https://1145.am/db/2352203/Novartis_Venture_Fund>,
        <https://1145.am/db/2352204/Novartis_Venture_Fund>,
        <https://1145.am/db/2352216/Novartis_Venture_Fund>,
        <https://1145.am/db/2353098/Novartis_Venture_Fund>,
        <https://1145.am/db/2356287/Novartis_Venture_Fund>,
        <https://1145.am/db/2356290/Novartis_Venture_Fund>,
        <https://1145.am/db/2356391/Novartis_Venture_Fund>,
        <https://1145.am/db/2356393/Novartis_Venture_Fund>,
        <https://1145.am/db/2356395/Novartis_Venture_Fund>,
        <https://1145.am/db/2356567/Novartis_Venture_Fund>,
        <https://1145.am/db/2358430/Novartis_Venture_Funds>,
        <https://1145.am/db/2358725/Novartis_Venture_Funds>,
        <https://1145.am/db/2358733/Novartis_Venture_Fund>,
        <https://1145.am/db/2361588/Novartis_Venture_Funds>,
        <https://1145.am/db/2362715/Novartis_Venture_Funds>,
        <https://1145.am/db/2363510/Novartis_Venture_Funds>,
        <https://1145.am/db/2363907/Novartis_Venture_Funds>,
        <https://1145.am/db/2367046/Novartis_Venture_Fund>,
        <https://1145.am/db/2369548/Novartis_Venture_Fund>,
        <https://1145.am/db/2551315/Novartis_Venture_Fund>,
        <https://1145.am/db/2570481/Novartis_Venture_Fund>,
        <https://1145.am/db/2570483/Novartis_Venture_Fund>,
        <https://1145.am/db/2578837/Novartis_Venture_Funds>,
        <https://1145.am/db/2592611/Novartis_Venture_Funds>,
        <https://1145.am/db/509733/Novartis_Venture_Fund>,
        <https://1145.am/db/866508/Novartis_Venture_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348356/Atmi> a org:Organization ;
    ns1:basedInLowRaw "US" ;
    ns1:documentDate "2012-03-28T15:57:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promethera Biosciences Raises $31.4m in Series B" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promethera-biosciences-raises-31-4m-series-b> ;
    ns1:foundName "ATMI" ;
    ns1:investor <https://1145.am/db/2348356/Series_B_Investment_Atmi_Boehringer_Ingelheim_Mitsui_Global_Investment_Promethera_Biosciences_Sambrinvest_Completed> ;
    ns1:name "ATMI" ;
    ns1:sameAsMedium <https://1145.am/db/2546579/Atmi_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348356/Boehringer_Ingelheim> a org:Organization ;
    ns1:basedInLowRaw "Belgium" ;
    ns1:documentDate "2012-03-28T15:57:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promethera Biosciences Raises $31.4m in Series B" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promethera-biosciences-raises-31-4m-series-b> ;
    ns1:foundName "Boehringer Ingelheim and Shire" ;
    ns1:investor <https://1145.am/db/2348356/Series_B_Investment_Atmi_Boehringer_Ingelheim_Mitsui_Global_Investment_Promethera_Biosciences_Sambrinvest_Completed> ;
    ns1:name "Boehringer Ingelheim" ;
    ns1:sameAsMedium <https://1145.am/db/1133669/Boehringer_Ingelheim>,
        <https://1145.am/db/1135149/Boehringer_Ingelheim>,
        <https://1145.am/db/1537106/Boehringer_Ingelheim>,
        <https://1145.am/db/1537985/Boehringer_Ingelheim>,
        <https://1145.am/db/1594413/Boehringer_Ingelheim>,
        <https://1145.am/db/2104084/Boehringer_Ingelheim>,
        <https://1145.am/db/2152172/Boehringer_Ingelheim>,
        <https://1145.am/db/2152174/Boehringer_Ingelheim>,
        <https://1145.am/db/2154401/Boehringer_Ingelheim>,
        <https://1145.am/db/2279867/Boehringer_Ingelheim>,
        <https://1145.am/db/2286657/Boehringer_Ingelheim>,
        <https://1145.am/db/2290507/Boehringer_Ingelheim>,
        <https://1145.am/db/2290919/Boehringer_Ingelheim>,
        <https://1145.am/db/2293168/Boehringer_Ingelheim>,
        <https://1145.am/db/2303974/Boehringer_Ingelheim_Gmbh>,
        <https://1145.am/db/2303980/Boehringer_Ingelheim>,
        <https://1145.am/db/2306173/Boehringer_Ingelheim>,
        <https://1145.am/db/2306755/Boehringer_Ingelheim_Gmbh>,
        <https://1145.am/db/2309115/Boehringer_Ingelheim>,
        <https://1145.am/db/2313544/Boehringer_Ingelheim>,
        <https://1145.am/db/2318248/Boehringer_Ingelheim>,
        <https://1145.am/db/2325525/Boehringer_Ingelheim>,
        <https://1145.am/db/2327902/Boehringer_Ingelheim>,
        <https://1145.am/db/2335703/Boehringer_Ingelheim>,
        <https://1145.am/db/2335705/Boehringer_Ingelheim>,
        <https://1145.am/db/2348805/Boehringer_Ingelheim>,
        <https://1145.am/db/2354380/Boehringer_Ingelheim>,
        <https://1145.am/db/2354388/Boehringer_Ingelheim>,
        <https://1145.am/db/2360080/Boehringer_Ingelheim>,
        <https://1145.am/db/2360086/Boehringer_Ingelheim>,
        <https://1145.am/db/2364810/Boehringer_Ingelheim>,
        <https://1145.am/db/2367430/Boehringer_Ingelheim>,
        <https://1145.am/db/2536400/Boehringer_Ingelheim>,
        <https://1145.am/db/2537396/Boehringer_Ingelheim>,
        <https://1145.am/db/2538082/Boehringer_Ingelheim>,
        <https://1145.am/db/2539012/Boehringer_Ingelheim>,
        <https://1145.am/db/2539572/Boehringer_Ingelheim>,
        <https://1145.am/db/2540249/Boehringer_Ingelheim>,
        <https://1145.am/db/2541725/Boehringer_Ingelheim>,
        <https://1145.am/db/2546160/Boehringer_Ingelheim>,
        <https://1145.am/db/2546781/Boehringer_Ingelheim>,
        <https://1145.am/db/2547189/Boehringer_Ingelheim>,
        <https://1145.am/db/2553131/Boehringer_Ingelheim>,
        <https://1145.am/db/2553750/Boehringer_Ingelheim>,
        <https://1145.am/db/2554242/Boehringer_Ingelheim>,
        <https://1145.am/db/2554535/Boehringer_Ingelheim>,
        <https://1145.am/db/2555393/Boehringer_Ingelheim>,
        <https://1145.am/db/2557861/Boehringer_Ingelheim>,
        <https://1145.am/db/2558025/Boehringer_Ingelheim>,
        <https://1145.am/db/2558026/Boehringer_Ingelheim>,
        <https://1145.am/db/2559641/Boehringer_Ingelheim>,
        <https://1145.am/db/2560253/Boehringer_Ingelheim>,
        <https://1145.am/db/2560865/Boehringer_Ingelheim>,
        <https://1145.am/db/2563447/Boehringer_Ingelheim>,
        <https://1145.am/db/2567800/Boehringer_Ingelheim>,
        <https://1145.am/db/2569425/Boehringer_Ingelheim>,
        <https://1145.am/db/2571316/Boehringer_Ingelheim>,
        <https://1145.am/db/2571525/Boehringer_Ingelheim>,
        <https://1145.am/db/2573259/Boehringer_Ingelheim>,
        <https://1145.am/db/2575575/Boehringer_Ingelheim>,
        <https://1145.am/db/2578745/Boehringer_Ingelheim>,
        <https://1145.am/db/2580383/Boehringer_Ingelheim>,
        <https://1145.am/db/2581309/Boehringer_Ingelheim>,
        <https://1145.am/db/2581768/Boehringer_Ingelheim>,
        <https://1145.am/db/2582681/Boehringer_Ingelheim>,
        <https://1145.am/db/2590739/Boehringer_Ingelheim>,
        <https://1145.am/db/2592924/Boehringer_Ingelheim>,
        <https://1145.am/db/2593232/Boehringer_Ingelheim>,
        <https://1145.am/db/2593463/Boehringer_Ingelheim>,
        <https://1145.am/db/2594262/Boehringer_Ingelheim>,
        <https://1145.am/db/2595226/Boehringer_Ingelheim>,
        <https://1145.am/db/385093/Boehringer_Ingelheim> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348356/Mitsui_Global_Investment> a org:Organization ;
    ns1:basedInHighGeoName "Japan" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1861060/about.rdf> ;
    ns1:basedInHighRaw "Japanese" ;
    ns1:documentDate "2012-03-28T15:57:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promethera Biosciences Raises $31.4m in Series B" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promethera-biosciences-raises-31-4m-series-b> ;
    ns1:foundName "Mitsui Global Investment" ;
    ns1:investor <https://1145.am/db/2348356/Series_B_Investment_Atmi_Boehringer_Ingelheim_Mitsui_Global_Investment_Promethera_Biosciences_Sambrinvest_Completed> ;
    ns1:name "Mitsui Global Investment" ;
    ns1:sameAsMedium <https://1145.am/db/1802098/Mitsui_Global_Investment>,
        <https://1145.am/db/1834224/Mitsui_Global_Investment>,
        <https://1145.am/db/1850989/Mitsui_Global_Investments>,
        <https://1145.am/db/1864900/Mitsui_Global_Investment>,
        <https://1145.am/db/2178960/Mitsui_Global_Investment>,
        <https://1145.am/db/2319644/Mitsui_Global_Investment>,
        <https://1145.am/db/2332478/Mitsui_Global_Investment>,
        <https://1145.am/db/2332479/Mitsui_Global_Investment>,
        <https://1145.am/db/2355051/Mitsui_Global_Investment>,
        <https://1145.am/db/2647328/Mitsui_Global_Investment> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351491/Thomas_Mcnerney___Partners> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2012-04-12T19:40:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tioga Pharmaceuticals Raises $10 Million to Advance Phase 3 Clinical Development of Asimadoline in Irritable Bowel Syndrome" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tioga-pharmaceuticals-raises-10-million-to-advance-phase-3-clinical-development-of> ;
    ns1:foundName "Thomas, McNerney & Partners" ;
    ns1:investor <https://1145.am/db/2351491/Equity_Investment_Thomas_Mcnerney___Partners_Tioga_Pharmaceuticals_Inc_Completed> ;
    ns1:name "Thomas, McNerney & Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2310073/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2310796/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2311221/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2317145/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2317961/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2324355/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2326486/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2328030/Thomas_Mcnerney___Partners_Llc>,
        <https://1145.am/db/2328034/Thomas_Mcnerney___Partners_Llc>,
        <https://1145.am/db/2328585/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2328600/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2330799/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2347076/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2351492/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2355936/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2355938/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2356124/Thomas_Mcnerney___Partners>,
        <https://1145.am/db/2537417/Thomas_Mcnerney___Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352489/Borealis_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Cambridge, MA" ;
    ns1:description "investment" ;
    ns1:documentDate "2012-04-18T13:10:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Wingu Announces Funding Led by Google Ventures: Software to Accelerate Distributed Drug Discovery for Pharmaceutical Industry" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/wingu-announces-funding-led-by-google-ventures-software-to-accelerate-distributed-drug> ;
    ns1:foundName "Borealis Ventures" ;
    ns1:investor <https://1145.am/db/2352489/Series_A_Investment_Borealis_Ventures_Google_Ventures_Wingu_Inc_Completed> ;
    ns1:name "Borealis Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1114628/Born2grow_Ventures>,
        <https://1145.am/db/1171136/Bluerun_Ventures>,
        <https://1145.am/db/1735560/Big_Start_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1766096/Borealis_Ventures>,
        <https://1145.am/db/1814854/Borealis_Ventures>,
        <https://1145.am/db/2153423/Borealis_Ventures>,
        <https://1145.am/db/2288209/Borealis_Ventures>,
        <https://1145.am/db/2319338/Borealis_Ventures>,
        <https://1145.am/db/2342862/Borealis_Ventures>,
        <https://1145.am/db/612707/Borealis_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352489/Google_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Cambridge, MA" ;
    ns1:description "funding" ;
    ns1:documentDate "2012-04-18T13:10:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Wingu Announces Funding Led by Google Ventures: Software to Accelerate Distributed Drug Discovery for Pharmaceutical Industry" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/wingu-announces-funding-led-by-google-ventures-software-to-accelerate-distributed-drug> ;
    ns1:foundName "Google Ventures" ;
    ns1:investor <https://1145.am/db/2352489/Series_A_Investment_Borealis_Ventures_Google_Ventures_Wingu_Inc_Completed> ;
    ns1:name "Google Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1114979/Google_Ventures>,
        <https://1145.am/db/1187183/Google_Ventures>,
        <https://1145.am/db/1189383/Google_Ventures>,
        <https://1145.am/db/1202509/Google_Ventures>,
        <https://1145.am/db/1397630/Google_Ventures>,
        <https://1145.am/db/1425239/Google_Ventures>,
        <https://1145.am/db/1427745/Google_Ventures>,
        <https://1145.am/db/1557175/Google_Ventures>,
        <https://1145.am/db/1558567/Google_Ventures>,
        <https://1145.am/db/1632690/Google_Ventures>,
        <https://1145.am/db/1758916/Google_Ventures>,
        <https://1145.am/db/1760954/Google_Ventures>,
        <https://1145.am/db/1760999/Google_Ventures>,
        <https://1145.am/db/1768511/Google_Ventures>,
        <https://1145.am/db/1773605/Google_Ventures>,
        <https://1145.am/db/1776575/Google_Ventures>,
        <https://1145.am/db/1780470/Google_Ventures>,
        <https://1145.am/db/1780582/Google_Ventures>,
        <https://1145.am/db/1781621/Gv>,
        <https://1145.am/db/1817262/Google_Ventures>,
        <https://1145.am/db/1820380/Google_Ventures>,
        <https://1145.am/db/1821752/Google_Ventures>,
        <https://1145.am/db/1827884/Google_Ventures>,
        <https://1145.am/db/1830101/Google_Ventures>,
        <https://1145.am/db/1831764/Google_Ventures>,
        <https://1145.am/db/1833010/Google_Ventures>,
        <https://1145.am/db/1838965/Google_Ventures>,
        <https://1145.am/db/1844180/Google_Ventures>,
        <https://1145.am/db/1853335/Google_Ventures>,
        <https://1145.am/db/1856811/Google_Ventures>,
        <https://1145.am/db/1857240/Google_Ventures>,
        <https://1145.am/db/1877178/Google_Ventures>,
        <https://1145.am/db/1877473/Google_Ventures>,
        <https://1145.am/db/1879716/Google_Ventures>,
        <https://1145.am/db/2056308/Googles_Venture_Capital_Arm>,
        <https://1145.am/db/2062655/Gv_(google_Ventures)>,
        <https://1145.am/db/2096258/Gv>,
        <https://1145.am/db/2191183/Google_Ventures>,
        <https://1145.am/db/2196786/Google_Ventures>,
        <https://1145.am/db/2198042/Google_Ventures>,
        <https://1145.am/db/2292675/Google_Ventures>,
        <https://1145.am/db/2323524/Google_Ventures>,
        <https://1145.am/db/2342725/Google_Ventures>,
        <https://1145.am/db/2356396/Google_Ventures>,
        <https://1145.am/db/2367681/Google_Ventures>,
        <https://1145.am/db/2370208/Google_Ventures>,
        <https://1145.am/db/2370240/Google_Ventures>,
        <https://1145.am/db/2679166/Google>,
        <https://1145.am/db/2718151/Gv>,
        <https://1145.am/db/658803/Google_Ventures>,
        <https://1145.am/db/773684/Google_Ventures>,
        <https://1145.am/db/8080/Google_Ventures>,
        <https://1145.am/db/823763/Google_Ventures>,
        <https://1145.am/db/962870/Google_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1150887/Google_Ventures>,
        <https://1145.am/db/1153184/Google_Ventures>,
        <https://1145.am/db/1156925/Google_Ventures>,
        <https://1145.am/db/1157294/Google_Ventures>,
        <https://1145.am/db/1202633/Google_Ventures>,
        <https://1145.am/db/1203099/Google_Ventures>,
        <https://1145.am/db/1714555/Google_Ventures>,
        <https://1145.am/db/1739125/Google_Ventures>,
        <https://1145.am/db/1752659/Google_Ventures>,
        <https://1145.am/db/1756840/Google_Ventures>,
        <https://1145.am/db/1764012/Google_Ventures>,
        <https://1145.am/db/1768021/Google_Ventures>,
        <https://1145.am/db/1769528/Google_Ventures>,
        <https://1145.am/db/1772778/Google_Ventures>,
        <https://1145.am/db/1773703/Google_Ventures>,
        <https://1145.am/db/1779277/Google_Ventures>,
        <https://1145.am/db/1786716/Google_Ventures>,
        <https://1145.am/db/1786818/Google_Ventures>,
        <https://1145.am/db/1793129/Google_Ventures>,
        <https://1145.am/db/1794049/Google_Ventures>,
        <https://1145.am/db/1798836/Google_Ventures>,
        <https://1145.am/db/1799162/Google_Ventures>,
        <https://1145.am/db/1803296/Google_Ventures>,
        <https://1145.am/db/1804887/Google_Ventures>,
        <https://1145.am/db/1805764/Google_Ventures>,
        <https://1145.am/db/1807288/Google_Ventures>,
        <https://1145.am/db/1808484/Google_Ventures>,
        <https://1145.am/db/1811851/Google_Ventures>,
        <https://1145.am/db/1813266/Google_Ventures>,
        <https://1145.am/db/1814186/Google_Ventures>,
        <https://1145.am/db/1816707/Google_Ventures>,
        <https://1145.am/db/1818901/Google_Ventures>,
        <https://1145.am/db/1821425/Google_Ventures>,
        <https://1145.am/db/1824026/Google_Ventures>,
        <https://1145.am/db/1826007/Google_Ventures>,
        <https://1145.am/db/1828072/Google_Ventures>,
        <https://1145.am/db/1830066/Google_Ventures>,
        <https://1145.am/db/1830452/Google_Ventures>,
        <https://1145.am/db/1832133/Google_Ventures>,
        <https://1145.am/db/1833657/Google_Ventures>,
        <https://1145.am/db/1833931/Google_Ventures>,
        <https://1145.am/db/1834481/Google_Ventures>,
        <https://1145.am/db/1834503/Google_Ventures>,
        <https://1145.am/db/1837499/Google_Ventures>,
        <https://1145.am/db/1840663/Google_Ventures>,
        <https://1145.am/db/1841061/Google_Ventures>,
        <https://1145.am/db/1842342/Google_Ventures>,
        <https://1145.am/db/1842817/Google_Ventures>,
        <https://1145.am/db/1843360/Google_Ventures>,
        <https://1145.am/db/1844551/Google_Ventures>,
        <https://1145.am/db/1845023/Google_Ventures>,
        <https://1145.am/db/1848084/Google_Ventures>,
        <https://1145.am/db/1848585/Google_Ventures>,
        <https://1145.am/db/1849884/Google_Ventures>,
        <https://1145.am/db/1849967/Google_Ventures>,
        <https://1145.am/db/1854208/Google_Ventures>,
        <https://1145.am/db/1854279/Google_Ventures>,
        <https://1145.am/db/1854797/Google_Ventures>,
        <https://1145.am/db/1857105/Google_Ventures>,
        <https://1145.am/db/1858438/Google_Ventures>,
        <https://1145.am/db/1858646/Google_Ventures>,
        <https://1145.am/db/1860878/Google_Ventures>,
        <https://1145.am/db/1861342/Google_Ventures>,
        <https://1145.am/db/1862168/Google_Ventures>,
        <https://1145.am/db/1864594/Google_Ventures>,
        <https://1145.am/db/1873505/Google_Ventures>,
        <https://1145.am/db/1876848/Google_Ventures>,
        <https://1145.am/db/1882810/Google_Ventures>,
        <https://1145.am/db/1883008/Google_Ventures>,
        <https://1145.am/db/1885998/Google_Ventures>,
        <https://1145.am/db/1886357/Google_Ventures>,
        <https://1145.am/db/1886978/Google_Ventures>,
        <https://1145.am/db/1887982/Google_Ventures>,
        <https://1145.am/db/1896364/Google_Ventures>,
        <https://1145.am/db/1896419/Google_Ventures>,
        <https://1145.am/db/1911314/Google_Ventures>,
        <https://1145.am/db/1947312/Google_Ventures>,
        <https://1145.am/db/2097368/Google_Ventures>,
        <https://1145.am/db/2154341/Google_Ventures>,
        <https://1145.am/db/2180867/Google_Ventures>,
        <https://1145.am/db/2181184/Google_Ventures>,
        <https://1145.am/db/2183352/Google_Ventures>,
        <https://1145.am/db/2194249/Google_Ventures>,
        <https://1145.am/db/2249658/Google_Ventures>,
        <https://1145.am/db/2269634/Google_Ventures>,
        <https://1145.am/db/2286291/Google_Ventures>,
        <https://1145.am/db/2307494/Google_Ventures>,
        <https://1145.am/db/2308700/Google_Ventures>,
        <https://1145.am/db/2311992/Google_Ventures>,
        <https://1145.am/db/2319338/Google_Ventures>,
        <https://1145.am/db/2333119/Google_Ventures>,
        <https://1145.am/db/2342724/Google_Ventures>,
        <https://1145.am/db/2349008/Google_Ventures>,
        <https://1145.am/db/2349426/Google_Ventures>,
        <https://1145.am/db/2350327/Google_Ventures>,
        <https://1145.am/db/2358888/Google_Ventures>,
        <https://1145.am/db/2359987/Google_Ventures>,
        <https://1145.am/db/2367199/Google_Ventures>,
        <https://1145.am/db/2367201/Google_Ventures>,
        <https://1145.am/db/2541350/Google_Ventures>,
        <https://1145.am/db/2583442/Google_Ventures>,
        <https://1145.am/db/490110/Google_Ventures>,
        <https://1145.am/db/494920/Google_Ventures>,
        <https://1145.am/db/923065/Google_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352508/Novo_Ventures> a org:Organization ;
    ns1:basedInLowRaw "BOTHELL, Wash" ;
    ns1:documentDate "2012-04-19T12:23:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alder-biopharmaceuticals-inc-closes-38-million-series-d-financing-to-accelerate-clinical> ;
    ns1:foundName "Novo Ventures" ;
    ns1:investor <https://1145.am/db/2352508/Series_D_Investment_Alder_Biopharmaceuticals_Inc_Novo_Ventures_Sevin_Rosen_Funds_Ventures_West_Sevin_Rosen_Funds_Ventures_West_Wrf_Capital_Hig_Ventures_Completed> ;
    ns1:name "Novo Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2251548/Novo_Ventures>,
        <https://1145.am/db/2284476/Novo_Ventures>,
        <https://1145.am/db/2313143/Novo_Ventures>,
        <https://1145.am/db/2326903/Novo_Ventures>,
        <https://1145.am/db/2330664/Novo_Ventures>,
        <https://1145.am/db/2330668/Novo_Ventures>,
        <https://1145.am/db/2336221/Novo_Ventures>,
        <https://1145.am/db/2339295/Novo_Ventures>,
        <https://1145.am/db/2343966/Novo_Ventures>,
        <https://1145.am/db/2350044/Novo_Ventures>,
        <https://1145.am/db/2353098/Novo_Ventures>,
        <https://1145.am/db/2353588/Novo_Ventures>,
        <https://1145.am/db/2353598/Novo_Ventures>,
        <https://1145.am/db/2353608/Novo_Ventures>,
        <https://1145.am/db/2354296/Novo_Ventures>,
        <https://1145.am/db/2354899/Novo_Ventures>,
        <https://1145.am/db/2354903/Novo_Ventures>,
        <https://1145.am/db/2356124/Novo_Ventures>,
        <https://1145.am/db/2358496/Novo_Ventures>,
        <https://1145.am/db/2358502/Novo_Ventures>,
        <https://1145.am/db/2361065/Novo_Ventures>,
        <https://1145.am/db/2362533/Novo_Ventures>,
        <https://1145.am/db/2363510/Novo_Ventures>,
        <https://1145.am/db/2365103/Novo_Ventures>,
        <https://1145.am/db/2370694/Novo_Ventures>,
        <https://1145.am/db/2371165/Novo_Ventures>,
        <https://1145.am/db/2371166/Novo_Ventures>,
        <https://1145.am/db/2570481/Novo_Ventures>,
        <https://1145.am/db/2570483/Novo_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352508/Sevin_Rosen_Funds_Ventures_West> a org:Organization ;
    ns1:basedInLowRaw "BOTHELL, Wash",
        "BOTHELL, Wash." ;
    ns1:description "Investing",
        "venture capital" ;
    ns1:documentDate "2012-04-19T12:23:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alder-biopharmaceuticals-inc-closes-38-million-series-d-financing-to-accelerate-clinical> ;
    ns1:foundName "Sevin Rosen Funds",
        "Sevin Rosen Funds, Ventures West",
        "Ventures West" ;
    ns1:investor <https://1145.am/db/2352508/Series_D_Investment_Alder_Biopharmaceuticals_Inc_Novo_Ventures_Sevin_Rosen_Funds_Ventures_West_Sevin_Rosen_Funds_Ventures_West_Wrf_Capital_Hig_Ventures_Completed> ;
    ns1:name "Sevin Rosen Funds",
        "Sevin Rosen Funds, Ventures West",
        "Ventures West" ;
    ns1:sameAsHigh <https://1145.am/db/1234126/Cemex_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352508/Tpg_Biotech> a org:Organization ;
    ns1:basedInLowRaw "BOTHELL, Wash" ;
    ns1:documentDate "2012-04-19T12:23:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alder-biopharmaceuticals-inc-closes-38-million-series-d-financing-to-accelerate-clinical> ;
    ns1:foundName "TPG Biotech" ;
    ns1:investor <https://1145.am/db/2352508/Series_D_Investment_Alder_Biopharmaceuticals_Inc_Novo_Ventures_Sevin_Rosen_Funds_Ventures_West_Sevin_Rosen_Funds_Ventures_West_Wrf_Capital_Hig_Ventures_Completed> ;
    ns1:name "TPG Biotech" ;
    ns1:sameAsMedium <https://1145.am/db/1863540/Tpg_Biotech>,
        <https://1145.am/db/1867543/Tpg_Biotech>,
        <https://1145.am/db/2299423/Tpg_Biotech>,
        <https://1145.am/db/2300337/Tpg_Biotech>,
        <https://1145.am/db/2302333/Tpg_Biotech>,
        <https://1145.am/db/2308700/Tpg_Biotech>,
        <https://1145.am/db/2336221/Tpg_Biotech>,
        <https://1145.am/db/2342557/Tpg_Biotech>,
        <https://1145.am/db/2342558/Tpg_Biotech>,
        <https://1145.am/db/2342724/Tpg_Biotech>,
        <https://1145.am/db/2344678/Tpg_Biotech>,
        <https://1145.am/db/2350044/Tpg_Biotech>,
        <https://1145.am/db/2351897/Tpg_Biotech>,
        <https://1145.am/db/2353588/Tpg_Biotech>,
        <https://1145.am/db/2353608/Tpg_Biotech>,
        <https://1145.am/db/2353771/Tpg_Biotech>,
        <https://1145.am/db/2353789/Tpg_Biotech>,
        <https://1145.am/db/2354537/Tpg_Biotech>,
        <https://1145.am/db/2354899/Tpg_Biotech>,
        <https://1145.am/db/2354903/Tpg_Biotech>,
        <https://1145.am/db/2358515/Tpg_Biotech>,
        <https://1145.am/db/2358888/Tpg_Biotech>,
        <https://1145.am/db/2359562/Tpg_Biotech>,
        <https://1145.am/db/2362457/Tpg_Biotech>,
        <https://1145.am/db/2364035/Tpg_Biotech>,
        <https://1145.am/db/2365868/Tpg_Biotech>,
        <https://1145.am/db/2368351/Tpg_Biotech>,
        <https://1145.am/db/316299/Tpg_Biotech> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352508/Wrf_Capital_Hig_Ventures> a org:Organization ;
    ns1:basedInLowRaw "BOTHELL, Wash" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-04-19T12:23:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alder-biopharmaceuticals-inc-closes-38-million-series-d-financing-to-accelerate-clinical> ;
    ns1:foundName "H.I.G. Ventures",
        "WRF Capital",
        "WRF Capital, H.I.G.",
        "WRF Capital, H.I.G. Ventures" ;
    ns1:investor <https://1145.am/db/2352508/Series_D_Investment_Alder_Biopharmaceuticals_Inc_Novo_Ventures_Sevin_Rosen_Funds_Ventures_West_Sevin_Rosen_Funds_Ventures_West_Wrf_Capital_Hig_Ventures_Completed> ;
    ns1:name "H.I.G. Ventures",
        "WRF Capital",
        "WRF Capital, H.I.G. Ventures" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352525/Astrazeneca> a org:Organization ;
    ns1:basedInLowRaw "Sweden" ;
    ns1:buyer <https://1145.am/db/2352525/Ardea_Biosciences_Acquisition> ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-04-23T12:05:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout" ;
    ns1:documentURL <https://www.fiercebiotech.com/financials/astrazeneca-to-acquire-ardea-biosciences-for-1-26-billion-including-lead-product> ;
    ns1:foundName "AstraZeneca" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "AstraZeneca" ;
    ns1:sameAsHigh <https://1145.am/db/1022806/Antares_Pharma>,
        <https://1145.am/db/1026859/Antares_Pharma>,
        <https://1145.am/db/1079444/Ascendis_Pharma_A_S>,
        <https://1145.am/db/1307202/Leo_Pharma>,
        <https://1145.am/db/1392122/Astrazeneca>,
        <https://1145.am/db/1633177/Astrazeneca>,
        <https://1145.am/db/171176/Astrazeneca>,
        <https://1145.am/db/172070/Astrazeneca>,
        <https://1145.am/db/173169/Astrazeneca>,
        <https://1145.am/db/1988637/Astellas_Pharma_Inc>,
        <https://1145.am/db/2010010/Astellas_Pharma_Inc>,
        <https://1145.am/db/2038202/Astellas_Pharma_Inc>,
        <https://1145.am/db/2039692/Rk_Pharma_Inc>,
        <https://1145.am/db/2071435/Astrazeneca>,
        <https://1145.am/db/2151794/Astrazeneca>,
        <https://1145.am/db/2154218/Astrazeneca>,
        <https://1145.am/db/2154845/Astellas_Pharma>,
        <https://1145.am/db/2201236/Astrazeneca>,
        <https://1145.am/db/2278880/Astrazeneca>,
        <https://1145.am/db/2279647/Astrazeneca>,
        <https://1145.am/db/2280668/Astrazeneca>,
        <https://1145.am/db/2282580/Astrazeneca>,
        <https://1145.am/db/2282957/Astrazeneca>,
        <https://1145.am/db/2283156/Astrazeneca>,
        <https://1145.am/db/2284338/Astrazeneca>,
        <https://1145.am/db/2285828/Astrazeneca>,
        <https://1145.am/db/2287488/Astrazeneca>,
        <https://1145.am/db/2290060/Astrazeneca>,
        <https://1145.am/db/2291200/Astellas_Pharma>,
        <https://1145.am/db/2292385/Astellas_Pharma>,
        <https://1145.am/db/2293132/Astrazeneca>,
        <https://1145.am/db/2299349/Astrazeneca>,
        <https://1145.am/db/2300810/Ea_Pharma>,
        <https://1145.am/db/2302117/Aton_Pharma>,
        <https://1145.am/db/2302618/Astellas_Pharma_Inc>,
        <https://1145.am/db/2303415/Astellas_Pharma>,
        <https://1145.am/db/2303920/Astrazeneca>,
        <https://1145.am/db/2304902/Astellas_Pharma>,
        <https://1145.am/db/2305152/Astrazeneca>,
        <https://1145.am/db/2305155/Astrazeneca>,
        <https://1145.am/db/2305866/Astrazeneca>,
        <https://1145.am/db/2306464/Asterand>,
        <https://1145.am/db/2306640/Leo_Pharma>,
        <https://1145.am/db/2306641/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2306905/Astrazeneca>,
        <https://1145.am/db/2307059/Astrazeneca>,
        <https://1145.am/db/2307068/Astrazeneca>,
        <https://1145.am/db/2307834/Astrazeneca>,
        <https://1145.am/db/2309183/Astrazeneca>,
        <https://1145.am/db/2310968/Astellas_Pharma_Inc>,
        <https://1145.am/db/2312088/Astellas_Pharma>,
        <https://1145.am/db/2312476/Astrazeneca>,
        <https://1145.am/db/2313501/Bioalliance_Pharma>,
        <https://1145.am/db/2314217/Alliant_Pharmaceuticals>,
        <https://1145.am/db/2318484/Astrazeneca>,
        <https://1145.am/db/2318485/Astrazeneca>,
        <https://1145.am/db/2318609/Astrazeneca>,
        <https://1145.am/db/2319111/Astellas_Pharma>,
        <https://1145.am/db/2319208/Astellas_Pharma>,
        <https://1145.am/db/2319211/Astellas_Pharma_Inc>,
        <https://1145.am/db/2319675/Astrazeneca>,
        <https://1145.am/db/2321861/Astion_Pharma>,
        <https://1145.am/db/2325196/Astellas_Pharma_Inc>,
        <https://1145.am/db/2327304/Astellas_Pharma_Inc>,
        <https://1145.am/db/2328825/Ascendis_Pharma>,
        <https://1145.am/db/2331796/Astellas_Pharma_Inc>,
        <https://1145.am/db/2334131/Astrazeneca>,
        <https://1145.am/db/2335717/Astrazeneca>,
        <https://1145.am/db/2336050/Astrazeneca>,
        <https://1145.am/db/2338888/Cerulean_Pharma>,
        <https://1145.am/db/2339206/Astrazeneca>,
        <https://1145.am/db/2342367/Astellas_Pharma>,
        <https://1145.am/db/2342687/Bioalliance_Pharma>,
        <https://1145.am/db/2342722/Astrazeneca>,
        <https://1145.am/db/2342996/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2343568/Ascendis_Pharma_A_S>,
        <https://1145.am/db/2343632/Astrazeneca>,
        <https://1145.am/db/2343892/Astrazeneca>,
        <https://1145.am/db/2343913/Astrazeneca>,
        <https://1145.am/db/2343920/Astrazeneca>,
        <https://1145.am/db/2344057/Astrazeneca>,
        <https://1145.am/db/2345187/Astrazeneca>,
        <https://1145.am/db/2345375/Astex_Pharmaceuticals_Inc>,
        <https://1145.am/db/2345426/Astrazeneca>,
        <https://1145.am/db/2345774/Aton_Pharma>,
        <https://1145.am/db/2345983/Astrazeneca>,
        <https://1145.am/db/2345996/Astrazeneca>,
        <https://1145.am/db/2347755/Leo_Pharma_Inc>,
        <https://1145.am/db/2347800/Astrazeneca>,
        <https://1145.am/db/2347970/Astrazeneca>,
        <https://1145.am/db/2347971/Astrazeneca>,
        <https://1145.am/db/2348851/Ascendis_Pharma>,
        <https://1145.am/db/2350134/Astellas_Pharma_Inc>,
        <https://1145.am/db/2352037/Alexion_Pharma>,
        <https://1145.am/db/2352067/Astrazeneca>,
        <https://1145.am/db/2352166/Acumen_Pharmaceuticals>,
        <https://1145.am/db/2352532/Astrazeneca>,
        <https://1145.am/db/2352716/Astrazeneca>,
        <https://1145.am/db/2353153/Astrazeneca>,
        <https://1145.am/db/2353550/Astrazeneca>,
        <https://1145.am/db/2353551/Astrazeneca>,
        <https://1145.am/db/2353753/Astrazeneca>,
        <https://1145.am/db/2354064/Astellas_Pharma_Inc>,
        <https://1145.am/db/2354086/Astellas_Pharma_Inc>,
        <https://1145.am/db/2354978/Astrazeneca>,
        <https://1145.am/db/2355029/Astrazeneca>,
        <https://1145.am/db/2356384/Astrazeneca>,
        <https://1145.am/db/2356965/Astellas_Pharma_Inc>,
        <https://1145.am/db/2357230/Astrazeneca>,
        <https://1145.am/db/2357962/Astellas_Pharma>,
        <https://1145.am/db/2358193/Astellas_Pharma_Inc>,
        <https://1145.am/db/2358734/Astellas_Pharma_Inc>,
        <https://1145.am/db/2358768/Astrazeneca>,
        <https://1145.am/db/2359437/Astrazeneca>,
        <https://1145.am/db/2359439/Astrazeneca>,
        <https://1145.am/db/2359539/Astrazeneca>,
        <https://1145.am/db/2359745/Astellas_Pharma>,
        <https://1145.am/db/2360237/Astrazeneca>,
        <https://1145.am/db/2360371/Astellas_Pharma>,
        <https://1145.am/db/2360562/Astrazeneca>,
        <https://1145.am/db/2360683/Astrazeneca>,
        <https://1145.am/db/2362425/Astellas_Pharma_Inc>,
        <https://1145.am/db/2362667/Astrazeneca>,
        <https://1145.am/db/2362670/Astrazeneca>,
        <https://1145.am/db/2362966/Astrazeneca>,
        <https://1145.am/db/2363405/Astrazeneca>,
        <https://1145.am/db/2364184/Astex_Pharmaceuticals>,
        <https://1145.am/db/2364191/Astex_Pharmaceuticals_Inc>,
        <https://1145.am/db/2364805/Astrazeneca>,
        <https://1145.am/db/2365403/Astrazeneca>,
        <https://1145.am/db/2366678/Astellas_Pharma_Inc>,
        <https://1145.am/db/2367645/Astrazeneca>,
        <https://1145.am/db/2367646/Astrazeneca>,
        <https://1145.am/db/2367730/Astellas_Pharma_Inc>,
        <https://1145.am/db/2367731/Astellas_Pharma>,
        <https://1145.am/db/2368632/Astrazeneca>,
        <https://1145.am/db/2368654/Astellas_Pharma>,
        <https://1145.am/db/2368742/Astrazeneca>,
        <https://1145.am/db/2368900/Astrazeneca>,
        <https://1145.am/db/2369491/Astrazeneca>,
        <https://1145.am/db/2369493/Astrazeneca>,
        <https://1145.am/db/2369520/Astellas_Pharma_Inc>,
        <https://1145.am/db/2369607/Astrazeneca>,
        <https://1145.am/db/2370029/Astellas_Pharma_Inc>,
        <https://1145.am/db/2370041/Astellas_Pharma_Inc>,
        <https://1145.am/db/2370174/Astrazeneca>,
        <https://1145.am/db/2370175/Astrazeneca>,
        <https://1145.am/db/2370274/Ascendis_Pharma_A_S>,
        <https://1145.am/db/2370409/Astellas_Pharma>,
        <https://1145.am/db/2371094/Astrazeneca>,
        <https://1145.am/db/2537410/Astrazeneca>,
        <https://1145.am/db/2538238/Astrazeneca>,
        <https://1145.am/db/2538239/Astrazeneca>,
        <https://1145.am/db/2538821/Astrazeneca>,
        <https://1145.am/db/2539508/Astrazeneca>,
        <https://1145.am/db/2539509/Astrazeneca>,
        <https://1145.am/db/2539517/Astrazeneca>,
        <https://1145.am/db/2540845/Astrazeneca>,
        <https://1145.am/db/2543372/Astellas_Pharma>,
        <https://1145.am/db/2543375/Astellas_Pharma_Inc>,
        <https://1145.am/db/2543378/Astellas_Pharma>,
        <https://1145.am/db/2544077/Astrazeneca>,
        <https://1145.am/db/2544536/Astrazeneca>,
        <https://1145.am/db/2545023/Astrazeneca>,
        <https://1145.am/db/2545125/Ascendis_Health>,
        <https://1145.am/db/2545184/Astrazeneca>,
        <https://1145.am/db/2545426/Astrazeneca>,
        <https://1145.am/db/2545610/Astellas_Pharma>,
        <https://1145.am/db/2546143/Astrazeneca>,
        <https://1145.am/db/2546314/Astrazeneca>,
        <https://1145.am/db/2547386/Astrazeneca>,
        <https://1145.am/db/2547785/Astrazeneca>,
        <https://1145.am/db/2548384/Astrazeneca>,
        <https://1145.am/db/2549670/Astellas_Pharma>,
        <https://1145.am/db/2549890/Astrazeneca>,
        <https://1145.am/db/2550962/Astrazeneca>,
        <https://1145.am/db/2551557/Aslan_Pharmaceuticals>,
        <https://1145.am/db/2553162/Astrazeneca>,
        <https://1145.am/db/2553168/Astrazeneca>,
        <https://1145.am/db/2553619/Astellas_Pharma>,
        <https://1145.am/db/2554064/Astrazeneca>,
        <https://1145.am/db/2554933/Astrazeneca>,
        <https://1145.am/db/2555142/Astrazeneca>,
        <https://1145.am/db/2556522/Astrazeneca>,
        <https://1145.am/db/2556536/Astrazeneca>,
        <https://1145.am/db/2556928/Astrazeneca>,
        <https://1145.am/db/2556979/Dream_Pharma>,
        <https://1145.am/db/2557406/Astrazeneca>,
        <https://1145.am/db/2558118/Astrazeneca>,
        <https://1145.am/db/2558133/Astellas_Pharma>,
        <https://1145.am/db/2559469/Astrazeneca>,
        <https://1145.am/db/2560865/Astellas_Pharma>,
        <https://1145.am/db/2561319/Astrazeneca>,
        <https://1145.am/db/2562249/Astrazeneca>,
        <https://1145.am/db/2563422/Astellas_Pharma>,
        <https://1145.am/db/2566037/Astrazeneca>,
        <https://1145.am/db/2566038/Astellas_Pharma>,
        <https://1145.am/db/2566415/Astrazeneca>,
        <https://1145.am/db/2566926/Astrazeneca>,
        <https://1145.am/db/2566929/Astrazeneca>,
        <https://1145.am/db/2567518/Astrazeneca>,
        <https://1145.am/db/2568895/Astrazeneca>,
        <https://1145.am/db/2569075/Astrazeneca_Plc>,
        <https://1145.am/db/2569356/Leo_Pharma_Inc>,
        <https://1145.am/db/2569709/Astrazeneca>,
        <https://1145.am/db/2570586/Astrazeneca>,
        <https://1145.am/db/2570592/Astrazeneca>,
        <https://1145.am/db/257192/Astrazeneca_Plc>,
        <https://1145.am/db/2572938/Astrazeneca>,
        <https://1145.am/db/2573339/Astellas_Pharma>,
        <https://1145.am/db/2573463/Astrazeneca>,
        <https://1145.am/db/2573978/Astrazeneca>,
        <https://1145.am/db/2573984/Astrazeneca>,
        <https://1145.am/db/2574096/Astrazeneca>,
        <https://1145.am/db/2575176/Astrazeneca>,
        <https://1145.am/db/2575183/Astrazeneca>,
        <https://1145.am/db/2575270/Astrazeneca>,
        <https://1145.am/db/257625/Astrazeneca_Plc>,
        <https://1145.am/db/2576923/Pharmgate>,
        <https://1145.am/db/2577419/Astellas_Pharma>,
        <https://1145.am/db/2577797/Astrazeneca>,
        <https://1145.am/db/2578213/Astrazeneca>,
        <https://1145.am/db/2578454/Astrazeneca>,
        <https://1145.am/db/2579507/Astrazeneca>,
        <https://1145.am/db/2579630/Astrazeneca>,
        <https://1145.am/db/2580038/Astrazeneca>,
        <https://1145.am/db/2580053/Astrazeneca>,
        <https://1145.am/db/2580491/Astrazeneca>,
        <https://1145.am/db/2580556/Astrazeneca>,
        <https://1145.am/db/2580632/Astrazeneca>,
        <https://1145.am/db/2580642/Astrazeneca>,
        <https://1145.am/db/2582242/Astrazeneca>,
        <https://1145.am/db/2583124/Astrazeneca>,
        <https://1145.am/db/2583402/Astellas_Pharma>,
        <https://1145.am/db/2585819/Astrazeneca>,
        <https://1145.am/db/2585861/Astrazeneca_Kk>,
        <https://1145.am/db/2586257/Astrazeneca>,
        <https://1145.am/db/2587500/Astrazeneca>,
        <https://1145.am/db/2588049/Astrazeneca>,
        <https://1145.am/db/2588660/Astrazeneca>,
        <https://1145.am/db/2590009/Astrazeneca>,
        <https://1145.am/db/2590159/Astellas_Pharma_Inc>,
        <https://1145.am/db/2591384/Astrazeneca>,
        <https://1145.am/db/2591652/Astrazeneca>,
        <https://1145.am/db/2591691/Astrazeneca>,
        <https://1145.am/db/2592696/Alliance_Pharma>,
        <https://1145.am/db/2592696/Astrazeneca>,
        <https://1145.am/db/2593265/Astrazeneca>,
        <https://1145.am/db/2594107/Astrazeneca>,
        <https://1145.am/db/2594183/Astex_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594184/Astex_Pharmaceuticals>,
        <https://1145.am/db/2594365/Astrazeneca>,
        <https://1145.am/db/2594602/Astellas_Pharma>,
        <https://1145.am/db/2595368/Astellas_Pharma>,
        <https://1145.am/db/2595413/Astellas_Pharma_Inc>,
        <https://1145.am/db/2595981/Astrazeneca>,
        <https://1145.am/db/2596046/Astrazeneca>,
        <https://1145.am/db/2596053/Astrazeneca>,
        <https://1145.am/db/2596838/Astex_Pharmaceuticals>,
        <https://1145.am/db/2597175/Astrazeneca>,
        <https://1145.am/db/2597935/Astellas_Pharma>,
        <https://1145.am/db/2598202/Astrazeneca>,
        <https://1145.am/db/2789987/Astrazeneca>,
        <https://1145.am/db/340451/Astrazeneca>,
        <https://1145.am/db/340474/Astrazeneca>,
        <https://1145.am/db/347044/Astrazeneca>,
        <https://1145.am/db/381681/Astrazeneca_Plc>,
        <https://1145.am/db/441284/Bryn_Pharma>,
        <https://1145.am/db/488413/Astrazeneca>,
        <https://1145.am/db/510316/Astrazeneca>,
        <https://1145.am/db/624169/Astrazeneca> ;
    ns1:sameAsMedium <https://1145.am/db/1180597/Astrazeneca>,
        <https://1145.am/db/1241325/Astrazeneca>,
        <https://1145.am/db/1536697/Astrazeneca>,
        <https://1145.am/db/1539672/Astrazeneca>,
        <https://1145.am/db/1627652/Astrazeneca>,
        <https://1145.am/db/2041475/Astrazeneca>,
        <https://1145.am/db/2280289/Astrazeneca>,
        <https://1145.am/db/2282916/Astrazeneca>,
        <https://1145.am/db/2283309/Astrazeneca>,
        <https://1145.am/db/2290860/Astrazeneca>,
        <https://1145.am/db/2291860/Astrazeneca>,
        <https://1145.am/db/2294263/Astrazeneca>,
        <https://1145.am/db/2296196/Astrazeneca>,
        <https://1145.am/db/2305826/Astrazeneca>,
        <https://1145.am/db/2307913/Astrazeneca>,
        <https://1145.am/db/2315716/Astrazeneca>,
        <https://1145.am/db/2316364/Astrazeneca>,
        <https://1145.am/db/2329585/Astrazeneca>,
        <https://1145.am/db/2331622/Astrazeneca>,
        <https://1145.am/db/2335286/Astrazeneca>,
        <https://1145.am/db/2340097/Astrazeneca>,
        <https://1145.am/db/2342213/Astrazeneca>,
        <https://1145.am/db/2354112/Astrazeneca>,
        <https://1145.am/db/2354774/Astrazeneca>,
        <https://1145.am/db/2354998/Astrazeneca>,
        <https://1145.am/db/2356098/Astrazeneca>,
        <https://1145.am/db/2358228/Astrazeneca>,
        <https://1145.am/db/252780/Astrazeneca>,
        <https://1145.am/db/2539787/Astrazeneca>,
        <https://1145.am/db/2544701/Astrazeneca>,
        <https://1145.am/db/2545769/Astrazeneca>,
        <https://1145.am/db/2554571/Astrazeneca>,
        <https://1145.am/db/2555141/Astrazeneca>,
        <https://1145.am/db/2559649/Astrazeneca>,
        <https://1145.am/db/2562728/Astrazeneca>,
        <https://1145.am/db/2564897/Astrazeneca>,
        <https://1145.am/db/2565399/Astrazeneca>,
        <https://1145.am/db/2565682/Astrazeneca>,
        <https://1145.am/db/2565951/Astrazeneca>,
        <https://1145.am/db/2575269/Astrazeneca>,
        <https://1145.am/db/2582823/Astrazeneca>,
        <https://1145.am/db/2582826/Astrazeneca>,
        <https://1145.am/db/2588089/Astrazeneca>,
        <https://1145.am/db/376382/Astrazeneca> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353522/Aurora_Funds> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:description "Series D financing" ;
    ns1:documentDate "2012-04-24T14:18:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/argos-therapeutics-secures-25-million-series-d-financing-to-commence-phase-3-adapt-study> ;
    ns1:foundName "Aurora Funds" ;
    ns1:investor <https://1145.am/db/2353522/Series_D_Investment_Argos_Therapeutics_Inc_Aurora_Funds_Forbion_Capital_Intersouth_Partners_Caisse_De_Depot_Et_Placement_Du_Quebec_Lumira_Capital_Morningside_Group_Tvm_Capital_Completed> ;
    ns1:name "Aurora Funds" ;
    ns1:sameAsHigh <https://1145.am/db/2303642/Aurora_Funds> ;
    ns1:sameAsMedium <https://1145.am/db/2303641/Aurora_Funds>,
        <https://1145.am/db/2309809/Aurora_Funds>,
        <https://1145.am/db/2328655/Aurora_Funds>,
        <https://1145.am/db/2344356/Aurora_Funds>,
        <https://1145.am/db/2347977/Aurora_Funds>,
        <https://1145.am/db/2347983/Aurora_Funds>,
        <https://1145.am/db/2353525/Aurora_Funds>,
        <https://1145.am/db/2358541/Aurora_Funds> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353522/Forbion_Capital> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:documentDate "2012-04-24T14:18:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/argos-therapeutics-secures-25-million-series-d-financing-to-commence-phase-3-adapt-study> ;
    ns1:foundName "Forbion Capital" ;
    ns1:investor <https://1145.am/db/2353522/Series_D_Investment_Argos_Therapeutics_Inc_Aurora_Funds_Forbion_Capital_Intersouth_Partners_Caisse_De_Depot_Et_Placement_Du_Quebec_Lumira_Capital_Morningside_Group_Tvm_Capital_Completed> ;
    ns1:name "Forbion Capital" ;
    ns1:sameAsMedium <https://1145.am/db/2347977/Forbion_Capital>,
        <https://1145.am/db/2347983/Forbion_Capital>,
        <https://1145.am/db/2353525/Forbion_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353522/Intersouth_Partners_Caisse_De_Depot_Et_Placement_Du_Quebec> a org:Organization ;
    ns1:basedInLowRaw "Canada",
        "U.S." ;
    ns1:description "Series D financing" ;
    ns1:documentDate "2012-04-24T14:18:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/argos-therapeutics-secures-25-million-series-d-financing-to-commence-phase-3-adapt-study> ;
    ns1:foundName "Caisse de depot et placement du Quebec",
        "Intersouth Partners",
        "Intersouth Partners, Caisse de depot et placement du Quebec" ;
    ns1:investor <https://1145.am/db/2353522/Series_D_Investment_Argos_Therapeutics_Inc_Aurora_Funds_Forbion_Capital_Intersouth_Partners_Caisse_De_Depot_Et_Placement_Du_Quebec_Lumira_Capital_Morningside_Group_Tvm_Capital_Completed> ;
    ns1:name "Caisse de depot et placement du Quebec",
        "Intersouth Partners",
        "Intersouth Partners, Caisse de depot et placement du Quebec" ;
    ns1:sameAsMedium <https://1145.am/db/2347977/Intersouth_Partners_Caisse_De_Depot_Et_Placement_De_Quebec> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353522/Lumira_Capital> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:documentDate "2012-04-24T14:18:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/argos-therapeutics-secures-25-million-series-d-financing-to-commence-phase-3-adapt-study> ;
    ns1:foundName "Lumira Capital" ;
    ns1:investor <https://1145.am/db/2353522/Series_D_Investment_Argos_Therapeutics_Inc_Aurora_Funds_Forbion_Capital_Intersouth_Partners_Caisse_De_Depot_Et_Placement_Du_Quebec_Lumira_Capital_Morningside_Group_Tvm_Capital_Completed> ;
    ns1:name "Lumira Capital" ;
    ns1:sameAsMedium <https://1145.am/db/2298869/Lumira_Capital>,
        <https://1145.am/db/2300233/Lumira_Capital>,
        <https://1145.am/db/2341904/Lumira_Capital>,
        <https://1145.am/db/2347977/Lumira_Capital>,
        <https://1145.am/db/2347983/Lumira_Capital>,
        <https://1145.am/db/2359637/Lumira_Capital>,
        <https://1145.am/db/2360317/Lumira_Capital>,
        <https://1145.am/db/2363442/Lumira_Capital>,
        <https://1145.am/db/2369027/Lumira_Capital>,
        <https://1145.am/db/2572436/Lumira_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353522/Morningside_Group> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:documentDate "2012-04-24T14:18:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/argos-therapeutics-secures-25-million-series-d-financing-to-commence-phase-3-adapt-study> ;
    ns1:foundName "Morningside Group" ;
    ns1:investor <https://1145.am/db/2353522/Series_D_Investment_Argos_Therapeutics_Inc_Aurora_Funds_Forbion_Capital_Intersouth_Partners_Caisse_De_Depot_Et_Placement_Du_Quebec_Lumira_Capital_Morningside_Group_Tvm_Capital_Completed> ;
    ns1:name "Morningside Group" ;
    ns1:sameAsMedium <https://1145.am/db/1739611/Morningside_Group>,
        <https://1145.am/db/1855817/Morningside_Group>,
        <https://1145.am/db/2190702/Morningside_Group>,
        <https://1145.am/db/2292616/Morningside_Group>,
        <https://1145.am/db/2325366/Morningside_Group>,
        <https://1145.am/db/2339427/Morningside_Groups>,
        <https://1145.am/db/2339428/Morningside_Groups>,
        <https://1145.am/db/2346532/Morningside_Group>,
        <https://1145.am/db/2346542/Morningside_Group>,
        <https://1145.am/db/2346972/Morningside_Group>,
        <https://1145.am/db/2346973/Morningside_Group>,
        <https://1145.am/db/2347977/Morningside_Group>,
        <https://1145.am/db/2347983/Morningside_Group>,
        <https://1145.am/db/2353525/Morningside_Group>,
        <https://1145.am/db/531354/Morningside_Group>,
        <https://1145.am/db/719976/Morningside_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353522/Tvm_Capital> a org:Organization ;
    ns1:basedInLowRaw "U.S." ;
    ns1:description "Series D financing" ;
    ns1:documentDate "2012-04-24T14:18:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/argos-therapeutics-secures-25-million-series-d-financing-to-commence-phase-3-adapt-study> ;
    ns1:foundName "TVM Capital" ;
    ns1:investor <https://1145.am/db/2353522/Series_D_Investment_Argos_Therapeutics_Inc_Aurora_Funds_Forbion_Capital_Intersouth_Partners_Caisse_De_Depot_Et_Placement_Du_Quebec_Lumira_Capital_Morningside_Group_Tvm_Capital_Completed> ;
    ns1:name "TVM Capital" ;
    ns1:sameAsHigh <https://1145.am/db/2289349/Tvm_Capital>,
        <https://1145.am/db/2336126/Tvm_Capital>,
        <https://1145.am/db/2347983/Tvm_Capital>,
        <https://1145.am/db/2353525/Tvm_Capital>,
        <https://1145.am/db/2358268/Tvm_Capital>,
        <https://1145.am/db/2564563/Tvm_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1919300/Tvm_Capital>,
        <https://1145.am/db/2298846/Tvm_Capital>,
        <https://1145.am/db/2303598/Tvm_Capital>,
        <https://1145.am/db/2314674/Tvm_Capital>,
        <https://1145.am/db/2317779/Tvm_Capital>,
        <https://1145.am/db/2322531/Tvm_Capital>,
        <https://1145.am/db/2323243/Tvm_Capital>,
        <https://1145.am/db/2325366/Tvm_Capital>,
        <https://1145.am/db/2326376/Tvm_Capital>,
        <https://1145.am/db/2327406/Tvm_Capital>,
        <https://1145.am/db/2347977/Tvm_Capital>,
        <https://1145.am/db/2352814/Tvm_Capital>,
        <https://1145.am/db/2352819/Tvm_Capital>,
        <https://1145.am/db/2352820/Tvm_Capital>,
        <https://1145.am/db/2353607/Tvm_Capital>,
        <https://1145.am/db/2353610/Tvm_Capital>,
        <https://1145.am/db/2358269/Tvm_Capital>,
        <https://1145.am/db/2365103/Tvm_Capital>,
        <https://1145.am/db/2366539/Tvm_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353524/Boulder_Ventures_Ltd> a org:Organization ;
    ns1:basedInHighGeoName "Boulder County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5574999/about.rdf> ;
    ns1:basedInHighRaw "BOULDER" ;
    ns1:documentDate "2012-04-24T14:20:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "miRagen Therapeutics Secures $20 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/miragen-therapeutics-secures-20-million-series-b-financing> ;
    ns1:foundName "Boulder Ventures Ltd." ;
    ns1:investor <https://1145.am/db/2353524/Series_B_Investment_Amgen_Ventures_Atlas_Venture_Boulder_Ventures_Ltd_Broadview_Ventures_Miragen_Therapeutics_Miragen_Therapeutics_Remeditex_Ventures_Completed> ;
    ns1:name "Boulder Ventures Ltd." ;
    ns1:sameAsMedium <https://1145.am/db/1722151/Boulder_Ventures>,
        <https://1145.am/db/1762561/Boulder_Ventures>,
        <https://1145.am/db/1831452/Boulder_Ventures>,
        <https://1145.am/db/2152752/Boulder_Ventures>,
        <https://1145.am/db/2330852/Boulder_Ventures>,
        <https://1145.am/db/2331870/Boulder_Ventures_Ltd>,
        <https://1145.am/db/2353525/Boulder_Ventures_Ltd>,
        <https://1145.am/db/2367740/Boulder_Ventures>,
        <https://1145.am/db/405209/Boulder_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353524/Broadview_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Colo" ;
    ns1:documentDate "2012-04-24T14:20:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "miRagen Therapeutics Secures $20 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/miragen-therapeutics-secures-20-million-series-b-financing> ;
    ns1:foundName "Broadview Ventures" ;
    ns1:investor <https://1145.am/db/2353524/Series_B_Investment_Amgen_Ventures_Atlas_Venture_Boulder_Ventures_Ltd_Broadview_Ventures_Miragen_Therapeutics_Miragen_Therapeutics_Remeditex_Ventures_Completed> ;
    ns1:name "Broadview Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1335370/Broadview_Ventures>,
        <https://1145.am/db/1528484/Broadview_Ventures>,
        <https://1145.am/db/1565424/Broadview_Ventures>,
        <https://1145.am/db/2284028/Broadview_Ventures>,
        <https://1145.am/db/2284454/Broadview_Ventures>,
        <https://1145.am/db/2353525/Broadview_Ventures>,
        <https://1145.am/db/2353974/Broadview_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353524/Remeditex_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "Boulder County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5574999/about.rdf> ;
    ns1:basedInHighRaw "BOULDER" ;
    ns1:documentDate "2012-04-24T14:20:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "miRagen Therapeutics Secures $20 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/miragen-therapeutics-secures-20-million-series-b-financing> ;
    ns1:foundName "Remeditex Ventures, LLC" ;
    ns1:investor <https://1145.am/db/2353524/Series_B_Investment_Amgen_Ventures_Atlas_Venture_Boulder_Ventures_Ltd_Broadview_Ventures_Miragen_Therapeutics_Miragen_Therapeutics_Remeditex_Ventures_Completed> ;
    ns1:name "Remeditex Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2296606/Remeditex_Ventures>,
        <https://1145.am/db/2342752/Remeditex_Ventures>,
        <https://1145.am/db/2344204/Remeditex_Ventures>,
        <https://1145.am/db/2353525/Remeditex_Ventures>,
        <https://1145.am/db/2365363/Remeditex_Ventures>,
        <https://1145.am/db/2367740/Remeditex_Ventures>,
        <https://1145.am/db/2370945/Remeditex_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354608/Flagship_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Cambridge, MA" ;
    ns1:documentDate "2012-05-08T10:07:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing- Company to Advance its lead Drug Candidate, EBI-005, into Clinic Development for Dry Eye Disease -" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/eleven-biotherapeutics-secures-20-million-and-expands-series-a-financing-company-to-advance> ;
    ns1:foundName "Flagship Ventures" ;
    ns1:investor <https://1145.am/db/2354608/Series_A_Investment_Eleven_Biotherapeutics_Flagship_Ventures_Jafco_Third_Rock_Ventures_Completed> ;
    ns1:name "Flagship Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2288209/Flagship_Ventures>,
        <https://1145.am/db/2292800/Flagship_Ventures>,
        <https://1145.am/db/2298439/Flagship_Ventures>,
        <https://1145.am/db/2302116/Flagship_Ventures>,
        <https://1145.am/db/2304650/Flagship_Ventures>,
        <https://1145.am/db/2306790/Flagship_Ventures>,
        <https://1145.am/db/2308952/Flagship_Ventures>,
        <https://1145.am/db/2308959/Flagship_Ventures>,
        <https://1145.am/db/2313305/Flagship_Ventures>,
        <https://1145.am/db/2314964/Flagship_Ventures>,
        <https://1145.am/db/2315931/Flagship_Ventures>,
        <https://1145.am/db/2315933/Flagship_Ventures>,
        <https://1145.am/db/2317918/Flagship_Ventures>,
        <https://1145.am/db/2321150/Flagship_Ventures>,
        <https://1145.am/db/2324431/Flagship_Ventures>,
        <https://1145.am/db/2334847/Flagship_Ventures>,
        <https://1145.am/db/2339413/Flagship_Ventures>,
        <https://1145.am/db/2341599/Flagship_Ventures>,
        <https://1145.am/db/2343592/Flagship_Ventures>,
        <https://1145.am/db/2343595/Flagship_Ventures>,
        <https://1145.am/db/2346988/Flagship_Ventures>,
        <https://1145.am/db/2347102/Flagship_Ventures>,
        <https://1145.am/db/2348074/Flagship_Ventures>,
        <https://1145.am/db/2354351/Flagship_Ventures>,
        <https://1145.am/db/2354613/Flagship_Ventures>,
        <https://1145.am/db/2354806/Flagship_Ventures>,
        <https://1145.am/db/2356730/Flagship_Ventures>,
        <https://1145.am/db/2356732/Flagship_Ventures>,
        <https://1145.am/db/2358234/Flagship_Ventures>,
        <https://1145.am/db/2358487/Flagship_Ventures>,
        <https://1145.am/db/2358506/Flagship_Ventures>,
        <https://1145.am/db/2358529/Flagship_Ventures>,
        <https://1145.am/db/2359287/Flagship_Ventures>,
        <https://1145.am/db/2366654/Flagship_Ventures>,
        <https://1145.am/db/2367381/Flagship_Ventures>,
        <https://1145.am/db/2367588/Flagship_Ventures>,
        <https://1145.am/db/2368493/Flagship_Ventures>,
        <https://1145.am/db/2369549/Flagship_Ventures>,
        <https://1145.am/db/2634324/Flagship_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354608/Jafco> a org:Organization ;
    ns1:basedInLowRaw "Japan" ;
    ns1:documentDate "2012-05-08T10:07:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing- Company to Advance its lead Drug Candidate, EBI-005, into Clinic Development for Dry Eye Disease -" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/eleven-biotherapeutics-secures-20-million-and-expands-series-a-financing-company-to-advance> ;
    ns1:foundName "JAFCO Co., Ltd." ;
    ns1:investor <https://1145.am/db/2354608/Series_A_Investment_Eleven_Biotherapeutics_Flagship_Ventures_Jafco_Third_Rock_Ventures_Completed> ;
    ns1:name "JAFCO" ;
    ns1:sameAsMedium <https://1145.am/db/1010026/Jafco>,
        <https://1145.am/db/1719460/Jafco>,
        <https://1145.am/db/1752809/Jafco>,
        <https://1145.am/db/1797834/Jafco>,
        <https://1145.am/db/1821299/Jafco>,
        <https://1145.am/db/1872512/Jafco>,
        <https://1145.am/db/2055707/Jafco>,
        <https://1145.am/db/2312444/Jafco>,
        <https://1145.am/db/2316674/Jafco>,
        <https://1145.am/db/2317737/Jafco>,
        <https://1145.am/db/2326176/Jafco>,
        <https://1145.am/db/2330712/Jafco>,
        <https://1145.am/db/2330852/Jafco>,
        <https://1145.am/db/2331754/Jafco>,
        <https://1145.am/db/2350717/Jafco>,
        <https://1145.am/db/2354613/Jafco>,
        <https://1145.am/db/2366561/Jafco>,
        <https://1145.am/db/2551315/Jafco> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355586/Alta_Partners> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:documentDate "2012-05-08T13:06:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sutro Closes $16.5 Million Second Tranche of Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sutro-closes-16-5-million-second-tranche-of-series-c-financing> ;
    ns1:foundName "Alta Partners" ;
    ns1:investor <https://1145.am/db/2355586/Series_C_Investment_Alta_Partners_Amgen_Ventures_Lilly_Ventures_Sv_Life_Sciences_Skyline_Ventures_Sutro_Biopharma_Completed> ;
    ns1:name "Alta Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1156304/Alta_Partners>,
        <https://1145.am/db/1230022/Alta_Partners>,
        <https://1145.am/db/1333948/Altas_Partners>,
        <https://1145.am/db/1334727/Altas_Partners>,
        <https://1145.am/db/2303810/Alta_Partners>,
        <https://1145.am/db/2303814/Alta_Partners>,
        <https://1145.am/db/2304769/Alta_Partners>,
        <https://1145.am/db/2304870/Alta_Partners>,
        <https://1145.am/db/2305729/Alta_Partners>,
        <https://1145.am/db/2305745/Alta_Partners>,
        <https://1145.am/db/2306281/Alta_Partners>,
        <https://1145.am/db/2306568/Alta_Partners>,
        <https://1145.am/db/2307682/Alta_Partners>,
        <https://1145.am/db/2307691/Alta_Partners>,
        <https://1145.am/db/2307824/Alta_Partners>,
        <https://1145.am/db/2307829/Alta_Partners>,
        <https://1145.am/db/2308855/Alta_Partners>,
        <https://1145.am/db/2311011/Alta_Partners>,
        <https://1145.am/db/2313143/Alta_Partners>,
        <https://1145.am/db/2313405/Alta_Partners>,
        <https://1145.am/db/2316391/Alta_Partners>,
        <https://1145.am/db/2318577/Alta_Partners>,
        <https://1145.am/db/2318635/Alta_Partners>,
        <https://1145.am/db/2322984/Alta_Partners>,
        <https://1145.am/db/2323003/Alta_Partners>,
        <https://1145.am/db/2323243/Alta_Partners>,
        <https://1145.am/db/2324012/Alta_Partners>,
        <https://1145.am/db/2324015/Alta_Partners>,
        <https://1145.am/db/2326176/Alta_Partners>,
        <https://1145.am/db/2326903/Alta_Partners>,
        <https://1145.am/db/2327441/Alta_Partners>,
        <https://1145.am/db/2327442/Alta_Partners>,
        <https://1145.am/db/2327677/Alta_Partners>,
        <https://1145.am/db/2328815/Alta_Partners>,
        <https://1145.am/db/2330075/Alta_Partners>,
        <https://1145.am/db/2330079/Alta_Partners>,
        <https://1145.am/db/2338126/Alta_Partners>,
        <https://1145.am/db/2338127/Alta_Partners>,
        <https://1145.am/db/2340887/Alta_Partners>,
        <https://1145.am/db/2341764/Alta_Partners>,
        <https://1145.am/db/2343547/Alta_Partners>,
        <https://1145.am/db/2344092/Alta_Partners>,
        <https://1145.am/db/2344100/Alta_Partners>,
        <https://1145.am/db/2346542/Alta_Partners>,
        <https://1145.am/db/2351224/Alta_Partners>,
        <https://1145.am/db/2351897/Alta_Partners>,
        <https://1145.am/db/2352167/Alta_Partners>,
        <https://1145.am/db/2352170/Alta_Partners>,
        <https://1145.am/db/2352362/Alta_Partners>,
        <https://1145.am/db/2352831/Alta_Partners>,
        <https://1145.am/db/2353439/Alta_Partners>,
        <https://1145.am/db/2353771/Alta_Partners>,
        <https://1145.am/db/2353789/Alta_Partners>,
        <https://1145.am/db/2354299/Alta_Partners>,
        <https://1145.am/db/2354307/Alta_Partners>,
        <https://1145.am/db/2354314/Alta_Partners>,
        <https://1145.am/db/2355183/Alta_Partners>,
        <https://1145.am/db/2355274/Alta_Partners>,
        <https://1145.am/db/2356216/Alta_Partners>,
        <https://1145.am/db/2358496/Alta_Partners>,
        <https://1145.am/db/2358502/Alta_Partners>,
        <https://1145.am/db/2362565/Alta_Partners>,
        <https://1145.am/db/2362566/Alta_Partners>,
        <https://1145.am/db/2362902/Alta_Partners>,
        <https://1145.am/db/2362909/Alta_Partners>,
        <https://1145.am/db/2362910/Alta_Partners>,
        <https://1145.am/db/2363364/Alta_Partners>,
        <https://1145.am/db/2363510/Alta_Partners>,
        <https://1145.am/db/2365748/Alta_Partners>,
        <https://1145.am/db/2366693/Alta_Partners>,
        <https://1145.am/db/2366700/Alta_Partners>,
        <https://1145.am/db/2367497/Alta_Partners>,
        <https://1145.am/db/328387/Altas_Partners>,
        <https://1145.am/db/443962/Altas_Partners>,
        <https://1145.am/db/750997/Alta_Partners>,
        <https://1145.am/db/979509/Alta_Partners>,
        <https://1145.am/db/987929/Alta_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355586/Lilly_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:documentDate "2012-05-08T13:06:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sutro Closes $16.5 Million Second Tranche of Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sutro-closes-16-5-million-second-tranche-of-series-c-financing> ;
    ns1:foundName "Lilly Ventures" ;
    ns1:investor <https://1145.am/db/2355586/Series_C_Investment_Alta_Partners_Amgen_Ventures_Lilly_Ventures_Sv_Life_Sciences_Skyline_Ventures_Sutro_Biopharma_Completed> ;
    ns1:name "Lilly Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2301739/Lilly_Ventures>,
        <https://1145.am/db/2317455/Lilly_Ventures>,
        <https://1145.am/db/2318733/Lilly_Ventures>,
        <https://1145.am/db/2319777/Lilly_Ventures>,
        <https://1145.am/db/2320082/Lilly_Ventures>,
        <https://1145.am/db/2322022/Lilly_Ventures>,
        <https://1145.am/db/2322984/Lilly_Ventures>,
        <https://1145.am/db/2323003/Lilly_Ventures>,
        <https://1145.am/db/2324042/Lilly_Ventures>,
        <https://1145.am/db/2326222/Lilly_Ventures>,
        <https://1145.am/db/2327441/Lilly_Ventures>,
        <https://1145.am/db/2327442/Lilly_Ventures>,
        <https://1145.am/db/2332864/Lilly_Ventures>,
        <https://1145.am/db/2332868/Lilly_Ventures>,
        <https://1145.am/db/2336328/Lilly_Ventures>,
        <https://1145.am/db/2339666/Lilly_Ventures>,
        <https://1145.am/db/2340096/Lilly_Ventures>,
        <https://1145.am/db/2340942/Lilly_Ventures>,
        <https://1145.am/db/2343723/Lilly_Ventures>,
        <https://1145.am/db/2343724/Lilly_Ventures>,
        <https://1145.am/db/2347682/Lilly_Ventures>,
        <https://1145.am/db/2348448/Lilly_Ventures>,
        <https://1145.am/db/2352414/Lilly_Ventures>,
        <https://1145.am/db/2353439/Lilly_Ventures>,
        <https://1145.am/db/2356048/Lilly_Ventures>,
        <https://1145.am/db/2357676/Lilly_Ventures>,
        <https://1145.am/db/2357679/Lilly_Ventures>,
        <https://1145.am/db/2357682/Lilly_Ventures>,
        <https://1145.am/db/2361581/Lilly_Ventures>,
        <https://1145.am/db/2362715/Lilly_Ventures>,
        <https://1145.am/db/2363396/Lilly_Ventures>,
        <https://1145.am/db/2368240/Lilly_Ventures>,
        <https://1145.am/db/2368322/Lilly_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355586/Skyline_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:documentDate "2012-05-08T13:06:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sutro Closes $16.5 Million Second Tranche of Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sutro-closes-16-5-million-second-tranche-of-series-c-financing> ;
    ns1:foundName "Skyline Ventures" ;
    ns1:investor <https://1145.am/db/2355586/Series_C_Investment_Alta_Partners_Amgen_Ventures_Lilly_Ventures_Sv_Life_Sciences_Skyline_Ventures_Sutro_Biopharma_Completed> ;
    ns1:name "Skyline Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2300653/Skyline_Ventures>,
        <https://1145.am/db/2303098/Skyline_Ventures>,
        <https://1145.am/db/2303598/Skyline_Ventures>,
        <https://1145.am/db/2305791/Skyline_Ventures>,
        <https://1145.am/db/2308925/Skyline_Ventures>,
        <https://1145.am/db/2308931/Skyline_Ventures>,
        <https://1145.am/db/2313305/Skyline_Ventures>,
        <https://1145.am/db/2313306/Skyline_Ventures>,
        <https://1145.am/db/2337571/Skyline_Ventures>,
        <https://1145.am/db/2337577/Skyline_Ventures>,
        <https://1145.am/db/2340204/Skyline_Ventures>,
        <https://1145.am/db/2340207/Skyline_Ventures>,
        <https://1145.am/db/2349753/Skyline_Ventures>,
        <https://1145.am/db/2353439/Skyline_Ventures>,
        <https://1145.am/db/2359287/Skyline_Ventures>,
        <https://1145.am/db/2365296/Skyline_Ventures>,
        <https://1145.am/db/2546216/Skyline_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355609/Cls_Capital> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2012-05-10T14:51:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Egalet Announces Series B Financing and Names Bob Radie Chief Executive Officer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/egalet-announces-series-b-financing-and-names-bob-radie-chief-executive-officer> ;
    ns1:foundName "CLS Capital" ;
    ns1:investor <https://1145.am/db/2355609/Series_B_Investment_Atlas_Venture_Cls_Capital_Egalet_Ltd_Index_Ventures_Omega_Funds_Sunstone_Capital_Completed> ;
    ns1:name "CLS Capital" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355609/Index_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2012-05-10T14:51:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Egalet Announces Series B Financing and Names Bob Radie Chief Executive Officer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/egalet-announces-series-b-financing-and-names-bob-radie-chief-executive-officer> ;
    ns1:foundName "Index Ventures" ;
    ns1:investor <https://1145.am/db/2355609/Series_B_Investment_Atlas_Venture_Cls_Capital_Egalet_Ltd_Index_Ventures_Omega_Funds_Sunstone_Capital_Completed> ;
    ns1:name "Index Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1151328/Index_Ventures>,
        <https://1145.am/db/1153706/Index_Ventures>,
        <https://1145.am/db/1247967/Index_Ventures>,
        <https://1145.am/db/1264587/Index_Ventures>,
        <https://1145.am/db/1358814/Index_Ventures>,
        <https://1145.am/db/1490485/Index_Ventures>,
        <https://1145.am/db/1493654/Index_Ventures>,
        <https://1145.am/db/1553352/Index_Ventures>,
        <https://1145.am/db/1693951/Index_Ventures>,
        <https://1145.am/db/1694279/Index_Ventures>,
        <https://1145.am/db/1699089/Index_Ventures>,
        <https://1145.am/db/1704793/Index_Ventures>,
        <https://1145.am/db/1711587/Index_Ventures>,
        <https://1145.am/db/1711731/Index_Ventures>,
        <https://1145.am/db/1711750/Index_Ventures>,
        <https://1145.am/db/1712506/Index_Ventures>,
        <https://1145.am/db/1717317/Index_Ventures>,
        <https://1145.am/db/1717574/Index_Ventures>,
        <https://1145.am/db/1725680/Index_Ventures>,
        <https://1145.am/db/1726121/Index_Ventures>,
        <https://1145.am/db/1726149/Index_Ventures>,
        <https://1145.am/db/1733028/Index_Ventures>,
        <https://1145.am/db/1735596/Index_Ventures>,
        <https://1145.am/db/1736117/Index_Ventures>,
        <https://1145.am/db/1737079/Index_Ventures>,
        <https://1145.am/db/1737527/Index_Ventures>,
        <https://1145.am/db/1737696/Index_Ventures>,
        <https://1145.am/db/1738402/Index_Ventures>,
        <https://1145.am/db/1738465/Index_Ventures>,
        <https://1145.am/db/1740781/Index_Ventures>,
        <https://1145.am/db/1742878/Index_Ventures>,
        <https://1145.am/db/1744753/Index_Ventures>,
        <https://1145.am/db/1745368/Index_Ventures>,
        <https://1145.am/db/1745702/Index_Ventures>,
        <https://1145.am/db/1746192/Index_Ventures>,
        <https://1145.am/db/1746800/Index_Ventures>,
        <https://1145.am/db/1746845/Index_Ventures>,
        <https://1145.am/db/1746947/Index_Ventures>,
        <https://1145.am/db/1747153/Index_Ventures>,
        <https://1145.am/db/1747208/Index_Ventures>,
        <https://1145.am/db/1748172/Index_Ventures>,
        <https://1145.am/db/1748621/Index_Ventures>,
        <https://1145.am/db/1750406/Index_Ventures>,
        <https://1145.am/db/1750420/Index_Ventures>,
        <https://1145.am/db/1750828/Index_Ventures>,
        <https://1145.am/db/1752154/Index_Ventures>,
        <https://1145.am/db/1755398/Index_Ventures>,
        <https://1145.am/db/1755899/Index_Ventures>,
        <https://1145.am/db/1756141/Index_Ventures>,
        <https://1145.am/db/1756768/Index_Ventures>,
        <https://1145.am/db/1756873/Index_Ventures>,
        <https://1145.am/db/1758069/Index_Ventures>,
        <https://1145.am/db/1758834/Index_Ventures>,
        <https://1145.am/db/1759939/Index_Ventures>,
        <https://1145.am/db/1760816/Index_Ventures>,
        <https://1145.am/db/1760954/Index_Ventures>,
        <https://1145.am/db/1760984/Index_Ventures>,
        <https://1145.am/db/1761566/Index_Ventures>,
        <https://1145.am/db/1761664/Index_Ventures>,
        <https://1145.am/db/1762988/Index_Ventures>,
        <https://1145.am/db/1763352/Index_Ventures>,
        <https://1145.am/db/1765809/Index_Ventures>,
        <https://1145.am/db/1765870/Index_Ventures>,
        <https://1145.am/db/1766059/Index_Ventures>,
        <https://1145.am/db/1766253/Index_Ventures>,
        <https://1145.am/db/1769654/Index_Ventures>,
        <https://1145.am/db/1770982/Index_Ventures>,
        <https://1145.am/db/1771672/Index_Ventures>,
        <https://1145.am/db/1771734/Index_Ventures>,
        <https://1145.am/db/1771773/Index_Ventures>,
        <https://1145.am/db/1775903/Index_Ventures>,
        <https://1145.am/db/1776139/Index_Ventures>,
        <https://1145.am/db/1776626/Index_Ventures>,
        <https://1145.am/db/1777546/Index_Ventures>,
        <https://1145.am/db/1778195/Index_Ventures>,
        <https://1145.am/db/1780507/Index_Ventures>,
        <https://1145.am/db/1780733/Index_Ventures>,
        <https://1145.am/db/1783754/Index_Ventures>,
        <https://1145.am/db/1787471/Index_Ventures>,
        <https://1145.am/db/1787621/Index_Ventures>,
        <https://1145.am/db/1788328/Index_Ventures>,
        <https://1145.am/db/1790777/Index_Ventures>,
        <https://1145.am/db/1791303/Index_Ventures>,
        <https://1145.am/db/1791667/Index_Ventures>,
        <https://1145.am/db/1791743/Index_Ventures>,
        <https://1145.am/db/1795469/Index_Ventures>,
        <https://1145.am/db/1796201/Index_Ventures>,
        <https://1145.am/db/1798568/Index_Ventures>,
        <https://1145.am/db/1798836/Index_Ventures>,
        <https://1145.am/db/1799293/Index_Ventures>,
        <https://1145.am/db/1800172/Index_Ventures>,
        <https://1145.am/db/1800232/Index_Ventures>,
        <https://1145.am/db/1800998/Index_Ventures>,
        <https://1145.am/db/1805201/Index_Ventures>,
        <https://1145.am/db/1805473/Index_Ventures>,
        <https://1145.am/db/1807173/Index_Ventures>,
        <https://1145.am/db/1808484/Index_Ventures>,
        <https://1145.am/db/1809821/Index_Ventures>,
        <https://1145.am/db/1810000/Index_Ventures>,
        <https://1145.am/db/1811357/Index_Ventures>,
        <https://1145.am/db/1812038/Index_Ventures>,
        <https://1145.am/db/1812890/Index_Ventures>,
        <https://1145.am/db/1813037/Index_Ventures>,
        <https://1145.am/db/1813404/Index_Ventures>,
        <https://1145.am/db/1814064/Index_Ventures>,
        <https://1145.am/db/1819133/Index_Ventures>,
        <https://1145.am/db/1819302/Index_Ventures>,
        <https://1145.am/db/1819387/Index_Ventures>,
        <https://1145.am/db/1821174/Index_Ventures>,
        <https://1145.am/db/1823078/Index_Ventures>,
        <https://1145.am/db/1823141/Index_Ventures>,
        <https://1145.am/db/1824561/Index_Ventures>,
        <https://1145.am/db/1828638/Index_Ventures>,
        <https://1145.am/db/1829991/Index_Ventures>,
        <https://1145.am/db/1830023/Index_Ventures>,
        <https://1145.am/db/1831440/Index_Ventures>,
        <https://1145.am/db/1832655/Index_Ventures>,
        <https://1145.am/db/1832808/Index_Ventures>,
        <https://1145.am/db/1832926/Index_Ventures>,
        <https://1145.am/db/1835321/Index_Ventures>,
        <https://1145.am/db/1835516/Index_Ventures>,
        <https://1145.am/db/1836455/Index_Ventures>,
        <https://1145.am/db/1836572/Index_Ventures>,
        <https://1145.am/db/1837081/Index_Ventures>,
        <https://1145.am/db/1837143/Index_Ventures>,
        <https://1145.am/db/1839663/Index_Ventures>,
        <https://1145.am/db/1840137/Index_Ventures>,
        <https://1145.am/db/1842402/Index_Ventures>,
        <https://1145.am/db/1843003/Index_Ventures>,
        <https://1145.am/db/1843031/Index_Ventures>,
        <https://1145.am/db/1845548/Index_Ventures>,
        <https://1145.am/db/1845841/Index_Ventures>,
        <https://1145.am/db/1846254/Index_Ventures>,
        <https://1145.am/db/1846794/Index_Ventures>,
        <https://1145.am/db/1847483/Index_Ventures>,
        <https://1145.am/db/1848631/Index_Ventures>,
        <https://1145.am/db/1849844/Index_Ventures>,
        <https://1145.am/db/1849884/Index_Ventures>,
        <https://1145.am/db/1849912/Index_Ventures>,
        <https://1145.am/db/1850428/Index_Ventures>,
        <https://1145.am/db/1851035/Index_Ventures>,
        <https://1145.am/db/1851744/Index_Ventures>,
        <https://1145.am/db/1853547/Index_Ventures>,
        <https://1145.am/db/1854191/Index_Ventures>,
        <https://1145.am/db/1856171/Index_Ventures>,
        <https://1145.am/db/1856191/Index_Ventures>,
        <https://1145.am/db/1856802/Index_Ventures>,
        <https://1145.am/db/1856967/Index_Ventures>,
        <https://1145.am/db/1857638/Index_Ventures>,
        <https://1145.am/db/1858520/Index_Ventures>,
        <https://1145.am/db/1858521/Index_Ventures>,
        <https://1145.am/db/1862594/Index_Ventures>,
        <https://1145.am/db/1863500/Index_Ventures>,
        <https://1145.am/db/1865106/Index_Ventures>,
        <https://1145.am/db/1865524/Index_Ventures>,
        <https://1145.am/db/1866804/Index_Ventures>,
        <https://1145.am/db/1868923/Index_Ventures>,
        <https://1145.am/db/1868935/Index_Ventures>,
        <https://1145.am/db/1870074/Index_Ventures>,
        <https://1145.am/db/1870079/Index_Ventures>,
        <https://1145.am/db/1870810/Index_Ventures>,
        <https://1145.am/db/1871091/Index_Ventures>,
        <https://1145.am/db/1876014/Index_Ventures>,
        <https://1145.am/db/1876914/Index_Ventures>,
        <https://1145.am/db/1878630/Index_Ventures>,
        <https://1145.am/db/1880386/Index_Ventures>,
        <https://1145.am/db/1881391/Index_Ventures>,
        <https://1145.am/db/1881430/Index_Ventures>,
        <https://1145.am/db/1882301/Index_Ventures>,
        <https://1145.am/db/1882686/Index_Ventures>,
        <https://1145.am/db/1884077/Index_Ventures>,
        <https://1145.am/db/1885147/Index_Ventures>,
        <https://1145.am/db/1890254/Index_Ventures>,
        <https://1145.am/db/1893255/Index_Ventures>,
        <https://1145.am/db/1894621/Index_Ventures>,
        <https://1145.am/db/1894627/Index_Ventures>,
        <https://1145.am/db/1896185/Index_Ventures>,
        <https://1145.am/db/1896379/Index_Ventures>,
        <https://1145.am/db/1899697/Index_Ventures>,
        <https://1145.am/db/1900904/Index_Ventures>,
        <https://1145.am/db/1902032/Index_Ventures>,
        <https://1145.am/db/1905858/Index_Ventures>,
        <https://1145.am/db/1910957/Index_Ventures>,
        <https://1145.am/db/1914220/Index_Ventures>,
        <https://1145.am/db/1915168/Index_Ventures>,
        <https://1145.am/db/1916258/Index_Ventures>,
        <https://1145.am/db/1916868/Index_Ventures>,
        <https://1145.am/db/1919238/Index_Ventures>,
        <https://1145.am/db/1967520/Index_Ventures>,
        <https://1145.am/db/1967683/Index_Ventures>,
        <https://1145.am/db/199212/Index_Ventures>,
        <https://1145.am/db/2028609/Index_Ventures>,
        <https://1145.am/db/2060465/Index_Ventures>,
        <https://1145.am/db/2062814/Index_Ventures>,
        <https://1145.am/db/2127786/Index_Ventures>,
        <https://1145.am/db/217906/Index_Ventures>,
        <https://1145.am/db/2198066/Index_Ventures>,
        <https://1145.am/db/2234558/Index_Ventures>,
        <https://1145.am/db/2290088/Index_Ventures>,
        <https://1145.am/db/2290200/Index_Ventures>,
        <https://1145.am/db/2297905/Index_Ventures>,
        <https://1145.am/db/2303009/Index_Ventures>,
        <https://1145.am/db/2303849/Index_Ventures>,
        <https://1145.am/db/2309490/Index_Ventures>,
        <https://1145.am/db/2309840/Index_Ventures>,
        <https://1145.am/db/2309847/Index_Ventures>,
        <https://1145.am/db/2313410/Index_Ventures>,
        <https://1145.am/db/2317779/Index_Ventures>,
        <https://1145.am/db/2325140/Index_Ventures>,
        <https://1145.am/db/2325147/Index_Ventures>,
        <https://1145.am/db/2327222/Index_Ventures>,
        <https://1145.am/db/2333601/Index_Ventures>,
        <https://1145.am/db/2338079/Index_Ventures>,
        <https://1145.am/db/2338193/Index_Ventures>,
        <https://1145.am/db/2338196/Index_Ventures>,
        <https://1145.am/db/2344127/Index_Ventures>,
        <https://1145.am/db/2347571/Index_Ventures>,
        <https://1145.am/db/2348012/Index_Ventures>,
        <https://1145.am/db/2348618/Index_Ventures>,
        <https://1145.am/db/2348620/Index_Ventures>,
        <https://1145.am/db/2350031/Index_Ventures>,
        <https://1145.am/db/2352142/Index_Ventures>,
        <https://1145.am/db/2352145/Index_Ventures>,
        <https://1145.am/db/2355952/Index_Ventures>,
        <https://1145.am/db/2357169/Index_Ventures>,
        <https://1145.am/db/2357356/Index_Ventures>,
        <https://1145.am/db/2358233/Index_Ventures>,
        <https://1145.am/db/2358246/Index_Ventures>,
        <https://1145.am/db/2362736/Index_Ventures>,
        <https://1145.am/db/2362737/Index_Ventures>,
        <https://1145.am/db/2364597/Index_Ventures>,
        <https://1145.am/db/2364600/Index_Ventures>,
        <https://1145.am/db/2507691/Index_Ventures>,
        <https://1145.am/db/2555540/Index_Ventures>,
        <https://1145.am/db/2589317/Index_Ventures>,
        <https://1145.am/db/2643797/Index_Ventures>,
        <https://1145.am/db/306236/Index_Ventures>,
        <https://1145.am/db/317470/Index_Ventures>,
        <https://1145.am/db/318142/Index_Ventures>,
        <https://1145.am/db/323273/Index_Ventures>,
        <https://1145.am/db/337401/Index_Ventures>,
        <https://1145.am/db/348633/Index_Ventures>,
        <https://1145.am/db/366983/Index_Ventures>,
        <https://1145.am/db/367008/Index_Ventures>,
        <https://1145.am/db/460454/Index_Ventures>,
        <https://1145.am/db/475105/Index_Ventures>,
        <https://1145.am/db/479113/Index_Ventures>,
        <https://1145.am/db/539919/Index_Ventures>,
        <https://1145.am/db/577120/Index_Ventures>,
        <https://1145.am/db/578277/Index_Ventures>,
        <https://1145.am/db/633695/Index_Ventures>,
        <https://1145.am/db/659010/Index_Ventures>,
        <https://1145.am/db/661818/Index_Ventures>,
        <https://1145.am/db/707126/Index_Ventures>,
        <https://1145.am/db/709798/Index_Ventures>,
        <https://1145.am/db/749147/Index_Ventures>,
        <https://1145.am/db/749209/Index_Ventures>,
        <https://1145.am/db/768008/Index_Ventures>,
        <https://1145.am/db/789218/Index_Ventures>,
        <https://1145.am/db/791505/Index_Ventures>,
        <https://1145.am/db/796629/Index_Ventures>,
        <https://1145.am/db/798095/Index_Ventures>,
        <https://1145.am/db/803541/Index_Ventures>,
        <https://1145.am/db/854512/Index_Ventures>,
        <https://1145.am/db/868352/Index_Ventures>,
        <https://1145.am/db/893076/Index_Ventures>,
        <https://1145.am/db/893316/Index_Ventures>,
        <https://1145.am/db/909344/Index_Ventures>,
        <https://1145.am/db/957097/Index_Ventures>,
        <https://1145.am/db/980375/Index_Ventures>,
        <https://1145.am/db/981840/Index_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355609/Omega_Funds> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2012-05-10T14:51:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Egalet Announces Series B Financing and Names Bob Radie Chief Executive Officer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/egalet-announces-series-b-financing-and-names-bob-radie-chief-executive-officer> ;
    ns1:foundName "Omega Funds" ;
    ns1:investor <https://1145.am/db/2355609/Series_B_Investment_Atlas_Venture_Cls_Capital_Egalet_Ltd_Index_Ventures_Omega_Funds_Sunstone_Capital_Completed> ;
    ns1:name "Omega Funds" ;
    ns1:sameAsMedium <https://1145.am/db/1297146/Omega_Fund>,
        <https://1145.am/db/1325968/Omega_Funds>,
        <https://1145.am/db/1628463/Omega_Funds>,
        <https://1145.am/db/1926411/Omega_Funds>,
        <https://1145.am/db/2032047/Omega_Funds>,
        <https://1145.am/db/2152399/Omega_Funds>,
        <https://1145.am/db/2282268/Omega_Fund_Management>,
        <https://1145.am/db/2282400/Omega_Funds>,
        <https://1145.am/db/2284412/Omega_Funds>,
        <https://1145.am/db/2286541/Omega_Funds>,
        <https://1145.am/db/2307682/Omega_Fund>,
        <https://1145.am/db/2307691/Omega_Fund>,
        <https://1145.am/db/2318310/Omega_Funds>,
        <https://1145.am/db/2347094/Omega_Funds>,
        <https://1145.am/db/2347102/Omega_Funds>,
        <https://1145.am/db/2361688/Omega_Funds>,
        <https://1145.am/db/474852/Omega_Fund>,
        <https://1145.am/db/545988/Omega_Funds>,
        <https://1145.am/db/704421/Omega_Funds> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356685/Entrepreneurs_Fund> a org:Organization ;
    ns1:basedInHighGeoName "London" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2643743/about.rdf> ;
    ns1:basedInHighRaw "London" ;
    ns1:description "investing" ;
    ns1:documentDate "2012-05-21T19:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Prosonix Extends Series B Financing Round to £17.1M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/prosonix-extends-series-b-financing-round-to-%C2%A317-1m> ;
    ns1:foundName "Entrepreneurs Fund (London, UK)" ;
    ns1:investor <https://1145.am/db/2356685/Series_B_Investment_Entrepreneurs_Fund_Gilde_Healthcare_Partners_Gimv_Prosonix_Quest_For_Growth_Solon_Ventures_Ventech_Completed> ;
    ns1:name "Entrepreneurs Fund" ;
    ns1:sameAsHigh <https://1145.am/db/1885567/Founders_Co-Op>,
        <https://1145.am/db/1894748/Founders_Co-Op>,
        <https://1145.am/db/428027/Founders_Co-Op> ;
    ns1:sameAsMedium <https://1145.am/db/1428371/Entrepreneurs_Equity_Fund>,
        <https://1145.am/db/1782629/Entrepreneurs_Fund>,
        <https://1145.am/db/1796967/Entrepreneurs_Investment_Fund>,
        <https://1145.am/db/2336410/Entrepreneurs_Fund>,
        <https://1145.am/db/2358747/Entrepreneurs_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356685/Gilde_Healthcare_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of the Netherlands" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2750405/about.rdf> ;
    ns1:basedInHighRaw "Netherlands" ;
    ns1:description "pharmaceutical" ;
    ns1:documentDate "2012-05-21T19:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Prosonix Extends Series B Financing Round to £17.1M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/prosonix-extends-series-b-financing-round-to-%C2%A317-1m> ;
    ns1:foundName "Gilde Healthcare Partners (Utrecht, Netherlands)" ;
    ns1:investor <https://1145.am/db/2356685/Series_B_Investment_Entrepreneurs_Fund_Gilde_Healthcare_Partners_Gimv_Prosonix_Quest_For_Growth_Solon_Ventures_Ventech_Completed> ;
    ns1:name "Gilde Healthcare Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1130666/Gilde_Healthcare>,
        <https://1145.am/db/1281079/Gilde_Healthcare>,
        <https://1145.am/db/1281647/Gilde_Healthcare>,
        <https://1145.am/db/1619849/Gilde_Healthcare>,
        <https://1145.am/db/2153641/Gilde_Healthcare>,
        <https://1145.am/db/2153646/Gilde_Healthcare>,
        <https://1145.am/db/2154438/Gilde_Healthcare>,
        <https://1145.am/db/2285850/Gilde_Healthcare>,
        <https://1145.am/db/2289349/Gilde_Healthcare>,
        <https://1145.am/db/2294667/Gilde_Healthcare_Service>,
        <https://1145.am/db/2296209/Gilde_Healthcare>,
        <https://1145.am/db/2299080/Gilde_Healthcare>,
        <https://1145.am/db/2299342/Gilde_Healthcare>,
        <https://1145.am/db/2299386/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2301160/Gilde_Healthcare>,
        <https://1145.am/db/2302380/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2308952/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2308959/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2309490/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2318829/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2329533/Gilde_Healthcare>,
        <https://1145.am/db/2329870/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2329919/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2338079/Gilde_Healthcare>,
        <https://1145.am/db/2346534/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2349048/Gilde_Healthcare>,
        <https://1145.am/db/2349301/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2352566/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2358747/Gilde_Healthcare_Partners>,
        <https://1145.am/db/2362148/Gilde_Healthcare>,
        <https://1145.am/db/2362156/Gilde_Healthcare>,
        <https://1145.am/db/2369953/Gilde_Healthcare>,
        <https://1145.am/db/2369987/Gilde_Healthcare>,
        <https://1145.am/db/770705/Gilde_Healthcare> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356685/Gimv> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:description "technology" ;
    ns1:documentDate "2012-05-21T19:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Prosonix Extends Series B Financing Round to £17.1M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/prosonix-extends-series-b-financing-round-to-%C2%A317-1m> ;
    ns1:foundName "Gimv" ;
    ns1:investor <https://1145.am/db/2356685/Series_B_Investment_Entrepreneurs_Fund_Gilde_Healthcare_Partners_Gimv_Prosonix_Quest_For_Growth_Solon_Ventures_Ventech_Completed> ;
    ns1:name "Gimv" ;
    ns1:sameAsMedium <https://1145.am/db/1724232/Gimv>,
        <https://1145.am/db/1806589/Gimv>,
        <https://1145.am/db/1830149/Gimv>,
        <https://1145.am/db/1854030/Gimv>,
        <https://1145.am/db/1866824/Gimv>,
        <https://1145.am/db/1883525/Gimv>,
        <https://1145.am/db/1914674/Gimv>,
        <https://1145.am/db/1919300/Gimv>,
        <https://1145.am/db/2154009/Gimv>,
        <https://1145.am/db/2280718/Gimv>,
        <https://1145.am/db/2281044/Gimv>,
        <https://1145.am/db/2286782/Gimv>,
        <https://1145.am/db/2294771/Gimv>,
        <https://1145.am/db/2299772/Gimv>,
        <https://1145.am/db/2301160/Gimv>,
        <https://1145.am/db/2302541/Gimv>,
        <https://1145.am/db/2302549/Gimv>,
        <https://1145.am/db/2316478/Gimv>,
        <https://1145.am/db/2328763/Gimv>,
        <https://1145.am/db/2328769/Gimv>,
        <https://1145.am/db/2336923/Gimv>,
        <https://1145.am/db/2346030/Gimv>,
        <https://1145.am/db/2352436/Gimv>,
        <https://1145.am/db/2352441/Gimv>,
        <https://1145.am/db/2352442/Gimv>,
        <https://1145.am/db/2365748/Gimv> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356685/Quest_For_Growth> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Belgium" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2802361/about.rdf> ;
    ns1:basedInHighRaw "Belgium" ;
    ns1:description "technology investor" ;
    ns1:documentDate "2012-05-21T19:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Prosonix Extends Series B Financing Round to £17.1M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/prosonix-extends-series-b-financing-round-to-%C2%A317-1m> ;
    ns1:foundName "Quest for Growth (Leuven, Belgium)" ;
    ns1:investor <https://1145.am/db/2356685/Series_B_Investment_Entrepreneurs_Fund_Gilde_Healthcare_Partners_Gimv_Prosonix_Quest_For_Growth_Solon_Ventures_Ventech_Completed> ;
    ns1:name "Quest for Growth" ;
    ns1:sameAsMedium <https://1145.am/db/2317934/Quest_For_Growth>,
        <https://1145.am/db/2324015/Quest_For_Growth>,
        <https://1145.am/db/2351224/Quest_For_Growth>,
        <https://1145.am/db/2358747/Quest_For_Growth> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356685/Solon_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "London" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2643743/about.rdf> ;
    ns1:basedInHighRaw "London" ;
    ns1:description "technology investor" ;
    ns1:documentDate "2012-05-21T19:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Prosonix Extends Series B Financing Round to £17.1M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/prosonix-extends-series-b-financing-round-to-%C2%A317-1m> ;
    ns1:foundName "Solon Ventures (London, UK)" ;
    ns1:investor <https://1145.am/db/2356685/Series_B_Investment_Entrepreneurs_Fund_Gilde_Healthcare_Partners_Gimv_Prosonix_Quest_For_Growth_Solon_Ventures_Ventech_Completed> ;
    ns1:name "Solon Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2143237/Cecilian_Partners>,
        <https://1145.am/db/6743/Nhn_Ventures>,
        <https://1145.am/db/945048/Nhn_Ventures>,
        <https://1145.am/db/946487/Nhn_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2358747/Solon_Ventures>,
        <https://1145.am/db/2364908/Solon_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356685/Ventech> a org:Organization ;
    ns1:basedInHighGeoName "Paris" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2988507/about.rdf> ;
    ns1:basedInHighRaw "Paris, France" ;
    ns1:description "technology investor" ;
    ns1:documentDate "2012-05-21T19:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Prosonix Extends Series B Financing Round to £17.1M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/prosonix-extends-series-b-financing-round-to-%C2%A317-1m> ;
    ns1:foundName "Ventech (Paris, France)" ;
    ns1:industry "pharmaceutical" ;
    ns1:investor <https://1145.am/db/2356685/Series_B_Investment_Entrepreneurs_Fund_Gilde_Healthcare_Partners_Gimv_Prosonix_Quest_For_Growth_Solon_Ventures_Ventech_Completed> ;
    ns1:name "Ventech" ;
    ns1:sameAsHigh <https://1145.am/db/1811087/Ventech>,
        <https://1145.am/db/1838206/Ventech>,
        <https://1145.am/db/1894754/Ventech>,
        <https://1145.am/db/2285411/Ventus_Therapeutics>,
        <https://1145.am/db/2305530/Ventirx_Pharmaceuticals>,
        <https://1145.am/db/2307236/Ventirx_Pharmaceuticals>,
        <https://1145.am/db/2307237/Ventirx_Pharmaceuticals>,
        <https://1145.am/db/2327638/Ventech>,
        <https://1145.am/db/2352161/Ventirx_Pharmaceuticals>,
        <https://1145.am/db/2356567/Ventech>,
        <https://1145.am/db/813478/Venturi_Partners>,
        <https://1145.am/db/814558/Venturi_Partners>,
        <https://1145.am/db/830052/Ventech> ;
    ns1:sameAsMedium <https://1145.am/db/1704141/Ventech>,
        <https://1145.am/db/1725598/Ventech>,
        <https://1145.am/db/1738448/Ventech>,
        <https://1145.am/db/1741357/Ventech>,
        <https://1145.am/db/1743481/Ventech>,
        <https://1145.am/db/1765401/Ventech>,
        <https://1145.am/db/1767974/Ventech>,
        <https://1145.am/db/1778401/Ventech>,
        <https://1145.am/db/1800466/Ventech>,
        <https://1145.am/db/1802167/Ventech>,
        <https://1145.am/db/1812656/Ventech>,
        <https://1145.am/db/1828915/Ventech>,
        <https://1145.am/db/1833939/Ventech>,
        <https://1145.am/db/1835236/Ventech>,
        <https://1145.am/db/1873872/Ventech>,
        <https://1145.am/db/1890664/Ventech>,
        <https://1145.am/db/1892120/Ventech>,
        <https://1145.am/db/1906801/Ventech>,
        <https://1145.am/db/2301770/Ventech>,
        <https://1145.am/db/2302541/Ventech>,
        <https://1145.am/db/2311395/Ventech>,
        <https://1145.am/db/2315532/Ventech>,
        <https://1145.am/db/2315547/Ventech>,
        <https://1145.am/db/2322162/Ventech>,
        <https://1145.am/db/2351312/Ventech>,
        <https://1145.am/db/2358233/Ventech>,
        <https://1145.am/db/2358246/Ventech>,
        <https://1145.am/db/2358747/Ventech>,
        <https://1145.am/db/2580665/Ventech>,
        <https://1145.am/db/2580671/Ventech>,
        <https://1145.am/db/2601004/Ventech>,
        <https://1145.am/db/447174/Ventech>,
        <https://1145.am/db/883525/Ventech> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356690/Baird_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Wisconsin" ;
    ns1:documentDate "2012-05-22T13:14:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biotechs raise new VC rounds to back inhalable drugs, antimicrobials" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotechs-raise-new-vc-rounds-to-back-inhalable-drugs-antimicrobials> ;
    ns1:foundName "Baird",
        "Baird Venture Partners" ;
    ns1:investor <https://1145.am/db/2356690/A_Investment_Baird_Venture_Partners_State_Of_Wisconsin_Investment_Board_Zurex_Pharma_Completed> ;
    ns1:name "Baird Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1826908/Baird_Venture_Partners>,
        <https://1145.am/db/2290410/Baird_Venture_Partners>,
        <https://1145.am/db/2293640/Baird_Venture_Partners>,
        <https://1145.am/db/2306790/Baird_Venture_Partners>,
        <https://1145.am/db/2367381/Baird_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356690/State_Of_Wisconsin_Investment_Board> a org:Organization ;
    ns1:basedInHighGeoName "Madison" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5261457/about.rdf> ;
    ns1:basedInHighRaw "Madison" ;
    ns1:documentDate "2012-05-22T13:14:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biotechs raise new VC rounds to back inhalable drugs, antimicrobials" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotechs-raise-new-vc-rounds-to-back-inhalable-drugs-antimicrobials> ;
    ns1:foundName "State of Wisconsin Investment Board",
        "the State of Wisconsin Investment Board" ;
    ns1:investor <https://1145.am/db/2356690/A_Investment_Baird_Venture_Partners_State_Of_Wisconsin_Investment_Board_Zurex_Pharma_Completed> ;
    ns1:name "State of Wisconsin Investment Board" ;
    ns1:sameAsMedium <https://1145.am/db/1794712/State_Of_Wisconsin_Investment_Board>,
        <https://1145.am/db/2343486/State_Of_Wisconsin_Investment_Board>,
        <https://1145.am/db/2369504/State_Of_Wisconsin_Investment_Board>,
        <https://1145.am/db/2556669/State_Of_Wisconsin_Investment_Board>,
        <https://1145.am/db/2583558/State_Of_Wisconsin_Investment_Board> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356690/Venture_Investment_Prosonix_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-22T13:14:33+00:00"^^xsd:dateTime ;
    ns1:documentExtract "The Oxford, U.K. - based Prosonix has hauled in an added $ 9 million for its second venture round and plans to put the money to use developing a slate of inhalable drugs using its particle engineering technology." ;
    ns1:documentTitle "Biotechs raise new VC rounds to back inhalable drugs, antimicrobials" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotechs-raise-new-vc-rounds-to-back-inhalable-drugs-antimicrobials> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2356690/Prosonix> ;
    ns1:targetDetails "venture" ;
    ns1:valueRaw "$ 27 million",
        "$ 9 million" ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "U.K." .

<https://1145.am/db/2357709/Investment_Halo_Therapeutics_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-23T15:31:34+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Halo Therapeutics Raises $ 1.1 Million to Expedite Phase 2 Study of HT-100.",
        "NEWTON, Mass., May 22, 2012 /PRNewswire via COMTEX/ - Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that it has received financial support totaling $ 1.1 million from 12 not-for-profit foundations serving the muscular dystrophy patient community." ;
    ns1:documentTitle "Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/halo-therapeutics-raises-1-1-million-to-expedite-phase-2-study-of-ht-100> ;
    ns1:foundName "Raises" ;
    ns1:name "Raises" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2357709/Halo_Therapeutics> ;
    ns1:valueRaw "$ 1.1 Million",
        "$ 1.1 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2357725/Leucadia_National_Corporation> a org:Organization ;
    ns1:basedInLowRaw "SAN DIEGO" ;
    ns1:documentDate "2012-05-24T19:25:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sangart-raises-additional-50m-series-g-funding-following-interim-safety-analysis-of-phase> ;
    ns1:foundName "Leucadia National Corporation" ;
    ns1:investor <https://1145.am/db/2357725/Equity_Investment_Leucadia_National_Corporation_Sangart_Completed> ;
    ns1:name "Leucadia National Corporation" ;
    ns1:sameAsMedium <https://1145.am/db/2366555/Leucadia_National_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358806/Aperture_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "Palo Alto" ;
    ns1:documentDate "2012-06-05T14:30:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ceptaris Secures $10 Million in Series D-1 Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ceptaris-secures-10-million-series-d-1-financing> ;
    ns1:foundName "Aperture Venture Partners" ;
    ns1:investor <https://1145.am/db/2358806/Series_D_Investment_Aperture_Venture_Partners_Bioadvance_Ceptaris_Therapeutics_Osage_Palo_Alto_Investors_Burrill___Company_Third_Point_Llc_Vivo_Ventures_Completed> ;
    ns1:name "Aperture Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2182698/Aperture_Venture_Partners>,
        <https://1145.am/db/2290894/Aperture_Venture_Partners>,
        <https://1145.am/db/2298869/Aperture_Venture_Partners>,
        <https://1145.am/db/2333573/Aperture_Venture_Partners>,
        <https://1145.am/db/2333577/Aperture_Venture_Partners>,
        <https://1145.am/db/2336221/Aperture_Venture_Partners>,
        <https://1145.am/db/2337106/Aperture_Venture_Partners>,
        <https://1145.am/db/2339516/Aperture_Venture_Partners>,
        <https://1145.am/db/2350044/Aperture_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358806/Bioadvance> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2012-06-05T14:30:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ceptaris Secures $10 Million in Series D-1 Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ceptaris-secures-10-million-series-d-1-financing> ;
    ns1:foundName "BioAdvance" ;
    ns1:investor <https://1145.am/db/2358806/Series_D_Investment_Aperture_Venture_Partners_Bioadvance_Ceptaris_Therapeutics_Osage_Palo_Alto_Investors_Burrill___Company_Third_Point_Llc_Vivo_Ventures_Completed> ;
    ns1:name "BioAdvance" ;
    ns1:sameAsMedium <https://1145.am/db/1196322/Bioadvance>,
        <https://1145.am/db/1223133/Bioadvance>,
        <https://1145.am/db/1223149/Bioadvance>,
        <https://1145.am/db/1326655/Bioadvance>,
        <https://1145.am/db/1326957/Bioadvance>,
        <https://1145.am/db/1571871/Bioadvance>,
        <https://1145.am/db/1623159/Bioadvance>,
        <https://1145.am/db/2306250/Bioadvance>,
        <https://1145.am/db/2317455/Bioadvance>,
        <https://1145.am/db/2322984/Bioadvance>,
        <https://1145.am/db/2323003/Bioadvance>,
        <https://1145.am/db/2325387/Bioadvance>,
        <https://1145.am/db/2332322/Bioadvance>,
        <https://1145.am/db/2336032/Bioadvance>,
        <https://1145.am/db/2351683/Bioadvance>,
        <https://1145.am/db/2351684/Bioadvance>,
        <https://1145.am/db/2572398/Bioadvance>,
        <https://1145.am/db/2585002/Bioadvance>,
        <https://1145.am/db/479135/Bioadvance>,
        <https://1145.am/db/577663/Bioadvance>,
        <https://1145.am/db/907506/Bioadvance>,
        <https://1145.am/db/907937/Bioadvance> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358806/Osage> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2012-06-05T14:30:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ceptaris Secures $10 Million in Series D-1 Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ceptaris-secures-10-million-series-d-1-financing> ;
    ns1:foundName "Osage" ;
    ns1:industry "pharmaceutical" ;
    ns1:investor <https://1145.am/db/2358806/Series_D_Investment_Aperture_Venture_Partners_Bioadvance_Ceptaris_Therapeutics_Osage_Palo_Alto_Investors_Burrill___Company_Third_Point_Llc_Vivo_Ventures_Completed> ;
    ns1:name "Osage" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358806/Palo_Alto_Investors_Burrill___Company> a org:Organization ;
    ns1:basedInHighGeoName "Palo Alto County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4870630/about.rdf> ;
    ns1:basedInHighRaw "Palo Alto" ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-06-05T14:30:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ceptaris Secures $10 Million in Series D-1 Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ceptaris-secures-10-million-series-d-1-financing> ;
    ns1:foundName "Burrill & Company",
        "Palo Alto Investors",
        "Palo Alto Investors, Burrill & Company" ;
    ns1:investor <https://1145.am/db/2358806/Series_D_Investment_Aperture_Venture_Partners_Bioadvance_Ceptaris_Therapeutics_Osage_Palo_Alto_Investors_Burrill___Company_Third_Point_Llc_Vivo_Ventures_Completed> ;
    ns1:name "Burrill & Company",
        "Palo Alto Investors",
        "Palo Alto Investors, Burrill & Company" ;
    ns1:sameAsHigh <https://1145.am/db/2358804/Vivo_Ventures_Palo_Alto_Investors_Burrill___Company> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358806/Third_Point_Llc> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "Investing" ;
    ns1:documentDate "2012-06-05T14:30:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ceptaris Secures $10 Million in Series D-1 Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ceptaris-secures-10-million-series-d-1-financing> ;
    ns1:foundName "Third Point, LLC" ;
    ns1:investor <https://1145.am/db/2358806/Series_D_Investment_Aperture_Venture_Partners_Bioadvance_Ceptaris_Therapeutics_Osage_Palo_Alto_Investors_Burrill___Company_Third_Point_Llc_Vivo_Ventures_Completed> ;
    ns1:name "Third Point, LLC" ;
    ns1:sameAsHigh <https://1145.am/db/2319672/Third_Point_Llc> ;
    ns1:sameAsMedium <https://1145.am/db/1282899/Third_Point>,
        <https://1145.am/db/1566784/Third_Point>,
        <https://1145.am/db/1691531/Third_Point>,
        <https://1145.am/db/1755209/Third_Point>,
        <https://1145.am/db/1756934/Third_Point>,
        <https://1145.am/db/1809781/Third_Point>,
        <https://1145.am/db/2279864/Third_Point>,
        <https://1145.am/db/2358804/Third_Point>,
        <https://1145.am/db/352665/Third_Point>,
        <https://1145.am/db/391997/Third_Point>,
        <https://1145.am/db/631196/Third_Point> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358806/Vivo_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Palo Alto" ;
    ns1:documentDate "2012-06-05T14:30:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ceptaris Secures $10 Million in Series D-1 Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ceptaris-secures-10-million-series-d-1-financing> ;
    ns1:foundName "Vivo Ventures" ;
    ns1:investor <https://1145.am/db/2358806/Series_D_Investment_Aperture_Venture_Partners_Bioadvance_Ceptaris_Therapeutics_Osage_Palo_Alto_Investors_Burrill___Company_Third_Point_Llc_Vivo_Ventures_Completed> ;
    ns1:name "Vivo Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2029866/Vivo_Ventures>,
        <https://1145.am/db/2233578/Vivo_Ventures>,
        <https://1145.am/db/2265965/Vivo_Ventures>,
        <https://1145.am/db/2302076/Vivo_Ventures>,
        <https://1145.am/db/2302091/Vivo_Ventures>,
        <https://1145.am/db/2302108/Vivo_Ventures>,
        <https://1145.am/db/2305507/Vivo_Ventures>,
        <https://1145.am/db/2305514/Vivo_Ventures>,
        <https://1145.am/db/2309163/Vivo_Ventures>,
        <https://1145.am/db/2310302/Vivo_Ventures>,
        <https://1145.am/db/2311353/Vivo_Ventures>,
        <https://1145.am/db/2318806/Vivo_Ventures>,
        <https://1145.am/db/2318851/Vivo_Ventures>,
        <https://1145.am/db/2319846/Vivo_Ventures>,
        <https://1145.am/db/2322989/Vivo_Ventures>,
        <https://1145.am/db/2322991/Vivo_Ventures>,
        <https://1145.am/db/2323001/Vivo_Ventures>,
        <https://1145.am/db/2326361/Vivo_Ventures>,
        <https://1145.am/db/2326373/Vivo_Ventures>,
        <https://1145.am/db/2330920/Vivo_Ventures>,
        <https://1145.am/db/2337166/Vivo_Ventures>,
        <https://1145.am/db/2339345/Vivo_Ventures>,
        <https://1145.am/db/2339516/Vivo_Ventures>,
        <https://1145.am/db/2341869/Vivo_Ventures>,
        <https://1145.am/db/2341897/Vivo_Ventures>,
        <https://1145.am/db/2347043/Vivo_Ventures>,
        <https://1145.am/db/2366710/Vivo_Ventures>,
        <https://1145.am/db/2366712/Vivo_Ventures>,
        <https://1145.am/db/2367022/Vivo_Ventures>,
        <https://1145.am/db/2367023/Vivo_Ventures>,
        <https://1145.am/db/2588372/Vivo_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358812/Johnson___Johnson_Development_Corporation> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-06-06T15:08:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PhaseBio Pharmaceuticals Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing For Advancement of Metabolic and Cardiovascular Product Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/phasebio-pharmaceuticals-received-an-additional-23-million-completion-of-third-tranche-of-a> ;
    ns1:foundName "Johnson & Johnson Development Corporation" ;
    ns1:investor <https://1145.am/db/2358812/Series_B_Investment_Fletcher_Spaght_Ventures_Hatteras_Venture_Partners_Johnson___Johnson_Development_Corporation_New_Enterprise_Associates_Osi_Investment_Holdings_Phasebio_Pharmaceuticals_Completed> ;
    ns1:name "Johnson & Johnson Development Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/1118732/Johnson___Johnson_Innovation>,
        <https://1145.am/db/1553175/Johnson___Johnson_Innovation_-_Jjdc_Inc>,
        <https://1145.am/db/1553459/Johnson___Johnson_Innovation_-_Jjdc_Inc>,
        <https://1145.am/db/1620209/Johnson___Johnson_Innovation_-_Jjdc_Inc>,
        <https://1145.am/db/2095032/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2196895/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2284205/Johnson___Johnson_Innovation>,
        <https://1145.am/db/2300306/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2308791/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2311069/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2311075/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2336890/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2337577/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2344597/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2352361/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358640/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358658/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2361581/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2363907/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2546216/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/768105/Johnson_And_Johnson_Innovation-Jjdc_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/1883008/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2291836/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292334/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292345/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292353/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2292975/Johnson___Johnson_Development_Corp>,
        <https://1145.am/db/2299864/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2300455/Johnson___Johnson_Development_Corp>,
        <https://1145.am/db/2303009/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2306163/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2308781/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2316619/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2316624/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2317934/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2321856/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2327212/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2327227/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2336943/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2337571/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2338236/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2338237/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2338527/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2341478/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2344605/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2346978/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2350327/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2352357/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2356290/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2358657/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2364457/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2364458/Johnson___Johnson_Development_Corporation>,
        <https://1145.am/db/2365296/Johnson___Johnson_Development_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358812/Osi_Investment_Holdings> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:description "Series B financing" ;
    ns1:documentDate "2012-06-06T15:08:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PhaseBio Pharmaceuticals Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing For Advancement of Metabolic and Cardiovascular Product Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/phasebio-pharmaceuticals-received-an-additional-23-million-completion-of-third-tranche-of-a> ;
    ns1:foundName "OSI Investment Holdings" ;
    ns1:investor <https://1145.am/db/2358812/Series_B_Investment_Fletcher_Spaght_Ventures_Hatteras_Venture_Partners_Johnson___Johnson_Development_Corporation_New_Enterprise_Associates_Osi_Investment_Holdings_Phasebio_Pharmaceuticals_Completed> ;
    ns1:name "OSI Investment Holdings" ;
    ns1:sameAsMedium <https://1145.am/db/2358640/Osi_Investment_Holdings>,
        <https://1145.am/db/2358658/Osi_Investment_Holdings> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359830/Oicr> a org:Organization ;
    ns1:documentDate "2012-06-07T16:06:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/oicr-funds-fluorinov-pharma-inc-to-further-develop-its-novel-drug-for-treatment-of-blood> ;
    ns1:foundName "OICR" ;
    ns1:investor <https://1145.am/db/2359830/Investment_Fluorinov_Pharma_Inc_The_Ontario_Institute_For_Cancer_Research_Has_Not_Happened> ;
    ns1:name "OICR" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359830/The_Ontario_Institute_For_Cancer_Research> a org:Organization ;
    ns1:basedInHighGeoName "Toronto" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6167865/about.rdf> ;
    ns1:basedInHighRaw "TORONTO" ;
    ns1:documentDate "2012-06-07T16:06:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/oicr-funds-fluorinov-pharma-inc-to-further-develop-its-novel-drug-for-treatment-of-blood> ;
    ns1:foundName "The Ontario Institute for Cancer Research" ;
    ns1:investor <https://1145.am/db/2359830/Investment_Fluorinov_Pharma_Inc_The_Ontario_Institute_For_Cancer_Research_Has_Not_Happened> ;
    ns1:name "The Ontario Institute for Cancer Research" ;
    ns1:sameAsMedium <https://1145.am/db/2309353/The_Ontario_Institute_For_Cancer_Research>,
        <https://1145.am/db/2362862/The_Ontario_Institute_For_Cancer_Research> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359863/The_Keiretsu_Forum> a org:Organization ;
    ns1:basedInHighGeoName "Austin" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4671654/about.rdf> ;
    ns1:basedInHighRaw "AUSTIN, Texas" ;
    ns1:documentDate "2012-06-12T16:30:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Savara Pharmaceuticals Raises $8.6 Million in Series B Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/savara-pharmaceuticals-raises-8-6-million-series-b-financing-round> ;
    ns1:foundName "The Keiretsu Forum" ;
    ns1:investor <https://1145.am/db/2359863/Series_B_Investment_Savara_Pharmaceuticals_The_Keiretsu_Forum_Completed> ;
    ns1:name "The Keiretsu Forum" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359865/Series_B_Investment_Savara_Pharmaceuticals_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-12T14:55:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "ALSO: In related VC news, Austin, TX - based Savara Pharmaceuticals announced that it raised $ 8.6 million in Series B cash to back its work on AeroVanc (vancomycin hydrochloride inhalation powder) through a Phase IIa clinical efficacy study." ;
    ns1:documentTitle "Third Rock takes lead on $33M C round for antibody upstart Igenica" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/third-rock-takes-lead-on-33m-c-round-for-antibody-upstart-igenica> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2359865/Aerovanc>,
        <https://1145.am/db/2359865/Savara_Pharmaceuticals> ;
    ns1:targetDetails "Series B" ;
    ns1:targetName "AeroVanc" ;
    ns1:valueRaw "$ 8.6 million" ;
    ns1:whereGeoName "Austin",
        "Burlingame" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4671654/about.rdf>,
        <https://sws.geonames.org/5331920/about.rdf> ;
    ns1:whereRaw "Austin",
        "Burlingame, CA" .

<https://1145.am/db/2359865/Third_Rock> a org:Organization ;
    ns1:basedInHighGeoName "Burlingame" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5331920/about.rdf> ;
    ns1:basedInHighRaw "Burlingame, CA" ;
    ns1:documentDate "2012-06-12T14:55:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Third Rock takes lead on $33M C round for antibody upstart Igenica" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/third-rock-takes-lead-on-33m-c-round-for-antibody-upstart-igenica> ;
    ns1:foundName "Third Rock" ;
    ns1:industry "biotech" ;
    ns1:investor <https://1145.am/db/2359865/C_Investment_Igenica_Igenica_Third_Rock_Has_Not_Happened> ;
    ns1:name "Third Rock" ;
    ns1:sameAsHigh <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2371304/Third_Rock> ;
    ns1:sameAsMedium <https://1145.am/db/2289887/Third_Rock>,
        <https://1145.am/db/2297664/Third_Rock>,
        <https://1145.am/db/2356352/Third_Rock>,
        <https://1145.am/db/2358296/Third_Rock>,
        <https://1145.am/db/2360004/Third_Rock> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359873/Ipsen> a org:Organization ;
    ns1:basedInLowRaw "Denmark" ;
    ns1:documentDate "2012-06-13T11:26:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/rhythm-raises-25m-series-b-financing-for-diabetes-and-obesity-therapeutics> ;
    ns1:foundName "Ipsen" ;
    ns1:investor <https://1145.am/db/2359873/Series_B_Investment_Ipsen_Mpm_Capital_New_Enterprise_Associates_Rhythm_Third_Rock_Ventures_Completed> ;
    ns1:name "Ipsen" ;
    ns1:sameAsMedium <https://1145.am/db/1161944/Ipsen>,
        <https://1145.am/db/1161957/Ipsen>,
        <https://1145.am/db/1163844/Ipsen_Sa>,
        <https://1145.am/db/1163848/Ipsen>,
        <https://1145.am/db/1163855/Ipsen>,
        <https://1145.am/db/1167451/Ipsen_Sa>,
        <https://1145.am/db/1176544/Ipsen>,
        <https://1145.am/db/1200853/Ipsen_Sa>,
        <https://1145.am/db/1202151/Ipsen_Sa>,
        <https://1145.am/db/1257196/Ipsen_Sa>,
        <https://1145.am/db/1257350/Ipsen_Sa>,
        <https://1145.am/db/1276041/Ipsen>,
        <https://1145.am/db/1626341/Ipsen>,
        <https://1145.am/db/1633106/Ipsen_Sa>,
        <https://1145.am/db/1633169/Ipsen_Sa>,
        <https://1145.am/db/1644477/Ipsen>,
        <https://1145.am/db/1645222/Ipsen>,
        <https://1145.am/db/2152544/Ipsen>,
        <https://1145.am/db/2153682/Ipsen>,
        <https://1145.am/db/2153782/Ipsen>,
        <https://1145.am/db/2153982/Ipsen>,
        <https://1145.am/db/2154368/Ipsen>,
        <https://1145.am/db/2155620/Ipsen>,
        <https://1145.am/db/2288192/Ipsen>,
        <https://1145.am/db/2288500/Ipsen>,
        <https://1145.am/db/2294817/Ipsen>,
        <https://1145.am/db/2295271/Ipsen>,
        <https://1145.am/db/2301863/Ipsen>,
        <https://1145.am/db/2302740/Ipsen>,
        <https://1145.am/db/2302958/Ipsen>,
        <https://1145.am/db/2309378/Ipsen_Sa>,
        <https://1145.am/db/2324027/Ipsen>,
        <https://1145.am/db/2329638/Ipsen>,
        <https://1145.am/db/2332815/Ipsen>,
        <https://1145.am/db/2336604/Ipsen>,
        <https://1145.am/db/2336987/Ipsen>,
        <https://1145.am/db/2337102/Ipsen>,
        <https://1145.am/db/2337689/Ipsen>,
        <https://1145.am/db/2339031/Ipsen>,
        <https://1145.am/db/2343954/Ipsen>,
        <https://1145.am/db/2346204/Ipsen>,
        <https://1145.am/db/2352361/Ipsen>,
        <https://1145.am/db/2354464/Ipsen>,
        <https://1145.am/db/2355419/Ipsen>,
        <https://1145.am/db/2360217/Ipsen>,
        <https://1145.am/db/2360232/Ipsen>,
        <https://1145.am/db/2364637/Ipsen>,
        <https://1145.am/db/2367100/Ipsen>,
        <https://1145.am/db/2367129/Ipsen>,
        <https://1145.am/db/2369202/Ipsen>,
        <https://1145.am/db/2370067/Ipsen>,
        <https://1145.am/db/2371455/Ipsen>,
        <https://1145.am/db/2539925/Ipsen>,
        <https://1145.am/db/2541727/Ipsen>,
        <https://1145.am/db/2544894/Ipsen>,
        <https://1145.am/db/2544901/Ipsen>,
        <https://1145.am/db/2561454/Ipsen>,
        <https://1145.am/db/2567081/Ipsen>,
        <https://1145.am/db/534524/Ipsen>,
        <https://1145.am/db/538860/Ipsen>,
        <https://1145.am/db/586242/Ipsen>,
        <https://1145.am/db/772473/Ipsen>,
        <https://1145.am/db/773879/Ipsen>,
        <https://1145.am/db/835053/Ipsen> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359883/Newron> a org:Organization ;
    ns1:basedInLowRaw "Sweden" ;
    ns1:buyer <https://1145.am/db/2359883/Neuronova_Acquisition> ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-06-13T14:40:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Newron to acquire Swedish neurogenesis company NeuroNova AB" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/newron-to-acquire-swedish-neurogenesis-company-neuronova-ab> ;
    ns1:foundName "Newron",
        "Newron Pharmaceuticals S.p.A." ;
    ns1:industry "Pharmaceutical" ;
    ns1:investor <https://1145.am/db/2359883/Neuronova_Acquisition> ;
    ns1:name "Newron" ;
    ns1:sameAsHigh <https://1145.am/db/1177426/Newron_Pharmaceuticals_Spa>,
        <https://1145.am/db/1177960/Newron_Pharmaceuticals_Spa>,
        <https://1145.am/db/1990974/Newron_Pharmaceuticals_Spa>,
        <https://1145.am/db/2131877/Newron_Pharmaceuticals_Spa>,
        <https://1145.am/db/2292647/Newron_Pharmaceuticals>,
        <https://1145.am/db/2307908/Newron_Pharmaceuticals>,
        <https://1145.am/db/2311082/Newron_Pharmaceuticals_Spa>,
        <https://1145.am/db/2320068/Newron_Pharmaceuticals>,
        <https://1145.am/db/2350237/Newron>,
        <https://1145.am/db/2350241/Newron_Pharmaceuticals>,
        <https://1145.am/db/2353663/Newron_Pharmaceuticals_Spa>,
        <https://1145.am/db/2353668/Newron_Pharmaceuticals>,
        <https://1145.am/db/2355647/Newron_Pharmaceuticals_Spa>,
        <https://1145.am/db/2359529/Newbridge_Pharmaceuticals>,
        <https://1145.am/db/2360045/Newron_Pharmaceuticals>,
        <https://1145.am/db/2362027/Newron>,
        <https://1145.am/db/2364093/Newron>,
        <https://1145.am/db/2368100/Newron_Pharmaceuticals_Spa>,
        <https://1145.am/db/452556/Newron_Pharmaceutical_Spa>,
        <https://1145.am/db/454784/Newron_Pharmaceutical_Spa>,
        <https://1145.am/db/555008/Newron_Pharmaceuticals_Spa>,
        <https://1145.am/db/557077/Newron_Pharmaceuticals_Spa> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360922/Industrifonden> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Denmark" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2623032/about.rdf> ;
    ns1:basedInHighRaw "Denmark" ;
    ns1:documentDate "2012-06-19T12:13:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nuevolution A/S Raises € 11 Million in New Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/nuevolution-a-s-raises-%E2%82%AC-11-million-new-financing-round> ;
    ns1:foundName "Industrifonden" ;
    ns1:investor <https://1145.am/db/2360922/Investment_Industrifonden_Nuevolution_A_S_Seb_Utvecklingsstiftelse_Seb_Venture_Capital_Sunstone_Capital_Completed> ;
    ns1:name "Industrifonden" ;
    ns1:sameAsMedium <https://1145.am/db/1583413/Industrifonden>,
        <https://1145.am/db/1584328/Industrifonden>,
        <https://1145.am/db/1699203/Industrifonden>,
        <https://1145.am/db/1703315/Industrifonden>,
        <https://1145.am/db/1708592/Industrifonden>,
        <https://1145.am/db/1757590/Industrifonden>,
        <https://1145.am/db/1762583/Industrifonden>,
        <https://1145.am/db/1772429/Industrifonden>,
        <https://1145.am/db/1776452/Industrifonden>,
        <https://1145.am/db/1784881/Industrifonden>,
        <https://1145.am/db/1795283/Industrifonden>,
        <https://1145.am/db/1800176/Industrifonden>,
        <https://1145.am/db/1819437/Industrifonden>,
        <https://1145.am/db/1837910/Industrifonden>,
        <https://1145.am/db/1855181/Industrifonden>,
        <https://1145.am/db/1857635/Industrifonden>,
        <https://1145.am/db/2357333/Industrifonden>,
        <https://1145.am/db/2368273/Industrifonden>,
        <https://1145.am/db/2368278/Industrifonden>,
        <https://1145.am/db/2370798/Industrifonden>,
        <https://1145.am/db/545774/Industrifonden> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360922/Seb_Utvecklingsstiftelse> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Denmark" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2623032/about.rdf> ;
    ns1:basedInHighRaw "Denmark" ;
    ns1:documentDate "2012-06-19T12:13:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nuevolution A/S Raises € 11 Million in New Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/nuevolution-a-s-raises-%E2%82%AC-11-million-new-financing-round> ;
    ns1:foundName "SEB Utvecklingsstiftelse" ;
    ns1:investor <https://1145.am/db/2360922/Investment_Industrifonden_Nuevolution_A_S_Seb_Utvecklingsstiftelse_Seb_Venture_Capital_Sunstone_Capital_Completed> ;
    ns1:name "SEB Utvecklingsstiftelse" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360922/Seb_Venture_Capital> a org:Organization ;
    ns1:basedInLowRaw "Denmark" ;
    ns1:description "Investing" ;
    ns1:documentDate "2012-06-19T12:13:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nuevolution A/S Raises € 11 Million in New Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/nuevolution-a-s-raises-%E2%82%AC-11-million-new-financing-round> ;
    ns1:foundName "SEB Venture Capital" ;
    ns1:investor <https://1145.am/db/2360922/Investment_Industrifonden_Nuevolution_A_S_Seb_Utvecklingsstiftelse_Seb_Venture_Capital_Sunstone_Capital_Completed> ;
    ns1:name "SEB Venture Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1405080/Backed_Vc>,
        <https://1145.am/db/1575657/Life_Sciences_Corporate_Venture_Capital>,
        <https://1145.am/db/1747510/Act_Venture_Capital>,
        <https://1145.am/db/1763964/Wing_Venture_Capital>,
        <https://1145.am/db/1773341/Sabadell_Venture_Capital>,
        <https://1145.am/db/1852951/Ff_Venture_Capital>,
        <https://1145.am/db/1856417/Institutional_Venture_Partners>,
        <https://1145.am/db/2291361/Act_Venture_Capital>,
        <https://1145.am/db/2798718/Speciale_Invest>,
        <https://1145.am/db/679989/Wing_Venture_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1808313/Seb_Venture_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363941/Mitsubishi_Tanabe_Pharma_Group> a org:Organization ;
    ns1:basedInHighGeoName "Japan" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1861060/about.rdf> ;
    ns1:basedInHighRaw "Japan" ;
    ns1:documentDate "2012-07-09T04:00:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biotech Genkyotex nails down $26M to fund drug for diabetic kidney disease" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotech-genkyotex-nails-down-26m-to-fund-drug-for-diabetic-kidney-disease> ;
    ns1:foundName "Mitsubishi Tanabe Pharma Group" ;
    ns1:industry "Pharma" ;
    ns1:name "Mitsubishi Tanabe Pharma Group" ;
    ns1:participant <https://1145.am/db/2363941/Investment_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Mitsubishi_Tanabe_Pharma_Group_Vesalius_Biocapital_Partners_Completed> ;
    ns1:sameAsHigh <https://1145.am/db/2296526/Mitsubishi_Tanabe>,
        <https://1145.am/db/2303144/Mitsubishi_Chemical_Holdings>,
        <https://1145.am/db/2311128/Mitsubishi_Tanabe_Pharma_Corporation>,
        <https://1145.am/db/2311133/Mitsubishi_Tanabe_Pharma_Corporation>,
        <https://1145.am/db/2327617/Mitsubishi_Pharma_Corporation>,
        <https://1145.am/db/2334147/Mitsubishi_Chemical_Holdings>,
        <https://1145.am/db/2334150/Mitsubishi_Pharma_Corporation>,
        <https://1145.am/db/2339016/Mitsubishi_Tanabe_Pharma_Corporation>,
        <https://1145.am/db/2339017/Mitsubishi_Tanabe_Pharma>,
        <https://1145.am/db/2552383/Mitsubishi_Tanabe_Pharma_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363950/Imperial_Innovations_Group> a org:Organization ;
    ns1:basedInLowRaw "LONDON" ;
    ns1:description "Innovations" ;
    ns1:documentDate "2012-07-09T16:23:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PsiOxus Therapeutics Secures GBP 22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/psioxus-therapeutics-secures-gbp-22-million-34-million-series-b-financing-to-drive-clinical> ;
    ns1:foundName "Imperial Innovations Group" ;
    ns1:investor <https://1145.am/db/2363950/Equity_Investment_Imperial_Innovations_Group_Invesco_Perpetual_Lundbeckfond_Ventures_Psioxus_Therapeutics_Ltd_Sr_One_Completed> ;
    ns1:name "Imperial Innovations Group" ;
    ns1:sameAsMedium <https://1145.am/db/1824653/Imperial_Innovations_Group>,
        <https://1145.am/db/1831846/Imperial_Innovations_Group>,
        <https://1145.am/db/2292350/Imperial_Innovations_Group>,
        <https://1145.am/db/2336890/Imperial_Innovations_Group_Plc>,
        <https://1145.am/db/2342266/Imperial_Innovations_Group_Plc>,
        <https://1145.am/db/2342564/Imperial_Innovations_Group_Plc>,
        <https://1145.am/db/2343301/Imperial_Innovations_Group_Plc>,
        <https://1145.am/db/2349961/Imperial_Innovations_Group_Plc>,
        <https://1145.am/db/2360485/Imperial_Innovations_Group_Plc>,
        <https://1145.am/db/2363947/Imperial_Innovations_Group>,
        <https://1145.am/db/2368251/Imperial_Innovations_Group_Plc>,
        <https://1145.am/db/2544138/Imperial_Innovations_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/Early_Stage_Partners> a org:Organization ;
    ns1:basedInLowRaw "CLEVELAND" ;
    ns1:description "venture firms" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "Early Stage Partners" ;
    ns1:investor <https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> ;
    ns1:name "Early Stage Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1051625/Declaration_Partners>,
        <https://1145.am/db/1140692/Renegade_Partners>,
        <https://1145.am/db/1204750/Digital+_Partners>,
        <https://1145.am/db/1578096/Primary_Venture_Partners>,
        <https://1145.am/db/1618333/Partners_Group>,
        <https://1145.am/db/1620477/Partners_Group>,
        <https://1145.am/db/1766390/Harmony_Partners>,
        <https://1145.am/db/1803251/Harmony_Partners>,
        <https://1145.am/db/2365444/Early_Stage_Partners>,
        <https://1145.am/db/2549919/Partners_Group>,
        <https://1145.am/db/2702871/Harmony_Partners>,
        <https://1145.am/db/556441/Partners_Group> ;
    ns1:sameAsMedium <https://1145.am/db/2299852/Early_Stage_Partners>,
        <https://1145.am/db/2330758/Early_Stage_Partners>,
        <https://1145.am/db/2330775/Early_Stage_Partners>,
        <https://1145.am/db/2364820/Early_Stage_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/Glengary> a org:Organization ;
    ns1:basedInLowRaw "CLEVELAND" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "Glengary" ;
    ns1:investor <https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> ;
    ns1:name "Glengary" ;
    ns1:sameAsMedium <https://1145.am/db/2365444/Glengary> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/Global_Cardiovascular_Innovation_Center> a org:Organization ;
    ns1:basedInLowRaw "CLEVELAND" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "Global Cardiovascular Innovation Center" ;
    ns1:investor <https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> ;
    ns1:name "Global Cardiovascular Innovation Center" ;
    ns1:sameAsMedium <https://1145.am/db/2365444/Global_Cardiovascular_Innovation_Center> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/New_Science_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CLEVELAND" ;
    ns1:description "venture firms" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "New Science Ventures" ;
    ns1:investor <https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> ;
    ns1:name "New Science Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2154415/New_Science_Ventures>,
        <https://1145.am/db/2309865/New_Science_Ventures>,
        <https://1145.am/db/2326139/New_Science_Ventures>,
        <https://1145.am/db/2339427/New_Science_Ventures>,
        <https://1145.am/db/2339932/New_Science_Ventures>,
        <https://1145.am/db/2339933/New_Science_Ventures>,
        <https://1145.am/db/2343140/New_Science_Ventures>,
        <https://1145.am/db/2343989/New_Science_Ventures>,
        <https://1145.am/db/2344978/New_Science_Ventures>,
        <https://1145.am/db/2370056/New_Science_Ventures>,
        <https://1145.am/db/704198/New_Science_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2304650/New_Science_Ventures>,
        <https://1145.am/db/2309872/New_Science_Ventures>,
        <https://1145.am/db/2314677/New_Science_Ventures>,
        <https://1145.am/db/2320692/New_Science_Ventures>,
        <https://1145.am/db/2322312/New_Science_Ventures>,
        <https://1145.am/db/2326130/New_Science_Ventures>,
        <https://1145.am/db/2331639/New_Science_Ventures>,
        <https://1145.am/db/2333573/New_Science_Ventures>,
        <https://1145.am/db/2333577/New_Science_Ventures>,
        <https://1145.am/db/2338987/New_Science_Ventures>,
        <https://1145.am/db/2339428/New_Science_Ventures>,
        <https://1145.am/db/2342717/New_Science_Ventures>,
        <https://1145.am/db/2363484/New_Science_Ventures>,
        <https://1145.am/db/2363485/New_Science_Ventures>,
        <https://1145.am/db/2364820/New_Science_Ventures>,
        <https://1145.am/db/2365444/New_Science_Ventures>,
        <https://1145.am/db/2370054/New_Science_Ventures>,
        <https://1145.am/db/2447981/New_Science_Ventures_Llc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/Reservoir_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "CLEVELAND" ;
    ns1:description "venture firms" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "Reservoir Venture Partners" ;
    ns1:investor <https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> ;
    ns1:name "Reservoir Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1824252/Reservoir_Venture_Partners>,
        <https://1145.am/db/2365444/Reservoir_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2330775/Reservoir_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/Takeda_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CLEVELAND" ;
    ns1:description "venture firms" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "Takeda Ventures" ;
    ns1:investor <https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> ;
    ns1:name "Takeda Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2365444/Takeda_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1115103/Takeda_Ventures>,
        <https://1145.am/db/1116076/Takeda_Ventures>,
        <https://1145.am/db/1469013/Takeda_Ventures>,
        <https://1145.am/db/1476658/Takeda_Ventures>,
        <https://1145.am/db/2280896/Takeda_Ventures>,
        <https://1145.am/db/2284001/Takeda_Ventures>,
        <https://1145.am/db/2336944/Takeda_Ventures>,
        <https://1145.am/db/2341074/Takeda_Ventures>,
        <https://1145.am/db/2353283/Takeda_Ventures>,
        <https://1145.am/db/2363593/Takeda_Ventures>,
        <https://1145.am/db/2363597/Takeda_Ventures>,
        <https://1145.am/db/2544087/Takeda_Ventures>,
        <https://1145.am/db/2555545/Takeda_Ventures>,
        <https://1145.am/db/564585/Takeda_Ventures_Inc>,
        <https://1145.am/db/566971/Takeda_Ventures_Inc>,
        <https://1145.am/db/847865/Takeda_Ventures>,
        <https://1145.am/db/979509/Takeda_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/Tri-State_Growth_Fund> a org:Organization ;
    ns1:basedInLowRaw "CLEVELAND" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "Tri-State Growth Fund" ;
    ns1:investor <https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> ;
    ns1:name "Tri-State Growth Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2365444/Tri-State_Growth_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/Triathlon_Medical_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "CLEVELAND" ;
    ns1:description "Venture capital" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "Triathlon Medical Venture Partners" ;
    ns1:investor <https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> ;
    ns1:name "Triathlon Medical Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2303695/Triathlon_Medical_Ventures>,
        <https://1145.am/db/2305706/Triathlon_Medical_Ventures>,
        <https://1145.am/db/2326139/Triathlon_Medical_Ventures>,
        <https://1145.am/db/2335764/Triathlon_Medical_Ventures>,
        <https://1145.am/db/2354752/Triathlon_Medical_Ventures>,
        <https://1145.am/db/2361588/Triathlon_Medical_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2309865/Triathlon_Medical_Venture_Partners>,
        <https://1145.am/db/2309872/Triathlon_Medical_Venture_Partners>,
        <https://1145.am/db/2339139/Triathlon_Medical_Venture_Partners>,
        <https://1145.am/db/2339163/Triathlon_Medical_Venture_Partners>,
        <https://1145.am/db/2364820/Triathlon_Medical_Venture_Partners>,
        <https://1145.am/db/2365444/Triathlon_Medical_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/Venture_Investors> a org:Organization ;
    ns1:basedInLowRaw "CLEVELAND" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "Venture Investors" ;
    ns1:investor <https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> ;
    ns1:name "Venture Investors" ;
    ns1:sameAsMedium <https://1145.am/db/1105339/Venture_Investors>,
        <https://1145.am/db/2299743/Venture_Investors>,
        <https://1145.am/db/2301714/Venture_Investors>,
        <https://1145.am/db/2301715/Venture_Investors>,
        <https://1145.am/db/2303695/Venture_Investors_Llc>,
        <https://1145.am/db/2311076/Venture_Investors>,
        <https://1145.am/db/2321713/Venture_Investors>,
        <https://1145.am/db/2354752/Venture_Investors_Llc>,
        <https://1145.am/db/2354770/Venture_Investors_Llc>,
        <https://1145.am/db/2365444/Venture_Investors>,
        <https://1145.am/db/2367046/Venture_Investors_Llc>,
        <https://1145.am/db/2369504/Venture_Investors_Llc>,
        <https://1145.am/db/2556669/Venture_Investors_Llc>,
        <https://1145.am/db/2575232/Venture_Investors_Llc>,
        <https://1145.am/db/2583558/Venture_Investors_Llc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364853/Ascent_Biomedical_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "New York" ;
    ns1:documentDate "2012-07-18T15:46:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Coferon, Inc. Announces $12 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/coferon-inc-announces-12-million-series-b-financing> ;
    ns1:foundName "Ascent Biomedical Ventures",
        "Ascent Biomedical Ventures of New York, N.Y" ;
    ns1:industry "biotechnology" ;
    ns1:investor <https://1145.am/db/2364853/Series_B_Investment_Ascent_Biomedical_Ventures_Coferon_Inc_Hatteras_Venture_Partners_Medimmune_Ventures_Completed> ;
    ns1:name "Ascent Biomedical Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2069495/Hikma_Ventures>,
        <https://1145.am/db/2314400/Sofinnova_Ventures>,
        <https://1145.am/db/2314964/Sofinnova_Ventures>,
        <https://1145.am/db/2315932/Bb_Biotech_Ventures>,
        <https://1145.am/db/2315932/Forward_Ventures>,
        <https://1145.am/db/2316380/Targeted_Technology_Ventures>,
        <https://1145.am/db/2321150/Flagship_Ventures>,
        <https://1145.am/db/2324195/Sofinnova_Ventures>,
        <https://1145.am/db/2328338/Sofinnova_Ventures>,
        <https://1145.am/db/2328585/Cmea_Ventures>,
        <https://1145.am/db/2363459/Rho_Ventures>,
        <https://1145.am/db/2370056/New_Science_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2303810/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2303814/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2310031/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2324354/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2342488/Ascent_Biomedical_Ventures>,
        <https://1145.am/db/2342498/Ascent_Biomedical_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364853/Gaithersburg_Md> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:documentDate "2012-07-18T15:46:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Coferon, Inc. Announces $12 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/coferon-inc-announces-12-million-series-b-financing> ;
    ns1:foundName "MedImmune Ventures of" ;
    ns1:industry "biotechnology" ;
    ns1:investor <https://1145.am/db/2364853/Series_B_Investment_Ascent_Biomedical_Ventures_Coferon_Inc_Hatteras_Venture_Partners_Medimmune_Ventures_Completed> ;
    ns1:name "Gaithersburg, MD" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366434/Imperial_Innovations> a org:Organization ;
    ns1:basedInLowRaw "UK" ;
    ns1:documentDate "2012-07-23T12:18:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cell Medica Secures £17 million ($26.5 million) Equity Investment to Establish US Operations and Fund Cell Therapy Development" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cell-medica-secures-%C2%A317-million-26-5-million-equity-investment-to-establish-us-operations> ;
    ns1:foundName "Imperial Innovations" ;
    ns1:investor <https://1145.am/db/2366434/Investment_Cell_Medica_Imperial_Innovations_Invesco_Perpetual_Has_Not_Happened> ;
    ns1:name "Imperial Innovations" ;
    ns1:sameAsMedium <https://1145.am/db/1816718/Imperial_Innovations>,
        <https://1145.am/db/1818630/Imperial_Innovations>,
        <https://1145.am/db/2292975/Imperial_Innovations>,
        <https://1145.am/db/2297304/Imperial_Innovations>,
        <https://1145.am/db/2302961/Imperial_Innovations>,
        <https://1145.am/db/2302965/Imperial_Innovations>,
        <https://1145.am/db/2304844/Imperial_Innovations>,
        <https://1145.am/db/2319447/Imperial_Innovations>,
        <https://1145.am/db/2334956/Imperial_Innovations>,
        <https://1145.am/db/2336335/Imperial_Innovations>,
        <https://1145.am/db/2341738/Imperial_Innovations>,
        <https://1145.am/db/2341760/Imperial_Innovations>,
        <https://1145.am/db/2342260/Imperial_Innovations>,
        <https://1145.am/db/2342261/Imperial_Innovations>,
        <https://1145.am/db/2348796/Imperial_Innovations>,
        <https://1145.am/db/2348797/Imperial_Innovations>,
        <https://1145.am/db/2354401/Imperial_Innovations>,
        <https://1145.am/db/2358586/Imperial_Innovations_Plc>,
        <https://1145.am/db/2366154/Imperial_Innovations>,
        <https://1145.am/db/2366156/Imperial_Innovations>,
        <https://1145.am/db/2368313/Imperial_Innovations>,
        <https://1145.am/db/2369699/Imperial_Innovations>,
        <https://1145.am/db/2370257/Imperial_Innovations>,
        <https://1145.am/db/2370262/Imperial_Innovations>,
        <https://1145.am/db/2370272/Imperial_Innovations> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2440017/Fund_Of_Mitsubishi_Ufj_Capital> a org:Organization ;
    ns1:basedInLowRaw "Japan" ;
    ns1:documentDate "2012-05-03T05:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Micropelt Raises 6'5 Mio EURO" ;
    ns1:documentURL <https://www.fierceelectronics.com/embedded/micropelt-raises-6-5-mio-euro> ;
    ns1:foundName "the Fund of Mitsubishi UFJ Capital" ;
    ns1:investor <https://1145.am/db/2440017/Investment_Fund_Of_Mitsubishi_Ufj_Capital_Ibg___Goodvent_Kfw_L-Bank_Ludgate_Environmental_Fund_Micropelt_Shs_Completed> ;
    ns1:name "Fund of Mitsubishi UFJ Capital" ;
    ns1:sourceName "Fierce Electronics" .

<https://1145.am/db/2440017/Ibg___Goodvent> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:documentDate "2012-05-03T05:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Micropelt Raises 6'5 Mio EURO" ;
    ns1:documentURL <https://www.fierceelectronics.com/embedded/micropelt-raises-6-5-mio-euro> ;
    ns1:foundName "IBG / Goodvent" ;
    ns1:investor <https://1145.am/db/2440017/Investment_Fund_Of_Mitsubishi_Ufj_Capital_Ibg___Goodvent_Kfw_L-Bank_Ludgate_Environmental_Fund_Micropelt_Shs_Completed> ;
    ns1:name "IBG / Goodvent" ;
    ns1:sameAsMedium <https://1145.am/db/2353607/Goodvent_Ibg>,
        <https://1145.am/db/2353610/Goodvent__Ibg> ;
    ns1:sourceName "Fierce Electronics" .

<https://1145.am/db/2440017/KFW> a org:Organization ;
    ns1:basedInHighGeoName "Federal Republic of Germany" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:basedInHighRaw "Germany" ;
    ns1:documentDate "2012-05-03T05:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Micropelt Raises 6'5 Mio EURO" ;
    ns1:documentURL <https://www.fierceelectronics.com/embedded/micropelt-raises-6-5-mio-euro> ;
    ns1:foundName "KfW" ;
    ns1:investor <https://1145.am/db/2440017/Investment_Fund_Of_Mitsubishi_Ufj_Capital_Ibg___Goodvent_Kfw_L-Bank_Ludgate_Environmental_Fund_Micropelt_Shs_Completed> ;
    ns1:name "KfW" ;
    ns1:sameAsMedium <https://1145.am/db/1115864/KFW>,
        <https://1145.am/db/1275433/KFW>,
        <https://1145.am/db/1291324/KFW>,
        <https://1145.am/db/1602418/KFW>,
        <https://1145.am/db/1667816/KFW>,
        <https://1145.am/db/1710755/KFW>,
        <https://1145.am/db/1754583/KFW>,
        <https://1145.am/db/1853264/KFW>,
        <https://1145.am/db/1898197/KFW>,
        <https://1145.am/db/1911897/KFW>,
        <https://1145.am/db/2296701/KFW>,
        <https://1145.am/db/2305628/KFW>,
        <https://1145.am/db/2347872/KFW>,
        <https://1145.am/db/2358030/KFW>,
        <https://1145.am/db/2360425/KFW>,
        <https://1145.am/db/2558803/KFW>,
        <https://1145.am/db/315335/KFW>,
        <https://1145.am/db/894768/KFW> ;
    ns1:sourceName "Fierce Electronics" .

<https://1145.am/db/2440017/L-Bank> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:documentDate "2012-05-03T05:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Micropelt Raises 6'5 Mio EURO" ;
    ns1:documentURL <https://www.fierceelectronics.com/embedded/micropelt-raises-6-5-mio-euro> ;
    ns1:foundName "L-Bank" ;
    ns1:investor <https://1145.am/db/2440017/Investment_Fund_Of_Mitsubishi_Ufj_Capital_Ibg___Goodvent_Kfw_L-Bank_Ludgate_Environmental_Fund_Micropelt_Shs_Completed> ;
    ns1:name "L-Bank" ;
    ns1:sameAsMedium <https://1145.am/db/1751509/L-Bank> ;
    ns1:sourceName "Fierce Electronics" .

<https://1145.am/db/2440017/Ludgate_Environmental_Fund> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:description "Investing" ;
    ns1:documentDate "2012-05-03T05:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Micropelt Raises 6'5 Mio EURO" ;
    ns1:documentURL <https://www.fierceelectronics.com/embedded/micropelt-raises-6-5-mio-euro> ;
    ns1:foundName "Ludgate Environmental Fund" ;
    ns1:investor <https://1145.am/db/2440017/Investment_Fund_Of_Mitsubishi_Ufj_Capital_Ibg___Goodvent_Kfw_L-Bank_Ludgate_Environmental_Fund_Micropelt_Shs_Completed> ;
    ns1:name "Ludgate Environmental Fund" ;
    ns1:sameAsHigh <https://1145.am/db/2434766/Ludgate_Environmental_Fund> ;
    ns1:sourceName "Fierce Electronics" .

<https://1145.am/db/2440017/SHS> a org:Organization ;
    ns1:basedInLowRaw "Germany" ;
    ns1:documentDate "2012-05-03T05:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Micropelt Raises 6'5 Mio EURO" ;
    ns1:documentURL <https://www.fierceelectronics.com/embedded/micropelt-raises-6-5-mio-euro> ;
    ns1:foundName "SHS" ;
    ns1:investor <https://1145.am/db/2440017/Investment_Fund_Of_Mitsubishi_Ufj_Capital_Ibg___Goodvent_Kfw_L-Bank_Ludgate_Environmental_Fund_Micropelt_Shs_Completed> ;
    ns1:name "SHS" ;
    ns1:sourceName "Fierce Electronics" .

<https://1145.am/db/2541195/National_Institute_Of_Allergy_And_Infectious_Diseases> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "a) a division of the National Institutes of Health (NIH) b" ;
    ns1:documentDate "2012-05-03T13:10:22+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Profectus BioSciences Receives NIAID Grant to Develop a Vesicular Stomatitis Virus-vectored Vaccine for Ebola and Marburg Viruses" ;
    ns1:documentURL <https://www.fiercepharma.com/vaccines/profectus-biosciences-receives-niaid-grant-to-develop-a-vesicular-stomatitis-virus> ;
    ns1:foundName "National Institute of Allergy and Infectious Diseases" ;
    ns1:investor <https://1145.am/db/2541195/Investment_Galveston_National_Laboratory_National_Institute_Of_Allergy_And_Infectious_Diseases_Profectus_Biosciences_Inc_Has_Not_Happened> ;
    ns1:name "National Institute of Allergy and Infectious Diseases" ;
    ns1:sameAsHigh <https://1145.am/db/2350042/National_Institute_Of_Allergy_And_Infectious_Diseases>,
        <https://1145.am/db/928346/National_Institute_Of_Allergy_And_Infectious_Diseases> ;
    ns1:sameAsMedium <https://1145.am/db/1123594/National_Institute_Of_Allergy_And_Infectious_Diseases>,
        <https://1145.am/db/1124966/National_Institute_Of_Allergy_And_Infectious_Diseases>,
        <https://1145.am/db/2312138/National_Institute_Of_Allergy_And_Infectious_Diseases>,
        <https://1145.am/db/2340334/National_Institute_Of_Allergy_And_Infectious_Disease>,
        <https://1145.am/db/2355950/National_Institute_Of_Allergy_And_Infectious_Diseases>,
        <https://1145.am/db/2582667/National_Institute_Of_Allergy_And_Infectious_Diseases> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2554659/John_Copanos> a org:Organization ;
    ns1:basedInHighGeoName "Fort Lauderdale" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4155966/about.rdf> ;
    ns1:basedInHighRaw "Fort Lauderdale" ;
    ns1:basedInLowRaw "TX" ;
    ns1:buyer <https://1145.am/db/2554659/Deltex_Pharmaceuticals_Acquisition>,
        <https://1145.am/db/2554659/Joint_Venture_John_Copanos_Has_Not_Happened> ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2012-07-23T19:41:21+00:00"^^xsd:dateTime ;
    ns1:documentTitle "New Florida drugmaker springs from debacle of another" ;
    ns1:documentURL <https://www.fiercepharma.com/regulatory/new-florida-drugmaker-springs-from-debacle-of-another> ;
    ns1:foundName "Copanos",
        "John Copanos" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:investor <https://1145.am/db/2554659/Deltex_Pharmaceuticals_Acquisition>,
        <https://1145.am/db/2554659/Investment_John_Copanos_Has_Not_Happened> ;
    ns1:name "Copanos",
        "John Copanos" ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2555683/Croda> a org:Organization ;
    ns1:basedInLowRaw "Italian" ;
    ns1:buyer <https://1145.am/db/2555683/Istituto_Di_Ricerche_Biotecnologiche_Acquisition> ;
    ns1:description "Chemicalmaking" ;
    ns1:documentDate "2012-07-24T11:44:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Michigan loses $3M on drug manufacturing try; API maker Croda buys a biotech firm;" ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/michigan-loses-3m-on-drug-manufacturing-try-api-maker-croda-buys-a-biotech-firm> ;
    ns1:foundName "Croda" ;
    ns1:industry "Chemicalmaker" ;
    ns1:name "Croda" ;
    ns1:sameAsHigh <https://1145.am/db/716279/Croda> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2572450/Stake_Acquisition_Gerot_Lannach_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-03-26T15:57:29+00:00"^^xsd:dateTime ;
    ns1:documentExtract "The Natur Produkt deal follows closely after Valeant snapped up some assets from Austrian branded-generics maker Gerot Lannach; some 90 % of the sales from those products comes from Russia." ;
    ns1:documentTitle "Valeant nabs Russia's Natur Produkt for $175M-plus" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/valeant-nabs-russia-s-natur-produkt-for-175m-plus> ;
    ns1:foundName "snapped" ;
    ns1:name "snapped" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:targetDetails "stake" ;
    ns1:vendor <https://1145.am/db/2572450/Gerot_Lannach> ;
    ns1:whereGeoName "Federative Republic of Brazil" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3469034/about.rdf> ;
    ns1:whereRaw "Brazil" .

<https://1145.am/db/2579168/Venture_Investment_Innopharma_Inc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-08T11:01:20+00:00"^^xsd:dateTime ;
    ns1:documentExtract "InnoPharma Inc. Raises $ 8 Million in Venture Debt.",
        "PISCATAWAY, N.J., June 7, 2012 /PRNewswire/ - InnoPharma, Inc. today." ;
    ns1:documentTitle "InnoPharma Inc. Raises $8 Million in Venture Debt" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/innopharma-inc-raises-8-million-venture-debt> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2579168/Innopharma_Inc> ;
    ns1:targetDetails "Venture" ;
    ns1:valueRaw "$ 8 Million",
        "$ 8 million" ;
    ns1:when "2012-06-07T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "June 7, 2012" ;
    ns1:whereGeoName "New Jersey" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5101760/about.rdf> ;
    ns1:whereRaw "N.J." .

<https://1145.am/db/2580140/Acquisition_Boehringer_Ingelheim_And_Eli_Lilly_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-06-15T02:41:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Boehringer Ingelheim and Eli Lilly ($ LLY) say they will begin selling Trajenta in India for Type 2 diabetes." ;
    ns1:documentTitle "Valeant nabs OraPharma; GSK get MenHibrix OK'd; Trajenta into India;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/valeant-nabs-orapharma-gsk-get-menhibrix-ok-d-trajenta-into-india> ;
    ns1:foundName "selling" ;
    ns1:name "selling" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:vendor <https://1145.am/db/2580140/Boehringer_Ingelheim_And_Eli_Lilly> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2580140/Glaxosmithkline> a org:Organization ;
    ns1:basedInLowRaw "U.K." ;
    ns1:buyer <https://1145.am/db/2580140/Orapharma_Acquisition> ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2012-06-15T02:41:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Valeant nabs OraPharma; GSK get MenHibrix OK'd; Trajenta into India;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/valeant-nabs-orapharma-gsk-get-menhibrix-ok-d-trajenta-into-india> ;
    ns1:foundName "GlaxoSmithKline" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "GlaxoSmithKline" ;
    ns1:sameAsHigh <https://1145.am/db/1002406/Glaxosmithkline_Plc>,
        <https://1145.am/db/1003861/Glaxosmithkline_Plc>,
        <https://1145.am/db/1034874/Glaxosmithkline_Plc>,
        <https://1145.am/db/1035942/GSK>,
        <https://1145.am/db/1036772/Glaxosmithkline_Plc>,
        <https://1145.am/db/1037557/GSK>,
        <https://1145.am/db/118625/GSK>,
        <https://1145.am/db/1368193/GSK>,
        <https://1145.am/db/1369714/GSK>,
        <https://1145.am/db/1972441/GSK>,
        <https://1145.am/db/1983958/Gsk_Plc>,
        <https://1145.am/db/2153110/Glaxosmithkline>,
        <https://1145.am/db/2156284/Glaxosmithkline>,
        <https://1145.am/db/2190363/Glaxosmithkline>,
        <https://1145.am/db/2192331/Glaxosmithkline>,
        <https://1145.am/db/2200884/Glaxosmithkline>,
        <https://1145.am/db/2204941/Glaxosmithkline>,
        <https://1145.am/db/2224597/Glaxosmithkline>,
        <https://1145.am/db/2278803/GSK>,
        <https://1145.am/db/2279371/Glaxosmithkline>,
        <https://1145.am/db/2282253/Glaxosmithkline>,
        <https://1145.am/db/2282592/Glaxosmithkline>,
        <https://1145.am/db/2283644/Glaxosmithkline>,
        <https://1145.am/db/2286031/Glaxosmithkline>,
        <https://1145.am/db/2287351/Glaxosmithkline>,
        <https://1145.am/db/2289482/Glaxosmithkline>,
        <https://1145.am/db/2290507/Glaxosmithkline>,
        <https://1145.am/db/2290596/Glaxosmithkline>,
        <https://1145.am/db/2291302/Glaxosmithkline>,
        <https://1145.am/db/2291743/Glaxosmithkline>,
        <https://1145.am/db/2292884/Glaxosmithkline>,
        <https://1145.am/db/2293175/Glaxosmithkline>,
        <https://1145.am/db/2297702/Glaxosmithkline>,
        <https://1145.am/db/2302462/Glaxosmithkline>,
        <https://1145.am/db/2303242/Glaxosmithkline>,
        <https://1145.am/db/2303245/Glaxosmithkline>,
        <https://1145.am/db/230344/Glaxosmithkline>,
        <https://1145.am/db/2305277/Glaxosmithkline>,
        <https://1145.am/db/2305279/Glaxosmithkline>,
        <https://1145.am/db/2306213/Glaxosmithkline>,
        <https://1145.am/db/2306799/Glaxosmithkline>,
        <https://1145.am/db/2307723/Glaxosmithkline>,
        <https://1145.am/db/2308007/Glaxosmithkline>,
        <https://1145.am/db/2309511/Glaxo>,
        <https://1145.am/db/2310192/Glaxosmithkline>,
        <https://1145.am/db/2311402/Glaxosmithkline_Plc>,
        <https://1145.am/db/2312131/Glaxosmithkline>,
        <https://1145.am/db/2312187/Glaxosmithkline>,
        <https://1145.am/db/2312416/Glaxosmithkline>,
        <https://1145.am/db/2312656/Glaxosmithkline>,
        <https://1145.am/db/2313289/Glaxosmithkline>,
        <https://1145.am/db/2314290/Glaxosmithkline>,
        <https://1145.am/db/2314853/Glaxosmithkline>,
        <https://1145.am/db/2315422/Glaxosmithkline>,
        <https://1145.am/db/2316364/Glaxosmithkline>,
        <https://1145.am/db/2316660/Glaxosmithkline>,
        <https://1145.am/db/2316797/Glaxosmithkline>,
        <https://1145.am/db/2317846/Glaxosmithkline>,
        <https://1145.am/db/2318310/Glaxosmithkline>,
        <https://1145.am/db/2318589/Glaxosmithkline>,
        <https://1145.am/db/2318644/Glaxosmithkline>,
        <https://1145.am/db/2318658/Glaxosmithkline_Plc>,
        <https://1145.am/db/2318681/Glaxosmithkline>,
        <https://1145.am/db/2318708/Glaxosmithkline>,
        <https://1145.am/db/2318919/Glaxosmithkline>,
        <https://1145.am/db/2319445/Glaxosmithkline>,
        <https://1145.am/db/2319763/Glaxosmithkline>,
        <https://1145.am/db/2319782/Glaxosmithkline>,
        <https://1145.am/db/2319892/Glaxosmithkline>,
        <https://1145.am/db/2320824/Glaxosmithkline>,
        <https://1145.am/db/2320992/Glaxosmithkline>,
        <https://1145.am/db/2321971/Glaxosmithkline>,
        <https://1145.am/db/2324095/Glaxosmithkline>,
        <https://1145.am/db/2324141/Glaxosmithkline>,
        <https://1145.am/db/2325359/Glaxosmithkline>,
        <https://1145.am/db/2325364/Glaxosmithkline>,
        <https://1145.am/db/2325490/Glaxosmithkline>,
        <https://1145.am/db/2325729/Glaxosmithkline_Plc>,
        <https://1145.am/db/2326266/Glaxosmithkline_(gsk)>,
        <https://1145.am/db/2326590/Glaxosmithkline>,
        <https://1145.am/db/2327305/Glaxosmithkline>,
        <https://1145.am/db/2327507/Glaxosmithkline>,
        <https://1145.am/db/2327529/Glaxosmithkline>,
        <https://1145.am/db/2327656/Glaxosmithkline>,
        <https://1145.am/db/2328471/Glaxosmithkline>,
        <https://1145.am/db/2328637/Glaxosmithkline>,
        <https://1145.am/db/2328666/Glaxosmithkline>,
        <https://1145.am/db/2328681/Glaxosmithkline>,
        <https://1145.am/db/2328981/Glaxosmithkline>,
        <https://1145.am/db/2330949/Glaxosmithkline>,
        <https://1145.am/db/2330955/Glaxosmithkline>,
        <https://1145.am/db/2330986/Glaxosmithkline>,
        <https://1145.am/db/2331010/Glaxosmithkline>,
        <https://1145.am/db/2331763/Glaxosmithkline>,
        <https://1145.am/db/2331819/Glaxosmithkline>,
        <https://1145.am/db/2331823/Glaxosmithkline>,
        <https://1145.am/db/2332005/Glaxosmithkline_Pliva>,
        <https://1145.am/db/2332660/Glaxosmithkline>,
        <https://1145.am/db/2332695/Glaxosmithkline>,
        <https://1145.am/db/2333658/Glaxosmithkline>,
        <https://1145.am/db/2335573/GSK>,
        <https://1145.am/db/2335582/Glaxosmithkline>,
        <https://1145.am/db/2335587/Glaxosmithkline>,
        <https://1145.am/db/2336060/Glaxosmithkline>,
        <https://1145.am/db/2336704/GSK>,
        <https://1145.am/db/2336990/Glaxosmithkline>,
        <https://1145.am/db/2337186/Glaxosmithkline>,
        <https://1145.am/db/2338296/Glaxosmithkline>,
        <https://1145.am/db/2339979/Glaxosmithkline>,
        <https://1145.am/db/2340071/Glaxosmithkline>,
        <https://1145.am/db/2340591/Glaxosmithkline>,
        <https://1145.am/db/2342074/Glaxosmithkline>,
        <https://1145.am/db/2342876/Glaxosmithkline>,
        <https://1145.am/db/2343855/Glaxosmithkline>,
        <https://1145.am/db/2343861/Glaxosmithkline>,
        <https://1145.am/db/2344023/Glaxosmithkline>,
        <https://1145.am/db/2344939/Glaxosmithkline>,
        <https://1145.am/db/2345251/GSK>,
        <https://1145.am/db/2345410/Glaxosmithkline>,
        <https://1145.am/db/2345604/Glaxosmithkline>,
        <https://1145.am/db/2348686/Glaxosmithkline>,
        <https://1145.am/db/2348693/Glaxosmithkline>,
        <https://1145.am/db/2349724/GSK>,
        <https://1145.am/db/2349724/Glaxosmithkline_Biologicals>,
        <https://1145.am/db/2352499/Glaxosmithkline>,
        <https://1145.am/db/2352506/Glaxosmithkline_Plc>,
        <https://1145.am/db/2353506/Glaxosmithkline>,
        <https://1145.am/db/2353547/Glaxosmithkline>,
        <https://1145.am/db/2354253/Glaxosmithkline>,
        <https://1145.am/db/2354577/Glaxosmithkline>,
        <https://1145.am/db/2355587/Glaxosmithkline>,
        <https://1145.am/db/2355595/Glaxosmithkline>,
        <https://1145.am/db/2355640/Cellzome>,
        <https://1145.am/db/2356391/Glaxosmithkline>,
        <https://1145.am/db/2356559/Glaxosmithkline>,
        <https://1145.am/db/2356560/Glaxosmithkline>,
        <https://1145.am/db/2356639/Glaxosmithkline>,
        <https://1145.am/db/2356654/Glaxosmithkline>,
        <https://1145.am/db/2357361/Glaxosmithkline_Plc>,
        <https://1145.am/db/2359072/Glaxosmithkline>,
        <https://1145.am/db/2359553/Glaxosmithkline>,
        <https://1145.am/db/2359727/GSK>,
        <https://1145.am/db/2359727/Glaxosmithkline>,
        <https://1145.am/db/2359836/Glaxosmithkline>,
        <https://1145.am/db/2359838/Glaxosmithkline>,
        <https://1145.am/db/2359858/Glaxosmithkline>,
        <https://1145.am/db/2360093/Glaxosmithkline>,
        <https://1145.am/db/2360094/Glaxosmithkline>,
        <https://1145.am/db/2360371/Glaxosmithkline>,
        <https://1145.am/db/2360552/Glaxosmithkline>,
        <https://1145.am/db/2360562/GSK>,
        <https://1145.am/db/2361700/GSK>,
        <https://1145.am/db/2364819/Glaxosmithkline>,
        <https://1145.am/db/2364846/Glaxosmithkline>,
        <https://1145.am/db/2367620/Glaxosmithkline>,
        <https://1145.am/db/2367621/Glaxosmithkline>,
        <https://1145.am/db/2368765/Glaxosmithkline>,
        <https://1145.am/db/2368770/Glaxosmithkline_Plc>,
        <https://1145.am/db/2369276/Glaxosmithkline>,
        <https://1145.am/db/2369449/Glaxosmithkline>,
        <https://1145.am/db/2369451/Glaxosmithkline>,
        <https://1145.am/db/2369755/GSK>,
        <https://1145.am/db/2369761/Glaxosmithkline>,
        <https://1145.am/db/2370635/GSK>,
        <https://1145.am/db/238329/Glaxosmithkline>,
        <https://1145.am/db/2536540/Glaxosmithkline>,
        <https://1145.am/db/2536585/Glaxosmithkline>,
        <https://1145.am/db/2536945/Glaxosmithkline>,
        <https://1145.am/db/2537064/Glaxosmithkline>,
        <https://1145.am/db/2537699/Glaxosmithkline>,
        <https://1145.am/db/2539219/Glaxosmithkline>,
        <https://1145.am/db/2539221/Glaxosmithkline>,
        <https://1145.am/db/2539308/Glaxosmithkline>,
        <https://1145.am/db/2539972/Glaxosmithkline>,
        <https://1145.am/db/2540020/Glaxosmithkline>,
        <https://1145.am/db/2540027/Glaxosmithkline>,
        <https://1145.am/db/2540091/Glaxosmithkline>,
        <https://1145.am/db/2540172/Glaxosmithkline>,
        <https://1145.am/db/2540527/Glaxosmithkline>,
        <https://1145.am/db/2541499/Glaxosmithkline>,
        <https://1145.am/db/2542064/GSK>,
        <https://1145.am/db/2542065/Glaxosmithkline>,
        <https://1145.am/db/2542090/Glaxosmithkline>,
        <https://1145.am/db/2542192/GSK>,
        <https://1145.am/db/2542499/Glaxosmithkline>,
        <https://1145.am/db/2542503/Glaxosmithkline>,
        <https://1145.am/db/2542506/Glaxosmithkline>,
        <https://1145.am/db/2543552/Glaxosmithkline>,
        <https://1145.am/db/2544274/Glaxosmithkline>,
        <https://1145.am/db/2544350/Glaxosmithkline>,
        <https://1145.am/db/2545023/Glaxosmithkline>,
        <https://1145.am/db/2545242/Glaxosmithkline>,
        <https://1145.am/db/2545284/Glaxosmithkline>,
        <https://1145.am/db/2545518/Glaxosmithkline>,
        <https://1145.am/db/2545537/Glaxosmithkline>,
        <https://1145.am/db/2546260/Glaxosmithkline>,
        <https://1145.am/db/2546574/Glaxosmithkline>,
        <https://1145.am/db/2546577/Glaxosmithkline>,
        <https://1145.am/db/2546616/Glaxosmithkline>,
        <https://1145.am/db/2546929/Glaxosmithkline>,
        <https://1145.am/db/2547142/Glaxosmithkline>,
        <https://1145.am/db/2547143/Glaxosmithkline>,
        <https://1145.am/db/2547835/Glaxosmithkline>,
        <https://1145.am/db/2547954/Glaxosmithkline>,
        <https://1145.am/db/2547976/Glaxosmithkline>,
        <https://1145.am/db/2548034/Glaxosmithkline>,
        <https://1145.am/db/2548208/Glaxosmithkline>,
        <https://1145.am/db/2548518/Glaxosmithkline>,
        <https://1145.am/db/2548523/Glaxosmithkline>,
        <https://1145.am/db/2549082/Glaxosmithkline>,
        <https://1145.am/db/2549876/Glaxosmithkline>,
        <https://1145.am/db/2550054/Glaxosmithkline>,
        <https://1145.am/db/2550318/Glaxosmithkline>,
        <https://1145.am/db/2550460/GSK>,
        <https://1145.am/db/2550460/Glaxosmithkline>,
        <https://1145.am/db/2550543/Glaxosmithkline>,
        <https://1145.am/db/2550662/Glaxosmithkline>,
        <https://1145.am/db/2551402/Glaxosmithkline>,
        <https://1145.am/db/2551695/Glaxosmithkline>,
        <https://1145.am/db/2552794/Glaxosmithkline>,
        <https://1145.am/db/2553168/GSK>,
        <https://1145.am/db/2553206/Glaxosmithkline>,
        <https://1145.am/db/2553462/Glaxosmithkline>,
        <https://1145.am/db/2554044/Glaxosmithkline>,
        <https://1145.am/db/2554324/Glaxosmithkline>,
        <https://1145.am/db/2554578/Glaxosmithkline>,
        <https://1145.am/db/2554641/Glaxosmithkline>,
        <https://1145.am/db/2554937/Glaxosmithkline>,
        <https://1145.am/db/2555012/Glaxosmithkline>,
        <https://1145.am/db/2556628/Glaxosmithkline>,
        <https://1145.am/db/2556820/Glaxosmithkline>,
        <https://1145.am/db/2556995/Glaxosmithkline>,
        <https://1145.am/db/2557515/Glaxosmithkline>,
        <https://1145.am/db/2558165/Glaxosmithkline>,
        <https://1145.am/db/2558862/GSK>,
        <https://1145.am/db/2558862/Glaxosmithkline>,
        <https://1145.am/db/2558927/Glaxosmithkline>,
        <https://1145.am/db/2558940/Glaxosmithkline>,
        <https://1145.am/db/2560234/Glaxosmithkline>,
        <https://1145.am/db/2560260/Glaxosmithkline>,
        <https://1145.am/db/2560633/Glaxosmithkline>,
        <https://1145.am/db/2560853/Glaxosmithkline>,
        <https://1145.am/db/2560873/Glaxosmithkline>,
        <https://1145.am/db/2561334/Glaxo>,
        <https://1145.am/db/2561353/Glaxosmithkline>,
        <https://1145.am/db/2561599/Glaxosmithkline>,
        <https://1145.am/db/2561650/GSK>,
        <https://1145.am/db/2561960/Glaxosmithkline>,
        <https://1145.am/db/2562951/Glaxosmithkline>,
        <https://1145.am/db/2563194/Glaxosmithkline>,
        <https://1145.am/db/2563381/Glaxosmithkline>,
        <https://1145.am/db/2564238/Glaxosmithkline>,
        <https://1145.am/db/2564695/Glaxosmithkline>,
        <https://1145.am/db/2564786/Glaxosmithkline>,
        <https://1145.am/db/2566186/GSK>,
        <https://1145.am/db/2566825/Glaxosmithkline>,
        <https://1145.am/db/2567009/Glaxosmithkline>,
        <https://1145.am/db/2567104/GSK>,
        <https://1145.am/db/2568932/Glaxosmithkline>,
        <https://1145.am/db/2568968/Glaxosmithkline>,
        <https://1145.am/db/2569734/Glaxosmithkline_Plc>,
        <https://1145.am/db/2569735/Glaxosmithkline_Plc>,
        <https://1145.am/db/2572429/Glaxosmithkline>,
        <https://1145.am/db/2572963/Glaxosmithkline>,
        <https://1145.am/db/2573002/Glaxosmithkline>,
        <https://1145.am/db/2573201/Glaxosmithkline>,
        <https://1145.am/db/2573585/Glaxosmithkline>,
        <https://1145.am/db/2574333/Glaxosmithkline>,
        <https://1145.am/db/2575289/Glaxosmithkline>,
        <https://1145.am/db/2575462/First_Glaxosmithkline>,
        <https://1145.am/db/2576042/Glaxosmithkline>,
        <https://1145.am/db/2576046/Glaxosmithkline>,
        <https://1145.am/db/2576156/Glaxosmithkline>,
        <https://1145.am/db/2576230/Glaxosmithkline_Plc>,
        <https://1145.am/db/2576242/Glaxosmithkline>,
        <https://1145.am/db/2576256/Glaxo>,
        <https://1145.am/db/2576263/Glaxosmithkline>,
        <https://1145.am/db/2576267/GSK>,
        <https://1145.am/db/2576267/Glaxosmithkline>,
        <https://1145.am/db/2576516/Glaxosmithkline>,
        <https://1145.am/db/2577566/First_Glaxosmithkline>,
        <https://1145.am/db/2577566/Glaxo>,
        <https://1145.am/db/2577747/Glaxosmithkline>,
        <https://1145.am/db/2577778/Glaxosmithkline>,
        <https://1145.am/db/2578161/Glaxosmithkline>,
        <https://1145.am/db/2578420/Glaxosmithkline>,
        <https://1145.am/db/2578528/GSK>,
        <https://1145.am/db/2578536/Glaxosmithkline>,
        <https://1145.am/db/2579172/Glaxosmithkline>,
        <https://1145.am/db/2579177/Glaxosmithkline>,
        <https://1145.am/db/2579180/GSK>,
        <https://1145.am/db/2579205/Glaxosmithkline>,
        <https://1145.am/db/2580047/Glaxosmithkline>,
        <https://1145.am/db/2580053/Glaxosmithkline>,
        <https://1145.am/db/2580509/Glaxosmithkline>,
        <https://1145.am/db/2580916/Glaxosmithkline>,
        <https://1145.am/db/2581141/Glaxosmithkline_Plc>,
        <https://1145.am/db/2581145/Glaxosmithkline>,
        <https://1145.am/db/2581176/Glaxosmithkline>,
        <https://1145.am/db/2581659/GSK>,
        <https://1145.am/db/2581661/Glaxosmithkline>,
        <https://1145.am/db/2582227/Glaxosmithkline>,
        <https://1145.am/db/2582344/Glaxosmithkline>,
        <https://1145.am/db/2582416/Glaxosmithkline>,
        <https://1145.am/db/2583228/Glaxosmithkline_Plc>,
        <https://1145.am/db/2583281/Glaxosmithkline>,
        <https://1145.am/db/2583584/Glaxosmithkline>,
        <https://1145.am/db/2584216/Glaxosmithkline>,
        <https://1145.am/db/2584538/Glaxosmithkline>,
        <https://1145.am/db/2585246/Glaxosmithkline_Plc>,
        <https://1145.am/db/2585251/Glaxosmithkline>,
        <https://1145.am/db/2586067/Glaxosmithkline>,
        <https://1145.am/db/2586099/Glaxosmithkline>,
        <https://1145.am/db/2586139/Glaxosmithkline>,
        <https://1145.am/db/2586802/GSK>,
        <https://1145.am/db/2586802/Glaxosmithkline>,
        <https://1145.am/db/2587282/Glaxosmithkline>,
        <https://1145.am/db/2587657/Glaxosmithkline>,
        <https://1145.am/db/2587770/Glaxosmithkline>,
        <https://1145.am/db/2587966/Glaxosmithkline>,
        <https://1145.am/db/2587967/GSK>,
        <https://1145.am/db/2587968/GSK>,
        <https://1145.am/db/2588258/Glaxosmithkline>,
        <https://1145.am/db/2588918/Glaxosmithkline>,
        <https://1145.am/db/2589035/Glaxosmithkline>,
        <https://1145.am/db/2589642/Glaxosmithkline>,
        <https://1145.am/db/2589701/GSK>,
        <https://1145.am/db/2589701/Glaxosmithkline>,
        <https://1145.am/db/2590051/Glaxosmithkline>,
        <https://1145.am/db/2590712/Glaxosmithkline>,
        <https://1145.am/db/2592987/Glaxosmithkline>,
        <https://1145.am/db/2593710/Glaxosmithkline>,
        <https://1145.am/db/2594208/Glaxosmithkline>,
        <https://1145.am/db/2594422/Glaxosmithkline>,
        <https://1145.am/db/2595001/Glaxosmithkline>,
        <https://1145.am/db/2595150/Glaxosmithkline>,
        <https://1145.am/db/2596213/Glaxosmithkline>,
        <https://1145.am/db/2596402/Glaxosmithkline_Plc>,
        <https://1145.am/db/2596577/Glaxosmithkline>,
        <https://1145.am/db/2596835/Glaxosmithkline>,
        <https://1145.am/db/2597004/GSK>,
        <https://1145.am/db/2597220/Glaxosmithkline>,
        <https://1145.am/db/2597554/Glaxosmithkline>,
        <https://1145.am/db/2597558/Glaxosmithkline_Pte>,
        <https://1145.am/db/2597960/Glaxosmithkline>,
        <https://1145.am/db/286227/Glaxosmithkline>,
        <https://1145.am/db/338242/Glaxosmithkline>,
        <https://1145.am/db/377761/Glaxosmithkline>,
        <https://1145.am/db/377769/Glaxosmithkline>,
        <https://1145.am/db/446194/Glaxosmithkline>,
        <https://1145.am/db/494811/Glaxosmithkline>,
        <https://1145.am/db/538122/Glaxosmithkline>,
        <https://1145.am/db/576236/Glaxosmithkline>,
        <https://1145.am/db/582690/GSK>,
        <https://1145.am/db/702938/Glaxosmithkline>,
        <https://1145.am/db/761748/Glaxosmithkline>,
        <https://1145.am/db/761841/Glaxosmithkline_Plc>,
        <https://1145.am/db/763207/Glaxosmithkline>,
        <https://1145.am/db/771701/Glaxosmithkline>,
        <https://1145.am/db/85758/Glaxosmithkline>,
        <https://1145.am/db/922192/Glaxosmithkline>,
        <https://1145.am/db/970746/Glaxosmithkline>,
        <https://1145.am/db/973116/Glaxosmithkline>,
        <https://1145.am/db/975768/Glaxosmithkline>,
        <https://1145.am/db/977067/Glaxosmithkline> ;
    ns1:sameAsMedium <https://1145.am/db/1022812/Glaxosmithkline_Plc>,
        <https://1145.am/db/1026879/Glaxosmithkline>,
        <https://1145.am/db/1209318/Glaxosmithkline>,
        <https://1145.am/db/2293631/Glaxosmithkline>,
        <https://1145.am/db/2295635/Glaxosmithkline>,
        <https://1145.am/db/2329533/Glaxosmithkline>,
        <https://1145.am/db/2335568/Glaxosmithkline>,
        <https://1145.am/db/2340260/Glaxosmithkline>,
        <https://1145.am/db/2364813/Glaxosmithkline>,
        <https://1145.am/db/2365103/Glaxosmithkline>,
        <https://1145.am/db/2370843/Glaxosmithkline>,
        <https://1145.am/db/2536493/Glaxosmithkline>,
        <https://1145.am/db/2540170/Glaxosmithkline>,
        <https://1145.am/db/2541733/Glaxosmithkline>,
        <https://1145.am/db/2544062/Glaxosmithkline>,
        <https://1145.am/db/2546136/Glaxosmithkline>,
        <https://1145.am/db/2549598/Glaxosmithkline>,
        <https://1145.am/db/2549694/Glaxosmithkline>,
        <https://1145.am/db/2552165/Glaxosmithkline>,
        <https://1145.am/db/2554902/Glaxosmithkline>,
        <https://1145.am/db/2556407/Glaxosmithkline>,
        <https://1145.am/db/2557221/Glaxosmithkline>,
        <https://1145.am/db/2560668/Glaxosmithkline>,
        <https://1145.am/db/2568973/Glaxosmithkline>,
        <https://1145.am/db/2570721/Glaxosmithkline>,
        <https://1145.am/db/2570791/Glaxosmithkline>,
        <https://1145.am/db/2577226/Glaxosmithkline>,
        <https://1145.am/db/2582233/Glaxosmithkline>,
        <https://1145.am/db/2594187/Glaxosmithkline>,
        <https://1145.am/db/2598461/Glaxosmithkline>,
        <https://1145.am/db/582690/Glaxosmithkline>,
        <https://1145.am/db/704642/Glaxosmithkline_Plc>,
        <https://1145.am/db/87287/Glaxosmithkline> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2580140/Ipo_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "ipo" ;
    ns1:documentDate "2012-06-15T02:41:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> GlaxoSmithKline ($ GSK) has gotten FDA approval for its vaccine MenHibrix, to be used to treat the rare but sometimes fatal disease Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b, in children 6 weeks through 18 months." ;
    ns1:documentTitle "Valeant nabs OraPharma; GSK get MenHibrix OK'd; Trajenta into India;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/valeant-nabs-orapharma-gsk-get-menhibrix-ok-d-trajenta-into-india> ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2580140/Teva> a org:Organization ;
    ns1:basedInLowRaw "Israel" ;
    ns1:buyer <https://1145.am/db/2580140/Ipo_Teva_Completed> ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-06-15T02:41:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Valeant nabs OraPharma; GSK get MenHibrix OK'd; Trajenta into India;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/valeant-nabs-orapharma-gsk-get-menhibrix-ok-d-trajenta-into-india> ;
    ns1:foundName "Teva" ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "Teva" ;
    ns1:sameAsHigh <https://1145.am/db/1177474/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/1178087/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/1522618/Teva_Pharmaceutical>,
        <https://1145.am/db/2070596/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2129381/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2151860/Teva>,
        <https://1145.am/db/2201211/Teva>,
        <https://1145.am/db/2239056/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2243196/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2244234/Teva_Pharmaceutical_Industries_Limited>,
        <https://1145.am/db/2259244/Teva>,
        <https://1145.am/db/2302310/Teva>,
        <https://1145.am/db/2302340/Teva>,
        <https://1145.am/db/2302799/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2303398/Teva>,
        <https://1145.am/db/2303404/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2304325/Teva_Pharmaceuticals>,
        <https://1145.am/db/2304451/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2305956/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2308917/Teva_Pharmaceuticals_Industries_Ltd>,
        <https://1145.am/db/2308946/Teva>,
        <https://1145.am/db/2308962/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2308964/Teva>,
        <https://1145.am/db/2309115/Teva>,
        <https://1145.am/db/2313246/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2313528/Teva>,
        <https://1145.am/db/2314439/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2316058/Teva>,
        <https://1145.am/db/2316537/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2317929/Teva_Pharmaceuticals>,
        <https://1145.am/db/2319919/Teva_Pharmaceutical_Industries_Limited>,
        <https://1145.am/db/2319919/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2320510/Teva>,
        <https://1145.am/db/2322476/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2324654/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2325949/Teva_Pharmaceutical>,
        <https://1145.am/db/2326087/Teva_Pharmaceutical>,
        <https://1145.am/db/2326095/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2327640/Teva>,
        <https://1145.am/db/2328509/Teva_Pharmaceuticals_Industries_Ltd>,
        <https://1145.am/db/2331853/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2333444/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2335886/Teva>,
        <https://1145.am/db/2335888/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2338474/Teva>,
        <https://1145.am/db/2338480/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2339602/Teva_Pharmaceutical_Industries_Limited>,
        <https://1145.am/db/2339763/Teva_Pharmaceutical>,
        <https://1145.am/db/2339813/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2340427/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2341991/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2342533/Teva_Pharmaceutical>,
        <https://1145.am/db/2342540/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2342764/Teva>,
        <https://1145.am/db/2342966/Teva>,
        <https://1145.am/db/2342970/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2342980/Teva>,
        <https://1145.am/db/2344775/Teva>,
        <https://1145.am/db/2345850/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2346033/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2347107/Teva_Americas_Generics>,
        <https://1145.am/db/2347630/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2349699/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2350564/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2350567/Teva_Pharmaceutical>,
        <https://1145.am/db/2351258/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2353121/Teva>,
        <https://1145.am/db/2356821/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2359165/Teva>,
        <https://1145.am/db/2360060/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2361881/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2362614/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2362877/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2364375/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2364393/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2364463/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2365818/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2367099/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2536415/Teva>,
        <https://1145.am/db/2536575/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2536576/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2537261/Teva_Pharmaceutical>,
        <https://1145.am/db/2537347/Teva>,
        <https://1145.am/db/2537383/Teva>,
        <https://1145.am/db/2537911/Teva>,
        <https://1145.am/db/2538861/Teva>,
        <https://1145.am/db/2538918/Teva>,
        <https://1145.am/db/2539357/Teva>,
        <https://1145.am/db/2541555/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2541838/Teva>,
        <https://1145.am/db/2541911/Teva>,
        <https://1145.am/db/2542380/Teva>,
        <https://1145.am/db/2542518/Teva_Pharmaceuticals>,
        <https://1145.am/db/2543548/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2544354/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2544399/Teva>,
        <https://1145.am/db/2544434/Teva>,
        <https://1145.am/db/2544552/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2544588/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2546097/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2546317/Teva>,
        <https://1145.am/db/2546583/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2547068/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2547181/Teva_Pharmaceutical>,
        <https://1145.am/db/2548005/Teva>,
        <https://1145.am/db/2548022/Teva>,
        <https://1145.am/db/2550094/Teva>,
        <https://1145.am/db/2550387/Teva>,
        <https://1145.am/db/2550476/Teva>,
        <https://1145.am/db/2551199/Teva>,
        <https://1145.am/db/2552222/Teva_Pharmaceutical>,
        <https://1145.am/db/2552465/Teva>,
        <https://1145.am/db/2552547/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2552799/Teva>,
        <https://1145.am/db/2553028/Teva_Pharmaceutical>,
        <https://1145.am/db/2553677/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2553841/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2554237/Teva>,
        <https://1145.am/db/2554286/Teva>,
        <https://1145.am/db/2554769/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2555705/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2555708/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2555873/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2556798/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2556903/Teva>,
        <https://1145.am/db/2557091/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2557469/Teva>,
        <https://1145.am/db/2557785/Teva>,
        <https://1145.am/db/2557821/Teva>,
        <https://1145.am/db/2559209/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2559637/Teva_Pharmaceutical>,
        <https://1145.am/db/2560610/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2560744/Teva>,
        <https://1145.am/db/2560844/Teva>,
        <https://1145.am/db/2561438/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2562902/Teva>,
        <https://1145.am/db/2562919/Teva>,
        <https://1145.am/db/2563815/Teva_Pharmaceutical>,
        <https://1145.am/db/2563858/Teva>,
        <https://1145.am/db/2564988/Teva>,
        <https://1145.am/db/2566019/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2567583/Teva_Pharmaceuticals>,
        <https://1145.am/db/2568379/Teva>,
        <https://1145.am/db/2569371/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2569442/Teva>,
        <https://1145.am/db/2570095/Teva>,
        <https://1145.am/db/2570098/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2570307/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2570353/Teva>,
        <https://1145.am/db/2570574/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2570841/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2570949/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2571326/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2571370/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2571373/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2571443/Teva>,
        <https://1145.am/db/2571706/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2571717/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2571723/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2572066/Teva>,
        <https://1145.am/db/2572137/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2572213/Teva>,
        <https://1145.am/db/2572452/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2572474/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2572533/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2572541/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2572542/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2572985/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2573173/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2573256/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2574106/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2574382/Teva_Pharmaceuticals>,
        <https://1145.am/db/2574807/Teva>,
        <https://1145.am/db/2574829/Teva>,
        <https://1145.am/db/2575004/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2575012/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2575028/Teva>,
        <https://1145.am/db/2575623/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2576122/Teva_Pharmaceuticals>,
        <https://1145.am/db/2577101/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2577657/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2577833/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2577839/Teva>,
        <https://1145.am/db/2578103/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2578166/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2578176/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2578393/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2578420/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2578466/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2578482/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2578490/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2578503/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2578908/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2578932/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2579090/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2579092/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2579093/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2579464/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2579467/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2580401/Teva_Pharmaceutical>,
        <https://1145.am/db/2580491/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2580562/Teva_Pharmaceuticals>,
        <https://1145.am/db/2580570/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2580872/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2580875/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2581347/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2582326/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2582327/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2582675/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2582685/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2582705/Teva>,
        <https://1145.am/db/2583627/Teva>,
        <https://1145.am/db/2584818/Teva_Pharmaceutical>,
        <https://1145.am/db/2586385/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2586692/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2586703/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2586716/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2587626/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2587948/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2587993/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2588510/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2588611/Teva_Pharmaceutical>,
        <https://1145.am/db/2588837/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2588941/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2588942/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2589459/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2590292/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2590783/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2590827/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2590891/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2590954/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2591396/Teva>,
        <https://1145.am/db/2591596/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2592620/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2592950/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2594992/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2595027/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2595051/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2595587/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2596015/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2596755/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2597184/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2598026/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2598250/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2598261/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2598266/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/2598391/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2598400/Teva>,
        <https://1145.am/db/2598408/Teva_Pharmaceutical_Industries>,
        <https://1145.am/db/2598543/Teva_Pharmaceutical_Industries_Limited>,
        <https://1145.am/db/576418/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/584349/Teva_Pharmaceutical_Industries_Ltd>,
        <https://1145.am/db/586645/Teva_Pharmaceutical_Industries_Ltd> ;
    ns1:sameAsMedium <https://1145.am/db/2302934/Teva>,
        <https://1145.am/db/2368702/Teva>,
        <https://1145.am/db/2543940/Teva>,
        <https://1145.am/db/2550091/Teva>,
        <https://1145.am/db/2552184/Teva>,
        <https://1145.am/db/2555939/Teva>,
        <https://1145.am/db/2570827/Teva> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2651427/Kyivstar> a org:Organization ;
    ns1:basedInHighGeoName "Ukraine" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/690791/about.rdf> ;
    ns1:basedInHighRaw "Ukraine" ;
    ns1:documentDate "2012-06-26T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Webwire: ITC examines Apple ruling; Microsoft goes social" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/webwire-itc-examines-apple-ruling-microsoft-goes-social> ;
    ns1:foundName "Kyivstar" ;
    ns1:industry "mobile operators" ;
    ns1:name "Kyivstar" ;
    ns1:protagonist <https://1145.am/db/2651427/Joint_Venture_Kyivstar_Mts_Completed> ;
    ns1:sameAsHigh <https://1145.am/db/2645977/Kyivstar>,
        <https://1145.am/db/2662999/Kyivstar> ;
    ns1:sameAsMedium <https://1145.am/db/1280738/Kyivstar> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2651427/MTS> a org:Organization ;
    ns1:basedInHighGeoName "Ukraine" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/690791/about.rdf> ;
    ns1:basedInHighRaw "Ukraine" ;
    ns1:documentDate "2012-06-26T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Webwire: ITC examines Apple ruling; Microsoft goes social" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/webwire-itc-examines-apple-ruling-microsoft-goes-social> ;
    ns1:foundName "MTS" ;
    ns1:industry "mobile operators" ;
    ns1:name "MTS" ;
    ns1:protagonist <https://1145.am/db/2651427/Joint_Venture_Kyivstar_Mts_Completed> ;
    ns1:sameAsHigh <https://1145.am/db/1209519/MTN>,
        <https://1145.am/db/1311630/MTN>,
        <https://1145.am/db/1328674/MTN>,
        <https://1145.am/db/1428751/Mtn_Group>,
        <https://1145.am/db/2083707/Mtn_Group>,
        <https://1145.am/db/2084469/MTN>,
        <https://1145.am/db/2622947/Mtn_Group>,
        <https://1145.am/db/2654421/MTN>,
        <https://1145.am/db/2660738/MTN>,
        <https://1145.am/db/2669143/MTN>,
        <https://1145.am/db/2671259/Mtn_Group>,
        <https://1145.am/db/2671276/Mtn_Group>,
        <https://1145.am/db/2674025/MTN>,
        <https://1145.am/db/2674324/MTN>,
        <https://1145.am/db/2676473/MTN>,
        <https://1145.am/db/2676511/MTN>,
        <https://1145.am/db/2679588/MTN>,
        <https://1145.am/db/626778/Mtn_Group_Ltd> ;
    ns1:sameAsMedium <https://1145.am/db/2608115/MTS>,
        <https://1145.am/db/2628087/MTS>,
        <https://1145.am/db/2664571/MTS>,
        <https://1145.am/db/2669228/MTS>,
        <https://1145.am/db/2670712/MTS>,
        <https://1145.am/db/2677796/MTS>,
        <https://1145.am/db/563144/MTS>,
        <https://1145.am/db/694224/MTS>,
        <https://1145.am/db/694228/MTS>,
        <https://1145.am/db/745846/MTS>,
        <https://1145.am/db/752912/MTS>,
        <https://1145.am/db/817625/MTS> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2651427/Microsoft> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:buyer <https://1145.am/db/2651427/Yammer_Joint_Venture> ;
    ns1:documentDate "2012-06-26T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Webwire: ITC examines Apple ruling; Microsoft goes social" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/webwire-itc-examines-apple-ruling-microsoft-goes-social> ;
    ns1:foundName "Microsoft" ;
    ns1:industry "IT" ;
    ns1:name "Microsoft" ;
    ns1:sameAsHigh <https://1145.am/db/1314290/Microsoft>,
        <https://1145.am/db/1343611/Microsoft_Corp>,
        <https://1145.am/db/1346180/Microsoft>,
        <https://1145.am/db/1382052/Microsoft_Corp>,
        <https://1145.am/db/1398821/Microsoft>,
        <https://1145.am/db/1487902/Microsoft>,
        <https://1145.am/db/1566732/Microsoft>,
        <https://1145.am/db/1617851/Microsoft>,
        <https://1145.am/db/1631476/Microsoft_Corp>,
        <https://1145.am/db/1695812/Microsoft>,
        <https://1145.am/db/1699320/Microsoft>,
        <https://1145.am/db/1726210/Microsoft>,
        <https://1145.am/db/1727481/Microsoft>,
        <https://1145.am/db/1734778/Microsoft>,
        <https://1145.am/db/1741120/Microsoft>,
        <https://1145.am/db/1747044/Microsoft>,
        <https://1145.am/db/1758900/Microsoft>,
        <https://1145.am/db/1762702/Microsoft>,
        <https://1145.am/db/1763332/Microsoft>,
        <https://1145.am/db/1772600/Microsoft>,
        <https://1145.am/db/1786991/Microsoft>,
        <https://1145.am/db/1788358/Microsoft>,
        <https://1145.am/db/1791808/Microsoft>,
        <https://1145.am/db/1818534/Microsoft>,
        <https://1145.am/db/1822222/Microsoft>,
        <https://1145.am/db/1835226/Microsoft>,
        <https://1145.am/db/1842562/Microsoft>,
        <https://1145.am/db/1875189/Microsoft>,
        <https://1145.am/db/1884277/Microsoft>,
        <https://1145.am/db/1941048/Microsoft_Corp>,
        <https://1145.am/db/1942901/Microsoft_Corp>,
        <https://1145.am/db/1947898/Microsoft>,
        <https://1145.am/db/1981521/Microsoft>,
        <https://1145.am/db/1984927/Microsoft>,
        <https://1145.am/db/1993523/Microsoft>,
        <https://1145.am/db/2007265/Microsoft>,
        <https://1145.am/db/2008078/Microsoft_Corp>,
        <https://1145.am/db/2011789/Microsoft>,
        <https://1145.am/db/2029229/Microsoft>,
        <https://1145.am/db/2034974/Microsoft_Corp>,
        <https://1145.am/db/2072814/Microsoft>,
        <https://1145.am/db/2093298/Microsoft>,
        <https://1145.am/db/2094024/Microsoft>,
        <https://1145.am/db/2122854/Microsoft>,
        <https://1145.am/db/2144448/Microsoft>,
        <https://1145.am/db/2198670/Microsoft>,
        <https://1145.am/db/2278997/Microsoft>,
        <https://1145.am/db/2508969/Microsoft>,
        <https://1145.am/db/2602130/Microsoft>,
        <https://1145.am/db/2602863/Microsoft>,
        <https://1145.am/db/2611481/Microsoft>,
        <https://1145.am/db/2612223/Microsoft>,
        <https://1145.am/db/2612606/Microsoft>,
        <https://1145.am/db/2620026/Microsoft>,
        <https://1145.am/db/2634487/Microsoft>,
        <https://1145.am/db/2653908/Microsoft>,
        <https://1145.am/db/2655064/Microsoft>,
        <https://1145.am/db/2655423/Microsoft>,
        <https://1145.am/db/2656101/Microsoft>,
        <https://1145.am/db/2656986/Microsoft>,
        <https://1145.am/db/2662486/Microsoft>,
        <https://1145.am/db/2667065/Microsoft>,
        <https://1145.am/db/2672066/Microsoft>,
        <https://1145.am/db/2683077/Microsoft> ;
    ns1:sameAsMedium <https://1145.am/db/1017437/Microsoft_Corp>,
        <https://1145.am/db/1025001/Microsoft_Corp>,
        <https://1145.am/db/1092654/Microsoft>,
        <https://1145.am/db/1190136/Microsoft>,
        <https://1145.am/db/1311662/Microsoft_Corp>,
        <https://1145.am/db/1428802/Microsoft>,
        <https://1145.am/db/1527244/Microsoft_Corp>,
        <https://1145.am/db/1558774/Microsoft>,
        <https://1145.am/db/1571096/Microsoft>,
        <https://1145.am/db/1600830/Microsoft_Corp>,
        <https://1145.am/db/1618044/Microsoft_Corp>,
        <https://1145.am/db/161893/Microsoft>,
        <https://1145.am/db/1633549/Microsoft>,
        <https://1145.am/db/1654251/Microsoft>,
        <https://1145.am/db/1655883/Microsoft>,
        <https://1145.am/db/1678251/Microsoft>,
        <https://1145.am/db/1689071/Microsoft>,
        <https://1145.am/db/1691718/Microsoft_Corp>,
        <https://1145.am/db/1697158/Microsoft>,
        <https://1145.am/db/1697321/Microsoft>,
        <https://1145.am/db/1697590/Microsoft>,
        <https://1145.am/db/1698342/Microsoft>,
        <https://1145.am/db/1699790/Microsoft>,
        <https://1145.am/db/1701497/Microsoft>,
        <https://1145.am/db/1703728/Microsoft_Corporation>,
        <https://1145.am/db/1706033/Microsoft>,
        <https://1145.am/db/1708523/Microsoft>,
        <https://1145.am/db/1708611/Microsoft>,
        <https://1145.am/db/1709652/Microsoft>,
        <https://1145.am/db/1709976/Microsoft>,
        <https://1145.am/db/1710427/Microsoft>,
        <https://1145.am/db/1710962/Microsoft>,
        <https://1145.am/db/1711305/Microsoft>,
        <https://1145.am/db/1712686/Microsoft_Corp>,
        <https://1145.am/db/1712862/Microsoft>,
        <https://1145.am/db/1714418/Microsoft>,
        <https://1145.am/db/1716650/Microsoft>,
        <https://1145.am/db/1717533/Microsoft>,
        <https://1145.am/db/1718033/Microsoft>,
        <https://1145.am/db/1718245/Microsoft>,
        <https://1145.am/db/1719232/Microsoft>,
        <https://1145.am/db/1721134/Microsoft>,
        <https://1145.am/db/1723140/Microsoft_Corp>,
        <https://1145.am/db/1734650/Microsoft>,
        <https://1145.am/db/1734931/Microsoft>,
        <https://1145.am/db/1735301/Microsoft>,
        <https://1145.am/db/1737935/Microsoft>,
        <https://1145.am/db/1741140/Microsoft>,
        <https://1145.am/db/1742118/Microsoft>,
        <https://1145.am/db/1746848/Microsoft>,
        <https://1145.am/db/1746971/Microsoft>,
        <https://1145.am/db/1747812/Microsoft>,
        <https://1145.am/db/1748887/Microsoft>,
        <https://1145.am/db/1749016/Microsoft>,
        <https://1145.am/db/1751726/Microsoft>,
        <https://1145.am/db/1752062/Microsoft>,
        <https://1145.am/db/1754464/Microsoft>,
        <https://1145.am/db/1755059/Microsoft>,
        <https://1145.am/db/1755209/Microsoft>,
        <https://1145.am/db/1758390/Microsoft>,
        <https://1145.am/db/1758924/Microsoft>,
        <https://1145.am/db/1759192/Microsoft>,
        <https://1145.am/db/1759760/Microsoft>,
        <https://1145.am/db/1759766/Microsoft>,
        <https://1145.am/db/1760029/Microsoft>,
        <https://1145.am/db/1760205/Microsoft>,
        <https://1145.am/db/1760729/Microsoft>,
        <https://1145.am/db/1760981/Microsoft>,
        <https://1145.am/db/1764427/Microsoft>,
        <https://1145.am/db/1768188/Microsoft>,
        <https://1145.am/db/1768388/Microsoft>,
        <https://1145.am/db/1769233/Microsoft>,
        <https://1145.am/db/1770225/Microsoft>,
        <https://1145.am/db/1770401/Microsoft>,
        <https://1145.am/db/1771744/Microsoft>,
        <https://1145.am/db/1772579/Microsoft>,
        <https://1145.am/db/1773454/Microsoft>,
        <https://1145.am/db/1777695/Microsoft>,
        <https://1145.am/db/1778043/Microsoft>,
        <https://1145.am/db/1778089/Microsoft>,
        <https://1145.am/db/1778879/Microsoft>,
        <https://1145.am/db/1780530/Microsoft>,
        <https://1145.am/db/1781499/Microsoft>,
        <https://1145.am/db/1782580/Microsoft>,
        <https://1145.am/db/1783135/Microsoft>,
        <https://1145.am/db/1786640/Microsoft>,
        <https://1145.am/db/1786753/Microsoft>,
        <https://1145.am/db/1790700/Microsoft>,
        <https://1145.am/db/1792227/Microsoft>,
        <https://1145.am/db/1792368/Microsoft>,
        <https://1145.am/db/1792666/Microsoft>,
        <https://1145.am/db/1792965/Microsoft>,
        <https://1145.am/db/1793015/Microsoft>,
        <https://1145.am/db/1794612/Microsoft>,
        <https://1145.am/db/1795244/Microsoft>,
        <https://1145.am/db/1795255/Microsoft>,
        <https://1145.am/db/1795869/Microsoft>,
        <https://1145.am/db/1795925/Microsoft>,
        <https://1145.am/db/1796232/Microsoft>,
        <https://1145.am/db/1796259/Microsoft>,
        <https://1145.am/db/1796273/Microsoft>,
        <https://1145.am/db/1798246/Microsoft>,
        <https://1145.am/db/1798437/Microsoft>,
        <https://1145.am/db/1800013/Microsoft>,
        <https://1145.am/db/1801241/Microsoft>,
        <https://1145.am/db/1802129/Microsoft>,
        <https://1145.am/db/1803214/Microsoft>,
        <https://1145.am/db/1807226/Microsoft>,
        <https://1145.am/db/1808409/Microsoft>,
        <https://1145.am/db/1809462/Microsoft>,
        <https://1145.am/db/1810877/Microsoft>,
        <https://1145.am/db/1811070/Microsoft>,
        <https://1145.am/db/1811482/Microsoft>,
        <https://1145.am/db/1813957/Microsoft>,
        <https://1145.am/db/1814632/Microsoft>,
        <https://1145.am/db/1814865/Microsoft>,
        <https://1145.am/db/1816265/Microsoft>,
        <https://1145.am/db/1816532/Microsoft>,
        <https://1145.am/db/1817819/Microsoft>,
        <https://1145.am/db/1818394/Microsoft>,
        <https://1145.am/db/1818533/Microsoft>,
        <https://1145.am/db/1819909/Microsoft>,
        <https://1145.am/db/1820048/Microsoft>,
        <https://1145.am/db/1823778/Microsoft>,
        <https://1145.am/db/1824780/Microsoft>,
        <https://1145.am/db/1825996/Microsoft>,
        <https://1145.am/db/1826121/Microsoft>,
        <https://1145.am/db/1827341/Microsoft>,
        <https://1145.am/db/1828648/Microsoft>,
        <https://1145.am/db/1828902/Microsoft>,
        <https://1145.am/db/1830298/Microsoft>,
        <https://1145.am/db/1831301/Microsoft>,
        <https://1145.am/db/1832770/Microsoft>,
        <https://1145.am/db/1833510/Microsoft>,
        <https://1145.am/db/1834475/Microsoft>,
        <https://1145.am/db/1835448/Microsoft>,
        <https://1145.am/db/1838210/Microsoft>,
        <https://1145.am/db/1838478/Microsoft>,
        <https://1145.am/db/1839207/Microsoft>,
        <https://1145.am/db/1841018/Microsoft_Corp>,
        <https://1145.am/db/1842887/Microsoft>,
        <https://1145.am/db/1843454/Microsoft>,
        <https://1145.am/db/1843539/Microsoft>,
        <https://1145.am/db/1843972/Microsoft>,
        <https://1145.am/db/1852125/Microsoft>,
        <https://1145.am/db/1853227/Microsoft>,
        <https://1145.am/db/1854780/Microsoft>,
        <https://1145.am/db/1854945/Microsoft>,
        <https://1145.am/db/1855966/Microsoft>,
        <https://1145.am/db/1856684/Microsoft>,
        <https://1145.am/db/1858254/Microsoft>,
        <https://1145.am/db/1858451/Microsoft>,
        <https://1145.am/db/1858692/Microsoft>,
        <https://1145.am/db/1860773/Microsoft>,
        <https://1145.am/db/1861339/Microsoft>,
        <https://1145.am/db/1871130/Microsoft>,
        <https://1145.am/db/1871611/Microsoft>,
        <https://1145.am/db/1874678/Microsoft>,
        <https://1145.am/db/1879673/Microsoft>,
        <https://1145.am/db/1879985/Microsoft>,
        <https://1145.am/db/1881214/Microsoft>,
        <https://1145.am/db/1882058/Microsoft>,
        <https://1145.am/db/1882161/Microsoft>,
        <https://1145.am/db/1885560/Microsoft>,
        <https://1145.am/db/1888008/Microsoft>,
        <https://1145.am/db/1895009/Microsoft>,
        <https://1145.am/db/1897581/Microsoft>,
        <https://1145.am/db/1901098/Microsoft>,
        <https://1145.am/db/1902016/Microsoft>,
        <https://1145.am/db/1902079/Microsoft>,
        <https://1145.am/db/1902847/Microsoft>,
        <https://1145.am/db/1903669/Microsoft>,
        <https://1145.am/db/1903721/Microsoft>,
        <https://1145.am/db/1905425/Microsoft>,
        <https://1145.am/db/1909119/Microsoft_Corp>,
        <https://1145.am/db/1910290/Microsoft_Corp>,
        <https://1145.am/db/1914747/Microsoft>,
        <https://1145.am/db/1915432/Microsoft>,
        <https://1145.am/db/1915560/Microsoft>,
        <https://1145.am/db/1943925/Microsoft_Corp>,
        <https://1145.am/db/1947749/Microsoft>,
        <https://1145.am/db/1948338/Microsoft>,
        <https://1145.am/db/1961649/Microsoft>,
        <https://1145.am/db/1974598/Microsoft>,
        <https://1145.am/db/1982175/Microsoft>,
        <https://1145.am/db/1986630/Microsoft>,
        <https://1145.am/db/1987503/Microsoft>,
        <https://1145.am/db/199718/Microsoft>,
        <https://1145.am/db/199816/Microsoft>,
        <https://1145.am/db/2002065/Microsoft_Corp>,
        <https://1145.am/db/2004213/Microsoft_Corp>,
        <https://1145.am/db/2006775/Microsoft>,
        <https://1145.am/db/2013724/Microsoft>,
        <https://1145.am/db/2015713/Microsoft_Corp>,
        <https://1145.am/db/2015981/Microsoft>,
        <https://1145.am/db/2033848/Microsoft>,
        <https://1145.am/db/2034613/Microsoft>,
        <https://1145.am/db/2036186/Microsoft>,
        <https://1145.am/db/2036982/Microsoft_Corp>,
        <https://1145.am/db/2037760/Microsoft>,
        <https://1145.am/db/2039253/Microsoft>,
        <https://1145.am/db/2040859/Microsoft>,
        <https://1145.am/db/2045433/Microsoft>,
        <https://1145.am/db/2047060/Microsoft>,
        <https://1145.am/db/2050229/Microsoft>,
        <https://1145.am/db/2053053/Microsoft>,
        <https://1145.am/db/2053123/Microsoft>,
        <https://1145.am/db/2053654/Microsoft>,
        <https://1145.am/db/2059318/Microsoft>,
        <https://1145.am/db/2059491/Microsoft>,
        <https://1145.am/db/2059502/Microsoft>,
        <https://1145.am/db/2059547/Microsoft>,
        <https://1145.am/db/2060416/Microsoft>,
        <https://1145.am/db/2060997/Microsoft>,
        <https://1145.am/db/2062372/Microsoft>,
        <https://1145.am/db/2063305/Microsoft>,
        <https://1145.am/db/2063335/Microsoft_Corp>,
        <https://1145.am/db/2063909/Microsoft>,
        <https://1145.am/db/2064352/Microsoft>,
        <https://1145.am/db/2065497/Microsoft>,
        <https://1145.am/db/2067787/Microsoft>,
        <https://1145.am/db/2083718/Microsoft>,
        <https://1145.am/db/2109233/Microsoft>,
        <https://1145.am/db/2120040/Microsoft>,
        <https://1145.am/db/2127651/Microsoft>,
        <https://1145.am/db/2145163/Microsoft>,
        <https://1145.am/db/2148259/Microsoft>,
        <https://1145.am/db/2162386/Microsoft>,
        <https://1145.am/db/217185/Microsoft>,
        <https://1145.am/db/2172604/Microsoft>,
        <https://1145.am/db/2173138/Microsoft>,
        <https://1145.am/db/2174297/Microsoft>,
        <https://1145.am/db/2178519/Microsoft>,
        <https://1145.am/db/2180858/Microsoft>,
        <https://1145.am/db/2187630/Microsoft>,
        <https://1145.am/db/2197267/Microsoft>,
        <https://1145.am/db/2198071/Microsoft>,
        <https://1145.am/db/2207923/Microsoft>,
        <https://1145.am/db/2225131/Microsoft>,
        <https://1145.am/db/2279241/Microsoft>,
        <https://1145.am/db/228046/Microsoft>,
        <https://1145.am/db/2284483/Microsoft>,
        <https://1145.am/db/232308/Microsoft_Corp>,
        <https://1145.am/db/232337/Microsoft_Corp>,
        <https://1145.am/db/2326224/Microsoft_Corp>,
        <https://1145.am/db/2601736/Microsoft>,
        <https://1145.am/db/2602724/Microsoft>,
        <https://1145.am/db/2602958/Microsoft>,
        <https://1145.am/db/2603484/Microsoft>,
        <https://1145.am/db/2604604/Microsoft>,
        <https://1145.am/db/2606540/Microsoft>,
        <https://1145.am/db/2611328/Microsoft>,
        <https://1145.am/db/2611331/Microsoft>,
        <https://1145.am/db/2613829/Microsoft>,
        <https://1145.am/db/2617989/Microsoft>,
        <https://1145.am/db/2620025/Microsoft>,
        <https://1145.am/db/2622354/Microsoft>,
        <https://1145.am/db/2623559/Microsoft>,
        <https://1145.am/db/2626449/Microsoft>,
        <https://1145.am/db/2627269/Microsoft>,
        <https://1145.am/db/2628760/Microsoft>,
        <https://1145.am/db/2634465/Microsoft>,
        <https://1145.am/db/2636189/Microsoft>,
        <https://1145.am/db/2636234/Microsoft>,
        <https://1145.am/db/2639094/Microsoft>,
        <https://1145.am/db/2640110/Microsoft>,
        <https://1145.am/db/2640182/Microsoft>,
        <https://1145.am/db/2644494/Microsoft>,
        <https://1145.am/db/2648410/Microsoft>,
        <https://1145.am/db/2648535/Microsoft>,
        <https://1145.am/db/2648546/Microsoft>,
        <https://1145.am/db/2651769/Microsoft>,
        <https://1145.am/db/2652890/Microsoft>,
        <https://1145.am/db/2653297/Microsoft>,
        <https://1145.am/db/2653310/Microsoft>,
        <https://1145.am/db/2653481/Microsoft>,
        <https://1145.am/db/2654138/Microsoft>,
        <https://1145.am/db/2654146/Microsoft>,
        <https://1145.am/db/2654238/Microsoft>,
        <https://1145.am/db/2654294/Microsoft>,
        <https://1145.am/db/2654510/Microsoft>,
        <https://1145.am/db/2654524/Microsoft>,
        <https://1145.am/db/2655146/Microsoft>,
        <https://1145.am/db/2655439/Microsoft>,
        <https://1145.am/db/2655461/Microsoft>,
        <https://1145.am/db/2656359/Microsoft>,
        <https://1145.am/db/2657038/Microsoft>,
        <https://1145.am/db/2658038/Microsoft>,
        <https://1145.am/db/2658913/Microsoft>,
        <https://1145.am/db/2659072/Microsoft>,
        <https://1145.am/db/2659897/Microsoft>,
        <https://1145.am/db/2659924/Microsoft>,
        <https://1145.am/db/2659958/Microsoft>,
        <https://1145.am/db/2661009/Microsoft>,
        <https://1145.am/db/2661125/Microsoft>,
        <https://1145.am/db/2661187/Microsoft>,
        <https://1145.am/db/2662106/Microsoft>,
        <https://1145.am/db/2662211/Microsoft>,
        <https://1145.am/db/2663295/Microsoft>,
        <https://1145.am/db/2663557/Microsoft>,
        <https://1145.am/db/2664293/Microsoft>,
        <https://1145.am/db/2664464/Microsoft>,
        <https://1145.am/db/2666156/Microsoft>,
        <https://1145.am/db/2667078/Microsoft>,
        <https://1145.am/db/2667474/Microsoft>,
        <https://1145.am/db/2667526/Microsoft>,
        <https://1145.am/db/2667660/Microsoft>,
        <https://1145.am/db/2669494/Microsoft>,
        <https://1145.am/db/2670705/Microsoft>,
        <https://1145.am/db/2671587/Microsoft>,
        <https://1145.am/db/2671878/Microsoft>,
        <https://1145.am/db/2672194/Microsoft>,
        <https://1145.am/db/2672819/Microsoft>,
        <https://1145.am/db/2673373/Microsoft>,
        <https://1145.am/db/2673385/Microsoft>,
        <https://1145.am/db/2673437/Microsoft>,
        <https://1145.am/db/2673898/Microsoft>,
        <https://1145.am/db/2675617/Microsoft>,
        <https://1145.am/db/2679159/Microsoft>,
        <https://1145.am/db/2679256/Microsoft>,
        <https://1145.am/db/2679342/Microsoft>,
        <https://1145.am/db/2681897/Microsoft>,
        <https://1145.am/db/2682508/Microsoft>,
        <https://1145.am/db/2683061/Microsoft>,
        <https://1145.am/db/2683066/Microsoft>,
        <https://1145.am/db/2683067/Microsoft>,
        <https://1145.am/db/2683069/Microsoft>,
        <https://1145.am/db/2683074/Microsoft>,
        <https://1145.am/db/2683079/Microsoft>,
        <https://1145.am/db/2683451/Microsoft>,
        <https://1145.am/db/2683465/Microsoft>,
        <https://1145.am/db/2683818/Microsoft>,
        <https://1145.am/db/2686285/Microsoft>,
        <https://1145.am/db/2686301/Microsoft>,
        <https://1145.am/db/2686449/Microsoft>,
        <https://1145.am/db/2700623/Microsoft>,
        <https://1145.am/db/2738271/Microsoft>,
        <https://1145.am/db/2754611/Microsoft>,
        <https://1145.am/db/2760139/Microsoft_Corp>,
        <https://1145.am/db/2761530/Microsoft_Corp>,
        <https://1145.am/db/2762134/Microsoft>,
        <https://1145.am/db/2762347/Microsoft_Corp>,
        <https://1145.am/db/2762562/Microsoft>,
        <https://1145.am/db/2776232/Microsoft>,
        <https://1145.am/db/2782429/Microsoft>,
        <https://1145.am/db/2801091/Microsoft_Corporation>,
        <https://1145.am/db/282538/Microsoft_Corp>,
        <https://1145.am/db/305288/Microsoft_Corp>,
        <https://1145.am/db/305594/Microsoft_Corp>,
        <https://1145.am/db/347978/Microsoft_Corp>,
        <https://1145.am/db/348031/Microsoft_Corp>,
        <https://1145.am/db/355324/Microsoft_Corp>,
        <https://1145.am/db/355332/Microsoft_Corp>,
        <https://1145.am/db/361491/Microsoft>,
        <https://1145.am/db/365521/Microsoft_Corp>,
        <https://1145.am/db/387846/Microsoft_Corp>,
        <https://1145.am/db/505767/Microsoft_Corp>,
        <https://1145.am/db/544757/Microsoft>,
        <https://1145.am/db/549213/Microsoft_Corp>,
        <https://1145.am/db/644370/Microsoft_Corp>,
        <https://1145.am/db/692886/Microsoft_Corp>,
        <https://1145.am/db/698837/Microsoft>,
        <https://1145.am/db/710355/Microsoft>,
        <https://1145.am/db/710798/Microsoft>,
        <https://1145.am/db/765281/Microsoft_Corp>,
        <https://1145.am/db/766576/Microsoft_Corp>,
        <https://1145.am/db/767841/Microsoft>,
        <https://1145.am/db/767857/Microsoft_Corp>,
        <https://1145.am/db/771073/Microsoft>,
        <https://1145.am/db/771474/Microsoft>,
        <https://1145.am/db/771701/Microsoft_Corp>,
        <https://1145.am/db/771800/Microsoft_Corp>,
        <https://1145.am/db/772395/Microsoft>,
        <https://1145.am/db/774623/Microsoft_Corp>,
        <https://1145.am/db/784797/Microsoft>,
        <https://1145.am/db/798667/Microsoft_Corp>,
        <https://1145.am/db/798704/Microsoft>,
        <https://1145.am/db/798950/Microsoft_Corp>,
        <https://1145.am/db/816467/Microsoft_Corp>,
        <https://1145.am/db/817822/Microsoft_Corp>,
        <https://1145.am/db/829840/Microsoft_Corp>,
        <https://1145.am/db/85685/Microsoft_Corp>,
        <https://1145.am/db/867602/Microsoft_Corporation>,
        <https://1145.am/db/871474/Microsoft_Corporation>,
        <https://1145.am/db/877583/Microsoft_Corp>,
        <https://1145.am/db/879601/Microsoft>,
        <https://1145.am/db/880066/Microsoft_Corp>,
        <https://1145.am/db/907229/Microsoft>,
        <https://1145.am/db/920712/Microsoft>,
        <https://1145.am/db/969129/Microsoft>,
        <https://1145.am/db/973870/Microsoft> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2653242/Corporate_Commercial_Bank> a org:Organization ;
    ns1:basedInHighRaw "Bulgarian" ;
    ns1:buyer <https://1145.am/db/2653242/Vivacom_Acquisition> ;
    ns1:description "Bulgarian lender" ;
    ns1:documentDate "2012-08-08T09:57:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Banks agree to buy Bulgaria's Vivacom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/banks-agree-to-buy-bulgaria-s-vivacom> ;
    ns1:foundName "Corporate Commercial Bank (CCBank)" ;
    ns1:name "Corporate Commercial Bank" ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2653242/Vtb_Capital> a org:Organization ;
    ns1:basedInHighGeoName "Russian Federation" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:basedInHighRaw "Russia" ;
    ns1:buyer <https://1145.am/db/2653242/Vivacom_Acquisition> ;
    ns1:description "a unit of Russia's VTB Bank" ;
    ns1:documentDate "2012-08-08T09:57:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Banks agree to buy Bulgaria's Vivacom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/banks-agree-to-buy-bulgaria-s-vivacom> ;
    ns1:foundName "VTB Capital" ;
    ns1:name "VTB Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1599449/VTB>,
        <https://1145.am/db/2032755/VTB>,
        <https://1145.am/db/2655942/VTB>,
        <https://1145.am/db/634400/VTB>,
        <https://1145.am/db/635015/VTB> ;
    ns1:sameAsMedium <https://1145.am/db/1858767/Vtb_Capital> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2678633/Alvarion> a org:Organization ;
    ns1:basedInHighGeoName "State of Israel" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/294640/about.rdf> ;
    ns1:basedInHighRaw "Israel" ;
    ns1:buyer <https://1145.am/db/2678633/Wavion_Acquisition> ;
    ns1:description "Wimax" ;
    ns1:documentDate "2012-05-30T08:25:36+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alvarion considers ditching Wimax" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/alvarion-considers-ditching-wimax> ;
    ns1:foundName "Alvarion" ;
    ns1:industry "Wimax" ;
    ns1:name "Alvarion" ;
    ns1:sameAsHigh <https://1145.am/db/2647920/Alvarion>,
        <https://1145.am/db/2668270/Alvarion> ;
    ns1:sameAsMedium <https://1145.am/db/2629904/Alvarion>,
        <https://1145.am/db/2630914/Alvarion>,
        <https://1145.am/db/2635886/Alvarion>,
        <https://1145.am/db/2636798/Alvarion> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2681282/Leap_Wireless> a org:Organization ;
    ns1:basedInLowRaw "USA" ;
    ns1:documentDate "2012-04-18T15:23:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Verizon: We'll sell 700 MHz spectrum to get cable companies' AWS spectrum" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/verizon-we-ll-sell-700-mhz-spectrum-to-get-cable-companies-aws-spectrum> ;
    ns1:foundName "Leap Wireless" ;
    ns1:investor <https://1145.am/db/2681282/Investment_Leap_Wireless_Metropcs_T-Mobile_Usa_Verizon_Wireless_Stopped> ;
    ns1:name "Leap Wireless" ;
    ns1:sameAsMedium <https://1145.am/db/1836084/Leap_Wireless>,
        <https://1145.am/db/2173415/Leap_Wireless>,
        <https://1145.am/db/2625775/Leap_Wireless>,
        <https://1145.am/db/2631033/Leap_Wireless>,
        <https://1145.am/db/2637762/Leap_Wireless>,
        <https://1145.am/db/2639625/Leap_Wireless>,
        <https://1145.am/db/2647888/Leap_Wireless>,
        <https://1145.am/db/2655150/Leap_Wireless>,
        <https://1145.am/db/2658466/Leap_Wireless>,
        <https://1145.am/db/2661159/Leap_Wireless>,
        <https://1145.am/db/2661168/Leap_Wireless>,
        <https://1145.am/db/2662193/Leap_Wireless>,
        <https://1145.am/db/2662378/Leap_Wireless>,
        <https://1145.am/db/2664378/Leap_Wireless>,
        <https://1145.am/db/2664500/Leap_Wireless>,
        <https://1145.am/db/2665469/Leap_Wireless>,
        <https://1145.am/db/2669926/Leap_Wireless>,
        <https://1145.am/db/2674567/Leap_Wireless>,
        <https://1145.am/db/2676099/Leap_Wireless>,
        <https://1145.am/db/2678516/Leap_Wireless>,
        <https://1145.am/db/2680894/Leap_Wireless>,
        <https://1145.am/db/2680897/Leap_Wireless>,
        <https://1145.am/db/2680900/Leap_Wireless>,
        <https://1145.am/db/2680905/Leap_Wireless>,
        <https://1145.am/db/2680906/Leap_Wireless>,
        <https://1145.am/db/2681584/Leap_Wireless>,
        <https://1145.am/db/2681695/Leap_Wireless>,
        <https://1145.am/db/2681734/Leap_Wireless>,
        <https://1145.am/db/2682715/Leap_Wireless>,
        <https://1145.am/db/2684439/Leap_Wireless>,
        <https://1145.am/db/2685183/Leap_Wireless>,
        <https://1145.am/db/2685314/Leap_Wireless>,
        <https://1145.am/db/2685799/Leap_Wireless>,
        <https://1145.am/db/2686174/Leap_Wireless>,
        <https://1145.am/db/2686488/Leap_Wireless> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2681282/Metropcs> a org:Organization ;
    ns1:basedInLowRaw "USA" ;
    ns1:documentDate "2012-04-18T15:23:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Verizon: We'll sell 700 MHz spectrum to get cable companies' AWS spectrum" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/verizon-we-ll-sell-700-mhz-spectrum-to-get-cable-companies-aws-spectrum> ;
    ns1:foundName "MetroPCS" ;
    ns1:investor <https://1145.am/db/2681282/Investment_Leap_Wireless_Metropcs_T-Mobile_Usa_Verizon_Wireless_Stopped> ;
    ns1:name "MetroPCS" ;
    ns1:sameAsMedium <https://1145.am/db/2625808/Metropcs>,
        <https://1145.am/db/2626494/Metropcs>,
        <https://1145.am/db/2631033/Metropcs>,
        <https://1145.am/db/2640440/Metropcs>,
        <https://1145.am/db/2650228/Metropcs>,
        <https://1145.am/db/2656845/Metropcs>,
        <https://1145.am/db/2656851/Metropcs>,
        <https://1145.am/db/2658569/Metropcs>,
        <https://1145.am/db/2658575/Metropcs>,
        <https://1145.am/db/2658580/Metropcs>,
        <https://1145.am/db/2658589/Metropcs>,
        <https://1145.am/db/2659586/Metropcs>,
        <https://1145.am/db/2659591/Metropcs>,
        <https://1145.am/db/2659597/Metropcs>,
        <https://1145.am/db/2659631/Metropcs>,
        <https://1145.am/db/2662860/Metropcs>,
        <https://1145.am/db/2662872/Metropcs>,
        <https://1145.am/db/2663892/Metropcs>,
        <https://1145.am/db/2664500/Metropcs>,
        <https://1145.am/db/2664986/Metropcs>,
        <https://1145.am/db/2666714/Metropcs>,
        <https://1145.am/db/2668208/Metropcs>,
        <https://1145.am/db/2668226/Metropcs>,
        <https://1145.am/db/2669319/Metropcs>,
        <https://1145.am/db/2669321/Metropcs>,
        <https://1145.am/db/2669338/Metropcs>,
        <https://1145.am/db/2670397/Metropcs>,
        <https://1145.am/db/2670454/Metropcs>,
        <https://1145.am/db/2671585/Metropcs>,
        <https://1145.am/db/2671623/Metropcs>,
        <https://1145.am/db/2671629/Metropcs>,
        <https://1145.am/db/2673938/Metropcs>,
        <https://1145.am/db/2676975/Metropcs>,
        <https://1145.am/db/2681285/Metropcs>,
        <https://1145.am/db/2681584/Metropcs>,
        <https://1145.am/db/2682450/Metropcs>,
        <https://1145.am/db/2683705/Metropcs>,
        <https://1145.am/db/2685314/Metropcs>,
        <https://1145.am/db/2685799/Metropcs>,
        <https://1145.am/db/2686488/Metropcs> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2681282/T-Mobile_Usa> a org:Organization ;
    ns1:basedInLowRaw "USA" ;
    ns1:buyer <https://1145.am/db/2681282/Acquisition_T-Mobile_Usa_Verizon_Wireless_Has_Not_Happened> ;
    ns1:description "buying Verizon's 700 MHz Lower A and B Block spectrum" ;
    ns1:documentDate "2012-04-18T15:23:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Verizon: We'll sell 700 MHz spectrum to get cable companies' AWS spectrum" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/verizon-we-ll-sell-700-mhz-spectrum-to-get-cable-companies-aws-spectrum> ;
    ns1:foundName "T-Mobile USA" ;
    ns1:investor <https://1145.am/db/2681282/Investment_Leap_Wireless_Metropcs_T-Mobile_Usa_Verizon_Wireless_Stopped> ;
    ns1:name "T-Mobile USA" ;
    ns1:sameAsHigh <https://1145.am/db/2683135/Us_Cellular> ;
    ns1:sameAsMedium <https://1145.am/db/1325578/T-Mobile_Us_Inc>,
        <https://1145.am/db/1333909/T-Mobile_Us>,
        <https://1145.am/db/1335192/T-Mobile_Usa>,
        <https://1145.am/db/1335249/T-Mobile_Usa>,
        <https://1145.am/db/1338725/T-Mobile_Us>,
        <https://1145.am/db/1673449/T-Mobile_Us>,
        <https://1145.am/db/1682956/T-Mobile_Us>,
        <https://1145.am/db/1845755/T-Mobile_Us>,
        <https://1145.am/db/1849778/T-Mobile_Usa>,
        <https://1145.am/db/1938719/T-Mobile_Us_Inc>,
        <https://1145.am/db/2050728/T-Mobile_Us>,
        <https://1145.am/db/2113124/T-Mobile_Usa>,
        <https://1145.am/db/2113624/T-Mobile_Us>,
        <https://1145.am/db/2156872/T-Mobile_Us>,
        <https://1145.am/db/2160856/T-Mobile_Us>,
        <https://1145.am/db/2624400/T-Mobile_Usa>,
        <https://1145.am/db/2625058/T-Mobile_Usa>,
        <https://1145.am/db/2625764/T-Mobile_Usa>,
        <https://1145.am/db/2625808/T-Mobile_Usa>,
        <https://1145.am/db/2627253/T-Mobile_Usa>,
        <https://1145.am/db/2627982/T-Mobile_Usa>,
        <https://1145.am/db/2628029/T-Mobile_Usa>,
        <https://1145.am/db/2628936/T-Mobile_Usa>,
        <https://1145.am/db/2628948/T-Mobile_Usa>,
        <https://1145.am/db/2629910/T-Mobile_Usa>,
        <https://1145.am/db/2630839/T-Mobile_Usa>,
        <https://1145.am/db/2639641/T-Mobile_Usa>,
        <https://1145.am/db/2640440/T-Mobile_Usa>,
        <https://1145.am/db/2640631/T-Mobile_Usa>,
        <https://1145.am/db/2643007/T-Mobile_Usa>,
        <https://1145.am/db/2644928/T-Mobile_Us>,
        <https://1145.am/db/2645879/T-Mobile_Us>,
        <https://1145.am/db/2650593/T-Mobile_Us>,
        <https://1145.am/db/2651447/T-Mobile_Usa>,
        <https://1145.am/db/2653683/T-Mobile_Us>,
        <https://1145.am/db/2653777/T-Mobile_Usa>,
        <https://1145.am/db/2654246/T-Mobile_Us>,
        <https://1145.am/db/2654263/T-Mobile_Us>,
        <https://1145.am/db/2655150/T-Mobile_Us>,
        <https://1145.am/db/2655154/T-Mobile_Us>,
        <https://1145.am/db/2656030/T-Mobile_Us>,
        <https://1145.am/db/2656226/T-Mobile_Us>,
        <https://1145.am/db/2656851/T-Mobile_Usa>,
        <https://1145.am/db/2657573/T-Mobile_Usa>,
        <https://1145.am/db/2658024/T-Mobile_Us>,
        <https://1145.am/db/2658043/T-Mobile_Us>,
        <https://1145.am/db/2658068/T-Mobile_Us>,
        <https://1145.am/db/2658213/T-Mobile_Us>,
        <https://1145.am/db/2658466/T-Mobile_Usa>,
        <https://1145.am/db/2658550/T-Mobile_Usa>,
        <https://1145.am/db/2658574/T-Mobile_Usa>,
        <https://1145.am/db/2658575/T-Mobile_Usa>,
        <https://1145.am/db/2659586/T-Mobile_Usa>,
        <https://1145.am/db/2659597/T-Mobile_Usa>,
        <https://1145.am/db/2661143/T-Mobile_Us>,
        <https://1145.am/db/2661274/T-Mobile_Usa>,
        <https://1145.am/db/2661290/T-Mobile_Usa>,
        <https://1145.am/db/2661405/T-Mobile_Us>,
        <https://1145.am/db/2661443/T-Mobile_Us>,
        <https://1145.am/db/2661680/T-Mobile_Usa>,
        <https://1145.am/db/2662808/T-Mobile_Usa>,
        <https://1145.am/db/2662860/T-Mobile_Usa>,
        <https://1145.am/db/2663146/T-Mobile_Us>,
        <https://1145.am/db/2663406/T-Mobile_Usa>,
        <https://1145.am/db/2663421/T-Mobile_Usa>,
        <https://1145.am/db/2663473/T-Mobile_Usa>,
        <https://1145.am/db/2663892/T-Mobile_Usa>,
        <https://1145.am/db/2664422/T-Mobile_Us>,
        <https://1145.am/db/2664500/T-Mobile_Usa>,
        <https://1145.am/db/2664505/T-Mobile_Usa>,
        <https://1145.am/db/2664517/T-Mobile_Usa>,
        <https://1145.am/db/2664547/T-Mobile_Usa>,
        <https://1145.am/db/2664692/T-Mobile_Us>,
        <https://1145.am/db/2665477/T-Mobile_Us>,
        <https://1145.am/db/2665579/T-Mobile_Usa>,
        <https://1145.am/db/2666714/T-Mobile_Usa>,
        <https://1145.am/db/2667620/T-Mobile_Us>,
        <https://1145.am/db/2668208/T-Mobile_Usa>,
        <https://1145.am/db/2668212/T-Mobile_Usa>,
        <https://1145.am/db/2668226/T-Mobile_Usa>,
        <https://1145.am/db/2668687/T-Mobile_Us>,
        <https://1145.am/db/2668814/T-Mobile_Usa>,
        <https://1145.am/db/2669319/T-Mobile_Usa>,
        <https://1145.am/db/2669321/T-Mobile_Usa>,
        <https://1145.am/db/2669338/T-Mobile_Usa>,
        <https://1145.am/db/2669512/T-Mobile_Us>,
        <https://1145.am/db/2669881/T-Mobile_Usa>,
        <https://1145.am/db/2669920/T-Mobile_Usa>,
        <https://1145.am/db/2669926/T-Mobile_Usa>,
        <https://1145.am/db/2670397/T-Mobile_Usa>,
        <https://1145.am/db/2671029/T-Mobile_Usa>,
        <https://1145.am/db/2671585/T-Mobile_Usa>,
        <https://1145.am/db/2671623/T-Mobile_Usa>,
        <https://1145.am/db/2671629/T-Mobile_Usa>,
        <https://1145.am/db/2672172/T-Mobile_Usa>,
        <https://1145.am/db/2672184/T-Mobile_Usa>,
        <https://1145.am/db/2673934/T-Mobile_Usa>,
        <https://1145.am/db/2674405/T-Mobile_Us>,
        <https://1145.am/db/2675647/T-Mobile_Us>,
        <https://1145.am/db/2676846/T-Mobile_Us>,
        <https://1145.am/db/2677262/T-Mobile_Usa>,
        <https://1145.am/db/2677564/T-Mobile_Us>,
        <https://1145.am/db/2677884/T-Mobile_Us>,
        <https://1145.am/db/2678023/T-Mobile_Us>,
        <https://1145.am/db/2679803/T-Mobile_Usa>,
        <https://1145.am/db/2679871/T-Mobile_Us>,
        <https://1145.am/db/2680365/T-Mobile_Usa>,
        <https://1145.am/db/2681407/T-Mobile_Us>,
        <https://1145.am/db/2681734/T-Mobile_Us>,
        <https://1145.am/db/2681889/T-Mobile_Us>,
        <https://1145.am/db/2682066/T-Mobile_Usa>,
        <https://1145.am/db/2682450/T-Mobile_Us>,
        <https://1145.am/db/2682698/T-Mobile_Usa>,
        <https://1145.am/db/2683912/T-Mobile_Usa>,
        <https://1145.am/db/2684079/T-Mobile_Usa>,
        <https://1145.am/db/2684148/T-Mobile_Us>,
        <https://1145.am/db/2684705/T-Mobile_Usa>,
        <https://1145.am/db/2685202/T-Mobile_Usa>,
        <https://1145.am/db/2685245/T-Mobile_Usa>,
        <https://1145.am/db/2685254/T-Mobile_Usa>,
        <https://1145.am/db/2685267/T-Mobile_Usa>,
        <https://1145.am/db/2685271/T-Mobile_Usa>,
        <https://1145.am/db/2685285/T-Mobile_Usa>,
        <https://1145.am/db/2685505/T-Mobile_Usa>,
        <https://1145.am/db/2685618/T-Mobile_Usa>,
        <https://1145.am/db/2685624/T-Mobile_Usa>,
        <https://1145.am/db/2685654/T-Mobile_Usa>,
        <https://1145.am/db/2685762/T-Mobile_Usa>,
        <https://1145.am/db/2685783/T-Mobile_Usa>,
        <https://1145.am/db/2685799/T-Mobile_Usa>,
        <https://1145.am/db/2685811/T-Mobile_Usa>,
        <https://1145.am/db/2685884/T-Mobile_Usa>,
        <https://1145.am/db/2685930/T-Mobile_Usa>,
        <https://1145.am/db/2685940/T-Mobile_Usa>,
        <https://1145.am/db/2686023/T-Mobile_Usa>,
        <https://1145.am/db/2686200/T-Mobile_Usa>,
        <https://1145.am/db/398217/T-Mobile_Us>,
        <https://1145.am/db/461272/T-Mobile_Us_Inc>,
        <https://1145.am/db/479322/T-Mobile_Us>,
        <https://1145.am/db/480217/T-Mobile_Us>,
        <https://1145.am/db/662586/T-Mobile_Usa>,
        <https://1145.am/db/665472/T-Mobile_Usa>,
        <https://1145.am/db/667175/T-Mobile_Usa>,
        <https://1145.am/db/97818/T-Mobile_Us> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2164966/Knology> a org:Organization ;
    ns1:basedInLowRaw "Nasdaq" ;
    ns1:description "expanding its market reach through the acquisition of smaller cable-TV providers" ;
    ns1:documentDate "2012-06-15T11:19:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Proxy firms urge Knology shareholders to approve WOW aquisition" ;
    ns1:documentURL <https://www.streamtvinsider.com/cable/proxy-firms-urge-knology-shareholders-to-approve-wow-aquisition> ;
    ns1:foundName "Knology" ;
    ns1:industry "cable-TV providers" ;
    ns1:name "Knology" ;
    ns1:sameAsHigh <https://1145.am/db/2159455/Knology>,
        <https://1145.am/db/2174875/Knology> ;
    ns1:sameAsMedium <https://1145.am/db/1619638/Knology>,
        <https://1145.am/db/2158777/Knology>,
        <https://1145.am/db/2159451/Knology>,
        <https://1145.am/db/2159499/Knology>,
        <https://1145.am/db/2161291/Knology>,
        <https://1145.am/db/2603672/Knology> ;
    ns1:sourceName "StreamTV Insider" .

<https://1145.am/db/2164966/Knology_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2012-06-15T11:19:32+00:00"^^xsd:dateTime ;
    ns1:documentExtract "WideOpenWest announced in April it would acquire Knology.",
        "WideOpenWest's pending $ 1.5 billion acquisition of Knology (Nasdaq: KNOL) got a boost from a pair of independent proxy advisory firms, recommending Knology shareholders approve the deal." ;
    ns1:documentTitle "Proxy firms urge Knology shareholders to approve WOW aquisition" ;
    ns1:documentURL <https://www.streamtvinsider.com/cable/proxy-firms-urge-knology-shareholders-to-approve-wow-aquisition> ;
    ns1:foundName "acquire",
        "acquisition" ;
    ns1:name "acquire",
        "acquisition" ;
    ns1:sourceName "StreamTV Insider" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2164966/Knology> ;
    ns1:targetName "Knology" ;
    ns1:valueRaw "$ 1.5 billion" ;
    ns1:whereRaw "Nasdaq" .

<https://1145.am/db/2176546/Hiro_Media> a org:Organization ;
    ns1:basedInHighGeoName "State of Israel" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/294640/about.rdf> ;
    ns1:basedInHighRaw "Israel" ;
    ns1:description "video advertising management and optimization technology" ;
    ns1:documentDate "2012-04-04T15:23:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "James Murdoch steps down from BSkyB; Hulu Plus lands on Android tablets" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/james-murdoch-steps-down-from-bskyb-hulu-plus-lands-android-tablets> ;
    ns1:foundName "HIRO Media",
        "HIRO Media," ;
    ns1:industry "Advertising" ;
    ns1:name "HIRO Media" ;
    ns1:sameAsMedium <https://1145.am/db/2176538/Hiro_Media> ;
    ns1:sourceName "StreamTV Insider" .

<https://1145.am/db/2176546/NDS> a org:Organization ;
    ns1:description "telecommunications" ;
    ns1:documentDate "2012-04-04T15:23:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "James Murdoch steps down from BSkyB; Hulu Plus lands on Android tablets" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/james-murdoch-steps-down-from-bskyb-hulu-plus-lands-android-tablets> ;
    ns1:foundName "NDS" ;
    ns1:name "NDS" ;
    ns1:sameAsMedium <https://1145.am/db/2164203/NDS>,
        <https://1145.am/db/2174817/NDS>,
        <https://1145.am/db/2604434/NDS>,
        <https://1145.am/db/2669154/NDS> ;
    ns1:sourceName "StreamTV Insider" .

<https://1145.am/db/2178025/Joint_Venture_Prosiebensat_1_Media_Ag_Stopped> a ns1:CorporateFinanceActivity ;
    ns1:activityType "joint venture" ;
    ns1:documentDate "2012-08-08T14:37:37+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> A German regional higher court has ruled against plans by commercial broadcasters ProSiebenSat 1 Media AG and RTL Television to launch an online video platform." ;
    ns1:documentTitle "HBO not talking with Netflix; Affectiva raises an 'emotional' $12 million" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/hbo-not-talking-netflix-affectiva-raises-emotional-12-million> ;
    ns1:foundName "launch" ;
    ns1:name "launch" ;
    ns1:sourceName "StreamTV Insider" ;
    ns1:status "stopped" ;
    ns1:whereRaw "Affectiva" .

<https://1145.am/db/2224478/Redmile_Group> a org:Organization ;
    ns1:description "health care" ;
    ns1:documentDate "2012-05-01T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Castlight Health Secures $100 Million in Series D Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/castlight-health-secures-100-million-series-d-funding> ;
    ns1:foundName "Redmile Group" ;
    ns1:investor <https://1145.am/db/2224478/Investment_Castlight_Health_Redmile_Group_T_Rowe_Price_Completed> ;
    ns1:name "Redmile Group" ;
    ns1:sameAsHigh <https://1145.am/db/2236068/Redmile_Group> ;
    ns1:sameAsMedium <https://1145.am/db/1086649/Redmile_Group>,
        <https://1145.am/db/1192327/Redmile_Group>,
        <https://1145.am/db/1533327/Redmile_Group>,
        <https://1145.am/db/1533685/Redmile_Group>,
        <https://1145.am/db/1752458/Redmile_Group>,
        <https://1145.am/db/1813216/Redmile_Group>,
        <https://1145.am/db/1822362/Redmile_Group>,
        <https://1145.am/db/1837663/Redmile_Group>,
        <https://1145.am/db/1984721/Redmile_Group>,
        <https://1145.am/db/2075963/Redmile_Group>,
        <https://1145.am/db/2080575/Redmile_Group>,
        <https://1145.am/db/2089412/Redmile_Group>,
        <https://1145.am/db/2152126/Redmile_Group>,
        <https://1145.am/db/2281211/Redmile_Group>,
        <https://1145.am/db/2285762/Redmile_Group>,
        <https://1145.am/db/2291414/Redmile_Group>,
        <https://1145.am/db/2291716/Redmile_Group>,
        <https://1145.am/db/2292160/Redmile_Group>,
        <https://1145.am/db/2307889/Redmile_Group>,
        <https://1145.am/db/2308540/Redmile_Group>,
        <https://1145.am/db/2321658/Redmile_Group>,
        <https://1145.am/db/2335748/Redmile_Group>,
        <https://1145.am/db/2341595/Redmile_Group>,
        <https://1145.am/db/2341599/Redmile_Group>,
        <https://1145.am/db/2360277/Redmile_Group>,
        <https://1145.am/db/2361695/Redmile_Group>,
        <https://1145.am/db/2362106/Redmile_Group>,
        <https://1145.am/db/2367043/Redmile_Group>,
        <https://1145.am/db/2368070/Redmile_Group>,
        <https://1145.am/db/2369304/Redmile_Group>,
        <https://1145.am/db/2371160/Redmile_Group>,
        <https://1145.am/db/2371163/Redmile_Group>,
        <https://1145.am/db/2584561/Redmile_Group>,
        <https://1145.am/db/342182/Redmile_Group>,
        <https://1145.am/db/577785/Redmile_Group>,
        <https://1145.am/db/585936/Redmile_Group>,
        <https://1145.am/db/602316/Redmile_Group> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2224478/T_Rowe_Price> a org:Organization ;
    ns1:description "mutual funds" ;
    ns1:documentDate "2012-05-01T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Castlight Health Secures $100 Million in Series D Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/castlight-health-secures-100-million-series-d-funding> ;
    ns1:foundName "T. Rowe Price" ;
    ns1:investor <https://1145.am/db/2224478/Investment_Castlight_Health_Redmile_Group_T_Rowe_Price_Completed> ;
    ns1:name "T. Rowe Price" ;
    ns1:sameAsHigh <https://1145.am/db/2236068/T_Rowe_Price> ;
    ns1:sameAsMedium <https://1145.am/db/112384/T_Rowe_Price>,
        <https://1145.am/db/112397/T_Rowe_Price>,
        <https://1145.am/db/1188418/T_Rowe_Price>,
        <https://1145.am/db/1231536/T_Rowe_Price>,
        <https://1145.am/db/1705750/T_Rowe_Price>,
        <https://1145.am/db/1739469/T_Rowe_Price>,
        <https://1145.am/db/1741830/T_Rowe_Price>,
        <https://1145.am/db/1742668/T_Rowe_Price>,
        <https://1145.am/db/1744371/T_Rowe_Price>,
        <https://1145.am/db/1748789/T_Rowe_Price>,
        <https://1145.am/db/1770312/T_Rowe_Price>,
        <https://1145.am/db/1770910/T_Rowe_Price>,
        <https://1145.am/db/1779826/T_Rowe_Price>,
        <https://1145.am/db/1797759/T_Rowe_Price>,
        <https://1145.am/db/1827503/T_Rowe_Price>,
        <https://1145.am/db/1829408/T_Rowe_Price>,
        <https://1145.am/db/1854098/T_Rowe_Price>,
        <https://1145.am/db/1856811/T_Rowe_Price>,
        <https://1145.am/db/200040/T_Rowe_Price>,
        <https://1145.am/db/2198338/T_Rowe_Price>,
        <https://1145.am/db/221051/T_Rowe_Price>,
        <https://1145.am/db/229855/T_Rowe_Price>,
        <https://1145.am/db/2307889/T_Rowe_Price>,
        <https://1145.am/db/2313135/T_Rowe_Price>,
        <https://1145.am/db/2313143/T_Rowe_Price>,
        <https://1145.am/db/2557987/T_Rowe_Price>,
        <https://1145.am/db/345025/T_Rowe_Price>,
        <https://1145.am/db/345083/T_Rowe_Price>,
        <https://1145.am/db/377391/T_Rowe_Price>,
        <https://1145.am/db/387521/T_Rowe_Price>,
        <https://1145.am/db/472389/T_Rowe_Price>,
        <https://1145.am/db/473354/T_Rowe_Price>,
        <https://1145.am/db/474072/Trowe_Price>,
        <https://1145.am/db/579022/T_Rowe_Price>,
        <https://1145.am/db/582541/T_Rowe_Price>,
        <https://1145.am/db/582815/T_Rowe_Price>,
        <https://1145.am/db/607880/T_Rowe_Price>,
        <https://1145.am/db/711371/T_Rowe_Price> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2236068/Redmile_Group> a org:Organization ;
    ns1:description "health care" ;
    ns1:documentDate "2012-05-01T13:13:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Castlight Health Secures $100 Million in Series D Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/castlight-health-secures-100-million-series-d-funding> ;
    ns1:foundName "Redmile Group" ;
    ns1:investor <https://1145.am/db/2236068/Investment_Castlight_Health_Redmile_Group_T_Rowe_Price_Completed> ;
    ns1:name "Redmile Group" ;
    ns1:sameAsHigh <https://1145.am/db/2224478/Redmile_Group> ;
    ns1:sameAsMedium <https://1145.am/db/1086649/Redmile_Group>,
        <https://1145.am/db/1192327/Redmile_Group>,
        <https://1145.am/db/1533327/Redmile_Group>,
        <https://1145.am/db/1533685/Redmile_Group>,
        <https://1145.am/db/1752458/Redmile_Group>,
        <https://1145.am/db/1813216/Redmile_Group>,
        <https://1145.am/db/1822362/Redmile_Group>,
        <https://1145.am/db/1837663/Redmile_Group>,
        <https://1145.am/db/1984721/Redmile_Group>,
        <https://1145.am/db/2075963/Redmile_Group>,
        <https://1145.am/db/2080575/Redmile_Group>,
        <https://1145.am/db/2089412/Redmile_Group>,
        <https://1145.am/db/2152126/Redmile_Group>,
        <https://1145.am/db/2281211/Redmile_Group>,
        <https://1145.am/db/2285762/Redmile_Group>,
        <https://1145.am/db/2291414/Redmile_Group>,
        <https://1145.am/db/2291716/Redmile_Group>,
        <https://1145.am/db/2292160/Redmile_Group>,
        <https://1145.am/db/2307889/Redmile_Group>,
        <https://1145.am/db/2308540/Redmile_Group>,
        <https://1145.am/db/2321658/Redmile_Group>,
        <https://1145.am/db/2335748/Redmile_Group>,
        <https://1145.am/db/2341595/Redmile_Group>,
        <https://1145.am/db/2341599/Redmile_Group>,
        <https://1145.am/db/2360277/Redmile_Group>,
        <https://1145.am/db/2361695/Redmile_Group>,
        <https://1145.am/db/2362106/Redmile_Group>,
        <https://1145.am/db/2367043/Redmile_Group>,
        <https://1145.am/db/2368070/Redmile_Group>,
        <https://1145.am/db/2369304/Redmile_Group>,
        <https://1145.am/db/2371160/Redmile_Group>,
        <https://1145.am/db/2371163/Redmile_Group>,
        <https://1145.am/db/2584561/Redmile_Group>,
        <https://1145.am/db/342182/Redmile_Group>,
        <https://1145.am/db/577785/Redmile_Group>,
        <https://1145.am/db/585936/Redmile_Group>,
        <https://1145.am/db/602316/Redmile_Group> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2236068/T_Rowe_Price> a org:Organization ;
    ns1:description "mutual funds" ;
    ns1:documentDate "2012-05-01T13:13:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Castlight Health Secures $100 Million in Series D Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/castlight-health-secures-100-million-series-d-funding> ;
    ns1:foundName "T. Rowe Price" ;
    ns1:investor <https://1145.am/db/2236068/Investment_Castlight_Health_Redmile_Group_T_Rowe_Price_Completed> ;
    ns1:name "T. Rowe Price" ;
    ns1:sameAsHigh <https://1145.am/db/2224478/T_Rowe_Price> ;
    ns1:sameAsMedium <https://1145.am/db/112384/T_Rowe_Price>,
        <https://1145.am/db/112397/T_Rowe_Price>,
        <https://1145.am/db/1188418/T_Rowe_Price>,
        <https://1145.am/db/1231536/T_Rowe_Price>,
        <https://1145.am/db/1705750/T_Rowe_Price>,
        <https://1145.am/db/1739469/T_Rowe_Price>,
        <https://1145.am/db/1741830/T_Rowe_Price>,
        <https://1145.am/db/1742668/T_Rowe_Price>,
        <https://1145.am/db/1744371/T_Rowe_Price>,
        <https://1145.am/db/1748789/T_Rowe_Price>,
        <https://1145.am/db/1770312/T_Rowe_Price>,
        <https://1145.am/db/1770910/T_Rowe_Price>,
        <https://1145.am/db/1779826/T_Rowe_Price>,
        <https://1145.am/db/1797759/T_Rowe_Price>,
        <https://1145.am/db/1827503/T_Rowe_Price>,
        <https://1145.am/db/1829408/T_Rowe_Price>,
        <https://1145.am/db/1854098/T_Rowe_Price>,
        <https://1145.am/db/1856811/T_Rowe_Price>,
        <https://1145.am/db/200040/T_Rowe_Price>,
        <https://1145.am/db/2198338/T_Rowe_Price>,
        <https://1145.am/db/221051/T_Rowe_Price>,
        <https://1145.am/db/229855/T_Rowe_Price>,
        <https://1145.am/db/2307889/T_Rowe_Price>,
        <https://1145.am/db/2313135/T_Rowe_Price>,
        <https://1145.am/db/2313143/T_Rowe_Price>,
        <https://1145.am/db/2557987/T_Rowe_Price>,
        <https://1145.am/db/345025/T_Rowe_Price>,
        <https://1145.am/db/345083/T_Rowe_Price>,
        <https://1145.am/db/377391/T_Rowe_Price>,
        <https://1145.am/db/387521/T_Rowe_Price>,
        <https://1145.am/db/472389/T_Rowe_Price>,
        <https://1145.am/db/473354/T_Rowe_Price>,
        <https://1145.am/db/474072/Trowe_Price>,
        <https://1145.am/db/579022/T_Rowe_Price>,
        <https://1145.am/db/582541/T_Rowe_Price>,
        <https://1145.am/db/582815/T_Rowe_Price>,
        <https://1145.am/db/607880/T_Rowe_Price>,
        <https://1145.am/db/711371/T_Rowe_Price> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2242523/Sunlink_Health_Systems> a org:Organization ;
    ns1:basedInHighGeoName "Houston" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4430529/about.rdf> ;
    ns1:basedInHighRaw "Houston, MS." ;
    ns1:description "health care" ;
    ns1:documentDate "2012-07-20T01:09:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "SunLink Health Systems Announces $9.975 Million Financing for Improvements at Trace Regional Hospital in Houston, MS, and for Partial Debt Refinancing" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/sunlink-health-systems-announces-9-975-million-financing-for-improvements-at-trace> ;
    ns1:foundName "SunLink Health Systems",
        "SunLink Health Systems, Inc" ;
    ns1:industry "health care" ;
    ns1:name "SunLink Health Systems" ;
    ns1:sameAsHigh <https://1145.am/db/2067321/Sunlink_Health_Systems_Inc>,
        <https://1145.am/db/2230927/Sunlink_Health_Systems>,
        <https://1145.am/db/2231989/Sunlink_Health_Systems>,
        <https://1145.am/db/2232013/Sunlink_Health_Systems>,
        <https://1145.am/db/2237855/Sunlink_Health_Systems>,
        <https://1145.am/db/2239374/Sunlink_Health_Systems>,
        <https://1145.am/db/356847/Sunway>,
        <https://1145.am/db/356858/Sunway>,
        <https://1145.am/db/361200/Sunway_Berhad>,
        <https://1145.am/db/361200/Sunway_Healthcare> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2242523/Trace_Regional_Hospital> a org:Organization ;
    ns1:basedInHighGeoName "Houston" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4430529/about.rdf> ;
    ns1:basedInHighRaw "Houston, MS" ;
    ns1:description "health" ;
    ns1:documentDate "2012-07-20T01:09:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "SunLink Health Systems Announces $9.975 Million Financing for Improvements at Trace Regional Hospital in Houston, MS, and for Partial Debt Refinancing" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/sunlink-health-systems-announces-9-975-million-financing-for-improvements-at-trace> ;
    ns1:foundName "Trace Regional Hospital" ;
    ns1:industry "Health Systems" ;
    ns1:name "Trace Regional Hospital" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2243235/Equity_Investment_Aerial_Biopharma_Rex_Health_Ventures_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-20T01:10:25+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Rex Health Ventures Announces Inaugural Investment in N.C. Firm, Aerial BioPharma.",
        "Rex Health Ventures, one of the nation's only venture-capital funds managed by a community, nonprofit hospital, is pleased to announce its first investment, a $ 500,000 equity placement in Aerial BioPharma." ;
    ns1:documentTitle "Rex Health Ventures Announces Inaugural Investment in N.C. Firm, Aerial BioPharma" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/rex-health-ventures-announces-inaugural-investment-n-c-firm-aerial-biopharma> ;
    ns1:foundName "Investment",
        "investment",
        "placement" ;
    ns1:name "Investment",
        "investment",
        "placement" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2243235/Aerial_Biopharma> ;
    ns1:targetDetails "equity",
        "equity placement" ;
    ns1:targetName "Aerial BioPharma" ;
    ns1:valueRaw "$ 500,000" ;
    ns1:whereGeoName "Morrisville",
        "North Carolina" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4480285/about.rdf>,
        <https://sws.geonames.org/4482348/about.rdf> ;
    ns1:whereRaw "Morrisville, N.C.",
        "North Carolina" .

<https://1145.am/db/2243235/Rex_Health_Ventures> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:description "venture-capital funds" ;
    ns1:documentDate "2012-07-20T01:10:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Rex Health Ventures Announces Inaugural Investment in N.C. Firm, Aerial BioPharma" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/rex-health-ventures-announces-inaugural-investment-n-c-firm-aerial-biopharma> ;
    ns1:foundName "Rex Health Ventures" ;
    ns1:industry "venture-capital funds" ;
    ns1:investor <https://1145.am/db/2243235/Equity_Investment_Aerial_Biopharma_Rex_Health_Ventures_Has_Not_Happened> ;
    ns1:name "Rex Health Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1635405/Rex_Health_Ventures>,
        <https://1145.am/db/2271510/Rex_Healthcare>,
        <https://1145.am/db/2366403/Rex_Health_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1386738/Rex_Health_Ventures>,
        <https://1145.am/db/1387057/Rex_Health_Ventures>,
        <https://1145.am/db/1635418/Rex_Health_Ventures>,
        <https://1145.am/db/1636089/Rex_Health_Ventures> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2249776/Amgen_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Thousand Oaks" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5402405/about.rdf> ;
    ns1:basedInHighRaw "THOUSAND OAKS, Calif." ;
    ns1:description "Business" ;
    ns1:documentDate "2012-03-07T14:20:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc." ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/amgen-completes-tender-offer-for-outstanding-shares-micromet-inc> ;
    ns1:foundName "Amgen Inc." ;
    ns1:name "Amgen Inc." ;
    ns1:participant <https://1145.am/db/2249776/Micromet_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/1434130/Amgen>,
        <https://1145.am/db/2008430/Amgen_Inc>,
        <https://1145.am/db/2012933/Amgen_Inc>,
        <https://1145.am/db/2013008/Amgen_Inc>,
        <https://1145.am/db/2326533/Amgen>,
        <https://1145.am/db/2543655/Amgen>,
        <https://1145.am/db/2578286/Amgen>,
        <https://1145.am/db/2585068/Amgen> ;
    ns1:sameAsMedium <https://1145.am/db/1252426/Amgen_Inc>,
        <https://1145.am/db/1253935/Amgen>,
        <https://1145.am/db/1254815/Amgen>,
        <https://1145.am/db/1258904/Amgen_Inc>,
        <https://1145.am/db/1262006/Amgen>,
        <https://1145.am/db/1406211/Amgen>,
        <https://1145.am/db/1488570/Amgen>,
        <https://1145.am/db/1541946/Amgen>,
        <https://1145.am/db/1568872/Amgen_Inc>,
        <https://1145.am/db/1570839/Amgen_Inc>,
        <https://1145.am/db/1573831/Amgen>,
        <https://1145.am/db/1574155/Amgen>,
        <https://1145.am/db/1575688/Amgen_Inc>,
        <https://1145.am/db/1576668/Amgen_Inc>,
        <https://1145.am/db/1673901/Amgen>,
        <https://1145.am/db/1929668/Amgen>,
        <https://1145.am/db/1981398/Amgen>,
        <https://1145.am/db/198163/Amgen>,
        <https://1145.am/db/2008790/Amgen>,
        <https://1145.am/db/2009117/Amgen_Inc>,
        <https://1145.am/db/2011679/Amgen>,
        <https://1145.am/db/2016970/Amgen>,
        <https://1145.am/db/2043001/Amgen>,
        <https://1145.am/db/2046726/Amgen>,
        <https://1145.am/db/2098829/Amgen>,
        <https://1145.am/db/2105082/Amgen>,
        <https://1145.am/db/2106270/Amgen>,
        <https://1145.am/db/2107919/Amgen>,
        <https://1145.am/db/2117067/Amgen>,
        <https://1145.am/db/2117986/Amgen>,
        <https://1145.am/db/2138386/Amgen>,
        <https://1145.am/db/2152715/Amgen>,
        <https://1145.am/db/2153258/Amgen>,
        <https://1145.am/db/2154415/Amgen>,
        <https://1145.am/db/2155409/Amgen>,
        <https://1145.am/db/2155659/Amgen>,
        <https://1145.am/db/2282387/Amgen>,
        <https://1145.am/db/2282934/Amgen>,
        <https://1145.am/db/2283321/Amgen>,
        <https://1145.am/db/2285195/Amgen>,
        <https://1145.am/db/2285614/Amgen>,
        <https://1145.am/db/2285991/Amgen>,
        <https://1145.am/db/2286174/Amgen>,
        <https://1145.am/db/2291231/Amgen>,
        <https://1145.am/db/2292224/Amgen>,
        <https://1145.am/db/2292876/Amgen>,
        <https://1145.am/db/2299349/Amgen>,
        <https://1145.am/db/2302052/Amgen>,
        <https://1145.am/db/2303414/Amgen>,
        <https://1145.am/db/2312121/Amgen>,
        <https://1145.am/db/2313429/Amgen>,
        <https://1145.am/db/2317845/Amgen>,
        <https://1145.am/db/2318877/Amgen>,
        <https://1145.am/db/2320754/Amgen>,
        <https://1145.am/db/2320759/Amgen>,
        <https://1145.am/db/2320765/Amgen>,
        <https://1145.am/db/2320771/Amgen>,
        <https://1145.am/db/2320775/Amgen>,
        <https://1145.am/db/2321459/Amgen>,
        <https://1145.am/db/2321989/Amgen>,
        <https://1145.am/db/2322040/Amgen>,
        <https://1145.am/db/2322632/Amgen>,
        <https://1145.am/db/2326559/Amgen>,
        <https://1145.am/db/2327526/Amgen>,
        <https://1145.am/db/2327547/Amgen>,
        <https://1145.am/db/2328748/Amgen>,
        <https://1145.am/db/2329762/Amgen>,
        <https://1145.am/db/2333460/Amgen>,
        <https://1145.am/db/2334046/Amgen>,
        <https://1145.am/db/2337433/Amgen>,
        <https://1145.am/db/2337435/Amgen_Inc>,
        <https://1145.am/db/2337848/Amgen>,
        <https://1145.am/db/2338027/Amgen>,
        <https://1145.am/db/2338329/Amgen>,
        <https://1145.am/db/2338346/Amgen>,
        <https://1145.am/db/2338828/Amgen>,
        <https://1145.am/db/2340408/Amgen>,
        <https://1145.am/db/2340634/Amgen>,
        <https://1145.am/db/2340669/Amgen>,
        <https://1145.am/db/2343511/Amgen>,
        <https://1145.am/db/2343601/Amgen>,
        <https://1145.am/db/2343780/Amgen>,
        <https://1145.am/db/2343862/Amgen>,
        <https://1145.am/db/2344369/Amgen>,
        <https://1145.am/db/2344631/Amgen>,
        <https://1145.am/db/2344864/Amgen>,
        <https://1145.am/db/2345191/Amgen>,
        <https://1145.am/db/2345783/Amgen>,
        <https://1145.am/db/2345886/Amgen>,
        <https://1145.am/db/2346293/Amgen>,
        <https://1145.am/db/2347966/Amgen>,
        <https://1145.am/db/2347970/Amgen>,
        <https://1145.am/db/2347976/Amgen>,
        <https://1145.am/db/2349030/Amgen>,
        <https://1145.am/db/2349444/Amgen>,
        <https://1145.am/db/2350029/Amgen>,
        <https://1145.am/db/2350465/Amgen>,
        <https://1145.am/db/2350471/Amgen>,
        <https://1145.am/db/2352800/Amgen>,
        <https://1145.am/db/2353167/Amgen>,
        <https://1145.am/db/2354835/Amgen>,
        <https://1145.am/db/2355378/Amgen>,
        <https://1145.am/db/2355383/Amgen>,
        <https://1145.am/db/2355392/Amgen>,
        <https://1145.am/db/2355427/Amgen>,
        <https://1145.am/db/2357269/Amgen>,
        <https://1145.am/db/2357271/Amgen>,
        <https://1145.am/db/2357303/Amgen>,
        <https://1145.am/db/2357336/Amgen>,
        <https://1145.am/db/2357451/Amgen>,
        <https://1145.am/db/2357454/Amgen>,
        <https://1145.am/db/2357920/Amgen>,
        <https://1145.am/db/2358934/Amgen>,
        <https://1145.am/db/2359165/Amgen>,
        <https://1145.am/db/2359462/Amgen>,
        <https://1145.am/db/2359481/Amgen>,
        <https://1145.am/db/2359498/Amgen>,
        <https://1145.am/db/2360080/Amgen>,
        <https://1145.am/db/2360086/Amgen>,
        <https://1145.am/db/2361037/Amgen>,
        <https://1145.am/db/2361971/Amgen>,
        <https://1145.am/db/2361972/Amgen>,
        <https://1145.am/db/2361973/Amgen>,
        <https://1145.am/db/2362552/Amgen>,
        <https://1145.am/db/2363673/Amgen>,
        <https://1145.am/db/2364216/Amgen>,
        <https://1145.am/db/2367430/Amgen_Inc>,
        <https://1145.am/db/2368788/Amgen_Inc>,
        <https://1145.am/db/2370120/Amgen>,
        <https://1145.am/db/2370174/Amgen>,
        <https://1145.am/db/2370215/Amgen>,
        <https://1145.am/db/2370217/Amgen>,
        <https://1145.am/db/2371301/Amgen>,
        <https://1145.am/db/2538019/Amgen>,
        <https://1145.am/db/2539787/Amgen>,
        <https://1145.am/db/2540225/Amgen>,
        <https://1145.am/db/2543232/Amgen>,
        <https://1145.am/db/2544701/Amgen>,
        <https://1145.am/db/2545663/Amgen>,
        <https://1145.am/db/2545765/Amgen>,
        <https://1145.am/db/2548575/Amgen>,
        <https://1145.am/db/2550685/Amgen>,
        <https://1145.am/db/2550884/Amgen>,
        <https://1145.am/db/2551883/Amgen>,
        <https://1145.am/db/2551884/Amgen>,
        <https://1145.am/db/2553162/Amgen>,
        <https://1145.am/db/2553564/Amgen>,
        <https://1145.am/db/2554152/Amgen>,
        <https://1145.am/db/2555175/Amgen>,
        <https://1145.am/db/2556729/Amgen>,
        <https://1145.am/db/2557364/Amgen>,
        <https://1145.am/db/2558012/Amgen>,
        <https://1145.am/db/2558039/Amgen>,
        <https://1145.am/db/2558051/Amgen>,
        <https://1145.am/db/2558418/Amgen>,
        <https://1145.am/db/2559077/Amgen>,
        <https://1145.am/db/2561305/Amgen>,
        <https://1145.am/db/2561317/Amgen>,
        <https://1145.am/db/2561325/Amgen>,
        <https://1145.am/db/2561650/Amgen>,
        <https://1145.am/db/2566335/Amgen>,
        <https://1145.am/db/2566348/Amgen>,
        <https://1145.am/db/2567468/Amgen>,
        <https://1145.am/db/2567517/Amgen>,
        <https://1145.am/db/2567960/Amgen>,
        <https://1145.am/db/2567981/Amgen>,
        <https://1145.am/db/2568005/Amgen>,
        <https://1145.am/db/2568075/Amgen>,
        <https://1145.am/db/2568519/Amgen>,
        <https://1145.am/db/2572535/Amgen>,
        <https://1145.am/db/2572655/Amgen>,
        <https://1145.am/db/2573455/Amgen>,
        <https://1145.am/db/2573903/Amgen>,
        <https://1145.am/db/2573924/Amgen>,
        <https://1145.am/db/2573976/Amgen>,
        <https://1145.am/db/2574586/Amgen>,
        <https://1145.am/db/2575263/Amgen>,
        <https://1145.am/db/2575289/Amgen>,
        <https://1145.am/db/2576018/Amgen>,
        <https://1145.am/db/2576242/Amgen>,
        <https://1145.am/db/2576498/Amgen>,
        <https://1145.am/db/2577110/Amgen>,
        <https://1145.am/db/2577115/Amgen>,
        <https://1145.am/db/2577120/Amgen>,
        <https://1145.am/db/2578110/Amgen>,
        <https://1145.am/db/2578164/Amgen>,
        <https://1145.am/db/2579211/Amgen>,
        <https://1145.am/db/2579278/Amgen>,
        <https://1145.am/db/2580209/Amgen>,
        <https://1145.am/db/2580211/Amgen>,
        <https://1145.am/db/2580383/Amgen_Inc>,
        <https://1145.am/db/2581309/Amgen>,
        <https://1145.am/db/2581359/Amgen>,
        <https://1145.am/db/2581917/Amgen>,
        <https://1145.am/db/2583990/Amgen>,
        <https://1145.am/db/2584352/Amgen>,
        <https://1145.am/db/2586068/Amgen>,
        <https://1145.am/db/2586750/Amgen>,
        <https://1145.am/db/2587009/Amgen>,
        <https://1145.am/db/2587770/Amgen>,
        <https://1145.am/db/258901/Amgen_Inc>,
        <https://1145.am/db/2589106/Amgen>,
        <https://1145.am/db/2590194/Amgen>,
        <https://1145.am/db/2590988/Amgen_Inc>,
        <https://1145.am/db/2590989/Amgen>,
        <https://1145.am/db/2591587/Amgen>,
        <https://1145.am/db/2591594/Amgen>,
        <https://1145.am/db/2592573/Amgen>,
        <https://1145.am/db/2592618/Amgen>,
        <https://1145.am/db/2592924/Amgen>,
        <https://1145.am/db/2593423/Amgen>,
        <https://1145.am/db/2593426/Amgen>,
        <https://1145.am/db/2593433/Amgen_Inc>,
        <https://1145.am/db/2593434/Amgen>,
        <https://1145.am/db/2593465/Amgen>,
        <https://1145.am/db/2593681/Amgen>,
        <https://1145.am/db/2593973/Amgen>,
        <https://1145.am/db/2594099/Amgen>,
        <https://1145.am/db/2594285/Amgen>,
        <https://1145.am/db/2594292/Amgen>,
        <https://1145.am/db/2594298/Amgen>,
        <https://1145.am/db/2594347/Amgen>,
        <https://1145.am/db/2594990/Amgen>,
        <https://1145.am/db/2594993/Amgen>,
        <https://1145.am/db/2595020/Amgen>,
        <https://1145.am/db/2595549/Amgen>,
        <https://1145.am/db/2595564/Amgen>,
        <https://1145.am/db/2595587/Amgen>,
        <https://1145.am/db/2595605/Amgen>,
        <https://1145.am/db/2595608/Amgen>,
        <https://1145.am/db/2595930/Amgen>,
        <https://1145.am/db/2596467/Amgen>,
        <https://1145.am/db/2596819/Amgen>,
        <https://1145.am/db/2597499/Amgen>,
        <https://1145.am/db/2598066/Amgen>,
        <https://1145.am/db/2716207/Amgen>,
        <https://1145.am/db/2789236/Amgen>,
        <https://1145.am/db/2802001/Amgen>,
        <https://1145.am/db/531806/Amgen_Inc>,
        <https://1145.am/db/559746/Amgen> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2249776/Micromet> a org:Organization ;
    ns1:basedInHighGeoName "Thousand Oaks" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5402405/about.rdf> ;
    ns1:basedInHighRaw "THOUSAND OAKS, Calif." ;
    ns1:description "Biotechnology" ;
    ns1:documentDate "2012-03-07T14:20:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc." ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/amgen-completes-tender-offer-for-outstanding-shares-micromet-inc> ;
    ns1:foundName "Micromet, Inc" ;
    ns1:name "Micromet" ;
    ns1:sameAsMedium <https://1145.am/db/2302112/Micromet>,
        <https://1145.am/db/2304395/Micromet>,
        <https://1145.am/db/2322945/Micromet>,
        <https://1145.am/db/2324417/Micromet>,
        <https://1145.am/db/2326910/Micromet>,
        <https://1145.am/db/2326912/Micromet>,
        <https://1145.am/db/2326913/Micromet>,
        <https://1145.am/db/2328502/Micromet>,
        <https://1145.am/db/2328514/Micromet>,
        <https://1145.am/db/2329862/Micromet>,
        <https://1145.am/db/2332739/Micromet>,
        <https://1145.am/db/2342663/Micromet_Inc>,
        <https://1145.am/db/2343292/Micromet>,
        <https://1145.am/db/2350471/Micromet>,
        <https://1145.am/db/2353461/Micromet>,
        <https://1145.am/db/2361971/Micromet>,
        <https://1145.am/db/2361972/Micromet>,
        <https://1145.am/db/2361973/Micromet>,
        <https://1145.am/db/2538653/Micromet>,
        <https://1145.am/db/2593681/Micromet>,
        <https://1145.am/db/2596467/Micromet> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2249776/Micromet_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2012-03-07T14:20:34+00:00"^^xsd:dateTime ;
    ns1:documentExtract "THOUSAND OAKS, Calif., March 7, 2012 /PRNewswire/ - Amgen Inc. (\"Amgen\") (NASDAQ: AMGN) announced today the expiration of the subsequent offering period of the tender offer (the \"Offer\") by a wholly owned subsidiary, \"Merger Sub ,\" to acquire all outstanding shares of common stock of Micromet, Inc. (\"Micromet\") (NASDAQ: MITI) for $ 11.00 per share in cash." ;
    ns1:documentTitle "Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc." ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/amgen-completes-tender-offer-for-outstanding-shares-micromet-inc> ;
    ns1:foundName "acquire",
        "tender offer" ;
    ns1:name "acquire",
        "tender offer" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2249776/Micromet> ;
    ns1:targetName "Micromet" ;
    ns1:when "2012-03-06T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "March 6, 2012" ;
    ns1:whereGeoName "Thousand Oaks" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5402405/about.rdf> ;
    ns1:whereRaw "THOUSAND OAKS, Calif" .

<https://1145.am/db/2273820/Gateway_Community_College_Foundation> a org:Organization ;
    ns1:basedInHighGeoName "Connecticut" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4831725/about.rdf> ;
    ns1:basedInHighRaw "Connecticut" ;
    ns1:documentDate "2012-03-13T19:10:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anthem Donates $150,000 to GCC Foundation's Building Campaign" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/anthem-donates-150-000-to-gcc-foundation-s-building-campaign> ;
    ns1:foundName "The Gateway Community College Foundation" ;
    ns1:name "Gateway Community College Foundation" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2273820/Investment_Anthem_Blue_Cross_And_Blue_Shield_Gateway_Community_College_Foundation_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-13T19:10:52+00:00"^^xsd:dateTime ;
    ns1:documentExtract "NEW HAVEN, Conn.- (BUSINESS WIRE) - The Gateway Community College Foundation (GCCF) announced today that Anthem Blue Cross and Blue Shield in Connecticut has donated $ 150,000 to its \"Your College." ;
    ns1:documentTitle "Anthem Donates $150,000 to GCC Foundation's Building Campaign" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/anthem-donates-150-000-to-gcc-foundation-s-building-campaign> ;
    ns1:foundName "donated" ;
    ns1:name "donated" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2273820/Gateway_Community_College_Foundation>,
        <https://1145.am/db/2273820/Your_College_Your_Future> ;
    ns1:targetName "\"Your College. Your Future" ;
    ns1:valueRaw "$ 150,000" ;
    ns1:whereGeoName "Connecticut" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4831725/about.rdf> ;
    ns1:whereRaw "Connecticut" .

<https://1145.am/db/2273820/Your_College_Your_Future> a org:Organization ;
    ns1:basedInHighGeoName "New Haven County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4839373/about.rdf> ;
    ns1:basedInHighRaw "NEW HAVEN, Conn." ;
    ns1:documentDate "2012-03-13T19:10:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anthem Donates $150,000 to GCC Foundation's Building Campaign" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/anthem-donates-150-000-to-gcc-foundation-s-building-campaign> ;
    ns1:foundName "\"Your College. Your Future" ;
    ns1:name "\"Your College. Your Future" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2276474/Insurance_Coordinators_Of_Montana> a org:Organization ;
    ns1:basedInLowRaw "Montana" ;
    ns1:description "employee-benefit administration services" ;
    ns1:documentDate "2012-04-15T00:22:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Molina sues over Missouri Medicaid contract; Cigna hires first chief nursing officer;" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/molina-sues-over-missouri-medicaid-contract-cigna-hires-first-chief-nursing-officer> ;
    ns1:foundName "Insurance Coordinators of Montana" ;
    ns1:industry "insurance" ;
    ns1:name "Insurance Coordinators of Montana" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2276474/Insurance_Coordinators_Of_Montana_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2012-04-15T00:22:28+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> The Blues companies in Montana and Idaho have together acquired and merged Peak 1 Administration and Insurance Coordinators of Montana, which offer health products and employee-benefit administration services." ;
    ns1:documentTitle "Molina sues over Missouri Medicaid contract; Cigna hires first chief nursing officer;" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/molina-sues-over-missouri-medicaid-contract-cigna-hires-first-chief-nursing-officer> ;
    ns1:foundName "acquired",
        "merged" ;
    ns1:name "acquired",
        "merged" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2276474/Insurance_Coordinators_Of_Montana> ;
    ns1:targetName "Insurance Coordinators of Montana" .

<https://1145.am/db/2276474/Peak_1_Administration> a org:Organization ;
    ns1:basedInLowRaw "Montana" ;
    ns1:description "health products and employee-benefit administration services" ;
    ns1:documentDate "2012-04-15T00:22:28+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Molina sues over Missouri Medicaid contract; Cigna hires first chief nursing officer;" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/molina-sues-over-missouri-medicaid-contract-cigna-hires-first-chief-nursing-officer> ;
    ns1:foundName "Peak 1 Administration" ;
    ns1:industry "health products and employee-benefit administration services" ;
    ns1:name "Peak 1 Administration" ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2276474/Peak_1_Administration_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2012-04-15T00:22:28+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> The Blues companies in Montana and Idaho have together acquired and merged Peak 1 Administration and Insurance Coordinators of Montana, which offer health products and employee-benefit administration services." ;
    ns1:documentTitle "Molina sues over Missouri Medicaid contract; Cigna hires first chief nursing officer;" ;
    ns1:documentURL <https://www.fiercehealthcare.com/payer/molina-sues-over-missouri-medicaid-contract-cigna-hires-first-chief-nursing-officer> ;
    ns1:foundName "acquired",
        "merged" ;
    ns1:name "acquired",
        "merged" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2276474/Peak_1_Administration> ;
    ns1:targetName "Peak 1 Administration" ;
    ns1:whereGeoName "Montana" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5667009/about.rdf> ;
    ns1:whereRaw "Montana" .

<https://1145.am/db/2287956/Dako> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Denmark" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2623032/about.rdf> ;
    ns1:basedInHighRaw "Denmark" ;
    ns1:description "cancer diagnostics" ;
    ns1:documentDate "2012-06-22T15:17:51+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Agilent closes $2.2B Dako deal" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/agilent-closes-2-2b-dako-deal> ;
    ns1:foundName "Dako" ;
    ns1:industry "life science" ;
    ns1:name "Dako" ;
    ns1:sameAsHigh <https://1145.am/db/1320425/Bioaffinity>,
        <https://1145.am/db/2152366/Lexent_Bio>,
        <https://1145.am/db/2288280/Mdxhealth>,
        <https://1145.am/db/2306329/Biodesix>,
        <https://1145.am/db/2325308/Castle_Biosciences>,
        <https://1145.am/db/2336448/Agendia_Bv>,
        <https://1145.am/db/2365399/Agendia>,
        <https://1145.am/db/2365416/Agendia>,
        <https://1145.am/db/2581159/Dako>,
        <https://1145.am/db/2583123/Agendia>,
        <https://1145.am/db/2584030/Agendia>,
        <https://1145.am/db/2587222/Biomoda> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2287956/Dako_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-06-22T15:17:51+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Agilent ($ A) has closed the deal it announced last month, paying $ 2.2 billion for Denmark's Dako, a cancer diagnostics firm." ;
    ns1:documentTitle "Agilent closes $2.2B Dako deal" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/agilent-closes-2-2b-dako-deal> ;
    ns1:foundName "paying" ;
    ns1:name "paying" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2287956/Dako> ;
    ns1:targetName "Dako" ;
    ns1:valueRaw "$ 2.2 billion" ;
    ns1:whereGeoName "Kingdom of Denmark" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2623032/about.rdf> ;
    ns1:whereRaw "Denmark" .

<https://1145.am/db/2287956/Illumina> a org:Organization ;
    ns1:basedInLowRaw "Indiana" ;
    ns1:documentDate "2012-06-22T15:17:51+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Agilent closes $2.2B Dako deal" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/agilent-closes-2-2b-dako-deal> ;
    ns1:foundName "Illumina" ;
    ns1:name "Illumina" ;
    ns1:sameAsMedium <https://1145.am/db/1088221/Illumina>,
        <https://1145.am/db/1202370/Illumina>,
        <https://1145.am/db/1217641/Illumina>,
        <https://1145.am/db/1232202/Illumina>,
        <https://1145.am/db/1240041/Illumina>,
        <https://1145.am/db/1311389/Illumina_Inc>,
        <https://1145.am/db/1311396/Illumina_Inc>,
        <https://1145.am/db/1315507/Illumina_Inc>,
        <https://1145.am/db/1318170/Illumina>,
        <https://1145.am/db/1319284/Illumina>,
        <https://1145.am/db/1320955/Illumina_Inc>,
        <https://1145.am/db/1321949/Illumina>,
        <https://1145.am/db/1322003/Illumina>,
        <https://1145.am/db/1339613/Illumina>,
        <https://1145.am/db/1354365/Illumina>,
        <https://1145.am/db/1357046/Illumina>,
        <https://1145.am/db/1577865/Illumina_Inc>,
        <https://1145.am/db/1668177/Illumina>,
        <https://1145.am/db/1936140/Illumina>,
        <https://1145.am/db/1938875/Illumina_Inc>,
        <https://1145.am/db/1957816/Illumina>,
        <https://1145.am/db/1974886/Illumina_Inc>,
        <https://1145.am/db/2019335/Illumina_Inc>,
        <https://1145.am/db/2029590/Illumina>,
        <https://1145.am/db/2033324/Illumina_Inc>,
        <https://1145.am/db/2033519/Illumina>,
        <https://1145.am/db/2059502/Illumina>,
        <https://1145.am/db/2083048/Illumina>,
        <https://1145.am/db/2108020/Illumina>,
        <https://1145.am/db/2141011/Illumina>,
        <https://1145.am/db/2142556/Illumina>,
        <https://1145.am/db/2143979/Illumina_Inc>,
        <https://1145.am/db/2144305/Illumina>,
        <https://1145.am/db/2144771/Illumina>,
        <https://1145.am/db/2154499/Illumina>,
        <https://1145.am/db/2154543/Illumina>,
        <https://1145.am/db/2279139/Illumina>,
        <https://1145.am/db/2279826/Illumina>,
        <https://1145.am/db/2281780/Illumina>,
        <https://1145.am/db/2282604/Illumina>,
        <https://1145.am/db/2283089/Illumina>,
        <https://1145.am/db/2283331/Illumina>,
        <https://1145.am/db/2284367/Illumina>,
        <https://1145.am/db/2294885/Illumina>,
        <https://1145.am/db/2294891/Illumina>,
        <https://1145.am/db/2294967/Illumina>,
        <https://1145.am/db/2296025/Illumina>,
        <https://1145.am/db/2296164/Illumina>,
        <https://1145.am/db/2296171/Illumina>,
        <https://1145.am/db/2296180/Illumina>,
        <https://1145.am/db/2296600/Illumina>,
        <https://1145.am/db/2296675/Illumina>,
        <https://1145.am/db/2296788/Illumina>,
        <https://1145.am/db/2297131/Illumina>,
        <https://1145.am/db/2297472/Illumina>,
        <https://1145.am/db/2297593/Illumina>,
        <https://1145.am/db/2297619/Illumina>,
        <https://1145.am/db/2298070/Illumina>,
        <https://1145.am/db/2306511/Illumina>,
        <https://1145.am/db/2306516/Illumina>,
        <https://1145.am/db/2307596/Illumina>,
        <https://1145.am/db/2311597/Illumina_Uk_Ltd>,
        <https://1145.am/db/2319601/Illumina>,
        <https://1145.am/db/2319603/Illumina_Inc>,
        <https://1145.am/db/2319627/Illumina>,
        <https://1145.am/db/2320930/Illumina>,
        <https://1145.am/db/2321784/Illumina>,
        <https://1145.am/db/2322901/Illumina>,
        <https://1145.am/db/2323244/Illumina>,
        <https://1145.am/db/2326093/Illumina>,
        <https://1145.am/db/2326094/Illumina>,
        <https://1145.am/db/2326119/Illumina>,
        <https://1145.am/db/2328637/Illumina>,
        <https://1145.am/db/2329403/Illumina>,
        <https://1145.am/db/2329404/Illumina>,
        <https://1145.am/db/2330521/Illumina>,
        <https://1145.am/db/2336625/Illumina>,
        <https://1145.am/db/2336627/Illumina_Inc>,
        <https://1145.am/db/2345558/Illumina>,
        <https://1145.am/db/2353287/Illumina_Inc>,
        <https://1145.am/db/2355226/Illumina>,
        <https://1145.am/db/2357075/Illumina>,
        <https://1145.am/db/2359655/Illumina_Inc>,
        <https://1145.am/db/2360982/Illumina>,
        <https://1145.am/db/2360997/Illumina>,
        <https://1145.am/db/2360999/Illumina>,
        <https://1145.am/db/2361624/Illumina>,
        <https://1145.am/db/2361632/Illumina>,
        <https://1145.am/db/2361994/Illumina>,
        <https://1145.am/db/2361998/Illumina>,
        <https://1145.am/db/2362001/Illumina>,
        <https://1145.am/db/2362034/Illumina>,
        <https://1145.am/db/2362590/Illumina>,
        <https://1145.am/db/2367043/Illumina>,
        <https://1145.am/db/2367537/Illumina>,
        <https://1145.am/db/2367708/Illumina>,
        <https://1145.am/db/2368611/Illumina_Inc>,
        <https://1145.am/db/2370715/Illumina>,
        <https://1145.am/db/2541350/Illumina>,
        <https://1145.am/db/2541672/Illumina>,
        <https://1145.am/db/2541685/Illumina>,
        <https://1145.am/db/2568519/Illumina>,
        <https://1145.am/db/2571613/Illumina>,
        <https://1145.am/db/2572452/Illumina>,
        <https://1145.am/db/2573339/Illumina>,
        <https://1145.am/db/2574083/Illumina>,
        <https://1145.am/db/2574281/Illumina>,
        <https://1145.am/db/2575289/Illumina>,
        <https://1145.am/db/2592803/Illumina>,
        <https://1145.am/db/2593666/Illumina>,
        <https://1145.am/db/2593713/Illumina>,
        <https://1145.am/db/2597109/Illumina>,
        <https://1145.am/db/2597648/Illumina>,
        <https://1145.am/db/294376/Illumina_Inc>,
        <https://1145.am/db/310868/Illumina_Inc>,
        <https://1145.am/db/356690/Illumina_Inc>,
        <https://1145.am/db/376116/Illumina_Inc>,
        <https://1145.am/db/385241/Illumina_Inc>,
        <https://1145.am/db/422712/Illumina>,
        <https://1145.am/db/425834/Illumina_Inc>,
        <https://1145.am/db/492277/Illumina>,
        <https://1145.am/db/580608/Illumina>,
        <https://1145.am/db/625378/Illumina_Inc>,
        <https://1145.am/db/782644/Illumina>,
        <https://1145.am/db/785864/Illumina>,
        <https://1145.am/db/791066/Illumina>,
        <https://1145.am/db/791240/Illumina>,
        <https://1145.am/db/810365/Illumina>,
        <https://1145.am/db/875920/Illumina>,
        <https://1145.am/db/876576/Illumina> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2287956/Investment_Qiagen_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-22T15:17:51+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Genomic Health and OncoMed Pharmaceuticals have teamed up to develop treatment-specific tests, and Qiagen ($ QGEN) has posted a positive first quarter on the heels of its acquisitions in the companion diagnostics field." ;
    ns1:documentTitle "Agilent closes $2.2B Dako deal" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/agilent-closes-2-2b-dako-deal> ;
    ns1:foundName "acquisitions" ;
    ns1:name "acquisitions" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" .

<https://1145.am/db/2288282/Geneassess> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:documentDate "2012-07-02T19:37:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biomarker companies raise funding to scale up sales and marketing, validate diagnostics; NIH plans to fund blood cancer biomarker research;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/biomarker-companies-raise-funding-to-scale-up-sales-and-marketing-validate> ;
    ns1:foundName "GeneAssess" ;
    ns1:name "GeneAssess" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288282/Mdxhealth> a org:Organization ;
    ns1:basedInLowRaw "U.S." ;
    ns1:documentDate "2012-07-02T19:37:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biomarker companies raise funding to scale up sales and marketing, validate diagnostics; NIH plans to fund blood cancer biomarker research;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/biomarker-companies-raise-funding-to-scale-up-sales-and-marketing-validate> ;
    ns1:foundName "MDxHealth" ;
    ns1:name "MDxHealth" ;
    ns1:sameAsMedium <https://1145.am/db/1249145/Mdxhealth_Sa>,
        <https://1145.am/db/2288280/Mdxhealth>,
        <https://1145.am/db/2288454/Mdxhealth>,
        <https://1145.am/db/2292096/Mdxhealth>,
        <https://1145.am/db/2324869/Mdxhealth>,
        <https://1145.am/db/2324877/Mdxhealth>,
        <https://1145.am/db/2368438/Mdxhealth_Sa>,
        <https://1145.am/db/545860/Mdxhealth>,
        <https://1145.am/db/607644/Mdxhealth> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288282/Nexdx> a org:Organization ;
    ns1:description "medical research" ;
    ns1:documentDate "2012-07-02T19:37:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biomarker companies raise funding to scale up sales and marketing, validate diagnostics; NIH plans to fund blood cancer biomarker research;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/biomarker-companies-raise-funding-to-scale-up-sales-and-marketing-validate> ;
    ns1:foundName "NexDx" ;
    ns1:name "NexDx" ;
    ns1:sameAsMedium <https://1145.am/db/2356859/Nexdx_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288613/Rhoen> a org:Organization ;
    ns1:basedInHighGeoName "Federal Republic of Germany" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:basedInHighRaw "Germany" ;
    ns1:description "hospital operator" ;
    ns1:documentDate "2012-07-13T12:25:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Report: B. Braun moves to block Fresenius' bid for Rhoen" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/report-b-braun-moves-to-block-fresenius-bid-for-rhoen> ;
    ns1:foundName "Rhoen",
        "Rhoen-Klinikum" ;
    ns1:industry "hospital operator" ;
    ns1:name "Rhoen" ;
    ns1:sameAsMedium <https://1145.am/db/2288626/Rhoen> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288633/Investment_Ge_Nanosonic_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-16T15:25:44+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> GE ($ GE) is investing $ 7.5 million in Nanosonic, an Australian medical device startup developing a tech that can disinfect ultrasound probes in 7 minutes." ;
    ns1:documentTitle "GE invests in ultrasound-disinfecting device; Cambridge looks at how to speed up device marketing;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/ge-invests-ultrasound-disinfecting-device-cambridge-looks-at-how-to-speed-up-device> ;
    ns1:foundName "investing" ;
    ns1:name "investing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2288633/Nanosonic> ;
    ns1:targetName "Nanosonic" ;
    ns1:valueRaw "$ 7.5 million" ;
    ns1:whereGeoName "Commonwealth of Australia" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2077456/about.rdf> ;
    ns1:whereRaw "Australia" .

<https://1145.am/db/2288633/Nanosonic> a org:Organization ;
    ns1:basedInHighGeoName "Commonwealth of Australia" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2077456/about.rdf> ;
    ns1:basedInHighRaw "Australia" ;
    ns1:description "medical device" ;
    ns1:documentDate "2012-07-16T15:25:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "GE invests in ultrasound-disinfecting device; Cambridge looks at how to speed up device marketing;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/ge-invests-ultrasound-disinfecting-device-cambridge-looks-at-how-to-speed-up-device> ;
    ns1:foundName "Nanosonic" ;
    ns1:industry "medical device" ;
    ns1:name "Nanosonic" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2288633/One_Lambda> a org:Organization ;
    ns1:documentDate "2012-07-16T15:25:44+00:00"^^xsd:dateTime ;
    ns1:documentTitle "GE invests in ultrasound-disinfecting device; Cambridge looks at how to speed up device marketing;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/ge-invests-ultrasound-disinfecting-device-cambridge-looks-at-how-to-speed-up-device> ;
    ns1:foundName "One Lambda" ;
    ns1:name "One Lambda" ;
    ns1:sameAsMedium <https://1145.am/db/2288630/One_Lambda>,
        <https://1145.am/db/2288992/One_Lambda>,
        <https://1145.am/db/2290572/One_Lambda>,
        <https://1145.am/db/2596408/One_Lambda> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2297119/Zoll_Medical> a org:Organization ;
    ns1:basedInHighGeoName "Chelmsford" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4932869/about.rdf> ;
    ns1:basedInHighRaw "Chelmsford, MA" ;
    ns1:documentDate "2012-03-12T11:53:08+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Asahi Kasei scoops up Zoll for $2.2B, reflecting Japanese companies' hunger for growth" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/asahi-kasei-scoops-up-zoll-for-2-2b-reflecting-japanese-companies-hunger-for-growth> ;
    ns1:foundName "Zoll",
        "Zoll Medical" ;
    ns1:industry "Health Care" ;
    ns1:name "Zoll",
        "Zoll Medical" ;
    ns1:protagonist <https://1145.am/db/2297119/Zoll_Medical_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/1351544/Zócalo_Health>,
        <https://1145.am/db/1352420/Zócalo_Health>,
        <https://1145.am/db/1395761/Zing_Health>,
        <https://1145.am/db/2095175/Zivian_Health>,
        <https://1145.am/db/2281052/Zoll_Medical>,
        <https://1145.am/db/2288468/Zoll_Medical>,
        <https://1145.am/db/2294957/Zoll_Medical>,
        <https://1145.am/db/2296378/Zoll_Medical>,
        <https://1145.am/db/2297118/Zoll_Medical>,
        <https://1145.am/db/2324880/Zoll_Medical> ;
    ns1:sameAsMedium <https://1145.am/db/2206145/Zoll_Medical_Corporation>,
        <https://1145.am/db/2289093/Zoll_Medical>,
        <https://1145.am/db/2294427/Zoll_Medical>,
        <https://1145.am/db/2298576/Zoll_Medical>,
        <https://1145.am/db/2344236/Zoll_Medical>,
        <https://1145.am/db/466417/Zoll_Medical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2297604/Good_Start_Genetics> a org:Organization ;
    ns1:description "genetic sequencing" ;
    ns1:documentDate "2012-04-02T14:10:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "2 molecular diagnostics companies grab major money" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/2-molecular-diagnostics-companies-grab-major-money> ;
    ns1:foundName "Good Start Genetics",
        "Good Start Genetics in Cambridge, MA" ;
    ns1:industry "Molecular diagnostics/genetic sequencing" ;
    ns1:name "Good Start Genetics" ;
    ns1:sameAsMedium <https://1145.am/db/2296069/Good_Start_Genetics>,
        <https://1145.am/db/2300074/Good_Start_Genetics>,
        <https://1145.am/db/2359125/Good_Start_Genetics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2297604/Investment_Good_Start_Genetics_Molecularmd_Has_Not_Happened> ns1:activityType "investment" ;
    ns1:documentDate "2012-04-02T14:10:43+00:00"^^xsd:dateTime ;
    ns1:documentExtract "MolecularMD, of Portland, OR, nailed a $ 6 million Series B equity financing, thanks to Nextech Invest, which joins Ballast Point Ventures as an investor." ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2297604/Molecularmd> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 6 million" ;
    ns1:whereGeoName "Cambridge" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:whereRaw "Cambridge, MA" .

<https://1145.am/db/2297604/Nextech_Invest> a org:Organization ;
    ns1:basedInLowRaw "Oregon" ;
    ns1:documentDate "2012-04-02T14:10:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "2 molecular diagnostics companies grab major money" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/2-molecular-diagnostics-companies-grab-major-money> ;
    ns1:foundName "Nextech Invest" ;
    ns1:investor <https://1145.am/db/2297604/Investment_Good_Start_Genetics_Molecularmd_Has_Not_Happened> ;
    ns1:name "Nextech Invest" ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Nextech_Invest>,
        <https://1145.am/db/1247997/Nextech_Invest>,
        <https://1145.am/db/2109798/Nextech_Invest>,
        <https://1145.am/db/2283431/Nextech_Invest>,
        <https://1145.am/db/2285762/Nextech_Invest>,
        <https://1145.am/db/2293667/Nextech_Invest>,
        <https://1145.am/db/2298642/Nextech_Invest>,
        <https://1145.am/db/2337294/Nextech_Invest>,
        <https://1145.am/db/2337976/Nextech_Invest>,
        <https://1145.am/db/2342754/Nextech_Invest_Ltd>,
        <https://1145.am/db/2342768/Nextech_Invest_Ltd>,
        <https://1145.am/db/2342771/Nextech_Invest>,
        <https://1145.am/db/2346197/Nextech_Invest_Ltd>,
        <https://1145.am/db/2346213/Nextech_Invest_Ltd>,
        <https://1145.am/db/2348350/Nextech_Invest>,
        <https://1145.am/db/2366561/Nextech_Invest>,
        <https://1145.am/db/425281/Nextech_Invest>,
        <https://1145.am/db/426160/Nextech_Invest>,
        <https://1145.am/db/490696/Nextech_Invest>,
        <https://1145.am/db/770684/Nextech_Invest> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2297604/Orbimed_Advisors> a org:Organization ;
    ns1:basedInLowRaw "Cambridge, MA" ;
    ns1:documentDate "2012-04-02T14:10:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "2 molecular diagnostics companies grab major money" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/2-molecular-diagnostics-companies-grab-major-money> ;
    ns1:foundName "OrbiMed Advisors" ;
    ns1:investor <https://1145.am/db/2297604/Series_B_Investment_Good_Start_Genetics_Orbimed_Advisors_Sv_Life_Sciences_Safeguard_Scientifics_Completed> ;
    ns1:name "OrbiMed Advisors" ;
    ns1:sameAsMedium <https://1145.am/db/1665536/Orbimed_Advisors>,
        <https://1145.am/db/1809007/Orbimed_Advisors>,
        <https://1145.am/db/2198816/Orbimed_Advisors>,
        <https://1145.am/db/2245885/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2281230/Orbimed_Advisors>,
        <https://1145.am/db/2284506/Orbimed_Advisors>,
        <https://1145.am/db/2289056/Orbimed_Advisors>,
        <https://1145.am/db/2290078/Orbimed_Advisors>,
        <https://1145.am/db/2290200/Orbimed_Advisors>,
        <https://1145.am/db/2290444/Orbimed_Advisors>,
        <https://1145.am/db/2298956/Orbimed_Advisors>,
        <https://1145.am/db/2303098/Orbimed_Advisors>,
        <https://1145.am/db/2304242/Orbimed_Advisors>,
        <https://1145.am/db/2305656/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306251/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306705/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2309491/Orbimed_Advisors>,
        <https://1145.am/db/2310922/Orbimed_Advisors>,
        <https://1145.am/db/2312233/Orbimed_Advisors>,
        <https://1145.am/db/2317918/Orbimed_Advisors>,
        <https://1145.am/db/2318133/Orbimed_Advisors>,
        <https://1145.am/db/2318829/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2318832/Orbimed_Advisers>,
        <https://1145.am/db/2318851/Orbimed_Advisors>,
        <https://1145.am/db/2319338/Orbimed_Advisors>,
        <https://1145.am/db/2320914/Orbimed_Advisors>,
        <https://1145.am/db/2322345/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2324226/Orbimed_Advisors>,
        <https://1145.am/db/2325257/Orbimed_Advisors>,
        <https://1145.am/db/2325880/Orbimed_Advisors>,
        <https://1145.am/db/2328599/Orbimed_Advisors>,
        <https://1145.am/db/2328700/Orbimed_Advisors>,
        <https://1145.am/db/2329260/Orbimed_Advisors>,
        <https://1145.am/db/2330799/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2330920/Orbimed_Advisors>,
        <https://1145.am/db/2332120/Orbimed_Advisors>,
        <https://1145.am/db/2333495/Orbimed_Advisors>,
        <https://1145.am/db/2333504/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2333966/Orbimed_Advisors>,
        <https://1145.am/db/2335743/Orbimed_Advisors>,
        <https://1145.am/db/2336221/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2336503/Orbimed_Advisors>,
        <https://1145.am/db/2336505/Orbimed_Advisors>,
        <https://1145.am/db/2336524/Orbimed_Advisors>,
        <https://1145.am/db/2337166/Orbimed_Advisors>,
        <https://1145.am/db/2337250/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2337254/Orbimed_Advisors>,
        <https://1145.am/db/2339885/Orbimed_Advisors>,
        <https://1145.am/db/2339886/Orbimed_Advisors>,
        <https://1145.am/db/2342862/Orbimed_Advisors>,
        <https://1145.am/db/2342925/Orbimed_Advisors>,
        <https://1145.am/db/2342937/Orbimed_Advisors>,
        <https://1145.am/db/2343244/Orbimed_Advisors>,
        <https://1145.am/db/2344735/Orbimed_Advisors>,
        <https://1145.am/db/2344786/Orbimed_Advisors>,
        <https://1145.am/db/2345435/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345453/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345456/Orbimed_Advisors>,
        <https://1145.am/db/2346030/Orbimed_Advisors>,
        <https://1145.am/db/2350034/Orbimed_Advisors>,
        <https://1145.am/db/2350044/Orbimed_Advisors>,
        <https://1145.am/db/2352436/Orbimed_Advisors>,
        <https://1145.am/db/2352441/Orbimed_Advisors>,
        <https://1145.am/db/2352442/Orbimed_Advisors>,
        <https://1145.am/db/2352701/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2352804/Orbimed_Advisors>,
        <https://1145.am/db/2352807/Orbimed_Advisors>,
        <https://1145.am/db/2355034/Orbimed_Advisors>,
        <https://1145.am/db/2356297/Orbimed_Advisors>,
        <https://1145.am/db/2356420/Orbimed_Advisors>,
        <https://1145.am/db/2357253/Orbimed_Advisors>,
        <https://1145.am/db/2357256/Orbimed_Advisors>,
        <https://1145.am/db/2357858/Orbimed_Advisors>,
        <https://1145.am/db/2359125/Orbimed_Advisors>,
        <https://1145.am/db/2359468/Orbimed_Advisors>,
        <https://1145.am/db/2359864/Orbimed_Advisors>,
        <https://1145.am/db/2360174/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2361018/Orbimed_Advisors>,
        <https://1145.am/db/2361022/Orbimed_Advisors>,
        <https://1145.am/db/2361027/Orbimed_Advisors>,
        <https://1145.am/db/2362475/Orbimed_Advisors>,
        <https://1145.am/db/2362481/Orbimed_Advisors>,
        <https://1145.am/db/2363339/Orbimed_Advisors>,
        <https://1145.am/db/2365679/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2365868/Orbimed_Advisors>,
        <https://1145.am/db/2366519/Orbimed_Advisors>,
        <https://1145.am/db/2574232/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2583013/Orbimed_Advisors>,
        <https://1145.am/db/428737/Orbimed_Advisors>,
        <https://1145.am/db/456081/Orbimed_Advisors>,
        <https://1145.am/db/456089/Orbimed_Advisors>,
        <https://1145.am/db/458377/Orbimed_Advisors>,
        <https://1145.am/db/674484/Orbimed_Advisors> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2298082/Investment_Bioanalítica_Inversiones_Sl_Vivia_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-16T15:41:11+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Vivia, which is based in Madrid, secured 7.2 million euros ($ 9.4 million) in a second round of financing fueled by a government grant and a separate equity investment from Bioanalítica Inversiones SL." ;
    ns1:documentTitle "Diagnostics startups Vivia, Molecular Detection raise millions" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/diagnostics-startups-vivia-molecular-detection-raise-millions> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2298082/Vivia> ;
    ns1:valueRaw "$ 9.4 million",
        "7.2 million euros" ;
    ns1:whereGeoName "Kingdom of Spain" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2510769/about.rdf> ;
    ns1:whereRaw "Spain" .

<https://1145.am/db/2298082/Molecular_Detection> a org:Organization ;
    ns1:basedInHighGeoName "Wayne County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5218273/about.rdf> ;
    ns1:basedInHighRaw "Wayne, PA" ;
    ns1:description "a medical company" ;
    ns1:documentDate "2012-04-16T15:41:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Diagnostics startups Vivia, Molecular Detection raise millions" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/diagnostics-startups-vivia-molecular-detection-raise-millions> ;
    ns1:foundName "Molecular Detection in Wayne",
        "Molecular Detection in Wayne, PA" ;
    ns1:name "Molecular Detection" ;
    ns1:sameAsMedium <https://1145.am/db/2319351/Molecular_Detection_Inc>,
        <https://1145.am/db/2343208/Molecular_Detection_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2298082/Vivia> a org:Organization ;
    ns1:basedInHighGeoName "Madrid" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3117735/about.rdf> ;
    ns1:basedInHighRaw "Madrid" ;
    ns1:description "hematologic cancers" ;
    ns1:documentDate "2012-04-16T15:41:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Diagnostics startups Vivia, Molecular Detection raise millions" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/diagnostics-startups-vivia-molecular-detection-raise-millions> ;
    ns1:foundName "Vivia" ;
    ns1:name "Vivia" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2298542/Aggredyne> a org:Organization ;
    ns1:description "diagnostics" ;
    ns1:documentDate "2012-04-22T14:52:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Boston Scientific completes enrollment for aortic valve trial; Diagnostics startup Aggredyne raises $3M;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/boston-scientific-completes-enrollment-for-aortic-valve-trial-diagnostics-startup> ;
    ns1:foundName "Aggredyne" ;
    ns1:industry "Diagnostics" ;
    ns1:name "Aggredyne" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2298542/Delcath_Systems> a org:Organization ;
    ns1:description "medical device and pharmaceutical company" ;
    ns1:documentDate "2012-04-22T14:52:42+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Boston Scientific completes enrollment for aortic valve trial; Diagnostics startup Aggredyne raises $3M;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/boston-scientific-completes-enrollment-for-aortic-valve-trial-diagnostics-startup> ;
    ns1:foundName "Delcath Systems" ;
    ns1:industry "medical device and pharmaceutical company" ;
    ns1:name "Delcath Systems" ;
    ns1:sameAsHigh <https://1145.am/db/2336915/Delcath_Systems_Inc>,
        <https://1145.am/db/2352141/Delcath_Systems_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2293771/Delcath_Systems>,
        <https://1145.am/db/2572649/Delcath_Systems>,
        <https://1145.am/db/399746/Delcath_Systems>,
        <https://1145.am/db/784570/Delcath_Systems>,
        <https://1145.am/db/814027/Delcath_Systems> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2298542/Investment_Activiews_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-22T14:52:42+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Wakefield, MA - based ActiViews has gained 510 (k) clearance for its flagship product, a needle guidance system designed for such CT-guided interventional procedures as biopsies and ablations." ;
    ns1:documentTitle "Boston Scientific completes enrollment for aortic valve trial; Diagnostics startup Aggredyne raises $3M;" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/boston-scientific-completes-enrollment-for-aortic-valve-trial-diagnostics-startup> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2327795/Oxford_Nanopore_Technologies_Ltd> a org:Organization ;
    ns1:basedInHighGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:basedInHighRaw "UK" ;
    ns1:basedInLowRaw "Oxford" ;
    ns1:description "R & D" ;
    ns1:documentDate "2012-05-07T12:07:19+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Oxford Nanopore announces £31.4 million ($50.8 million) fundraising" ;
    ns1:documentURL <https://www.fiercebiotech.com/it/oxford-nanopore-announces-%C2%A331-4-million-50-8-million-fundraising> ;
    ns1:foundName "Oxford Nanopore",
        "Oxford Nanopore Technologies Ltd" ;
    ns1:name "Oxford Nanopore",
        "Oxford Nanopore Technologies Ltd" ;
    ns1:sameAsHigh <https://1145.am/db/2322431/Oxford_Nanopore>,
        <https://1145.am/db/2364766/Oxford_Nanopore_Technologies> ;
    ns1:sameAsMedium <https://1145.am/db/2299566/Oxford_Nanopore_Technologies>,
        <https://1145.am/db/2311597/Oxford_Nanopore_Technologies_Ltd>,
        <https://1145.am/db/2315234/Oxford_Nanopore_Technologies_Ltd>,
        <https://1145.am/db/2320930/Oxford_Nanopore_Tech>,
        <https://1145.am/db/2326079/Oxford_Nanopore_Technologies_Ltd>,
        <https://1145.am/db/2368550/Oxford_Nanopore_Technologies_Ltd>,
        <https://1145.am/db/512413/Oxford_Nanopore_Technologies> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2327843/Genomoncology> a org:Organization ;
    ns1:basedInLowRaw "Northeast Ohio" ;
    ns1:description "cancer treatment" ;
    ns1:documentDate "2012-06-06T19:40:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "JumpStart Invests $250,000 in GenomOncology" ;
    ns1:documentURL <https://www.fiercebiotech.com/it/jumpstart-invests-250-000-genomoncology> ;
    ns1:foundName "GenomOncology" ;
    ns1:name "GenomOncology" ;
    ns1:sameAsMedium <https://1145.am/db/2369846/Genomoncology>,
        <https://1145.am/db/2371494/Genomoncology>,
        <https://1145.am/db/952764/Genomoncology> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2327843/Investment_Genomoncology_Jumpstart_Inc_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-06T19:40:43+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CLEVELAND, June 5, 2012 /PRNewswire/ - Nonprofit venture development organization JumpStart Inc. (www.jumpstartinc.org) has committed $ 250,000 to GenomOncology (www.genomoncology.com) , a Cleveland - based company developing technology to automate the analysis of sequenced genetic information.",
        "JumpStart Invests $ 250,000 in GenomOncology. Northeast Ohio Company Views Unlocking DNA as Boon to Cancer Treatment." ;
    ns1:documentTitle "JumpStart Invests $250,000 in GenomOncology" ;
    ns1:documentURL <https://www.fiercebiotech.com/it/jumpstart-invests-250-000-genomoncology> ;
    ns1:foundName "Invests",
        "committed" ;
    ns1:name "Invests",
        "committed" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2327843/Genomoncology> ;
    ns1:targetName "GenomOncology" ;
    ns1:valueRaw "$ 250,000" ;
    ns1:whereGeoName "Cleveland",
        "Northeast Ohio" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/12216898/about.rdf>,
        <https://sws.geonames.org/5150529/about.rdf> ;
    ns1:whereRaw "Cleveland",
        "Northeast Ohio" .

<https://1145.am/db/2328931/Clinical_Outcome_Assessment_Solutions_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-07-09T13:50:50+00:00"^^xsd:dateTime ;
    ns1:documentExtract "ERT Acquires invivodata to Establish the Industry's Most Experienced Provider of Clinical Outcome Assessment Solutions.",
        "PHILADELPHIA, PA, July 9, 2012 - ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations (CROs) , announced today the acquisition of invivodata, Inc, a leading provider of electronic Patient Reported Outcomes (ePRO) solutions and consulting services, based in Pittsburgh, PA." ;
    ns1:documentTitle "ERT Acquires invivodata to Establish the Industry's Most Experienced Provider of Clinical Outcome Assessment Solutions" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/ert-acquires-invivodata-to-establish-industry-s-most-experienced-provider-clinical-outcome> ;
    ns1:foundName "Acquires",
        "acquisition" ;
    ns1:name "Acquires",
        "acquisition" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2328931/Invivodata> ;
    ns1:targetName "Clinical Outcome Assessment Solutions",
        "invivodata" ;
    ns1:when "2012-07-09T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "July 9, 2012" ;
    ns1:whereGeoName "Pittsburgh" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5206379/about.rdf> ;
    ns1:whereRaw "Pittsburgh, PA" .

<https://1145.am/db/2328931/Invivodata> a org:Organization ;
    ns1:basedInHighGeoName "Pittsburgh" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5206379/about.rdf> ;
    ns1:basedInHighRaw "Pittsburgh, PA" ;
    ns1:description "a leading provider of electronic Patient Reported Outcomes (ePRO) solutions and" ;
    ns1:documentDate "2012-07-09T13:50:50+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ERT Acquires invivodata to Establish the Industry's Most Experienced Provider of Clinical Outcome Assessment Solutions" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/ert-acquires-invivodata-to-establish-industry-s-most-experienced-provider-clinical-outcome> ;
    ns1:foundName "invivodata, Inc" ;
    ns1:industry "health outcomes services" ;
    ns1:name "invivodata" ;
    ns1:sameAsMedium <https://1145.am/db/2328930/Invivodata>,
        <https://1145.am/db/2335062/Invivodata> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335700/Ptc_Therapeutics_Inc> a org:Organization ;
    ns1:basedInHighGeoName "South Plainfield" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5104844/about.rdf> ;
    ns1:basedInHighRaw "SOUTH PLAINFIELD, N.J." ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-07-23T15:59:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $30 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-30-million-financing> ;
    ns1:foundName "PTC Therapeutics",
        "PTC Therapeutics, Inc." ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "PTC Therapeutics",
        "PTC Therapeutics, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2304340/Ptc_Therapeutics>,
        <https://1145.am/db/2305030/Ptc_Therapeutics>,
        <https://1145.am/db/2306291/Ptc_Therapeutics>,
        <https://1145.am/db/2345070/Ptc_Therapeutics_Inc>,
        <https://1145.am/db/2346028/Ptc_Therapeutics>,
        <https://1145.am/db/2347783/Ptc_Therapeutics>,
        <https://1145.am/db/2357307/Ptc_Therapeutics_Inc>,
        <https://1145.am/db/2362643/Ptc_Therapeutics>,
        <https://1145.am/db/2546781/Ptc_Therapeutics>,
        <https://1145.am/db/2584056/Ptc_Therapeutics_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2293338/Ptc_Therapeutics>,
        <https://1145.am/db/2304335/Ptc_Therapeutics_Inc>,
        <https://1145.am/db/2331623/Ptc_Therapeutics>,
        <https://1145.am/db/2335913/Ptc_Therapeutics_Inc>,
        <https://1145.am/db/2340819/Ptc_Therapeutics_Inc>,
        <https://1145.am/db/2346877/Ptc_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335700/The_Column_Group> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:documentDate "2012-07-23T15:59:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $30 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-30-million-financing> ;
    ns1:foundName "The Column Group" ;
    ns1:investor <https://1145.am/db/2335700/Investment_Celgene_Credit_Suisse_First_Boston_Equity_Partners_Delphi_Ventures_Hbm_Bioventures_Novo_A_S_Ptc_Therapeutics_Inc_The_Column_Group_Vulcan_Ventures_Completed> ;
    ns1:name "The Column Group" ;
    ns1:sameAsMedium <https://1145.am/db/1503058/The_Column_Group>,
        <https://1145.am/db/1533327/The_Column_Group>,
        <https://1145.am/db/1533685/The_Column_Group>,
        <https://1145.am/db/1536915/The_Column_Group>,
        <https://1145.am/db/1624208/The_Column_Group>,
        <https://1145.am/db/2283431/The_Column_Group>,
        <https://1145.am/db/2287253/The_Column_Group>,
        <https://1145.am/db/2291277/The_Column_Group>,
        <https://1145.am/db/2294202/The_Column_Group>,
        <https://1145.am/db/2304335/The_Column_Group>,
        <https://1145.am/db/2304340/The_Column_Group>,
        <https://1145.am/db/2304769/The_Column_Group>,
        <https://1145.am/db/2305256/The_Column_Group>,
        <https://1145.am/db/2327474/The_Column_Group>,
        <https://1145.am/db/2336503/The_Column_Group>,
        <https://1145.am/db/2336505/The_Column_Group>,
        <https://1145.am/db/2336524/The_Column_Group>,
        <https://1145.am/db/2339704/The_Column_Group>,
        <https://1145.am/db/2339883/The_Column_Group>,
        <https://1145.am/db/2344735/The_Column_Group>,
        <https://1145.am/db/2347885/The_Column_Group>,
        <https://1145.am/db/2350364/The_Column_Group>,
        <https://1145.am/db/2351394/The_Column_Group>,
        <https://1145.am/db/2351397/The_Column_Group>,
        <https://1145.am/db/2359334/The_Column_Group>,
        <https://1145.am/db/2359468/The_Column_Group>,
        <https://1145.am/db/2359864/The_Column_Group>,
        <https://1145.am/db/2362475/The_Column_Group>,
        <https://1145.am/db/2362481/The_Column_Group>,
        <https://1145.am/db/2362565/The_Column_Group>,
        <https://1145.am/db/2362566/The_Column_Group>,
        <https://1145.am/db/2365363/The_Column_Group>,
        <https://1145.am/db/2368280/The_Column_Group>,
        <https://1145.am/db/2368501/The_Column_Group>,
        <https://1145.am/db/2583013/The_Column_Group>,
        <https://1145.am/db/2584056/The_Column_Group>,
        <https://1145.am/db/2584561/The_Column_Group>,
        <https://1145.am/db/425281/The_Column_Group>,
        <https://1145.am/db/426160/The_Column_Group>,
        <https://1145.am/db/490696/The_Column_Group>,
        <https://1145.am/db/75445/The_Column_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335701/Chiasma> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-07-23T16:25:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Chiasma Closes $38.5 Million Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/chiasma-closes-38-5-million-equity-financing-0> ;
    ns1:foundName "Chiasma",
        "Inc." ;
    ns1:industry "biopharma" ;
    ns1:name "Chiasma" ;
    ns1:sameAsHigh <https://1145.am/db/2335699/Chiasma>,
        <https://1145.am/db/2335714/Chiasma>,
        <https://1145.am/db/2337140/Chiasma>,
        <https://1145.am/db/2337144/Chiasma>,
        <https://1145.am/db/2340065/Chiasma>,
        <https://1145.am/db/2340066/Chiasma>,
        <https://1145.am/db/2340114/Chiasma>,
        <https://1145.am/db/2340934/Chiasma>,
        <https://1145.am/db/2354393/Chiasma>,
        <https://1145.am/db/2369238/Chiasma>,
        <https://1145.am/db/2369609/Chiasma>,
        <https://1145.am/db/2571145/Chiasma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335701/Mpm_Capital> a org:Organization ;
    ns1:basedInLowRaw "JERUSALEM" ;
    ns1:description "equity financing" ;
    ns1:documentDate "2012-07-23T16:25:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Chiasma Closes $38.5 Million Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/chiasma-closes-38-5-million-equity-financing-0> ;
    ns1:foundName "MPM Capital" ;
    ns1:investor <https://1145.am/db/2335701/Investment_7_Med_Health_Ventures_Arch_Venture_Partners_Abingworth_Chiasma_F3_Ventures_Fredric_Price_Mpm_Capital_Completed> ;
    ns1:name "MPM Capital" ;
    ns1:sameAsHigh <https://1145.am/db/2300455/Mpm_Capital>,
        <https://1145.am/db/2303855/Mpm_Capital>,
        <https://1145.am/db/2312309/Mpm_Capital>,
        <https://1145.am/db/2323563/Mpm_Capital>,
        <https://1145.am/db/2346204/Mpm_Capital>,
        <https://1145.am/db/2347469/Mpm_Capital>,
        <https://1145.am/db/2356396/Mpm_Capital>,
        <https://1145.am/db/2359001/Mpm_Capital>,
        <https://1145.am/db/2367199/Mpm_Capital>,
        <https://1145.am/db/2541350/Mpm_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1325968/Mpm_Capital>,
        <https://1145.am/db/1752458/Mpm_Capital>,
        <https://1145.am/db/2285876/Mpm_Capital>,
        <https://1145.am/db/2287191/Mpm_Capital>,
        <https://1145.am/db/2292334/Mpm_Capital>,
        <https://1145.am/db/2292353/Mpm_Capital>,
        <https://1145.am/db/2301901/Mpm_Capital>,
        <https://1145.am/db/2303391/Mpm_Capital>,
        <https://1145.am/db/2303833/Mpm_Capital>,
        <https://1145.am/db/2304634/Mpm_Capital>,
        <https://1145.am/db/2305503/Mpm_Capital>,
        <https://1145.am/db/2305656/Mpm_Capital>,
        <https://1145.am/db/2306705/Mpm_Capital>,
        <https://1145.am/db/2308887/Mpm_Capital>,
        <https://1145.am/db/2309845/Mpm_Capital>,
        <https://1145.am/db/2311551/Mpm_Capital>,
        <https://1145.am/db/2312285/Mpm_Capital>,
        <https://1145.am/db/2316391/Mpm_Capital>,
        <https://1145.am/db/2323055/Mpm_Capital>,
        <https://1145.am/db/2323066/Mpm_Capital>,
        <https://1145.am/db/2323094/Mpm_Capital>,
        <https://1145.am/db/2323568/Mpm_Capital>,
        <https://1145.am/db/2324195/Mpm_Capital>,
        <https://1145.am/db/2324226/Mpm_Capital>,
        <https://1145.am/db/2328338/Mpm_Capital>,
        <https://1145.am/db/2333119/Mpm_Capital>,
        <https://1145.am/db/2333525/Mpm_Capital>,
        <https://1145.am/db/2335714/Mpm_Capital>,
        <https://1145.am/db/2337140/Mpm_Capital>,
        <https://1145.am/db/2340957/Mpm_Capital>,
        <https://1145.am/db/2345299/Mpm_Capital>,
        <https://1145.am/db/2345318/Mpm_Capital>,
        <https://1145.am/db/2347140/Mpm_Capital>,
        <https://1145.am/db/2347984/Mpm_Capital>,
        <https://1145.am/db/2348484/Mpm_Capital>,
        <https://1145.am/db/2350030/Mpm_Capital>,
        <https://1145.am/db/2352172/Mpm_Capital>,
        <https://1145.am/db/2352362/Mpm_Capital>,
        <https://1145.am/db/2352899/Mpm_Capital>,
        <https://1145.am/db/2353365/Mpm_Capital>,
        <https://1145.am/db/2353404/Mpm_Capital>,
        <https://1145.am/db/2353413/Mpm_Capital>,
        <https://1145.am/db/2353415/Mpm_Capital>,
        <https://1145.am/db/2358979/Mpm_Capital>,
        <https://1145.am/db/2359873/Mpm_Capital>,
        <https://1145.am/db/2359875/Mpm_Capital>,
        <https://1145.am/db/2360526/Mpm_Capital>,
        <https://1145.am/db/2362871/Mpm_Capital>,
        <https://1145.am/db/2364492/Mpm_Capital>,
        <https://1145.am/db/2365098/Mpm_Capital>,
        <https://1145.am/db/2366744/Mpm_Capital>,
        <https://1145.am/db/2369202/Mpm_Capital>,
        <https://1145.am/db/2370582/Mpm_Capital>,
        <https://1145.am/db/677075/Mpm_Capital>,
        <https://1145.am/db/678997/Mpm_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336102/Altima_Partners> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "Altima Partners" ;
    ns1:investor <https://1145.am/db/2336102/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Altima Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2318779/Altima_Partners>,
        <https://1145.am/db/2336109/Altima_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336102/Biomed_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "BioMed Ventures" ;
    ns1:investor <https://1145.am/db/2336102/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "BioMed Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2335675/Biomed_Ventures>,
        <https://1145.am/db/2336109/Biomed_Ventures>,
        <https://1145.am/db/2345037/Biomed_Ventures>,
        <https://1145.am/db/2354295/Biomed_Ventures>,
        <https://1145.am/db/2366046/Biomed_Ventures>,
        <https://1145.am/db/2366049/Biomed_Ventures>,
        <https://1145.am/db/2366055/Biomed_Ventures>,
        <https://1145.am/db/2368333/Biomed_Ventures>,
        <https://1145.am/db/2369916/Biomed_Ventures>,
        <https://1145.am/db/2569522/Biomed_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336102/Boston_Millennia_Partners> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "Boston Millennia Partners" ;
    ns1:investor <https://1145.am/db/2336102/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Boston Millennia Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2336109/Boston_Millennia_Partners>,
        <https://1145.am/db/2338428/Boston_Millennia_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2102258/Boston_Millennia_Partners>,
        <https://1145.am/db/2189544/Boston_Millennia_Partners>,
        <https://1145.am/db/2300861/Boston_Millennia_Partners>,
        <https://1145.am/db/2318779/Boston_Millennia_Partners>,
        <https://1145.am/db/2318807/Boston_Millennia_Partners>,
        <https://1145.am/db/2340204/Boston_Millennia_Partners>,
        <https://1145.am/db/2340207/Boston_Millennia_Partners>,
        <https://1145.am/db/676953/Boston_Millennia_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336102/Fintech_Gimv_Fund> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "FinTech GIMV Fund, L.P" ;
    ns1:investor <https://1145.am/db/2336102/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "FinTech GIMV Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2336109/Fintech_Gimv_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336102/Foundation_Medical_Partners> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "Foundation Medical Partners" ;
    ns1:investor <https://1145.am/db/2336102/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Foundation Medical Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2287777/Foundation_Medical_Partners>,
        <https://1145.am/db/2295207/Foundation_Medical_Partners>,
        <https://1145.am/db/2313171/Foundation_Medical_Partners>,
        <https://1145.am/db/2317467/Foundation_Medical_Partners>,
        <https://1145.am/db/2318779/Foundation_Medical_Partners>,
        <https://1145.am/db/2322231/Foundation_Medical_Partners>,
        <https://1145.am/db/2336109/Foundation_Medical_Partners>,
        <https://1145.am/db/2361625/Foundation_Medical_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336102/Inflection_Point_Capital> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "Inflection Point Capital" ;
    ns1:investor <https://1145.am/db/2336102/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Inflection Point Capital" ;
    ns1:sameAsHigh <https://1145.am/db/2336109/Inflection_Point_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336102/Prochon_Holdings_Bv> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:description "Regenerative medicine" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "ProChon Holdings BV" ;
    ns1:investor <https://1145.am/db/2336102/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "ProChon Holdings BV" ;
    ns1:sameAsMedium <https://1145.am/db/2336109/Prochon_Holdings_Bv> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336102/Sofinnova_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "Sofinnova Ventures" ;
    ns1:investor <https://1145.am/db/2336102/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Sofinnova Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1831577/Sofinnova_Ventures>,
        <https://1145.am/db/1876390/Sofinnova_Ventures>,
        <https://1145.am/db/2295539/Sofinnova_Ventures>,
        <https://1145.am/db/2301093/Sofinnova_Ventures>,
        <https://1145.am/db/2303548/Sofinnova_Ventures>,
        <https://1145.am/db/2303560/Sofinnova_Ventures>,
        <https://1145.am/db/2304598/Sofinnova_Ventures>,
        <https://1145.am/db/2304606/Sofinnova_Ventures>,
        <https://1145.am/db/2305328/Sofinnova_Ventures>,
        <https://1145.am/db/2306568/Sofinnova_Ventures>,
        <https://1145.am/db/2310073/Sofinnova_Ventures>,
        <https://1145.am/db/2311069/Sofinnova_Ventures>,
        <https://1145.am/db/2311075/Sofinnova_Ventures>,
        <https://1145.am/db/2312051/Sofinnova_Ventures>,
        <https://1145.am/db/2313171/Sofinnova_Ventures>,
        <https://1145.am/db/2314397/Sofinnova_Ventures>,
        <https://1145.am/db/2314400/Sofinnova_Ventures>,
        <https://1145.am/db/2314964/Sofinnova_Ventures>,
        <https://1145.am/db/2317750/Sofinnova_Ventures>,
        <https://1145.am/db/2317753/Sofinnova_Ventures>,
        <https://1145.am/db/2322231/Sofinnova_Ventures>,
        <https://1145.am/db/2324195/Sofinnova_Ventures>,
        <https://1145.am/db/2324223/Sofinnova_Ventures>,
        <https://1145.am/db/2325549/Sofinnova_Ventures>,
        <https://1145.am/db/2328338/Sofinnova_Ventures>,
        <https://1145.am/db/2330799/Sofinnova_Ventures>,
        <https://1145.am/db/2330914/Sofinnova_Ventures>,
        <https://1145.am/db/2330920/Sofinnova_Ventures>,
        <https://1145.am/db/2331700/Sofinnova_Ventures>,
        <https://1145.am/db/2336109/Sofinnova_Ventures>,
        <https://1145.am/db/2337140/Sofinnova_Ventures>,
        <https://1145.am/db/2339666/Sofinnova_Ventures>,
        <https://1145.am/db/2340542/Sofinnova_Ventures>,
        <https://1145.am/db/2340888/Sofinnova_Ventures>,
        <https://1145.am/db/2340890/Sofinnova_Ventures>,
        <https://1145.am/db/2341869/Sofinnova_Ventures>,
        <https://1145.am/db/2341896/Sofinnova_Ventures>,
        <https://1145.am/db/2341897/Sofinnova_Ventures>,
        <https://1145.am/db/2342998/Sofinnova_Ventures>,
        <https://1145.am/db/2345047/Sofinnova_Ventures>,
        <https://1145.am/db/2345262/Sofinnova_Ventures>,
        <https://1145.am/db/2348857/Sofinnova_Ventures>,
        <https://1145.am/db/2349013/Sofinnova_Ventures>,
        <https://1145.am/db/2349096/Sofinnova_Ventures>,
        <https://1145.am/db/2349834/Sofinnova_Ventures>,
        <https://1145.am/db/2350231/Sofinnova_Ventures>,
        <https://1145.am/db/2350855/Sofinnova_Ventures>,
        <https://1145.am/db/2352059/Sofinnova_Ventures>,
        <https://1145.am/db/2353771/Sofinnova_Ventures>,
        <https://1145.am/db/2353789/Sofinnova_Ventures>,
        <https://1145.am/db/2355183/Sofinnova_Ventures>,
        <https://1145.am/db/2357105/Sofinnova_Ventures>,
        <https://1145.am/db/2357356/Sofinnova_Ventures>,
        <https://1145.am/db/2358050/Sofinnova_Ventures>,
        <https://1145.am/db/2358234/Sofinnova_Ventures>,
        <https://1145.am/db/2358725/Sofinnova_Ventures>,
        <https://1145.am/db/2359124/Sofinnova_Ventures>,
        <https://1145.am/db/2360266/Sofinnova_Ventures>,
        <https://1145.am/db/2360647/Sofinnova_Ventures>,
        <https://1145.am/db/2362902/Sofinnova_Ventures>,
        <https://1145.am/db/2362909/Sofinnova_Ventures>,
        <https://1145.am/db/2362910/Sofinnova_Ventures>,
        <https://1145.am/db/2366710/Sofinnova_Ventures>,
        <https://1145.am/db/2366712/Sofinnova_Ventures>,
        <https://1145.am/db/2367022/Sofinnova_Ventures>,
        <https://1145.am/db/2367023/Sofinnova_Ventures>,
        <https://1145.am/db/2368982/Sofinnova_Ventures>,
        <https://1145.am/db/2371160/Sofinnova_Ventures>,
        <https://1145.am/db/2371163/Sofinnova_Ventures>,
        <https://1145.am/db/2569522/Sofinnova_Ventures>,
        <https://1145.am/db/2570520/Sofinnova_Ventures>,
        <https://1145.am/db/2570523/Sofinnova_Ventures>,
        <https://1145.am/db/2577022/Sofinnova_Ventures>,
        <https://1145.am/db/2578627/Sofinnova_Ventures>,
        <https://1145.am/db/2588372/Sofinnova_Ventures>,
        <https://1145.am/db/2592611/Sofinnova_Ventures>,
        <https://1145.am/db/2630808/Sofinnova_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336102/Split_Rock_Partners> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "Split Rock Partners" ;
    ns1:investor <https://1145.am/db/2336102/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Split Rock Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1799028/Split_Rock_Partners>,
        <https://1145.am/db/1825267/Split_Rock_Partners>,
        <https://1145.am/db/1828720/Split_Rock_Partners>,
        <https://1145.am/db/1847599/Split_Rock_Partners>,
        <https://1145.am/db/1849310/Split_Rock_Partners>,
        <https://1145.am/db/1852471/Split_Rock_Partners>,
        <https://1145.am/db/1861540/Split_Rock_Partners>,
        <https://1145.am/db/1882621/Split_Rock_Partners>,
        <https://1145.am/db/1919287/Split_Rock_Partners>,
        <https://1145.am/db/2240880/Split_Rock_Partners>,
        <https://1145.am/db/2289616/Split_Rock_Partners>,
        <https://1145.am/db/2293312/Split_Rock_Partners>,
        <https://1145.am/db/2296640/Split_Rock_Partners>,
        <https://1145.am/db/2326571/Split_Rock_Partners>,
        <https://1145.am/db/2329524/Split_Rock_Partners>,
        <https://1145.am/db/2329531/Split_Rock_Partners>,
        <https://1145.am/db/2336109/Split_Rock_Partners>,
        <https://1145.am/db/889770/Split_Rock_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336109/Altima_Partners> a org:Organization ;
    ns1:basedInLowRaw "BV" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "Altima Partners" ;
    ns1:investor <https://1145.am/db/2336109/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Altima Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2318779/Altima_Partners>,
        <https://1145.am/db/2336102/Altima_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336109/Boston_Millennia_Partners> a org:Organization ;
    ns1:basedInLowRaw "Boston" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "Boston Millennia Partners" ;
    ns1:investor <https://1145.am/db/2336109/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Boston Millennia Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2336102/Boston_Millennia_Partners>,
        <https://1145.am/db/2338428/Boston_Millennia_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2102258/Boston_Millennia_Partners>,
        <https://1145.am/db/2189544/Boston_Millennia_Partners>,
        <https://1145.am/db/2300861/Boston_Millennia_Partners>,
        <https://1145.am/db/2318779/Boston_Millennia_Partners>,
        <https://1145.am/db/2318807/Boston_Millennia_Partners>,
        <https://1145.am/db/2340204/Boston_Millennia_Partners>,
        <https://1145.am/db/2340207/Boston_Millennia_Partners>,
        <https://1145.am/db/676953/Boston_Millennia_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336109/Fintech_Gimv_Fund> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "FinTech GIMV Fund, L.P",
        "FinTech GIMV Fund, L.P." ;
    ns1:investor <https://1145.am/db/2336109/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "FinTech GIMV Fund" ;
    ns1:sameAsMedium <https://1145.am/db/2336102/Fintech_Gimv_Fund> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336109/Foundation_Medical_Partners> a org:Organization ;
    ns1:basedInLowRaw "BV" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "Foundation Medical Partners" ;
    ns1:investor <https://1145.am/db/2336109/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Foundation Medical Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2301824/Nexus_Medical_Partners>,
        <https://1145.am/db/2361625/Foundation_Medical_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/2287777/Foundation_Medical_Partners>,
        <https://1145.am/db/2295207/Foundation_Medical_Partners>,
        <https://1145.am/db/2313171/Foundation_Medical_Partners>,
        <https://1145.am/db/2317467/Foundation_Medical_Partners>,
        <https://1145.am/db/2318779/Foundation_Medical_Partners>,
        <https://1145.am/db/2322231/Foundation_Medical_Partners>,
        <https://1145.am/db/2336102/Foundation_Medical_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336109/Inflection_Point_Capital> a org:Organization ;
    ns1:basedInLowRaw "Boston" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "Inflection Point Capital" ;
    ns1:investor <https://1145.am/db/2336109/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Inflection Point Capital" ;
    ns1:sameAsHigh <https://1145.am/db/2336102/Inflection_Point_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336109/Prochon_Holdings_Bv> a org:Organization ;
    ns1:basedInLowRaw "Netherlands" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "ProChon Holdings BV" ;
    ns1:investor <https://1145.am/db/2336109/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "ProChon Holdings BV" ;
    ns1:sameAsMedium <https://1145.am/db/2336102/Prochon_Holdings_Bv> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336109/Sofinnova_Ventures> a org:Organization ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "Sofinnova Ventures" ;
    ns1:investor <https://1145.am/db/2336109/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Sofinnova Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1831577/Sofinnova_Ventures>,
        <https://1145.am/db/1876390/Sofinnova_Ventures>,
        <https://1145.am/db/2295539/Sofinnova_Ventures>,
        <https://1145.am/db/2301093/Sofinnova_Ventures>,
        <https://1145.am/db/2303548/Sofinnova_Ventures>,
        <https://1145.am/db/2303560/Sofinnova_Ventures>,
        <https://1145.am/db/2304598/Sofinnova_Ventures>,
        <https://1145.am/db/2304606/Sofinnova_Ventures>,
        <https://1145.am/db/2305328/Sofinnova_Ventures>,
        <https://1145.am/db/2306568/Sofinnova_Ventures>,
        <https://1145.am/db/2310073/Sofinnova_Ventures>,
        <https://1145.am/db/2311069/Sofinnova_Ventures>,
        <https://1145.am/db/2311075/Sofinnova_Ventures>,
        <https://1145.am/db/2312051/Sofinnova_Ventures>,
        <https://1145.am/db/2313171/Sofinnova_Ventures>,
        <https://1145.am/db/2314397/Sofinnova_Ventures>,
        <https://1145.am/db/2314400/Sofinnova_Ventures>,
        <https://1145.am/db/2314964/Sofinnova_Ventures>,
        <https://1145.am/db/2317750/Sofinnova_Ventures>,
        <https://1145.am/db/2317753/Sofinnova_Ventures>,
        <https://1145.am/db/2322231/Sofinnova_Ventures>,
        <https://1145.am/db/2324195/Sofinnova_Ventures>,
        <https://1145.am/db/2324223/Sofinnova_Ventures>,
        <https://1145.am/db/2325549/Sofinnova_Ventures>,
        <https://1145.am/db/2328338/Sofinnova_Ventures>,
        <https://1145.am/db/2330799/Sofinnova_Ventures>,
        <https://1145.am/db/2330914/Sofinnova_Ventures>,
        <https://1145.am/db/2330920/Sofinnova_Ventures>,
        <https://1145.am/db/2331700/Sofinnova_Ventures>,
        <https://1145.am/db/2336102/Sofinnova_Ventures>,
        <https://1145.am/db/2337140/Sofinnova_Ventures>,
        <https://1145.am/db/2339666/Sofinnova_Ventures>,
        <https://1145.am/db/2340542/Sofinnova_Ventures>,
        <https://1145.am/db/2340888/Sofinnova_Ventures>,
        <https://1145.am/db/2340890/Sofinnova_Ventures>,
        <https://1145.am/db/2341869/Sofinnova_Ventures>,
        <https://1145.am/db/2341896/Sofinnova_Ventures>,
        <https://1145.am/db/2341897/Sofinnova_Ventures>,
        <https://1145.am/db/2342998/Sofinnova_Ventures>,
        <https://1145.am/db/2345047/Sofinnova_Ventures>,
        <https://1145.am/db/2345262/Sofinnova_Ventures>,
        <https://1145.am/db/2348857/Sofinnova_Ventures>,
        <https://1145.am/db/2349013/Sofinnova_Ventures>,
        <https://1145.am/db/2349096/Sofinnova_Ventures>,
        <https://1145.am/db/2349834/Sofinnova_Ventures>,
        <https://1145.am/db/2350231/Sofinnova_Ventures>,
        <https://1145.am/db/2350855/Sofinnova_Ventures>,
        <https://1145.am/db/2352059/Sofinnova_Ventures>,
        <https://1145.am/db/2353771/Sofinnova_Ventures>,
        <https://1145.am/db/2353789/Sofinnova_Ventures>,
        <https://1145.am/db/2355183/Sofinnova_Ventures>,
        <https://1145.am/db/2357105/Sofinnova_Ventures>,
        <https://1145.am/db/2357356/Sofinnova_Ventures>,
        <https://1145.am/db/2358050/Sofinnova_Ventures>,
        <https://1145.am/db/2358234/Sofinnova_Ventures>,
        <https://1145.am/db/2358725/Sofinnova_Ventures>,
        <https://1145.am/db/2359124/Sofinnova_Ventures>,
        <https://1145.am/db/2360266/Sofinnova_Ventures>,
        <https://1145.am/db/2360647/Sofinnova_Ventures>,
        <https://1145.am/db/2362902/Sofinnova_Ventures>,
        <https://1145.am/db/2362909/Sofinnova_Ventures>,
        <https://1145.am/db/2362910/Sofinnova_Ventures>,
        <https://1145.am/db/2366710/Sofinnova_Ventures>,
        <https://1145.am/db/2366712/Sofinnova_Ventures>,
        <https://1145.am/db/2367022/Sofinnova_Ventures>,
        <https://1145.am/db/2367023/Sofinnova_Ventures>,
        <https://1145.am/db/2368982/Sofinnova_Ventures>,
        <https://1145.am/db/2371160/Sofinnova_Ventures>,
        <https://1145.am/db/2371163/Sofinnova_Ventures>,
        <https://1145.am/db/2569522/Sofinnova_Ventures>,
        <https://1145.am/db/2570520/Sofinnova_Ventures>,
        <https://1145.am/db/2570523/Sofinnova_Ventures>,
        <https://1145.am/db/2577022/Sofinnova_Ventures>,
        <https://1145.am/db/2578627/Sofinnova_Ventures>,
        <https://1145.am/db/2588372/Sofinnova_Ventures>,
        <https://1145.am/db/2592611/Sofinnova_Ventures>,
        <https://1145.am/db/2630808/Sofinnova_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336109/Split_Rock_Partners> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "Split Rock Partners" ;
    ns1:investor <https://1145.am/db/2336109/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "Split Rock Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1828720/Split_Rock_Partners>,
        <https://1145.am/db/1849310/Split_Rock_Partners>,
        <https://1145.am/db/1861540/Split_Rock_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1799028/Split_Rock_Partners>,
        <https://1145.am/db/1825267/Split_Rock_Partners>,
        <https://1145.am/db/1847599/Split_Rock_Partners>,
        <https://1145.am/db/1852471/Split_Rock_Partners>,
        <https://1145.am/db/1882621/Split_Rock_Partners>,
        <https://1145.am/db/1919287/Split_Rock_Partners>,
        <https://1145.am/db/2240880/Split_Rock_Partners>,
        <https://1145.am/db/2289616/Split_Rock_Partners>,
        <https://1145.am/db/2293312/Split_Rock_Partners>,
        <https://1145.am/db/2296640/Split_Rock_Partners>,
        <https://1145.am/db/2326571/Split_Rock_Partners>,
        <https://1145.am/db/2329524/Split_Rock_Partners>,
        <https://1145.am/db/2329531/Split_Rock_Partners>,
        <https://1145.am/db/2336102/Split_Rock_Partners>,
        <https://1145.am/db/889770/Split_Rock_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336125/Coda_Therapeutics> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2012-07-24T21:20:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CoDa Therapeutics Completes $40 Million Series B Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/coda-therapeutics-completes-40-million-series-b-equity-financing> ;
    ns1:foundName "CoDa Therapeutics",
        "CoDa Therapeutics, Inc." ;
    ns1:name "CoDa Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2366710/Vicept_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2303793/Coda_Therapeutics>,
        <https://1145.am/db/2338488/Coda_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337971/Fidelity_Biosciences> a org:Organization ;
    ns1:basedInHighGeoName "Cambridgeshire" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2653940/about.rdf> ;
    ns1:basedInHighRaw "CAMBRIDGE" ;
    ns1:description "Investing" ;
    ns1:documentDate "2012-07-31T14:27:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates> ;
    ns1:foundName "Fidelity Biosciences" ;
    ns1:investor <https://1145.am/db/2337971/Series_A_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_New_Enterprise_Associates_Pfizer_Venture_Investments_Proquest_Investments_Rho_Ventures_Completed> ;
    ns1:name "Fidelity Biosciences" ;
    ns1:sameAsHigh <https://1145.am/db/2223723/Fidelity_Biosciences>,
        <https://1145.am/db/2303275/Fidelity_Biosciences>,
        <https://1145.am/db/2352350/Fidelity_Biosciences> ;
    ns1:sameAsMedium <https://1145.am/db/1801792/Fidelity_Biosciences>,
        <https://1145.am/db/1849746/Fidelity_Biosciences>,
        <https://1145.am/db/2304028/Fidelity_Biosciences>,
        <https://1145.am/db/2304044/Fidelity_Biosciences>,
        <https://1145.am/db/2306790/Fidelity_Biosciences>,
        <https://1145.am/db/2313305/Fidelity_Biosciences>,
        <https://1145.am/db/2316601/Fidelity_Biosciences>,
        <https://1145.am/db/2316605/Fidelity_Biosciences>,
        <https://1145.am/db/2317737/Fidelity_Biosciences>,
        <https://1145.am/db/2318905/Fidelity_Biosciences>,
        <https://1145.am/db/2325553/Fidelity_Biosciences>,
        <https://1145.am/db/2326576/Fidelity_Biosciences>,
        <https://1145.am/db/2336890/Fidelity_Biosciences>,
        <https://1145.am/db/2337972/Fidelity_Biosciences>,
        <https://1145.am/db/2339666/Fidelity_Biosciences>,
        <https://1145.am/db/2340581/Fidelity_Biosciences>,
        <https://1145.am/db/2341869/Fidelity_Biosciences>,
        <https://1145.am/db/2341897/Fidelity_Biosciences>,
        <https://1145.am/db/2342754/Fidelity_Biosciences>,
        <https://1145.am/db/2342768/Fidelity_Biosciences>,
        <https://1145.am/db/2342771/Fidelity_Biosciences>,
        <https://1145.am/db/2344017/Fidelity_Biosciences>,
        <https://1145.am/db/2348149/Fidelity_Biosciences>,
        <https://1145.am/db/2349048/Fidelity_Biosciences>,
        <https://1145.am/db/2349050/Fidelity_Biosciences>,
        <https://1145.am/db/2350891/Fidelity_Biosciences>,
        <https://1145.am/db/2352349/Fidelity_Biosciences>,
        <https://1145.am/db/2354537/Fidelity_Biosciences>,
        <https://1145.am/db/2356048/Fidelity_Biosciences>,
        <https://1145.am/db/2356124/Fidelity_Biosciences>,
        <https://1145.am/db/2357722/Fidelity_Biosciences>,
        <https://1145.am/db/2359227/Fidelity_Biosciences>,
        <https://1145.am/db/2359240/Fidelity_Biosciences>,
        <https://1145.am/db/2359287/Fidelity_Biosciences>,
        <https://1145.am/db/2359562/Fidelity_Biosciences>,
        <https://1145.am/db/2359683/Fidelity_Biosciences>,
        <https://1145.am/db/2361065/Fidelity_Biosciences>,
        <https://1145.am/db/2363510/Fidelity_Biosciences>,
        <https://1145.am/db/2366710/Fidelity_Biosciences>,
        <https://1145.am/db/2366712/Fidelity_Biosciences>,
        <https://1145.am/db/2367022/Fidelity_Biosciences>,
        <https://1145.am/db/2367023/Fidelity_Biosciences>,
        <https://1145.am/db/2367381/Fidelity_Biosciences>,
        <https://1145.am/db/2369644/Fidelity_Biosciences>,
        <https://1145.am/db/2549505/Fidelity_Biosciences>,
        <https://1145.am/db/2549507/Fidelity_Biosciences>,
        <https://1145.am/db/2551315/Fidelity_Biosciences>,
        <https://1145.am/db/2569831/Fidelity_Biosciences>,
        <https://1145.am/db/2587938/Fidelity_Biosciences>,
        <https://1145.am/db/2588372/Fidelity_Biosciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337971/Harris_And_Harris_Group> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:description "Investing" ;
    ns1:documentDate "2012-07-31T14:27:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates> ;
    ns1:foundName "Harris and Harris Group" ;
    ns1:investor <https://1145.am/db/2337971/Series_A_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_New_Enterprise_Associates_Pfizer_Venture_Investments_Proquest_Investments_Rho_Ventures_Completed> ;
    ns1:name "Harris and Harris Group" ;
    ns1:sameAsMedium <https://1145.am/db/2309865/Harris___Harris_Group>,
        <https://1145.am/db/2309872/Harris___Harris_Group>,
        <https://1145.am/db/2322312/Harris_And_Harris_Group>,
        <https://1145.am/db/2324756/Harris_And_Harris_Group>,
        <https://1145.am/db/2325681/Harris___Harris_Group>,
        <https://1145.am/db/2337972/Harris_And_Harris_Group>,
        <https://1145.am/db/2343184/Harris___Harris_Group>,
        <https://1145.am/db/2343185/Harris___Harris_Group>,
        <https://1145.am/db/2344356/Harris___Harris_Group>,
        <https://1145.am/db/2369000/Harris___Harris_Group>,
        <https://1145.am/db/2449833/Harris___Harris_Group>,
        <https://1145.am/db/2545510/Harris___Harris_Group>,
        <https://1145.am/db/2587938/Harris_And_Harris_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337971/Proquest_Investments> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:description "biopharmaceutical company" ;
    ns1:documentDate "2012-07-31T14:27:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates> ;
    ns1:foundName "ProQuest Investments" ;
    ns1:investor <https://1145.am/db/2337971/Series_A_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_New_Enterprise_Associates_Pfizer_Venture_Investments_Proquest_Investments_Rho_Ventures_Completed> ;
    ns1:name "ProQuest Investments" ;
    ns1:sameAsMedium <https://1145.am/db/2242614/Proquest_Investments>,
        <https://1145.am/db/2296169/Proquest_Investments>,
        <https://1145.am/db/2300340/Proquest_Investments>,
        <https://1145.am/db/2301790/Proquest_Investments>,
        <https://1145.am/db/2307644/Proquest_Investments>,
        <https://1145.am/db/2309506/Proquest_Investments>,
        <https://1145.am/db/2309507/Proquest_Investments>,
        <https://1145.am/db/2311011/Proquest_Investments>,
        <https://1145.am/db/2318851/Proquest_Investments>,
        <https://1145.am/db/2319029/Proquest_Investments>,
        <https://1145.am/db/2326362/Proquest_Investments>,
        <https://1145.am/db/2331048/Proquest_Investments>,
        <https://1145.am/db/2337972/Proquest_Investments>,
        <https://1145.am/db/2343547/Proquest_Investments>,
        <https://1145.am/db/2355706/Proquest_Investments>,
        <https://1145.am/db/2356721/Proquest_Investments>,
        <https://1145.am/db/2362565/Proquest_Investments>,
        <https://1145.am/db/2362566/Proquest_Investments>,
        <https://1145.am/db/2363475/Proquest_Investments>,
        <https://1145.am/db/2364422/Proquest_Investments>,
        <https://1145.am/db/2538407/Proquest_Investments>,
        <https://1145.am/db/2587938/Proquest_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337971/Rho_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:description "Investing" ;
    ns1:documentDate "2012-07-31T14:27:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates> ;
    ns1:foundName "Rho Ventures" ;
    ns1:investor <https://1145.am/db/2337971/Series_A_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_New_Enterprise_Associates_Pfizer_Venture_Investments_Proquest_Investments_Rho_Ventures_Completed> ;
    ns1:name "Rho Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1007995/Capital_One_Ventures>,
        <https://1145.am/db/1010371/Capital_One_Ventures>,
        <https://1145.am/db/1061906/Agya_Ventures>,
        <https://1145.am/db/1068382/Oquirrh_Ventures>,
        <https://1145.am/db/1079459/137_Ventures>,
        <https://1145.am/db/1087308/Nexo_Ventures>,
        <https://1145.am/db/1091523/Nexo_Ventures>,
        <https://1145.am/db/1111458/Spring_Ventures>,
        <https://1145.am/db/1111951/Spring_Ventures>,
        <https://1145.am/db/1119661/Menlo_Ventures>,
        <https://1145.am/db/1122753/Menlo_Ventures>,
        <https://1145.am/db/1124122/Delphi_Ventures>,
        <https://1145.am/db/1130744/Coingecko_Ventures>,
        <https://1145.am/db/1138738/Ap_Ventures>,
        <https://1145.am/db/1138829/Sozo_Ventures>,
        <https://1145.am/db/1140806/Ap_Ventures>,
        <https://1145.am/db/1141082/Sozo_Ventures>,
        <https://1145.am/db/1150154/Finistere_Ventures>,
        <https://1145.am/db/1156304/Astellas_Venture_Management>,
        <https://1145.am/db/1195265/Alpha_Ascent_Ventures>,
        <https://1145.am/db/1197990/Proje_Ventures_Inc>,
        <https://1145.am/db/1202633/Alix_Ventures>,
        <https://1145.am/db/1202633/Fpv_Ventures>,
        <https://1145.am/db/1202770/Seae_Ventures>,
        <https://1145.am/db/1203099/Alix_Ventures>,
        <https://1145.am/db/1203099/Fpv_Ventures>,
        <https://1145.am/db/1203467/Seae_Ventures>,
        <https://1145.am/db/1204350/Allegion_Ventures>,
        <https://1145.am/db/1205708/Allegion_Ventures>,
        <https://1145.am/db/1208612/Ia_Ventures>,
        <https://1145.am/db/1247764/Allos_Ventures>,
        <https://1145.am/db/1248635/Allos_Ventures>,
        <https://1145.am/db/1249241/Ulu_Ventures>,
        <https://1145.am/db/1290854/Mistry_Ventures>,
        <https://1145.am/db/1291767/Mistry_Ventures>,
        <https://1145.am/db/1297175/Nextview_Ventures>,
        <https://1145.am/db/1297529/Nextview_Ventures>,
        <https://1145.am/db/1318775/Waycross_Ventures>,
        <https://1145.am/db/1319026/Waycross_Ventures>,
        <https://1145.am/db/1334395/Eir_Ventures>,
        <https://1145.am/db/1334395/Gu_Ventures>,
        <https://1145.am/db/1366307/Hscm_Ventures>,
        <https://1145.am/db/1366825/Hscm_Ventures>,
        <https://1145.am/db/1375182/Sevenx_Ventures>,
        <https://1145.am/db/1406211/Exor_Ventures>,
        <https://1145.am/db/1433134/Haymaker_Ventures>,
        <https://1145.am/db/1451918/Engage_Ventures>,
        <https://1145.am/db/1453960/At_One_Ventures>,
        <https://1145.am/db/1470525/Nextview_Ventures>,
        <https://1145.am/db/1490295/M13_Ventures>,
        <https://1145.am/db/1503198/Illuminate_Ventures>,
        <https://1145.am/db/1503204/Illuminate_Ventures>,
        <https://1145.am/db/1503205/Illuminate_Ventures>,
        <https://1145.am/db/1504977/Sogal_Ventures>,
        <https://1145.am/db/1504983/Element_Ventures>,
        <https://1145.am/db/1523935/Chui_Ventures>,
        <https://1145.am/db/1558423/Grand_Ventures>,
        <https://1145.am/db/1615580/Alpha_Wave_Ventures>,
        <https://1145.am/db/1659940/Credo_Ventures>,
        <https://1145.am/db/1697098/Trinity_Ventures>,
        <https://1145.am/db/1698200/Liquid2_Ventures>,
        <https://1145.am/db/1704356/Dcm_Ventures>,
        <https://1145.am/db/1708599/Promus_Ventures>,
        <https://1145.am/db/1708892/Gatecap_Ventures>,
        <https://1145.am/db/1717613/Trinity_Ventures>,
        <https://1145.am/db/1737539/C4_Ventures>,
        <https://1145.am/db/1738305/East_Ventures>,
        <https://1145.am/db/1740448/212_Ventures>,
        <https://1145.am/db/1743085/Eventures>,
        <https://1145.am/db/1744228/M12_Ventures>,
        <https://1145.am/db/1744629/Oneway_Ventures>,
        <https://1145.am/db/1746172/Prosus_Ventures>,
        <https://1145.am/db/1746463/Allegion_Ventures>,
        <https://1145.am/db/1746463/Pathbreaker_Ventures>,
        <https://1145.am/db/1746463/West_Ventures>,
        <https://1145.am/db/1747510/Frontline_Ventures>,
        <https://1145.am/db/1747745/East_Ventures>,
        <https://1145.am/db/1747847/East_Ventures>,
        <https://1145.am/db/1748318/Mehta_Ventures>,
        <https://1145.am/db/1748858/Prosus_Ventures>,
        <https://1145.am/db/1753648/Yl_Ventures>,
        <https://1145.am/db/1756445/Menlo_Ventures>,
        <https://1145.am/db/1757432/Evolv_Ventures>,
        <https://1145.am/db/1757706/Menlo_Ventures>,
        <https://1145.am/db/1758679/Hv_Ventures>,
        <https://1145.am/db/1758927/At_One_Ventures>,
        <https://1145.am/db/1758927/Inmotion_Ventures>,
        <https://1145.am/db/1759769/7pc_Ventures>,
        <https://1145.am/db/1760406/Alpha_Bridge_Ventures>,
        <https://1145.am/db/1761089/Prosus_Ventures>,
        <https://1145.am/db/1761247/Connect_Ventures>,
        <https://1145.am/db/1761347/Ia_Ventures>,
        <https://1145.am/db/1762125/Gron_Ventures>,
        <https://1145.am/db/1762896/Amity_Ventures>,
        <https://1145.am/db/1763652/C4_Ventures>,
        <https://1145.am/db/1764066/Avid_Ventures>,
        <https://1145.am/db/1765903/Cathexis_Ventures>,
        <https://1145.am/db/1766725/Eqt_Ventures>,
        <https://1145.am/db/1767814/Dcm_Ventures>,
        <https://1145.am/db/1768556/Valar_Ventures>,
        <https://1145.am/db/1769467/Trinity_Ventures>,
        <https://1145.am/db/1775794/Helion_Ventures>,
        <https://1145.am/db/1775950/United_Ventures>,
        <https://1145.am/db/1776620/Sogal_Ventures>,
        <https://1145.am/db/1777489/Check24_Ventures>,
        <https://1145.am/db/1777903/Menlo_Ventures>,
        <https://1145.am/db/1779277/Ia_Ventures>,
        <https://1145.am/db/1780319/Dcm_Ventures>,
        <https://1145.am/db/1780319/Morningside_Ventures>,
        <https://1145.am/db/1789460/Capnamic_Ventures>,
        <https://1145.am/db/1789594/Partech_Ventures>,
        <https://1145.am/db/1790116/Dcm_Ventures>,
        <https://1145.am/db/1791642/Ia_Ventures>,
        <https://1145.am/db/1793575/Trinity_Ventures>,
        <https://1145.am/db/1794794/Placid_Ventures>,
        <https://1145.am/db/1794996/Idg_Ventures>,
        <https://1145.am/db/1808409/Trinity_Ventures>,
        <https://1145.am/db/1810437/Menlo_Ventures>,
        <https://1145.am/db/1813873/Valar_Ventures>,
        <https://1145.am/db/1815038/Ine_Ventures>,
        <https://1145.am/db/1820911/Horizon_Ventures>,
        <https://1145.am/db/1823954/Ia_Ventures>,
        <https://1145.am/db/1827409/Plus_Ventures>,
        <https://1145.am/db/1836989/Morgenthaler_Ventures>,
        <https://1145.am/db/1839836/Morgenthaler_Ventures>,
        <https://1145.am/db/1840889/Connect_Ventures>,
        <https://1145.am/db/1844180/Sherpa_Ventures>,
        <https://1145.am/db/1846679/Connect_Ventures>,
        <https://1145.am/db/1847463/Trinity_Ventures>,
        <https://1145.am/db/1850876/Partech_Ventures>,
        <https://1145.am/db/1853156/Idg_Ventures>,
        <https://1145.am/db/1855137/Lool_Ventures>,
        <https://1145.am/db/1858481/Xg_Ventures>,
        <https://1145.am/db/1866409/Menlo_Ventures>,
        <https://1145.am/db/1879023/Revolution_Ventures>,
        <https://1145.am/db/1879069/Ascend_Ventures>,
        <https://1145.am/db/1886260/Trinity_Ventures>,
        <https://1145.am/db/1886771/Onset_Ventures>,
        <https://1145.am/db/1890208/Star_Ventures>,
        <https://1145.am/db/1893502/Nextview_Ventures>,
        <https://1145.am/db/1894610/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1896364/Nextview_Ventures>,
        <https://1145.am/db/1898837/Trinity_Ventures>,
        <https://1145.am/db/1935365/Ac_Venture>,
        <https://1145.am/db/1942254/Audeo_Ventures>,
        <https://1145.am/db/196586/H_L_Ventures>,
        <https://1145.am/db/2003542/Valo_Ventures>,
        <https://1145.am/db/2017126/Stellar_Ventures>,
        <https://1145.am/db/2017188/Techpro_Ventures>,
        <https://1145.am/db/2023596/Ret_Ventures>,
        <https://1145.am/db/2052534/Level_Ventures>,
        <https://1145.am/db/2075625/Horizon_Ventures>,
        <https://1145.am/db/2133628/Prelude_Ventures>,
        <https://1145.am/db/2150240/Utiliti_Ventures>,
        <https://1145.am/db/2153423/Borealis_Ventures>,
        <https://1145.am/db/2196875/Maverick_Ventures>,
        <https://1145.am/db/2304637/Ampersand_Ventures>,
        <https://1145.am/db/2307644/Morgenthaler_Ventures>,
        <https://1145.am/db/2309005/Epic_Ventures>,
        <https://1145.am/db/2311075/Morgenthaler_Ventures>,
        <https://1145.am/db/2311595/Clarus_Ventures>,
        <https://1145.am/db/2315279/123_Ventures>,
        <https://1145.am/db/2317455/Rk_Venture_Group>,
        <https://1145.am/db/2320476/Astellas_Venture_Management>,
        <https://1145.am/db/2323586/Morgenthaler_Ventures>,
        <https://1145.am/db/2330876/Aberdare_Ventures>,
        <https://1145.am/db/2339732/Morningside_Ventures>,
        <https://1145.am/db/2342937/Morgenthaler_Ventures>,
        <https://1145.am/db/2346532/Sanderling_Ventures>,
        <https://1145.am/db/2358640/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358658/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2369785/Enso_Ventures>,
        <https://1145.am/db/2369872/Arcus_Ventures>,
        <https://1145.am/db/2370582/Astellas_Venture_Management>,
        <https://1145.am/db/2423622/Tdk_Ventures_Inc>,
        <https://1145.am/db/2587938/Rho_Ventures>,
        <https://1145.am/db/2604027/Nxt_Ventures>,
        <https://1145.am/db/2611628/Yl_Ventures>,
        <https://1145.am/db/2700208/Highsage_Ventures>,
        <https://1145.am/db/2717146/Allos_Ventures>,
        <https://1145.am/db/2799006/Stellantis_Ventures>,
        <https://1145.am/db/309011/Oca_Ventures>,
        <https://1145.am/db/309011/Seae_Ventures>,
        <https://1145.am/db/350275/Artis_Ventures>,
        <https://1145.am/db/364168/Grotech_Ventures>,
        <https://1145.am/db/429084/Capital_One_Ventures>,
        <https://1145.am/db/438400/Nextview_Ventures>,
        <https://1145.am/db/471253/Arch_Ventures>,
        <https://1145.am/db/490458/Molex_Ventures_Llc>,
        <https://1145.am/db/491313/Oca_Ventures>,
        <https://1145.am/db/509930/Arka_Ventures>,
        <https://1145.am/db/539571/Oca_Ventures>,
        <https://1145.am/db/587045/Creacion_Ventures>,
        <https://1145.am/db/591613/Creacion_Ventures>,
        <https://1145.am/db/594487/Highsage_Ventures>,
        <https://1145.am/db/601951/Ia_Ventures>,
        <https://1145.am/db/623441/Ascension_Ventures>,
        <https://1145.am/db/626473/Se_Ventures>,
        <https://1145.am/db/643962/Pathfinder_Ventures_Inc>,
        <https://1145.am/db/662514/Tdk_Ventures_Inc>,
        <https://1145.am/db/668624/Trinity_Ventures>,
        <https://1145.am/db/693216/Springtide_Ventures>,
        <https://1145.am/db/696617/Gsv_Ventures>,
        <https://1145.am/db/701859/Tdk_Ventures>,
        <https://1145.am/db/708697/Iu_Ventures>,
        <https://1145.am/db/731691/Co-Win_Ventures>,
        <https://1145.am/db/734916/Valar_Ventures>,
        <https://1145.am/db/75445/Droia_Ventures>,
        <https://1145.am/db/768089/Alix_Ventures>,
        <https://1145.am/db/769568/Artis_Ventures>,
        <https://1145.am/db/770705/Morningside_Ventures>,
        <https://1145.am/db/792608/Nextcoast_Ventures>,
        <https://1145.am/db/815550/Prosus_Ventures>,
        <https://1145.am/db/854084/Tegna_Ventures>,
        <https://1145.am/db/867116/Forever_Ventures>,
        <https://1145.am/db/867116/Lavrock_Ventures>,
        <https://1145.am/db/868933/Prosus_Ventures>,
        <https://1145.am/db/869652/Lavrock_Ventures>,
        <https://1145.am/db/882636/Prosus_Ventures>,
        <https://1145.am/db/886445/Eqt_Ventures>,
        <https://1145.am/db/886722/At_One_Ventures>,
        <https://1145.am/db/893076/Teamworthy_Ventures>,
        <https://1145.am/db/893076/Trium_Venture_Partners>,
        <https://1145.am/db/893316/Teamworthy_Ventures>,
        <https://1145.am/db/893316/Trium_Venture_Partners>,
        <https://1145.am/db/893416/Joseph_Ventures>,
        <https://1145.am/db/894336/Joseph_Ventures>,
        <https://1145.am/db/896550/Prelude_Ventures>,
        <https://1145.am/db/897410/Prelude_Ventures>,
        <https://1145.am/db/903689/Co-Win_Ventures>,
        <https://1145.am/db/903761/Tengro_Ventures>,
        <https://1145.am/db/911551/Astanor_Ventures>,
        <https://1145.am/db/935242/Cobalt_Ventures>,
        <https://1145.am/db/935686/Lool_Ventures>,
        <https://1145.am/db/941871/Eshelman_Ventures>,
        <https://1145.am/db/944358/Cortado_Ventures>,
        <https://1145.am/db/951514/Axilor_Ventures>,
        <https://1145.am/db/952832/Axilor_Ventures>,
        <https://1145.am/db/962870/Sozo_Ventures_Crv>,
        <https://1145.am/db/973424/Kawn_Ventures>,
        <https://1145.am/db/993478/Highgate_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1706416/Rho_Ventures>,
        <https://1145.am/db/1710930/Rho_Ventures>,
        <https://1145.am/db/1712520/Rho_Ventures>,
        <https://1145.am/db/1731187/Rho_Ventures>,
        <https://1145.am/db/1786612/Rho_Ventures>,
        <https://1145.am/db/1826683/Rho_Ventures>,
        <https://1145.am/db/1834943/Rho_Ventures>,
        <https://1145.am/db/1855403/Rho_Ventures>,
        <https://1145.am/db/1860832/Rho_Ventures>,
        <https://1145.am/db/1861355/Rho_Ventures>,
        <https://1145.am/db/1866478/Rho_Ventures>,
        <https://1145.am/db/1872936/Rho_Ventures>,
        <https://1145.am/db/1886354/Rho_Ventures>,
        <https://1145.am/db/1886445/Rho_Ventures>,
        <https://1145.am/db/1890208/Rho_Ventures>,
        <https://1145.am/db/1891490/Rho_Ventures>,
        <https://1145.am/db/2159775/Rho_Ventures>,
        <https://1145.am/db/2234358/Rho_Ventures>,
        <https://1145.am/db/2300708/Rho_Ventures>,
        <https://1145.am/db/2302351/Rho_Ventures>,
        <https://1145.am/db/2309506/Rho_Ventures>,
        <https://1145.am/db/2309507/Rho_Ventures>,
        <https://1145.am/db/2323578/Rho_Ventures>,
        <https://1145.am/db/2337972/Rho_Ventures>,
        <https://1145.am/db/2339883/Rho_Ventures>,
        <https://1145.am/db/2342485/Rho_Ventures>,
        <https://1145.am/db/2342488/Rho_Ventures>,
        <https://1145.am/db/2342498/Rho_Ventures>,
        <https://1145.am/db/2362902/Rho_Ventures>,
        <https://1145.am/db/2362909/Rho_Ventures>,
        <https://1145.am/db/2362910/Rho_Ventures>,
        <https://1145.am/db/2363459/Rho_Ventures>,
        <https://1145.am/db/2363460/Rho_Ventures>,
        <https://1145.am/db/2364505/Rho_Ventures>,
        <https://1145.am/db/2364508/Rho_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337972/Fidelity_Biosciences> a org:Organization ;
    ns1:documentDate "2012-07-31T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana grabs $27M from Pfizer, NEA and others for muscled cancer drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/mersana-grabs-27m-from-pfizer-nea-and-others-for-muscled-cancer-drugs> ;
    ns1:foundName "Fidelity Biosciences" ;
    ns1:investor <https://1145.am/db/2337972/Series_A-1_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_Nea_Proquest_Investments_Rho_Ventures_Venture_Investments_Completed> ;
    ns1:name "Fidelity Biosciences" ;
    ns1:sameAsMedium <https://1145.am/db/1801792/Fidelity_Biosciences>,
        <https://1145.am/db/1849746/Fidelity_Biosciences>,
        <https://1145.am/db/2223723/Fidelity_Biosciences>,
        <https://1145.am/db/2303275/Fidelity_Biosciences>,
        <https://1145.am/db/2304028/Fidelity_Biosciences>,
        <https://1145.am/db/2304044/Fidelity_Biosciences>,
        <https://1145.am/db/2306790/Fidelity_Biosciences>,
        <https://1145.am/db/2313305/Fidelity_Biosciences>,
        <https://1145.am/db/2316601/Fidelity_Biosciences>,
        <https://1145.am/db/2316605/Fidelity_Biosciences>,
        <https://1145.am/db/2317737/Fidelity_Biosciences>,
        <https://1145.am/db/2318905/Fidelity_Biosciences>,
        <https://1145.am/db/2325553/Fidelity_Biosciences>,
        <https://1145.am/db/2326576/Fidelity_Biosciences>,
        <https://1145.am/db/2336890/Fidelity_Biosciences>,
        <https://1145.am/db/2337971/Fidelity_Biosciences>,
        <https://1145.am/db/2339666/Fidelity_Biosciences>,
        <https://1145.am/db/2340581/Fidelity_Biosciences>,
        <https://1145.am/db/2341869/Fidelity_Biosciences>,
        <https://1145.am/db/2341897/Fidelity_Biosciences>,
        <https://1145.am/db/2342754/Fidelity_Biosciences>,
        <https://1145.am/db/2342768/Fidelity_Biosciences>,
        <https://1145.am/db/2342771/Fidelity_Biosciences>,
        <https://1145.am/db/2344017/Fidelity_Biosciences>,
        <https://1145.am/db/2348149/Fidelity_Biosciences>,
        <https://1145.am/db/2349048/Fidelity_Biosciences>,
        <https://1145.am/db/2349050/Fidelity_Biosciences>,
        <https://1145.am/db/2350891/Fidelity_Biosciences>,
        <https://1145.am/db/2352349/Fidelity_Biosciences>,
        <https://1145.am/db/2352350/Fidelity_Biosciences>,
        <https://1145.am/db/2354537/Fidelity_Biosciences>,
        <https://1145.am/db/2356048/Fidelity_Biosciences>,
        <https://1145.am/db/2356124/Fidelity_Biosciences>,
        <https://1145.am/db/2357722/Fidelity_Biosciences>,
        <https://1145.am/db/2359227/Fidelity_Biosciences>,
        <https://1145.am/db/2359240/Fidelity_Biosciences>,
        <https://1145.am/db/2359287/Fidelity_Biosciences>,
        <https://1145.am/db/2359562/Fidelity_Biosciences>,
        <https://1145.am/db/2359683/Fidelity_Biosciences>,
        <https://1145.am/db/2361065/Fidelity_Biosciences>,
        <https://1145.am/db/2363510/Fidelity_Biosciences>,
        <https://1145.am/db/2366710/Fidelity_Biosciences>,
        <https://1145.am/db/2366712/Fidelity_Biosciences>,
        <https://1145.am/db/2367022/Fidelity_Biosciences>,
        <https://1145.am/db/2367023/Fidelity_Biosciences>,
        <https://1145.am/db/2367381/Fidelity_Biosciences>,
        <https://1145.am/db/2369644/Fidelity_Biosciences>,
        <https://1145.am/db/2549505/Fidelity_Biosciences>,
        <https://1145.am/db/2549507/Fidelity_Biosciences>,
        <https://1145.am/db/2551315/Fidelity_Biosciences>,
        <https://1145.am/db/2569831/Fidelity_Biosciences>,
        <https://1145.am/db/2587938/Fidelity_Biosciences>,
        <https://1145.am/db/2588372/Fidelity_Biosciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337972/Harris_And_Harris_Group> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-31T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana grabs $27M from Pfizer, NEA and others for muscled cancer drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/mersana-grabs-27m-from-pfizer-nea-and-others-for-muscled-cancer-drugs> ;
    ns1:foundName "Harris and Harris Group" ;
    ns1:investor <https://1145.am/db/2337972/Series_A-1_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_Nea_Proquest_Investments_Rho_Ventures_Venture_Investments_Completed> ;
    ns1:name "Harris and Harris Group" ;
    ns1:sameAsHigh <https://1145.am/db/2309865/Harris___Harris_Group> ;
    ns1:sameAsMedium <https://1145.am/db/2309872/Harris___Harris_Group>,
        <https://1145.am/db/2322312/Harris_And_Harris_Group>,
        <https://1145.am/db/2324756/Harris_And_Harris_Group>,
        <https://1145.am/db/2325681/Harris___Harris_Group>,
        <https://1145.am/db/2337971/Harris_And_Harris_Group>,
        <https://1145.am/db/2343184/Harris___Harris_Group>,
        <https://1145.am/db/2343185/Harris___Harris_Group>,
        <https://1145.am/db/2344356/Harris___Harris_Group>,
        <https://1145.am/db/2369000/Harris___Harris_Group>,
        <https://1145.am/db/2449833/Harris___Harris_Group>,
        <https://1145.am/db/2545510/Harris___Harris_Group>,
        <https://1145.am/db/2587938/Harris_And_Harris_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337972/Proquest_Investments> a org:Organization ;
    ns1:documentDate "2012-07-31T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana grabs $27M from Pfizer, NEA and others for muscled cancer drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/mersana-grabs-27m-from-pfizer-nea-and-others-for-muscled-cancer-drugs> ;
    ns1:foundName "ProQuest Investments" ;
    ns1:investor <https://1145.am/db/2337972/Series_A-1_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_Nea_Proquest_Investments_Rho_Ventures_Venture_Investments_Completed> ;
    ns1:name "ProQuest Investments" ;
    ns1:sameAsMedium <https://1145.am/db/2242614/Proquest_Investments>,
        <https://1145.am/db/2296169/Proquest_Investments>,
        <https://1145.am/db/2300340/Proquest_Investments>,
        <https://1145.am/db/2301790/Proquest_Investments>,
        <https://1145.am/db/2307644/Proquest_Investments>,
        <https://1145.am/db/2309506/Proquest_Investments>,
        <https://1145.am/db/2309507/Proquest_Investments>,
        <https://1145.am/db/2311011/Proquest_Investments>,
        <https://1145.am/db/2318851/Proquest_Investments>,
        <https://1145.am/db/2319029/Proquest_Investments>,
        <https://1145.am/db/2326362/Proquest_Investments>,
        <https://1145.am/db/2331048/Proquest_Investments>,
        <https://1145.am/db/2337971/Proquest_Investments>,
        <https://1145.am/db/2343547/Proquest_Investments>,
        <https://1145.am/db/2355706/Proquest_Investments>,
        <https://1145.am/db/2356721/Proquest_Investments>,
        <https://1145.am/db/2362565/Proquest_Investments>,
        <https://1145.am/db/2362566/Proquest_Investments>,
        <https://1145.am/db/2363475/Proquest_Investments>,
        <https://1145.am/db/2364422/Proquest_Investments>,
        <https://1145.am/db/2538407/Proquest_Investments>,
        <https://1145.am/db/2587938/Proquest_Investments> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337972/Rho_Ventures> a org:Organization ;
    ns1:documentDate "2012-07-31T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana grabs $27M from Pfizer, NEA and others for muscled cancer drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/mersana-grabs-27m-from-pfizer-nea-and-others-for-muscled-cancer-drugs> ;
    ns1:foundName "Rho Ventures" ;
    ns1:investor <https://1145.am/db/2337972/Series_A-1_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_Nea_Proquest_Investments_Rho_Ventures_Venture_Investments_Completed> ;
    ns1:name "Rho Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1706416/Rho_Ventures>,
        <https://1145.am/db/1710930/Rho_Ventures>,
        <https://1145.am/db/1712520/Rho_Ventures>,
        <https://1145.am/db/1731187/Rho_Ventures>,
        <https://1145.am/db/1786612/Rho_Ventures>,
        <https://1145.am/db/1826683/Rho_Ventures>,
        <https://1145.am/db/1834943/Rho_Ventures>,
        <https://1145.am/db/1855403/Rho_Ventures>,
        <https://1145.am/db/1860832/Rho_Ventures>,
        <https://1145.am/db/1861355/Rho_Ventures>,
        <https://1145.am/db/1866478/Rho_Ventures>,
        <https://1145.am/db/1872936/Rho_Ventures>,
        <https://1145.am/db/1886354/Rho_Ventures>,
        <https://1145.am/db/1886445/Rho_Ventures>,
        <https://1145.am/db/1890208/Rho_Ventures>,
        <https://1145.am/db/1891490/Rho_Ventures>,
        <https://1145.am/db/2159775/Rho_Ventures>,
        <https://1145.am/db/2234358/Rho_Ventures>,
        <https://1145.am/db/2300708/Rho_Ventures>,
        <https://1145.am/db/2302351/Rho_Ventures>,
        <https://1145.am/db/2309506/Rho_Ventures>,
        <https://1145.am/db/2309507/Rho_Ventures>,
        <https://1145.am/db/2323578/Rho_Ventures>,
        <https://1145.am/db/2337971/Rho_Ventures>,
        <https://1145.am/db/2339883/Rho_Ventures>,
        <https://1145.am/db/2342485/Rho_Ventures>,
        <https://1145.am/db/2342488/Rho_Ventures>,
        <https://1145.am/db/2342498/Rho_Ventures>,
        <https://1145.am/db/2362902/Rho_Ventures>,
        <https://1145.am/db/2362909/Rho_Ventures>,
        <https://1145.am/db/2362910/Rho_Ventures>,
        <https://1145.am/db/2363459/Rho_Ventures>,
        <https://1145.am/db/2363460/Rho_Ventures>,
        <https://1145.am/db/2364505/Rho_Ventures>,
        <https://1145.am/db/2364508/Rho_Ventures>,
        <https://1145.am/db/2587938/Rho_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337974/Cytomx_Therapeutics> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2012-07-31T14:27:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CytomX Therapeutics Expands Series B Financing; Canaan Partners Joins Syndicate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-expands-series-b-financing-canaan-partners-joins-syndicate> ;
    ns1:foundName "CytomX Therapeutics",
        "CytomX Therapeutics, Inc." ;
    ns1:industry "biotechnology" ;
    ns1:name "CytomX Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2151786/Cytomx_Therapeutics>,
        <https://1145.am/db/2154105/Cytomx>,
        <https://1145.am/db/2299752/Cytox>,
        <https://1145.am/db/2337958/Cytomx_Therapeutics>,
        <https://1145.am/db/2339513/Cytomx>,
        <https://1145.am/db/2339908/Cytomx_Therapeutics>,
        <https://1145.am/db/2340913/Cytomx>,
        <https://1145.am/db/2343178/Cytomx_Therapeutics>,
        <https://1145.am/db/2347024/Cytomedix_Inc>,
        <https://1145.am/db/2354469/Cytomx_Therapeutics>,
        <https://1145.am/db/2355041/Cytomx>,
        <https://1145.am/db/2355043/Cytomx>,
        <https://1145.am/db/2356089/Cytomx>,
        <https://1145.am/db/2356791/Cytomx>,
        <https://1145.am/db/2357499/Cytomx>,
        <https://1145.am/db/2358191/Cytovance_Biologics>,
        <https://1145.am/db/2361245/Cytogenix>,
        <https://1145.am/db/2361695/Cytomx>,
        <https://1145.am/db/2364249/Cytomx_Therapeutics>,
        <https://1145.am/db/2364255/Cytomx>,
        <https://1145.am/db/2364283/Cytomx_Therapeutics>,
        <https://1145.am/db/2365825/Cytomx>,
        <https://1145.am/db/2366301/Cytomx_Therapeutics>,
        <https://1145.am/db/2366304/Cytomx>,
        <https://1145.am/db/2369631/Cytomx_Therapeutics>,
        <https://1145.am/db/522087/Cytomx_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/812566/Cytomx_Therapeutics>,
        <https://1145.am/db/926316/Cytomx_Therapeutics>,
        <https://1145.am/db/979386/Cytomx_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339535/Business_Acquisition_Stemgent_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-08-01T13:01:24+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Stemgent Completes Acquisition of Asterand's Human Tissue Business.",
        "Stemgent, Inc. announced today that it has completed the acquisition of Asterand Plc's Human Tissue Business for $ 9 million." ;
    ns1:documentTitle "Stemgent Completes Acquisition of Asterand's Human Tissue Business" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemgent-completes-acquisition-asterand-s-human-tissue-business> ;
    ns1:foundName "Acquisition",
        "acquisition" ;
    ns1:name "Acquisition",
        "acquisition" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:targetDetails "Business" ;
    ns1:valueRaw "$ 9 million" ;
    ns1:vendor <https://1145.am/db/2339535/Stemgent> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2342165/4s3_Bioscience> a org:Organization ;
    ns1:description "a biotherapeutics company" ;
    ns1:documentDate "2012-03-05T15:05:51+00:00"^^xsd:dateTime ;
    ns1:documentTitle "4s3 Bioscience, Inc. Secures $20M in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/4s3-bioscience-inc-secures-20m-series-a-financing> ;
    ns1:foundName "4s3 Bioscience, Inc",
        "4s3 Bioscience, Inc." ;
    ns1:industry "Biotherapeutics" ;
    ns1:name "4s3 Bioscience" ;
    ns1:sameAsMedium <https://1145.am/db/2569600/4s3_Bioscience> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342165/Series_A_Investment_4s3_Bioscience_Klp_Enterprises_Llc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-05T15:05:51+00:00"^^xsd:dateTime ;
    ns1:documentExtract "4s3 Bioscience, Inc. Secures $ 20M in Series A Financing.",
        "Medford, MA, USA, March 5, 2012 - 4s3 Bioscience, Inc. (4s3) , a privately-held biotherapeutics company focused on developing genetic disease therapies for orphan neuromuscular disorders announced today the closing of a $ 20 million Series A financing with KLP Enterprises, LLC (KLP) ." ;
    ns1:documentTitle "4s3 Bioscience, Inc. Secures $20M in Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/4s3-bioscience-inc-secures-20m-series-a-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2342165/4s3_Bioscience> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 20 million",
        "$ 20M" ;
    ns1:when "2012-03-05T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "March 5, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2342365/Urogenix> a org:Organization ;
    ns1:basedInHighGeoName "Durham County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4464374/about.rdf> ;
    ns1:basedInHighRaw "Durham, NC" ;
    ns1:description "drug discovery" ;
    ns1:documentDate "2012-08-06T12:52:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Astellas to Close Urogenix, North Carolina-based Urology Research Facility" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/astellas-to-close-urogenix-north-carolina-based-urology-research-facility> ;
    ns1:foundName "Urogenix, Inc",
        "Urogenix, Inc." ;
    ns1:industry "Pharma" ;
    ns1:name "Urogenix" ;
    ns1:sameAsHigh <https://1145.am/db/1334297/Urogen_Pharma_Ltd>,
        <https://1145.am/db/1335009/Urogen_Pharma_Ltd>,
        <https://1145.am/db/1488519/Urogen_Pharma_Ltd>,
        <https://1145.am/db/2068567/Urogen_Pharma_Ltd>,
        <https://1145.am/db/2072573/Urogen_Pharma_Ltd>,
        <https://1145.am/db/277078/Urogen_Pharma_Ltd> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343197/Exonhit> a org:Organization ;
    ns1:basedInLowRaw "European Union" ;
    ns1:documentDate "2012-03-07T14:41:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Exonhit is Beneficiary of a Grant from the European Union within the Responsify Consortium" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/exonhit-beneficiary-of-a-grant-from-european-union-within-responsify-consortium> ;
    ns1:foundName "Exonhit" ;
    ns1:name "Exonhit" ;
    ns1:sameAsMedium <https://1145.am/db/2288883/Exonhit>,
        <https://1145.am/db/2345773/Exonhit> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343206/Sequent_Medical> a org:Organization ;
    ns1:description "Life science" ;
    ns1:documentDate "2012-03-07T16:52:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sequent Medical Announces Closing of $26.0 Million Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sequent-medical-announces-closing-of-26-0-million-venture-financing> ;
    ns1:foundName "Sequent Medical",
        "Sequent Medical, Inc." ;
    ns1:name "Sequent Medical" ;
    ns1:sameAsMedium <https://1145.am/db/2297102/Sequent_Medical>,
        <https://1145.am/db/2299776/Sequent_Medical>,
        <https://1145.am/db/2316152/Sequent_Medical>,
        <https://1145.am/db/2317231/Sequent_Medical>,
        <https://1145.am/db/2537899/Sequent_Medical> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343206/Us_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "US" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-03-07T16:52:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sequent Medical Announces Closing of $26.0 Million Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sequent-medical-announces-closing-of-26-0-million-venture-financing> ;
    ns1:foundName "US Venture Partners" ;
    ns1:investor <https://1145.am/db/2343206/Series_C_Investment_Delphi_Ventures_Domain_Associates_Sequent_Medical_Us_Venture_Partners_Versant_Ventures_Completed> ;
    ns1:name "US Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1006950/Shell_Ventures>,
        <https://1145.am/db/1014186/Soma_Capital>,
        <https://1145.am/db/1014305/Sp_Ventures>,
        <https://1145.am/db/1049509/021_Capital>,
        <https://1145.am/db/1083572/Spero_Ventures>,
        <https://1145.am/db/1085737/Spero_Ventures>,
        <https://1145.am/db/1106541/Jumpstart_Ventures>,
        <https://1145.am/db/1119699/Xplorer_Capital>,
        <https://1145.am/db/1122750/Xplorer_Capital>,
        <https://1145.am/db/1133402/Silicon_Road_Ventures>,
        <https://1145.am/db/1134486/Silicon_Road_Ventures>,
        <https://1145.am/db/1140286/B_Capital_Group>,
        <https://1145.am/db/1140286/Commerce_Ventures>,
        <https://1145.am/db/1151339/Big_Idea_Ventures>,
        <https://1145.am/db/1165515/Jumpstart_Ventures>,
        <https://1145.am/db/1174129/Stage_1_Ventures>,
        <https://1145.am/db/1175198/Sure_Ventures>,
        <https://1145.am/db/1175459/Khosla_Ventures>,
        <https://1145.am/db/1196728/Gsr_Ventures>,
        <https://1145.am/db/1199177/Gsr_Ventures>,
        <https://1145.am/db/1200402/Xseed_Capital>,
        <https://1145.am/db/1232192/Lfg_Ventures>,
        <https://1145.am/db/1238845/Union_Square_Ventures>,
        <https://1145.am/db/1247755/Syn_Ventures>,
        <https://1145.am/db/1248631/Syn_Ventures>,
        <https://1145.am/db/1269968/Usvp>,
        <https://1145.am/db/1282835/Khosla_Ventures>,
        <https://1145.am/db/1285848/Syn_Ventures>,
        <https://1145.am/db/1287496/D1_Capital>,
        <https://1145.am/db/1288309/Psl_Ventures>,
        <https://1145.am/db/1322711/Venture_Stars>,
        <https://1145.am/db/1329887/Shell_Ventures>,
        <https://1145.am/db/1329887/Sosv>,
        <https://1145.am/db/1340587/Xseed_Capital>,
        <https://1145.am/db/1341445/Xseed_Capital>,
        <https://1145.am/db/1354722/Psl_Ventures>,
        <https://1145.am/db/1354749/Psl_Ventures>,
        <https://1145.am/db/1375916/Sv_Pacific_Ventures>,
        <https://1145.am/db/1376353/Sv_Pacific_Ventures>,
        <https://1145.am/db/1394919/Exsight_Ventures>,
        <https://1145.am/db/1408996/Khosla_Ventures>,
        <https://1145.am/db/1419583/Strongher_Vc>,
        <https://1145.am/db/1419583/Venture_Catalyst>,
        <https://1145.am/db/1445935/97212_Ventures>,
        <https://1145.am/db/1452107/Soma_Capital>,
        <https://1145.am/db/1454909/Us_Venture_Partners>,
        <https://1145.am/db/1455119/Jumpstart_Ventures>,
        <https://1145.am/db/1455616/Soma_Capital>,
        <https://1145.am/db/1468368/Sanabil_Investments>,
        <https://1145.am/db/1470303/Union_Square_Ventures>,
        <https://1145.am/db/1475091/Soma_Capital>,
        <https://1145.am/db/1489698/Stage_1_Ventures>,
        <https://1145.am/db/1582111/Khosla_Ventures>,
        <https://1145.am/db/1584937/Sharad_Sanghi>,
        <https://1145.am/db/1584937/Yournest_Venture_Capital>,
        <https://1145.am/db/1653506/Sve_Capital>,
        <https://1145.am/db/166138/Royal_Street_Ventures>,
        <https://1145.am/db/1663572/Khosla_Ventures>,
        <https://1145.am/db/1679431/Booz_Allen_Ventures_Llc>,
        <https://1145.am/db/1690703/021_Capital>,
        <https://1145.am/db/1691364/Hv_Capital>,
        <https://1145.am/db/1693658/Shima_Capital>,
        <https://1145.am/db/1694448/B37_Ventures>,
        <https://1145.am/db/1696614/Z_Venture_Capital>,
        <https://1145.am/db/1698130/Union_Square_Ventures>,
        <https://1145.am/db/1698180/Shasta_Ventures>,
        <https://1145.am/db/1698192/Saison_Capital>,
        <https://1145.am/db/1699877/Sutter_Hill_Ventures>,
        <https://1145.am/db/1702019/Sutter_Hill_Ventures>,
        <https://1145.am/db/1704402/Sosv>,
        <https://1145.am/db/1710011/Z_Venture_Capital>,
        <https://1145.am/db/1711384/Union_Square_Ventures>,
        <https://1145.am/db/1713248/Xplorer_Capital>,
        <https://1145.am/db/1714154/Psl_Ventures>,
        <https://1145.am/db/1714544/Hv_Capital>,
        <https://1145.am/db/1722058/Union_Square_Ventures>,
        <https://1145.am/db/1722914/B_Capital>,
        <https://1145.am/db/1722944/Soma_Capital>,
        <https://1145.am/db/1723099/Union_Square_Ventures>,
        <https://1145.am/db/1724641/Union_Square_Ventures>,
        <https://1145.am/db/1726121/Khosla_Ventures>,
        <https://1145.am/db/1730882/Union_Square_Ventures>,
        <https://1145.am/db/1732364/Sutter_Hill_Ventures>,
        <https://1145.am/db/1734681/Union_Square_Ventures>,
        <https://1145.am/db/1736478/Z_Venture_Capital>,
        <https://1145.am/db/1736668/Amit_Kapur>,
        <https://1145.am/db/1738378/S_Capital_Vc>,
        <https://1145.am/db/1739022/Khosla_Ventures>,
        <https://1145.am/db/1741014/Khosla_Ventures>,
        <https://1145.am/db/1742276/Shasta_Ventures>,
        <https://1145.am/db/1743316/Khosla_Ventures>,
        <https://1145.am/db/1745326/Venture_Stars>,
        <https://1145.am/db/1747732/Khosla_Ventures>,
        <https://1145.am/db/1747805/Khosla_Ventures>,
        <https://1145.am/db/1749148/Khosla_Ventures>,
        <https://1145.am/db/1749226/Khosla_Ventures>,
        <https://1145.am/db/1750460/Francisco_Partners>,
        <https://1145.am/db/1750483/Hv_Capital>,
        <https://1145.am/db/1750867/Fin_Vc>,
        <https://1145.am/db/1751312/Khosla_Ventures>,
        <https://1145.am/db/1753725/Z_Venture_Capital>,
        <https://1145.am/db/1754057/Spero_Ventures>,
        <https://1145.am/db/1754996/B_Capital>,
        <https://1145.am/db/1755846/Khosla_Ventures>,
        <https://1145.am/db/1756103/Union_Square_Ventures>,
        <https://1145.am/db/1756775/Khosla_Ventures>,
        <https://1145.am/db/1757376/1982_Ventures>,
        <https://1145.am/db/1757432/B37_Ventures>,
        <https://1145.am/db/1757987/R2>,
        <https://1145.am/db/1759567/Spero_Ventures>,
        <https://1145.am/db/1760730/Esun_Venture_Capital>,
        <https://1145.am/db/1762512/Khosla_Ventures>,
        <https://1145.am/db/1767643/Shasta_Ventures>,
        <https://1145.am/db/1768138/Vas_Ventures>,
        <https://1145.am/db/1771112/Khosla_Ventures>,
        <https://1145.am/db/1773491/Sosv>,
        <https://1145.am/db/1775532/Resolute_Venture_Partners>,
        <https://1145.am/db/1776687/Khosla_Ventures>,
        <https://1145.am/db/1777067/Scott>,
        <https://1145.am/db/1778179/Union_Square_Ventures>,
        <https://1145.am/db/1779627/Fosun>,
        <https://1145.am/db/1784405/Venture_51>,
        <https://1145.am/db/1784577/Khosla_Ventures>,
        <https://1145.am/db/1785920/Khosla_Ventures>,
        <https://1145.am/db/1786720/Union_Square_Ventures>,
        <https://1145.am/db/1786861/Ms___Ad_Ventures>,
        <https://1145.am/db/1787190/Gsr_Ventures>,
        <https://1145.am/db/1789140/Sosv>,
        <https://1145.am/db/1790631/Union_Square_Ventures>,
        <https://1145.am/db/1793825/Softtech_Vc>,
        <https://1145.am/db/1795210/Khosla_Ventures>,
        <https://1145.am/db/1795934/Shasta_Ventures>,
        <https://1145.am/db/1797561/Khosla_Ventures>,
        <https://1145.am/db/1799099/Softtech_Vc>,
        <https://1145.am/db/1799102/Softtech_Vc>,
        <https://1145.am/db/1802288/Khosla_Ventures>,
        <https://1145.am/db/1802352/Smedvig_Capital>,
        <https://1145.am/db/1803458/Union_Square_Ventures>,
        <https://1145.am/db/1804091/Active_Venture_Partners>,
        <https://1145.am/db/1804960/Khosla_Ventures>,
        <https://1145.am/db/1807542/Earlybird_Ventures>,
        <https://1145.am/db/1809007/Khosla_Ventures>,
        <https://1145.am/db/1812267/Us_Venture_Partners>,
        <https://1145.am/db/1815701/Khosla_Ventures>,
        <https://1145.am/db/1815910/E-Ventures>,
        <https://1145.am/db/1816423/Usvp>,
        <https://1145.am/db/1818161/Shasta_Ventures>,
        <https://1145.am/db/1818174/Eventures>,
        <https://1145.am/db/1821929/Khosla_Ventures>,
        <https://1145.am/db/1823663/Ifc>,
        <https://1145.am/db/1825387/Shasta_Ventures>,
        <https://1145.am/db/1826265/Mkii_Ventures>,
        <https://1145.am/db/1827021/Shasta_Ventures>,
        <https://1145.am/db/1828336/Khosla_Ventures>,
        <https://1145.am/db/1829581/Union_Square_Ventures>,
        <https://1145.am/db/1829612/Khosla_Ventures>,
        <https://1145.am/db/1829878/Active_Venture_Partners>,
        <https://1145.am/db/1830613/Sutter_Hill_Ventures>,
        <https://1145.am/db/1834279/Xseed_Capital>,
        <https://1145.am/db/1835126/Khosla_Ventures>,
        <https://1145.am/db/1835229/Sparklabs_Global_Ventures>,
        <https://1145.am/db/1835825/Shasta_Ventures>,
        <https://1145.am/db/1837155/Xseed_Capital>,
        <https://1145.am/db/1840793/Khosla_Ventures>,
        <https://1145.am/db/1842301/Khosla_Ventures>,
        <https://1145.am/db/1842466/Us_Venture_Partners>,
        <https://1145.am/db/1843362/Khosla_Ventures>,
        <https://1145.am/db/1846483/Softtech_Vc>,
        <https://1145.am/db/1846721/Union_Square_Ventures>,
        <https://1145.am/db/1852806/Us_Venture_Partners>,
        <https://1145.am/db/1853548/Khosla_Ventures>,
        <https://1145.am/db/1854200/Khosla_Ventures>,
        <https://1145.am/db/1855363/Sk_Ventures>,
        <https://1145.am/db/1856376/Khosla_Ventures>,
        <https://1145.am/db/1857635/Active_Venture_Partners>,
        <https://1145.am/db/1857930/Softtech_Vc>,
        <https://1145.am/db/1858323/Union_Square_Ventures>,
        <https://1145.am/db/1858991/Active_Venture_Partners>,
        <https://1145.am/db/1859199/Khosla_Ventures>,
        <https://1145.am/db/1860091/Union_Square_Ventures>,
        <https://1145.am/db/1860196/Union_Square_Ventures>,
        <https://1145.am/db/1861355/Khosla_Ventures>,
        <https://1145.am/db/1862590/Sutter_Hill_Ventures>,
        <https://1145.am/db/1863500/Khosla_Ventures>,
        <https://1145.am/db/1868107/Shasta_Ventures>,
        <https://1145.am/db/1868572/Union_Square_Ventures>,
        <https://1145.am/db/1871784/Us_Venture_Partners>,
        <https://1145.am/db/1872654/Sutter_Hill_Ventures>,
        <https://1145.am/db/1874278/Khosla_Ventures>,
        <https://1145.am/db/1875709/Sutter_Hill_Ventures>,
        <https://1145.am/db/1876758/Union_Square_Ventures>,
        <https://1145.am/db/1879026/Us_Venture_Partners>,
        <https://1145.am/db/1881464/Khosla_Ventures>,
        <https://1145.am/db/1884155/Us_Venture_Partners>,
        <https://1145.am/db/1892472/Union_Square_Ventures>,
        <https://1145.am/db/1895951/Khosla_Ventures>,
        <https://1145.am/db/1896368/New_Wave_Ventures>,
        <https://1145.am/db/1896530/Khosla_Ventures>,
        <https://1145.am/db/1899282/Mk_Capital>,
        <https://1145.am/db/1899737/Union_Square_Ventures>,
        <https://1145.am/db/1900812/Khosla_Ventures>,
        <https://1145.am/db/1904202/Shasta_Ventures>,
        <https://1145.am/db/1911584/Stage_1_Ventures>,
        <https://1145.am/db/1911840/Shasta_Ventures>,
        <https://1145.am/db/1915640/Us_Venture_Partners>,
        <https://1145.am/db/1917671/Fidelity_Ventures>,
        <https://1145.am/db/1922138/Softtech_Vc>,
        <https://1145.am/db/1931918/Svb_Financial_Group>,
        <https://1145.am/db/1939990/Gsr_Ventures>,
        <https://1145.am/db/1947193/Starbloom_Capital>,
        <https://1145.am/db/1947303/B37_Ventures>,
        <https://1145.am/db/1960888/Khosla_Ventures>,
        <https://1145.am/db/1962819/Jumpstart_Ventures>,
        <https://1145.am/db/2009653/Nationwide_Ventures>,
        <https://1145.am/db/2032146/Booz_Allen_Ventures>,
        <https://1145.am/db/2056931/L___S_Venture_Capital>,
        <https://1145.am/db/2071531/A_o>,
        <https://1145.am/db/2082923/Psl_Ventures>,
        <https://1145.am/db/2090647/Khosla_Ventures>,
        <https://1145.am/db/2092604/Srmg_Ventures>,
        <https://1145.am/db/2099365/Do_Ventures>,
        <https://1145.am/db/2114292/Khosla_Ventures>,
        <https://1145.am/db/2114498/Khosla_Ventures>,
        <https://1145.am/db/2134994/Union_Square_Ventures>,
        <https://1145.am/db/2135622/Khosla_Ventures>,
        <https://1145.am/db/2135690/Better_Ventures>,
        <https://1145.am/db/2142825/Commerce_Ventures>,
        <https://1145.am/db/2151946/Khosla_Ventures>,
        <https://1145.am/db/2153616/South>,
        <https://1145.am/db/2154009/Andera_Partners>,
        <https://1145.am/db/2155474/Sig>,
        <https://1145.am/db/2194249/Union_Square_Ventures>,
        <https://1145.am/db/2210557/Softtech_Vc>,
        <https://1145.am/db/2285566/Sabadell_Venture_Capital>,
        <https://1145.am/db/2288251/Us_Venture_Partners>,
        <https://1145.am/db/2300288/Spark_Ventures>,
        <https://1145.am/db/2300466/Khosla_Ventures>,
        <https://1145.am/db/2305964/Sls_Venture>,
        <https://1145.am/db/2310285/Valley_Ventures>,
        <https://1145.am/db/2311076/Venture_Investors>,
        <https://1145.am/db/2315754/Valley_Ventures>,
        <https://1145.am/db/2319675/Sac>,
        <https://1145.am/db/2348356/Sambrinvest>,
        <https://1145.am/db/2352804/Enterprise_Partners>,
        <https://1145.am/db/2354752/Venture_Investors_Llc>,
        <https://1145.am/db/2354770/Venture_Investors_Llc>,
        <https://1145.am/db/2364014/Ro_Invest>,
        <https://1145.am/db/2567406/Exsight_Ventures>,
        <https://1145.am/db/2575232/Venture_Investors_Llc>,
        <https://1145.am/db/2616685/Silver_Creek_Ventures>,
        <https://1145.am/db/2641337/Valuestream_Ventures>,
        <https://1145.am/db/2790795/Shima_Capital>,
        <https://1145.am/db/365631/Khosla_Ventures>,
        <https://1145.am/db/376872/K50_Ventures>,
        <https://1145.am/db/396307/B_Capital_Group>,
        <https://1145.am/db/407681/Khosla_Ventures>,
        <https://1145.am/db/425922/Royal_Street_Ventures>,
        <https://1145.am/db/426637/Khosla_Ventures>,
        <https://1145.am/db/428324/Khosla_Ventures>,
        <https://1145.am/db/429179/Shasta_Ventures>,
        <https://1145.am/db/430553/Shasta_Ventures>,
        <https://1145.am/db/430986/Olsf_Ventures>,
        <https://1145.am/db/432552/Valuestream_Ventures>,
        <https://1145.am/db/437556/Khosla_Ventures>,
        <https://1145.am/db/438632/Khosla_Ventures>,
        <https://1145.am/db/447456/Starta_Vc>,
        <https://1145.am/db/486858/Khosla_Ventures>,
        <https://1145.am/db/486901/Khosla_Ventures>,
        <https://1145.am/db/502886/Sutter_Hill_Ventures>,
        <https://1145.am/db/506085/Sutter_Hill_Ventures>,
        <https://1145.am/db/523013/Hscm_Ventures>,
        <https://1145.am/db/523013/Sure_Ventures>,
        <https://1145.am/db/527960/Hscm_Ventures>,
        <https://1145.am/db/527960/Sure_Ventures>,
        <https://1145.am/db/562996/Shasta_Ventures>,
        <https://1145.am/db/564008/Secure_Ventures>,
        <https://1145.am/db/572414/A-Street_Ventures>,
        <https://1145.am/db/577305/A-Street_Ventures>,
        <https://1145.am/db/587038/Hv_Capital>,
        <https://1145.am/db/606074/Elementum_Ventures>,
        <https://1145.am/db/661747/Sosv>,
        <https://1145.am/db/663618/Sosv>,
        <https://1145.am/db/676938/Khosla_Ventures>,
        <https://1145.am/db/678262/Khosla_Ventures>,
        <https://1145.am/db/678416/St_Engineering_Ventures_Pte_Ltd>,
        <https://1145.am/db/679989/Khosla_Ventures>,
        <https://1145.am/db/696617/Suro_Capital>,
        <https://1145.am/db/753251/Sosv>,
        <https://1145.am/db/753759/Ms___Ad_Ventures>,
        <https://1145.am/db/75860/Sws_Venture_Capital>,
        <https://1145.am/db/778025/Soma_Capital>,
        <https://1145.am/db/784869/Hbse_Ventures>,
        <https://1145.am/db/791643/Cssd_Capital>,
        <https://1145.am/db/800101/Khosla_Ventures>,
        <https://1145.am/db/807080/Adb_Ventures>,
        <https://1145.am/db/817162/Khosla_Ventures>,
        <https://1145.am/db/817162/Shell_Ventures>,
        <https://1145.am/db/883036/Big_Idea_Ventures>,
        <https://1145.am/db/890955/S2g_Ventures>,
        <https://1145.am/db/906393/1982_Ventures>,
        <https://1145.am/db/912943/Khosla_Ventures>,
        <https://1145.am/db/928782/Psl_Ventures>,
        <https://1145.am/db/930464/Psl_Ventures>,
        <https://1145.am/db/935046/Gsr_Ventures>,
        <https://1145.am/db/940913/Xplorer_Capital>,
        <https://1145.am/db/952434/K50_Ventures>,
        <https://1145.am/db/979911/Khosla_Ventures>,
        <https://1145.am/db/980951/Khosla_Ventures>,
        <https://1145.am/db/996940/Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1147854/Us_Venture_Partners>,
        <https://1145.am/db/1418766/Us_Venture_Partners>,
        <https://1145.am/db/1681426/Us_Venture_Partners>,
        <https://1145.am/db/1697656/Us_Venture_Partners>,
        <https://1145.am/db/1701580/Us_Venture_Partners>,
        <https://1145.am/db/1710567/Us_Venture_Partners>,
        <https://1145.am/db/1712506/Us_Venture_Partners>,
        <https://1145.am/db/1718048/Us_Venture_Partners>,
        <https://1145.am/db/1725165/Us_Venture_Partners>,
        <https://1145.am/db/1737882/Us_Venture_Partners>,
        <https://1145.am/db/1748970/Us_Venture_Partners>,
        <https://1145.am/db/1758985/Us_Venture_Partners>,
        <https://1145.am/db/1763964/Us_Venture_Partners>,
        <https://1145.am/db/1771750/Us_Venture_Partners>,
        <https://1145.am/db/1787502/Us_Venture_Partners>,
        <https://1145.am/db/1796259/Us_Venture_Partners>,
        <https://1145.am/db/1797905/Us_Venture_Partners>,
        <https://1145.am/db/1831222/Us_Venture_Partners>,
        <https://1145.am/db/1834392/Us_Venture_Partners>,
        <https://1145.am/db/1842350/Us_Venture_Partners>,
        <https://1145.am/db/1844571/Us_Venture_Partners>,
        <https://1145.am/db/1845308/Us_Venture_Partners>,
        <https://1145.am/db/1845321/Us_Venture_Partners>,
        <https://1145.am/db/1845924/Us_Venture_Partners>,
        <https://1145.am/db/1846470/Us_Venture_Partners>,
        <https://1145.am/db/1847323/Us_Venture_Partners>,
        <https://1145.am/db/1851689/Us_Venture_Partners>,
        <https://1145.am/db/1863147/Us_Venture_Partners>,
        <https://1145.am/db/1864900/Us_Venture_Partners>,
        <https://1145.am/db/1867951/Us_Venture_Partners>,
        <https://1145.am/db/1870790/Us_Venture_Partners>,
        <https://1145.am/db/1877830/Us_Venture_Partners>,
        <https://1145.am/db/1895986/Us_Venture_Partners>,
        <https://1145.am/db/2050254/Us_Venture_Partners>,
        <https://1145.am/db/2150562/Us_Venture_Partners>,
        <https://1145.am/db/2192716/Us_Venture_Partners>,
        <https://1145.am/db/2257512/Us_Venture_Partners>,
        <https://1145.am/db/2278799/Us_Venture_Partners>,
        <https://1145.am/db/2279124/Us_Venture_Partners>,
        <https://1145.am/db/2288899/Us_Venture_Partners>,
        <https://1145.am/db/2293765/Us_Venture_Partners>,
        <https://1145.am/db/2299776/Us_Venture_Partners>,
        <https://1145.am/db/2301809/Us_Venture_Partners>,
        <https://1145.am/db/2319658/Us_Venture_Partners>,
        <https://1145.am/db/2357858/Us_Venture_Partners>,
        <https://1145.am/db/2358430/Us_Venture_Partners>,
        <https://1145.am/db/2367204/Us_Venture_Partners>,
        <https://1145.am/db/2645160/Us_Venture_Partners>,
        <https://1145.am/db/425262/Us_Venture_Partners>,
        <https://1145.am/db/838691/Us_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344196/Bellicum_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Houston" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4699066/about.rdf> ;
    ns1:basedInHighRaw "HOUSTON" ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-03-08T14:18:26+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Bellicum Closes $20 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bellicum-closes-20-million-series-b-financing> ;
    ns1:foundName "Bellicum",
        "Bellicum Pharmaceuticals, Inc." ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Bellicum",
        "Bellicum Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1178004/Bellicum_Pharmaceuticals>,
        <https://1145.am/db/1391161/Bellicum_Pharmaceuticals>,
        <https://1145.am/db/2287858/Bellicum>,
        <https://1145.am/db/2301054/Bellicum_Pharma>,
        <https://1145.am/db/2324755/Bellicum_Pharmaceuticals>,
        <https://1145.am/db/2324758/Bellicum_Pharmaceuticals>,
        <https://1145.am/db/2342752/Bellicum_Pharmaceuticals>,
        <https://1145.am/db/2344204/Bellicum_Pharmaceuticals>,
        <https://1145.am/db/2346754/Bellicum_Pharmaceuticals>,
        <https://1145.am/db/2352969/Bellicum_Pharmaceuticals>,
        <https://1145.am/db/2352970/Bellicum_Pharmaceuticals>,
        <https://1145.am/db/2360097/Bellicum_Pharmaceuticals>,
        <https://1145.am/db/2360277/Bellicum_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344196/Investment_Bellicum_Pharmaceuticals_Cancer_Prevention_And_Research_Institute_Of_Texas_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-08T14:18:26+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Bellicum Closes $ 20 Million Series B Financing.",
        "HOUSTON, March 8, 2012 /PRNewswire/ - Bellicum Pharmaceuticals, Inc. today announced that it has raised $ 20 million in a Series B financing.",
        "The additional funding strengthens Bellicum's balance sheet with $ 26 million of committed capital, including a $ 6.1 million award from the Cancer Prevention and Research Institute of Texas (CPRIT)." ;
    ns1:documentTitle "Bellicum Closes $20 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/bellicum-closes-20-million-series-b-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2344196/Bellicum_Pharmaceuticals> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 20 Million",
        "$ 20 million",
        "$ 6.1 million" ;
    ns1:when "2012-03-08T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "March 8, 2012" ;
    ns1:whereGeoName "Houston" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4699066/about.rdf> ;
    ns1:whereRaw "HOUSTON" .

<https://1145.am/db/2344219/Aastrom_Biosciences> a org:Organization ;
    ns1:description "developing patient-specific, expanded multicellular therapies" ;
    ns1:documentDate "2012-03-09T16:47:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aastrom Biosciences Completes $40 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aastrom-biosciences-completes-40-million-financing> ;
    ns1:foundName "Aastrom",
        "Aastrom Biosciences",
        "Aastrom Biosciences, Inc." ;
    ns1:name "Aastrom Biosciences" ;
    ns1:sameAsHigh <https://1145.am/db/2337050/Aastrom_Biosciences_Inc>,
        <https://1145.am/db/2343573/Aastrom_Biosciences> ;
    ns1:sameAsMedium <https://1145.am/db/2310065/Aastrom_Biosciences>,
        <https://1145.am/db/2310233/Aastrom_Biosciences>,
        <https://1145.am/db/2311257/Aastrom_Biosciences>,
        <https://1145.am/db/2313621/Aastrom_Biosciences>,
        <https://1145.am/db/2324328/Aastrom_Biosciences>,
        <https://1145.am/db/2335735/Aastrom_Biosciences>,
        <https://1145.am/db/2344080/Aastrom_Biosciences>,
        <https://1145.am/db/2357222/Aastrom_Biosciences>,
        <https://1145.am/db/2357442/Aastrom_Biosciences>,
        <https://1145.am/db/2358239/Aastrom_Biosciences_Inc>,
        <https://1145.am/db/2362489/Aastrom_Biosciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344256/Lighthouse_Capital_Partners> a org:Organization ;
    ns1:basedInLowRaw "WALTHAM" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-03-14T12:43:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing-0> ;
    ns1:foundName "Lighthouse Capital Partners" ;
    ns1:investor <https://1145.am/db/2344256/Investment_Kala_Pharmaceuticals_Lighthouse_Capital_Partners_Lux_Capital_Polaris_Venture_Partners_Third_Rock_Ventures_Completed> ;
    ns1:name "Lighthouse Capital Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2320925/Lighthouse_Capital_Partners>,
        <https://1145.am/db/2345224/Lighthouse_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344256/Lux_Capital> a org:Organization ;
    ns1:basedInLowRaw "WALTHAM, Mass" ;
    ns1:description "venture investors" ;
    ns1:documentDate "2012-03-14T12:43:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing-0> ;
    ns1:foundName "Lux Capital" ;
    ns1:investor <https://1145.am/db/2344256/Investment_Kala_Pharmaceuticals_Lighthouse_Capital_Partners_Lux_Capital_Polaris_Venture_Partners_Third_Rock_Ventures_Completed> ;
    ns1:name "Lux Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1119661/Lux_Capital>,
        <https://1145.am/db/1122753/Lux_Capital>,
        <https://1145.am/db/1376203/Lux_Capital>,
        <https://1145.am/db/1536915/Lux_Capital>,
        <https://1145.am/db/1838965/Lux_Capital>,
        <https://1145.am/db/2303675/Lux_Capital>,
        <https://1145.am/db/2345224/Lux_Capital>,
        <https://1145.am/db/2365296/Lux_Capital_Management>,
        <https://1145.am/db/424834/Lux_Capital>,
        <https://1145.am/db/425188/Lux_Capital>,
        <https://1145.am/db/425281/Lux_Capital>,
        <https://1145.am/db/426160/Lux_Capital>,
        <https://1145.am/db/918904/Lux_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1105217/Lux_Capital>,
        <https://1145.am/db/1106865/Lux_Capital>,
        <https://1145.am/db/1119433/Lux_Capital>,
        <https://1145.am/db/1139654/Lux_Capital>,
        <https://1145.am/db/1143903/Lux_Capital>,
        <https://1145.am/db/1238486/Lux_Capital>,
        <https://1145.am/db/1285901/Lux_Capital>,
        <https://1145.am/db/1374025/Lux_Capital>,
        <https://1145.am/db/1375318/Lux_Capital>,
        <https://1145.am/db/1407553/Lux_Capital>,
        <https://1145.am/db/1553919/Lux_Capital>,
        <https://1145.am/db/1555013/Lux_Capital>,
        <https://1145.am/db/1632690/Lux_Capital>,
        <https://1145.am/db/1669908/Lux_Capital>,
        <https://1145.am/db/1697296/Lux_Capital>,
        <https://1145.am/db/1734597/Lux_Capital>,
        <https://1145.am/db/1737151/Lux_Capital>,
        <https://1145.am/db/1737409/Lux_Capital>,
        <https://1145.am/db/174200/Lux_Capital>,
        <https://1145.am/db/1743303/Lux_Capital>,
        <https://1145.am/db/1758194/Lux_Capital>,
        <https://1145.am/db/1761607/Lux_Capital>,
        <https://1145.am/db/1762041/Lux_Capital>,
        <https://1145.am/db/1763354/Lux_Capital>,
        <https://1145.am/db/1766887/Lux_Capital>,
        <https://1145.am/db/1777184/Lux_Capital>,
        <https://1145.am/db/1782221/Lux_Capital>,
        <https://1145.am/db/1792186/Lux_Capital>,
        <https://1145.am/db/1796593/Lux_Capital>,
        <https://1145.am/db/1803458/Lux_Capital>,
        <https://1145.am/db/1808133/Lux_Capital>,
        <https://1145.am/db/1809178/Lux_Capital>,
        <https://1145.am/db/1811725/Lux_Capital>,
        <https://1145.am/db/1815044/Lux_Capital>,
        <https://1145.am/db/1817051/Lux_Capital>,
        <https://1145.am/db/1818204/Lux_Capital>,
        <https://1145.am/db/1819710/Lux_Capital>,
        <https://1145.am/db/1827904/Lux_Capital>,
        <https://1145.am/db/1829422/Lux_Capital>,
        <https://1145.am/db/1845217/Lux_Capital>,
        <https://1145.am/db/1846254/Lux_Capital>,
        <https://1145.am/db/1930816/Lux_Capital>,
        <https://1145.am/db/1932856/Lux_Capital>,
        <https://1145.am/db/2006781/Lux_Capital>,
        <https://1145.am/db/2138013/Lux_Capital>,
        <https://1145.am/db/2141058/Lux_Capital>,
        <https://1145.am/db/2178040/Lux_Capital>,
        <https://1145.am/db/2284256/Lux_Capital>,
        <https://1145.am/db/2291716/Lux_Capital>,
        <https://1145.am/db/2291901/Lux_Capital>,
        <https://1145.am/db/2304963/Lux_Capital>,
        <https://1145.am/db/2305327/Lux_Capital>,
        <https://1145.am/db/2328280/Lux_Capital>,
        <https://1145.am/db/2331549/Lux_Capital>,
        <https://1145.am/db/2335750/Lux_Capital>,
        <https://1145.am/db/2335755/Lux_Capital>,
        <https://1145.am/db/2337522/Lux_Capital>,
        <https://1145.am/db/2337571/Lux_Capital>,
        <https://1145.am/db/2337577/Lux_Capital>,
        <https://1145.am/db/2345439/Lux_Capital>,
        <https://1145.am/db/2347102/Lux_Capital>,
        <https://1145.am/db/2348448/Lux_Capital>,
        <https://1145.am/db/2352414/Lux_Capital>,
        <https://1145.am/db/2546216/Lux_Capital>,
        <https://1145.am/db/2633440/Lux_Capital>,
        <https://1145.am/db/2801014/Lux_Capital>,
        <https://1145.am/db/412847/Lux_Capital>,
        <https://1145.am/db/516176/Lux_Capital>,
        <https://1145.am/db/516613/Lux_Capital>,
        <https://1145.am/db/540507/Lux_Capital>,
        <https://1145.am/db/684792/Lux_Capital>,
        <https://1145.am/db/747771/Lux_Capital>,
        <https://1145.am/db/765641/Lux_Capital>,
        <https://1145.am/db/823763/Lux_Capital>,
        <https://1145.am/db/863878/Lux_Capital>,
        <https://1145.am/db/935910/Lux_Capital>,
        <https://1145.am/db/936989/Lux_Capital>,
        <https://1145.am/db/940684/Lux_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345224/Lighthouse_Capital_Partners> a org:Organization ;
    ns1:basedInLowRaw "Mass" ;
    ns1:description "venture investors" ;
    ns1:documentDate "2012-03-14T14:02:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing> ;
    ns1:foundName "Lighthouse Capital Partners" ;
    ns1:investor <https://1145.am/db/2345224/Investment_Kala_Pharmaceuticals_Lighthouse_Capital_Partners_Lux_Capital_Polaris_Venture_Partners_Third_Rock_Ventures_Completed> ;
    ns1:name "Lighthouse Capital Partners" ;
    ns1:sameAsHigh <https://1145.am/db/2320925/Lighthouse_Capital_Partners>,
        <https://1145.am/db/2344256/Lighthouse_Capital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345224/Lux_Capital> a org:Organization ;
    ns1:basedInLowRaw "WALTHAM, Mass" ;
    ns1:description "venture investors" ;
    ns1:documentDate "2012-03-14T14:02:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing> ;
    ns1:foundName "Lux Capital" ;
    ns1:investor <https://1145.am/db/2345224/Investment_Kala_Pharmaceuticals_Lighthouse_Capital_Partners_Lux_Capital_Polaris_Venture_Partners_Third_Rock_Ventures_Completed> ;
    ns1:name "Lux Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1119661/Lux_Capital>,
        <https://1145.am/db/1122753/Lux_Capital>,
        <https://1145.am/db/1376203/Lux_Capital>,
        <https://1145.am/db/1536915/Lux_Capital>,
        <https://1145.am/db/1838965/Lux_Capital>,
        <https://1145.am/db/2303675/Lux_Capital>,
        <https://1145.am/db/2344256/Lux_Capital>,
        <https://1145.am/db/2365296/Lux_Capital_Management>,
        <https://1145.am/db/424834/Lux_Capital>,
        <https://1145.am/db/425188/Lux_Capital>,
        <https://1145.am/db/425281/Lux_Capital>,
        <https://1145.am/db/426160/Lux_Capital>,
        <https://1145.am/db/918904/Lux_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1105217/Lux_Capital>,
        <https://1145.am/db/1106865/Lux_Capital>,
        <https://1145.am/db/1119433/Lux_Capital>,
        <https://1145.am/db/1139654/Lux_Capital>,
        <https://1145.am/db/1143903/Lux_Capital>,
        <https://1145.am/db/1238486/Lux_Capital>,
        <https://1145.am/db/1285901/Lux_Capital>,
        <https://1145.am/db/1374025/Lux_Capital>,
        <https://1145.am/db/1375318/Lux_Capital>,
        <https://1145.am/db/1407553/Lux_Capital>,
        <https://1145.am/db/1553919/Lux_Capital>,
        <https://1145.am/db/1555013/Lux_Capital>,
        <https://1145.am/db/1632690/Lux_Capital>,
        <https://1145.am/db/1669908/Lux_Capital>,
        <https://1145.am/db/1697296/Lux_Capital>,
        <https://1145.am/db/1734597/Lux_Capital>,
        <https://1145.am/db/1737151/Lux_Capital>,
        <https://1145.am/db/1737409/Lux_Capital>,
        <https://1145.am/db/174200/Lux_Capital>,
        <https://1145.am/db/1743303/Lux_Capital>,
        <https://1145.am/db/1758194/Lux_Capital>,
        <https://1145.am/db/1761607/Lux_Capital>,
        <https://1145.am/db/1762041/Lux_Capital>,
        <https://1145.am/db/1763354/Lux_Capital>,
        <https://1145.am/db/1766887/Lux_Capital>,
        <https://1145.am/db/1777184/Lux_Capital>,
        <https://1145.am/db/1782221/Lux_Capital>,
        <https://1145.am/db/1792186/Lux_Capital>,
        <https://1145.am/db/1796593/Lux_Capital>,
        <https://1145.am/db/1803458/Lux_Capital>,
        <https://1145.am/db/1808133/Lux_Capital>,
        <https://1145.am/db/1809178/Lux_Capital>,
        <https://1145.am/db/1811725/Lux_Capital>,
        <https://1145.am/db/1815044/Lux_Capital>,
        <https://1145.am/db/1817051/Lux_Capital>,
        <https://1145.am/db/1818204/Lux_Capital>,
        <https://1145.am/db/1819710/Lux_Capital>,
        <https://1145.am/db/1827904/Lux_Capital>,
        <https://1145.am/db/1829422/Lux_Capital>,
        <https://1145.am/db/1845217/Lux_Capital>,
        <https://1145.am/db/1846254/Lux_Capital>,
        <https://1145.am/db/1930816/Lux_Capital>,
        <https://1145.am/db/1932856/Lux_Capital>,
        <https://1145.am/db/2006781/Lux_Capital>,
        <https://1145.am/db/2138013/Lux_Capital>,
        <https://1145.am/db/2141058/Lux_Capital>,
        <https://1145.am/db/2178040/Lux_Capital>,
        <https://1145.am/db/2284256/Lux_Capital>,
        <https://1145.am/db/2291716/Lux_Capital>,
        <https://1145.am/db/2291901/Lux_Capital>,
        <https://1145.am/db/2304963/Lux_Capital>,
        <https://1145.am/db/2305327/Lux_Capital>,
        <https://1145.am/db/2328280/Lux_Capital>,
        <https://1145.am/db/2331549/Lux_Capital>,
        <https://1145.am/db/2335750/Lux_Capital>,
        <https://1145.am/db/2335755/Lux_Capital>,
        <https://1145.am/db/2337522/Lux_Capital>,
        <https://1145.am/db/2337571/Lux_Capital>,
        <https://1145.am/db/2337577/Lux_Capital>,
        <https://1145.am/db/2345439/Lux_Capital>,
        <https://1145.am/db/2347102/Lux_Capital>,
        <https://1145.am/db/2348448/Lux_Capital>,
        <https://1145.am/db/2352414/Lux_Capital>,
        <https://1145.am/db/2546216/Lux_Capital>,
        <https://1145.am/db/2633440/Lux_Capital>,
        <https://1145.am/db/2801014/Lux_Capital>,
        <https://1145.am/db/412847/Lux_Capital>,
        <https://1145.am/db/516176/Lux_Capital>,
        <https://1145.am/db/516613/Lux_Capital>,
        <https://1145.am/db/540507/Lux_Capital>,
        <https://1145.am/db/684792/Lux_Capital>,
        <https://1145.am/db/747771/Lux_Capital>,
        <https://1145.am/db/765641/Lux_Capital>,
        <https://1145.am/db/823763/Lux_Capital>,
        <https://1145.am/db/863878/Lux_Capital>,
        <https://1145.am/db/935910/Lux_Capital>,
        <https://1145.am/db/936989/Lux_Capital>,
        <https://1145.am/db/940684/Lux_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345268/Foresite_Capital> a org:Organization ;
    ns1:basedInLowRaw "PHILADELPHIA" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-03-16T13:14:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tarsa-therapeutics-completes-28-million-series-b-financing-to-advance-ostora%E2%84%A2-oral> ;
    ns1:foundName "Foresite Capital" ;
    ns1:investor <https://1145.am/db/2345268/Series_B_Investment_Foresite_Capital_Novo_A_S_Tarsa_Therapeutics_Completed> ;
    ns1:name "Foresite Capital" ;
    ns1:sameAsHigh <https://1145.am/db/1006252/Menlo_Ventures>,
        <https://1145.am/db/1006262/Com_Prelude_Ventures>,
        <https://1145.am/db/1006574/Integr8d_Capital>,
        <https://1145.am/db/1006880/Root_Ventures>,
        <https://1145.am/db/1007193/Capital_One_Ventures>,
        <https://1145.am/db/1007527/Integr8d_Capital>,
        <https://1145.am/db/1008085/Root_Ventures>,
        <https://1145.am/db/1008260/Servicenow_Ventures>,
        <https://1145.am/db/1010064/Greatpoint_Ventures>,
        <https://1145.am/db/1010064/Maverick_Ventures>,
        <https://1145.am/db/1010199/One9_Ventures>,
        <https://1145.am/db/102038/Allegion_Ventures>,
        <https://1145.am/db/102038/Pathbreaker_Ventures>,
        <https://1145.am/db/102038/West_Ventures>,
        <https://1145.am/db/1023252/Digitalbridge_Ventures>,
        <https://1145.am/db/1024247/Digitalbridge_Ventures>,
        <https://1145.am/db/1024483/Investbridge_Capital>,
        <https://1145.am/db/1026319/Able_Partners>,
        <https://1145.am/db/1034591/Valia_Ventures>,
        <https://1145.am/db/1041601/Kineo_Finance>,
        <https://1145.am/db/1042250/Kineo_Finance>,
        <https://1145.am/db/1043051/Sequoia_Capital>,
        <https://1145.am/db/1043259/Sequoia_Capital>,
        <https://1145.am/db/1043342/Root_Ventures>,
        <https://1145.am/db/1043516/Kineo_Finance>,
        <https://1145.am/db/1045242/Dipalo_Ventures>,
        <https://1145.am/db/1045384/Sequoia_Capital>,
        <https://1145.am/db/1051115/Dn_Capital>,
        <https://1145.am/db/1051644/Vestigo_Ventures>,
        <https://1145.am/db/1052155/Gate_Ventures>,
        <https://1145.am/db/1059993/Tera_Ventures>,
        <https://1145.am/db/1060146/Ulu_Ventures>,
        <https://1145.am/db/1061824/Bluebird_Ventures>,
        <https://1145.am/db/1061911/Ulu_Ventures>,
        <https://1145.am/db/1065366/Applied_Ventures_Llc>,
        <https://1145.am/db/1065544/Menlo_Ventures>,
        <https://1145.am/db/1066120/Crosslink_Capital>,
        <https://1145.am/db/1081175/Rse_Ventures>,
        <https://1145.am/db/1081490/Vinco_Ventures>,
        <https://1145.am/db/1081888/Ggv_Capital>,
        <https://1145.am/db/1082613/Rse_Ventures>,
        <https://1145.am/db/1082719/Dorilton_Ventures>,
        <https://1145.am/db/1082814/Cathexis_Ventures>,
        <https://1145.am/db/1082814/Promus_Ventures>,
        <https://1145.am/db/1082814/Type_One_Ventures>,
        <https://1145.am/db/1084014/Ret_Ventures>,
        <https://1145.am/db/1085867/Ret_Ventures>,
        <https://1145.am/db/1086604/Alerion_Ventures>,
        <https://1145.am/db/1086673/Wintrust_Ventures>,
        <https://1145.am/db/1089416/Nexo_Ventures>,
        <https://1145.am/db/1090643/Argon_Ventures>,
        <https://1145.am/db/1090643/Glasswing_Ventures>,
        <https://1145.am/db/1101244/Acequia_Capital>,
        <https://1145.am/db/1103270/Acequia_Capital>,
        <https://1145.am/db/1106082/Northpond_Ventures>,
        <https://1145.am/db/1106670/Sequoia_Capital>,
        <https://1145.am/db/1111505/Nissay_Capital>,
        <https://1145.am/db/1111505/Remiges_Ventures>,
        <https://1145.am/db/1112074/Nissay_Capital>,
        <https://1145.am/db/1112074/Remiges_Ventures>,
        <https://1145.am/db/1114979/Catapult_Ventures>,
        <https://1145.am/db/1115103/Northpond_Ventures>,
        <https://1145.am/db/1119456/Truist_Ventures>,
        <https://1145.am/db/1119699/Prelude_Ventures>,
        <https://1145.am/db/1120030/Morpheus_Ventures>,
        <https://1145.am/db/1120030/Point72_Ventures>,
        <https://1145.am/db/1120071/Morpheus_Ventures>,
        <https://1145.am/db/1120071/Point72_Ventures>,
        <https://1145.am/db/1122750/Prelude_Ventures>,
        <https://1145.am/db/1129561/Redbeard_Ventures>,
        <https://1145.am/db/1130744/Redbeard_Ventures>,
        <https://1145.am/db/1133003/Sequoia_Capital>,
        <https://1145.am/db/1134165/Boldstart_Ventures>,
        <https://1145.am/db/1136173/Boldstart_Ventures>,
        <https://1145.am/db/1137178/CRV>,
        <https://1145.am/db/1138154/Ggv_Capital>,
        <https://1145.am/db/1139703/Industry_Ventures>,
        <https://1145.am/db/1140286/Origin_Ventures>,
        <https://1145.am/db/1141736/Redpoint_Ventures>,
        <https://1145.am/db/1150154/Riv_Capital>,
        <https://1145.am/db/1150529/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/1150529/Solasta_Ventures>,
        <https://1145.am/db/1151328/Index_Ventures>,
        <https://1145.am/db/1151736/True_Ventures>,
        <https://1145.am/db/1152929/Aperiamventures>,
        <https://1145.am/db/1153706/Index_Ventures>,
        <https://1145.am/db/1154242/True_Ventures>,
        <https://1145.am/db/1163139/Sentiero_Ventures>,
        <https://1145.am/db/1163139/Skyriver_Ventures>,
        <https://1145.am/db/1164299/Lavrock_Ventures>,
        <https://1145.am/db/1164299/Progress_Ventures>,
        <https://1145.am/db/1164688/Abstract_Ventures>,
        <https://1145.am/db/1164688/Spacecadet_Ventures>,
        <https://1145.am/db/1164845/Lavrock_Ventures>,
        <https://1145.am/db/1164845/Progress_Ventures>,
        <https://1145.am/db/1165515/G2_Group_Ventures>,
        <https://1145.am/db/1166154/Allos_Ventures>,
        <https://1145.am/db/1166957/Seedil_Ventures>,
        <https://1145.am/db/1168757/Accomplice_Ventures>,
        <https://1145.am/db/1169687/Artiman_Ventures>,
        <https://1145.am/db/1169687/J_Ventures>,
        <https://1145.am/db/1169687/Nd_Capital>,
        <https://1145.am/db/1169815/Accomplice_Ventures>,
        <https://1145.am/db/1170971/Equinor_Ventures>,
        <https://1145.am/db/1173428/Equinor_Ventures>,
        <https://1145.am/db/1175576/Divcowest_Ventures>,
        <https://1145.am/db/1175576/Point72_Ventures>,
        <https://1145.am/db/1175576/Signia_Ventures>,
        <https://1145.am/db/1176018/First_Star_Ventures>,
        <https://1145.am/db/1187600/Caymus_Equity_Partners_Llc>,
        <https://1145.am/db/11887/Adv>,
        <https://1145.am/db/1190097/Caymus_Equity_Partners_Llc>,
        <https://1145.am/db/1190127/Animo_Ventures>,
        <https://1145.am/db/1190127/Chaac_Ventures>,
        <https://1145.am/db/1190127/Ulu_Ventures>,
        <https://1145.am/db/1196068/Arthur_Ventures>,
        <https://1145.am/db/1196728/Greatpoint_Ventures>,
        <https://1145.am/db/1199177/Greatpoint_Ventures>,
        <https://1145.am/db/1199182/Boxone_Ventures>,
        <https://1145.am/db/1202673/Basecamp_Ventures>,
        <https://1145.am/db/1203180/Basecamp_Ventures>,
        <https://1145.am/db/1206820/Tenoneten_Ventures>,
        <https://1145.am/db/1208519/Tappanhill_Ventures>,
        <https://1145.am/db/1208749/Industry_Ventures>,
        <https://1145.am/db/1208749/Keshif_Ventures>,
        <https://1145.am/db/1208749/Tenoneten_Ventures>,
        <https://1145.am/db/1213076/Equinor_Ventures>,
        <https://1145.am/db/1213076/Scf_Ventures>,
        <https://1145.am/db/1213119/Nevcaut_Ventures>,
        <https://1145.am/db/1215930/Northpond_Ventures>,
        <https://1145.am/db/1219982/Soma_Ventures>,
        <https://1145.am/db/1221237/C2_Ventures>,
        <https://1145.am/db/1222789/Glasswing_Ventures>,
        <https://1145.am/db/1232497/Droia_Ventures>,
        <https://1145.am/db/1232497/Gv>,
        <https://1145.am/db/1233314/Citta_Capital>,
        <https://1145.am/db/1236549/Adit_Ventures>,
        <https://1145.am/db/1247755/Sinewave_Ventures>,
        <https://1145.am/db/1247761/Clear_Ventures>,
        <https://1145.am/db/1248631/Sinewave_Ventures>,
        <https://1145.am/db/1252447/Gaingels>,
        <https://1145.am/db/1256269/Ampd_Ventures_Inc>,
        <https://1145.am/db/1264028/K3_Ventures>,
        <https://1145.am/db/1264587/Index_Ventures>,
        <https://1145.am/db/1268150/Pender_Ventures>,
        <https://1145.am/db/1269968/Abstract_Ventures>,
        <https://1145.am/db/1272468/Launchpad_Capital>,
        <https://1145.am/db/1279264/Roosh_Ventures>,
        <https://1145.am/db/1281079/Morgenthaler_Ventures>,
        <https://1145.am/db/1281647/Morgenthaler_Ventures>,
        <https://1145.am/db/1282820/Agya_Ventures>,
        <https://1145.am/db/1286872/Morevc>,
        <https://1145.am/db/1287476/Felicis_Ventures>,
        <https://1145.am/db/1297417/Bitkraft_Ventures>,
        <https://1145.am/db/1299578/Seedtob_Capital>,
        <https://1145.am/db/1307620/Inventus_Capital_Partners>,
        <https://1145.am/db/1311917/Avid_Ventures>,
        <https://1145.am/db/1311917/Canapi_Ventures>,
        <https://1145.am/db/1322441/Solana_Ventures>,
        <https://1145.am/db/1326376/Dexcom_Ventures>,
        <https://1145.am/db/1329887/Peter_Nagar>,
        <https://1145.am/db/1331691/Pelion_Ventures>,
        <https://1145.am/db/1332798/Acrobator_Ventures>,
        <https://1145.am/db/1334186/First_Ascent_Ventures>,
        <https://1145.am/db/1334193/Version_One_Ventures>,
        <https://1145.am/db/1334395/Gv>,
        <https://1145.am/db/1334895/Soleus_Capital>,
        <https://1145.am/db/1335073/Yl_Ventures>,
        <https://1145.am/db/1335080/Dorilton_Ventures>,
        <https://1145.am/db/1344240/Neotribe_Ventures>,
        <https://1145.am/db/1352420/Vamos_Ventures>,
        <https://1145.am/db/1353145/Infinity_Ventures>,
        <https://1145.am/db/1362743/Cobalt_Ventures>,
        <https://1145.am/db/1373683/BGV>,
        <https://1145.am/db/1375916/J2_Ventures>,
        <https://1145.am/db/1376353/J2_Ventures>,
        <https://1145.am/db/1378599/Menlo_Ventures>,
        <https://1145.am/db/1381832/Northpond_Ventures>,
        <https://1145.am/db/1382787/Northpond_Ventures>,
        <https://1145.am/db/1383818/Newlin_Ventures>,
        <https://1145.am/db/1387557/Naventures>,
        <https://1145.am/db/138878/Metacartel_Ventures>,
        <https://1145.am/db/1398057/Owen_Van_Natta_Temaris___Associates>,
        <https://1145.am/db/1398917/Trousdale_Ventures>,
        <https://1145.am/db/1407553/Sequoia_Capital>,
        <https://1145.am/db/1407614/C2_Ventures>,
        <https://1145.am/db/1411289/Sequoia_Capital>,
        <https://1145.am/db/1411934/Riptide_Ventures>,
        <https://1145.am/db/1425749/Menlo_Ventures>,
        <https://1145.am/db/1425749/Se_Ventures>,
        <https://1145.am/db/1433429/Crosslink_Capital>,
        <https://1145.am/db/1445378/Mvp_Ventures>,
        <https://1145.am/db/1445935/Verissimo_Ventures>,
        <https://1145.am/db/1449316/+Nd_Capital>,
        <https://1145.am/db/1449740/Mistral_Ventures>,
        <https://1145.am/db/1452107/Abstract_Ventures>,
        <https://1145.am/db/1455216/Engage_Ventures>,
        <https://1145.am/db/1455616/Abstract_Ventures>,
        <https://1145.am/db/1463829/1sharpe_Ventures>,
        <https://1145.am/db/1467693/Preseed_Ventures>,
        <https://1145.am/db/1467892/M_Ventures>,
        <https://1145.am/db/1467932/Sequoia_Capital_Gv>,
        <https://1145.am/db/1468981/Preseed_Ventures>,
        <https://1145.am/db/1476448/Origin_Ventures>,
        <https://1145.am/db/1480152/True_Ventures>,
        <https://1145.am/db/1480651/Glasswing_Ventures>,
        <https://1145.am/db/1480989/Infinity_Ventures>,
        <https://1145.am/db/1481875/Infinity_Ventures>,
        <https://1145.am/db/1482705/Oif_Ventures>,
        <https://1145.am/db/1484103/Boxone_Ventures>,
        <https://1145.am/db/1484857/Iu_Ventures>,
        <https://1145.am/db/1488858/Alkeon_Capital>,
        <https://1145.am/db/1490126/Seedtob_Capital>,
        <https://1145.am/db/1490183/Sofinnova_Partners>,
        <https://1145.am/db/1490978/Seedtob_Capital>,
        <https://1145.am/db/1492889/Future_Ventures>,
        <https://1145.am/db/1492889/Radical_Ventures>,
        <https://1145.am/db/1494028/Alkeon_Capital>,
        <https://1145.am/db/1496360/Realist_Ventures>,
        <https://1145.am/db/1503768/Nevateam_Partners>,
        <https://1145.am/db/1508325/Aramco_Ventures>,
        <https://1145.am/db/1509462/F7_Ventures>,
        <https://1145.am/db/1512891/Acme_Capital>,
        <https://1145.am/db/1515109/Cmfg_Ventures>,
        <https://1145.am/db/1515916/Sequoia_Capital>,
        <https://1145.am/db/1520070/Menlo_Ventures>,
        <https://1145.am/db/1520070/Northpond_Ventures>,
        <https://1145.am/db/1520772/January_Ventures>,
        <https://1145.am/db/1537166/Catalio_Capital_Management>,
        <https://1145.am/db/1537970/Catalio_Capital_Management>,
        <https://1145.am/db/1541308/Panoramic_Ventures>,
        <https://1145.am/db/1541797/G1_Ventures>,
        <https://1145.am/db/1545833/Alerion_Ventures>,
        <https://1145.am/db/1545994/Noemis_Ventures>,
        <https://1145.am/db/1546945/Alerion_Ventures>,
        <https://1145.am/db/1546965/Citi_Ventures>,
        <https://1145.am/db/1546965/Truist_Ventures>,
        <https://1145.am/db/1547281/Noemis_Ventures>,
        <https://1145.am/db/1548592/Gopoint_Ventures>,
        <https://1145.am/db/1556397/Dnx_Ventures>,
        <https://1145.am/db/1556442/C16_Ventures>,
        <https://1145.am/db/1557877/Embark_Ventures>,
        <https://1145.am/db/1559824/Embark_Ventures>,
        <https://1145.am/db/1560704/Breaktrail_Ventures>,
        <https://1145.am/db/1563623/Amex_Ventures>,
        <https://1145.am/db/1564049/Amex_Ventures>,
        <https://1145.am/db/1571330/Seae_Ventures>,
        <https://1145.am/db/1571330/Venturesouth>,
        <https://1145.am/db/1572216/Seae_Ventures>,
        <https://1145.am/db/1572216/Venturesouth>,
        <https://1145.am/db/1574557/True_Ventures>,
        <https://1145.am/db/1574647/Vanterra_Ventures>,
        <https://1145.am/db/1575612/Interlace_Ventures>,
        <https://1145.am/db/1575612/Valia_Ventures>,
        <https://1145.am/db/1578178/N49p>,
        <https://1145.am/db/1578178/Naventures>,
        <https://1145.am/db/1578327/Crit_Ventures>,
        <https://1145.am/db/1578327/Nextview_Ventures>,
        <https://1145.am/db/1579770/Schams_Ventures>,
        <https://1145.am/db/1579792/Crit_Ventures>,
        <https://1145.am/db/1579792/Nextview_Ventures>,
        <https://1145.am/db/1580468/Cohort_Ventures>,
        <https://1145.am/db/1582024/Avalon_Ventures>,
        <https://1145.am/db/1582111/Forepont_Capital_Partners>,
        <https://1145.am/db/1583413/Navigare_Ventures>,
        <https://1145.am/db/1615195/Digitalis_Ventures>,
        <https://1145.am/db/1616990/Digitalis_Ventures>,
        <https://1145.am/db/1632002/Catalio_Capital_Management>,
        <https://1145.am/db/1632028/Catalio_Capital_Management>,
        <https://1145.am/db/1632131/Catalio_Capital_Management>,
        <https://1145.am/db/1632156/Catalio_Capital_Management>,
        <https://1145.am/db/1638640/1digi_Ventures>,
        <https://1145.am/db/1649691/Sequoia_Capital>,
        <https://1145.am/db/1653506/Ascendum_Capital>,
        <https://1145.am/db/1653506/Citta_Capital>,
        <https://1145.am/db/1653506/Morgenthaler_Ventures>,
        <https://1145.am/db/1664837/Civilization_Ventures>,
        <https://1145.am/db/1664948/Dreamit_Ventures>,
        <https://1145.am/db/1669908/Aviso_Ventures>,
        <https://1145.am/db/1670128/Primary_Ventures>,
        <https://1145.am/db/1676513/Connect_Ventures>,
        <https://1145.am/db/1685482/Lavrock_Ventures>,
        <https://1145.am/db/1690703/Arkam_Ventures>,
        <https://1145.am/db/1690703/Prosus_Ventures>,
        <https://1145.am/db/1691060/Veblen_Ventures>,
        <https://1145.am/db/1691364/Ts_Ventures>,
        <https://1145.am/db/1693592/Cventures>,
        <https://1145.am/db/1693668/Sunny_Side_Ventures>,
        <https://1145.am/db/1693981/Boldstart_Ventures>,
        <https://1145.am/db/1694241/True_Ventures>,
        <https://1145.am/db/1694301/Dn_Capital>,
        <https://1145.am/db/1694417/Sequoia_Capital>,
        <https://1145.am/db/1694448/Presidio_Ventures>,
        <https://1145.am/db/1694592/Credo_Ventures>,
        <https://1145.am/db/1694592/Susa_Ventures>,
        <https://1145.am/db/1694798/Udc_Ventures>,
        <https://1145.am/db/1694947/Intersouth_Partners>,
        <https://1145.am/db/1695849/Salesforce_Ventures>,
        <https://1145.am/db/1695885/True_Ventures>,
        <https://1145.am/db/1697044/Palomar_Ventures>,
        <https://1145.am/db/1697044/Sequoia_Capital>,
        <https://1145.am/db/1697373/Lerer_Ventures>,
        <https://1145.am/db/1697910/Entrepia_Ventures>,
        <https://1145.am/db/1697910/Innovacom>,
        <https://1145.am/db/1698516/Engage_Ventures>,
        <https://1145.am/db/1698516/Tyh_Ventures>,
        <https://1145.am/db/1698644/Inovia_Capital>,
        <https://1145.am/db/1699263/Contour_Venture_Partners>,
        <https://1145.am/db/1700565/Sequoia_Capital>,
        <https://1145.am/db/1700572/Contour_Venture_Partners>,
        <https://1145.am/db/1701414/Sequoia_Capital>,
        <https://1145.am/db/1702003/Ventures_West>,
        <https://1145.am/db/1702065/Kreos_Capital>,
        <https://1145.am/db/1702472/Chiratae_Ventures>,
        <https://1145.am/db/1702483/Sure_Ventures_Usvp>,
        <https://1145.am/db/1702517/Prime_Ventures>,
        <https://1145.am/db/1702871/Charles_River_Ventures>,
        <https://1145.am/db/1703120/Point72_Ventures>,
        <https://1145.am/db/1703551/People_Ventures>,
        <https://1145.am/db/1703907/T-Venture>,
        <https://1145.am/db/1704404/True_Ventures>,
        <https://1145.am/db/1704740/T-Venture>,
        <https://1145.am/db/1704842/Se_Ventures>,
        <https://1145.am/db/1704871/Yl_Ventures>,
        <https://1145.am/db/1705825/Ventures_Platform>,
        <https://1145.am/db/1707227/Schams_Ventures>,
        <https://1145.am/db/1707540/Prosus_Ventures>,
        <https://1145.am/db/1707567/Contour_Venture_Partners>,
        <https://1145.am/db/1707567/Reign_Ventures>,
        <https://1145.am/db/1707637/Resolute_Ventures>,
        <https://1145.am/db/1707736/Artiman_Ventures>,
        <https://1145.am/db/1708555/20vc>,
        <https://1145.am/db/1708903/Kaedan_Capital>,
        <https://1145.am/db/1709168/Morgenthaler_Ventures>,
        <https://1145.am/db/1710027/Contour_Venture_Partners>,
        <https://1145.am/db/1711208/Sequoia_Capital>,
        <https://1145.am/db/1711383/Aviso_Ventures>,
        <https://1145.am/db/1711383/Pelion_Ventures>,
        <https://1145.am/db/1711750/Index_Ventures>,
        <https://1145.am/db/1711790/CRV>,
        <https://1145.am/db/1711849/K20_Ventures>,
        <https://1145.am/db/1712471/Cervin_Ventures>,
        <https://1145.am/db/1713712/Grotech_Ventures>,
        <https://1145.am/db/1714098/Charles_River_Ventures>,
        <https://1145.am/db/1714148/Ulu_Ventures>,
        <https://1145.am/db/1714624/Abstract_Ventures>,
        <https://1145.am/db/1714630/January_Ventures>,
        <https://1145.am/db/1716124/Appian_Ventures>,
        <https://1145.am/db/1716168/Onset_Ventures>,
        <https://1145.am/db/1716667/Dag_Ventures>,
        <https://1145.am/db/1717317/Index_Ventures>,
        <https://1145.am/db/1718012/Dag_Ventures>,
        <https://1145.am/db/1718012/Presidio_Ventures>,
        <https://1145.am/db/1718018/Ggv_Capital>,
        <https://1145.am/db/1718081/Jafco_Ventures>,
        <https://1145.am/db/1718748/Truist_Ventures>,
        <https://1145.am/db/1718787/J_Ventures>,
        <https://1145.am/db/1719362/True_Ventures>,
        <https://1145.am/db/1719370/Bv_Capital>,
        <https://1145.am/db/1720145/Bessemer_Ventures>,
        <https://1145.am/db/1720182/Convivialité_Ventures>,
        <https://1145.am/db/1720441/Origin_Ventures>,
        <https://1145.am/db/1721171/Citi_Ventures>,
        <https://1145.am/db/1721392/Redpoint_Ventures>,
        <https://1145.am/db/1721393/Trinity_Ventures>,
        <https://1145.am/db/1721548/Ggv_Capital>,
        <https://1145.am/db/1721548/Menlo_Ventures>,
        <https://1145.am/db/1722252/Onset_Ventures>,
        <https://1145.am/db/1723165/Menlo_Ventures>,
        <https://1145.am/db/1723664/T-Venture>,
        <https://1145.am/db/1723932/Citi_Ventures>,
        <https://1145.am/db/1724979/Jafco_Ventures>,
        <https://1145.am/db/1724979/Sequoia_Capital>,
        <https://1145.am/db/1725680/Index_Ventures>,
        <https://1145.am/db/1726088/Zeev_Ventures>,
        <https://1145.am/db/1726121/Index_Ventures>,
        <https://1145.am/db/1726149/Index_Ventures>,
        <https://1145.am/db/1726544/Ei_Ventures>,
        <https://1145.am/db/1727288/Sozo_Ventures>,
        <https://1145.am/db/1728569/Redpoint_Ventures>,
        <https://1145.am/db/1729186/Catamount_Ventures>,
        <https://1145.am/db/1731187/Rho_Ventures>,
        <https://1145.am/db/1731419/Redpoint_Ventures>,
        <https://1145.am/db/1734104/Alpana_Ventures>,
        <https://1145.am/db/1734104/Highsage_Ventures>,
        <https://1145.am/db/1734728/Talis_Capital>,
        <https://1145.am/db/1735194/Eqt_Ventures>,
        <https://1145.am/db/1735248/Corigin_Ventures>,
        <https://1145.am/db/1735726/Nextview_Ventures>,
        <https://1145.am/db/1735755/Firebolt_Ventures>,
        <https://1145.am/db/1735774/Alpha4_Ventures>,
        <https://1145.am/db/1736136/Ggv_Capital>,
        <https://1145.am/db/1737278/Crosslink_Capital>,
        <https://1145.am/db/1737392/Moxxie_Ventures>,
        <https://1145.am/db/1737979/CRV>,
        <https://1145.am/db/1738162/3one4_Capital>,
        <https://1145.am/db/1738300/Chryscapital>,
        <https://1145.am/db/1738415/Capnamic_Ventures>,
        <https://1145.am/db/1738444/Prosus_Ventures>,
        <https://1145.am/db/1738776/Illuminate_Ventures>,
        <https://1145.am/db/1739022/Eventures>,
        <https://1145.am/db/1739042/Experior_Venture_Fund>,
        <https://1145.am/db/1739064/Jsw_Ventures>,
        <https://1145.am/db/1739106/Sequoia_Capital>,
        <https://1145.am/db/1739120/Sequoia_Capital>,
        <https://1145.am/db/1739285/Sequoia_Capital>,
        <https://1145.am/db/1739630/Redsea_Ventures>,
        <https://1145.am/db/1739719/Seedplus>,
        <https://1145.am/db/1739851/Signum_Capital>,
        <https://1145.am/db/1739909/Root_Ventures>,
        <https://1145.am/db/1739946/Dn_Capital>,
        <https://1145.am/db/1740077/3one4_Capital>,
        <https://1145.am/db/1740665/First_Bridge_Ventures>,
        <https://1145.am/db/1740832/J_Ventures>,
        <https://1145.am/db/1740832/Susa_Ventures>,
        <https://1145.am/db/1740859/Ggv_Capital>,
        <https://1145.am/db/1741357/Dn_Capital>,
        <https://1145.am/db/1741575/Addventure>,
        <https://1145.am/db/1741635/Zeev_Ventures>,
        <https://1145.am/db/1742267/Firebolt_Ventures>,
        <https://1145.am/db/1742267/Point72_Ventures>,
        <https://1145.am/db/1743271/Liil_Ventures>,
        <https://1145.am/db/1743348/Felicis_Ventures>,
        <https://1145.am/db/1743409/Dreamit_Ventures>,
        <https://1145.am/db/1743737/Regah_Ventures>,
        <https://1145.am/db/1744229/R7>,
        <https://1145.am/db/1744775/Point72_Ventures>,
        <https://1145.am/db/1744864/Sequoia_Capital>,
        <https://1145.am/db/1744922/Aglaé_Ventures>,
        <https://1145.am/db/1745326/Eqt_Ventures>,
        <https://1145.am/db/1745326/Lios_Ventures>,
        <https://1145.am/db/1745326/Prime_Ventures>,
        <https://1145.am/db/1745746/Garuda_Ventures>,
        <https://1145.am/db/1745746/Starling_Ventures>,
        <https://1145.am/db/1745920/Sequoia_Capital>,
        <https://1145.am/db/1747252/Citi_Ventures>,
        <https://1145.am/db/1747391/Sequoia_Capital>,
        <https://1145.am/db/1747400/Eqt_Ventures>,
        <https://1145.am/db/1747503/Brighteye_Ventures>,
        <https://1145.am/db/1747722/Shinhan_Capital>,
        <https://1145.am/db/1747943/Altai_Ventures>,
        <https://1145.am/db/1748417/Zeev_Ventures>,
        <https://1145.am/db/1749226/Dn_Capital>,
        <https://1145.am/db/1749425/Ac_Ventures>,
        <https://1145.am/db/1749651/Colle_Capital>,
        <https://1145.am/db/1749911/Khwarizmi_Ventures>,
        <https://1145.am/db/1750942/Celesta_Capital>,
        <https://1145.am/db/1750942/Chiratae_Ventures>,
        <https://1145.am/db/1751135/Inovia_Capital>,
        <https://1145.am/db/1751312/Abstract_Ventures>,
        <https://1145.am/db/1751361/Kreos_Capital>,
        <https://1145.am/db/1751506/Ggv_Capital>,
        <https://1145.am/db/1751551/Gaingels>,
        <https://1145.am/db/1751553/Canapi_Ventures>,
        <https://1145.am/db/1751743/Intudo_Ventures>,
        <https://1145.am/db/1751800/Morpheus_Ventures>,
        <https://1145.am/db/1751954/Novastar_Ventures>,
        <https://1145.am/db/1752102/Origin_Ventures>,
        <https://1145.am/db/1752403/Yl_Ventures>,
        <https://1145.am/db/1752998/Aglaé_Ventures>,
        <https://1145.am/db/1753704/Apex_Ventures>,
        <https://1145.am/db/1753721/Financial_Venture_Studio>,
        <https://1145.am/db/1753721/Resolute_Ventures>,
        <https://1145.am/db/1753745/2i_Ventures>,
        <https://1145.am/db/1754211/Citi_Ventures>,
        <https://1145.am/db/1754211/Menlo_Ventures>,
        <https://1145.am/db/1754242/Gsv_Ventures>,
        <https://1145.am/db/1754595/Global_Ventures>,
        <https://1145.am/db/1754595/Otg_Ventures>,
        <https://1145.am/db/1754751/Menlo_Ventures>,
        <https://1145.am/db/1754787/Letsventure>,
        <https://1145.am/db/1754997/Alkeon_Capital>,
        <https://1145.am/db/1755086/Kollective_Ventures>,
        <https://1145.am/db/1755278/Zeev_Ventures>,
        <https://1145.am/db/1755704/Promus_Ventures>,
        <https://1145.am/db/1755828/Future_Ventures>,
        <https://1145.am/db/1755860/Dg_Ventures>,
        <https://1145.am/db/1755860/Intudo_Ventures>,
        <https://1145.am/db/1756040/Altos_Ventures>,
        <https://1145.am/db/1756094/CRV>,
        <https://1145.am/db/1756141/Index_Ventures>,
        <https://1145.am/db/1756231/Kreos_Capital>,
        <https://1145.am/db/1756326/Neotribe_Ventures>,
        <https://1145.am/db/1756384/Abstract_Ventures>,
        <https://1145.am/db/1756384/Lightspeed_Ventures>,
        <https://1145.am/db/1756599/True_Ventures>,
        <https://1145.am/db/1757035/Vectr_Ventures>,
        <https://1145.am/db/1757365/Will_Ventures>,
        <https://1145.am/db/1757382/Gl_Ventures>,
        <https://1145.am/db/1757590/Kreos_Capital>,
        <https://1145.am/db/1757772/Lorimer_Ventures>,
        <https://1145.am/db/1758193/Tenoneten_Ventures>,
        <https://1145.am/db/1758193/Valia_Ventures>,
        <https://1145.am/db/1758313/Venture_Field>,
        <https://1145.am/db/1758622/Oca_Ventures>,
        <https://1145.am/db/1759048/Avid_Ventures>,
        <https://1145.am/db/1759048/Lightspeed_Ventures>,
        <https://1145.am/db/1759567/J_Ventures>,
        <https://1145.am/db/1759922/Verance_Capital>,
        <https://1145.am/db/1760383/True_Ventures>,
        <https://1145.am/db/1760520/Prologis_Ventures>,
        <https://1145.am/db/1760816/Index_Ventures>,
        <https://1145.am/db/1760984/Index_Ventures>,
        <https://1145.am/db/1760984/Sequoia_Capital>,
        <https://1145.am/db/1760985/Frontier_Ventures>,
        <https://1145.am/db/1761126/Redpoint_Ventures>,
        <https://1145.am/db/1761566/Index_Ventures>,
        <https://1145.am/db/1761607/Menlo_Ventures>,
        <https://1145.am/db/1761607/Sinewave_Ventures>,
        <https://1145.am/db/1761957/Alkeon_Capital>,
        <https://1145.am/db/1761999/Ggv_Capital>,
        <https://1145.am/db/1762031/Menlo_Ventures>,
        <https://1145.am/db/1762055/Altos_Ventures>,
        <https://1145.am/db/1762277/Ac_Ventures>,
        <https://1145.am/db/1762453/Line_Ventures>,
        <https://1145.am/db/1762561/Grotech_Ventures>,
        <https://1145.am/db/1762669/Creandum>,
        <https://1145.am/db/1762844/Signum_Capital>,
        <https://1145.am/db/1763356/Aglaé_Ventures>,
        <https://1145.am/db/1763371/Spacecadet_Ventures>,
        <https://1145.am/db/1763395/Idc_Ventures>,
        <https://1145.am/db/1763565/Felicis_Ventures>,
        <https://1145.am/db/1763774/Ggv_Capital>,
        <https://1145.am/db/1763795/Ventures_Platform>,
        <https://1145.am/db/1763795/Xyz_Ventures>,
        <https://1145.am/db/1763875/Golden_Gate_Ventures>,
        <https://1145.am/db/1764027/Menlo_Ventures>,
        <https://1145.am/db/1764255/Pathbreaker_Ventures>,
        <https://1145.am/db/1764255/Stageone_Ventures>,
        <https://1145.am/db/1764345/Talis_Capital>,
        <https://1145.am/db/1764527/Presidio_Ventures>,
        <https://1145.am/db/1764527/Yl_Ventures>,
        <https://1145.am/db/1765273/Adevinta_Ventures>,
        <https://1145.am/db/1765273/Venturefriends>,
        <https://1145.am/db/1765372/Irobot_Ventures>,
        <https://1145.am/db/1765377/Redpoint_Ventures>,
        <https://1145.am/db/1765550/Sequoia_Capital>,
        <https://1145.am/db/1765646/Amiti_Ventures>,
        <https://1145.am/db/1765673/Salesforce_Ventures>,
        <https://1145.am/db/1766091/Inreach_Ventures>,
        <https://1145.am/db/1766096/Borealis_Ventures>,
        <https://1145.am/db/1766096/Northpond_Ventures>,
        <https://1145.am/db/1766253/Redpoint_Ventures>,
        <https://1145.am/db/1766253/True_Ventures>,
        <https://1145.am/db/1766540/Industry_Ventures>,
        <https://1145.am/db/1766978/Rga_Ventures>,
        <https://1145.am/db/1768099/Eventures>,
        <https://1145.am/db/1768363/Golden_Gate_Ventures>,
        <https://1145.am/db/1768841/Sequoia_Capital>,
        <https://1145.am/db/1769188/Felicis_Ventures>,
        <https://1145.am/db/1770095/Crosslink_Capital>,
        <https://1145.am/db/1770139/Victress_Capital>,
        <https://1145.am/db/1770265/Techstars_Ventures>,
        <https://1145.am/db/1770372/Avalon_Ventures>,
        <https://1145.am/db/1770372/Korelya_Capital>,
        <https://1145.am/db/1770802/Sequoia_Capital>,
        <https://1145.am/db/1770982/Gv>,
        <https://1145.am/db/1770982/Index_Ventures>,
        <https://1145.am/db/1771011/Ggv_Capital>,
        <https://1145.am/db/1771548/Seekdource_Capital>,
        <https://1145.am/db/1771613/Creandum>,
        <https://1145.am/db/1771642/Felicis_Ventures>,
        <https://1145.am/db/1772004/Raed_Ventures>,
        <https://1145.am/db/1772004/Seed_Equity_Venture_Partners>,
        <https://1145.am/db/1772381/Altos_Ventures>,
        <https://1145.am/db/1772452/Connect_Ventures>,
        <https://1145.am/db/1773130/Capnamic_Ventures>,
        <https://1145.am/db/1773143/Venturefriends>,
        <https://1145.am/db/1773323/Crosslink_Capital>,
        <https://1145.am/db/1774348/True_Ventures>,
        <https://1145.am/db/1774535/Felicis_Ventures>,
        <https://1145.am/db/1774535/Susa_Ventures>,
        <https://1145.am/db/1774658/Gv>,
        <https://1145.am/db/1775965/Felicis_Ventures>,
        <https://1145.am/db/1776340/Ggv_Capital>,
        <https://1145.am/db/1776340/Menlo_Ventures>,
        <https://1145.am/db/1776537/Origin_Ventures>,
        <https://1145.am/db/1776537/Tekton_Ventures>,
        <https://1145.am/db/1776621/Redpoint_Ventures>,
        <https://1145.am/db/1777289/Dn_Capital>,
        <https://1145.am/db/1777563/Evolv_Ventures>,
        <https://1145.am/db/1777563/Ggv_Capital>,
        <https://1145.am/db/1777848/Industry_Ventures>,
        <https://1145.am/db/1778935/Oryzn_Capital>,
        <https://1145.am/db/1780024/Partech_Ventures>,
        <https://1145.am/db/1782098/Addventure>,
        <https://1145.am/db/1782221/Point72_Ventures>,
        <https://1145.am/db/1783189/Citi_Ventures>,
        <https://1145.am/db/1784644/Creathor_Ventures>,
        <https://1145.am/db/1784964/Clear_Ventures>,
        <https://1145.am/db/1785361/M_Ventures>,
        <https://1145.am/db/1786249/Redpoint_Ventures>,
        <https://1145.am/db/1786249/Resolute_Ventures>,
        <https://1145.am/db/1786663/Edenred_Capital_Partners>,
        <https://1145.am/db/1786663/Eqt_Ventures>,
        <https://1145.am/db/1787249/Kpn_Ventures>,
        <https://1145.am/db/1787342/Korelya_Capital>,
        <https://1145.am/db/1787536/Point72_Ventures>,
        <https://1145.am/db/1787791/True_Ventures>,
        <https://1145.am/db/1787886/True_Ventures>,
        <https://1145.am/db/1788328/Index_Ventures>,
        <https://1145.am/db/1788570/Sequoia_Capital>,
        <https://1145.am/db/1788726/Redbeat_Capital>,
        <https://1145.am/db/1789460/Eventures>,
        <https://1145.am/db/1789754/Advancit_Capital>,
        <https://1145.am/db/1790280/Arthur_Ventures>,
        <https://1145.am/db/1790399/Capnamic_Ventures>,
        <https://1145.am/db/1790574/Crosslink_Capital>,
        <https://1145.am/db/1790574/Red_Swan_Ventures>,
        <https://1145.am/db/1790574/Sherpa_Ventures>,
        <https://1145.am/db/1790641/Dn_Capital>,
        <https://1145.am/db/1790771/Redpoint_Ventures>,
        <https://1145.am/db/1790777/Connect_Ventures>,
        <https://1145.am/db/1791216/True_Ventures>,
        <https://1145.am/db/1791303/Index_Ventures>,
        <https://1145.am/db/1791628/Industry_Ventures>,
        <https://1145.am/db/1791838/Advancit_Capital>,
        <https://1145.am/db/1792186/Sequoia_Capital>,
        <https://1145.am/db/1792771/Softtechvc>,
        <https://1145.am/db/1792887/Kaedan_Capital>,
        <https://1145.am/db/1792887/Stageone_Ventures>,
        <https://1145.am/db/1794699/Ws_Ventures>,
        <https://1145.am/db/1794935/Intervest_Co_Ltd>,
        <https://1145.am/db/1795020/Redpoint_Ventures>,
        <https://1145.am/db/1795210/Sequoia_Capital>,
        <https://1145.am/db/1795469/Index_Ventures>,
        <https://1145.am/db/1795538/Skystar_Capital>,
        <https://1145.am/db/1796109/Contour_Venture_Partners>,
        <https://1145.am/db/1796593/Tenoneten_Ventures>,
        <https://1145.am/db/1796901/Red_Swan_Ventures>,
        <https://1145.am/db/1796922/Cagni_Ventures>,
        <https://1145.am/db/1797209/Kdwc_Ventures>,
        <https://1145.am/db/1797518/Sequoia_Capital>,
        <https://1145.am/db/1797899/Brave_Ventures>,
        <https://1145.am/db/1797999/Redpoint_Ventures>,
        <https://1145.am/db/1798568/Index_Ventures>,
        <https://1145.am/db/1799099/Inovia_Capital>,
        <https://1145.am/db/1799184/Ggv_Capital>,
        <https://1145.am/db/1800232/Index_Ventures>,
        <https://1145.am/db/1800929/Ventureast>,
        <https://1145.am/db/1802086/High_Line_Ventures>,
        <https://1145.am/db/1802227/Advancit_Capital>,
        <https://1145.am/db/1802288/Sequoia_Capital>,
        <https://1145.am/db/1802336/Capnamic_Ventures>,
        <https://1145.am/db/1804102/True_Ventures>,
        <https://1145.am/db/1804247/Holtzbrinck_Ventures>,
        <https://1145.am/db/1804476/Felicis_Ventures>,
        <https://1145.am/db/1804476/True_Ventures>,
        <https://1145.am/db/1804992/Talis_Capital>,
        <https://1145.am/db/1805389/Industry_Ventures>,
        <https://1145.am/db/1805604/Connect_Ventures>,
        <https://1145.am/db/1805604/Inreach_Ventures>,
        <https://1145.am/db/1806644/Sequoia_Capital>,
        <https://1145.am/db/1806739/Golden_Gate_Ventures>,
        <https://1145.am/db/1808047/Salesforce_Ventures>,
        <https://1145.am/db/1808505/Helion_Ventures>,
        <https://1145.am/db/1808723/Mindworks_Ventures>,
        <https://1145.am/db/1808735/Commonangels_Ventures>,
        <https://1145.am/db/1809007/Sequoia_Capital>,
        <https://1145.am/db/1809844/Real_Ventures>,
        <https://1145.am/db/1809862/Acequia_Capital>,
        <https://1145.am/db/1810384/Starstrike_Ventures>,
        <https://1145.am/db/1810710/Ia_Ventures>,
        <https://1145.am/db/1810714/Catalus_Capital>,
        <https://1145.am/db/1810769/Eventures>,
        <https://1145.am/db/1810769/Sequoia_Capital>,
        <https://1145.am/db/1811357/Index_Ventures>,
        <https://1145.am/db/1812233/Sequoia_Capital>,
        <https://1145.am/db/1812856/Exfinity_Ventures>,
        <https://1145.am/db/1813375/Creandum>,
        <https://1145.am/db/1813575/Ggv_Capital>,
        <https://1145.am/db/1813944/Menlo_Ventures>,
        <https://1145.am/db/1814064/Index_Ventures>,
        <https://1145.am/db/1814643/Corigin_Ventures>,
        <https://1145.am/db/1814643/Launchcapital>,
        <https://1145.am/db/1815038/Plus_Ventures>,
        <https://1145.am/db/1815507/Globis_Capital_Partners>,
        <https://1145.am/db/1815697/Cherubic_Ventures>,
        <https://1145.am/db/1815701/True_Ventures>,
        <https://1145.am/db/1815886/Teneleven_Ventures>,
        <https://1145.am/db/1816491/Grotech_Ventures>,
        <https://1145.am/db/1818174/Advancit_Capital>,
        <https://1145.am/db/1818876/Kreos_Capital>,
        <https://1145.am/db/1818901/Sequoia_Capital>,
        <https://1145.am/db/1819374/Rothenberg_Ventures>,
        <https://1145.am/db/1819387/Index_Ventures>,
        <https://1145.am/db/1820882/Inven_Capital>,
        <https://1145.am/db/1821174/Index_Ventures>,
        <https://1145.am/db/1821711/Winton_Ventures>,
        <https://1145.am/db/1821752/Sequoia_Capital>,
        <https://1145.am/db/1823162/True_Ventures>,
        <https://1145.am/db/1823217/Kdc_Ventures>,
        <https://1145.am/db/1823217/Nbm_Ventures>,
        <https://1145.am/db/1823684/Dcm_Ventures>,
        <https://1145.am/db/1823684/Idg_Ventures>,
        <https://1145.am/db/1824252/Allos_Ventures>,
        <https://1145.am/db/1824253/Trinity_Ventures>,
        <https://1145.am/db/1824944/True_Ventures>,
        <https://1145.am/db/1825465/Ben_Narasin>,
        <https://1145.am/db/1825713/Menlo_Ventures>,
        <https://1145.am/db/1825946/Lerer_Ventures>,
        <https://1145.am/db/1826265/Idg_Ventures>,
        <https://1145.am/db/1826648/True_Ventures>,
        <https://1145.am/db/1826922/Ggv_Capital>,
        <https://1145.am/db/1827021/Dag_Ventures>,
        <https://1145.am/db/1828036/Redpoint_Ventures>,
        <https://1145.am/db/1828092/Eden_Ventures>,
        <https://1145.am/db/1828251/Golden_Gate_Ventures>,
        <https://1145.am/db/1828455/Quotidien_Ventures>,
        <https://1145.am/db/1828658/Focus_Ventures>,
        <https://1145.am/db/1828663/Great_Oaks_Ventures>,
        <https://1145.am/db/1828663/Inovia_Capital>,
        <https://1145.am/db/1829257/Sequoia_Capital>,
        <https://1145.am/db/1829422/Felicis_Ventures>,
        <https://1145.am/db/1829422/Rothenberg_Ventures>,
        <https://1145.am/db/1829612/Lerer_Ventures>,
        <https://1145.am/db/1830502/Frontline_Ventures>,
        <https://1145.am/db/1830613/True_Ventures>,
        <https://1145.am/db/1830809/Numecent>,
        <https://1145.am/db/1830809/T-Ventures>,
        <https://1145.am/db/1830817/Charles_River_Ventures>,
        <https://1145.am/db/1831577/Artiman_Ventures>,
        <https://1145.am/db/1831577/Sofinnova_Ventures>,
        <https://1145.am/db/1831764/Sequoia_Capital>,
        <https://1145.am/db/1832038/True_Ventures>,
        <https://1145.am/db/1832316/Partech_Ventures>,
        <https://1145.am/db/1832316/Scentan_Ventures>,
        <https://1145.am/db/1832316/Startcaps_Ventures>,
        <https://1145.am/db/1832856/Grotech_Ventures>,
        <https://1145.am/db/1834224/Avalon_Ventures>,
        <https://1145.am/db/1834224/Orix_Ventures>,
        <https://1145.am/db/1834305/Charles_River_Ventures>,
        <https://1145.am/db/1834334/Altos_Ventures>,
        <https://1145.am/db/1834334/Baseline_Ventures>,
        <https://1145.am/db/1834334/Firebolt_Ventures>,
        <https://1145.am/db/1834334/Lazerow_Ventures>,
        <https://1145.am/db/1834520/Ben_Horowitz>,
        <https://1145.am/db/1834541/Avalon_Ventures>,
        <https://1145.am/db/1834708/Sherpa_Ventures>,
        <https://1145.am/db/1834965/Lerer_Ventures>,
        <https://1145.am/db/1835229/Lerer_Ventures>,
        <https://1145.am/db/1835229/Trinity_Ventures>,
        <https://1145.am/db/1835229/Xg_Ventures>,
        <https://1145.am/db/1835740/Lerer_Ventures>,
        <https://1145.am/db/1835749/Gree_Ventures>,
        <https://1145.am/db/1835825/Focus_Ventures>,
        <https://1145.am/db/1836984/Siemer_Ventures>,
        <https://1145.am/db/1836984/Tekton_Ventures>,
        <https://1145.am/db/1837741/Menlo_Ventures>,
        <https://1145.am/db/1838026/Plus_Ventures>,
        <https://1145.am/db/1840775/Ggv_Capital>,
        <https://1145.am/db/1840881/Felicis_Ventures>,
        <https://1145.am/db/1840881/Trinity_Ventures>,
        <https://1145.am/db/1841176/Lerer_Ventures>,
        <https://1145.am/db/1841176/True_Ventures>,
        <https://1145.am/db/1842402/Index_Ventures>,
        <https://1145.am/db/1842402/Redpoint_Ventures>,
        <https://1145.am/db/1842898/Grotech_Ventures>,
        <https://1145.am/db/1843003/Eventures>,
        <https://1145.am/db/1843003/Index_Ventures>,
        <https://1145.am/db/1843031/Index_Ventures>,
        <https://1145.am/db/1843449/Redpoint_Ventures>,
        <https://1145.am/db/1843602/Nextview_Ventures>,
        <https://1145.am/db/1843659/Sequoia_Capital>,
        <https://1145.am/db/1844143/Inovia_Capital>,
        <https://1145.am/db/1844472/Sequoia_Capital>,
        <https://1145.am/db/1844737/True_Ventures>,
        <https://1145.am/db/1844931/Charles_River_Ventures>,
        <https://1145.am/db/1845308/Ia_Ventures>,
        <https://1145.am/db/1845960/Lerer_Ventures>,
        <https://1145.am/db/1846254/Index_Ventures>,
        <https://1145.am/db/1846483/Inovia_Capital>,
        <https://1145.am/db/1847463/Prism_Ventureworks>,
        <https://1145.am/db/1847752/T-Venture>,
        <https://1145.am/db/1848523/Trinity_Ventures>,
        <https://1145.am/db/1849673/Inventure_Partners>,
        <https://1145.am/db/1849884/Index_Ventures>,
        <https://1145.am/db/1849949/Holtzbrinck_Ventures>,
        <https://1145.am/db/1850020/Sequoia_Capital>,
        <https://1145.am/db/1850668/True_Ventures>,
        <https://1145.am/db/1850989/Artiman_Ventures>,
        <https://1145.am/db/1850989/Sequoia_Capital>,
        <https://1145.am/db/1851035/Acequia_Capital>,
        <https://1145.am/db/1851035/Index_Ventures>,
        <https://1145.am/db/1851035/Redpoint_Ventures>,
        <https://1145.am/db/1851705/Promus_Ventures>,
        <https://1145.am/db/1851854/Partech_Ventures>,
        <https://1145.am/db/1851923/Dag_Ventures>,
        <https://1145.am/db/1852308/Plus_Ventures>,
        <https://1145.am/db/1852513/Quotidian_Ventures>,
        <https://1145.am/db/1852513/Trestle_Ventures>,
        <https://1145.am/db/1852556/Dave_Morin>,
        <https://1145.am/db/1852806/Redpoint_Ventures>,
        <https://1145.am/db/1852870/Golden_Gate_Ventures>,
        <https://1145.am/db/1852870/Siemer_Ventures>,
        <https://1145.am/db/1853417/Catamount_Ventures>,
        <https://1145.am/db/1853496/T-Ventures>,
        <https://1145.am/db/1854200/Ggv_Capital>,
        <https://1145.am/db/1854201/Charles_River_Ventures>,
        <https://1145.am/db/1854786/Eden_Ventures>,
        <https://1145.am/db/1854874/Crosslink_Capital>,
        <https://1145.am/db/1854874/Sherpa_Ventures>,
        <https://1145.am/db/1854874/Softtech>,
        <https://1145.am/db/1855353/Sequoia_Capital>,
        <https://1145.am/db/1855363/True_Ventures>,
        <https://1145.am/db/1855403/Rho_Ventures>,
        <https://1145.am/db/1855780/Bds_Ventures>,
        <https://1145.am/db/1855780/Ggv_Capital>,
        <https://1145.am/db/1856191/Creandum>,
        <https://1145.am/db/1856380/Softtech>,
        <https://1145.am/db/1856402/Sequoia_Capital>,
        <https://1145.am/db/1856457/Aeris_Capital>,
        <https://1145.am/db/1856616/Redpoint_Ventures>,
        <https://1145.am/db/1856834/Sequoia_Capital>,
        <https://1145.am/db/1857635/Rikard_Steiber>,
        <https://1145.am/db/1857659/Revolution_Ventures>,
        <https://1145.am/db/1857930/Inovia_Capital>,
        <https://1145.am/db/1857930/Version_One_Ventures>,
        <https://1145.am/db/1858323/Avalon_Ventures>,
        <https://1145.am/db/1858545/Sequoia_Capital>,
        <https://1145.am/db/1858592/Apex_Venture_Partners>,
        <https://1145.am/db/1858592/Origin_Ventures>,
        <https://1145.am/db/1858991/Capnamic_Ventures>,
        <https://1145.am/db/1859199/True_Ventures>,
        <https://1145.am/db/1859314/Version_One_Ventures>,
        <https://1145.am/db/1860163/Inovia_Capital>,
        <https://1145.am/db/1860345/Commonangels>,
        <https://1145.am/db/1860345/Launchcapital>,
        <https://1145.am/db/1861054/Sequoia_Capital>,
        <https://1145.am/db/1861355/Rho_Ventures>,
        <https://1145.am/db/1862590/Felicis_Ventures>,
        <https://1145.am/db/1862878/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1863147/Apex_Venture_Partners>,
        <https://1145.am/db/1864601/Trinity_Ventures>,
        <https://1145.am/db/1864646/Inventus_Capital>,
        <https://1145.am/db/1865436/Sequoia_Capital>,
        <https://1145.am/db/1865480/Felicis_Ventures>,
        <https://1145.am/db/1865480/Sequoia_Capital>,
        <https://1145.am/db/1865480/Sherpalo_Ventures>,
        <https://1145.am/db/1866032/Launchcapital>,
        <https://1145.am/db/1866134/Embarcadero_Ventures>,
        <https://1145.am/db/1866134/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1866155/Presidio_Ventures>,
        <https://1145.am/db/1867543/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1867599/Cava_Capital>,
        <https://1145.am/db/1868107/Redpoint_Ventures>,
        <https://1145.am/db/1868109/Charles_River_Ventures>,
        <https://1145.am/db/1868178/True_Ventures>,
        <https://1145.am/db/1870015/Redpoint_Ventures>,
        <https://1145.am/db/1870465/Nextview_Ventures>,
        <https://1145.am/db/1871221/True_Ventures>,
        <https://1145.am/db/1871574/Redpoint_Ventures>,
        <https://1145.am/db/1871777/Charles_River_Ventures>,
        <https://1145.am/db/1871784/Charles_River_Ventures>,
        <https://1145.am/db/1871888/Charles_River_Ventures>,
        <https://1145.am/db/1873191/El_Dorado_Ventures>,
        <https://1145.am/db/1873680/Crosslink_Capital>,
        <https://1145.am/db/1873680/Lerer_Ventures>,
        <https://1145.am/db/1873680/Xg_Ventures>,
        <https://1145.am/db/1874749/True_Ventures>,
        <https://1145.am/db/1874937/Quotidian_Ventures>,
        <https://1145.am/db/1877243/Felicis_Ventures>,
        <https://1145.am/db/1877283/Northzone_Ventures>,
        <https://1145.am/db/1877473/True_Ventures>,
        <https://1145.am/db/1877642/Dag_Ventures>,
        <https://1145.am/db/1878620/Ggv_Capital>,
        <https://1145.am/db/1879279/High_Line_Ventures>,
        <https://1145.am/db/1879759/T-Venture>,
        <https://1145.am/db/1880679/Northzone_Ventures>,
        <https://1145.am/db/1881464/Ggv_Capital>,
        <https://1145.am/db/1881748/Morgenthaler_Ventures>,
        <https://1145.am/db/1882330/New_World_Ventures>,
        <https://1145.am/db/1882727/Charles_River_Ventures>,
        <https://1145.am/db/1882907/Starfish_Ventures>,
        <https://1145.am/db/1883568/Eden_Ventures>,
        <https://1145.am/db/1883572/Astutia_Ventures>,
        <https://1145.am/db/1886402/New_Atlantic_Ventures>,
        <https://1145.am/db/1886566/Sequoia_Capital>,
        <https://1145.am/db/1889394/Focus_Ventures>,
        <https://1145.am/db/1889629/Sequoia_Capital>,
        <https://1145.am/db/1890000/Lerer_Ventures>,
        <https://1145.am/db/1890122/East_Ventures>,
        <https://1145.am/db/1890133/Crosslink_Capital>,
        <https://1145.am/db/1890133/Dag_Ventures>,
        <https://1145.am/db/1890133/Focus_Ventures>,
        <https://1145.am/db/1890157/Morgenthaler_Ventures>,
        <https://1145.am/db/1890208/Menlo_Ventures>,
        <https://1145.am/db/1890619/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1890839/Inovia_Capital>,
        <https://1145.am/db/1890903/Miven_Ventures>,
        <https://1145.am/db/1891615/Holtzbrinck_Ventures>,
        <https://1145.am/db/1891777/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1891913/New_World_Ventures>,
        <https://1145.am/db/1891913/Oca_Ventures>,
        <https://1145.am/db/1891926/New_World_Ventures>,
        <https://1145.am/db/1892050/Charles_River_Ventures>,
        <https://1145.am/db/1892105/Crosscreek_Capital>,
        <https://1145.am/db/1892105/Industry_Ventures>,
        <https://1145.am/db/1892106/Altos_Ventures>,
        <https://1145.am/db/1892106/Illuminate_Ventures>,
        <https://1145.am/db/1892620/True_Ventures>,
        <https://1145.am/db/1892674/Appian_Ventures>,
        <https://1145.am/db/1892902/Crosslink_Capital>,
        <https://1145.am/db/1892955/Guy_Gamzu>,
        <https://1145.am/db/1895072/Nextview_Ventures>,
        <https://1145.am/db/1895951/Windward_Ventures>,
        <https://1145.am/db/1896159/Ia_Ventures>,
        <https://1145.am/db/1896185/Index_Ventures>,
        <https://1145.am/db/1896379/Index_Ventures>,
        <https://1145.am/db/1896379/Redpoint_Ventures>,
        <https://1145.am/db/1896419/True_Ventures>,
        <https://1145.am/db/1902330/Baseline_Ventures>,
        <https://1145.am/db/1905483/Industry_Ventures>,
        <https://1145.am/db/1905858/Index_Ventures>,
        <https://1145.am/db/1907771/Dag_Ventures>,
        <https://1145.am/db/1909430/Menlo_Ventures>,
        <https://1145.am/db/1909651/Revolution_Ventures>,
        <https://1145.am/db/1910694/True_Ventures>,
        <https://1145.am/db/1910922/Charles_River_Ventures>,
        <https://1145.am/db/1912684/Charles_River_Ventures>,
        <https://1145.am/db/1913863/Tl_Ventures>,
        <https://1145.am/db/1913874/Redpoint_Ventures>,
        <https://1145.am/db/1914220/Index_Ventures>,
        <https://1145.am/db/1915393/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1915862/Dag_Ventures>,
        <https://1145.am/db/1915862/Focus_Ventures>,
        <https://1145.am/db/1919724/Dag_Ventures>,
        <https://1145.am/db/1920478/Dawntreader_Ventures>,
        <https://1145.am/db/1920837/Onset_Ventures>,
        <https://1145.am/db/1927817/Trm_Ventures>,
        <https://1145.am/db/1939926/Cobalt_Ventures>,
        <https://1145.am/db/1945479/Crosslink_Capital>,
        <https://1145.am/db/1947303/Cavallo_Ventures>,
        <https://1145.am/db/1947312/Boldstart_Ventures>,
        <https://1145.am/db/1952989/Singularity_Ventures>,
        <https://1145.am/db/1954147/Accomplice_Ventures>,
        <https://1145.am/db/1957179/Sozo_Ventures>,
        <https://1145.am/db/1958963/Prosus_Ventures>,
        <https://1145.am/db/1959001/Capital_Technology_Ventures>,
        <https://1145.am/db/1959001/Glasswing_Ventures>,
        <https://1145.am/db/1962819/Connetic_Ventures>,
        <https://1145.am/db/1967592/Firebolt_Ventures>,
        <https://1145.am/db/1967683/Dig_Ventures_Vine_Ventures>,
        <https://1145.am/db/1975490/Northview_Ventures>,
        <https://1145.am/db/1975547/Nanban_Ventures>,
        <https://1145.am/db/1975547/Sinewave_Ventures>,
        <https://1145.am/db/1986122/Menlo_Ventures>,
        <https://1145.am/db/1995926/Neotribe_Ventures>,
        <https://1145.am/db/1998196/Gni_Group_Ltd>,
        <https://1145.am/db/1999771/Servicenow_Ventures>,
        <https://1145.am/db/2004427/Convivialité_Ventures>,
        <https://1145.am/db/2005131/Wwventures>,
        <https://1145.am/db/2007132/Nventures>,
        <https://1145.am/db/2020041/Inovia_Capital>,
        <https://1145.am/db/2020041/TCV>,
        <https://1145.am/db/2023596/Salesforce_Ventures>,
        <https://1145.am/db/2025081/True_Ventures>,
        <https://1145.am/db/2029648/Sequoia_Capital>,
        <https://1145.am/db/2035454/Gv>,
        <https://1145.am/db/2036021/Clear_Ventures>,
        <https://1145.am/db/2038783/Sequoia_Capital>,
        <https://1145.am/db/2039177/Stellantis_Ventures>,
        <https://1145.am/db/2041480/Brunnur_Ventures>,
        <https://1145.am/db/2042858/Gv>,
        <https://1145.am/db/2044380/20sales>,
        <https://1145.am/db/2045587/Veritec_Ventures>,
        <https://1145.am/db/2050229/Nventures>,
        <https://1145.am/db/2050359/At_One_Ventures>,
        <https://1145.am/db/2051164/Aviso_Ventures>,
        <https://1145.am/db/2053027/Glasswing_Ventures>,
        <https://1145.am/db/2055707/Globis_Capital_Partners>,
        <https://1145.am/db/2056931/We_Ventures>,
        <https://1145.am/db/2060003/Crit_Ventures_100___100_Ventures>,
        <https://1145.am/db/2061278/Incisive_Ventures>,
        <https://1145.am/db/2061278/Volo_Ventures>,
        <https://1145.am/db/2063642/Clear_Bridge_Ventures>,
        <https://1145.am/db/2063967/Vsquared_Ventures>,
        <https://1145.am/db/2069147/Boldstart_Ventures>,
        <https://1145.am/db/2069147/Pelion_Ventures>,
        <https://1145.am/db/2069147/Salesforce_Ventures>,
        <https://1145.am/db/2069495/Intermountain_Ventures>,
        <https://1145.am/db/2069495/Northpond_Ventures>,
        <https://1145.am/db/2073129/Abstract_Ventures>,
        <https://1145.am/db/2073132/Idc_Ventures>,
        <https://1145.am/db/2073480/Astellas_Venture_Management>,
        <https://1145.am/db/2075625/Rocketship_Ventures>,
        <https://1145.am/db/2081180/S4s_Ventures>,
        <https://1145.am/db/2081674/Capital_One_Ventures>,
        <https://1145.am/db/2082068/Arctern_Ventures>,
        <https://1145.am/db/2082068/Prelude_Ventures>,
        <https://1145.am/db/2083987/Vanterra_Ventures>,
        <https://1145.am/db/2087289/Jven_Capital>,
        <https://1145.am/db/2087289/Northpond_Ventures>,
        <https://1145.am/db/2089206/Crescendo_Venture_Partners>,
        <https://1145.am/db/2093427/Yl_Ventures>,
        <https://1145.am/db/2093713/Yl_Ventures>,
        <https://1145.am/db/209861/Crosslink_Capital>,
        <https://1145.am/db/2100116/Epic_Ventures>,
        <https://1145.am/db/2107533/Globis_Capital_Partners>,
        <https://1145.am/db/2109529/Point72_Ventures>,
        <https://1145.am/db/2109799/Sofinnova_Partners>,
        <https://1145.am/db/2109932/Catalio_Capital_Management>,
        <https://1145.am/db/2109932/Epic_Ventures>,
        <https://1145.am/db/2109932/Intermountain_Ventures>,
        <https://1145.am/db/2109932/North_South_Ventures>,
        <https://1145.am/db/2116769/Celesta_Capital>,
        <https://1145.am/db/2116769/Chiratae_Ventures>,
        <https://1145.am/db/2123953/Amex_Ventures>,
        <https://1145.am/db/2123953/Industry_Ventures>,
        <https://1145.am/db/2123953/Infinity_Ventures>,
        <https://1145.am/db/2124766/P1_Ventures>,
        <https://1145.am/db/2125182/Nevcaut_Ventures>,
        <https://1145.am/db/2125182/Ulu_Ventures>,
        <https://1145.am/db/2125927/1984_Ventures>,
        <https://1145.am/db/2127882/Akkadian_Ventures>,
        <https://1145.am/db/2134989/Clear_Ventures>,
        <https://1145.am/db/2134989/Felicis_Ventures>,
        <https://1145.am/db/2141183/S_Ventures>,
        <https://1145.am/db/2141328/Connetic_Ventures>,
        <https://1145.am/db/2143438/Scorpio_Capital>,
        <https://1145.am/db/2147767/Catapult_Ventures>,
        <https://1145.am/db/2147767/Tenoneten_Ventures>,
        <https://1145.am/db/2151983/CRV>,
        <https://1145.am/db/2151983/Greatpoint_Ventures>,
        <https://1145.am/db/2155426/Brighteyes_Ventures>,
        <https://1145.am/db/2155625/Sofinnova_Partners>,
        <https://1145.am/db/2164121/Menlo_Ventures>,
        <https://1145.am/db/2169799/Nwise_Ventures>,
        <https://1145.am/db/217906/Sequoia_Capital>,
        <https://1145.am/db/2181016/Foresite_Capital>,
        <https://1145.am/db/2182443/Global_Ventures>,
        <https://1145.am/db/2183352/Optum_Ventures>,
        <https://1145.am/db/2186568/Frist_Cressey_Ventures>,
        <https://1145.am/db/2186568/Springrock_Ventures>,
        <https://1145.am/db/2186949/Greatpoint_Ventures_And_Cross_Creek>,
        <https://1145.am/db/2186949/Springrock_Ventures>,
        <https://1145.am/db/2190141/Link_Ventures>,
        <https://1145.am/db/2192636/TCV>,
        <https://1145.am/db/219311/Origin_Ventures>,
        <https://1145.am/db/2196875/Sequoia_Capital>,
        <https://1145.am/db/2208603/McKesson_Ventures>,
        <https://1145.am/db/2210557/True_Ventures>,
        <https://1145.am/db/221321/Ggv_Capital>,
        <https://1145.am/db/2214690/Idg_Ventures>,
        <https://1145.am/db/2254568/Felicis_Ventures>,
        <https://1145.am/db/2264763/True_Ventures>,
        <https://1145.am/db/2283006/Catalio_Capital_Management>,
        <https://1145.am/db/2283185/Catalio_Capital_Management>,
        <https://1145.am/db/2283185/Northpond_Ventures>,
        <https://1145.am/db/2284412/Soleus_Capital>,
        <https://1145.am/db/2286665/Shanda_Group>,
        <https://1145.am/db/2288209/Echelon_Ventures>,
        <https://1145.am/db/2288596/Sanderling_Ventures>,
        <https://1145.am/db/2291277/Foresite_Capital>,
        <https://1145.am/db/2293172/Prospect_Ventures>,
        <https://1145.am/db/2294202/Trinitas_Capital>,
        <https://1145.am/db/2294815/Foresite_Capital>,
        <https://1145.am/db/2295253/Arkitekt_Ventures>,
        <https://1145.am/db/2295539/Sofinnova_Ventures>,
        <https://1145.am/db/2296249/Proxima_Ventures>,
        <https://1145.am/db/2296869/Dcm_Ventures>,
        <https://1145.am/db/2297406/Sequoia_Capital>,
        <https://1145.am/db/2298897/Eshelman_Ventures>,
        <https://1145.am/db/2300254/Sequoia_Capital>,
        <https://1145.am/db/2302351/Rho_Ventures>,
        <https://1145.am/db/2302731/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/2302750/Sofinnova_Partners>,
        <https://1145.am/db/2302897/Ventures_West_Capital>,
        <https://1145.am/db/2303098/Seaflower_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304606/Prism_Ventureworks>,
        <https://1145.am/db/2304606/Sofinnova_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2305745/Sanderling_Ventures>,
        <https://1145.am/db/2306281/Sanderling_Ventures>,
        <https://1145.am/db/2306568/Cmea_Ventures>,
        <https://1145.am/db/2306568/Sofinnova_Ventures>,
        <https://1145.am/db/2309507/Rho_Ventures>,
        <https://1145.am/db/2309840/Index_Ventures>,
        <https://1145.am/db/2311069/Morgenthaler_Ventures>,
        <https://1145.am/db/2311069/Sofinnova_Ventures>,
        <https://1145.am/db/2312288/Pappas_Ventures>,
        <https://1145.am/db/2312792/Onset_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2314380/Puretech_Ventures>,
        <https://1145.am/db/2314397/Pappas_Ventures>,
        <https://1145.am/db/2314397/Sofinnova_Ventures>,
        <https://1145.am/db/2314400/Pappas_Ventures>,
        <https://1145.am/db/2314400/Sofinnova_Ventures>,
        <https://1145.am/db/2314515/Apjohnventures>,
        <https://1145.am/db/2315754/Arcturus_Capital>,
        <https://1145.am/db/2317779/Index_Ventures>,
        <https://1145.am/db/2317779/Sofinnova_Partners>,
        <https://1145.am/db/2319777/Astellas_Venture_Management>,
        <https://1145.am/db/2321856/Ventures_West_Capital_Ltd>,
        <https://1145.am/db/2323785/Eshelman_Ventures>,
        <https://1145.am/db/2324195/Sofinnova_Ventures>,
        <https://1145.am/db/2325015/True_Ventures>,
        <https://1145.am/db/2325140/Index_Ventures>,
        <https://1145.am/db/2325257/Ventures_West>,
        <https://1145.am/db/2325337/Resolvyx>,
        <https://1145.am/db/2326080/Felicis_Ventures>,
        <https://1145.am/db/2326362/Nextech_Venture>,
        <https://1145.am/db/2326404/Intersouth_Partners>,
        <https://1145.am/db/2328585/Cmea_Ventures>,
        <https://1145.am/db/2329870/Sofinnova_Partners>,
        <https://1145.am/db/2330775/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335587/Sofinnova_Partners>,
        <https://1145.am/db/2338023/Cipla_Ventures>,
        <https://1145.am/db/2338196/Index_Ventures>,
        <https://1145.am/db/2338236/Sanderling_Ventures>,
        <https://1145.am/db/2338703/Wavepoint_Ventures>,
        <https://1145.am/db/2339206/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2340429/Mohr_Davidow_Ventures>,
        <https://1145.am/db/2341896/Sofinnova_Ventures>,
        <https://1145.am/db/2341942/High-Tech_Gründerfonds>,
        <https://1145.am/db/2342998/Sofinnova_Ventures>,
        <https://1145.am/db/2343184/Jven_Capital>,
        <https://1145.am/db/2345017/Venture_Investments>,
        <https://1145.am/db/2346300/High-Tech_Gründerfonds>,
        <https://1145.am/db/2346452/Aescap_Venture>,
        <https://1145.am/db/2346532/Pappas_Ventures>,
        <https://1145.am/db/2346978/Ventures_West_Capital>,
        <https://1145.am/db/2347571/Index_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2348618/Index_Ventures>,
        <https://1145.am/db/2349096/Sofinnova_Partners>,
        <https://1145.am/db/2349096/Sofinnova_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2350044/Avalon_Ventures>,
        <https://1145.am/db/2352436/Forward_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2356384/Sofinnova_Partners>,
        <https://1145.am/db/2357487/Savitr_Capital>,
        <https://1145.am/db/2358050/Sofinnova_Ventures>,
        <https://1145.am/db/2358657/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358725/Sofinnova_Ventures>,
        <https://1145.am/db/2358747/Solon_Ventures>,
        <https://1145.am/db/2358812/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2359562/Pappas_Ventures>,
        <https://1145.am/db/2359960/Sofinnova_Partners>,
        <https://1145.am/db/2362638/Launchpad_Venture_Group>,
        <https://1145.am/db/2363460/Rho_Ventures>,
        <https://1145.am/db/2363854/Chrysalis_Ventures>,
        <https://1145.am/db/2364820/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2365103/Aescap_Venture>,
        <https://1145.am/db/2367675/Avalon_Ventures>,
        <https://1145.am/db/2369967/Foresite_Capital>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2371160/Sofinnova_Ventures>,
        <https://1145.am/db/238282/Carnrite_Ventures>,
        <https://1145.am/db/2400536/Capital_One_Ventures>,
        <https://1145.am/db/2423653/Venturewell>,
        <https://1145.am/db/253438/Esplanade_Ventures>,
        <https://1145.am/db/254357/Ulu_Ventures>,
        <https://1145.am/db/2549491/Ktb_Ventures>,
        <https://1145.am/db/2552636/Morningside_Ventures>,
        <https://1145.am/db/2569491/High-Tech_Gründerfonds>,
        <https://1145.am/db/2570138/Sherpa_Ventures>,
        <https://1145.am/db/2570481/Morgenthaler_Ventures>,
        <https://1145.am/db/2570483/Morgenthaler_Ventures>,
        <https://1145.am/db/2577022/Sofinnova_Partners>,
        <https://1145.am/db/2577022/Sofinnova_Ventures>,
        <https://1145.am/db/2603254/Salesforce_Ventures>,
        <https://1145.am/db/2628424/Verana_Networks>,
        <https://1145.am/db/2628848/Neocarta_Ventures>,
        <https://1145.am/db/2635849/Mohr_Davidow_Ventures>,
        <https://1145.am/db/2638432/Nissay_Capital>,
        <https://1145.am/db/2641337/Promus_Ventures>,
        <https://1145.am/db/2641337/True_Ventures>,
        <https://1145.am/db/2654391/Biggell_Finance>,
        <https://1145.am/db/265532/Ulu_Ventures>,
        <https://1145.am/db/2702871/Inovia_Capital>,
        <https://1145.am/db/274170/G1_Ventures>,
        <https://1145.am/db/2754677/Golden_Gate_Ventures>,
        <https://1145.am/db/2765022/Garuda_Ventures>,
        <https://1145.am/db/2765030/Daniel_Ventures>,
        <https://1145.am/db/2765418/Rw3_Ventures>,
        <https://1145.am/db/2786411/Allegion_Ventures>,
        <https://1145.am/db/2788052/Rx_Ventures>,
        <https://1145.am/db/2790064/Novastar_Ventures>,
        <https://1145.am/db/2794396/Snowpoint_Ventures>,
        <https://1145.am/db/2797562/Menlo_Ventures>,
        <https://1145.am/db/283272/Salesforce_Ventures>,
        <https://1145.am/db/283607/Salesforce_Ventures>,
        <https://1145.am/db/293715/Signum_Capital>,
        <https://1145.am/db/293849/Felicis_Ventures>,
        <https://1145.am/db/293891/Ggv_Capital>,
        <https://1145.am/db/299738/Steadfast_Capital_Ventures>,
        <https://1145.am/db/306236/Index_Ventures>,
        <https://1145.am/db/319155/Bgv_Ventures>,
        <https://1145.am/db/323273/Index_Ventures>,
        <https://1145.am/db/341984/Salesforce_Ventures>,
        <https://1145.am/db/341984/Sequoia_Capital>,
        <https://1145.am/db/341990/Salesforce_Ventures>,
        <https://1145.am/db/341990/Sequoia_Capital>,
        <https://1145.am/db/343459/F7_Ventures>,
        <https://1145.am/db/346598/Salesforce_Ventures>,
        <https://1145.am/db/348442/Triventures>,
        <https://1145.am/db/348659/Launchpad_Capital>,
        <https://1145.am/db/361303/Sequoia_Capital>,
        <https://1145.am/db/364168/Alerion_Ventures>,
        <https://1145.am/db/367592/Gv>,
        <https://1145.am/db/367592/Sequoia_Capital>,
        <https://1145.am/db/388551/Vestigo_Ventures>,
        <https://1145.am/db/396305/Real_Ventures>,
        <https://1145.am/db/402103/1776_Ventures>,
        <https://1145.am/db/402701/January_Ventures>,
        <https://1145.am/db/403810/Riverstone_Ventures>,
        <https://1145.am/db/410322/Gv>,
        <https://1145.am/db/410473/Celesta_Capital>,
        <https://1145.am/db/410473/Lytical_Ventures_And_Nepenthe_Capital>,
        <https://1145.am/db/410529/Goodyear_Ventures>,
        <https://1145.am/db/411539/Zeev_Ventures>,
        <https://1145.am/db/412020/Defi_Ventures_Inc>,
        <https://1145.am/db/415322/CRV>,
        <https://1145.am/db/416041/Akkadian_Ventures>,
        <https://1145.am/db/416041/Signia_Ventures>,
        <https://1145.am/db/416041/Zeev_Ventures>,
        <https://1145.am/db/419489/Point72_Ventures>,
        <https://1145.am/db/424877/North_First_Ventures>,
        <https://1145.am/db/425262/Yl_Ventures>,
        <https://1145.am/db/425423/True_Ventures>,
        <https://1145.am/db/425973/Will_Ventures>,
        <https://1145.am/db/426615/Sequoia_Capital>,
        <https://1145.am/db/429179/C5_Capital>,
        <https://1145.am/db/430986/Cortado_Ventures>,
        <https://1145.am/db/434334/1up_Ventures>,
        <https://1145.am/db/435691/Klick_Ventures>,
        <https://1145.am/db/439819/Cavu_Ventures>,
        <https://1145.am/db/441319/Celesta_Capital>,
        <https://1145.am/db/444105/Exfinity_Ventures>,
        <https://1145.am/db/445365/Revolution_Ventures>,
        <https://1145.am/db/446341/Sinewave_Ventures>,
        <https://1145.am/db/455558/Intudo_Ventures>,
        <https://1145.am/db/457435/Alerce>,
        <https://1145.am/db/457435/Clin>,
        <https://1145.am/db/460454/Index_Ventures>,
        <https://1145.am/db/471253/Gv>,
        <https://1145.am/db/471436/Citi_Ventures>,
        <https://1145.am/db/471504/Canapi_Ventures>,
        <https://1145.am/db/473030/Highsage_Ventures>,
        <https://1145.am/db/474928/Susa_Ventures>,
        <https://1145.am/db/478049/Worldquant_Ventures>,
        <https://1145.am/db/479113/Index_Ventures>,
        <https://1145.am/db/479113/Menlo_Ventures>,
        <https://1145.am/db/485616/K3_Ventures>,
        <https://1145.am/db/486858/Gaingels>,
        <https://1145.am/db/486901/Gaingels>,
        <https://1145.am/db/488743/Salesforce_Ventures>,
        <https://1145.am/db/491130/Raiven_Capital>,
        <https://1145.am/db/491338/Raiven_Capital>,
        <https://1145.am/db/493560/Tyh_Ventures>,
        <https://1145.am/db/495912/Regah_Ventures>,
        <https://1145.am/db/506588/Trinity_Ventures>,
        <https://1145.am/db/508145/Sora_Finance>,
        <https://1145.am/db/508161/Sora_Finance>,
        <https://1145.am/db/510565/Epic_Ventures>,
        <https://1145.am/db/513305/Avid_Ventures>,
        <https://1145.am/db/513305/Canapi_Ventures>,
        <https://1145.am/db/513897/Rlc_Ventures>,
        <https://1145.am/db/514151/Rlc_Ventures>,
        <https://1145.am/db/516396/Acequia_Capital>,
        <https://1145.am/db/517213/Acequia_Capital>,
        <https://1145.am/db/523349/Osf_Ventures>,
        <https://1145.am/db/523776/Root_Ventures>,
        <https://1145.am/db/525285/Inventum_Ventures>,
        <https://1145.am/db/525285/Optima_Ventures>,
        <https://1145.am/db/526109/Ggv_Capital>,
        <https://1145.am/db/526175/Ridgeline_Ventures>,
        <https://1145.am/db/529812/Inventum_Ventures>,
        <https://1145.am/db/529812/Optima_Ventures>,
        <https://1145.am/db/532016/Id_Ventures>,
        <https://1145.am/db/539571/Origin_Ventures>,
        <https://1145.am/db/545843/Capital_One_Ventures>,
        <https://1145.am/db/545852/Boxone_Ventures>,
        <https://1145.am/db/545852/Panache_Ventures>,
        <https://1145.am/db/547770/BGV>,
        <https://1145.am/db/547944/BGV>,
        <https://1145.am/db/554552/Konvoy_Ventures>,
        <https://1145.am/db/555193/Illumina_Ventures>,
        <https://1145.am/db/555193/Technology_Venture_Partners>,
        <https://1145.am/db/556705/Congress_Ave_Ventures>,
        <https://1145.am/db/558005/Illumina_Ventures>,
        <https://1145.am/db/558005/Technology_Venture_Partners>,
        <https://1145.am/db/558877/Falabella_Ventures>,
        <https://1145.am/db/559220/Ulu_Ventures>,
        <https://1145.am/db/561662/Redpoint_Ventures>,
        <https://1145.am/db/561662/Vandelay_Ventures>,
        <https://1145.am/db/562745/Vinmar_Ventures>,
        <https://1145.am/db/563575/Celesta_Capital>,
        <https://1145.am/db/564008/D1_Ventures>,
        <https://1145.am/db/571769/Illumina_Ventures>,
        <https://1145.am/db/571769/M_Ventures>,
        <https://1145.am/db/572097/Menlo_Ventures>,
        <https://1145.am/db/572097/Teneleven_Ventures>,
        <https://1145.am/db/575249/TCV>,
        <https://1145.am/db/576186/Konvoy_Ventures>,
        <https://1145.am/db/577120/Index_Ventures>,
        <https://1145.am/db/586525/Tenoneten_Ventures>,
        <https://1145.am/db/587038/Coparion>,
        <https://1145.am/db/591566/Morningside_Ventures>,
        <https://1145.am/db/596145/Anorak_Ventures>,
        <https://1145.am/db/596564/Anorak_Ventures>,
        <https://1145.am/db/601455/Morningside_Ventures>,
        <https://1145.am/db/603725/Ignitexl_Ventures>,
        <https://1145.am/db/606074/Fiscus_Ventures>,
        <https://1145.am/db/606144/Ggv_Capital>,
        <https://1145.am/db/615337/Companyon_Ventures>,
        <https://1145.am/db/619284/Scf_Ventures>,
        <https://1145.am/db/619366/Capital_One_Ventures>,
        <https://1145.am/db/619736/Lightspeed_Ventures>,
        <https://1145.am/db/623178/Array_Ventures>,
        <https://1145.am/db/625791/Sofinnova_Partners>,
        <https://1145.am/db/626781/Dnx_Ventures>,
        <https://1145.am/db/627030/Launchpad_Capital>,
        <https://1145.am/db/628654/Prologis_Ventures>,
        <https://1145.am/db/633238/True_Ventures>,
        <https://1145.am/db/633869/Skywell_Capital_Partners>,
        <https://1145.am/db/633869/Stageone_Ventures>,
        <https://1145.am/db/640939/Ggv_Capital>,
        <https://1145.am/db/642123/Charles_River_Ventures>,
        <https://1145.am/db/642518/Network_Ventures>,
        <https://1145.am/db/643600/Vinco_Ventures>,
        <https://1145.am/db/648552/True_Ventures>,
        <https://1145.am/db/659010/Index_Ventures>,
        <https://1145.am/db/659675/Gv>,
        <https://1145.am/db/661747/Adit_Ventures>,
        <https://1145.am/db/661818/Index_Ventures>,
        <https://1145.am/db/665129/Ac_Ventures>,
        <https://1145.am/db/665776/Firstime_Ventures>,
        <https://1145.am/db/676217/Steelsky_Ventures>,
        <https://1145.am/db/676869/Ggv_Capital>,
        <https://1145.am/db/678140/Ggv_Capital>,
        <https://1145.am/db/678587/Lightshed_Ventures>,
        <https://1145.am/db/678593/Solana_Ventures>,
        <https://1145.am/db/687538/Kayyak_Ventures>,
        <https://1145.am/db/689460/True_Ventures>,
        <https://1145.am/db/694513/Authentic_Ventures>,
        <https://1145.am/db/694924/Avid_Ventures>,
        <https://1145.am/db/700171/Sequoia_Capital>,
        <https://1145.am/db/700327/Menlo_Ventures>,
        <https://1145.am/db/700877/Gaingels>,
        <https://1145.am/db/703983/Eqventure>,
        <https://1145.am/db/704489/Eqventure>,
        <https://1145.am/db/704753/Felicis_Ventures>,
        <https://1145.am/db/704753/Menlo_Ventures>,
        <https://1145.am/db/704793/Quidnet_Ventures>,
        <https://1145.am/db/704991/Gaingels>,
        <https://1145.am/db/709633/Connetic_Ventures>,
        <https://1145.am/db/726461/Contour_Ventures>,
        <https://1145.am/db/729628/Kyber_Ventures>,
        <https://1145.am/db/729628/Signum_Capital>,
        <https://1145.am/db/738920/Oca_Ventures>,
        <https://1145.am/db/738920/Susa_Ventures>,
        <https://1145.am/db/739538/Morpheus_Ventures>,
        <https://1145.am/db/739538/Oca_Ventures>,
        <https://1145.am/db/739538/Susa_Ventures>,
        <https://1145.am/db/747051/Tenoneten_Ventures>,
        <https://1145.am/db/747771/Ta_Ventures>,
        <https://1145.am/db/749147/1984_Ventures>,
        <https://1145.am/db/749147/Index_Ventures>,
        <https://1145.am/db/749209/1984_Ventures>,
        <https://1145.am/db/749209/Index_Ventures>,
        <https://1145.am/db/750305/Yl_Ventures>,
        <https://1145.am/db/750725/Vestigo_Ventures>,
        <https://1145.am/db/751176/Maverick_Ventures>,
        <https://1145.am/db/751176/Susa_Ventures>,
        <https://1145.am/db/751387/Menlo_Ventures>,
        <https://1145.am/db/753120/Sequoia_Capital>,
        <https://1145.am/db/753251/Savantus_Ventures>,
        <https://1145.am/db/753913/Brunnur_Ventures>,
        <https://1145.am/db/755844/Sequoia_Capital>,
        <https://1145.am/db/758206/Great_North_Ventures>,
        <https://1145.am/db/758206/Grotech_Ventures>,
        <https://1145.am/db/759749/Cava_Capital>,
        <https://1145.am/db/763083/Gaingels>,
        <https://1145.am/db/764875/Rev1_Ventures>,
        <https://1145.am/db/764896/Rev1_Ventures>,
        <https://1145.am/db/765216/True_Ventures>,
        <https://1145.am/db/768172/Gaingels>,
        <https://1145.am/db/768172/Type_One_Ventures>,
        <https://1145.am/db/768349/Salesforce_Ventures>,
        <https://1145.am/db/768852/Felicis_Ventures>,
        <https://1145.am/db/769568/Axon_Ventures>,
        <https://1145.am/db/772099/Array_Ventures>,
        <https://1145.am/db/773235/Prelude_Ventures>,
        <https://1145.am/db/773684/Fulgur_Ventures>,
        <https://1145.am/db/773794/Array_Ventures>,
        <https://1145.am/db/778025/Felicis_Ventures>,
        <https://1145.am/db/778423/Sentiero_Ventures>,
        <https://1145.am/db/779637/Felicis_Ventures>,
        <https://1145.am/db/779867/Genesis_Block_Ventures>,
        <https://1145.am/db/780272/East_Ventures>,
        <https://1145.am/db/780289/East_Ventures>,
        <https://1145.am/db/783431/Cathay_Venture_Inc>,
        <https://1145.am/db/784093/Boldstart_Ventures>,
        <https://1145.am/db/787806/Boldstart_Ventures>,
        <https://1145.am/db/788016/Boldstart_Ventures>,
        <https://1145.am/db/791505/Index_Ventures>,
        <https://1145.am/db/796250/Sp_Ventures>,
        <https://1145.am/db/796629/Index_Ventures>,
        <https://1145.am/db/797597/Lansdowne_Partners>,
        <https://1145.am/db/798095/Index_Ventures>,
        <https://1145.am/db/798753/Sofinnova_Partners>,
        <https://1145.am/db/800093/Sequoia_Capital>,
        <https://1145.am/db/800101/Gaingels>,
        <https://1145.am/db/803541/Credo_Ventures>,
        <https://1145.am/db/803541/Index_Ventures>,
        <https://1145.am/db/803541/Sequoia_Capital>,
        <https://1145.am/db/8045/Greatpoint_Ventures>,
        <https://1145.am/db/806828/Promus_Ventures>,
        <https://1145.am/db/806994/Companyon_Ventures>,
        <https://1145.am/db/807080/K3_Ventures>,
        <https://1145.am/db/808020/Starlight_Ventures>,
        <https://1145.am/db/808020/Valo_Ventures>,
        <https://1145.am/db/8146/Rev1_Ventures>,
        <https://1145.am/db/817162/Orbia_Ventures>,
        <https://1145.am/db/818444/1984_Ventures>,
        <https://1145.am/db/821135/Se_Ventures>,
        <https://1145.am/db/823763/Infinity_Ventures>,
        <https://1145.am/db/828716/Idc_Ventures>,
        <https://1145.am/db/829118/Salesforce_Ventures>,
        <https://1145.am/db/830571/Company_Ventures>,
        <https://1145.am/db/830689/Soleus_Capital>,
        <https://1145.am/db/832264/Salesforce_Ventures>,
        <https://1145.am/db/832573/Solasta_Ventures>,
        <https://1145.am/db/834864/Ggv_Capital>,
        <https://1145.am/db/834864/K3_Ventures>,
        <https://1145.am/db/836848/Technexus_Venture_Collaborative>,
        <https://1145.am/db/836908/Frontier_Ventures>,
        <https://1145.am/db/837034/Redpoint_Ventures>,
        <https://1145.am/db/838138/Root_Ventures>,
        <https://1145.am/db/838181/Sequoia_Capital>,
        <https://1145.am/db/838691/Crosslink_Capital>,
        <https://1145.am/db/847157/Signum_Capital>,
        <https://1145.am/db/847862/Wise_Ventures>,
        <https://1145.am/db/854001/Gv>,
        <https://1145.am/db/854589/Verance_Capital>,
        <https://1145.am/db/854654/Mrtnz_Ventures>,
        <https://1145.am/db/854795/Menlo_Ventures>,
        <https://1145.am/db/867865/Applied_Ventures>,
        <https://1145.am/db/868093/Cobro_Ventures>,
        <https://1145.am/db/869652/Forever_Ventures>,
        <https://1145.am/db/874394/Nextview_Ventures>,
        <https://1145.am/db/874394/True_Ventures>,
        <https://1145.am/db/880050/Crosslink_Capital>,
        <https://1145.am/db/881298/At_One_Ventures>,
        <https://1145.am/db/882723/At_One_Ventures>,
        <https://1145.am/db/884787/Foresite_Capital>,
        <https://1145.am/db/884787/Gv>,
        <https://1145.am/db/884787/Northpond_Ventures>,
        <https://1145.am/db/886445/Gv>,
        <https://1145.am/db/887062/Panoramic_Ventures>,
        <https://1145.am/db/889246/At_One_Ventures>,
        <https://1145.am/db/890271/Panoramic_Ventures>,
        <https://1145.am/db/891162/Emergingvc>,
        <https://1145.am/db/891162/Launchpad_Venture_Group>,
        <https://1145.am/db/903689/Vectr_Ventures>,
        <https://1145.am/db/904276/Nextview_Ventures>,
        <https://1145.am/db/906393/East_Ventures>,
        <https://1145.am/db/907844/Argon_Ventures>,
        <https://1145.am/db/907844/Glasswing_Ventures>,
        <https://1145.am/db/913422/Sequoia_Capital>,
        <https://1145.am/db/913678/Sandbridge_Capital>,
        <https://1145.am/db/919636/Menlo_Ventures>,
        <https://1145.am/db/921704/Scop_Ventures>,
        <https://1145.am/db/92200/Knoll_Ventures>,
        <https://1145.am/db/922066/Irrvrnt_Vc>,
        <https://1145.am/db/922192/Gv>,
        <https://1145.am/db/922498/Sozo_Ventures>,
        <https://1145.am/db/923723/Scop_Ventures>,
        <https://1145.am/db/928711/Frontline_Ventures>,
        <https://1145.am/db/934946/Ggv_Capital>,
        <https://1145.am/db/935046/Origin_Ventures>,
        <https://1145.am/db/935249/Victress_Capital>,
        <https://1145.am/db/935322/Alpana_Ventures>,
        <https://1145.am/db/935322/M_Ventures>,
        <https://1145.am/db/935796/Salesforce_Ventures>,
        <https://1145.am/db/935962/Digitalbridge_Ventures>,
        <https://1145.am/db/936045/Lpc_Ventures>,
        <https://1145.am/db/936057/Noemis_Ventures>,
        <https://1145.am/db/936154/Salesforce_Ventures>,
        <https://1145.am/db/936448/Ggv_Capital>,
        <https://1145.am/db/936862/Lool_Ventures>,
        <https://1145.am/db/936906/Neotribe_Ventures>,
        <https://1145.am/db/937210/Citi_Ventures>,
        <https://1145.am/db/937210/Firebolt_Ventures>,
        <https://1145.am/db/937460/Sequoia_Capital>,
        <https://1145.am/db/938108/Conti_Ventures>,
        <https://1145.am/db/938555/Digitalbridge_Ventures>,
        <https://1145.am/db/938586/Venturesouth>,
        <https://1145.am/db/938921/Redpoint_Ventures>,
        <https://1145.am/db/938975/Ggv_Capital>,
        <https://1145.am/db/939163/Goodyear_Ventures>,
        <https://1145.am/db/940740/Agnc_Ventures>,
        <https://1145.am/db/940913/True_Ventures>,
        <https://1145.am/db/941816/Radical_Ventures>,
        <https://1145.am/db/942825/Argon_Ventures>,
        <https://1145.am/db/946710/Citi_Ventures>,
        <https://1145.am/db/947238/Kyros_Ventures>,
        <https://1145.am/db/952434/Verissimo_Ventures>,
        <https://1145.am/db/955201/Gv>,
        <https://1145.am/db/960022/Verance_Capital>,
        <https://1145.am/db/961837/Sequoia_Capital>,
        <https://1145.am/db/962622/Sequoia_Capital>,
        <https://1145.am/db/970950/Ulu_Ventures>,
        <https://1145.am/db/971415/Altai_Ventures>,
        <https://1145.am/db/971450/Allon_Ventures>,
        <https://1145.am/db/971939/Formic_Ventures>,
        <https://1145.am/db/975114/Formic_Ventures>,
        <https://1145.am/db/979753/Menlo_Ventures>,
        <https://1145.am/db/980678/Menlo_Ventures>,
        <https://1145.am/db/984645/Vinco_Ventures>,
        <https://1145.am/db/987688/Brightspark_Ventures>,
        <https://1145.am/db/987700/Infinityvc>,
        <https://1145.am/db/988084/Abstract_Ventures>,
        <https://1145.am/db/988084/Blank_Ventures>,
        <https://1145.am/db/988318/Arthur_Ventures>,
        <https://1145.am/db/988482/Brightspark_Ventures>,
        <https://1145.am/db/988979/Infinityvc>,
        <https://1145.am/db/989392/Arthur_Ventures>,
        <https://1145.am/db/990085/Radical_Ventures>,
        <https://1145.am/db/995593/Raiven_Capital>,
        <https://1145.am/db/995737/Nuoyan_Capital>,
        <https://1145.am/db/996563/Raiven_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1061824/Foresite_Capital>,
        <https://1145.am/db/1411936/Foresite_Capital>,
        <https://1145.am/db/1412727/Foresite_Capital>,
        <https://1145.am/db/1664837/Foresite_Capital>,
        <https://1145.am/db/1745868/Foresite_Capital>,
        <https://1145.am/db/1747873/Foresite_Capital>,
        <https://1145.am/db/1750470/Foresite_Capital>,
        <https://1145.am/db/2075754/Foresite_Capital>,
        <https://1145.am/db/2129215/Foresite_Capital>,
        <https://1145.am/db/2153988/Foresite_Capital>,
        <https://1145.am/db/2155146/Foresite_Capital>,
        <https://1145.am/db/2181257/Foresite_Capital>,
        <https://1145.am/db/2198816/Foresite_Capital>,
        <https://1145.am/db/2291403/Foresite_Capital>,
        <https://1145.am/db/2292554/Foresite_Capital>,
        <https://1145.am/db/2339214/Foresite_Capital>,
        <https://1145.am/db/2339223/Foresite_Capital>,
        <https://1145.am/db/2345273/Foresite_Capital>,
        <https://1145.am/db/2361416/Foresite_Capital>,
        <https://1145.am/db/2361422/Foresite_Capital>,
        <https://1145.am/db/2361424/Foresite_Capital>,
        <https://1145.am/db/2364496/Foresite_Capital>,
        <https://1145.am/db/2368322/Foresite_Capital>,
        <https://1145.am/db/2370436/Foresite_Capital>,
        <https://1145.am/db/2371160/Foresite_Capital>,
        <https://1145.am/db/2371163/Foresite_Capital>,
        <https://1145.am/db/248626/Foresite_Capital>,
        <https://1145.am/db/595702/Foresite_Capital>,
        <https://1145.am/db/694272/Foresite_Capital>,
        <https://1145.am/db/745407/Foresite_Capital>,
        <https://1145.am/db/873820/Foresite_Capital>,
        <https://1145.am/db/874843/Foresite_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345268/Tarsa_Therapeutics> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-03-16T13:14:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tarsa-therapeutics-completes-28-million-series-b-financing-to-advance-ostora%E2%84%A2-oral> ;
    ns1:foundName "Tarsa Therapeutics",
        "Tarsa Therapeutics, Inc." ;
    ns1:name "Tarsa Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2318106/Tarsa_Therapeutics>,
        <https://1145.am/db/2345273/Tarsa_Therapeutics>,
        <https://1145.am/db/2358116/Tarsa_Therapeutics>,
        <https://1145.am/db/2361842/Tarsa_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2341491/Tarsa_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346307/Altacor> a org:Organization ;
    ns1:basedInHighGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:basedInHighRaw "U.K." ;
    ns1:description "ophthalmology" ;
    ns1:documentDate "2012-03-21T13:58:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "NicOx eyes global status in eye drug game with up to $30.9M buyout of Altacor" ;
    ns1:documentURL <https://www.fiercebiotech.com/financials/nicox-eyes-global-status-eye-drug-game-up-to-30-9m-buyout-of-altacor> ;
    ns1:foundName "Altacor" ;
    ns1:industry "ophthalmology" ;
    ns1:name "Altacor" ;
    ns1:sameAsHigh <https://1145.am/db/1006299/Us_Eye>,
        <https://1145.am/db/1115245/Sightmd>,
        <https://1145.am/db/1143952/Ace_Vision_Group>,
        <https://1145.am/db/1340128/4bio>,
        <https://1145.am/db/1344426/Sightmd>,
        <https://1145.am/db/1362843/Armesto_Eye_Associates>,
        <https://1145.am/db/1381753/Eyesouth>,
        <https://1145.am/db/1422581/Aviceda>,
        <https://1145.am/db/1423406/Aviceda>,
        <https://1145.am/db/1533888/Sightmd>,
        <https://1145.am/db/1555841/Okyo>,
        <https://1145.am/db/1620957/Premier_Eye_Care>,
        <https://1145.am/db/1675944/Sightmd>,
        <https://1145.am/db/1956544/Sightmd>,
        <https://1145.am/db/1978914/Sightmd>,
        <https://1145.am/db/2084616/Sightmd>,
        <https://1145.am/db/2099377/Sightmd>,
        <https://1145.am/db/2099480/Sightmd>,
        <https://1145.am/db/2132240/Sightmd>,
        <https://1145.am/db/2140055/Sightmd>,
        <https://1145.am/db/2249739/Akorn_Inc>,
        <https://1145.am/db/2346308/Altacor>,
        <https://1145.am/db/2539070/Ryuji_Ueno>,
        <https://1145.am/db/696207/Ocuterra> ;
    ns1:sameAsMedium <https://1145.am/db/2346313/Altacor> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346467/Discovery_Science_And_Neotope_Biosciences_Divestment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "divestment",
        "ipo" ;
    ns1:documentDate "2012-08-13T13:01:55+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders.",
        "Elan Corporation, plc (NYSE: ELN) announced today that its Board of Directors has approved the spin-off of the discovery science and Neotope Biosciences from the company." ;
    ns1:documentTitle "Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/elan-announces-plan-to-spin-off-discovery-science-and-neotope-biosciences-to-shareholders> ;
    ns1:foundName "Spin-Off",
        "spin-off" ;
    ns1:name "Spin-Off",
        "spin-off" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2346467/Discovery_Science_And_Neotope_Biosciences> ;
    ns1:targetName "Discovery Science And Neotope Biosciences",
        "Neotope Biosciences" ;
    ns1:vendor <https://1145.am/db/2346467/Discovery_Science_And_Neotope_Biosciences> .

<https://1145.am/db/2346467/Elan_Corporation> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "investment" ;
    ns1:documentDate "2012-08-13T13:01:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/elan-announces-plan-to-spin-off-discovery-science-and-neotope-biosciences-to-shareholders> ;
    ns1:foundName "Elan Corporation, plc" ;
    ns1:name "Elan Corporation" ;
    ns1:protagonist <https://1145.am/db/2346467/Discovery_Science_And_Neotope_Biosciences_Divestment> ;
    ns1:sameAsHigh <https://1145.am/db/1045846/Amplo>,
        <https://1145.am/db/1173960/Amplo>,
        <https://1145.am/db/1740799/Ecapital>,
        <https://1145.am/db/1746151/Elron>,
        <https://1145.am/db/2595063/Elan_Corporation>,
        <https://1145.am/db/557636/Elad_Gil> ;
    ns1:sameAsMedium <https://1145.am/db/2249118/Elan_Corporation>,
        <https://1145.am/db/2268635/Elan_Corporation>,
        <https://1145.am/db/2308845/Elan>,
        <https://1145.am/db/2308886/Elan>,
        <https://1145.am/db/2308890/Elan_Corporation>,
        <https://1145.am/db/2309137/Elan>,
        <https://1145.am/db/2309970/Elan>,
        <https://1145.am/db/2319399/Elan>,
        <https://1145.am/db/2327327/Elan>,
        <https://1145.am/db/2331746/Elan_Corporation>,
        <https://1145.am/db/2332005/Elan_Corporation>,
        <https://1145.am/db/2335881/Elan>,
        <https://1145.am/db/2335887/Elan>,
        <https://1145.am/db/2336358/Elan>,
        <https://1145.am/db/2336983/Elan>,
        <https://1145.am/db/2339086/Elan_Corporation>,
        <https://1145.am/db/2339096/Elan_Corporation>,
        <https://1145.am/db/2339950/Elan_Corporation>,
        <https://1145.am/db/2340188/Elan>,
        <https://1145.am/db/2340189/Elan_Corporation>,
        <https://1145.am/db/2341772/Elan_Corporation>,
        <https://1145.am/db/2342686/Elan_Corporation>,
        <https://1145.am/db/2343835/Elan>,
        <https://1145.am/db/2345479/Elan_Corporation>,
        <https://1145.am/db/2345992/Elan_Corporation>,
        <https://1145.am/db/2345999/Elan>,
        <https://1145.am/db/2346795/Elan_Corporation>,
        <https://1145.am/db/2346976/Elan_Corporation>,
        <https://1145.am/db/2347453/Elan_Corporation>,
        <https://1145.am/db/2348227/Elan_Corporation>,
        <https://1145.am/db/2349078/Elan_Corporation>,
        <https://1145.am/db/2350115/Elan>,
        <https://1145.am/db/2350116/Elan_Corporation>,
        <https://1145.am/db/2350550/Elan_Corporation>,
        <https://1145.am/db/2351144/Elan>,
        <https://1145.am/db/2351145/Elan_Corporation>,
        <https://1145.am/db/2358431/Elan>,
        <https://1145.am/db/2359529/Elan>,
        <https://1145.am/db/2359600/Elan_Corporation>,
        <https://1145.am/db/2359604/Elan_Corporation>,
        <https://1145.am/db/2360786/Elan_Corporation>,
        <https://1145.am/db/2363656/Elan_Corporation>,
        <https://1145.am/db/2364580/Elan_Corporation>,
        <https://1145.am/db/2364583/Elan>,
        <https://1145.am/db/2364612/Elan_Corporation>,
        <https://1145.am/db/2366961/Elan_Corporation>,
        <https://1145.am/db/2367151/Elan_Corporation>,
        <https://1145.am/db/2537542/Elan>,
        <https://1145.am/db/2554897/Elan>,
        <https://1145.am/db/2560865/Elan>,
        <https://1145.am/db/2573572/Elan>,
        <https://1145.am/db/2575100/Elan_Corporation>,
        <https://1145.am/db/2576104/Elan>,
        <https://1145.am/db/2576144/Elan>,
        <https://1145.am/db/2577010/Elan_Corporation>,
        <https://1145.am/db/2577059/Elan_Corporation>,
        <https://1145.am/db/2580122/Elan>,
        <https://1145.am/db/2583839/Elan>,
        <https://1145.am/db/2584383/Elan>,
        <https://1145.am/db/2584834/Elan>,
        <https://1145.am/db/2584909/Elan>,
        <https://1145.am/db/2585770/Elan>,
        <https://1145.am/db/2586703/Elan>,
        <https://1145.am/db/2589750/Elan>,
        <https://1145.am/db/2590594/Elan>,
        <https://1145.am/db/2590596/Elan_Corporation>,
        <https://1145.am/db/2592543/Elan>,
        <https://1145.am/db/2593465/Elan>,
        <https://1145.am/db/2597331/Elan_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346485/Pracinostat> a org:Organization ;
    ns1:basedInLowRaw "Singapore" ;
    ns1:description "Biotechnology",
        "Oncology" ;
    ns1:documentDate "2012-08-13T16:34:36+00:00"^^xsd:dateTime ;
    ns1:documentTitle "MEI Pharma to buy S*BIO's rights to HDAC inhibitor, Pracinostat" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mei-pharma-to-buy-s-bio-s-rights-to-hdac-inhibitor-pracinostat> ;
    ns1:foundName "S * BIO",
        "S * BIO Pte Ltd" ;
    ns1:industry "biotechnology" ;
    ns1:name "Pracinostat",
        "S * BIO Pte Ltd" ;
    ns1:sameAsHigh <https://1145.am/db/1009450/Biocompare>,
        <https://1145.am/db/1023985/Orgenesis_Inc>,
        <https://1145.am/db/1048034/Exicure>,
        <https://1145.am/db/1051761/Curative_Biotechnology_Inc>,
        <https://1145.am/db/1066819/Biocentriq_Inc>,
        <https://1145.am/db/1088717/Biosynth>,
        <https://1145.am/db/1089921/Biosynth>,
        <https://1145.am/db/1102964/Biontech_Se>,
        <https://1145.am/db/1116501/Alvotech_Sa>,
        <https://1145.am/db/1117630/Alvotech_Sa>,
        <https://1145.am/db/1124798/Accustem_Sciences>,
        <https://1145.am/db/1130652/Cogent_Biosciences>,
        <https://1145.am/db/1132106/Cogent_Biosciences>,
        <https://1145.am/db/1140693/Curative_Biotechnology_Inc>,
        <https://1145.am/db/1142391/Cogent_Biosciences_Inc>,
        <https://1145.am/db/1143081/Bioinvent_International_Ab>,
        <https://1145.am/db/1154042/Applied_Biology>,
        <https://1145.am/db/1167874/Ensysce_Biosciences>,
        <https://1145.am/db/1174373/Biosynth>,
        <https://1145.am/db/1175242/Biosynth>,
        <https://1145.am/db/1179100/Ensysce_Biosciences>,
        <https://1145.am/db/1198669/Bioventus_Inc>,
        <https://1145.am/db/1216524/Forbion>,
        <https://1145.am/db/1216997/180_Life_Sciences>,
        <https://1145.am/db/1222768/180_Life_Sciences_Corp>,
        <https://1145.am/db/1229517/Enveric_Biosciences>,
        <https://1145.am/db/1236975/Enveric_Biosciences>,
        <https://1145.am/db/1252190/Forbion>,
        <https://1145.am/db/1271538/Ensysce_Biosciences>,
        <https://1145.am/db/1278078/Monod_Bio>,
        <https://1145.am/db/1278479/Monod_Bio>,
        <https://1145.am/db/1293677/Biosion>,
        <https://1145.am/db/1295884/Brii_Biosciences_Limited>,
        <https://1145.am/db/1320133/Hc_Bioscience>,
        <https://1145.am/db/133486/Devacell_Inc>,
        <https://1145.am/db/1336573/Hc_Bioscience>,
        <https://1145.am/db/1354619/Biogen>,
        <https://1145.am/db/1382711/Solid_Biosciences_Inc>,
        <https://1145.am/db/1386738/Vergent_Bioscience>,
        <https://1145.am/db/1387057/Vergent_Bioscience>,
        <https://1145.am/db/1408611/Alvotech>,
        <https://1145.am/db/1453380/Peak_Bio>,
        <https://1145.am/db/1490000/Enavate_Sciences>,
        <https://1145.am/db/1506505/Biodesix>,
        <https://1145.am/db/1509205/Biodesix>,
        <https://1145.am/db/1522275/Stagezero_Life_Sciences_Ltd>,
        <https://1145.am/db/1534347/Enveric_Biosciences>,
        <https://1145.am/db/1536048/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/1537082/Vergent_Bioscience>,
        <https://1145.am/db/1537788/Vergent_Bioscience>,
        <https://1145.am/db/1547927/Solid_Biosciences_Inc>,
        <https://1145.am/db/1548092/Innoforce>,
        <https://1145.am/db/1548093/Alvotech>,
        <https://1145.am/db/1553518/Solid_Biosciences_Inc>,
        <https://1145.am/db/1562950/Ensysce_Biosciences>,
        <https://1145.am/db/1573937/Celcuity_Inc>,
        <https://1145.am/db/1577542/Bioasis>,
        <https://1145.am/db/1585988/Alvotech>,
        <https://1145.am/db/1585992/Alvotech>,
        <https://1145.am/db/1586236/Alvotech>,
        <https://1145.am/db/1586786/Bioasis>,
        <https://1145.am/db/1619665/Bioversys_Ag>,
        <https://1145.am/db/1630753/Solid_Biosciences_Inc>,
        <https://1145.am/db/1639462/Forte_Biosciences>,
        <https://1145.am/db/1640582/Forte_Biosciences>,
        <https://1145.am/db/1664988/Upstream_Bio>,
        <https://1145.am/db/1668597/Verily>,
        <https://1145.am/db/1685433/Enveric_Biosciences>,
        <https://1145.am/db/1689320/Innamed>,
        <https://1145.am/db/1696213/Genentech>,
        <https://1145.am/db/1696383/Biontech>,
        <https://1145.am/db/1728598/Life_Technologies_Corporation>,
        <https://1145.am/db/1787025/Verily>,
        <https://1145.am/db/1821833/Verily>,
        <https://1145.am/db/1936265/Provention_Bio>,
        <https://1145.am/db/1945850/Puretech>,
        <https://1145.am/db/2000772/Biosynth>,
        <https://1145.am/db/2010010/Iveric_Bio_Inc>,
        <https://1145.am/db/2019705/Eqt_Life_Sciences>,
        <https://1145.am/db/2023773/Genentech>,
        <https://1145.am/db/2032047/Enavate_Sciences>,
        <https://1145.am/db/2032047/Upstream_Bio>,
        <https://1145.am/db/2053399/Univercells_Technologies>,
        <https://1145.am/db/2061027/Roivant_Sciences>,
        <https://1145.am/db/2073555/Puretech_Scientific>,
        <https://1145.am/db/209111/Bioage>,
        <https://1145.am/db/2113176/Genentech>,
        <https://1145.am/db/2115362/2seventy_Bio>,
        <https://1145.am/db/2123899/Biosynth>,
        <https://1145.am/db/2152786/Aruvant_Sciences>,
        <https://1145.am/db/2152862/Therachon>,
        <https://1145.am/db/2152961/Arcus_Biosciences>,
        <https://1145.am/db/2153083/Arcus_Biosciences>,
        <https://1145.am/db/2153509/Or>,
        <https://1145.am/db/2154521/Baergic_Bio>,
        <https://1145.am/db/2154848/Brii_Biosciences>,
        <https://1145.am/db/2155108/Roivant_Sciences>,
        <https://1145.am/db/2155252/Bioagilytix>,
        <https://1145.am/db/2156304/Puretech>,
        <https://1145.am/db/2181432/Verily>,
        <https://1145.am/db/2188567/Verily_Life_Sciences>,
        <https://1145.am/db/2189613/Genapsys>,
        <https://1145.am/db/2198949/Cellectricon>,
        <https://1145.am/db/222819/Bioventus_Inc>,
        <https://1145.am/db/222920/Genapsys_Inc>,
        <https://1145.am/db/2230848/Bioohio>,
        <https://1145.am/db/2232759/Genentech>,
        <https://1145.am/db/2280215/Concentra_Biosciences>,
        <https://1145.am/db/2280734/Forte_Biosciences>,
        <https://1145.am/db/2281285/Locus_Biosciences>,
        <https://1145.am/db/2281875/Solid_Biosciences>,
        <https://1145.am/db/2282549/Coave>,
        <https://1145.am/db/2282760/Bioreliance>,
        <https://1145.am/db/2282760/Inotiv>,
        <https://1145.am/db/2283398/Sab>,
        <https://1145.am/db/2283480/Hcbioscience>,
        <https://1145.am/db/2285390/Cellarity>,
        <https://1145.am/db/2285399/Solid_Biosciences>,
        <https://1145.am/db/2285897/Hologic>,
        <https://1145.am/db/2285963/Iveric_Bio>,
        <https://1145.am/db/2286634/Therachon>,
        <https://1145.am/db/2286677/Roivant_Sciences>,
        <https://1145.am/db/2287185/Brii_Biosciences>,
        <https://1145.am/db/2290342/Biotech_Sector>,
        <https://1145.am/db/2290381/Life_Sciences>,
        <https://1145.am/db/2292237/Bioinvent>,
        <https://1145.am/db/2293367/Ascentage>,
        <https://1145.am/db/2293654/Eleven_Bio>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2295596/Roivant_Sciences>,
        <https://1145.am/db/2295654/Sv>,
        <https://1145.am/db/2295929/Life_Technologies>,
        <https://1145.am/db/2296584/Enterin>,
        <https://1145.am/db/2296692/Tp>,
        <https://1145.am/db/2297083/Biogen_Idec>,
        <https://1145.am/db/2297978/Ocugen>,
        <https://1145.am/db/2298237/Life_Technologies>,
        <https://1145.am/db/2298404/Bioz>,
        <https://1145.am/db/2298499/Inthera_Bioscience>,
        <https://1145.am/db/2298505/Inventisbio>,
        <https://1145.am/db/2298709/Life_Technologies>,
        <https://1145.am/db/2298866/Biosafe_Group>,
        <https://1145.am/db/2298948/Bioverativ>,
        <https://1145.am/db/2299124/Life_Technologies>,
        <https://1145.am/db/2299472/Aadi_Bioscience>,
        <https://1145.am/db/2300786/Axovant_Sciences>,
        <https://1145.am/db/2300790/Axovant_Sciences>,
        <https://1145.am/db/2301003/Roivant_Sciences>,
        <https://1145.am/db/2301684/Biogen_Idec_Inc>,
        <https://1145.am/db/2301979/Biogen_Idec_Inc>,
        <https://1145.am/db/2301983/Biogen_Idec>,
        <https://1145.am/db/2302002/Biogen_Idec>,
        <https://1145.am/db/2303130/Bioreliance_Corporation>,
        <https://1145.am/db/2303317/Applied_Biosystems>,
        <https://1145.am/db/2303604/Biogen_Idec>,
        <https://1145.am/db/2304650/Bioprocessors_Corp>,
        <https://1145.am/db/2304650/Life>,
        <https://1145.am/db/2305210/Biogen_Idec>,
        <https://1145.am/db/2306250/Bioadvance>,
        <https://1145.am/db/2306259/Bioanalab>,
        <https://1145.am/db/2306288/Bioanalab>,
        <https://1145.am/db/2307654/Bioton_Sa>,
        <https://1145.am/db/2308142/Biogen_Idec>,
        <https://1145.am/db/2308972/Genentech>,
        <https://1145.am/db/2309520/Biopure>,
        <https://1145.am/db/2310216/Biogen_Idec>,
        <https://1145.am/db/2310216/Genentech>,
        <https://1145.am/db/2310979/Cogenics>,
        <https://1145.am/db/2311995/Biovitrum>,
        <https://1145.am/db/2312238/Prometic_Life_Sciences>,
        <https://1145.am/db/2313533/Biosource_International>,
        <https://1145.am/db/2313760/Sistemic_Ltd>,
        <https://1145.am/db/2313762/Sistemic_Ltd>,
        <https://1145.am/db/2313763/Biomarin>,
        <https://1145.am/db/2314526/Bio-Rad>,
        <https://1145.am/db/2314943/Esbatech_Ag>,
        <https://1145.am/db/2314947/Esbatech_Ag>,
        <https://1145.am/db/2315615/Anormed>,
        <https://1145.am/db/2316066/Biogen_Idec>,
        <https://1145.am/db/2317136/Biogen_Idec_Inc>,
        <https://1145.am/db/2317455/Bioadvance>,
        <https://1145.am/db/2318537/Genomics>,
        <https://1145.am/db/2318603/Bioenvision>,
        <https://1145.am/db/2319551/Medevol>,
        <https://1145.am/db/2319959/Progentech>,
        <https://1145.am/db/2320138/Biogen_Idec>,
        <https://1145.am/db/2320164/Anaptys_Biosciences>,
        <https://1145.am/db/2320435/Ym_Biosciences_Inc>,
        <https://1145.am/db/2322209/Genentech>,
        <https://1145.am/db/2322417/Bio-Quant>,
        <https://1145.am/db/2322417/Biotox_Sciences>,
        <https://1145.am/db/2322984/Bioadvance>,
        <https://1145.am/db/2323003/Bioadvance>,
        <https://1145.am/db/2325377/Celmed_Biosciences>,
        <https://1145.am/db/2325387/Bioadvance>,
        <https://1145.am/db/2326063/Biooutsource>,
        <https://1145.am/db/2327447/Biosystems>,
        <https://1145.am/db/2327640/Applied_Biosystems>,
        <https://1145.am/db/2327677/Fundamental_Applied_Biology>,
        <https://1145.am/db/2327982/Biovex_Inc>,
        <https://1145.am/db/2328028/Biotrove>,
        <https://1145.am/db/2328815/Fundamental_Applied_Biology>,
        <https://1145.am/db/2329870/Complex_Biosystems_Gmbh>,
        <https://1145.am/db/2330058/Bio-Quant>,
        <https://1145.am/db/2330348/Blaze_Bioscience>,
        <https://1145.am/db/2332771/S_*_Bio>,
        <https://1145.am/db/2333005/Genizon_Biosciences>,
        <https://1145.am/db/2334156/Genizon>,
        <https://1145.am/db/2335943/Genentech>,
        <https://1145.am/db/2336178/Biocon_Limited>,
        <https://1145.am/db/2336178/Biocon_Ltd>,
        <https://1145.am/db/2336383/Biocrates_Life_Sciences_Ag>,
        <https://1145.am/db/2336736/Coherus_Biosciences>,
        <https://1145.am/db/2336983/Biogen_Idec>,
        <https://1145.am/db/2337110/Bioutah>,
        <https://1145.am/db/2337412/Blaze_Bioscience>,
        <https://1145.am/db/2337664/Advent_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338373/Promedior>,
        <https://1145.am/db/2338682/Genentech>,
        <https://1145.am/db/2338837/Coherus_Biosciences>,
        <https://1145.am/db/2340408/Biovex_Group>,
        <https://1145.am/db/2340408/Group_Inc>,
        <https://1145.am/db/2340502/Massbio>,
        <https://1145.am/db/2340513/Massbio>,
        <https://1145.am/db/2340560/Puretech>,
        <https://1145.am/db/2341443/Biosystems_International>,
        <https://1145.am/db/2341509/Epic_Sciences>,
        <https://1145.am/db/2341676/Bioforward>,
        <https://1145.am/db/2342754/Fidelity_Biosciences>,
        <https://1145.am/db/2342768/Fidelity_Biosciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343761/Ovascience>,
        <https://1145.am/db/2343777/Ovascience>,
        <https://1145.am/db/2343791/Bioniche_Life_Sciences_Inc>,
        <https://1145.am/db/2344535/Biovex_Inc>,
        <https://1145.am/db/2344638/Coherus_Biosciences>,
        <https://1145.am/db/2345112/Med_Biogene_Inc>,
        <https://1145.am/db/2345132/Biocon>,
        <https://1145.am/db/2345213/Biocritica>,
        <https://1145.am/db/2345214/Biocritica>,
        <https://1145.am/db/2345999/Biogen_Idec>,
        <https://1145.am/db/2346347/Biospecifics_Technologies_Corp>,
        <https://1145.am/db/2347467/Theraclone_Sciences>,
        <https://1145.am/db/2347950/Epic_Sciences>,
        <https://1145.am/db/2348109/Immatics_Biotechnologies_Gmbh>,
        <https://1145.am/db/2348776/Genentech>,
        <https://1145.am/db/2349436/Ovascience>,
        <https://1145.am/db/2350267/Harvard_Bioscience_Inc>,
        <https://1145.am/db/2350471/Biovex>,
        <https://1145.am/db/2350645/Biochrom_Ag>,
        <https://1145.am/db/2351192/Genticel>,
        <https://1145.am/db/2351312/Themis_Bioscience>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2351472/Mymetics>,
        <https://1145.am/db/2351853/Life_Technologies>,
        <https://1145.am/db/2351921/Ovascience>,
        <https://1145.am/db/2352069/Biogen_Idec>,
        <https://1145.am/db/2352165/Bio>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2352800/Biovex_Group>,
        <https://1145.am/db/2354237/Biodelivery_Sciences_International>,
        <https://1145.am/db/2354537/Fidelity_Biosciences>,
        <https://1145.am/db/2354835/Biovex>,
        <https://1145.am/db/2355219/Stellar_Biotechnologies_Inc>,
        <https://1145.am/db/2355236/Stellar_Biotechnologies_Inc>,
        <https://1145.am/db/2356064/Frontline_Bioventures>,
        <https://1145.am/db/2356509/Inq_Biosciences_Corporation>,
        <https://1145.am/db/2357079/Techne_Corporation>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358296/Biogen_Idec>,
        <https://1145.am/db/2359227/Fidelity_Biosciences>,
        <https://1145.am/db/2359685/Bioatla_Llc>,
        <https://1145.am/db/2360075/Bionomics>,
        <https://1145.am/db/2360313/Engene>,
        <https://1145.am/db/2361502/Ovascience>,
        <https://1145.am/db/2362433/Leonardo_Biosystems>,
        <https://1145.am/db/2362647/Bioqual>,
        <https://1145.am/db/2362737/Life_Sciences>,
        <https://1145.am/db/2363484/Bioscale>,
        <https://1145.am/db/2363485/Bioscale_Inc>,
        <https://1145.am/db/2363668/Ovasciencesm>,
        <https://1145.am/db/2364681/Biogen_Idec>,
        <https://1145.am/db/2366745/Biocontrol_Limited>,
        <https://1145.am/db/2366915/Biogen_Idec>,
        <https://1145.am/db/2367302/Biocept>,
        <https://1145.am/db/2368752/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/2369498/Genentech>,
        <https://1145.am/db/2370383/Prometic_Life_Sciences>,
        <https://1145.am/db/2370548/Bionovion>,
        <https://1145.am/db/2370549/Bionovion>,
        <https://1145.am/db/2370806/Alvotech>,
        <https://1145.am/db/2536788/Biomics_Biotechnologies>,
        <https://1145.am/db/2538197/Orgenesis>,
        <https://1145.am/db/2540757/Biontech>,
        <https://1145.am/db/2542617/Core_Biogenesis>,
        <https://1145.am/db/2542993/Biogen_Idec>,
        <https://1145.am/db/2550495/Bioatla>,
        <https://1145.am/db/2552636/Ark_Biosciences>,
        <https://1145.am/db/2553773/Mabxience>,
        <https://1145.am/db/2562317/Bioatla_Llc>,
        <https://1145.am/db/2563996/Biocnd>,
        <https://1145.am/db/256464/Atai_Life_Sciences>,
        <https://1145.am/db/2566932/Exosomics>,
        <https://1145.am/db/2567231/Genentech>,
        <https://1145.am/db/2568479/Subintro>,
        <https://1145.am/db/2571023/Biochrom_Ag>,
        <https://1145.am/db/2576944/Biocritica>,
        <https://1145.am/db/2577183/Biogen_Idec>,
        <https://1145.am/db/2577644/Presage_Biosciences>,
        <https://1145.am/db/2578308/Intermune>,
        <https://1145.am/db/2578528/Biogen_Idec>,
        <https://1145.am/db/2580665/Themis_Bioscience>,
        <https://1145.am/db/2580671/Themis_Bioscience>,
        <https://1145.am/db/2581359/Biovex_Group>,
        <https://1145.am/db/2581359/Group_Inc>,
        <https://1145.am/db/2584538/Bionovion>,
        <https://1145.am/db/2589106/Biovex_Group>,
        <https://1145.am/db/2594353/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2797140/Biotheus>,
        <https://1145.am/db/322594/Roivant_Sciences>,
        <https://1145.am/db/356493/Atai_Life_Sciences_Bv>,
        <https://1145.am/db/396787/Biotheryx>,
        <https://1145.am/db/417096/Solid_Biosciences_Inc>,
        <https://1145.am/db/417543/180_Life_Sciences_Corp>,
        <https://1145.am/db/417568/Ultivue>,
        <https://1145.am/db/425981/180_Life_Sciences_Corp>,
        <https://1145.am/db/436937/Triad_Life_Sciences>,
        <https://1145.am/db/471380/Insidescientific>,
        <https://1145.am/db/481671/Biolegend>,
        <https://1145.am/db/482988/Biolegend>,
        <https://1145.am/db/486391/Biolife_Solutions>,
        <https://1145.am/db/505292/Ensysce_Biosciences>,
        <https://1145.am/db/520363/Biohive>,
        <https://1145.am/db/521860/Tosoh_Bioscience_Llc>,
        <https://1145.am/db/523221/Biohive>,
        <https://1145.am/db/540091/Curative_Biotechnology_Inc>,
        <https://1145.am/db/540784/Coherus_Biosciences_Inc>,
        <https://1145.am/db/544370/Replicel_Life_Sciences_Inc>,
        <https://1145.am/db/591563/180_Life_Sciences>,
        <https://1145.am/db/591858/Pascal_Biosciences>,
        <https://1145.am/db/624546/Ensysce_Biosciences>,
        <https://1145.am/db/710299/Bioatla>,
        <https://1145.am/db/730321/Biosion>,
        <https://1145.am/db/739185/Sqz_Biotechnologies>,
        <https://1145.am/db/767994/Biotech_Prokidney_Lp>,
        <https://1145.am/db/781794/Biontech>,
        <https://1145.am/db/818850/Ensysce_Biosciences>,
        <https://1145.am/db/830101/2seventy_Bio>,
        <https://1145.am/db/877317/Accustem_Sciences>,
        <https://1145.am/db/922807/Biolabs>,
        <https://1145.am/db/941576/Orgenesis_Inc>,
        <https://1145.am/db/948136/Ensysce_Biosciences_Inc>,
        <https://1145.am/db/958575/Biocompare>,
        <https://1145.am/db/958575/Scilan>,
        <https://1145.am/db/968301/Ansa_Biotechnologies>,
        <https://1145.am/db/972968/Ansa_Biotechnologies>,
        <https://1145.am/db/979663/Biostrand>,
        <https://1145.am/db/979842/Biostrand_Bv>,
        <https://1145.am/db/986828/Ensysce_Biosciences>,
        <https://1145.am/db/991347/Genovac> ;
    ns1:sameAsMedium <https://1145.am/db/2332777/S_*_Bio>,
        <https://1145.am/db/2352516/S_*_Bio>,
        <https://1145.am/db/2357754/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2364274/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2364276/S_*_Bio> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2346485/Pracinostat_Rights_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-08-13T16:34:36+00:00"^^xsd:dateTime ;
    ns1:documentExtract "MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for the treatment of cancer, has entered into a definitive asset purchase agreement with S * BIO Pte Ltd, a privately held biotechnology company, pursuant to which MEI Pharma will acquire S * BIO's exclusive worldwide rights to Pracinostat, an investigational, potential best-in-class, oral histone deacetylase (HDAC) inhibitor." ;
    ns1:documentTitle "MEI Pharma to buy S*BIO's rights to HDAC inhibitor, Pracinostat" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mei-pharma-to-buy-s-bio-s-rights-to-hdac-inhibitor-pracinostat> ;
    ns1:foundName "asset purchase" ;
    ns1:name "asset purchase" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2346485/Pracinostat> ;
    ns1:targetDetails "rights" ;
    ns1:targetName "Pracinostat" ;
    ns1:whereGeoName "Republic of Singapore" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:whereRaw "Singapore" .

<https://1145.am/db/2347327/Anaphore> a org:Organization ;
    ns1:basedInHighGeoName "La Jolla" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5363943/about.rdf> ;
    ns1:basedInHighRaw "La Jolla, CA" ;
    ns1:buyer <https://1145.am/db/2347327/Ruiti_Acquisition> ;
    ns1:description "discovering biologics that target G-protein coupled receptors" ;
    ns1:documentDate "2012-03-23T16:13:06+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anaphore scoops up Chinese biotech; Clovis reveals $75M offering;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anaphore-scoops-up-chinese-biotech-clovis-reveals-75m-offering> ;
    ns1:foundName "Anaphore" ;
    ns1:industry "biotech" ;
    ns1:name "Anaphore" ;
    ns1:sameAsHigh <https://1145.am/db/2320883/Anaphore>,
        <https://1145.am/db/2323226/Anaphore_Inc>,
        <https://1145.am/db/2347327/Ruiti>,
        <https://1145.am/db/2354543/Anaphore_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2318733/Anaphore>,
        <https://1145.am/db/2320878/Anaphore_Inc>,
        <https://1145.am/db/2323210/Anaphore>,
        <https://1145.am/db/2347324/Anaphore_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2347327/Clovis_Oncology> a org:Organization ;
    ns1:basedInHighGeoName "Boulder County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5574999/about.rdf> ;
    ns1:basedInHighRaw "Boulder, CO" ;
    ns1:description "cancer drug development" ;
    ns1:documentDate "2012-03-23T16:13:06+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anaphore scoops up Chinese biotech; Clovis reveals $75M offering;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anaphore-scoops-up-chinese-biotech-clovis-reveals-75m-offering> ;
    ns1:foundName "Clovis Oncology" ;
    ns1:industry "drug" ;
    ns1:name "Clovis Oncology" ;
    ns1:sameAsHigh <https://1145.am/db/2237359/Clovis_Oncology>,
        <https://1145.am/db/2321963/Clovis_Oncology>,
        <https://1145.am/db/2336839/Clovis_Oncology>,
        <https://1145.am/db/2336840/Clovis_Oncology>,
        <https://1145.am/db/2367677/Clovis_Oncology>,
        <https://1145.am/db/2367679/Clovis_Oncology>,
        <https://1145.am/db/2367802/Clovis_Oncology> ;
    ns1:sameAsMedium <https://1145.am/db/2339396/Clovis_Oncology>,
        <https://1145.am/db/2362598/Clovis_Oncology>,
        <https://1145.am/db/2362677/Clovis_Oncology>,
        <https://1145.am/db/2368080/Clovis_Oncology>,
        <https://1145.am/db/2369669/Clovis_Oncology>,
        <https://1145.am/db/2561703/Clovis_Oncology>,
        <https://1145.am/db/411407/Clovis_Oncology> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2347327/Enterome> a org:Organization ;
    ns1:basedInHighGeoName "Paris" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2988507/about.rdf> ;
    ns1:basedInHighRaw "Paris" ;
    ns1:documentDate "2012-03-23T16:13:06+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anaphore scoops up Chinese biotech; Clovis reveals $75M offering;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anaphore-scoops-up-chinese-biotech-clovis-reveals-75m-offering> ;
    ns1:foundName "Enterome" ;
    ns1:name "Enterome" ;
    ns1:sameAsMedium <https://1145.am/db/2155490/Enterome>,
        <https://1145.am/db/2289865/Enterome>,
        <https://1145.am/db/2297587/Enterome>,
        <https://1145.am/db/2300680/Enterome>,
        <https://1145.am/db/2301536/Enterome>,
        <https://1145.am/db/2336716/Enterome> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2347327/Ruiti_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "ipo" ;
    ns1:documentDate "2012-03-23T16:13:06+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> La Jolla, CA - based biotech Anaphore said that it has acquired Shanghai - based RuiTi, which specializes in discovering biologics that target G-protein coupled receptors." ;
    ns1:documentTitle "Anaphore scoops up Chinese biotech; Clovis reveals $75M offering;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anaphore-scoops-up-chinese-biotech-clovis-reveals-75m-offering> ;
    ns1:foundName "acquired",
        "public offering" ;
    ns1:name "acquired",
        "public offering" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2347327/Ruiti> ;
    ns1:targetName "RuiTi" ;
    ns1:valueRaw "$ 75 million" ;
    ns1:whereGeoName "Shanghai" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1796236/about.rdf> ;
    ns1:whereRaw "Shanghai" .

<https://1145.am/db/2348350/Imaginab> a org:Organization ;
    ns1:description "a clinical-stage company developing in vivo imaging agents for Positron Emission" ;
    ns1:documentDate "2012-03-28T14:04:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ImaginAb Concludes $12.5m Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/imaginab-concludes-12-5m-series-a-financing> ;
    ns1:foundName "ImaginAb",
        "ImaginAb, Inc." ;
    ns1:name "ImaginAb" ;
    ns1:sameAsMedium <https://1145.am/db/2337294/Imaginab>,
        <https://1145.am/db/2337976/Imaginab>,
        <https://1145.am/db/2346458/Imaginab>,
        <https://1145.am/db/2355985/Imaginab>,
        <https://1145.am/db/2369271/Imaginab_Inc>,
        <https://1145.am/db/2370547/Imaginab_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348350/Nextech_Invest> a org:Organization ;
    ns1:basedInLowRaw "LOS ANGELES" ;
    ns1:documentDate "2012-03-28T14:04:39+00:00"^^xsd:dateTime ;
    ns1:documentTitle "ImaginAb Concludes $12.5m Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/imaginab-concludes-12-5m-series-a-financing> ;
    ns1:foundName "Nextech Invest" ;
    ns1:investor <https://1145.am/db/2348350/Series_A_Investment_Cycad_Group_Imaginab_Merieux_Developpement_Momentum_Biosciences_Nextech_Invest_Novartis_Venture_Funds_Completed> ;
    ns1:name "Nextech Invest" ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Nextech_Invest>,
        <https://1145.am/db/1247997/Nextech_Invest>,
        <https://1145.am/db/2109798/Nextech_Invest>,
        <https://1145.am/db/2283431/Nextech_Invest>,
        <https://1145.am/db/2285762/Nextech_Invest>,
        <https://1145.am/db/2293667/Nextech_Invest>,
        <https://1145.am/db/2297604/Nextech_Invest>,
        <https://1145.am/db/2298642/Nextech_Invest>,
        <https://1145.am/db/2337294/Nextech_Invest>,
        <https://1145.am/db/2337976/Nextech_Invest>,
        <https://1145.am/db/2342754/Nextech_Invest_Ltd>,
        <https://1145.am/db/2342768/Nextech_Invest_Ltd>,
        <https://1145.am/db/2342771/Nextech_Invest>,
        <https://1145.am/db/2346197/Nextech_Invest_Ltd>,
        <https://1145.am/db/2346213/Nextech_Invest_Ltd>,
        <https://1145.am/db/2366561/Nextech_Invest>,
        <https://1145.am/db/425281/Nextech_Invest>,
        <https://1145.am/db/426160/Nextech_Invest>,
        <https://1145.am/db/490696/Nextech_Invest>,
        <https://1145.am/db/770684/Nextech_Invest> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348356/Promethera_Biosciences> a org:Organization ;
    ns1:description "a cell therapy company" ;
    ns1:documentDate "2012-03-28T15:57:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promethera Biosciences Raises $31.4m in Series B" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promethera-biosciences-raises-31-4m-series-b> ;
    ns1:foundName "Promethera Biosciences",
        "Promethera Biosciences," ;
    ns1:industry "cell therapy" ;
    ns1:name "Promethera Biosciences" ;
    ns1:sameAsMedium <https://1145.am/db/2152849/Promethera_Biosciences>,
        <https://1145.am/db/2152875/Promethera_Biosciences>,
        <https://1145.am/db/2290753/Promethera_Biosciences>,
        <https://1145.am/db/2291214/Promethera_Biosciences>,
        <https://1145.am/db/2298163/Promethera_Biosciences>,
        <https://1145.am/db/2298600/Promethera_Biosciences>,
        <https://1145.am/db/2338832/Promethera_Biosciences>,
        <https://1145.am/db/2348352/Promethera_Biosciences>,
        <https://1145.am/db/2348805/Promethera_Biosciences>,
        <https://1145.am/db/2348827/Promethera_Biosciences>,
        <https://1145.am/db/2351932/Promethera_Biosciences>,
        <https://1145.am/db/2557291/Promethera_Biosciences>,
        <https://1145.am/db/326452/Promethera_Biosciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348356/Sambrinvest> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Belgium" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2802361/about.rdf> ;
    ns1:basedInHighRaw "Belgium" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-03-28T15:57:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promethera Biosciences Raises $31.4m in Series B" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promethera-biosciences-raises-31-4m-series-b> ;
    ns1:foundName "Sambrinvest" ;
    ns1:investor <https://1145.am/db/2348356/Series_B_Investment_Atmi_Boehringer_Ingelheim_Mitsui_Global_Investment_Promethera_Biosciences_Sambrinvest_Completed> ;
    ns1:name "Sambrinvest" ;
    ns1:sameAsHigh <https://1145.am/db/1006950/Shell_Ventures>,
        <https://1145.am/db/1014186/Soma_Capital>,
        <https://1145.am/db/1014305/Sp_Ventures>,
        <https://1145.am/db/1049509/021_Capital>,
        <https://1145.am/db/1083572/Spero_Ventures>,
        <https://1145.am/db/1085737/Spero_Ventures>,
        <https://1145.am/db/1106541/Jumpstart_Ventures>,
        <https://1145.am/db/1119699/Xplorer_Capital>,
        <https://1145.am/db/1122750/Xplorer_Capital>,
        <https://1145.am/db/1133402/Silicon_Road_Ventures>,
        <https://1145.am/db/1134486/Silicon_Road_Ventures>,
        <https://1145.am/db/1140286/B_Capital_Group>,
        <https://1145.am/db/1140286/Commerce_Ventures>,
        <https://1145.am/db/1151339/Big_Idea_Ventures>,
        <https://1145.am/db/1165515/Jumpstart_Ventures>,
        <https://1145.am/db/1174129/Stage_1_Ventures>,
        <https://1145.am/db/1175198/Sure_Ventures>,
        <https://1145.am/db/1175459/Khosla_Ventures>,
        <https://1145.am/db/1196728/Gsr_Ventures>,
        <https://1145.am/db/1199177/Gsr_Ventures>,
        <https://1145.am/db/1200402/Xseed_Capital>,
        <https://1145.am/db/1232192/Lfg_Ventures>,
        <https://1145.am/db/1238845/Union_Square_Ventures>,
        <https://1145.am/db/1247755/Syn_Ventures>,
        <https://1145.am/db/1248631/Syn_Ventures>,
        <https://1145.am/db/1269968/Usvp>,
        <https://1145.am/db/1282835/Khosla_Ventures>,
        <https://1145.am/db/1285848/Syn_Ventures>,
        <https://1145.am/db/1287496/D1_Capital>,
        <https://1145.am/db/1288309/Psl_Ventures>,
        <https://1145.am/db/1322711/Venture_Stars>,
        <https://1145.am/db/1329887/Shell_Ventures>,
        <https://1145.am/db/1329887/Sosv>,
        <https://1145.am/db/1340587/Xseed_Capital>,
        <https://1145.am/db/1341445/Xseed_Capital>,
        <https://1145.am/db/1354722/Psl_Ventures>,
        <https://1145.am/db/1354749/Psl_Ventures>,
        <https://1145.am/db/1375916/Sv_Pacific_Ventures>,
        <https://1145.am/db/1376353/Sv_Pacific_Ventures>,
        <https://1145.am/db/1394919/Exsight_Ventures>,
        <https://1145.am/db/1408996/Khosla_Ventures>,
        <https://1145.am/db/1419583/Strongher_Vc>,
        <https://1145.am/db/1419583/Venture_Catalyst>,
        <https://1145.am/db/1445935/97212_Ventures>,
        <https://1145.am/db/1452107/Soma_Capital>,
        <https://1145.am/db/1454909/Us_Venture_Partners>,
        <https://1145.am/db/1455119/Jumpstart_Ventures>,
        <https://1145.am/db/1455616/Soma_Capital>,
        <https://1145.am/db/1468368/Sanabil_Investments>,
        <https://1145.am/db/1470303/Union_Square_Ventures>,
        <https://1145.am/db/1475091/Soma_Capital>,
        <https://1145.am/db/1489698/Stage_1_Ventures>,
        <https://1145.am/db/1582111/Khosla_Ventures>,
        <https://1145.am/db/1584937/Sharad_Sanghi>,
        <https://1145.am/db/1584937/Yournest_Venture_Capital>,
        <https://1145.am/db/1653506/Sve_Capital>,
        <https://1145.am/db/166138/Royal_Street_Ventures>,
        <https://1145.am/db/1663572/Khosla_Ventures>,
        <https://1145.am/db/1679431/Booz_Allen_Ventures_Llc>,
        <https://1145.am/db/1690703/021_Capital>,
        <https://1145.am/db/1691364/Hv_Capital>,
        <https://1145.am/db/1693658/Shima_Capital>,
        <https://1145.am/db/1694448/B37_Ventures>,
        <https://1145.am/db/1696614/Z_Venture_Capital>,
        <https://1145.am/db/1698130/Union_Square_Ventures>,
        <https://1145.am/db/1698180/Shasta_Ventures>,
        <https://1145.am/db/1698192/Saison_Capital>,
        <https://1145.am/db/1699877/Sutter_Hill_Ventures>,
        <https://1145.am/db/1702019/Sutter_Hill_Ventures>,
        <https://1145.am/db/1704402/Sosv>,
        <https://1145.am/db/1710011/Z_Venture_Capital>,
        <https://1145.am/db/1711384/Union_Square_Ventures>,
        <https://1145.am/db/1713248/Xplorer_Capital>,
        <https://1145.am/db/1714154/Psl_Ventures>,
        <https://1145.am/db/1714544/Hv_Capital>,
        <https://1145.am/db/1722058/Union_Square_Ventures>,
        <https://1145.am/db/1722914/B_Capital>,
        <https://1145.am/db/1722944/Soma_Capital>,
        <https://1145.am/db/1723099/Union_Square_Ventures>,
        <https://1145.am/db/1724641/Union_Square_Ventures>,
        <https://1145.am/db/1726121/Khosla_Ventures>,
        <https://1145.am/db/1730882/Union_Square_Ventures>,
        <https://1145.am/db/1732364/Sutter_Hill_Ventures>,
        <https://1145.am/db/1734681/Union_Square_Ventures>,
        <https://1145.am/db/1736478/Z_Venture_Capital>,
        <https://1145.am/db/1736668/Amit_Kapur>,
        <https://1145.am/db/1738378/S_Capital_Vc>,
        <https://1145.am/db/1739022/Khosla_Ventures>,
        <https://1145.am/db/1741014/Khosla_Ventures>,
        <https://1145.am/db/1742276/Shasta_Ventures>,
        <https://1145.am/db/1743316/Khosla_Ventures>,
        <https://1145.am/db/1745326/Venture_Stars>,
        <https://1145.am/db/1747732/Khosla_Ventures>,
        <https://1145.am/db/1747805/Khosla_Ventures>,
        <https://1145.am/db/1749148/Khosla_Ventures>,
        <https://1145.am/db/1749226/Khosla_Ventures>,
        <https://1145.am/db/1750460/Francisco_Partners>,
        <https://1145.am/db/1750483/Hv_Capital>,
        <https://1145.am/db/1750867/Fin_Vc>,
        <https://1145.am/db/1751312/Khosla_Ventures>,
        <https://1145.am/db/1753725/Z_Venture_Capital>,
        <https://1145.am/db/1754057/Spero_Ventures>,
        <https://1145.am/db/1754996/B_Capital>,
        <https://1145.am/db/1755846/Khosla_Ventures>,
        <https://1145.am/db/1756103/Union_Square_Ventures>,
        <https://1145.am/db/1756775/Khosla_Ventures>,
        <https://1145.am/db/1757376/1982_Ventures>,
        <https://1145.am/db/1757432/B37_Ventures>,
        <https://1145.am/db/1757987/R2>,
        <https://1145.am/db/1759567/Spero_Ventures>,
        <https://1145.am/db/1760730/Esun_Venture_Capital>,
        <https://1145.am/db/1762512/Khosla_Ventures>,
        <https://1145.am/db/1767643/Shasta_Ventures>,
        <https://1145.am/db/1768138/Vas_Ventures>,
        <https://1145.am/db/1771112/Khosla_Ventures>,
        <https://1145.am/db/1773491/Sosv>,
        <https://1145.am/db/1775532/Resolute_Venture_Partners>,
        <https://1145.am/db/1776687/Khosla_Ventures>,
        <https://1145.am/db/1777067/Scott>,
        <https://1145.am/db/1778179/Union_Square_Ventures>,
        <https://1145.am/db/1779627/Fosun>,
        <https://1145.am/db/1784405/Venture_51>,
        <https://1145.am/db/1784577/Khosla_Ventures>,
        <https://1145.am/db/1785920/Khosla_Ventures>,
        <https://1145.am/db/1786720/Union_Square_Ventures>,
        <https://1145.am/db/1786861/Ms___Ad_Ventures>,
        <https://1145.am/db/1787190/Gsr_Ventures>,
        <https://1145.am/db/1789140/Sosv>,
        <https://1145.am/db/1790631/Union_Square_Ventures>,
        <https://1145.am/db/1793825/Softtech_Vc>,
        <https://1145.am/db/1795210/Khosla_Ventures>,
        <https://1145.am/db/1795934/Shasta_Ventures>,
        <https://1145.am/db/1797561/Khosla_Ventures>,
        <https://1145.am/db/1799099/Softtech_Vc>,
        <https://1145.am/db/1799102/Softtech_Vc>,
        <https://1145.am/db/1802288/Khosla_Ventures>,
        <https://1145.am/db/1802352/Smedvig_Capital>,
        <https://1145.am/db/1803458/Union_Square_Ventures>,
        <https://1145.am/db/1804091/Active_Venture_Partners>,
        <https://1145.am/db/1804960/Khosla_Ventures>,
        <https://1145.am/db/1807542/Earlybird_Ventures>,
        <https://1145.am/db/1809007/Khosla_Ventures>,
        <https://1145.am/db/1812267/Us_Venture_Partners>,
        <https://1145.am/db/1815701/Khosla_Ventures>,
        <https://1145.am/db/1815910/E-Ventures>,
        <https://1145.am/db/1816423/Usvp>,
        <https://1145.am/db/1818161/Shasta_Ventures>,
        <https://1145.am/db/1818174/Eventures>,
        <https://1145.am/db/1821929/Khosla_Ventures>,
        <https://1145.am/db/1823663/Ifc>,
        <https://1145.am/db/1825387/Shasta_Ventures>,
        <https://1145.am/db/1826265/Mkii_Ventures>,
        <https://1145.am/db/1827021/Shasta_Ventures>,
        <https://1145.am/db/1828336/Khosla_Ventures>,
        <https://1145.am/db/1829581/Union_Square_Ventures>,
        <https://1145.am/db/1829612/Khosla_Ventures>,
        <https://1145.am/db/1829878/Active_Venture_Partners>,
        <https://1145.am/db/1830613/Sutter_Hill_Ventures>,
        <https://1145.am/db/1834279/Xseed_Capital>,
        <https://1145.am/db/1835126/Khosla_Ventures>,
        <https://1145.am/db/1835229/Sparklabs_Global_Ventures>,
        <https://1145.am/db/1835825/Shasta_Ventures>,
        <https://1145.am/db/1837155/Xseed_Capital>,
        <https://1145.am/db/1840793/Khosla_Ventures>,
        <https://1145.am/db/1842301/Khosla_Ventures>,
        <https://1145.am/db/1842466/Us_Venture_Partners>,
        <https://1145.am/db/1843362/Khosla_Ventures>,
        <https://1145.am/db/1846483/Softtech_Vc>,
        <https://1145.am/db/1846721/Union_Square_Ventures>,
        <https://1145.am/db/1852806/Us_Venture_Partners>,
        <https://1145.am/db/1853548/Khosla_Ventures>,
        <https://1145.am/db/1854200/Khosla_Ventures>,
        <https://1145.am/db/1855363/Sk_Ventures>,
        <https://1145.am/db/1856376/Khosla_Ventures>,
        <https://1145.am/db/1857635/Active_Venture_Partners>,
        <https://1145.am/db/1857930/Softtech_Vc>,
        <https://1145.am/db/1858323/Union_Square_Ventures>,
        <https://1145.am/db/1858991/Active_Venture_Partners>,
        <https://1145.am/db/1859199/Khosla_Ventures>,
        <https://1145.am/db/1860091/Union_Square_Ventures>,
        <https://1145.am/db/1860196/Union_Square_Ventures>,
        <https://1145.am/db/1861355/Khosla_Ventures>,
        <https://1145.am/db/1862590/Sutter_Hill_Ventures>,
        <https://1145.am/db/1863500/Khosla_Ventures>,
        <https://1145.am/db/1868107/Shasta_Ventures>,
        <https://1145.am/db/1868572/Union_Square_Ventures>,
        <https://1145.am/db/1871784/Us_Venture_Partners>,
        <https://1145.am/db/1872654/Sutter_Hill_Ventures>,
        <https://1145.am/db/1874278/Khosla_Ventures>,
        <https://1145.am/db/1875709/Sutter_Hill_Ventures>,
        <https://1145.am/db/1876758/Union_Square_Ventures>,
        <https://1145.am/db/1879026/Us_Venture_Partners>,
        <https://1145.am/db/1881464/Khosla_Ventures>,
        <https://1145.am/db/1884155/Us_Venture_Partners>,
        <https://1145.am/db/1892472/Union_Square_Ventures>,
        <https://1145.am/db/1895951/Khosla_Ventures>,
        <https://1145.am/db/1896368/New_Wave_Ventures>,
        <https://1145.am/db/1896530/Khosla_Ventures>,
        <https://1145.am/db/1899282/Mk_Capital>,
        <https://1145.am/db/1899737/Union_Square_Ventures>,
        <https://1145.am/db/1900812/Khosla_Ventures>,
        <https://1145.am/db/1904202/Shasta_Ventures>,
        <https://1145.am/db/1911584/Stage_1_Ventures>,
        <https://1145.am/db/1911840/Shasta_Ventures>,
        <https://1145.am/db/1915640/Us_Venture_Partners>,
        <https://1145.am/db/1917671/Fidelity_Ventures>,
        <https://1145.am/db/1922138/Softtech_Vc>,
        <https://1145.am/db/1931918/Svb_Financial_Group>,
        <https://1145.am/db/1939990/Gsr_Ventures>,
        <https://1145.am/db/1947193/Starbloom_Capital>,
        <https://1145.am/db/1947303/B37_Ventures>,
        <https://1145.am/db/1960888/Khosla_Ventures>,
        <https://1145.am/db/1962819/Jumpstart_Ventures>,
        <https://1145.am/db/2009653/Nationwide_Ventures>,
        <https://1145.am/db/2032146/Booz_Allen_Ventures>,
        <https://1145.am/db/2056931/L___S_Venture_Capital>,
        <https://1145.am/db/2071531/A_o>,
        <https://1145.am/db/2082923/Psl_Ventures>,
        <https://1145.am/db/2090647/Khosla_Ventures>,
        <https://1145.am/db/2092604/Srmg_Ventures>,
        <https://1145.am/db/2099365/Do_Ventures>,
        <https://1145.am/db/2114292/Khosla_Ventures>,
        <https://1145.am/db/2114498/Khosla_Ventures>,
        <https://1145.am/db/2134994/Union_Square_Ventures>,
        <https://1145.am/db/2135622/Khosla_Ventures>,
        <https://1145.am/db/2135690/Better_Ventures>,
        <https://1145.am/db/2142825/Commerce_Ventures>,
        <https://1145.am/db/2151946/Khosla_Ventures>,
        <https://1145.am/db/2153616/South>,
        <https://1145.am/db/2154009/Andera_Partners>,
        <https://1145.am/db/2155474/Sig>,
        <https://1145.am/db/2194249/Union_Square_Ventures>,
        <https://1145.am/db/2210557/Softtech_Vc>,
        <https://1145.am/db/2285566/Sabadell_Venture_Capital>,
        <https://1145.am/db/2288251/Us_Venture_Partners>,
        <https://1145.am/db/2300288/Spark_Ventures>,
        <https://1145.am/db/2300466/Khosla_Ventures>,
        <https://1145.am/db/2305964/Sls_Venture>,
        <https://1145.am/db/2310285/Valley_Ventures>,
        <https://1145.am/db/2311076/Venture_Investors>,
        <https://1145.am/db/2315754/Valley_Ventures>,
        <https://1145.am/db/2319675/Sac>,
        <https://1145.am/db/2343206/Us_Venture_Partners>,
        <https://1145.am/db/2352804/Enterprise_Partners>,
        <https://1145.am/db/2354752/Venture_Investors_Llc>,
        <https://1145.am/db/2354770/Venture_Investors_Llc>,
        <https://1145.am/db/2364014/Ro_Invest>,
        <https://1145.am/db/2567406/Exsight_Ventures>,
        <https://1145.am/db/2575232/Venture_Investors_Llc>,
        <https://1145.am/db/2616685/Silver_Creek_Ventures>,
        <https://1145.am/db/2641337/Valuestream_Ventures>,
        <https://1145.am/db/2790795/Shima_Capital>,
        <https://1145.am/db/365631/Khosla_Ventures>,
        <https://1145.am/db/376872/K50_Ventures>,
        <https://1145.am/db/396307/B_Capital_Group>,
        <https://1145.am/db/407681/Khosla_Ventures>,
        <https://1145.am/db/425922/Royal_Street_Ventures>,
        <https://1145.am/db/426637/Khosla_Ventures>,
        <https://1145.am/db/428324/Khosla_Ventures>,
        <https://1145.am/db/429179/Shasta_Ventures>,
        <https://1145.am/db/430553/Shasta_Ventures>,
        <https://1145.am/db/430986/Olsf_Ventures>,
        <https://1145.am/db/432552/Valuestream_Ventures>,
        <https://1145.am/db/437556/Khosla_Ventures>,
        <https://1145.am/db/438632/Khosla_Ventures>,
        <https://1145.am/db/447456/Starta_Vc>,
        <https://1145.am/db/486858/Khosla_Ventures>,
        <https://1145.am/db/486901/Khosla_Ventures>,
        <https://1145.am/db/502886/Sutter_Hill_Ventures>,
        <https://1145.am/db/506085/Sutter_Hill_Ventures>,
        <https://1145.am/db/523013/Hscm_Ventures>,
        <https://1145.am/db/523013/Sure_Ventures>,
        <https://1145.am/db/527960/Hscm_Ventures>,
        <https://1145.am/db/527960/Sure_Ventures>,
        <https://1145.am/db/562996/Shasta_Ventures>,
        <https://1145.am/db/564008/Secure_Ventures>,
        <https://1145.am/db/572414/A-Street_Ventures>,
        <https://1145.am/db/577305/A-Street_Ventures>,
        <https://1145.am/db/587038/Hv_Capital>,
        <https://1145.am/db/606074/Elementum_Ventures>,
        <https://1145.am/db/661747/Sosv>,
        <https://1145.am/db/663618/Sosv>,
        <https://1145.am/db/676938/Khosla_Ventures>,
        <https://1145.am/db/678262/Khosla_Ventures>,
        <https://1145.am/db/678416/St_Engineering_Ventures_Pte_Ltd>,
        <https://1145.am/db/679989/Khosla_Ventures>,
        <https://1145.am/db/696617/Suro_Capital>,
        <https://1145.am/db/753251/Sosv>,
        <https://1145.am/db/753759/Ms___Ad_Ventures>,
        <https://1145.am/db/75860/Sws_Venture_Capital>,
        <https://1145.am/db/778025/Soma_Capital>,
        <https://1145.am/db/784869/Hbse_Ventures>,
        <https://1145.am/db/791643/Cssd_Capital>,
        <https://1145.am/db/800101/Khosla_Ventures>,
        <https://1145.am/db/807080/Adb_Ventures>,
        <https://1145.am/db/817162/Khosla_Ventures>,
        <https://1145.am/db/817162/Shell_Ventures>,
        <https://1145.am/db/883036/Big_Idea_Ventures>,
        <https://1145.am/db/890955/S2g_Ventures>,
        <https://1145.am/db/906393/1982_Ventures>,
        <https://1145.am/db/912943/Khosla_Ventures>,
        <https://1145.am/db/928782/Psl_Ventures>,
        <https://1145.am/db/930464/Psl_Ventures>,
        <https://1145.am/db/935046/Gsr_Ventures>,
        <https://1145.am/db/940913/Xplorer_Capital>,
        <https://1145.am/db/952434/K50_Ventures>,
        <https://1145.am/db/979911/Khosla_Ventures>,
        <https://1145.am/db/980951/Khosla_Ventures>,
        <https://1145.am/db/996940/Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2283963/Sambrinvest> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349406/Allocure> a org:Organization ;
    ns1:description "kidney disease" ;
    ns1:documentDate "2012-04-02T14:49:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "AlloCure Raises $25 Million Series B Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/allocure-raises-25-million-series-b-venture-financing> ;
    ns1:foundName "AlloCure",
        "AlloCure, Inc." ;
    ns1:industry "biotechnology" ;
    ns1:name "AlloCure" ;
    ns1:sameAsHigh <https://1145.am/db/1048034/Exicure>,
        <https://1145.am/db/1054185/Exicure>,
        <https://1145.am/db/1064384/Celcuity_Inc>,
        <https://1145.am/db/1070403/Projenx_Inc>,
        <https://1145.am/db/1070709/Celularity_Inc>,
        <https://1145.am/db/1105043/Celularity>,
        <https://1145.am/db/1195567/Sqz_Biotechnologies>,
        <https://1145.am/db/1198717/Sqz_Biotechnologies>,
        <https://1145.am/db/1215930/Enavate_Sciences>,
        <https://1145.am/db/1322507/Gro_Biosciences_Inc>,
        <https://1145.am/db/1343489/Celcuity_Inc>,
        <https://1145.am/db/1354258/Cellistic>,
        <https://1145.am/db/1354263/Cellistic>,
        <https://1145.am/db/1359764/Aspect_Biosystems>,
        <https://1145.am/db/1360407/Aspect_Biosystems>,
        <https://1145.am/db/1381832/Coatue>,
        <https://1145.am/db/1382787/Coatue>,
        <https://1145.am/db/1415520/Obatala_Sciences>,
        <https://1145.am/db/1573937/Celcuity_Inc>,
        <https://1145.am/db/1621368/Celularity>,
        <https://1145.am/db/1683183/Exicure>,
        <https://1145.am/db/1945773/Morphimmune>,
        <https://1145.am/db/1966379/Dyve_Biosciences>,
        <https://1145.am/db/1984401/Exicure_Inc>,
        <https://1145.am/db/2021165/Exicure>,
        <https://1145.am/db/2052967/Morphimmune>,
        <https://1145.am/db/2095258/Exicure_Inc>,
        <https://1145.am/db/2114372/Actio_Biosciences>,
        <https://1145.am/db/2133590/Morphimmune>,
        <https://1145.am/db/2234316/Intercell_Ag>,
        <https://1145.am/db/2301876/Genizon_Biosciences>,
        <https://1145.am/db/2307362/Discovery_Laboratories_Inc>,
        <https://1145.am/db/2309472/Cel-Sci_Corporation>,
        <https://1145.am/db/2312827/Biotime_Inc>,
        <https://1145.am/db/2313884/Com)>,
        <https://1145.am/db/2321137/Le_@_P_Technology>,
        <https://1145.am/db/2334165/Genizon_Biosciences_Inc>,
        <https://1145.am/db/2336754/Biotime>,
        <https://1145.am/db/2337993/Progderm>,
        <https://1145.am/db/2338371/Inc>,
        <https://1145.am/db/2338373/Inc>,
        <https://1145.am/db/2339726/Discovery_Laboratories_Inc>,
        <https://1145.am/db/2340408/Group_Inc>,
        <https://1145.am/db/2341747/Techne_Corporation>,
        <https://1145.am/db/2343807/Cortice_Biosciences>,
        <https://1145.am/db/2347124/Orgenesis_Inc>,
        <https://1145.am/db/2347571/Advent_Life_Sciences>,
        <https://1145.am/db/2348618/Advent_Life_Sciences>,
        <https://1145.am/db/2348868/Biotime_Inc>,
        <https://1145.am/db/2351955/Biotime>,
        <https://1145.am/db/2357417/Biotime_Inc>,
        <https://1145.am/db/2359274/Neostem_Inc>,
        <https://1145.am/db/2361237/Discovery_Laboratories>,
        <https://1145.am/db/2361671/Discovery_Laboratories_Inc>,
        <https://1145.am/db/2367144/Allocure_Inc>,
        <https://1145.am/db/2367147/Allocure_Inc>,
        <https://1145.am/db/2367461/Discovery_Laboratories_Inc>,
        <https://1145.am/db/2369874/Biotime>,
        <https://1145.am/db/2370050/M3_Biotechnology_Inc>,
        <https://1145.am/db/2581359/Group_Inc>,
        <https://1145.am/db/407158/Altasciences>,
        <https://1145.am/db/464787/Biosight_Ltd>,
        <https://1145.am/db/504446/Acrigen_Biosciences_Inc>,
        <https://1145.am/db/585936/Gro_Biosciences_Inc>,
        <https://1145.am/db/622178/Gro_Biosciences_Inc>,
        <https://1145.am/db/632040/Biosight>,
        <https://1145.am/db/660979/Celcuity>,
        <https://1145.am/db/683685/Gro_Biosciences_Inc>,
        <https://1145.am/db/704448/Biosight>,
        <https://1145.am/db/764965/Gro_Biosciences_Inc>,
        <https://1145.am/db/812748/Altasciences>,
        <https://1145.am/db/922231/Ocugen> ;
    ns1:sameAsMedium <https://1145.am/db/2349405/Allocure> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350465/Amgen> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:buyer <https://1145.am/db/2350465/Kai-4169_Acquisition> ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-04-10T13:17:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Amgen to Acquire Privately Held KAI Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/financials/amgen-to-acquire-privately-held-kai-pharmaceuticals> ;
    ns1:foundName "Amgen" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Amgen" ;
    ns1:sameAsHigh <https://1145.am/db/1003058/Microbiologics>,
        <https://1145.am/db/1003231/Microbiologics>,
        <https://1145.am/db/1252426/Amgen_Inc>,
        <https://1145.am/db/1262006/Amgen>,
        <https://1145.am/db/1271008/Biohaven>,
        <https://1145.am/db/1322590/Biora_Therapeutics_Inc>,
        <https://1145.am/db/1488570/Amgen>,
        <https://1145.am/db/1541946/Amgen>,
        <https://1145.am/db/1574155/Amgen>,
        <https://1145.am/db/1620251/Pheast_Therapeutics>,
        <https://1145.am/db/1629415/Anivive_Lifesciences>,
        <https://1145.am/db/1684691/Theravance_Biopharma_Inc>,
        <https://1145.am/db/1956623/Concept_Life_Sciences>,
        <https://1145.am/db/1965949/Glenmark_Life_Sciences_Ltd>,
        <https://1145.am/db/2051134/Vernal_Biosciences>,
        <https://1145.am/db/2117986/Generate:_Biomedicines>,
        <https://1145.am/db/2153653/Myoscience>,
        <https://1145.am/db/2154415/Amgen>,
        <https://1145.am/db/2249221/Biomimetic_Therapeutics>,
        <https://1145.am/db/2283107/Concentra_Biosciences>,
        <https://1145.am/db/2286154/Q32_Bio>,
        <https://1145.am/db/2293310/Biogen>,
        <https://1145.am/db/2295270/Biomodex>,
        <https://1145.am/db/2296062/Arix_Bioscience>,
        <https://1145.am/db/2301414/Clinicalrm>,
        <https://1145.am/db/2304044/Fidelity_Biosciences>,
        <https://1145.am/db/2310302/Charter_Life_Sciences>,
        <https://1145.am/db/2311353/Charter_Life_Sciences>,
        <https://1145.am/db/2312121/Amgen>,
        <https://1145.am/db/2313305/Fidelity_Biosciences>,
        <https://1145.am/db/2314836/Ricerca_Biosciences>,
        <https://1145.am/db/2316380/Aeon_Bioscience>,
        <https://1145.am/db/2317581/Progen_Pharmaceuticals_Limited>,
        <https://1145.am/db/2317737/Fidelity_Biosciences>,
        <https://1145.am/db/2318795/Axial_Biotech>,
        <https://1145.am/db/2318905/Fidelity_Biosciences>,
        <https://1145.am/db/2320771/Amgen>,
        <https://1145.am/db/2320775/Amgen>,
        <https://1145.am/db/2322531/Forbion>,
        <https://1145.am/db/2322632/Amgen>,
        <https://1145.am/db/2324422/Intermune>,
        <https://1145.am/db/2326361/Charter_Life_Sciences>,
        <https://1145.am/db/2326373/Charter_Life_Sciences>,
        <https://1145.am/db/2326576/Fidelity_Biosciences>,
        <https://1145.am/db/2327649/Connetics>,
        <https://1145.am/db/2328012/Intermune>,
        <https://1145.am/db/2328729/Connetics>,
        <https://1145.am/db/2331983/Drugabuse_Sciences>,
        <https://1145.am/db/2333460/Amgen>,
        <https://1145.am/db/2337433/Amgen>,
        <https://1145.am/db/2337435/Amgen_Inc>,
        <https://1145.am/db/2337455/Clal_Biotechnology_Industries>,
        <https://1145.am/db/2338346/Amgen>,
        <https://1145.am/db/2339175/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2340040/Coherus_Biosciences>,
        <https://1145.am/db/2340882/Coherus_Biosciences>,
        <https://1145.am/db/2341621/Clal_Biotechnology_Industries>,
        <https://1145.am/db/2343862/Amgen>,
        <https://1145.am/db/2344864/Amgen>,
        <https://1145.am/db/2345886/Amgen>,
        <https://1145.am/db/2347976/Amgen>,
        <https://1145.am/db/2349030/Amgen>,
        <https://1145.am/db/2349444/Amgen>,
        <https://1145.am/db/2350029/Amgen>,
        <https://1145.am/db/2353167/Amgen>,
        <https://1145.am/db/2355392/Amgen>,
        <https://1145.am/db/2357070/Orgenesis_Inc>,
        <https://1145.am/db/2357303/Amgen>,
        <https://1145.am/db/2357336/Amgen>,
        <https://1145.am/db/2357451/Amgen>,
        <https://1145.am/db/2357905/The_Medicines_Company>,
        <https://1145.am/db/2359498/Amgen>,
        <https://1145.am/db/2361037/Amgen>,
        <https://1145.am/db/2362425/Osi_Pharmaceuticals>,
        <https://1145.am/db/2362756/Anavex_Life_Sciences_Corp>,
        <https://1145.am/db/2364216/Amgen>,
        <https://1145.am/db/2367430/Amgen_Inc>,
        <https://1145.am/db/2368189/Index_Pharmaceuticals>,
        <https://1145.am/db/2368788/Amgen_Inc>,
        <https://1145.am/db/2370120/Amgen>,
        <https://1145.am/db/2370174/Amgen>,
        <https://1145.am/db/2370215/Amgen>,
        <https://1145.am/db/2370217/Amgen>,
        <https://1145.am/db/2550523/Quotient_Bioresearch>,
        <https://1145.am/db/2550884/Amgen>,
        <https://1145.am/db/2551315/Fidelity_Biosciences>,
        <https://1145.am/db/2553162/Amgen>,
        <https://1145.am/db/2553564/Amgen>,
        <https://1145.am/db/2557364/Amgen>,
        <https://1145.am/db/2559940/Plumbline_Life_Sciences>,
        <https://1145.am/db/2561325/Amgen>,
        <https://1145.am/db/2566335/Amgen>,
        <https://1145.am/db/2567752/Biogen>,
        <https://1145.am/db/2572655/Amgen>,
        <https://1145.am/db/2573455/Amgen>,
        <https://1145.am/db/2575289/Amgen>,
        <https://1145.am/db/2576242/Amgen>,
        <https://1145.am/db/2577120/Amgen>,
        <https://1145.am/db/2578164/Amgen>,
        <https://1145.am/db/2579211/Amgen>,
        <https://1145.am/db/2580383/Amgen_Inc>,
        <https://1145.am/db/2581917/Amgen>,
        <https://1145.am/db/2584951/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2585500/Univercells>,
        <https://1145.am/db/2586750/Amgen>,
        <https://1145.am/db/2587009/Amgen>,
        <https://1145.am/db/2588372/Fidelity_Biosciences>,
        <https://1145.am/db/2590988/Amgen_Inc>,
        <https://1145.am/db/2591587/Amgen>,
        <https://1145.am/db/2591594/Amgen>,
        <https://1145.am/db/2591596/Agila_Specialties>,
        <https://1145.am/db/2592126/Intermune>,
        <https://1145.am/db/2592618/Amgen>,
        <https://1145.am/db/2593423/Amgen>,
        <https://1145.am/db/2593426/Amgen>,
        <https://1145.am/db/2593433/Amgen_Inc>,
        <https://1145.am/db/2593434/Amgen>,
        <https://1145.am/db/2593973/Amgen>,
        <https://1145.am/db/2594298/Amgen>,
        <https://1145.am/db/2594347/Amgen>,
        <https://1145.am/db/2594858/Afexa_Life_Sciences_Inc>,
        <https://1145.am/db/2595020/Amgen>,
        <https://1145.am/db/2595549/Amgen>,
        <https://1145.am/db/2595587/Amgen>,
        <https://1145.am/db/2595608/Amgen>,
        <https://1145.am/db/2596467/Amgen>,
        <https://1145.am/db/2596819/Amgen>,
        <https://1145.am/db/2598012/Afexa_Life_Sciences>,
        <https://1145.am/db/2598032/Afexa_Life_Sciences_Inc>,
        <https://1145.am/db/2598066/Amgen>,
        <https://1145.am/db/559746/Amgen>,
        <https://1145.am/db/696633/Aragen_Life_Sciences>,
        <https://1145.am/db/701847/Specific_Biologics_Inc>,
        <https://1145.am/db/714395/Arix_Bioscience_Plc>,
        <https://1145.am/db/763450/Boundless_Bio>,
        <https://1145.am/db/812449/Boundless_Bio>,
        <https://1145.am/db/979879/Advanced_Clinical>,
        <https://1145.am/db/980904/Advanced_Clinical> ;
    ns1:sameAsMedium <https://1145.am/db/1253935/Amgen>,
        <https://1145.am/db/1254815/Amgen>,
        <https://1145.am/db/1258904/Amgen_Inc>,
        <https://1145.am/db/1406211/Amgen>,
        <https://1145.am/db/1434130/Amgen>,
        <https://1145.am/db/1568872/Amgen_Inc>,
        <https://1145.am/db/1570839/Amgen_Inc>,
        <https://1145.am/db/1573831/Amgen>,
        <https://1145.am/db/1575688/Amgen_Inc>,
        <https://1145.am/db/1576668/Amgen_Inc>,
        <https://1145.am/db/1673901/Amgen>,
        <https://1145.am/db/1929668/Amgen>,
        <https://1145.am/db/1981398/Amgen>,
        <https://1145.am/db/198163/Amgen>,
        <https://1145.am/db/2008430/Amgen_Inc>,
        <https://1145.am/db/2008790/Amgen>,
        <https://1145.am/db/2009117/Amgen_Inc>,
        <https://1145.am/db/2011679/Amgen>,
        <https://1145.am/db/2012933/Amgen_Inc>,
        <https://1145.am/db/2013008/Amgen_Inc>,
        <https://1145.am/db/2016970/Amgen>,
        <https://1145.am/db/2043001/Amgen>,
        <https://1145.am/db/2046726/Amgen>,
        <https://1145.am/db/2098829/Amgen>,
        <https://1145.am/db/2105082/Amgen>,
        <https://1145.am/db/2106270/Amgen>,
        <https://1145.am/db/2107919/Amgen>,
        <https://1145.am/db/2117067/Amgen>,
        <https://1145.am/db/2117986/Amgen>,
        <https://1145.am/db/2138386/Amgen>,
        <https://1145.am/db/2152715/Amgen>,
        <https://1145.am/db/2153258/Amgen>,
        <https://1145.am/db/2155409/Amgen>,
        <https://1145.am/db/2155659/Amgen>,
        <https://1145.am/db/2249776/Amgen_Inc>,
        <https://1145.am/db/2282387/Amgen>,
        <https://1145.am/db/2282934/Amgen>,
        <https://1145.am/db/2283321/Amgen>,
        <https://1145.am/db/2285195/Amgen>,
        <https://1145.am/db/2285614/Amgen>,
        <https://1145.am/db/2285991/Amgen>,
        <https://1145.am/db/2286174/Amgen>,
        <https://1145.am/db/2291231/Amgen>,
        <https://1145.am/db/2292224/Amgen>,
        <https://1145.am/db/2292876/Amgen>,
        <https://1145.am/db/2299349/Amgen>,
        <https://1145.am/db/2302052/Amgen>,
        <https://1145.am/db/2303414/Amgen>,
        <https://1145.am/db/2313429/Amgen>,
        <https://1145.am/db/2317845/Amgen>,
        <https://1145.am/db/2318877/Amgen>,
        <https://1145.am/db/2320754/Amgen>,
        <https://1145.am/db/2320759/Amgen>,
        <https://1145.am/db/2320765/Amgen>,
        <https://1145.am/db/2321459/Amgen>,
        <https://1145.am/db/2321989/Amgen>,
        <https://1145.am/db/2322040/Amgen>,
        <https://1145.am/db/2326533/Amgen>,
        <https://1145.am/db/2326559/Amgen>,
        <https://1145.am/db/2327526/Amgen>,
        <https://1145.am/db/2327547/Amgen>,
        <https://1145.am/db/2328748/Amgen>,
        <https://1145.am/db/2329762/Amgen>,
        <https://1145.am/db/2334046/Amgen>,
        <https://1145.am/db/2337848/Amgen>,
        <https://1145.am/db/2338027/Amgen>,
        <https://1145.am/db/2338329/Amgen>,
        <https://1145.am/db/2338828/Amgen>,
        <https://1145.am/db/2340408/Amgen>,
        <https://1145.am/db/2340634/Amgen>,
        <https://1145.am/db/2340669/Amgen>,
        <https://1145.am/db/2343511/Amgen>,
        <https://1145.am/db/2343601/Amgen>,
        <https://1145.am/db/2343780/Amgen>,
        <https://1145.am/db/2344369/Amgen>,
        <https://1145.am/db/2344631/Amgen>,
        <https://1145.am/db/2345191/Amgen>,
        <https://1145.am/db/2345783/Amgen>,
        <https://1145.am/db/2346293/Amgen>,
        <https://1145.am/db/2347966/Amgen>,
        <https://1145.am/db/2347970/Amgen>,
        <https://1145.am/db/2350471/Amgen>,
        <https://1145.am/db/2352800/Amgen>,
        <https://1145.am/db/2354835/Amgen>,
        <https://1145.am/db/2355378/Amgen>,
        <https://1145.am/db/2355383/Amgen>,
        <https://1145.am/db/2355427/Amgen>,
        <https://1145.am/db/2357269/Amgen>,
        <https://1145.am/db/2357271/Amgen>,
        <https://1145.am/db/2357454/Amgen>,
        <https://1145.am/db/2357920/Amgen>,
        <https://1145.am/db/2358934/Amgen>,
        <https://1145.am/db/2359165/Amgen>,
        <https://1145.am/db/2359462/Amgen>,
        <https://1145.am/db/2359481/Amgen>,
        <https://1145.am/db/2360080/Amgen>,
        <https://1145.am/db/2360086/Amgen>,
        <https://1145.am/db/2361971/Amgen>,
        <https://1145.am/db/2361972/Amgen>,
        <https://1145.am/db/2361973/Amgen>,
        <https://1145.am/db/2362552/Amgen>,
        <https://1145.am/db/2363673/Amgen>,
        <https://1145.am/db/2371301/Amgen>,
        <https://1145.am/db/2538019/Amgen>,
        <https://1145.am/db/2539787/Amgen>,
        <https://1145.am/db/2540225/Amgen>,
        <https://1145.am/db/2543232/Amgen>,
        <https://1145.am/db/2543655/Amgen>,
        <https://1145.am/db/2544701/Amgen>,
        <https://1145.am/db/2545663/Amgen>,
        <https://1145.am/db/2545765/Amgen>,
        <https://1145.am/db/2548575/Amgen>,
        <https://1145.am/db/2550685/Amgen>,
        <https://1145.am/db/2551883/Amgen>,
        <https://1145.am/db/2551884/Amgen>,
        <https://1145.am/db/2554152/Amgen>,
        <https://1145.am/db/2555175/Amgen>,
        <https://1145.am/db/2556729/Amgen>,
        <https://1145.am/db/2558012/Amgen>,
        <https://1145.am/db/2558039/Amgen>,
        <https://1145.am/db/2558051/Amgen>,
        <https://1145.am/db/2558418/Amgen>,
        <https://1145.am/db/2559077/Amgen>,
        <https://1145.am/db/2561305/Amgen>,
        <https://1145.am/db/2561317/Amgen>,
        <https://1145.am/db/2561650/Amgen>,
        <https://1145.am/db/2566348/Amgen>,
        <https://1145.am/db/2567468/Amgen>,
        <https://1145.am/db/2567517/Amgen>,
        <https://1145.am/db/2567960/Amgen>,
        <https://1145.am/db/2567981/Amgen>,
        <https://1145.am/db/2568005/Amgen>,
        <https://1145.am/db/2568075/Amgen>,
        <https://1145.am/db/2568519/Amgen>,
        <https://1145.am/db/2572535/Amgen>,
        <https://1145.am/db/2573903/Amgen>,
        <https://1145.am/db/2573924/Amgen>,
        <https://1145.am/db/2573976/Amgen>,
        <https://1145.am/db/2574586/Amgen>,
        <https://1145.am/db/2575263/Amgen>,
        <https://1145.am/db/2576018/Amgen>,
        <https://1145.am/db/2576498/Amgen>,
        <https://1145.am/db/2577110/Amgen>,
        <https://1145.am/db/2577115/Amgen>,
        <https://1145.am/db/2578110/Amgen>,
        <https://1145.am/db/2578286/Amgen>,
        <https://1145.am/db/2579278/Amgen>,
        <https://1145.am/db/2580209/Amgen>,
        <https://1145.am/db/2580211/Amgen>,
        <https://1145.am/db/2581309/Amgen>,
        <https://1145.am/db/2581359/Amgen>,
        <https://1145.am/db/2583990/Amgen>,
        <https://1145.am/db/2584352/Amgen>,
        <https://1145.am/db/2585068/Amgen>,
        <https://1145.am/db/2586068/Amgen>,
        <https://1145.am/db/2587770/Amgen>,
        <https://1145.am/db/258901/Amgen_Inc>,
        <https://1145.am/db/2589106/Amgen>,
        <https://1145.am/db/2590194/Amgen>,
        <https://1145.am/db/2590989/Amgen>,
        <https://1145.am/db/2592573/Amgen>,
        <https://1145.am/db/2592924/Amgen>,
        <https://1145.am/db/2593465/Amgen>,
        <https://1145.am/db/2593681/Amgen>,
        <https://1145.am/db/2594099/Amgen>,
        <https://1145.am/db/2594285/Amgen>,
        <https://1145.am/db/2594292/Amgen>,
        <https://1145.am/db/2594990/Amgen>,
        <https://1145.am/db/2594993/Amgen>,
        <https://1145.am/db/2595564/Amgen>,
        <https://1145.am/db/2595605/Amgen>,
        <https://1145.am/db/2595930/Amgen>,
        <https://1145.am/db/2597499/Amgen>,
        <https://1145.am/db/2716207/Amgen>,
        <https://1145.am/db/2789236/Amgen>,
        <https://1145.am/db/2802001/Amgen>,
        <https://1145.am/db/531806/Amgen_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350465/Kai-4169> a org:Organization ;
    ns1:basedInHighGeoName "South San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5397765/about.rdf> ;
    ns1:basedInHighRaw "South San Francisco" ;
    ns1:description "Patients with Chronic Kidney Disease who are on Dialysis",
        "pharmaceutical company" ;
    ns1:documentDate "2012-04-10T13:17:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Amgen to Acquire Privately Held KAI Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/financials/amgen-to-acquire-privately-held-kai-pharmaceuticals> ;
    ns1:foundName "KAI",
        "KAI Pharmaceuticals" ;
    ns1:industry "Pharmaceuticals",
        "pharmaceutical" ;
    ns1:name "KAI Pharmaceuticals",
        "KAI-4169" ;
    ns1:participant <https://1145.am/db/2350465/Kai-4169_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/2304914/Kai_Pharmaceuticals>,
        <https://1145.am/db/2333460/Kai_Pharmaceuticals>,
        <https://1145.am/db/2350471/Kai-4169> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351491/Equity_Investment_Thomas_Mcnerney___Partners_Tioga_Pharmaceuticals_Inc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-12T19:40:55+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN DIEGO, April 12, 2012 /PRNewswire/ - Tioga Pharmaceuticals, Inc. today announced the closing of a $ 10 million Series B equity financing led by new investor Thomas, McNerney & Partners, which invested $ 8 million in the round.",
        "Tioga Pharmaceuticals Raises $ 10 Million to Advance Phase 3 Clinical Development of Asimadoline in Irritable Bowel Syndrome." ;
    ns1:documentTitle "Tioga Pharmaceuticals Raises $10 Million to Advance Phase 3 Clinical Development of Asimadoline in Irritable Bowel Syndrome" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tioga-pharmaceuticals-raises-10-million-to-advance-phase-3-clinical-development-of> ;
    ns1:foundName "Raises",
        "financing" ;
    ns1:name "Raises",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2351491/Tioga_Pharmaceuticals_Inc> ;
    ns1:targetDetails "Series B",
        "equity" ;
    ns1:valueRaw "$ 10 Million",
        "$ 10 million",
        "$ 8 million" ;
    ns1:when "2012-04-12T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "April 12, 2012" ;
    ns1:whereGeoName "Tioga County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5141045/about.rdf> ;
    ns1:whereRaw "Tioga Pharmaceuticals" .

<https://1145.am/db/2351491/Tioga_Pharmaceuticals_Inc> a org:Organization ;
    ns1:basedInHighGeoName "San Diego County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:basedInHighRaw "SAN DIEGO" ;
    ns1:documentDate "2012-04-12T19:40:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tioga Pharmaceuticals Raises $10 Million to Advance Phase 3 Clinical Development of Asimadoline in Irritable Bowel Syndrome" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tioga-pharmaceuticals-raises-10-million-to-advance-phase-3-clinical-development-of> ;
    ns1:foundName "Tioga Pharmaceuticals",
        "Tioga Pharmaceuticals, Inc." ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Tioga Pharmaceuticals",
        "Tioga Pharmaceuticals, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2315932/Tioga_Pharmaceuticals>,
        <https://1145.am/db/2315934/Tioga_Pharmaceuticals_Inc>,
        <https://1145.am/db/2327632/Tioga_Pharmaceuticals>,
        <https://1145.am/db/2351492/Tioga_Pharmaceuticals>,
        <https://1145.am/db/2365655/Tigris_Pharmaceuticals>,
        <https://1145.am/db/2365664/Tigris_Pharmaceuticals>,
        <https://1145.am/db/2370582/Tizona_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351519/Alcresta> a org:Organization ;
    ns1:description "VCs" ;
    ns1:documentDate "2012-04-17T11:22:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alcresta Launches Innovative Enzyme-Based Nutritional Company; Secures $10 Million Series A Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alcresta-launches-innovative-enzyme-based-nutritional-company-secures-10-million-series-a-round> ;
    ns1:foundName "Alcresta",
        "Alcresta™" ;
    ns1:industry "biotech" ;
    ns1:name "Alcresta" ;
    ns1:sameAsHigh <https://1145.am/db/1080761/Alithea>,
        <https://1145.am/db/1082184/Alithea>,
        <https://1145.am/db/1629918/Cbr_International>,
        <https://1145.am/db/2089412/Abcuro>,
        <https://1145.am/db/2153744/Sam_Waksal>,
        <https://1145.am/db/2299609/Crn00808>,
        <https://1145.am/db/2313907/Arpida>,
        <https://1145.am/db/2313909/Arpida>,
        <https://1145.am/db/2351520/Alcresta>,
        <https://1145.am/db/2366128/Coda>,
        <https://1145.am/db/2567701/Aurinia>,
        <https://1145.am/db/556138/Abcuro> ;
    ns1:sameAsMedium <https://1145.am/db/2319444/Alcresta>,
        <https://1145.am/db/2339925/Alcresta>,
        <https://1145.am/db/2339926/Alcresta>,
        <https://1145.am/db/2362654/Alcresta>,
        <https://1145.am/db/2368600/Alcresta> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351519/Allena_Pharmaceuticals> a org:Organization ;
    ns1:documentDate "2012-04-17T11:22:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alcresta Launches Innovative Enzyme-Based Nutritional Company; Secures $10 Million Series A Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alcresta-launches-innovative-enzyme-based-nutritional-company-secures-10-million-series-a-round> ;
    ns1:foundName "Allena Pharmaceuticals" ;
    ns1:industry "biotech" ;
    ns1:name "Allena Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1156401/Artios_Pharma_Limited>,
        <https://1145.am/db/1604485/Aeon_Biopharma>,
        <https://1145.am/db/1606180/Aeon_Biopharma>,
        <https://1145.am/db/2065968/Aeon_Biopharma>,
        <https://1145.am/db/2153279/Artios_Pharma>,
        <https://1145.am/db/2254330/Avecia_Biologics>,
        <https://1145.am/db/2281204/Adarx_Pharmaceuticals>,
        <https://1145.am/db/2290753/Karo_Pharma>,
        <https://1145.am/db/2293662/Artios_Pharma>,
        <https://1145.am/db/2299423/Tpg_Biotech>,
        <https://1145.am/db/2319111/Aeras>,
        <https://1145.am/db/2322526/Genetix_Pharmaceuticals>,
        <https://1145.am/db/2323608/Genetix_Pharmaceuticals>,
        <https://1145.am/db/2339922/Biotech_Investment_Group>,
        <https://1145.am/db/2341380/Alexion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2342894/Savara_Pharmaceuticals>,
        <https://1145.am/db/2345996/Alphacore_Pharma>,
        <https://1145.am/db/2347301/Aeras>,
        <https://1145.am/db/2349489/Alexza_Pharma>,
        <https://1145.am/db/2349856/Allena_Pharmaceuticals>,
        <https://1145.am/db/2353588/Tpg_Biotech>,
        <https://1145.am/db/2353608/Tpg_Biotech>,
        <https://1145.am/db/2355318/Aeras>,
        <https://1145.am/db/2356408/Acadia_Pharmaceuticals>,
        <https://1145.am/db/2360526/Sideris_Pharmaceuticals>,
        <https://1145.am/db/2366977/Inspire_Pharmaceuticals>,
        <https://1145.am/db/2368346/Aeras>,
        <https://1145.am/db/2369363/Akari_Therapeutics>,
        <https://1145.am/db/2541473/Elona_Biotechnologies>,
        <https://1145.am/db/2545610/Altus_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2338625/Allena_Pharmaceuticals>,
        <https://1145.am/db/2347122/Allena_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2351519/Series_A_Investment_Alcresta_Alcresta_Allena_Pharmaceuticals_Frazier_Healthcare_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-17T11:22:53+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Alcresta Launches Innovative Enzyme - Based Nutritional Company; Secures $ 10 Million Series A Round.",
        "Alcresta™, a company developing innovative enzyme - based nutritional products for infants, adults and patients battling acute or chronic conditions, today announced a $ 10 million Series A venture capital financing." ;
    ns1:documentTitle "Alcresta Launches Innovative Enzyme-Based Nutritional Company; Secures $10 Million Series A Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alcresta-launches-innovative-enzyme-based-nutritional-company-secures-10-million-series-a-round> ;
    ns1:foundName "capital",
        "financing" ;
    ns1:name "capital",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2351519/Alcresta>,
        <https://1145.am/db/2351519/Allena_Pharmaceuticals> ;
    ns1:targetDetails "Series A",
        "venture",
        "venture capital" ;
    ns1:valueRaw "$ 10 Million",
        "$ 10 million" .

<https://1145.am/db/2352489/Wingu_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Cambridge" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:basedInHighRaw "Cambridge, MA" ;
    ns1:description "drug discovery",
        "pharmaceutical research and discovery" ;
    ns1:documentDate "2012-04-18T13:10:47+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Wingu Announces Funding Led by Google Ventures: Software to Accelerate Distributed Drug Discovery for Pharmaceutical Industry" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/wingu-announces-funding-led-by-google-ventures-software-to-accelerate-distributed-drug> ;
    ns1:foundName "Wingu",
        "Wingu Inc." ;
    ns1:industry "Pharmaceutical",
        "pharmaceutical research and discovery" ;
    ns1:name "Wingu",
        "Wingu Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2326744/Wingu> ;
    ns1:sameAsMedium <https://1145.am/db/1886357/Wingu> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352508/Alder_Biopharmaceuticals_Inc> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-04-19T12:23:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alder-biopharmaceuticals-inc-closes-38-million-series-d-financing-to-accelerate-clinical> ;
    ns1:foundName "Alder BioPharmaceuticals Inc." ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Alder BioPharmaceuticals Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2156104/Alder_Biopharmaceuticals>,
        <https://1145.am/db/2156130/Alder_Biopharmaceuticals>,
        <https://1145.am/db/2347170/Alder_Biopharmaceuticals_Inc>,
        <https://1145.am/db/2360257/Aldea_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2302333/Alder_Biopharmaceuticals_Inc>,
        <https://1145.am/db/2337285/Alder_Biopharmaceuticals_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352525/Ardea_Biosciences> a org:Organization ;
    ns1:basedInHighGeoName "San Diego County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:basedInHighRaw "San Diego, California" ;
    ns1:description "Pharmaceuticals",
        "the development of small-molecule therapeutics" ;
    ns1:documentDate "2012-04-23T12:05:11+00:00"^^xsd:dateTime ;
    ns1:documentTitle "AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout" ;
    ns1:documentURL <https://www.fiercebiotech.com/financials/astrazeneca-to-acquire-ardea-biosciences-for-1-26-billion-including-lead-product> ;
    ns1:foundName "Ardea",
        "Ardea Biosciences",
        "Ardea Biosciences, Inc" ;
    ns1:industry "biotechnology" ;
    ns1:name "Ardea",
        "Ardea Biosciences" ;
    ns1:protagonist <https://1145.am/db/2352525/Ardea_Biosciences_Acquisition> ;
    ns1:sameAsHigh <https://1145.am/db/1534528/Selecta_Biosciences>,
        <https://1145.am/db/2327763/Selecta_Biosciences>,
        <https://1145.am/db/2339745/Selecta_Biosciences>,
        <https://1145.am/db/2370163/Selecta_Biosciences_Inc>,
        <https://1145.am/db/2370166/Selecta_Biosciences_Inc>,
        <https://1145.am/db/486287/Selecta_Biosciences>,
        <https://1145.am/db/648552/Tiamat_Sciences>,
        <https://1145.am/db/961045/Selecta_Biosciences_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2306687/Ardea_Biosciences>,
        <https://1145.am/db/2310900/Ardea_Biosciences>,
        <https://1145.am/db/2329475/Ardea_Biosciences>,
        <https://1145.am/db/2329740/Ardea_Biosciences>,
        <https://1145.am/db/2331031/Ardea_Biosciences>,
        <https://1145.am/db/2331218/Ardea_Biosciences_Inc>,
        <https://1145.am/db/2352532/Ardea_Biosciences>,
        <https://1145.am/db/2353547/Ardea_Biosciences>,
        <https://1145.am/db/2363999/Ardea_Biosciences_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353522/Argos_Therapeutics_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Durham County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4464374/about.rdf> ;
    ns1:basedInHighRaw "DURHAM, N.C." ;
    ns1:basedInLowRaw "U.S." ;
    ns1:documentDate "2012-04-24T14:18:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/argos-therapeutics-secures-25-million-series-d-financing-to-commence-phase-3-adapt-study> ;
    ns1:foundName "Argos Therapeutics",
        "Argos Therapeutics Inc",
        "Argos Therapeutics Inc." ;
    ns1:name "Argos Therapeutics",
        "Argos Therapeutics Inc",
        "Argos Therapeutics Inc." ;
    ns1:sameAsMedium <https://1145.am/db/2308914/Argos_Therapeutics>,
        <https://1145.am/db/2325366/Argos_Therapeutics>,
        <https://1145.am/db/2336844/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2342845/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2345712/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2346087/Argos_Therapeutics>,
        <https://1145.am/db/2347977/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2347983/Argos_Therapeutics>,
        <https://1145.am/db/2350002/Argos_Therapeutics>,
        <https://1145.am/db/2353525/Argos_Therapeutics>,
        <https://1145.am/db/2365891/Argos_Therapeutics>,
        <https://1145.am/db/2370565/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2370600/Argos_Therapeutics>,
        <https://1145.am/db/2551380/Argos_Therapeutics_Inc>,
        <https://1145.am/db/2552553/Argos_Therapeutics>,
        <https://1145.am/db/2559208/Argos_Therapeutics>,
        <https://1145.am/db/2561312/Argos_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353524/Amgen_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Colo" ;
    ns1:documentDate "2012-04-24T14:20:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "miRagen Therapeutics Secures $20 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/miragen-therapeutics-secures-20-million-series-b-financing> ;
    ns1:foundName "Amgen Ventures" ;
    ns1:investor <https://1145.am/db/2353524/Series_B_Investment_Amgen_Ventures_Atlas_Venture_Boulder_Ventures_Ltd_Broadview_Ventures_Miragen_Therapeutics_Miragen_Therapeutics_Remeditex_Ventures_Completed> ;
    ns1:name "Amgen Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1018050/Amgen_Ventures>,
        <https://1145.am/db/1065608/Amgen_Ventures>,
        <https://1145.am/db/1066448/Amgen_Ventures>,
        <https://1145.am/db/1115103/Amgen_Ventures>,
        <https://1145.am/db/1116076/Amgen_Ventures>,
        <https://1145.am/db/1168715/Amgen_Ventures>,
        <https://1145.am/db/1169697/Amgen_Ventures>,
        <https://1145.am/db/1219346/Amgen_Ventures>,
        <https://1145.am/db/1219817/Amgen_Ventures>,
        <https://1145.am/db/1422234/Amgen_Ventures>,
        <https://1145.am/db/1422725/Amgen_Ventures>,
        <https://1145.am/db/1503058/Amgen_Ventures>,
        <https://1145.am/db/2141183/Amgen_Ventures>,
        <https://1145.am/db/2152096/Amgen_Ventures>,
        <https://1145.am/db/2197183/Amgen_Ventures>,
        <https://1145.am/db/2280119/Amgen_Ventures>,
        <https://1145.am/db/2280896/Amgen_Ventures>,
        <https://1145.am/db/2284256/Amgen_Ventures>,
        <https://1145.am/db/2298167/Amgen_Ventures>,
        <https://1145.am/db/2315446/Amgen_Ventures>,
        <https://1145.am/db/2318635/Amgen_Ventures>,
        <https://1145.am/db/2320476/Amgen_Ventures>,
        <https://1145.am/db/2342629/Amgen_Ventures>,
        <https://1145.am/db/2344782/Amgen_Ventures>,
        <https://1145.am/db/2344926/Amgen_Ventures>,
        <https://1145.am/db/2345223/Amgen_Ventures>,
        <https://1145.am/db/2347469/Amgen_Ventures>,
        <https://1145.am/db/2349717/Amgen_Ventures>,
        <https://1145.am/db/2349722/Amgen_Ventures>,
        <https://1145.am/db/2352203/Amgen_Ventures>,
        <https://1145.am/db/2352204/Amgen_Ventures>,
        <https://1145.am/db/2352216/Amgen_Ventures>,
        <https://1145.am/db/2352349/Amgen_Ventures>,
        <https://1145.am/db/2352350/Amgen_Ventures>,
        <https://1145.am/db/2353439/Amgen_Ventures>,
        <https://1145.am/db/2353525/Amgen_Ventures>,
        <https://1145.am/db/2355586/Amgen_Ventures>,
        <https://1145.am/db/2356048/Amgen_Ventures>,
        <https://1145.am/db/2365138/Amgen_Ventures>,
        <https://1145.am/db/2365171/Amgen_Ventures>,
        <https://1145.am/db/2366693/Amgen_Ventures>,
        <https://1145.am/db/2366700/Amgen_Ventures>,
        <https://1145.am/db/2367740/Amgen_Ventures>,
        <https://1145.am/db/2569831/Amgen_Ventures>,
        <https://1145.am/db/2570481/Amgen_Ventures>,
        <https://1145.am/db/2570483/Amgen_Ventures>,
        <https://1145.am/db/770366/Amgen_Ventures>,
        <https://1145.am/db/874503/Amgen_Ventures>,
        <https://1145.am/db/919784/Amgen_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353524/Atlas_Venture> a org:Organization ;
    ns1:basedInHighGeoName "Boulder County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5574999/about.rdf> ;
    ns1:basedInHighRaw "BOULDER" ;
    ns1:documentDate "2012-04-24T14:20:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "miRagen Therapeutics Secures $20 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/miragen-therapeutics-secures-20-million-series-b-financing> ;
    ns1:foundName "Atlas",
        "Atlas Venture" ;
    ns1:investor <https://1145.am/db/2353524/Series_B_Investment_Amgen_Ventures_Atlas_Venture_Boulder_Ventures_Ltd_Broadview_Ventures_Miragen_Therapeutics_Miragen_Therapeutics_Remeditex_Ventures_Completed> ;
    ns1:name "Atlas Venture" ;
    ns1:sameAsMedium <https://1145.am/db/1334624/Atlas_Venture>,
        <https://1145.am/db/1608803/Atlas_Venture>,
        <https://1145.am/db/1698345/Atlas_Venture>,
        <https://1145.am/db/1788233/Atlas_Venture>,
        <https://1145.am/db/1814782/Atlas_Venture>,
        <https://1145.am/db/1824026/Atlas_Venture>,
        <https://1145.am/db/1824878/Atlas_Venture>,
        <https://1145.am/db/1827753/Atlas_Venture>,
        <https://1145.am/db/1828416/Atlas_Venture>,
        <https://1145.am/db/1830149/Atlas_Venture>,
        <https://1145.am/db/1833567/Atlas_Venture>,
        <https://1145.am/db/1834305/Atlas_Venture>,
        <https://1145.am/db/1838696/Atlas_Venture>,
        <https://1145.am/db/1838850/Atlas_Venture>,
        <https://1145.am/db/1838944/Atlas_Venture>,
        <https://1145.am/db/1838979/Atlas_Venture>,
        <https://1145.am/db/1840388/Atlas_Venture>,
        <https://1145.am/db/1840776/Atlas_Venture>,
        <https://1145.am/db/1841385/Atlas_Venture>,
        <https://1145.am/db/1843823/Atlas_Venture>,
        <https://1145.am/db/1847483/Atlas_Venture>,
        <https://1145.am/db/1855553/Atlas_Venture>,
        <https://1145.am/db/1855780/Atlas_Venture>,
        <https://1145.am/db/1857243/Atlas_Venture>,
        <https://1145.am/db/1857978/Atlas_Venture>,
        <https://1145.am/db/1858399/Atlas_Venture>,
        <https://1145.am/db/1863373/Atlas_Venture>,
        <https://1145.am/db/1868932/Atlas_Venture>,
        <https://1145.am/db/1877727/Atlas_Venture>,
        <https://1145.am/db/1878546/Atlas_Venture>,
        <https://1145.am/db/1880181/Atlas_Venture>,
        <https://1145.am/db/1880537/Atlas_Venture>,
        <https://1145.am/db/1891067/Atlas_Venture>,
        <https://1145.am/db/1893502/Atlas_Venture>,
        <https://1145.am/db/1895072/Atlas_Venture>,
        <https://1145.am/db/1901641/Atlas_Venture>,
        <https://1145.am/db/1913598/Atlas_Venture>,
        <https://1145.am/db/1917671/Atlas_Venture>,
        <https://1145.am/db/2062003/Atlas_Venture>,
        <https://1145.am/db/2109798/Atlas_Venture>,
        <https://1145.am/db/2110113/Atlas_Venture>,
        <https://1145.am/db/2178988/Atlas_Venture>,
        <https://1145.am/db/2286541/Atlas_Venture>,
        <https://1145.am/db/2287244/Atlas_Venture>,
        <https://1145.am/db/2290028/Atlas_Venture>,
        <https://1145.am/db/2292284/Atlas_Venture>,
        <https://1145.am/db/2297439/Atlas_Venture>,
        <https://1145.am/db/2298485/Atlas_Venture>,
        <https://1145.am/db/2299411/Atlas_Venture>,
        <https://1145.am/db/2299772/Atlas_Venture>,
        <https://1145.am/db/2303656/Atlas_Venture>,
        <https://1145.am/db/2304044/Atlas_Venture>,
        <https://1145.am/db/2304237/Atlas_Venture>,
        <https://1145.am/db/2309821/Atlas_Venture>,
        <https://1145.am/db/2309840/Atlas_Venture>,
        <https://1145.am/db/2309847/Atlas_Venture>,
        <https://1145.am/db/2310940/Atlas_Venture>,
        <https://1145.am/db/2318778/Atlas_Venture>,
        <https://1145.am/db/2319412/Atlas_Venture>,
        <https://1145.am/db/2325326/Atlas_Venture>,
        <https://1145.am/db/2327406/Atlas_Venture>,
        <https://1145.am/db/2330852/Atlas_Venture>,
        <https://1145.am/db/2330882/Atlas_Venture>,
        <https://1145.am/db/2331870/Atlas_Venture>,
        <https://1145.am/db/2333601/Atlas_Venture>,
        <https://1145.am/db/2336782/Atlas_Venture>,
        <https://1145.am/db/2337455/Atlas_Venture>,
        <https://1145.am/db/2340096/Atlas_Venture>,
        <https://1145.am/db/2340581/Atlas_Venture>,
        <https://1145.am/db/2341478/Atlas_Venture>,
        <https://1145.am/db/2347106/Atlas_Venture>,
        <https://1145.am/db/2347682/Atlas_Venture>,
        <https://1145.am/db/2352967/Atlas_Venture>,
        <https://1145.am/db/2353525/Atlas_Venture>,
        <https://1145.am/db/2354307/Atlas_Venture>,
        <https://1145.am/db/2354314/Atlas_Venture>,
        <https://1145.am/db/2354856/Atlas_Venture>,
        <https://1145.am/db/2355609/Atlas_Venture>,
        <https://1145.am/db/2356048/Atlas_Venture>,
        <https://1145.am/db/2357676/Atlas_Venture>,
        <https://1145.am/db/2357679/Atlas_Venture>,
        <https://1145.am/db/2357682/Atlas_Venture>,
        <https://1145.am/db/2357905/Atlas_Venture>,
        <https://1145.am/db/2358301/Atlas_Venture>,
        <https://1145.am/db/2358860/Atlas_Venture>,
        <https://1145.am/db/2359683/Atlas_Venture>,
        <https://1145.am/db/2359818/Atlas_Venture>,
        <https://1145.am/db/2360814/Atlas_Venture>,
        <https://1145.am/db/2361018/Atlas_Venture>,
        <https://1145.am/db/2361022/Atlas_Venture>,
        <https://1145.am/db/2361027/Atlas_Venture>,
        <https://1145.am/db/2363396/Atlas_Venture>,
        <https://1145.am/db/2365103/Atlas_Venture>,
        <https://1145.am/db/2367740/Atlas_Venture>,
        <https://1145.am/db/2369004/Atlas_Venture>,
        <https://1145.am/db/2369718/Atlas_Venture>,
        <https://1145.am/db/2370094/Atlas_Venture>,
        <https://1145.am/db/2370540/Atlas_Venture>,
        <https://1145.am/db/2570138/Atlas_Venture>,
        <https://1145.am/db/2573068/Atlas_Venture>,
        <https://1145.am/db/2638432/Atlas_Venture>,
        <https://1145.am/db/2787561/Atlas_Venture>,
        <https://1145.am/db/545988/Atlas_Venture>,
        <https://1145.am/db/75445/Atlas_Venture>,
        <https://1145.am/db/979509/Atlas_Venture> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2353524/Miragen_Therapeutics> a org:Organization ;
    ns1:basedInHighGeoName "Boulder County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5574999/about.rdf> ;
    ns1:basedInHighRaw "BOULDER",
        "BOULDER, Colo." ;
    ns1:description "cardiovascular and muscle disease",
        "microRNA - based therapeutics",
        "treating patients who suffer from cardiovascular and muscle disease" ;
    ns1:documentDate "2012-04-24T14:20:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "miRagen Therapeutics Secures $20 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/miragen-therapeutics-secures-20-million-series-b-financing> ;
    ns1:foundName "MiRagen Therapeutics, Inc.",
        "miRagen",
        "miRagen Therapeutics" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "MiRagen",
        "MiRagen Therapeutics",
        "miRagen" ;
    ns1:sameAsHigh <https://1145.am/db/2331870/Miragen_Therapeutics>,
        <https://1145.am/db/2353526/Miragen_Therapeutics>,
        <https://1145.am/db/2363716/Miragen_Therapeutics>,
        <https://1145.am/db/2367740/Miragen_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2330852/Miragen_Therapeutics>,
        <https://1145.am/db/2353525/Miragen_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2354608/Eleven_Biotherapeutics> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-05-08T10:07:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing- Company to Advance its lead Drug Candidate, EBI-005, into Clinic Development for Dry Eye Disease -" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/eleven-biotherapeutics-secures-20-million-and-expands-series-a-financing-company-to-advance> ;
    ns1:foundName "Eleven Biotherapeutics",
        "Eleven Biotherapeutics, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Eleven Biotherapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2315933/Eleven_Biotherapeutics>,
        <https://1145.am/db/2337261/Eleven_Biotherapeutics>,
        <https://1145.am/db/2337994/Eleven_Biotherapeutics>,
        <https://1145.am/db/2341720/Eleven_Biotherapeutics>,
        <https://1145.am/db/2348808/Eleven_Biotherapeutics>,
        <https://1145.am/db/2349967/Eleven_Biotherapeutics>,
        <https://1145.am/db/2352629/Eleven_Biotherapeutics>,
        <https://1145.am/db/2354613/Eleven_Biotherapeutics>,
        <https://1145.am/db/2355309/Eleven_Biotherapeutics>,
        <https://1145.am/db/2361085/Northwest_Biotherapeutics>,
        <https://1145.am/db/2361104/Northwest_Biotherapeutics_Gmbh>,
        <https://1145.am/db/2366340/Eleven_Biotherapeutics>,
        <https://1145.am/db/2369840/Eleven_Biotherapeutics>,
        <https://1145.am/db/2537188/Caliber_Biotherapeutics>,
        <https://1145.am/db/2541239/Caliber_Biotherapeutics>,
        <https://1145.am/db/531765/Aro_Biotherapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2351656/Eleven_Biotherapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355586/Amgen_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:description "Investing in biotech" ;
    ns1:documentDate "2012-05-08T13:06:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sutro Closes $16.5 Million Second Tranche of Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sutro-closes-16-5-million-second-tranche-of-series-c-financing> ;
    ns1:foundName "Amgen Ventures" ;
    ns1:investor <https://1145.am/db/2355586/Series_C_Investment_Alta_Partners_Amgen_Ventures_Lilly_Ventures_Sv_Life_Sciences_Skyline_Ventures_Sutro_Biopharma_Completed> ;
    ns1:name "Amgen Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1283038/Arkin_Bio_Ventures>,
        <https://1145.am/db/1657080/Alpha_Wave_Ventures>,
        <https://1145.am/db/2301824/Sagamore_Bioventures>,
        <https://1145.am/db/2302897/Sagamore_Bioventures>,
        <https://1145.am/db/2325348/Biogen_Idec_New_Ventures>,
        <https://1145.am/db/2331988/Bioventures_Investors>,
        <https://1145.am/db/2339932/Biogeneration_Ventures>,
        <https://1145.am/db/2342557/Tpg_Biotech>,
        <https://1145.am/db/2353607/Biogen_Idec_New_Ventures>,
        <https://1145.am/db/2361588/Agechem_Venture>,
        <https://1145.am/db/2371163/Sofinnova_Ventures>,
        <https://1145.am/db/527072/Biobrit_Llc>,
        <https://1145.am/db/545842/Hx_Bio_Ventures>,
        <https://1145.am/db/674484/Trinity_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1018050/Amgen_Ventures>,
        <https://1145.am/db/1065608/Amgen_Ventures>,
        <https://1145.am/db/1066448/Amgen_Ventures>,
        <https://1145.am/db/1115103/Amgen_Ventures>,
        <https://1145.am/db/1116076/Amgen_Ventures>,
        <https://1145.am/db/1168715/Amgen_Ventures>,
        <https://1145.am/db/1169697/Amgen_Ventures>,
        <https://1145.am/db/1219346/Amgen_Ventures>,
        <https://1145.am/db/1219817/Amgen_Ventures>,
        <https://1145.am/db/1422234/Amgen_Ventures>,
        <https://1145.am/db/1422725/Amgen_Ventures>,
        <https://1145.am/db/1503058/Amgen_Ventures>,
        <https://1145.am/db/2141183/Amgen_Ventures>,
        <https://1145.am/db/2152096/Amgen_Ventures>,
        <https://1145.am/db/2197183/Amgen_Ventures>,
        <https://1145.am/db/2280119/Amgen_Ventures>,
        <https://1145.am/db/2280896/Amgen_Ventures>,
        <https://1145.am/db/2284256/Amgen_Ventures>,
        <https://1145.am/db/2298167/Amgen_Ventures>,
        <https://1145.am/db/2315446/Amgen_Ventures>,
        <https://1145.am/db/2318635/Amgen_Ventures>,
        <https://1145.am/db/2320476/Amgen_Ventures>,
        <https://1145.am/db/2342629/Amgen_Ventures>,
        <https://1145.am/db/2344782/Amgen_Ventures>,
        <https://1145.am/db/2344926/Amgen_Ventures>,
        <https://1145.am/db/2345223/Amgen_Ventures>,
        <https://1145.am/db/2347469/Amgen_Ventures>,
        <https://1145.am/db/2349717/Amgen_Ventures>,
        <https://1145.am/db/2349722/Amgen_Ventures>,
        <https://1145.am/db/2352203/Amgen_Ventures>,
        <https://1145.am/db/2352204/Amgen_Ventures>,
        <https://1145.am/db/2352216/Amgen_Ventures>,
        <https://1145.am/db/2352349/Amgen_Ventures>,
        <https://1145.am/db/2352350/Amgen_Ventures>,
        <https://1145.am/db/2353439/Amgen_Ventures>,
        <https://1145.am/db/2353524/Amgen_Ventures>,
        <https://1145.am/db/2353525/Amgen_Ventures>,
        <https://1145.am/db/2356048/Amgen_Ventures>,
        <https://1145.am/db/2365138/Amgen_Ventures>,
        <https://1145.am/db/2365171/Amgen_Ventures>,
        <https://1145.am/db/2366693/Amgen_Ventures>,
        <https://1145.am/db/2366700/Amgen_Ventures>,
        <https://1145.am/db/2367740/Amgen_Ventures>,
        <https://1145.am/db/2569831/Amgen_Ventures>,
        <https://1145.am/db/2570481/Amgen_Ventures>,
        <https://1145.am/db/2570483/Amgen_Ventures>,
        <https://1145.am/db/770366/Amgen_Ventures>,
        <https://1145.am/db/874503/Amgen_Ventures>,
        <https://1145.am/db/919784/Amgen_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355586/Sutro_Biopharma> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:description "Biopharma" ;
    ns1:documentDate "2012-05-08T13:06:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sutro Closes $16.5 Million Second Tranche of Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sutro-closes-16-5-million-second-tranche-of-series-c-financing> ;
    ns1:foundName "Sutro",
        "Sutro Biopharma" ;
    ns1:name "Sutro",
        "Sutro Biopharma" ;
    ns1:sameAsHigh <https://1145.am/db/2279596/Sutro>,
        <https://1145.am/db/2353439/Sutro_Biopharma>,
        <https://1145.am/db/2360764/Sutro_Biopharma>,
        <https://1145.am/db/2360774/Sutro_Biopharma> ;
    ns1:sameAsMedium <https://1145.am/db/1443534/Sutro_Biopharma>,
        <https://1145.am/db/2291433/Sutro_Biopharma>,
        <https://1145.am/db/2309878/Sutro_Biopharma>,
        <https://1145.am/db/2310591/Sutro_Biopharma>,
        <https://1145.am/db/2336468/Sutro_Biopharma>,
        <https://1145.am/db/2338978/Sutro_Biopharma>,
        <https://1145.am/db/2341885/Sutro_Biopharma>,
        <https://1145.am/db/2341905/Sutro_Biopharma>,
        <https://1145.am/db/2353438/Sutro_Biopharma>,
        <https://1145.am/db/2354679/Sutro_Biopharma>,
        <https://1145.am/db/2370638/Sutro_Biopharma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355609/Atlas_Venture> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2012-05-10T14:51:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Egalet Announces Series B Financing and Names Bob Radie Chief Executive Officer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/egalet-announces-series-b-financing-and-names-bob-radie-chief-executive-officer> ;
    ns1:foundName "Atlas Venture" ;
    ns1:investor <https://1145.am/db/2355609/Series_B_Investment_Atlas_Venture_Cls_Capital_Egalet_Ltd_Index_Ventures_Omega_Funds_Sunstone_Capital_Completed> ;
    ns1:name "Atlas Venture" ;
    ns1:sameAsMedium <https://1145.am/db/1334624/Atlas_Venture>,
        <https://1145.am/db/1608803/Atlas_Venture>,
        <https://1145.am/db/1698345/Atlas_Venture>,
        <https://1145.am/db/1788233/Atlas_Venture>,
        <https://1145.am/db/1814782/Atlas_Venture>,
        <https://1145.am/db/1824026/Atlas_Venture>,
        <https://1145.am/db/1824878/Atlas_Venture>,
        <https://1145.am/db/1827753/Atlas_Venture>,
        <https://1145.am/db/1828416/Atlas_Venture>,
        <https://1145.am/db/1830149/Atlas_Venture>,
        <https://1145.am/db/1833567/Atlas_Venture>,
        <https://1145.am/db/1834305/Atlas_Venture>,
        <https://1145.am/db/1838696/Atlas_Venture>,
        <https://1145.am/db/1838850/Atlas_Venture>,
        <https://1145.am/db/1838944/Atlas_Venture>,
        <https://1145.am/db/1838979/Atlas_Venture>,
        <https://1145.am/db/1840388/Atlas_Venture>,
        <https://1145.am/db/1840776/Atlas_Venture>,
        <https://1145.am/db/1841385/Atlas_Venture>,
        <https://1145.am/db/1843823/Atlas_Venture>,
        <https://1145.am/db/1847483/Atlas_Venture>,
        <https://1145.am/db/1855553/Atlas_Venture>,
        <https://1145.am/db/1855780/Atlas_Venture>,
        <https://1145.am/db/1857243/Atlas_Venture>,
        <https://1145.am/db/1857978/Atlas_Venture>,
        <https://1145.am/db/1858399/Atlas_Venture>,
        <https://1145.am/db/1863373/Atlas_Venture>,
        <https://1145.am/db/1868932/Atlas_Venture>,
        <https://1145.am/db/1877727/Atlas_Venture>,
        <https://1145.am/db/1878546/Atlas_Venture>,
        <https://1145.am/db/1880181/Atlas_Venture>,
        <https://1145.am/db/1880537/Atlas_Venture>,
        <https://1145.am/db/1891067/Atlas_Venture>,
        <https://1145.am/db/1893502/Atlas_Venture>,
        <https://1145.am/db/1895072/Atlas_Venture>,
        <https://1145.am/db/1901641/Atlas_Venture>,
        <https://1145.am/db/1913598/Atlas_Venture>,
        <https://1145.am/db/1917671/Atlas_Venture>,
        <https://1145.am/db/2062003/Atlas_Venture>,
        <https://1145.am/db/2109798/Atlas_Venture>,
        <https://1145.am/db/2110113/Atlas_Venture>,
        <https://1145.am/db/2178988/Atlas_Venture>,
        <https://1145.am/db/2286541/Atlas_Venture>,
        <https://1145.am/db/2287244/Atlas_Venture>,
        <https://1145.am/db/2290028/Atlas_Venture>,
        <https://1145.am/db/2292284/Atlas_Venture>,
        <https://1145.am/db/2297439/Atlas_Venture>,
        <https://1145.am/db/2298485/Atlas_Venture>,
        <https://1145.am/db/2299411/Atlas_Venture>,
        <https://1145.am/db/2299772/Atlas_Venture>,
        <https://1145.am/db/2303656/Atlas_Venture>,
        <https://1145.am/db/2304044/Atlas_Venture>,
        <https://1145.am/db/2304237/Atlas_Venture>,
        <https://1145.am/db/2309821/Atlas_Venture>,
        <https://1145.am/db/2309840/Atlas_Venture>,
        <https://1145.am/db/2309847/Atlas_Venture>,
        <https://1145.am/db/2310940/Atlas_Venture>,
        <https://1145.am/db/2318778/Atlas_Venture>,
        <https://1145.am/db/2319412/Atlas_Venture>,
        <https://1145.am/db/2325326/Atlas_Venture>,
        <https://1145.am/db/2327406/Atlas_Venture>,
        <https://1145.am/db/2330852/Atlas_Venture>,
        <https://1145.am/db/2330882/Atlas_Venture>,
        <https://1145.am/db/2331870/Atlas_Venture>,
        <https://1145.am/db/2333601/Atlas_Venture>,
        <https://1145.am/db/2336782/Atlas_Venture>,
        <https://1145.am/db/2337455/Atlas_Venture>,
        <https://1145.am/db/2340096/Atlas_Venture>,
        <https://1145.am/db/2340581/Atlas_Venture>,
        <https://1145.am/db/2341478/Atlas_Venture>,
        <https://1145.am/db/2347106/Atlas_Venture>,
        <https://1145.am/db/2347682/Atlas_Venture>,
        <https://1145.am/db/2352967/Atlas_Venture>,
        <https://1145.am/db/2353524/Atlas_Venture>,
        <https://1145.am/db/2353525/Atlas_Venture>,
        <https://1145.am/db/2354307/Atlas_Venture>,
        <https://1145.am/db/2354314/Atlas_Venture>,
        <https://1145.am/db/2354856/Atlas_Venture>,
        <https://1145.am/db/2356048/Atlas_Venture>,
        <https://1145.am/db/2357676/Atlas_Venture>,
        <https://1145.am/db/2357679/Atlas_Venture>,
        <https://1145.am/db/2357682/Atlas_Venture>,
        <https://1145.am/db/2357905/Atlas_Venture>,
        <https://1145.am/db/2358301/Atlas_Venture>,
        <https://1145.am/db/2358860/Atlas_Venture>,
        <https://1145.am/db/2359683/Atlas_Venture>,
        <https://1145.am/db/2359818/Atlas_Venture>,
        <https://1145.am/db/2360814/Atlas_Venture>,
        <https://1145.am/db/2361018/Atlas_Venture>,
        <https://1145.am/db/2361022/Atlas_Venture>,
        <https://1145.am/db/2361027/Atlas_Venture>,
        <https://1145.am/db/2363396/Atlas_Venture>,
        <https://1145.am/db/2365103/Atlas_Venture>,
        <https://1145.am/db/2367740/Atlas_Venture>,
        <https://1145.am/db/2369004/Atlas_Venture>,
        <https://1145.am/db/2369718/Atlas_Venture>,
        <https://1145.am/db/2370094/Atlas_Venture>,
        <https://1145.am/db/2370540/Atlas_Venture>,
        <https://1145.am/db/2570138/Atlas_Venture>,
        <https://1145.am/db/2573068/Atlas_Venture>,
        <https://1145.am/db/2638432/Atlas_Venture>,
        <https://1145.am/db/2787561/Atlas_Venture>,
        <https://1145.am/db/545988/Atlas_Venture>,
        <https://1145.am/db/75445/Atlas_Venture>,
        <https://1145.am/db/979509/Atlas_Venture> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355609/Egalet_Ltd> a org:Organization ;
    ns1:basedInHighGeoName "Malvern" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5199600/about.rdf> ;
    ns1:basedInHighRaw "MALVERN, Pa." ;
    ns1:description "developing safe, effective and abuse-resistant medications" ;
    ns1:documentDate "2012-05-10T14:51:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Egalet Announces Series B Financing and Names Bob Radie Chief Executive Officer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/egalet-announces-series-b-financing-and-names-bob-radie-chief-executive-officer> ;
    ns1:foundName "Egalet",
        "Egalet Ltd." ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Egalet",
        "Egalet Ltd." ;
    ns1:sameAsHigh <https://1145.am/db/2305958/Esprit>,
        <https://1145.am/db/2309847/Egalet>,
        <https://1145.am/db/2333601/Egalet>,
        <https://1145.am/db/2347136/Egalet_Corporation>,
        <https://1145.am/db/2352142/Egalet_Ltd>,
        <https://1145.am/db/2355608/Egalet>,
        <https://1145.am/db/2356308/Egalet_Ltd>,
        <https://1145.am/db/2368009/Egalet_Corporation>,
        <https://1145.am/db/2371064/Egalet>,
        <https://1145.am/db/2558566/Egalet> ;
    ns1:sameAsMedium <https://1145.am/db/2309840/Egalet>,
        <https://1145.am/db/2349969/Egalet_Corporation>,
        <https://1145.am/db/2355984/Egalet> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355609/Sunstone_Capital> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2012-05-10T14:51:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Egalet Announces Series B Financing and Names Bob Radie Chief Executive Officer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/egalet-announces-series-b-financing-and-names-bob-radie-chief-executive-officer> ;
    ns1:foundName "Sunstone Capital" ;
    ns1:investor <https://1145.am/db/2355609/Series_B_Investment_Atlas_Venture_Cls_Capital_Egalet_Ltd_Index_Ventures_Omega_Funds_Sunstone_Capital_Completed> ;
    ns1:name "Sunstone Capital" ;
    ns1:sameAsMedium <https://1145.am/db/1717714/Sunstone_Capital>,
        <https://1145.am/db/1776660/Sunstone_Capital>,
        <https://1145.am/db/1780157/Sunstone_Capital>,
        <https://1145.am/db/1791743/Sunstone_Capital>,
        <https://1145.am/db/1797413/Sunstone_Capital>,
        <https://1145.am/db/1800466/Sunstone_Capital>,
        <https://1145.am/db/1803787/Sunstone_Capital>,
        <https://1145.am/db/1808488/Sunstone_Capital>,
        <https://1145.am/db/1813404/Sunstone_Capital>,
        <https://1145.am/db/1821174/Sunstone_Capital>,
        <https://1145.am/db/1832434/Sunstone_Capital>,
        <https://1145.am/db/1833000/Sunstone_Capital>,
        <https://1145.am/db/1833646/Sunstone_Capital>,
        <https://1145.am/db/1850593/Sunstone_Capital>,
        <https://1145.am/db/1850760/Sunstone_Capital>,
        <https://1145.am/db/1854996/Sunstone_Capital>,
        <https://1145.am/db/1858818/Sunstone_Capital>,
        <https://1145.am/db/1859597/Sunstone_Capital>,
        <https://1145.am/db/1862019/Sunstone_Capital>,
        <https://1145.am/db/1868935/Sunstone_Capital>,
        <https://1145.am/db/1869517/Sunstone_Capital>,
        <https://1145.am/db/1870079/Sunstone_Capital>,
        <https://1145.am/db/1877786/Sunstone_Capital>,
        <https://1145.am/db/1879213/Sunstone_Capital>,
        <https://1145.am/db/1885147/Sunstone_Capital>,
        <https://1145.am/db/1888954/Sunstone_Capital>,
        <https://1145.am/db/2323700/Sunstone_Capital>,
        <https://1145.am/db/2329919/Sunstone_Capital>,
        <https://1145.am/db/2336622/Sunstone_Capital>,
        <https://1145.am/db/2341942/Sunstone_Capital>,
        <https://1145.am/db/2346452/Sunstone_Capital>,
        <https://1145.am/db/2347980/Sunstone_Capital>,
        <https://1145.am/db/2348003/Sunstone_Capital>,
        <https://1145.am/db/2352203/Sunstone_Capital>,
        <https://1145.am/db/2352204/Sunstone_Capital>,
        <https://1145.am/db/2352216/Sunstone_Capital>,
        <https://1145.am/db/2355841/Sunstone_Capital>,
        <https://1145.am/db/2360127/Sunstone_Capital>,
        <https://1145.am/db/2360922/Sunstone_Capital>,
        <https://1145.am/db/2367218/Sunstone_Capital>,
        <https://1145.am/db/2569491/Sunstone_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356690/Zurex_Pharma> a org:Organization ;
    ns1:basedInHighGeoName "Madison" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5261457/about.rdf> ;
    ns1:basedInHighRaw "Madison, WI" ;
    ns1:documentDate "2012-05-22T13:14:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biotechs raise new VC rounds to back inhalable drugs, antimicrobials" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotechs-raise-new-vc-rounds-to-back-inhalable-drugs-antimicrobials> ;
    ns1:foundName "Zurex Pharma" ;
    ns1:industry "Pharma" ;
    ns1:name "Zurex Pharma" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357709/Halo_Therapeutics> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-05-23T15:31:34+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/halo-therapeutics-raises-1-1-million-to-expedite-phase-2-study-of-ht-100> ;
    ns1:foundName "Halo Therapeutics",
        "Halo Therapeutics, LLC" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Halo Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/1003874/Halozyme_Therapeutics>,
        <https://1145.am/db/1005174/Halozyme_Therapeutics>,
        <https://1145.am/db/1022806/Halozyme_Therapeutics>,
        <https://1145.am/db/1026859/Halozyme_Therapeutics>,
        <https://1145.am/db/1035154/Halozyme_Therapeutics>,
        <https://1145.am/db/1038193/Halozyme_Therapeutics>,
        <https://1145.am/db/2314209/Halozyme_Therapeutics>,
        <https://1145.am/db/2318716/Halozyme_Therapeutics>,
        <https://1145.am/db/2340647/Halozyme_Therapeutics>,
        <https://1145.am/db/2340694/Halozyme_Therapeutics>,
        <https://1145.am/db/2341981/Halozyme_Therapeutics>,
        <https://1145.am/db/2347138/Halozyme_Therapeutics>,
        <https://1145.am/db/2347178/Halozyme_Therapeutics_Inc>,
        <https://1145.am/db/2359632/Halozyme_Therapeutics>,
        <https://1145.am/db/2360296/Halozyme_Therapeutics>,
        <https://1145.am/db/2360775/Halozyme_Therapeutics>,
        <https://1145.am/db/2369065/Halozyme_Therapeutics>,
        <https://1145.am/db/2369611/Halozyme_Therapeutics>,
        <https://1145.am/db/2553920/Halozyme>,
        <https://1145.am/db/978324/Halozyme_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2357725/Equity_Investment_Leucadia_National_Corporation_Sangart_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-24T19:25:49+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN DIEGO, May 24, 2012 /PRNewswire via COMTEX/ - Sangart, Inc., a global biopharmaceutical company dedicated to developing and commercializing targeted rescue therapies for patients in acute ischemic crisis, today announced that it recently received $ 50 million in additional equity funding from existing investor, Leucadia National Corporation.",
        "Sangart Raises Additional $ 50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock." ;
    ns1:documentTitle "Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sangart-raises-additional-50m-series-g-funding-following-interim-safety-analysis-of-phase> ;
    ns1:foundName "Funding",
        "Raises",
        "funding" ;
    ns1:name "Funding",
        "Raises",
        "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2357725/Sangart> ;
    ns1:targetDetails "Series G",
        "equity" ;
    ns1:valueRaw "$ 50 million",
        "$ 50M" ;
    ns1:when "2012-05-24T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "May 24, 2012" ;
    ns1:whereGeoName "San Diego County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391832/about.rdf> ;
    ns1:whereRaw "SAN DIEGO" .

<https://1145.am/db/2357725/Sangart> a org:Organization ;
    ns1:description "medical research" ;
    ns1:documentDate "2012-05-24T19:25:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sangart-raises-additional-50m-series-g-funding-following-interim-safety-analysis-of-phase> ;
    ns1:foundName "Sangart",
        "Sangart, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Sangart" ;
    ns1:sameAsHigh <https://1145.am/db/2305552/Sangart_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2305549/Sangart>,
        <https://1145.am/db/2319780/Sangart>,
        <https://1145.am/db/2366555/Sangart_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358806/Ceptaris_Therapeutics> a org:Organization ;
    ns1:basedInHighGeoName "Malvern" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5199600/about.rdf> ;
    ns1:basedInHighRaw "MALVERN, Pa." ;
    ns1:description "pharmaceutical company" ;
    ns1:documentDate "2012-06-05T14:30:23+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Ceptaris Secures $10 Million in Series D-1 Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ceptaris-secures-10-million-series-d-1-financing> ;
    ns1:foundName "Ceptaris",
        "Ceptaris Therapeutics, Inc." ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Ceptaris",
        "Ceptaris Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2342789/Ceptaris_Therapeutics>,
        <https://1145.am/db/2358804/Ceptaris> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358812/Hatteras_Venture_Partners> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-06-06T15:08:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PhaseBio Pharmaceuticals Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing For Advancement of Metabolic and Cardiovascular Product Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/phasebio-pharmaceuticals-received-an-additional-23-million-completion-of-third-tranche-of-a> ;
    ns1:foundName "Hatteras Venture Partners" ;
    ns1:investor <https://1145.am/db/2358812/Series_B_Investment_Fletcher_Spaght_Ventures_Hatteras_Venture_Partners_Johnson___Johnson_Development_Corporation_New_Enterprise_Associates_Osi_Investment_Holdings_Phasebio_Pharmaceuticals_Completed> ;
    ns1:name "Hatteras Venture Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1115103/Hatteras_Venture_Partners>,
        <https://1145.am/db/1335370/Hatteras_Venture_Partners>,
        <https://1145.am/db/1464210/Hatteras_Venture_Partners>,
        <https://1145.am/db/1896251/Hatteras_Venture_Partners>,
        <https://1145.am/db/1957179/Hatteras_Venture_Partners>,
        <https://1145.am/db/2306163/Hatteras_Venture_Partners>,
        <https://1145.am/db/2315247/Hatteras_Venture_Partners>,
        <https://1145.am/db/2339206/Hatteras_Venture_Partners>,
        <https://1145.am/db/2351316/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353671/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353674/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358657/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358658/Hatteras_Venture_Partners>,
        <https://1145.am/db/2360521/Hatteras_Venture_Partners>,
        <https://1145.am/db/2363442/Hatteras_Venture_Partners>,
        <https://1145.am/db/601404/Hatteras_Venture_Partners>,
        <https://1145.am/db/885068/Hatteras_Venture_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1465033/Hatteras_Venture_Partners>,
        <https://1145.am/db/1565424/Hatteras_Venture_Partners>,
        <https://1145.am/db/2153141/Hatteras_Venture_Partners>,
        <https://1145.am/db/2224522/Hatteras_Venture_Partners>,
        <https://1145.am/db/2236817/Hatteras_Venture_Partners>,
        <https://1145.am/db/2284028/Hatteras_Venture_Partners>,
        <https://1145.am/db/2315248/Hatteras_Venture_Partners>,
        <https://1145.am/db/2319640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2321694/Hatteras_Venture_Partners>,
        <https://1145.am/db/2323511/Hatteras_Venture_Partners>,
        <https://1145.am/db/2328194/Hatteras_Venture_Partners>,
        <https://1145.am/db/2328196/Hatteras_Venture_Partners>,
        <https://1145.am/db/2332459/Hatteras_Venture_Partners>,
        <https://1145.am/db/2349717/Hatteras_Venture_Partners>,
        <https://1145.am/db/2349722/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2354648/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2359452/Hatteras_Venture_Partners>,
        <https://1145.am/db/2360526/Hatteras_Venture_Partners>,
        <https://1145.am/db/2363396/Hatteras_Venture_Partners>,
        <https://1145.am/db/2364853/Hatteras_Venture_Partners>,
        <https://1145.am/db/2365171/Hatteras_Venture_Partners>,
        <https://1145.am/db/495996/Hatteras_Venture_Partners>,
        <https://1145.am/db/496377/Hatteras_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358812/Malvern> a org:Organization ;
    ns1:basedInHighGeoName "Chongqing" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1814906/about.rdf> ;
    ns1:basedInHighRaw "Pa" ;
    ns1:documentDate "2012-06-06T15:08:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PhaseBio Pharmaceuticals Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing For Advancement of Metabolic and Cardiovascular Product Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/phasebio-pharmaceuticals-received-an-additional-23-million-completion-of-third-tranche-of-a> ;
    ns1:foundName "MALVERN, Pa" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "MALVERN" ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358812/Phasebio_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Malvern" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5199600/about.rdf> ;
    ns1:basedInHighRaw "MALVERN, Pa." ;
    ns1:description "developing drugs to treat diabetes, metabolic disease and cardiovascular disease" ;
    ns1:documentDate "2012-06-06T15:08:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PhaseBio Pharmaceuticals Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing For Advancement of Metabolic and Cardiovascular Product Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/phasebio-pharmaceuticals-received-an-additional-23-million-completion-of-third-tranche-of-a> ;
    ns1:foundName "PhaseBio",
        "PhaseBio Pharmaceuticals, Inc." ;
    ns1:industry "biotechnology" ;
    ns1:name "PhaseBio Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1649045/Phasebio_Pharmaceuticals>,
        <https://1145.am/db/2306163/Phasebio_Pharmaceuticals>,
        <https://1145.am/db/2306167/Phasebio_Pharmaceuticals>,
        <https://1145.am/db/2339206/Phasebio_Pharmaceuticals>,
        <https://1145.am/db/2355331/Phasebio_Pharmaceuticals>,
        <https://1145.am/db/2358640/Phasebio_Pharmaceuticals_Inc>,
        <https://1145.am/db/2358658/Phasebio_Pharmaceuticals_Inc>,
        <https://1145.am/db/606168/Phasebio_Pharmaceuticals>,
        <https://1145.am/db/631441/Phasebio_Pharmaceuticals>,
        <https://1145.am/db/636071/Phasebio_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359830/Fluorinov_Pharma_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Toronto" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6167865/about.rdf> ;
    ns1:basedInHighRaw "Toronto" ;
    ns1:description "Pharmaceuticals",
        "developing drugs" ;
    ns1:documentDate "2012-06-07T16:06:40+00:00"^^xsd:dateTime ;
    ns1:documentTitle "OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/oicr-funds-fluorinov-pharma-inc-to-further-develop-its-novel-drug-for-treatment-of-blood> ;
    ns1:foundName "Fluorinov Pharma Inc.",
        "Fluorinov Pharma, Inc" ;
    ns1:industry "Pharmaceutical",
        "pharmaceutical" ;
    ns1:investor <https://1145.am/db/2359830/Investment_Fluorinov_Pharma_Inc_The_Ontario_Institute_For_Cancer_Research_Has_Not_Happened> ;
    ns1:name "Fluorinov Pharma",
        "Fluorinov Pharma Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2356491/Fluorinov_Pharma>,
        <https://1145.am/db/2359827/Fluorinov_Pharma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359863/Series_B_Investment_Savara_Pharmaceuticals_The_Keiretsu_Forum_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-12T16:30:29+00:00"^^xsd:dateTime ;
    ns1:documentExtract "AUSTIN, Texas, June 12, 2012 /PRNewswire via COMTEX/ - Savara Pharmaceuticals, an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions, today announced that it has raised $ 8.6 million in the first closing of a Series B round of financing.",
        "Savara Pharmaceuticals Raises $ 8.6 Million in Series B Financing Round." ;
    ns1:documentTitle "Savara Pharmaceuticals Raises $8.6 Million in Series B Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/savara-pharmaceuticals-raises-8-6-million-series-b-financing-round> ;
    ns1:foundName "Financing",
        "financing",
        "raised" ;
    ns1:name "Financing",
        "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2359863/Savara_Pharmaceuticals> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 8.6 Million",
        "$ 8.6 million" ;
    ns1:when "2012-06-12T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "June 12, 2012" ;
    ns1:whereGeoName "Texas" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4736286/about.rdf> ;
    ns1:whereRaw "Texas" .

<https://1145.am/db/2359864/Investment_Third_Rock_Ventures_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-12T14:59:53+00:00"^^xsd:dateTime ;
    ns1:documentExtract "- Third Rock Ventures joins syndicate in new financing round - - Proceeds to advance antibody discovery engine and IND candidates toward clinical trials -" ;
    ns1:documentTitle "Igenica Closes $33 Million in Series C Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/igenica-closes-33-million-series-c-funding> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2359864/Orbimed_Advisors> a org:Organization ;
    ns1:basedInLowRaw "BURLINGAME, Calif" ;
    ns1:documentDate "2012-06-12T14:59:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Igenica Closes $33 Million in Series C Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/igenica-closes-33-million-series-c-funding> ;
    ns1:foundName "Orbimed Advisors" ;
    ns1:investor <https://1145.am/db/2359864/Series_C_Investment_5am_Ventures_Igenica_Orbimed_Advisors_The_Column_Group_Third_Rock_Ventures_Completed> ;
    ns1:name "Orbimed Advisors" ;
    ns1:sameAsMedium <https://1145.am/db/1665536/Orbimed_Advisors>,
        <https://1145.am/db/1809007/Orbimed_Advisors>,
        <https://1145.am/db/2198816/Orbimed_Advisors>,
        <https://1145.am/db/2245885/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2281230/Orbimed_Advisors>,
        <https://1145.am/db/2284506/Orbimed_Advisors>,
        <https://1145.am/db/2289056/Orbimed_Advisors>,
        <https://1145.am/db/2290078/Orbimed_Advisors>,
        <https://1145.am/db/2290200/Orbimed_Advisors>,
        <https://1145.am/db/2290444/Orbimed_Advisors>,
        <https://1145.am/db/2297604/Orbimed_Advisors>,
        <https://1145.am/db/2298956/Orbimed_Advisors>,
        <https://1145.am/db/2303098/Orbimed_Advisors>,
        <https://1145.am/db/2304242/Orbimed_Advisors>,
        <https://1145.am/db/2305656/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306251/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2306705/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2309491/Orbimed_Advisors>,
        <https://1145.am/db/2310922/Orbimed_Advisors>,
        <https://1145.am/db/2312233/Orbimed_Advisors>,
        <https://1145.am/db/2317918/Orbimed_Advisors>,
        <https://1145.am/db/2318133/Orbimed_Advisors>,
        <https://1145.am/db/2318829/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2318832/Orbimed_Advisers>,
        <https://1145.am/db/2318851/Orbimed_Advisors>,
        <https://1145.am/db/2319338/Orbimed_Advisors>,
        <https://1145.am/db/2320914/Orbimed_Advisors>,
        <https://1145.am/db/2322345/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2324226/Orbimed_Advisors>,
        <https://1145.am/db/2325257/Orbimed_Advisors>,
        <https://1145.am/db/2325880/Orbimed_Advisors>,
        <https://1145.am/db/2328599/Orbimed_Advisors>,
        <https://1145.am/db/2328700/Orbimed_Advisors>,
        <https://1145.am/db/2329260/Orbimed_Advisors>,
        <https://1145.am/db/2330799/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2330920/Orbimed_Advisors>,
        <https://1145.am/db/2332120/Orbimed_Advisors>,
        <https://1145.am/db/2333495/Orbimed_Advisors>,
        <https://1145.am/db/2333504/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2333966/Orbimed_Advisors>,
        <https://1145.am/db/2335743/Orbimed_Advisors>,
        <https://1145.am/db/2336221/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2336503/Orbimed_Advisors>,
        <https://1145.am/db/2336505/Orbimed_Advisors>,
        <https://1145.am/db/2336524/Orbimed_Advisors>,
        <https://1145.am/db/2337166/Orbimed_Advisors>,
        <https://1145.am/db/2337250/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2337254/Orbimed_Advisors>,
        <https://1145.am/db/2339885/Orbimed_Advisors>,
        <https://1145.am/db/2339886/Orbimed_Advisors>,
        <https://1145.am/db/2342862/Orbimed_Advisors>,
        <https://1145.am/db/2342925/Orbimed_Advisors>,
        <https://1145.am/db/2342937/Orbimed_Advisors>,
        <https://1145.am/db/2343244/Orbimed_Advisors>,
        <https://1145.am/db/2344735/Orbimed_Advisors>,
        <https://1145.am/db/2344786/Orbimed_Advisors>,
        <https://1145.am/db/2345435/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345453/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2345456/Orbimed_Advisors>,
        <https://1145.am/db/2346030/Orbimed_Advisors>,
        <https://1145.am/db/2350034/Orbimed_Advisors>,
        <https://1145.am/db/2350044/Orbimed_Advisors>,
        <https://1145.am/db/2352436/Orbimed_Advisors>,
        <https://1145.am/db/2352441/Orbimed_Advisors>,
        <https://1145.am/db/2352442/Orbimed_Advisors>,
        <https://1145.am/db/2352701/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2352804/Orbimed_Advisors>,
        <https://1145.am/db/2352807/Orbimed_Advisors>,
        <https://1145.am/db/2355034/Orbimed_Advisors>,
        <https://1145.am/db/2356297/Orbimed_Advisors>,
        <https://1145.am/db/2356420/Orbimed_Advisors>,
        <https://1145.am/db/2357253/Orbimed_Advisors>,
        <https://1145.am/db/2357256/Orbimed_Advisors>,
        <https://1145.am/db/2357858/Orbimed_Advisors>,
        <https://1145.am/db/2359125/Orbimed_Advisors>,
        <https://1145.am/db/2359468/Orbimed_Advisors>,
        <https://1145.am/db/2360174/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2361018/Orbimed_Advisors>,
        <https://1145.am/db/2361022/Orbimed_Advisors>,
        <https://1145.am/db/2361027/Orbimed_Advisors>,
        <https://1145.am/db/2362475/Orbimed_Advisors>,
        <https://1145.am/db/2362481/Orbimed_Advisors>,
        <https://1145.am/db/2363339/Orbimed_Advisors>,
        <https://1145.am/db/2365679/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2365868/Orbimed_Advisors>,
        <https://1145.am/db/2366519/Orbimed_Advisors>,
        <https://1145.am/db/2574232/Orbimed_Advisors_Llc>,
        <https://1145.am/db/2583013/Orbimed_Advisors>,
        <https://1145.am/db/428737/Orbimed_Advisors>,
        <https://1145.am/db/456081/Orbimed_Advisors>,
        <https://1145.am/db/456089/Orbimed_Advisors>,
        <https://1145.am/db/458377/Orbimed_Advisors>,
        <https://1145.am/db/674484/Orbimed_Advisors> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359864/The_Column_Group> a org:Organization ;
    ns1:basedInLowRaw "BURLINGAME, Calif" ;
    ns1:description "The Column Group is a person or organization that is typically involved in:" ;
    ns1:documentDate "2012-06-12T14:59:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Igenica Closes $33 Million in Series C Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/igenica-closes-33-million-series-c-funding> ;
    ns1:foundName "The Column Group" ;
    ns1:investor <https://1145.am/db/2359864/Series_C_Investment_5am_Ventures_Igenica_Orbimed_Advisors_The_Column_Group_Third_Rock_Ventures_Completed> ;
    ns1:name "The Column Group" ;
    ns1:sameAsMedium <https://1145.am/db/1503058/The_Column_Group>,
        <https://1145.am/db/1533327/The_Column_Group>,
        <https://1145.am/db/1533685/The_Column_Group>,
        <https://1145.am/db/1536915/The_Column_Group>,
        <https://1145.am/db/1624208/The_Column_Group>,
        <https://1145.am/db/2283431/The_Column_Group>,
        <https://1145.am/db/2287253/The_Column_Group>,
        <https://1145.am/db/2291277/The_Column_Group>,
        <https://1145.am/db/2294202/The_Column_Group>,
        <https://1145.am/db/2304335/The_Column_Group>,
        <https://1145.am/db/2304340/The_Column_Group>,
        <https://1145.am/db/2304769/The_Column_Group>,
        <https://1145.am/db/2305256/The_Column_Group>,
        <https://1145.am/db/2327474/The_Column_Group>,
        <https://1145.am/db/2335700/The_Column_Group>,
        <https://1145.am/db/2336503/The_Column_Group>,
        <https://1145.am/db/2336505/The_Column_Group>,
        <https://1145.am/db/2336524/The_Column_Group>,
        <https://1145.am/db/2339704/The_Column_Group>,
        <https://1145.am/db/2339883/The_Column_Group>,
        <https://1145.am/db/2344735/The_Column_Group>,
        <https://1145.am/db/2347885/The_Column_Group>,
        <https://1145.am/db/2350364/The_Column_Group>,
        <https://1145.am/db/2351394/The_Column_Group>,
        <https://1145.am/db/2351397/The_Column_Group>,
        <https://1145.am/db/2359334/The_Column_Group>,
        <https://1145.am/db/2359468/The_Column_Group>,
        <https://1145.am/db/2362475/The_Column_Group>,
        <https://1145.am/db/2362481/The_Column_Group>,
        <https://1145.am/db/2362565/The_Column_Group>,
        <https://1145.am/db/2362566/The_Column_Group>,
        <https://1145.am/db/2365363/The_Column_Group>,
        <https://1145.am/db/2368280/The_Column_Group>,
        <https://1145.am/db/2368501/The_Column_Group>,
        <https://1145.am/db/2583013/The_Column_Group>,
        <https://1145.am/db/2584056/The_Column_Group>,
        <https://1145.am/db/2584561/The_Column_Group>,
        <https://1145.am/db/425281/The_Column_Group>,
        <https://1145.am/db/426160/The_Column_Group>,
        <https://1145.am/db/490696/The_Column_Group>,
        <https://1145.am/db/75445/The_Column_Group> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359865/Aerovanc> a org:Organization ;
    ns1:basedInHighGeoName "Austin" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4671654/about.rdf> ;
    ns1:basedInHighRaw "Austin, TX" ;
    ns1:description "VC" ;
    ns1:documentDate "2012-06-12T14:55:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Third Rock takes lead on $33M C round for antibody upstart Igenica" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/third-rock-takes-lead-on-33m-c-round-for-antibody-upstart-igenica> ;
    ns1:foundName "AeroVanc" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "AeroVanc" ;
    ns1:sameAsHigh <https://1145.am/db/2370373/Aerovanc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359865/C_Investment_Igenica_Igenica_Third_Rock_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-12T14:55:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Antibody drug upstart Igenica has added Third Rock to its list of top-level venture backers.",
        "The Burlingame, CA - based biotech says Third Rock led a $ 33 million C round for the company, bringing its total venture haul to $ 55 million as it preps for clinical studies of its cancer treatment programs." ;
    ns1:documentTitle "Third Rock takes lead on $33M C round for antibody upstart Igenica" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/third-rock-takes-lead-on-33m-c-round-for-antibody-upstart-igenica> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2359865/Igenica> ;
    ns1:targetDetails "C" ;
    ns1:valueRaw "$ 33 million",
        "$ 55 million" ;
    ns1:whereGeoName "Burlingame" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5331920/about.rdf> ;
    ns1:whereRaw "Burlingame, CA" .

<https://1145.am/db/2359873/Mpm_Capital> a org:Organization ;
    ns1:basedInLowRaw "BOSTON" ;
    ns1:documentDate "2012-06-13T11:26:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/rhythm-raises-25m-series-b-financing-for-diabetes-and-obesity-therapeutics> ;
    ns1:foundName "MPM Capital" ;
    ns1:investor <https://1145.am/db/2359873/Series_B_Investment_Ipsen_Mpm_Capital_New_Enterprise_Associates_Rhythm_Third_Rock_Ventures_Completed> ;
    ns1:name "MPM Capital" ;
    ns1:sameAsMedium <https://1145.am/db/1325968/Mpm_Capital>,
        <https://1145.am/db/1752458/Mpm_Capital>,
        <https://1145.am/db/2285876/Mpm_Capital>,
        <https://1145.am/db/2287191/Mpm_Capital>,
        <https://1145.am/db/2292334/Mpm_Capital>,
        <https://1145.am/db/2292353/Mpm_Capital>,
        <https://1145.am/db/2300455/Mpm_Capital>,
        <https://1145.am/db/2301901/Mpm_Capital>,
        <https://1145.am/db/2303391/Mpm_Capital>,
        <https://1145.am/db/2303833/Mpm_Capital>,
        <https://1145.am/db/2303855/Mpm_Capital>,
        <https://1145.am/db/2304634/Mpm_Capital>,
        <https://1145.am/db/2305503/Mpm_Capital>,
        <https://1145.am/db/2305656/Mpm_Capital>,
        <https://1145.am/db/2306705/Mpm_Capital>,
        <https://1145.am/db/2308887/Mpm_Capital>,
        <https://1145.am/db/2309845/Mpm_Capital>,
        <https://1145.am/db/2311551/Mpm_Capital>,
        <https://1145.am/db/2312285/Mpm_Capital>,
        <https://1145.am/db/2312309/Mpm_Capital>,
        <https://1145.am/db/2316391/Mpm_Capital>,
        <https://1145.am/db/2323055/Mpm_Capital>,
        <https://1145.am/db/2323066/Mpm_Capital>,
        <https://1145.am/db/2323094/Mpm_Capital>,
        <https://1145.am/db/2323563/Mpm_Capital>,
        <https://1145.am/db/2323568/Mpm_Capital>,
        <https://1145.am/db/2324195/Mpm_Capital>,
        <https://1145.am/db/2324226/Mpm_Capital>,
        <https://1145.am/db/2328338/Mpm_Capital>,
        <https://1145.am/db/2333119/Mpm_Capital>,
        <https://1145.am/db/2333525/Mpm_Capital>,
        <https://1145.am/db/2335701/Mpm_Capital>,
        <https://1145.am/db/2335714/Mpm_Capital>,
        <https://1145.am/db/2337140/Mpm_Capital>,
        <https://1145.am/db/2340957/Mpm_Capital>,
        <https://1145.am/db/2345299/Mpm_Capital>,
        <https://1145.am/db/2345318/Mpm_Capital>,
        <https://1145.am/db/2346204/Mpm_Capital>,
        <https://1145.am/db/2347140/Mpm_Capital>,
        <https://1145.am/db/2347469/Mpm_Capital>,
        <https://1145.am/db/2347984/Mpm_Capital>,
        <https://1145.am/db/2348484/Mpm_Capital>,
        <https://1145.am/db/2350030/Mpm_Capital>,
        <https://1145.am/db/2352172/Mpm_Capital>,
        <https://1145.am/db/2352362/Mpm_Capital>,
        <https://1145.am/db/2352899/Mpm_Capital>,
        <https://1145.am/db/2353365/Mpm_Capital>,
        <https://1145.am/db/2353404/Mpm_Capital>,
        <https://1145.am/db/2353413/Mpm_Capital>,
        <https://1145.am/db/2353415/Mpm_Capital>,
        <https://1145.am/db/2356396/Mpm_Capital>,
        <https://1145.am/db/2358979/Mpm_Capital>,
        <https://1145.am/db/2359001/Mpm_Capital>,
        <https://1145.am/db/2359875/Mpm_Capital>,
        <https://1145.am/db/2360526/Mpm_Capital>,
        <https://1145.am/db/2362871/Mpm_Capital>,
        <https://1145.am/db/2364492/Mpm_Capital>,
        <https://1145.am/db/2365098/Mpm_Capital>,
        <https://1145.am/db/2366744/Mpm_Capital>,
        <https://1145.am/db/2367199/Mpm_Capital>,
        <https://1145.am/db/2369202/Mpm_Capital>,
        <https://1145.am/db/2370582/Mpm_Capital>,
        <https://1145.am/db/2541350/Mpm_Capital>,
        <https://1145.am/db/677075/Mpm_Capital>,
        <https://1145.am/db/678997/Mpm_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359873/Rhythm> a org:Organization ;
    ns1:description "small-peptide therapeutics" ;
    ns1:documentDate "2012-06-13T11:26:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/rhythm-raises-25m-series-b-financing-for-diabetes-and-obesity-therapeutics> ;
    ns1:foundName "Rhythm" ;
    ns1:name "Rhythm" ;
    ns1:sameAsHigh <https://1145.am/db/2323563/Rhythm_Pharmaceuticals>,
        <https://1145.am/db/2352235/Rhythm>,
        <https://1145.am/db/2358058/Rhythm>,
        <https://1145.am/db/2366509/Rhythm>,
        <https://1145.am/db/2366513/Rhythm>,
        <https://1145.am/db/2592638/Rhythm> ;
    ns1:sameAsMedium <https://1145.am/db/2154422/Rhythm>,
        <https://1145.am/db/2286542/Rhythm>,
        <https://1145.am/db/2342242/Rhythm>,
        <https://1145.am/db/2351918/Rhythm>,
        <https://1145.am/db/2351943/Rhythm>,
        <https://1145.am/db/2352227/Rhythm>,
        <https://1145.am/db/2359104/Rhythm>,
        <https://1145.am/db/2366514/Rhythm>,
        <https://1145.am/db/2583133/Rhythm> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359883/Neuronova> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Sweden" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2661886/about.rdf> ;
    ns1:basedInHighRaw "Sweden" ;
    ns1:description "Neurogenesis" ;
    ns1:documentDate "2012-06-13T14:40:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Newron to acquire Swedish neurogenesis company NeuroNova AB" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/newron-to-acquire-swedish-neurogenesis-company-neuronova-ab> ;
    ns1:foundName "NeuroNova",
        "NeuroNova AB" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "NeuroNova" ;
    ns1:sameAsHigh <https://1145.am/db/2286608/Neurogene>,
        <https://1145.am/db/2305061/Neurogen_Corporation>,
        <https://1145.am/db/2306813/Neurogen>,
        <https://1145.am/db/2306816/Neurogen>,
        <https://1145.am/db/2339193/Neurovance>,
        <https://1145.am/db/2360045/Neuronova>,
        <https://1145.am/db/2361451/Neurovance>,
        <https://1145.am/db/371325/Neuroprotexeon_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2359882/Neuronova> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360922/Nuevolution_A_S> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Denmark" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2623032/about.rdf> ;
    ns1:basedInHighRaw "Denmark" ;
    ns1:description "Pharmaceutical research" ;
    ns1:documentDate "2012-06-19T12:13:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nuevolution A/S Raises € 11 Million in New Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/nuevolution-a-s-raises-%E2%82%AC-11-million-new-financing-round> ;
    ns1:foundName "Nuevolution A/S" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Nuevolution A/S" ;
    ns1:sameAsHigh <https://1145.am/db/1019870/Moderna>,
        <https://1145.am/db/1028098/A2pg>,
        <https://1145.am/db/1028744/Apnimed>,
        <https://1145.am/db/1029882/Apnimed>,
        <https://1145.am/db/1041428/Dr>,
        <https://1145.am/db/1042161/Wellgistics>,
        <https://1145.am/db/1042221/Wellgistics>,
        <https://1145.am/db/1096114/Astorg>,
        <https://1145.am/db/1096677/Astorg>,
        <https://1145.am/db/1138447/Apnimed>,
        <https://1145.am/db/1139445/Apnimed>,
        <https://1145.am/db/1152269/Alpha-5>,
        <https://1145.am/db/1163849/Productlife_Group>,
        <https://1145.am/db/1172760/Apexigen>,
        <https://1145.am/db/1215735/Astorg>,
        <https://1145.am/db/1219810/Prokidney_Corp>,
        <https://1145.am/db/1271008/Reviral_Ltd>,
        <https://1145.am/db/1272754/Prokidney_Corp>,
        <https://1145.am/db/1294637/LTS>,
        <https://1145.am/db/1307202/Leo_Pharma>,
        <https://1145.am/db/1309648/Achrom>,
        <https://1145.am/db/1323486/Glo_Pharma>,
        <https://1145.am/db/1374672/Sp_Industries>,
        <https://1145.am/db/1384852/Moderna_Inc>,
        <https://1145.am/db/1391799/Pharnext>,
        <https://1145.am/db/1454905/Aquestive>,
        <https://1145.am/db/1505021/Pharmaceutics_International_Inc>,
        <https://1145.am/db/1540522/Atec>,
        <https://1145.am/db/1541946/Abiomed>,
        <https://1145.am/db/1562763/Indivior>,
        <https://1145.am/db/1613904/Apnimed_Inc>,
        <https://1145.am/db/1615580/Apnimed>,
        <https://1145.am/db/1617770/Pharnext_Sa>,
        <https://1145.am/db/1648815/Indevr>,
        <https://1145.am/db/1681016/Enveric_Biosciences>,
        <https://1145.am/db/1745685/Drugstoc>,
        <https://1145.am/db/1838777/Medikly>,
        <https://1145.am/db/1936167/Reviral_Ltd>,
        <https://1145.am/db/1962783/Ora_Inc>,
        <https://1145.am/db/2039692/Rk_Pharma_Inc>,
        <https://1145.am/db/2051589/Ora_Inc>,
        <https://1145.am/db/2060641/Abionyx_Pharma>,
        <https://1145.am/db/2073336/Ose>,
        <https://1145.am/db/2132018/Solutions>,
        <https://1145.am/db/2139917/Leo_Pharma>,
        <https://1145.am/db/2151848/D___D_Pharmatech>,
        <https://1145.am/db/2152469/Sobi003>,
        <https://1145.am/db/2152499/Highchem>,
        <https://1145.am/db/2152633/Themis>,
        <https://1145.am/db/2152849/Therachon>,
        <https://1145.am/db/2152901/Abcellera>,
        <https://1145.am/db/2154166/Leo_Pharma>,
        <https://1145.am/db/2154252/Phoremost>,
        <https://1145.am/db/2155490/Enterome>,
        <https://1145.am/db/2155631/Achillion>,
        <https://1145.am/db/2155863/Therachon>,
        <https://1145.am/db/2212420/Cel-Sci_Corporation>,
        <https://1145.am/db/2235873/M3_Usa>,
        <https://1145.am/db/2244405/Seek>,
        <https://1145.am/db/2281535/Eqt_Life_Sciences>,
        <https://1145.am/db/2281676/Apnimed>,
        <https://1145.am/db/2283559/Oric>,
        <https://1145.am/db/2283918/Indivior>,
        <https://1145.am/db/2286215/Pandion>,
        <https://1145.am/db/2289550/Well>,
        <https://1145.am/db/2290753/Medivir>,
        <https://1145.am/db/2294621/Pharmaceutics_International>,
        <https://1145.am/db/2296235/Apexigen>,
        <https://1145.am/db/2297631/Clarient>,
        <https://1145.am/db/2298376/Caprion>,
        <https://1145.am/db/2301879/Magen_Biosciences>,
        <https://1145.am/db/2302863/Amri>,
        <https://1145.am/db/2303412/Hologic>,
        <https://1145.am/db/2303415/Amevive>,
        <https://1145.am/db/2303612/Intradigm_Corporation>,
        <https://1145.am/db/2303675/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2303720/Covance>,
        <https://1145.am/db/2305572/Covance_Inc>,
        <https://1145.am/db/2305703/Pinnacle_Bioventures>,
        <https://1145.am/db/2306640/Atryn>,
        <https://1145.am/db/2306640/Leo_Pharma>,
        <https://1145.am/db/2306724/Dermatech_Pty_Ltd>,
        <https://1145.am/db/2306725/Prevalere_Life_Sciences_Inc>,
        <https://1145.am/db/2306946/Amatsigroup>,
        <https://1145.am/db/2307526/Bioserv_Corporation>,
        <https://1145.am/db/2307529/Bioserv>,
        <https://1145.am/db/2307714/GTCR>,
        <https://1145.am/db/2308069/Bionomics>,
        <https://1145.am/db/2308807/Etrials_Worldwide>,
        <https://1145.am/db/2309352/Epicept_Corporation>,
        <https://1145.am/db/2309696/Encap>,
        <https://1145.am/db/2309697/Encap>,
        <https://1145.am/db/2310799/Inventiv_Health>,
        <https://1145.am/db/2312191/Medigene_Ag>,
        <https://1145.am/db/2312788/Leo_Pharma>,
        <https://1145.am/db/2312797/Leo_Pharma_A_S>,
        <https://1145.am/db/2312994/Upm>,
        <https://1145.am/db/2313383/Companyâ€™>,
        <https://1145.am/db/2314613/Advent_International>,
        <https://1145.am/db/2315373/Nitromed>,
        <https://1145.am/db/2315424/Covance_Inc>,
        <https://1145.am/db/2316707/Catalyst_Pharmaceutical>,
        <https://1145.am/db/2316856/Viranative_Ab>,
        <https://1145.am/db/2317006/Amri>,
        <https://1145.am/db/2317060/Ception>,
        <https://1145.am/db/2317144/Leo_Pharma>,
        <https://1145.am/db/2317334/Aesica>,
        <https://1145.am/db/2317369/Relthy>,
        <https://1145.am/db/2320351/Prochieve>,
        <https://1145.am/db/2320947/Nitromed>,
        <https://1145.am/db/2321635/Celator>,
        <https://1145.am/db/2322824/Amri>,
        <https://1145.am/db/2322826/Amri>,
        <https://1145.am/db/2323790/Amri>,
        <https://1145.am/db/2323861/Amri>,
        <https://1145.am/db/2324112/Nitromed>,
        <https://1145.am/db/2324118/Rem_Medical_Corporation>,
        <https://1145.am/db/2324350/Celmed_Biosciences_Inc>,
        <https://1145.am/db/2324394/Amdl>,
        <https://1145.am/db/2324985/Amri>,
        <https://1145.am/db/2325553/Fidelity_Biosciences>,
        <https://1145.am/db/2327076/Amri>,
        <https://1145.am/db/2327088/Covance>,
        <https://1145.am/db/2327241/Preotact_(r)>,
        <https://1145.am/db/2327258/Biocon_Limited>,
        <https://1145.am/db/2327374/Diamedica_Inc>,
        <https://1145.am/db/2327424/Innopharm>,
        <https://1145.am/db/2328008/Epicept_Corporation>,
        <https://1145.am/db/2328318/Medpointe>,
        <https://1145.am/db/2328713/Sepracor>,
        <https://1145.am/db/2329333/Biopharma_Services_Inc>,
        <https://1145.am/db/2330808/Sepracor>,
        <https://1145.am/db/2331911/Clarient>,
        <https://1145.am/db/2332005/R___d>,
        <https://1145.am/db/2332200/Compendia_Bioscience>,
        <https://1145.am/db/2332920/Nastech>,
        <https://1145.am/db/2333644/Targent>,
        <https://1145.am/db/2334020/Accovion>,
        <https://1145.am/db/2336287/Biomotiv>,
        <https://1145.am/db/2336355/Correvio>,
        <https://1145.am/db/2336625/Biota>,
        <https://1145.am/db/2336998/Medivation_Inc>,
        <https://1145.am/db/2337028/Medivation>,
        <https://1145.am/db/2337078/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2338888/Cerulean_Pharma>,
        <https://1145.am/db/2338939/Nuevolution_A_S>,
        <https://1145.am/db/2339816/Nuevolution_A_S>,
        <https://1145.am/db/2339997/(Appa)>,
        <https://1145.am/db/2340054/Amri>,
        <https://1145.am/db/2340115/Mission>,
        <https://1145.am/db/2340160/Intercell_Ag>,
        <https://1145.am/db/2340507/Rho>,
        <https://1145.am/db/2341572/Aesica>,
        <https://1145.am/db/2341869/Fidelity_Biosciences>,
        <https://1145.am/db/2341897/Fidelity_Biosciences>,
        <https://1145.am/db/2342581/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2342628/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2343325/Medivir>,
        <https://1145.am/db/2344595/Mabxience>,
        <https://1145.am/db/2347172/Medivir_Ab>,
        <https://1145.am/db/2347755/Leo_Pharma_Inc>,
        <https://1145.am/db/2348448/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2348675/Signum_Biosciences>,
        <https://1145.am/db/2349050/Fidelity_Biosciences>,
        <https://1145.am/db/2349373/Asmacure>,
        <https://1145.am/db/2349740/Signum_Biosciences_Inc>,
        <https://1145.am/db/2349983/Leading_Biosciences_Inc>,
        <https://1145.am/db/2349990/Aesica>,
        <https://1145.am/db/2350847/Covance>,
        <https://1145.am/db/2351198/(Ptc)>,
        <https://1145.am/db/2351259/Biotime_Inc>,
        <https://1145.am/db/2352414/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2353223/Medivation_Inc>,
        <https://1145.am/db/2354375/Sorrento>,
        <https://1145.am/db/2355036/Moderna>,
        <https://1145.am/db/2355194/Moderna>,
        <https://1145.am/db/2356488/Cerulean_Pharma>,
        <https://1145.am/db/2358197/Biopharma_Services_Inc>,
        <https://1145.am/db/2358403/Pht_Corporation>,
        <https://1145.am/db/2358637/Eurand>,
        <https://1145.am/db/2358638/Eurand_Nv>,
        <https://1145.am/db/2358734/Prosidion>,
        <https://1145.am/db/2358953/Abgent>,
        <https://1145.am/db/2359025/Nectid>,
        <https://1145.am/db/2359113/Eurand_Nv>,
        <https://1145.am/db/2359380/Amri>,
        <https://1145.am/db/2359577/Geno>,
        <https://1145.am/db/2359670/Biotie>,
        <https://1145.am/db/2359951/Entremed>,
        <https://1145.am/db/2360371/Preglem>,
        <https://1145.am/db/2360702/Cominnex>,
        <https://1145.am/db/2361675/Amri>,
        <https://1145.am/db/2361747/Servier>,
        <https://1145.am/db/2361926/Pharm-Olam_International_Ltd>,
        <https://1145.am/db/2362453/Pharnext>,
        <https://1145.am/db/2362607/Abide_Therapeutics>,
        <https://1145.am/db/2363722/Moderna>,
        <https://1145.am/db/2363725/Moderna>,
        <https://1145.am/db/2367022/Fidelity_Biosciences>,
        <https://1145.am/db/2367023/Fidelity_Biosciences>,
        <https://1145.am/db/2367298/Amri>,
        <https://1145.am/db/2368106/Obseva>,
        <https://1145.am/db/2368242/Symic>,
        <https://1145.am/db/2368257/Almirall>,
        <https://1145.am/db/2368329/Amri>,
        <https://1145.am/db/2368332/Amri>,
        <https://1145.am/db/2368333/R___d>,
        <https://1145.am/db/2368601/Promosome>,
        <https://1145.am/db/2368824/Almirall_Inc>,
        <https://1145.am/db/2369042/Abide_Therapeutics>,
        <https://1145.am/db/2369128/Aegerion>,
        <https://1145.am/db/2369269/R___d>,
        <https://1145.am/db/2369446/Presage_Biosciences>,
        <https://1145.am/db/2369490/Medivation>,
        <https://1145.am/db/2369708/Promedior>,
        <https://1145.am/db/2370156/Pharming_Group_Nv>,
        <https://1145.am/db/2370164/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2370265/Ose_Pharma>,
        <https://1145.am/db/2370267/Ose_Pharma>,
        <https://1145.am/db/2370437/MSD>,
        <https://1145.am/db/2370557/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2370579/Arvinas>,
        <https://1145.am/db/2370659/Nuevolution>,
        <https://1145.am/db/2370828/Nuevolution>,
        <https://1145.am/db/2371158/Moderna>,
        <https://1145.am/db/2371408/Business_Management>,
        <https://1145.am/db/2536140/Scinopharm>,
        <https://1145.am/db/2536209/TPG>,
        <https://1145.am/db/2536305/Radient>,
        <https://1145.am/db/2536469/Agila_Specialties>,
        <https://1145.am/db/2536473/Encap>,
        <https://1145.am/db/2536575/G___w>,
        <https://1145.am/db/2536576/G___w>,
        <https://1145.am/db/2536612/Pharmaceutics_International_Inc>,
        <https://1145.am/db/2536776/Oramed>,
        <https://1145.am/db/2538112/Pharmedium>,
        <https://1145.am/db/2539816/P___R_Group>,
        <https://1145.am/db/2539858/Aesica>,
        <https://1145.am/db/2539890/Scinopharm>,
        <https://1145.am/db/2540218/Amri>,
        <https://1145.am/db/2540222/Amri>,
        <https://1145.am/db/2540931/Accucaps>,
        <https://1145.am/db/2540931/Pharmtek>,
        <https://1145.am/db/2541419/Amri>,
        <https://1145.am/db/2541469/Agila_Specialties>,
        <https://1145.am/db/2542113/Profectus_Biosciences>,
        <https://1145.am/db/2542472/Aesica>,
        <https://1145.am/db/2543530/Covance>,
        <https://1145.am/db/2544087/Univercells>,
        <https://1145.am/db/2544258/C___O_Pharmaceutical_Technology>,
        <https://1145.am/db/2544596/Bioton>,
        <https://1145.am/db/2545125/Ascendis_Health>,
        <https://1145.am/db/2545545/Agila_Specialties>,
        <https://1145.am/db/2546430/Bal_Pharma>,
        <https://1145.am/db/2546892/Aphena>,
        <https://1145.am/db/2547568/Amec>,
        <https://1145.am/db/2548137/Innopharm>,
        <https://1145.am/db/2548674/Sepracor>,
        <https://1145.am/db/2548840/Btcp_Pharma_Llc>,
        <https://1145.am/db/2549082/British_Company>,
        <https://1145.am/db/2549201/Rexall_Health>,
        <https://1145.am/db/2550632/Amri>,
        <https://1145.am/db/2550638/Amri>,
        <https://1145.am/db/2553761/Mabxience>,
        <https://1145.am/db/2553978/Bioverativ>,
        <https://1145.am/db/2554838/Amri>,
        <https://1145.am/db/2555168/Prokidney>,
        <https://1145.am/db/2555326/Leo_Pharma>,
        <https://1145.am/db/2556356/Medivation>,
        <https://1145.am/db/2556744/Leo_Pharma>,
        <https://1145.am/db/2557034/West_Pharmaceutical>,
        <https://1145.am/db/2557482/Idifarma>,
        <https://1145.am/db/2558133/Lifehealth>,
        <https://1145.am/db/2559160/West_Pharmaceutical>,
        <https://1145.am/db/2560277/Aesica>,
        <https://1145.am/db/2560277/Consort>,
        <https://1145.am/db/2560766/Accucaps>,
        <https://1145.am/db/2560808/Novamedica>,
        <https://1145.am/db/2561121/Bioserv>,
        <https://1145.am/db/2562459/Eurand>,
        <https://1145.am/db/2563255/MSD>,
        <https://1145.am/db/2563772/Apiject>,
        <https://1145.am/db/2564003/Leo_Pharma>,
        <https://1145.am/db/2564490/Accucaps>,
        <https://1145.am/db/2564490/Pharmtek>,
        <https://1145.am/db/2565613/Servier>,
        <https://1145.am/db/2566037/Almirall>,
        <https://1145.am/db/2566348/Indivior>,
        <https://1145.am/db/2566348/Opiant>,
        <https://1145.am/db/2568711/West_Pharmaceutical>,
        <https://1145.am/db/2569107/Almirall_Sa>,
        <https://1145.am/db/2569356/Leo_Pharma_Inc>,
        <https://1145.am/db/2569393/R___d>,
        <https://1145.am/db/2570064/Aegerion>,
        <https://1145.am/db/2570177/Oramed>,
        <https://1145.am/db/2572329/Incivo®>,
        <https://1145.am/db/2572567/Northera>,
        <https://1145.am/db/2573050/Amatsigroup>,
        <https://1145.am/db/2573913/TPG>,
        <https://1145.am/db/2575143/Almirall>,
        <https://1145.am/db/2576254/Fougera>,
        <https://1145.am/db/2576550/TPG>,
        <https://1145.am/db/2576923/Pharmgate>,
        <https://1145.am/db/2576925/Pharmgate>,
        <https://1145.am/db/2577894/Advance_Properties_Ood>,
        <https://1145.am/db/2578052/Advent_International>,
        <https://1145.am/db/2578052/United_Medical>,
        <https://1145.am/db/2578645/Almirall>,
        <https://1145.am/db/2578667/Almirall>,
        <https://1145.am/db/2578667/Fycompa>,
        <https://1145.am/db/2579211/Proximagen>,
        <https://1145.am/db/2581197/Irom_Pharmaceutical>,
        <https://1145.am/db/2581832/West>,
        <https://1145.am/db/2586253/United_Biosource_Corporation>,
        <https://1145.am/db/2586420/Acuform>,
        <https://1145.am/db/2587709/Pharmstandard>,
        <https://1145.am/db/2589178/Oriel>,
        <https://1145.am/db/2590195/Nectid>,
        <https://1145.am/db/2590489/Amatsigroup>,
        <https://1145.am/db/2590528/C___O_Pharmaceutical>,
        <https://1145.am/db/2590556/Nycomed_Us>,
        <https://1145.am/db/2590827/Affairs>,
        <https://1145.am/db/2591609/Pharmstandard>,
        <https://1145.am/db/2591622/Pharmstandard>,
        <https://1145.am/db/2593060/Inventiv_Health>,
        <https://1145.am/db/2593265/Leo_Pharma>,
        <https://1145.am/db/2594186/Agila_Specialties>,
        <https://1145.am/db/2594699/Osi>,
        <https://1145.am/db/2595688/Fougera>,
        <https://1145.am/db/2598181/Amri>,
        <https://1145.am/db/2739044/Moderna>,
        <https://1145.am/db/2791590/Civica>,
        <https://1145.am/db/295168/Orifarm>,
        <https://1145.am/db/317543/Productlife_Group>,
        <https://1145.am/db/423883/Sohm_Inc>,
        <https://1145.am/db/449041/Advent_International>,
        <https://1145.am/db/515764/Sohm_Inc>,
        <https://1145.am/db/561196/Pharnext_Sa>,
        <https://1145.am/db/618115/Sohm>,
        <https://1145.am/db/654792/Innobic>,
        <https://1145.am/db/676564/Alvotech>,
        <https://1145.am/db/716162/Pharnext_Sa>,
        <https://1145.am/db/806327/Pharma_Nobis_Llc>,
        <https://1145.am/db/807295/Pharma_Nobis_Llc>,
        <https://1145.am/db/834480/Pharnext_Sa>,
        <https://1145.am/db/835269/Grand_Pharmaceutical_Group_Limited>,
        <https://1145.am/db/837157/Leo_Pharma_Inc>,
        <https://1145.am/db/848323/Pharmaceutics_International_Inc>,
        <https://1145.am/db/872336/Sohm_Inc>,
        <https://1145.am/db/882142/Aim>,
        <https://1145.am/db/886663/Théa>,
        <https://1145.am/db/888994/Théa>,
        <https://1145.am/db/943000/Pharnext>,
        <https://1145.am/db/965490/Reviral_Ltd> ;
    ns1:sameAsMedium <https://1145.am/db/2152715/Nuevolution>,
        <https://1145.am/db/2370211/Nuevolution>,
        <https://1145.am/db/2370405/Nuevolution>,
        <https://1145.am/db/2370423/Nuevolution_A_S> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2360922/Sunstone_Capital> a org:Organization ;
    ns1:basedInLowRaw "Denmark" ;
    ns1:description "Investing" ;
    ns1:documentDate "2012-06-19T12:13:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Nuevolution A/S Raises € 11 Million in New Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/nuevolution-a-s-raises-%E2%82%AC-11-million-new-financing-round> ;
    ns1:foundName "Sunstone Capital" ;
    ns1:investor <https://1145.am/db/2360922/Investment_Industrifonden_Nuevolution_A_S_Seb_Utvecklingsstiftelse_Seb_Venture_Capital_Sunstone_Capital_Completed> ;
    ns1:name "Sunstone Capital" ;
    ns1:sameAsHigh <https://1145.am/db/154461/Sun_Capital_Partners>,
        <https://1145.am/db/962978/Sun_Capital_Partners_Inc>,
        <https://1145.am/db/980014/Sunfox_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1717714/Sunstone_Capital>,
        <https://1145.am/db/1776660/Sunstone_Capital>,
        <https://1145.am/db/1780157/Sunstone_Capital>,
        <https://1145.am/db/1791743/Sunstone_Capital>,
        <https://1145.am/db/1797413/Sunstone_Capital>,
        <https://1145.am/db/1800466/Sunstone_Capital>,
        <https://1145.am/db/1803787/Sunstone_Capital>,
        <https://1145.am/db/1808488/Sunstone_Capital>,
        <https://1145.am/db/1813404/Sunstone_Capital>,
        <https://1145.am/db/1821174/Sunstone_Capital>,
        <https://1145.am/db/1832434/Sunstone_Capital>,
        <https://1145.am/db/1833000/Sunstone_Capital>,
        <https://1145.am/db/1833646/Sunstone_Capital>,
        <https://1145.am/db/1850593/Sunstone_Capital>,
        <https://1145.am/db/1850760/Sunstone_Capital>,
        <https://1145.am/db/1854996/Sunstone_Capital>,
        <https://1145.am/db/1858818/Sunstone_Capital>,
        <https://1145.am/db/1859597/Sunstone_Capital>,
        <https://1145.am/db/1862019/Sunstone_Capital>,
        <https://1145.am/db/1868935/Sunstone_Capital>,
        <https://1145.am/db/1869517/Sunstone_Capital>,
        <https://1145.am/db/1870079/Sunstone_Capital>,
        <https://1145.am/db/1877786/Sunstone_Capital>,
        <https://1145.am/db/1879213/Sunstone_Capital>,
        <https://1145.am/db/1885147/Sunstone_Capital>,
        <https://1145.am/db/1888954/Sunstone_Capital>,
        <https://1145.am/db/2323700/Sunstone_Capital>,
        <https://1145.am/db/2329919/Sunstone_Capital>,
        <https://1145.am/db/2336622/Sunstone_Capital>,
        <https://1145.am/db/2341942/Sunstone_Capital>,
        <https://1145.am/db/2346452/Sunstone_Capital>,
        <https://1145.am/db/2347980/Sunstone_Capital>,
        <https://1145.am/db/2348003/Sunstone_Capital>,
        <https://1145.am/db/2352203/Sunstone_Capital>,
        <https://1145.am/db/2352204/Sunstone_Capital>,
        <https://1145.am/db/2352216/Sunstone_Capital>,
        <https://1145.am/db/2355609/Sunstone_Capital>,
        <https://1145.am/db/2355841/Sunstone_Capital>,
        <https://1145.am/db/2360127/Sunstone_Capital>,
        <https://1145.am/db/2367218/Sunstone_Capital>,
        <https://1145.am/db/2569491/Sunstone_Capital> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363938/Eclosion> a org:Organization ;
    ns1:basedInHighGeoName "Switzerland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:basedInHighRaw "Switzerland" ;
    ns1:documentDate "2012-07-08T20:26:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genkyotex Raises CHF25 Million in Series C Round Extension" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/genkyotex-raises-chf25-million-series-c-round-extension> ;
    ns1:foundName "Eclosion" ;
    ns1:investor <https://1145.am/db/2363938/Series_C_Investment_Eclosion_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Vesalius_Biocapital_Partners_Completed> ;
    ns1:name "Eclosion" ;
    ns1:sameAsMedium <https://1145.am/db/2363941/Eclosion> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363938/Edmond_De_Rothschild_Investment_Partners> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:documentDate "2012-07-08T20:26:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genkyotex Raises CHF25 Million in Series C Round Extension" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/genkyotex-raises-chf25-million-series-c-round-extension> ;
    ns1:foundName "Edmond de Rothschild Investment Partners" ;
    ns1:investor <https://1145.am/db/2363938/Series_C_Investment_Eclosion_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Vesalius_Biocapital_Partners_Completed> ;
    ns1:name "Edmond de Rothschild Investment Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2289591/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2297507/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2299423/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301041/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301096/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303210/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303641/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303642/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303849/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313401/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313410/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2320503/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2325831/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2336923/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338023/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338193/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338196/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2348331/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2350101/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2351191/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2351192/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353607/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353610/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2356567/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358268/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358269/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358541/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2363941/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2367201/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2368740/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369953/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369982/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369999/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2555540/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2701527/Edmond_De_Rothschild_Investment_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363938/Mp_Healthcare_Venture> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-08T20:26:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genkyotex Raises CHF25 Million in Series C Round Extension" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/genkyotex-raises-chf25-million-series-c-round-extension> ;
    ns1:foundName "MP Healthcare Venture" ;
    ns1:industry "Healthcare" ;
    ns1:investor <https://1145.am/db/2363938/Series_C_Investment_Eclosion_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Vesalius_Biocapital_Partners_Completed> ;
    ns1:name "MP Healthcare Venture" ;
    ns1:sameAsHigh <https://1145.am/db/2062003/Mp_Healthcare_Venture_Management>,
        <https://1145.am/db/2365103/Mp_Healthcare_Venture> ;
    ns1:sameAsMedium <https://1145.am/db/2337571/Mp_Healthcare_Ventures>,
        <https://1145.am/db/2337577/Mp_Healthcare_Ventures>,
        <https://1145.am/db/2363941/Mp_Healthcare_Venture>,
        <https://1145.am/db/2546216/Mp_Healthcare_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363938/Vesalius_Biocapital_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Switzerland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:basedInHighRaw "Switzerland" ;
    ns1:documentDate "2012-07-08T20:26:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genkyotex Raises CHF25 Million in Series C Round Extension" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/genkyotex-raises-chf25-million-series-c-round-extension> ;
    ns1:foundName "Vesalius Biocapital Partners" ;
    ns1:investor <https://1145.am/db/2363938/Series_C_Investment_Eclosion_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Vesalius_Biocapital_Partners_Completed> ;
    ns1:name "Vesalius Biocapital Partners" ;
    ns1:sameAsMedium <https://1145.am/db/2198401/Vesalius_Biocapital_Partners>,
        <https://1145.am/db/2363941/Vesalius_Biocapital_Partners>,
        <https://1145.am/db/2370955/Vesalius_Biocapital_Ii_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363941/Eclosion> a org:Organization ;
    ns1:basedInHighGeoName "Switzerland" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:basedInHighRaw "Switzerland" ;
    ns1:documentDate "2012-07-09T04:00:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biotech Genkyotex nails down $26M to fund drug for diabetic kidney disease" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotech-genkyotex-nails-down-26m-to-fund-drug-for-diabetic-kidney-disease> ;
    ns1:foundName "Eclosion" ;
    ns1:investor <https://1145.am/db/2363941/Investment_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Mitsubishi_Tanabe_Pharma_Group_Vesalius_Biocapital_Partners_Completed> ;
    ns1:name "Eclosion" ;
    ns1:sameAsMedium <https://1145.am/db/2363938/Eclosion> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363941/Edmond_De_Rothschild_Investment_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Republic of France" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3017382/about.rdf> ;
    ns1:basedInHighRaw "France" ;
    ns1:description "investment" ;
    ns1:documentDate "2012-07-09T04:00:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biotech Genkyotex nails down $26M to fund drug for diabetic kidney disease" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotech-genkyotex-nails-down-26m-to-fund-drug-for-diabetic-kidney-disease> ;
    ns1:foundName "Edmond de Rothschild Investment Partners" ;
    ns1:investor <https://1145.am/db/2363941/Investment_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Mitsubishi_Tanabe_Pharma_Group_Vesalius_Biocapital_Partners_Completed> ;
    ns1:name "Edmond de Rothschild Investment Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1165283/Rothschild___Co>,
        <https://1145.am/db/1165370/Rothschild___Co>,
        <https://1145.am/db/1667613/Rothschild___Co>,
        <https://1145.am/db/1673944/Rothschild___Co>,
        <https://1145.am/db/2053586/Rothschild___Co>,
        <https://1145.am/db/2057230/Rothschild>,
        <https://1145.am/db/2297507/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301096/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313410/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2315279/De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2320503/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2325831/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338196/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2356567/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358268/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2605925/Rothschild>,
        <https://1145.am/db/2701527/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/289938/Rothschild___Co>,
        <https://1145.am/db/668085/Rothschild___Co>,
        <https://1145.am/db/936350/Rothschild___Co> ;
    ns1:sameAsMedium <https://1145.am/db/2289591/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2299423/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2301041/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303210/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303641/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303642/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2303849/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2313401/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2336923/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338023/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2338193/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2348331/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2350101/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2351191/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2351192/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353607/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2353610/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358269/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2358541/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2363938/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2367201/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2368740/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369953/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369982/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2369999/Edmond_De_Rothschild_Investment_Partners>,
        <https://1145.am/db/2555540/Edmond_De_Rothschild_Investment_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363941/Mp_Healthcare_Venture> a org:Organization ;
    ns1:basedInHighGeoName "Japan" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1861060/about.rdf> ;
    ns1:basedInHighRaw "Japan" ;
    ns1:documentDate "2012-07-09T04:00:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biotech Genkyotex nails down $26M to fund drug for diabetic kidney disease" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotech-genkyotex-nails-down-26m-to-fund-drug-for-diabetic-kidney-disease> ;
    ns1:foundName "MP Healthcare Venture" ;
    ns1:investor <https://1145.am/db/2363941/Investment_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Mitsubishi_Tanabe_Pharma_Group_Vesalius_Biocapital_Partners_Completed> ;
    ns1:name "MP Healthcare Venture" ;
    ns1:sameAsMedium <https://1145.am/db/2337571/Mp_Healthcare_Ventures>,
        <https://1145.am/db/2337577/Mp_Healthcare_Ventures>,
        <https://1145.am/db/2363938/Mp_Healthcare_Venture>,
        <https://1145.am/db/2365103/Mp_Healthcare_Venture>,
        <https://1145.am/db/2546216/Mp_Healthcare_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363941/Vesalius_Biocapital_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Grand Duchy of Luxembourg" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2960313/about.rdf> ;
    ns1:basedInHighRaw "Luxembourg" ;
    ns1:description "VC" ;
    ns1:documentDate "2012-07-09T04:00:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biotech Genkyotex nails down $26M to fund drug for diabetic kidney disease" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotech-genkyotex-nails-down-26m-to-fund-drug-for-diabetic-kidney-disease> ;
    ns1:foundName "Vesalius Biocapital Partners",
        "Vesalius Biocapital Partners in Luxembourg" ;
    ns1:investor <https://1145.am/db/2363941/Investment_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Mitsubishi_Tanabe_Pharma_Group_Vesalius_Biocapital_Partners_Completed> ;
    ns1:name "Vesalius Biocapital Partners" ;
    ns1:sameAsHigh <https://1145.am/db/1769608/Vesalius_Biocapital_Iii>,
        <https://1145.am/db/2370955/Vesalius_Biocapital_Ii_Partners>,
        <https://1145.am/db/2790236/Vesalius_Biocapital>,
        <https://1145.am/db/831774/Vesalius_Biocapital> ;
    ns1:sameAsMedium <https://1145.am/db/2198401/Vesalius_Biocapital_Partners>,
        <https://1145.am/db/2363938/Vesalius_Biocapital_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363950/Invesco_Perpetual> a org:Organization ;
    ns1:basedInLowRaw "LONDON" ;
    ns1:description "equity financing" ;
    ns1:documentDate "2012-07-09T16:23:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PsiOxus Therapeutics Secures GBP 22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/psioxus-therapeutics-secures-gbp-22-million-34-million-series-b-financing-to-drive-clinical> ;
    ns1:foundName "Invesco Perpetual" ;
    ns1:investor <https://1145.am/db/2363950/Equity_Investment_Imperial_Innovations_Group_Invesco_Perpetual_Lundbeckfond_Ventures_Psioxus_Therapeutics_Ltd_Sr_One_Completed> ;
    ns1:name "Invesco Perpetual" ;
    ns1:sameAsHigh <https://1145.am/db/2544138/Invesco_Perpetual> ;
    ns1:sameAsMedium <https://1145.am/db/2302961/Invesco_Perpetual>,
        <https://1145.am/db/2302965/Invesco_Perpetual>,
        <https://1145.am/db/2304832/Invesco_Perpetual>,
        <https://1145.am/db/2304844/Invesco_Perpetual>,
        <https://1145.am/db/2311597/Invesco_Perpetual>,
        <https://1145.am/db/2318529/Invesco_Perpetual>,
        <https://1145.am/db/2318537/Invesco_Perpetual>,
        <https://1145.am/db/2339108/Invesco_Perpetual>,
        <https://1145.am/db/2339111/Invesco_Perpetual>,
        <https://1145.am/db/2340559/Invesco_Perpetual>,
        <https://1145.am/db/2341738/Invesco_Perpetual>,
        <https://1145.am/db/2341760/Invesco_Perpetual>,
        <https://1145.am/db/2348796/Invesco_Perpetual>,
        <https://1145.am/db/2363947/Invesco_Perpetual>,
        <https://1145.am/db/2366154/Invesco_Perpetual>,
        <https://1145.am/db/2366156/Invesco_Perpetual>,
        <https://1145.am/db/2366434/Invesco_Perpetual>,
        <https://1145.am/db/2367043/Invesco_Perpetual> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363950/Sr_One> a org:Organization ;
    ns1:basedInLowRaw "LONDON" ;
    ns1:documentDate "2012-07-09T16:23:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PsiOxus Therapeutics Secures GBP 22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/psioxus-therapeutics-secures-gbp-22-million-34-million-series-b-financing-to-drive-clinical> ;
    ns1:foundName "SR One" ;
    ns1:investor <https://1145.am/db/2363950/Equity_Investment_Imperial_Innovations_Group_Invesco_Perpetual_Lundbeckfond_Ventures_Psioxus_Therapeutics_Ltd_Sr_One_Completed> ;
    ns1:name "SR One" ;
    ns1:sameAsMedium <https://1145.am/db/1169952/Sr_One>,
        <https://1145.am/db/1334624/Sr_One>,
        <https://1145.am/db/1949427/Sr_One>,
        <https://1145.am/db/2095130/Sr_One>,
        <https://1145.am/db/2110113/Sr_One>,
        <https://1145.am/db/2280707/Sr_One>,
        <https://1145.am/db/2305791/Sr_One>,
        <https://1145.am/db/2317934/Sr_One>,
        <https://1145.am/db/2317951/Sr_One>,
        <https://1145.am/db/2318310/Sr_One>,
        <https://1145.am/db/2326222/Sr_One_Ltd>,
        <https://1145.am/db/2327305/Sr_One>,
        <https://1145.am/db/2327488/Sr_One_Ltd>,
        <https://1145.am/db/2331763/Sr_One>,
        <https://1145.am/db/2336328/Sr_One>,
        <https://1145.am/db/2337571/Sr_One>,
        <https://1145.am/db/2337577/Sr_One>,
        <https://1145.am/db/2340096/Sr_One>,
        <https://1145.am/db/2341904/Sr_One>,
        <https://1145.am/db/2342084/Sr_One>,
        <https://1145.am/db/2342983/Sr_One>,
        <https://1145.am/db/2343301/Sr_One>,
        <https://1145.am/db/2345675/Sr_One>,
        <https://1145.am/db/2347482/Sr_One>,
        <https://1145.am/db/2347594/Sr_One>,
        <https://1145.am/db/2349233/Sr_One>,
        <https://1145.am/db/2350030/Sr_One>,
        <https://1145.am/db/2350364/Sr_One>,
        <https://1145.am/db/2353917/Sr_One>,
        <https://1145.am/db/2356402/Sr_One>,
        <https://1145.am/db/2356411/Sr_One>,
        <https://1145.am/db/2357676/Sr_One>,
        <https://1145.am/db/2357679/Sr_One>,
        <https://1145.am/db/2357682/Sr_One>,
        <https://1145.am/db/2358430/Sr_One>,
        <https://1145.am/db/2358860/Sr_One>,
        <https://1145.am/db/2359334/Sr_One>,
        <https://1145.am/db/2362533/Sr_One>,
        <https://1145.am/db/2362715/Sr_One>,
        <https://1145.am/db/2363947/Sr_One>,
        <https://1145.am/db/2365103/Sr_One>,
        <https://1145.am/db/2365104/Sr_One>,
        <https://1145.am/db/2365105/Sr_One>,
        <https://1145.am/db/2365296/Sr_One>,
        <https://1145.am/db/2365300/Sr_One>,
        <https://1145.am/db/2367549/Sr_One>,
        <https://1145.am/db/2368501/Sr_One>,
        <https://1145.am/db/2371191/Sr_One>,
        <https://1145.am/db/2371304/Sr_One>,
        <https://1145.am/db/2544138/Sr_One>,
        <https://1145.am/db/2544140/Sr_One>,
        <https://1145.am/db/2546216/Sr_One>,
        <https://1145.am/db/2573068/Sr_One>,
        <https://1145.am/db/2595958/Sr_One> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/Fletcher_Spaght_Ventures> a org:Organization ;
    ns1:basedInLowRaw "CLEVELAND" ;
    ns1:description "venture firms" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "Fletcher Spaght Ventures" ;
    ns1:investor <https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> ;
    ns1:name "Fletcher Spaght Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1636396/Ridge_Ventures>,
        <https://1145.am/db/1775932/Hv_Holtzbrinck_Ventures>,
        <https://1145.am/db/250010/Martin_Ventures>,
        <https://1145.am/db/2603222/Ridge_Ventures>,
        <https://1145.am/db/478025/Ridge_Ventures>,
        <https://1145.am/db/583528/Ridge_Ventures>,
        <https://1145.am/db/612996/Ridge_Ventures>,
        <https://1145.am/db/772099/Ridge_Ventures>,
        <https://1145.am/db/773794/Ridge_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/2289940/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2292313/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2296640/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2306163/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2324756/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2330775/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2339206/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358640/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358657/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358658/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358812/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2364820/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2365444/Fletcher_Spaght_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364827/Juventas_Therapeutics> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "Juventas Therapeutics" ;
    ns1:industry "regenerative medicine" ;
    ns1:name "Juventas Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/1301940/Horizon_Therapeutics_Plc>,
        <https://1145.am/db/1303603/Horizon_Therapeutics_Plc>,
        <https://1145.am/db/1423237/Sfa_Therapeutics>,
        <https://1145.am/db/1554381/Prime_Therapeutics_Llc>,
        <https://1145.am/db/1601518/Outlook_Therapeutics>,
        <https://1145.am/db/1683147/Horizon_Therapeutics_Plc>,
        <https://1145.am/db/2153295/Horizon_Therapeutics>,
        <https://1145.am/db/217556/Horizon_Therapeutics_Plc>,
        <https://1145.am/db/2297214/United_Therapeutics>,
        <https://1145.am/db/2304792/Cv_Therapeutics>,
        <https://1145.am/db/2324241/Cv_Therapeutics>,
        <https://1145.am/db/2324249/Cv_Therapeutics>,
        <https://1145.am/db/2325189/Cv_Therapeutics>,
        <https://1145.am/db/2325196/Cv_Therapeutics>,
        <https://1145.am/db/2329773/Horizon_Therapeutics>,
        <https://1145.am/db/2331731/Horizon_Therapeutics>,
        <https://1145.am/db/2345709/United_Therapeutics_Corporation>,
        <https://1145.am/db/2350349/Northwest_Biotherapeutics>,
        <https://1145.am/db/2350354/Northwest_Biotherapeutics>,
        <https://1145.am/db/2351401/Northwest_Biotherapeutics>,
        <https://1145.am/db/2352422/Northwest_Biotherapeutics>,
        <https://1145.am/db/2360075/Eclipse_Therapeutics>,
        <https://1145.am/db/2363251/Oxford_Biotherapeutics>,
        <https://1145.am/db/2365444/Juventas_Therapeutics>,
        <https://1145.am/db/2369358/United_Therapeutics_Corporation>,
        <https://1145.am/db/2507172/Summit_Therapeutics>,
        <https://1145.am/db/2548696/Cv_Therapeutics>,
        <https://1145.am/db/2559810/Cv_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2336441/Juventas_Therapeutics>,
        <https://1145.am/db/2336472/Juventas_Therapeutics>,
        <https://1145.am/db/2353337/Juventas_Therapeutics>,
        <https://1145.am/db/2353339/Juventas_Therapeutics>,
        <https://1145.am/db/2353939/Juventas_Therapeutics>,
        <https://1145.am/db/2364820/Juventas_Therapeutics>,
        <https://1145.am/db/2367067/Juventas_Therapeutics>,
        <https://1145.am/db/2558017/Juventas_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364853/Coferon_Inc> a org:Organization ;
    ns1:basedInHighGeoName "New York City" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:basedInHighRaw "New York" ;
    ns1:description "Biotechnology" ;
    ns1:documentDate "2012-07-18T15:46:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Coferon, Inc. Announces $12 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/coferon-inc-announces-12-million-series-b-financing> ;
    ns1:foundName "Coferon Inc.",
        "Coferon, Inc." ;
    ns1:industry "biotechnology" ;
    ns1:name "Coferon Inc.",
        "Coferon, Inc." ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364853/Hatteras_Venture_Partners> a org:Organization ;
    ns1:basedInHighGeoName "Durham County" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4464374/about.rdf> ;
    ns1:basedInHighRaw "Durham, N.C." ;
    ns1:documentDate "2012-07-18T15:46:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Coferon, Inc. Announces $12 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/coferon-inc-announces-12-million-series-b-financing> ;
    ns1:foundName "Hatteras Venture Partners" ;
    ns1:investor <https://1145.am/db/2364853/Series_B_Investment_Ascent_Biomedical_Ventures_Coferon_Inc_Hatteras_Venture_Partners_Medimmune_Ventures_Completed> ;
    ns1:name "Hatteras Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1115103/Hatteras_Venture_Partners>,
        <https://1145.am/db/1335370/Hatteras_Venture_Partners>,
        <https://1145.am/db/1464210/Hatteras_Venture_Partners>,
        <https://1145.am/db/1465033/Hatteras_Venture_Partners>,
        <https://1145.am/db/1565424/Hatteras_Venture_Partners>,
        <https://1145.am/db/1896251/Hatteras_Venture_Partners>,
        <https://1145.am/db/1957179/Hatteras_Venture_Partners>,
        <https://1145.am/db/2153141/Hatteras_Venture_Partners>,
        <https://1145.am/db/2224522/Hatteras_Venture_Partners>,
        <https://1145.am/db/2236817/Hatteras_Venture_Partners>,
        <https://1145.am/db/2284028/Hatteras_Venture_Partners>,
        <https://1145.am/db/2306163/Hatteras_Venture_Partners>,
        <https://1145.am/db/2315247/Hatteras_Venture_Partners>,
        <https://1145.am/db/2315248/Hatteras_Venture_Partners>,
        <https://1145.am/db/2319640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2321694/Hatteras_Venture_Partners>,
        <https://1145.am/db/2323511/Hatteras_Venture_Partners>,
        <https://1145.am/db/2328194/Hatteras_Venture_Partners>,
        <https://1145.am/db/2328196/Hatteras_Venture_Partners>,
        <https://1145.am/db/2332459/Hatteras_Venture_Partners>,
        <https://1145.am/db/2339206/Hatteras_Venture_Partners>,
        <https://1145.am/db/2349717/Hatteras_Venture_Partners>,
        <https://1145.am/db/2349722/Hatteras_Venture_Partners>,
        <https://1145.am/db/2351316/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353671/Hatteras_Venture_Partners>,
        <https://1145.am/db/2353674/Hatteras_Venture_Partners>,
        <https://1145.am/db/2354648/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358640/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358657/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358658/Hatteras_Venture_Partners>,
        <https://1145.am/db/2358812/Hatteras_Venture_Partners>,
        <https://1145.am/db/2359452/Hatteras_Venture_Partners>,
        <https://1145.am/db/2360521/Hatteras_Venture_Partners>,
        <https://1145.am/db/2360526/Hatteras_Venture_Partners>,
        <https://1145.am/db/2363396/Hatteras_Venture_Partners>,
        <https://1145.am/db/2363442/Hatteras_Venture_Partners>,
        <https://1145.am/db/2365171/Hatteras_Venture_Partners>,
        <https://1145.am/db/495996/Hatteras_Venture_Partners>,
        <https://1145.am/db/496377/Hatteras_Venture_Partners>,
        <https://1145.am/db/601404/Hatteras_Venture_Partners>,
        <https://1145.am/db/885068/Hatteras_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2364853/Medimmune_Ventures> a org:Organization ;
    ns1:basedInHighGeoName "Gaithersburg" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4355843/about.rdf> ;
    ns1:basedInHighRaw "Gaithersburg, MD" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-07-18T15:46:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Coferon, Inc. Announces $12 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/coferon-inc-announces-12-million-series-b-financing> ;
    ns1:foundName "MedImmune Ventures",
        "MedImmune Ventures of Gaithersburg, MD" ;
    ns1:investor <https://1145.am/db/2364853/Series_B_Investment_Ascent_Biomedical_Ventures_Coferon_Inc_Hatteras_Venture_Partners_Medimmune_Ventures_Completed> ;
    ns1:name "MedImmune Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1223133/Bioadvance>,
        <https://1145.am/db/1223149/Bioadvance>,
        <https://1145.am/db/1422234/Forbion_Ventures>,
        <https://1145.am/db/1422725/Forbion_Ventures>,
        <https://1145.am/db/1867543/Tpg_Biotech>,
        <https://1145.am/db/1926411/Bioqube_Ventures>,
        <https://1145.am/db/1990861/Bioqube_Ventures>,
        <https://1145.am/db/2060484/Healthtech_Capital>,
        <https://1145.am/db/2155146/Biomatics_Capital_Partners>,
        <https://1145.am/db/2280492/Biovision_Ventures>,
        <https://1145.am/db/2285038/Time_Bioventures>,
        <https://1145.am/db/2286671/Forbion>,
        <https://1145.am/db/2298954/Biossom_Investment_Management>,
        <https://1145.am/db/2298978/Advent_Life_Sciences>,
        <https://1145.am/db/2301741/Bio_*_One_Capital>,
        <https://1145.am/db/2301792/Fonds_Bio-Innovation_Sec>,
        <https://1145.am/db/2302351/Medimmune_Ventures>,
        <https://1145.am/db/2305587/Medimmune_Ventures>,
        <https://1145.am/db/2309840/Bio_Fund>,
        <https://1145.am/db/2310285/Medventure_Associates>,
        <https://1145.am/db/2313322/Biomedinvest>,
        <https://1145.am/db/2313322/Hbm_Bioventures>,
        <https://1145.am/db/2313401/Biogen_Idec_New_Ventures>,
        <https://1145.am/db/2313438/Biomedinvest>,
        <https://1145.am/db/2313438/Hbm_Biocapital>,
        <https://1145.am/db/2313438/Hbm_Bioventures>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314400/Hbm_Biocapital>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314573/Avlar_Bioventures>,
        <https://1145.am/db/2316709/Bioadvance_Ventures>,
        <https://1145.am/db/2317737/Mc_Life_Sciences_Ventures>,
        <https://1145.am/db/2317779/Bio_*_One_Capital>,
        <https://1145.am/db/2319360/Medimmune_Ventures>,
        <https://1145.am/db/2321097/Healthcare_Ventures>,
        <https://1145.am/db/2323785/Medimmune_Ventures>,
        <https://1145.am/db/2324015/Medsciences_Capital>,
        <https://1145.am/db/2324195/Lotus_Bioscience_Ventures>,
        <https://1145.am/db/2325831/Bb_Biotech>,
        <https://1145.am/db/2325831/Hbm_Bioventures>,
        <https://1145.am/db/2336109/Biomed_Ventures>,
        <https://1145.am/db/2338673/Hopen_Life_Science_Ventures>,
        <https://1145.am/db/2339295/Biomedinvest>,
        <https://1145.am/db/2345037/Biomed_Ventures>,
        <https://1145.am/db/2347571/Advent_Life_Sciences>,
        <https://1145.am/db/2352382/Biomedinvest>,
        <https://1145.am/db/2352633/Advanced_Biotechnologies_Venture_Fund>,
        <https://1145.am/db/2354295/Biomed_Ventures>,
        <https://1145.am/db/2359240/Frontline_Bioventures>,
        <https://1145.am/db/2365171/Healthcare_Ventures>,
        <https://1145.am/db/2366049/Biomed_Ventures>,
        <https://1145.am/db/2366055/Biomed_Ventures>,
        <https://1145.am/db/2366133/Biopacificventures>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2369916/Biomed_Ventures>,
        <https://1145.am/db/363714/Palliare>,
        <https://1145.am/db/564585/Bioqube_Ventures>,
        <https://1145.am/db/566971/Bioqube_Ventures>,
        <https://1145.am/db/684123/Biourja_Ventures>,
        <https://1145.am/db/938108/Bioeconomy_Capital>,
        <https://1145.am/db/971939/I___I_Biotech_Fund>,
        <https://1145.am/db/975114/I___I_Biotech_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2302192/Medimmune_Ventures>,
        <https://1145.am/db/2314492/Medimmune_Ventures>,
        <https://1145.am/db/2316823/Medimmune_Ventures>,
        <https://1145.am/db/2317561/Medimmune_Ventures>,
        <https://1145.am/db/2317564/Medimmune_Ventures>,
        <https://1145.am/db/2317737/Medimmune_Ventures>,
        <https://1145.am/db/2318656/Medimmune_Ventures>,
        <https://1145.am/db/2318657/Medimmune_Ventures>,
        <https://1145.am/db/2322012/Medimmune_Ventures>,
        <https://1145.am/db/2322022/Medimmune_Ventures>,
        <https://1145.am/db/2322939/Medimmune_Ventures>,
        <https://1145.am/db/2324159/Medimmune_Ventures>,
        <https://1145.am/db/2324289/Medimmune_Ventures>,
        <https://1145.am/db/2327379/Medimmune_Ventures>,
        <https://1145.am/db/2330867/Medimmune_Ventures>,
        <https://1145.am/db/2336313/Medimmune_Ventures>,
        <https://1145.am/db/2342213/Medimmune_Ventures>,
        <https://1145.am/db/2343722/Medimmune_Ventures>,
        <https://1145.am/db/2343725/Medimmune_Ventures>,
        <https://1145.am/db/2343737/Medimmune_Ventures>,
        <https://1145.am/db/2346030/Medimmune_Ventures>,
        <https://1145.am/db/2347389/Medimmune_Ventures>,
        <https://1145.am/db/2350199/Medimmune_Ventures>,
        <https://1145.am/db/2352436/Medimmune_Ventures>,
        <https://1145.am/db/2352442/Medimmune_Ventures>,
        <https://1145.am/db/2356420/Medimmune_Ventures>,
        <https://1145.am/db/2360756/Medimmune_Ventures>,
        <https://1145.am/db/2360758/Medimmune_Ventures>,
        <https://1145.am/db/2362472/Medimmune_Ventures>,
        <https://1145.am/db/2363442/Medimmune_Ventures>,
        <https://1145.am/db/2363459/Medimmune_Ventures>,
        <https://1145.am/db/2363460/Medimmune_Ventures>,
        <https://1145.am/db/2551315/Medimmune_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366403/Equity_Investment_Aerial_Biopharma_Rex_Health_Ventures_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-20T01:07:59+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Rex Health Ventures Announces Inaugural Investment in N.C. Firm, Aerial BioPharma.",
        "Rex Health Ventures, one of the nation's only venture-capital funds managed by a community, nonprofit hospital, is pleased to announce its first investment, a $ 500,000 equity placement in Aerial BioPharma." ;
    ns1:documentTitle "Rex Health Ventures Announces Inaugural Investment in N.C. Firm, Aerial BioPharma" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/rex-health-ventures-announces-inaugural-investment-n-c-firm-aerial-biopharma> ;
    ns1:foundName "Investment",
        "investment",
        "placement" ;
    ns1:name "Investment",
        "investment",
        "placement" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2366403/Aerial_Biopharma> ;
    ns1:targetDetails "equity",
        "equity placement" ;
    ns1:targetName "Aerial BioPharma" ;
    ns1:valueRaw "$ 500,000" ;
    ns1:whereGeoName "Morrisville",
        "North Carolina" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4480285/about.rdf>,
        <https://sws.geonames.org/4482348/about.rdf> ;
    ns1:whereRaw "Morrisville, N.C.",
        "North Carolina" .

<https://1145.am/db/2366403/Rex_Health_Ventures> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:description "venture-capital funds" ;
    ns1:documentDate "2012-07-20T01:07:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Rex Health Ventures Announces Inaugural Investment in N.C. Firm, Aerial BioPharma" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/rex-health-ventures-announces-inaugural-investment-n-c-firm-aerial-biopharma> ;
    ns1:foundName "Rex Health Ventures" ;
    ns1:industry "venture-capital funds" ;
    ns1:investor <https://1145.am/db/2366403/Equity_Investment_Aerial_Biopharma_Rex_Health_Ventures_Has_Not_Happened> ;
    ns1:name "Rex Health Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1635405/Rex_Health_Ventures>,
        <https://1145.am/db/2243235/Rex_Health_Ventures>,
        <https://1145.am/db/2271510/Rex_Healthcare> ;
    ns1:sameAsMedium <https://1145.am/db/1386738/Rex_Health_Ventures>,
        <https://1145.am/db/1387057/Rex_Health_Ventures>,
        <https://1145.am/db/1635418/Rex_Health_Ventures>,
        <https://1145.am/db/1636089/Rex_Health_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366434/Invesco_Perpetual> a org:Organization ;
    ns1:basedInLowRaw "London" ;
    ns1:documentDate "2012-07-23T12:18:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cell Medica Secures £17 million ($26.5 million) Equity Investment to Establish US Operations and Fund Cell Therapy Development" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cell-medica-secures-%C2%A317-million-26-5-million-equity-investment-to-establish-us-operations> ;
    ns1:foundName "Invesco Perpetual" ;
    ns1:investor <https://1145.am/db/2366434/Investment_Cell_Medica_Imperial_Innovations_Invesco_Perpetual_Has_Not_Happened> ;
    ns1:name "Invesco Perpetual" ;
    ns1:sameAsMedium <https://1145.am/db/2302961/Invesco_Perpetual>,
        <https://1145.am/db/2302965/Invesco_Perpetual>,
        <https://1145.am/db/2304832/Invesco_Perpetual>,
        <https://1145.am/db/2304844/Invesco_Perpetual>,
        <https://1145.am/db/2311597/Invesco_Perpetual>,
        <https://1145.am/db/2318529/Invesco_Perpetual>,
        <https://1145.am/db/2318537/Invesco_Perpetual>,
        <https://1145.am/db/2339108/Invesco_Perpetual>,
        <https://1145.am/db/2339111/Invesco_Perpetual>,
        <https://1145.am/db/2340559/Invesco_Perpetual>,
        <https://1145.am/db/2341738/Invesco_Perpetual>,
        <https://1145.am/db/2341760/Invesco_Perpetual>,
        <https://1145.am/db/2348796/Invesco_Perpetual>,
        <https://1145.am/db/2363947/Invesco_Perpetual>,
        <https://1145.am/db/2363950/Invesco_Perpetual>,
        <https://1145.am/db/2366154/Invesco_Perpetual>,
        <https://1145.am/db/2366156/Invesco_Perpetual>,
        <https://1145.am/db/2367043/Invesco_Perpetual>,
        <https://1145.am/db/2544138/Invesco_Perpetual> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2440017/Micropelt> a org:Organization ;
    ns1:basedInHighGeoName "Freiburg Region" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2925180/about.rdf> ;
    ns1:basedInHighRaw "FREIBURG, Germany" ;
    ns1:description "cleantech" ;
    ns1:documentDate "2012-05-03T05:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Micropelt Raises 6'5 Mio EURO" ;
    ns1:documentURL <https://www.fierceelectronics.com/embedded/micropelt-raises-6-5-mio-euro> ;
    ns1:foundName "Micropelt" ;
    ns1:name "Micropelt" ;
    ns1:sameAsMedium <https://1145.am/db/2434766/Micropelt_Gmbh> ;
    ns1:sourceName "Fierce Electronics" .

<https://1145.am/db/2541195/Galveston_National_Laboratory> a org:Organization ;
    ns1:basedInHighGeoName "Texas" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4736286/about.rdf> ;
    ns1:basedInHighRaw "Texas" ;
    ns1:description "research" ;
    ns1:documentDate "2012-05-03T13:10:22+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Profectus BioSciences Receives NIAID Grant to Develop a Vesicular Stomatitis Virus-vectored Vaccine for Ebola and Marburg Viruses" ;
    ns1:documentURL <https://www.fiercepharma.com/vaccines/profectus-biosciences-receives-niaid-grant-to-develop-a-vesicular-stomatitis-virus> ;
    ns1:foundName "at the University of Texas Medical Branch at Galveston",
        "the Galveston National Laboratory" ;
    ns1:name "Galveston National Laboratory" ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2541195/Investment_Galveston_National_Laboratory_National_Institute_Of_Allergy_And_Infectious_Diseases_Profectus_Biosciences_Inc_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-03T13:10:22+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Profectus BioSciences Receives NIAID Grant to Develop a Vesicular Stomatitis Virus-vectored Vaccine for Ebola and Marburg Viruses.",
        "Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases, and the Galveston National Laboratory (GNL) at the University of Texas Medical Branch at Galveston announced today that they have received a 5 year $ 5.4 M grant from the National Institute of Allergy and Infectious Diseases (NIAID) , a division of the National Institutes of Health (NIH) ." ;
    ns1:documentTitle "Profectus BioSciences Receives NIAID Grant to Develop a Vesicular Stomatitis Virus-vectored Vaccine for Ebola and Marburg Viruses" ;
    ns1:documentURL <https://www.fiercepharma.com/vaccines/profectus-biosciences-receives-niaid-grant-to-develop-a-vesicular-stomatitis-virus> ;
    ns1:foundName "Grant",
        "grant" ;
    ns1:name "Grant",
        "grant" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2541195/Galveston_National_Laboratory>,
        <https://1145.am/db/2541195/Profectus_Biosciences_Inc> ;
    ns1:valueRaw "$ 5.4 M",
        "5 year" ;
    ns1:whereGeoName "Galveston County",
        "Laboratory",
        "Ratcliff" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4127899/about.rdf>,
        <https://sws.geonames.org/4474625/about.rdf>,
        <https://sws.geonames.org/4692856/about.rdf> ;
    ns1:whereRaw "Galveston National Laboratory" .

<https://1145.am/db/2541195/Profectus_Biosciences_Inc> a org:Organization ;
    ns1:basedInLowRaw "Galveston",
        "United States" ;
    ns1:description "Vaccine development",
        "the development of therapeutic and preventive vaccines against infectious diseases" ;
    ns1:documentDate "2012-05-03T13:10:22+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Profectus BioSciences Receives NIAID Grant to Develop a Vesicular Stomatitis Virus-vectored Vaccine for Ebola and Marburg Viruses" ;
    ns1:documentURL <https://www.fiercepharma.com/vaccines/profectus-biosciences-receives-niaid-grant-to-develop-a-vesicular-stomatitis-virus> ;
    ns1:foundName "Profectus BioSciences",
        "Profectus BioSciences, Inc." ;
    ns1:name "Profectus BioSciences",
        "Profectus BioSciences, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/2542113/Profectus_Biosciences> ;
    ns1:sameAsMedium <https://1145.am/db/2303018/Profectus_Biosciences>,
        <https://1145.am/db/2303025/Profectus_Biosciences>,
        <https://1145.am/db/2304843/Profectus_Biosciences> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2544140/Sr_One> a org:Organization ;
    ns1:documentDate "2012-07-09T19:51:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PsiOxus lands $34M for cancer vax research" ;
    ns1:documentURL <https://www.fiercepharma.com/r-d/psioxus-lands-34m-for-cancer-vax-research> ;
    ns1:foundName "SR One" ;
    ns1:investor <https://1145.am/db/2544140/Investment_Lundbeckfond_Ventures_Psioxus_Therapeutics_Sr_One_Has_Not_Happened> ;
    ns1:name "SR One" ;
    ns1:sameAsMedium <https://1145.am/db/1169952/Sr_One>,
        <https://1145.am/db/1334624/Sr_One>,
        <https://1145.am/db/1949427/Sr_One>,
        <https://1145.am/db/2095130/Sr_One>,
        <https://1145.am/db/2110113/Sr_One>,
        <https://1145.am/db/2280707/Sr_One>,
        <https://1145.am/db/2305791/Sr_One>,
        <https://1145.am/db/2317934/Sr_One>,
        <https://1145.am/db/2317951/Sr_One>,
        <https://1145.am/db/2318310/Sr_One>,
        <https://1145.am/db/2326222/Sr_One_Ltd>,
        <https://1145.am/db/2327305/Sr_One>,
        <https://1145.am/db/2327488/Sr_One_Ltd>,
        <https://1145.am/db/2331763/Sr_One>,
        <https://1145.am/db/2336328/Sr_One>,
        <https://1145.am/db/2337571/Sr_One>,
        <https://1145.am/db/2337577/Sr_One>,
        <https://1145.am/db/2340096/Sr_One>,
        <https://1145.am/db/2341904/Sr_One>,
        <https://1145.am/db/2342084/Sr_One>,
        <https://1145.am/db/2342983/Sr_One>,
        <https://1145.am/db/2343301/Sr_One>,
        <https://1145.am/db/2345675/Sr_One>,
        <https://1145.am/db/2347482/Sr_One>,
        <https://1145.am/db/2347594/Sr_One>,
        <https://1145.am/db/2349233/Sr_One>,
        <https://1145.am/db/2350030/Sr_One>,
        <https://1145.am/db/2350364/Sr_One>,
        <https://1145.am/db/2353917/Sr_One>,
        <https://1145.am/db/2356402/Sr_One>,
        <https://1145.am/db/2356411/Sr_One>,
        <https://1145.am/db/2357676/Sr_One>,
        <https://1145.am/db/2357679/Sr_One>,
        <https://1145.am/db/2357682/Sr_One>,
        <https://1145.am/db/2358430/Sr_One>,
        <https://1145.am/db/2358860/Sr_One>,
        <https://1145.am/db/2359334/Sr_One>,
        <https://1145.am/db/2362533/Sr_One>,
        <https://1145.am/db/2362715/Sr_One>,
        <https://1145.am/db/2363947/Sr_One>,
        <https://1145.am/db/2363950/Sr_One>,
        <https://1145.am/db/2365103/Sr_One>,
        <https://1145.am/db/2365104/Sr_One>,
        <https://1145.am/db/2365105/Sr_One>,
        <https://1145.am/db/2365296/Sr_One>,
        <https://1145.am/db/2365300/Sr_One>,
        <https://1145.am/db/2367549/Sr_One>,
        <https://1145.am/db/2368501/Sr_One>,
        <https://1145.am/db/2371191/Sr_One>,
        <https://1145.am/db/2371304/Sr_One>,
        <https://1145.am/db/2544138/Sr_One>,
        <https://1145.am/db/2546216/Sr_One>,
        <https://1145.am/db/2573068/Sr_One>,
        <https://1145.am/db/2595958/Sr_One> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2554659/Deltex_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Rosenberg" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4723914/about.rdf> ;
    ns1:basedInHighRaw "Rosenberg, TX" ;
    ns1:description "manufacturing infractions" ;
    ns1:documentDate "2012-07-23T19:41:21+00:00"^^xsd:dateTime ;
    ns1:documentTitle "New Florida drugmaker springs from debacle of another" ;
    ns1:documentURL <https://www.fiercepharma.com/regulatory/new-florida-drugmaker-springs-from-debacle-of-another> ;
    ns1:foundName "Deltex Pharmaceuticals of Rosenberg, TX" ;
    ns1:industry "pharmaceuticals" ;
    ns1:name "Deltex Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2318984/Dov_Pharmaceuticals>,
        <https://1145.am/db/2335654/Delmar_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344005/Delmar_Pharmaceuticals> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2554659/Investment_John_Copanos_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-23T19:41:21+00:00"^^xsd:dateTime ;
    ns1:documentExtract "John Copanos is starting BioRamo in Fort Lauderdale, where it will make both branded and prescription liquids, creams, ointments and gels." ;
    ns1:documentTitle "New Florida drugmaker springs from debacle of another" ;
    ns1:documentURL <https://www.fiercepharma.com/regulatory/new-florida-drugmaker-springs-from-debacle-of-another> ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:whereGeoName "Fort Lauderdale" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4155966/about.rdf> ;
    ns1:whereRaw "Fort Lauderdale" .

<https://1145.am/db/2554659/Joint_Venture_John_Copanos_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "joint venture" ;
    ns1:documentDate "2012-07-23T19:41:21+00:00"^^xsd:dateTime ;
    ns1:documentExtract "John Copanos is starting BioRamo in Fort Lauderdale, where it will make both branded and prescription liquids, creams, ointments and gels." ;
    ns1:documentTitle "New Florida drugmaker springs from debacle of another" ;
    ns1:documentURL <https://www.fiercepharma.com/regulatory/new-florida-drugmaker-springs-from-debacle-of-another> ;
    ns1:foundName "starting" ;
    ns1:name "starting" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:whereGeoName "Fort Lauderdale" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4155966/about.rdf> ;
    ns1:whereRaw "Fort Lauderdale" .

<https://1145.am/db/2555683/Istituto_Di_Ricerche_Biotecnologiche> a org:Organization ;
    ns1:basedInHighGeoName "Italian Republic" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3175395/about.rdf> ;
    ns1:basedInHighRaw "Italy" ;
    ns1:description "Research" ;
    ns1:documentDate "2012-07-24T11:44:07+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Michigan loses $3M on drug manufacturing try; API maker Croda buys a biotech firm;" ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/michigan-loses-3m-on-drug-manufacturing-try-api-maker-croda-buys-a-biotech-firm> ;
    ns1:foundName "Istituto di Ricerche Biotecnologiche" ;
    ns1:industry "biotech" ;
    ns1:name "Istituto di Ricerche Biotecnologiche" ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2555683/Istituto_Di_Ricerche_Biotecnologiche_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2012-07-24T11:44:07+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Chemicalmaker Croda has paid £5.9 million ($ 9.2 million) to buy the Italian biotech company Istituto di Ricerche Biotecnologiche and will merge it with its Sederma skin care business." ;
    ns1:documentTitle "Michigan loses $3M on drug manufacturing try; API maker Croda buys a biotech firm;" ;
    ns1:documentURL <https://www.fiercepharma.com/manufacturing/michigan-loses-3m-on-drug-manufacturing-try-api-maker-croda-buys-a-biotech-firm> ;
    ns1:foundName "buy",
        "merge" ;
    ns1:name "buy",
        "merge" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2555683/Istituto_Di_Ricerche_Biotecnologiche> ;
    ns1:targetName "Istituto di Ricerche Biotecnologiche" ;
    ns1:valueRaw "$ 9.2 million",
        "£5.9 million" ;
    ns1:whereGeoName "Italian Republic" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3175395/about.rdf> ;
    ns1:whereRaw "Italy" .

<https://1145.am/db/2572450/Eyetech> a org:Organization ;
    ns1:basedInHighGeoName "Florida" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4155751/about.rdf> ;
    ns1:basedInHighRaw "Florida" ;
    ns1:description "eye-drug" ;
    ns1:documentDate "2012-03-26T15:57:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Valeant nabs Russia's Natur Produkt for $175M-plus" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/valeant-nabs-russia-s-natur-produkt-for-175m-plus> ;
    ns1:foundName "Eyetech" ;
    ns1:industry "eye-drug" ;
    ns1:name "Eyetech" ;
    ns1:sameAsHigh <https://1145.am/db/1157791/Eyepoint_Pharmaceuticals>,
        <https://1145.am/db/1188455/Eyenovia>,
        <https://1145.am/db/1195796/Eyepoint_Pharmaceuticals>,
        <https://1145.am/db/1195924/Eyepoint_Pharmaceuticals_Inc>,
        <https://1145.am/db/1216801/Eyenovia>,
        <https://1145.am/db/1616372/Eyepoint_Pharmaceuticals>,
        <https://1145.am/db/2293419/Novartis>,
        <https://1145.am/db/2306164/Eyegate_Pharma>,
        <https://1145.am/db/2315547/Eyegate_Pharma>,
        <https://1145.am/db/2322162/Eyegate>,
        <https://1145.am/db/2331956/Eyegate_Pharma>,
        <https://1145.am/db/2337683/Eyegate_Pharmaceuticals>,
        <https://1145.am/db/2344947/Eyevensys>,
        <https://1145.am/db/2346523/Eye-Drug>,
        <https://1145.am/db/2349068/Eyevensys>,
        <https://1145.am/db/2366298/Eyegate_Pharma>,
        <https://1145.am/db/2366467/Eyetech>,
        <https://1145.am/db/2366468/Eyetech>,
        <https://1145.am/db/2369057/Ophthotech_Corporation>,
        <https://1145.am/db/2370595/Eyegate_Pharmaceuticals>,
        <https://1145.am/db/2536832/Eyegate_Pharmaceuticals>,
        <https://1145.am/db/2551089/Ocular_Technologies>,
        <https://1145.am/db/2574001/Eyegate_Pharmaceuticals_Inc>,
        <https://1145.am/db/2595853/Eyetech_Inc>,
        <https://1145.am/db/403490/Eyegate_Pharmaceuticals>,
        <https://1145.am/db/628681/Eyepoint_Pharmaceuticals_Inc>,
        <https://1145.am/db/629638/Eyepoint_Pharmaceuticals_Inc>,
        <https://1145.am/db/634144/Eyepoint_Pharmaceuticals_Inc>,
        <https://1145.am/db/812277/Eyenovia>,
        <https://1145.am/db/877326/Eyenovia_Inc>,
        <https://1145.am/db/881652/Eyepoint_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2321167/Eyetech>,
        <https://1145.am/db/2592575/Eyetech> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2572450/Eyetech_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-26T15:57:29+00:00"^^xsd:dateTime ;
    ns1:documentExtract "In February, Valeant bought the Florida - based eye-drug company Eyetech, plus a Brazilian supplements maker, Probiotica, for about $ 55 million." ;
    ns1:documentTitle "Valeant nabs Russia's Natur Produkt for $175M-plus" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/valeant-nabs-russia-s-natur-produkt-for-175m-plus> ;
    ns1:foundName "bought" ;
    ns1:name "bought" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2572450/Eyetech> ;
    ns1:targetName "Eyetech" ;
    ns1:whereGeoName "Florida" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4155751/about.rdf> ;
    ns1:whereRaw "Florida" .

<https://1145.am/db/2572450/Pele_Nova_Assets_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-03-26T15:57:29+00:00"^^xsd:dateTime ;
    ns1:documentExtract "The Natur Produkt deal follows closely after Valeant snapped up some assets from Austrian branded-generics maker Gerot Lannach; some 90 % of the sales from those products comes from Russia." ;
    ns1:documentTitle "Valeant nabs Russia's Natur Produkt for $175M-plus" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/valeant-nabs-russia-s-natur-produkt-for-175m-plus> ;
    ns1:foundName "snapped" ;
    ns1:name "snapped" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2572450/Pele_Nova> ;
    ns1:targetDetails "assets" ;
    ns1:targetName "Pele Nova" ;
    ns1:vendor <https://1145.am/db/2572450/Gerot_Lannach> ;
    ns1:whereGeoName "Federative Republic of Brazil" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3469034/about.rdf> ;
    ns1:whereRaw "Brazil" .

<https://1145.am/db/2572450/Stake_Investment_Gerot_Lannach_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-26T15:57:29+00:00"^^xsd:dateTime ;
    ns1:documentExtract "The Natur Produkt deal follows closely after Valeant snapped up some assets from Austrian branded-generics maker Gerot Lannach; some 90 % of the sales from those products comes from Russia." ;
    ns1:documentTitle "Valeant nabs Russia's Natur Produkt for $175M-plus" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/valeant-nabs-russia-s-natur-produkt-for-175m-plus> ;
    ns1:foundName "bought" ;
    ns1:name "bought" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2572450/Gerot_Lannach>,
        <https://1145.am/db/2572450/Pele_Nova> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "Pele Nova" ;
    ns1:whereGeoName "Federative Republic of Brazil" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/3469034/about.rdf> ;
    ns1:whereRaw "Brazil" .

<https://1145.am/db/2572450/Valeant> a org:Organization ;
    ns1:basedInLowRaw "Canada" ;
    ns1:buyer <https://1145.am/db/2572450/Pele_Nova_Assets_Acquisition> ;
    ns1:description "branded-generics maker" ;
    ns1:documentDate "2012-03-26T15:57:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Valeant nabs Russia's Natur Produkt for $175M-plus" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/valeant-nabs-russia-s-natur-produkt-for-175m-plus> ;
    ns1:foundName "Valeant" ;
    ns1:industry "pharmaceuticals" ;
    ns1:investor <https://1145.am/db/2572450/Eyetech_Investment>,
        <https://1145.am/db/2572450/Stake_Investment_Gerot_Lannach_Completed> ;
    ns1:name "Valeant" ;
    ns1:sameAsHigh <https://1145.am/db/2294967/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2295456/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2302002/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2302007/Valeant_Canada_Limited>,
        <https://1145.am/db/2302007/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2302826/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2305757/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2305758/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2306724/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2306813/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2308734/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2312215/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2312221/Valeant>,
        <https://1145.am/db/2313272/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2313282/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2313320/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2313365/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2315100/Valeant>,
        <https://1145.am/db/2318350/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2318405/Valeant>,
        <https://1145.am/db/2319331/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2319722/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2322159/Valeant>,
        <https://1145.am/db/2322776/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2323106/Valeant>,
        <https://1145.am/db/2323111/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2324422/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2325692/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2325895/Valeant>,
        <https://1145.am/db/2330074/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2332074/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2335641/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2336083/Valeant>,
        <https://1145.am/db/2336258/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2336278/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2337634/Valeant>,
        <https://1145.am/db/2341518/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2346832/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2346833/Valeant_Canada_Limited>,
        <https://1145.am/db/2346833/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2348864/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2349239/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2349461/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2350907/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2353646/Valeant>,
        <https://1145.am/db/2354801/Valeant>,
        <https://1145.am/db/2354804/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2356945/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2357416/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2360703/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2361172/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2361190/Valeant>,
        <https://1145.am/db/2362893/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2362898/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2362898/Valeant_Pharmaceuticals_North_America_Llc>,
        <https://1145.am/db/2363430/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2365199/Valeant>,
        <https://1145.am/db/2365200/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2366467/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2366468/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2369037/Valeant>,
        <https://1145.am/db/2369371/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2369374/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2369618/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2538017/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2539802/Valeant>,
        <https://1145.am/db/2540219/Valeant>,
        <https://1145.am/db/2540467/Valeant>,
        <https://1145.am/db/2543893/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2543904/Valeant>,
        <https://1145.am/db/2544888/Valeant>,
        <https://1145.am/db/2545075/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2550867/Valeant>,
        <https://1145.am/db/2556458/Valeant>,
        <https://1145.am/db/2556718/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2556805/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2557472/Valeant>,
        <https://1145.am/db/2560716/Valeant>,
        <https://1145.am/db/2560770/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2566037/Valeant>,
        <https://1145.am/db/2568778/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2568799/Valeant_Canada>,
        <https://1145.am/db/2568808/Valeant_Canada>,
        <https://1145.am/db/2569148/Valeant>,
        <https://1145.am/db/2569149/Valeant>,
        <https://1145.am/db/2570033/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2570121/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2570390/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2571019/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2571068/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2572086/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2572449/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2572552/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2572553/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2572568/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2572605/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2572612/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2572932/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2573147/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2573199/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2573880/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2574433/Valeant>,
        <https://1145.am/db/2575134/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2575289/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2575552/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2575615/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2575800/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2576039/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2576047/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2576205/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2576478/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2576482/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2576956/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2576962/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2577145/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2577419/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2577770/Valeant>,
        <https://1145.am/db/2577771/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2577774/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2577775/Valeant>,
        <https://1145.am/db/2577846/Valeant>,
        <https://1145.am/db/2577958/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2578188/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2578333/Valeant_Canada>,
        <https://1145.am/db/2578700/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2579147/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2580042/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2580047/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2580122/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2580140/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2580774/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2580775/Valeant>,
        <https://1145.am/db/2580831/Valeant>,
        <https://1145.am/db/2581225/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2582260/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2582935/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2583270/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2583732/Valeant>,
        <https://1145.am/db/2583843/Valeant_Pharmaceuticals_North_America>,
        <https://1145.am/db/2584209/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2584216/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2584226/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2584644/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2584750/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2584818/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2585746/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2586657/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2586658/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2587640/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2588178/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2589040/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2589223/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2589781/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2590589/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2591690/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2592575/And_Valeant>,
        <https://1145.am/db/2593443/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2593831/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594087/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594236/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594249/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594252/Valeant>,
        <https://1145.am/db/2594253/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2594281/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594413/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594414/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594557/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594858/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2595025/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2595150/Valeant>,
        <https://1145.am/db/2595287/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2595706/Valeant>,
        <https://1145.am/db/2595853/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2595929/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2596290/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2596891/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2597119/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597158/Valeant>,
        <https://1145.am/db/2597223/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597433/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597433/Valeant_Pharmaceuticals_North_America_Llc>,
        <https://1145.am/db/2597542/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2597746/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597769/Valeant>,
        <https://1145.am/db/2598012/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2598032/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2598205/Valeant>,
        <https://1145.am/db/2598266/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2598558/Valeant_Pharmaceuticals_International> ;
    ns1:sameAsMedium <https://1145.am/db/2288428/Valeant>,
        <https://1145.am/db/2288758/Valeant>,
        <https://1145.am/db/2328143/Valeant>,
        <https://1145.am/db/2367825/Valeant>,
        <https://1145.am/db/2547983/Valeant>,
        <https://1145.am/db/2571740/Valeant>,
        <https://1145.am/db/2572930/Valeant>,
        <https://1145.am/db/2573485/Valeant>,
        <https://1145.am/db/2575133/Valeant>,
        <https://1145.am/db/2576212/Valeant>,
        <https://1145.am/db/2579823/Valeant>,
        <https://1145.am/db/2582257/Valeant>,
        <https://1145.am/db/2582894/Valeant>,
        <https://1145.am/db/2583845/Valeant>,
        <https://1145.am/db/2584676/Valeant>,
        <https://1145.am/db/2589971/Valeant>,
        <https://1145.am/db/2590366/Valeant>,
        <https://1145.am/db/2593483/Valeant> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2579168/Innopharma_Inc> a org:Organization ;
    ns1:basedInHighGeoName "Piscataway" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5102713/about.rdf> ;
    ns1:basedInHighRaw "PISCATAWAY, N.J." ;
    ns1:documentDate "2012-06-08T11:01:20+00:00"^^xsd:dateTime ;
    ns1:documentTitle "InnoPharma Inc. Raises $8 Million in Venture Debt" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/innopharma-inc-raises-8-million-venture-debt> ;
    ns1:foundName "InnoPharma Inc.",
        "InnoPharma, Inc." ;
    ns1:industry "Pharmaceutical" ;
    ns1:name "InnoPharma Inc.",
        "InnoPharma, Inc." ;
    ns1:sameAsHigh <https://1145.am/db/1997839/Incyte>,
        <https://1145.am/db/2154375/Incyte>,
        <https://1145.am/db/2154897/Incyte>,
        <https://1145.am/db/2283809/Innovent>,
        <https://1145.am/db/2284274/Innovheart>,
        <https://1145.am/db/2285189/Incyte>,
        <https://1145.am/db/2287873/Incyte>,
        <https://1145.am/db/2335867/Innopharma>,
        <https://1145.am/db/2339780/Incyte>,
        <https://1145.am/db/2344848/Innopharma_Inc>,
        <https://1145.am/db/2345824/Incyte>,
        <https://1145.am/db/2371016/Incyte>,
        <https://1145.am/db/2539516/Innopharma>,
        <https://1145.am/db/2555896/Innopharma>,
        <https://1145.am/db/2570672/Innocutis_Holdings_Llc>,
        <https://1145.am/db/2573465/Innopharma>,
        <https://1145.am/db/2579180/Innopharma>,
        <https://1145.am/db/2583165/Innopharma_Inc>,
        <https://1145.am/db/2583172/Innopharma>,
        <https://1145.am/db/308999/Innobic_(asia)>,
        <https://1145.am/db/709704/Intouch_Group> ;
    ns1:sameAsMedium <https://1145.am/db/2573466/Innopharma> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2580140/Boehringer_Ingelheim_And_Eli_Lilly> a org:Organization ;
    ns1:basedInLowRaw "Austria",
        "India" ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2012-06-15T02:41:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Valeant nabs OraPharma; GSK get MenHibrix OK'd; Trajenta into India;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/valeant-nabs-orapharma-gsk-get-menhibrix-ok-d-trajenta-into-india> ;
    ns1:foundName "Boehringer Ingelheim",
        "Boehringer Ingelheim and Eli Lilly",
        "Eli Lilly" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Boehringer Ingelheim",
        "Boehringer Ingelheim and Eli Lilly",
        "Eli Lilly" ;
    ns1:sameAsHigh <https://1145.am/db/1038901/Eli_Lilly_And_Company>,
        <https://1145.am/db/1072187/Eli_Lilly_And_Company>,
        <https://1145.am/db/1087869/Eli_Lilly_And_Company>,
        <https://1145.am/db/1133669/Boehringer_Ingelheim>,
        <https://1145.am/db/1135149/Boehringer_Ingelheim>,
        <https://1145.am/db/1217359/Eli_Lilly_And_Company>,
        <https://1145.am/db/1272276/Eli_Lilly_And_Company>,
        <https://1145.am/db/1272276/Lilly>,
        <https://1145.am/db/1340338/Eli_Lilly_And_Company>,
        <https://1145.am/db/1425255/Eli_Lilly_And_Company>,
        <https://1145.am/db/1428583/Eli_Lilly_And_Company>,
        <https://1145.am/db/1428583/Lilly>,
        <https://1145.am/db/1432746/Eli_Lilly>,
        <https://1145.am/db/1534004/Eli_Lilly_And_Company>,
        <https://1145.am/db/1534438/Eli_Lilly_And_Company>,
        <https://1145.am/db/1537106/Boehringer_Ingelheim>,
        <https://1145.am/db/1537985/Boehringer_Ingelheim>,
        <https://1145.am/db/1546070/Eli_Lilly_And_Company>,
        <https://1145.am/db/1553175/Eli_Lilly___Company>,
        <https://1145.am/db/1553459/Eli_Lilly___Company>,
        <https://1145.am/db/1594413/Boehringer_Ingelheim>,
        <https://1145.am/db/1663572/Eli_Lilly_And_Company>,
        <https://1145.am/db/174741/Eli_Lilly_And_Co>,
        <https://1145.am/db/1979697/Eli_Lilly>,
        <https://1145.am/db/1984558/Eli_Lilly_And_Company>,
        <https://1145.am/db/2043001/Eli_Lilly_And_Co>,
        <https://1145.am/db/2045539/Eli_Lilly_And_Company>,
        <https://1145.am/db/2053734/Eli_Lilly_And_Co>,
        <https://1145.am/db/2055009/Eli_Lilly_And_Company>,
        <https://1145.am/db/2058865/Eli_Lilly_And_Company>,
        <https://1145.am/db/2062260/Eli_Lilly>,
        <https://1145.am/db/2065629/Eli_Lilly_And_Company>,
        <https://1145.am/db/2134678/Eli_Lilly_And_Co>,
        <https://1145.am/db/2136466/Eli_Lilly_And_Co>,
        <https://1145.am/db/2139015/Eli_Lilly_And_Company>,
        <https://1145.am/db/2152172/Boehringer_Ingelheim>,
        <https://1145.am/db/2152174/Boehringer_Ingelheim>,
        <https://1145.am/db/2152285/Boehringer>,
        <https://1145.am/db/2154037/Eli_Lilly>,
        <https://1145.am/db/2154391/Eli_Lilly>,
        <https://1145.am/db/2154401/Boehringer_Ingelheim>,
        <https://1145.am/db/2155453/Lilly_Usa>,
        <https://1145.am/db/2281211/Eli_Lilly>,
        <https://1145.am/db/2282739/Eli_Lilly>,
        <https://1145.am/db/2282930/Eli_Lilly>,
        <https://1145.am/db/2283595/Eli_Lilly>,
        <https://1145.am/db/2284615/Lilly>,
        <https://1145.am/db/2285156/Eli_Lilly>,
        <https://1145.am/db/2285189/Eli_Lilly>,
        <https://1145.am/db/2285525/Eli_Lilly>,
        <https://1145.am/db/2286402/Eli_Lilly>,
        <https://1145.am/db/2286404/Eli_Lilly>,
        <https://1145.am/db/2286617/Eli_Lilly>,
        <https://1145.am/db/2286657/Boehringer_Ingelheim>,
        <https://1145.am/db/2286911/Eli_Lilly>,
        <https://1145.am/db/2286998/Eli_Lilly>,
        <https://1145.am/db/2287005/Eli_Lilly>,
        <https://1145.am/db/2288158/Eli_Lilly>,
        <https://1145.am/db/2290507/Boehringer_Ingelheim>,
        <https://1145.am/db/2290919/Boehringer_Ingelheim>,
        <https://1145.am/db/229232/Eli_Lilly>,
        <https://1145.am/db/2293168/Boehringer_Ingelheim>,
        <https://1145.am/db/2294118/Eli_Lilly>,
        <https://1145.am/db/2298022/Eli_Lilly>,
        <https://1145.am/db/2299157/Eli_Lilly>,
        <https://1145.am/db/2301879/Eli_Lilly_And_Company>,
        <https://1145.am/db/2302104/Eli_Lilly_And_Company>,
        <https://1145.am/db/2303974/Boehringer_Ingelheim_Gmbh>,
        <https://1145.am/db/2303980/Boehringer_Ingelheim>,
        <https://1145.am/db/2305497/Eli_Lilly>,
        <https://1145.am/db/2306173/Boehringer_Ingelheim>,
        <https://1145.am/db/2306807/Eli_Lilly_And_Company>,
        <https://1145.am/db/2307651/Eli_Lilly>,
        <https://1145.am/db/2309473/Eli_Lilly>,
        <https://1145.am/db/2309599/Eli_Lilly>,
        <https://1145.am/db/2313544/Boehringer_Ingelheim>,
        <https://1145.am/db/2314412/Eli_Lilly_And_Company>,
        <https://1145.am/db/2316092/Eli_Lilly>,
        <https://1145.am/db/2316549/Eli_Lilly>,
        <https://1145.am/db/2318248/Boehringer_Ingelheim>,
        <https://1145.am/db/2318587/Eli_Lilly>,
        <https://1145.am/db/2320006/Eli_Lilly>,
        <https://1145.am/db/2320338/Eli_Lilly>,
        <https://1145.am/db/2322619/Eli_Lilly_And_Company>,
        <https://1145.am/db/2323165/Eli_Lilly_And_Company>,
        <https://1145.am/db/2325525/Boehringer_Ingelheim>,
        <https://1145.am/db/2325557/Eli_Lilly_And_Company>,
        <https://1145.am/db/2326272/Lilly_Usa>,
        <https://1145.am/db/2327587/Eli_Lilly_And_Company>,
        <https://1145.am/db/2328527/Eli_Lilly>,
        <https://1145.am/db/2328554/Eli_Lilly_And_Company>,
        <https://1145.am/db/2328718/Eli_Lilly>,
        <https://1145.am/db/2329107/Lilly>,
        <https://1145.am/db/2329114/Eli_Lilly>,
        <https://1145.am/db/2329115/Lilly>,
        <https://1145.am/db/2334645/Eli_Lilly>,
        <https://1145.am/db/2335594/Eli_Lilly_And_Company>,
        <https://1145.am/db/2335703/Boehringer_Ingelheim>,
        <https://1145.am/db/2335705/Boehringer_Ingelheim>,
        <https://1145.am/db/2335908/Boehringer>,
        <https://1145.am/db/2336074/Eli_Lilly_And_Company>,
        <https://1145.am/db/2338059/Eli_Lilly>,
        <https://1145.am/db/2340948/Eli_Lilly>,
        <https://1145.am/db/2341481/Eli_Lilly>,
        <https://1145.am/db/2341496/Eli_Lilly>,
        <https://1145.am/db/2342503/Eli_Lilly_And_Company>,
        <https://1145.am/db/2343945/Eli_Lilly_And_Company>,
        <https://1145.am/db/2344800/Eli_Lilly_And_Company>,
        <https://1145.am/db/2344808/Eli_Lilly>,
        <https://1145.am/db/2344991/Eli_Lilly>,
        <https://1145.am/db/2345213/Eli_Lilly>,
        <https://1145.am/db/2345214/Eli_Lilly>,
        <https://1145.am/db/2346629/Novo_Nordisk_Eli_Lilly>,
        <https://1145.am/db/2349020/Eli_Lilly_And_Company>,
        <https://1145.am/db/2349300/Eli_Lilly_And_Company>,
        <https://1145.am/db/2352358/Eli_Lilly>,
        <https://1145.am/db/2353350/Eli_Lilly>,
        <https://1145.am/db/2354380/Boehringer_Ingelheim>,
        <https://1145.am/db/2354388/Boehringer_Ingelheim>,
        <https://1145.am/db/2354761/Eli_Lilly_And_Company>,
        <https://1145.am/db/2354853/Eli_Lilly_And_Company>,
        <https://1145.am/db/2359240/Eli_Lilly>,
        <https://1145.am/db/2360080/Boehringer_Ingelheim>,
        <https://1145.am/db/2360086/Boehringer_Ingelheim>,
        <https://1145.am/db/2361027/Eli_Lilly>,
        <https://1145.am/db/2363310/Eli_Lilly_And_Company_(lly)>,
        <https://1145.am/db/2364605/Eli_Lilly>,
        <https://1145.am/db/2364810/Boehringer_Ingelheim>,
        <https://1145.am/db/2365178/Eli_Lilly_And_Company>,
        <https://1145.am/db/2366948/Eli_Lilly_And_Company>,
        <https://1145.am/db/2366948/Lilly>,
        <https://1145.am/db/2366953/Eli_Lilly_And_Company>,
        <https://1145.am/db/2366953/Lilly>,
        <https://1145.am/db/2367430/Boehringer_Ingelheim>,
        <https://1145.am/db/2368562/Eli_Lilly_And_Company>,
        <https://1145.am/db/2369000/Eli_Lilly_And_Company>,
        <https://1145.am/db/2370162/Eli_Lilly>,
        <https://1145.am/db/2370523/Boehringer>,
        <https://1145.am/db/2371016/Eli_Lilly>,
        <https://1145.am/db/2371058/Eli_Lilly_And_Company>,
        <https://1145.am/db/2371075/Eli_Lilly_And_Company>,
        <https://1145.am/db/2371075/Lilly>,
        <https://1145.am/db/2536400/Boehringer_Ingelheim>,
        <https://1145.am/db/2536960/Eli_Lilly>,
        <https://1145.am/db/2537335/Eli_Lilly_And_Company>,
        <https://1145.am/db/2537665/Eli_Lilly>,
        <https://1145.am/db/2537666/Eli_Lilly>,
        <https://1145.am/db/2537817/Eli_Lilly_And_Company>,
        <https://1145.am/db/2537826/Eli_Lilly_And_Company>,
        <https://1145.am/db/2539012/Boehringer_Ingelheim>,
        <https://1145.am/db/2539287/Eli_Lilly>,
        <https://1145.am/db/2539970/Eli_Lilly>,
        <https://1145.am/db/2540249/Boehringer_Ingelheim>,
        <https://1145.am/db/2541725/Boehringer_Ingelheim>,
        <https://1145.am/db/2543185/Eli_Lilly>,
        <https://1145.am/db/2545618/Eli_Lilly>,
        <https://1145.am/db/2546160/Boehringer_Ingelheim>,
        <https://1145.am/db/2546781/Boehringer_Ingelheim>,
        <https://1145.am/db/2547189/Boehringer_Ingelheim>,
        <https://1145.am/db/2549450/Eli_Lilly>,
        <https://1145.am/db/2550996/Eli_Lilly>,
        <https://1145.am/db/2551049/Eli_Lilly>,
        <https://1145.am/db/2551101/Eli_Lilly>,
        <https://1145.am/db/2553131/Boehringer_Ingelheim>,
        <https://1145.am/db/2553131/Eli_Lilly>,
        <https://1145.am/db/2553551/Eli_Lilly>,
        <https://1145.am/db/2553750/Boehringer_Ingelheim>,
        <https://1145.am/db/2554242/Boehringer_Ingelheim>,
        <https://1145.am/db/2554535/Boehringer_Ingelheim>,
        <https://1145.am/db/2555393/Boehringer_Ingelheim>,
        <https://1145.am/db/2555921/Boehringer_Ingelheim_Group_Of_Companies>,
        <https://1145.am/db/2555925/Boehringer_Ingelheim_Plant>,
        <https://1145.am/db/2556906/Eli_Lilly_And_Company>,
        <https://1145.am/db/2556969/Eli_Lilly>,
        <https://1145.am/db/2557861/Boehringer_Ingelheim>,
        <https://1145.am/db/2558025/Boehringer_Ingelheim>,
        <https://1145.am/db/2558026/Boehringer_Ingelheim>,
        <https://1145.am/db/2559125/Eli_Lilly_And_Company>,
        <https://1145.am/db/2560253/Boehringer_Ingelheim>,
        <https://1145.am/db/2560487/Eli_Lilly>,
        <https://1145.am/db/2560865/Boehringer_Ingelheim>,
        <https://1145.am/db/2561357/Eli_Lilly>,
        <https://1145.am/db/2561960/Eli_Lilly>,
        <https://1145.am/db/2562442/Eli_Lilly>,
        <https://1145.am/db/2562576/Eli_Lilly>,
        <https://1145.am/db/2564389/Eli_Lilly___Co>,
        <https://1145.am/db/2566845/Lilly>,
        <https://1145.am/db/2567343/Eli_Lilly>,
        <https://1145.am/db/2567800/Boehringer_Ingelheim>,
        <https://1145.am/db/2569425/Boehringer_Ingelheim>,
        <https://1145.am/db/2569829/Eli_Lilly>,
        <https://1145.am/db/2571316/Boehringer_Ingelheim>,
        <https://1145.am/db/2571525/Boehringer_Ingelheim>,
        <https://1145.am/db/2572312/Eli_Lilly_And_Company>,
        <https://1145.am/db/2572711/Eli_Lilly_And_Company>,
        <https://1145.am/db/2572711/Lilly>,
        <https://1145.am/db/2572957/Eli_Lilly_And_Company>,
        <https://1145.am/db/2573259/Boehringer_Ingelheim>,
        <https://1145.am/db/2573885/Eli_Lilly>,
        <https://1145.am/db/2574421/Boehringer_Ingelheim_Group_Of_Companies>,
        <https://1145.am/db/2575554/Eli_Lilly_And_Company>,
        <https://1145.am/db/2575575/Boehringer_Ingelheim>,
        <https://1145.am/db/2575909/Eli_Lilly>,
        <https://1145.am/db/2575972/Eli_Lilly>,
        <https://1145.am/db/2576086/Eli_Lilly>,
        <https://1145.am/db/2576171/Eli_Lilly_And_Company>,
        <https://1145.am/db/2576460/Eli_Lilly_And_Company>,
        <https://1145.am/db/2576462/Eli_Lilly_And_Company>,
        <https://1145.am/db/2576892/Eli_Lilly>,
        <https://1145.am/db/2576933/Eli_Lilly>,
        <https://1145.am/db/2576944/Eli_Lilly>,
        <https://1145.am/db/2577171/Eli_Lilly_And_Company>,
        <https://1145.am/db/2578048/Eli_Lilly_And_Company>,
        <https://1145.am/db/2578603/Eli_Lilly>,
        <https://1145.am/db/2578745/Boehringer_Ingelheim>,
        <https://1145.am/db/2578827/Boehringer>,
        <https://1145.am/db/2578874/Eli_Lilly>,
        <https://1145.am/db/2578876/Eli_Lilly_And_Company>,
        <https://1145.am/db/2580383/Boehringer_Ingelheim>,
        <https://1145.am/db/2581257/Eli_Lilly_And_Company>,
        <https://1145.am/db/2581309/Boehringer_Ingelheim>,
        <https://1145.am/db/2581745/Eli_Lilly_And_Company>,
        <https://1145.am/db/2582681/Boehringer_Ingelheim>,
        <https://1145.am/db/2583703/Eli_Lilly>,
        <https://1145.am/db/2584135/Eli_Lilly>,
        <https://1145.am/db/2584766/Eli_Lilly_And_Company>,
        <https://1145.am/db/2585710/Eli_Lilly>,
        <https://1145.am/db/2586025/Lilly>,
        <https://1145.am/db/2586687/Eli_Lilly_And_Company>,
        <https://1145.am/db/2587099/Boehringer>,
        <https://1145.am/db/2587104/Boehringer_Ingelheim_Plant>,
        <https://1145.am/db/2587215/Eli_Lilly_And_Company>,
        <https://1145.am/db/2587605/Elanco>,
        <https://1145.am/db/2587605/Eli_Lilly>,
        <https://1145.am/db/2587690/Eli_Lilly_And_Company>,
        <https://1145.am/db/2587699/Eli_Lilly_And_Company>,
        <https://1145.am/db/2587853/Eli_Lilly_And_Company>,
        <https://1145.am/db/2589156/Eli_Lilly_And_Company>,
        <https://1145.am/db/2589535/Eli_Lilly>,
        <https://1145.am/db/2589700/Eli_Lilly>,
        <https://1145.am/db/2590071/Eli_Lilly_And_Company>,
        <https://1145.am/db/2590486/Eli_Lilly>,
        <https://1145.am/db/2590739/Boehringer_Ingelheim>,
        <https://1145.am/db/2590997/Eli_Lilly_And_Company>,
        <https://1145.am/db/2591001/Eli_Lilly>,
        <https://1145.am/db/2591708/Eli_Lilly_And_Company>,
        <https://1145.am/db/2592790/Boehringer_Ingelheim_Usa_Corporation>,
        <https://1145.am/db/2592924/Boehringer_Ingelheim>,
        <https://1145.am/db/2593232/Boehringer_Ingelheim>,
        <https://1145.am/db/2593463/Boehringer_Ingelheim>,
        <https://1145.am/db/2593780/Eli_Lilly>,
        <https://1145.am/db/2594262/Boehringer_Ingelheim>,
        <https://1145.am/db/2594485/Eli_Lilly_And_Company>,
        <https://1145.am/db/2594494/Eli_Lilly_And_Company>,
        <https://1145.am/db/2595226/Boehringer_Ingelheim>,
        <https://1145.am/db/2596644/Eli_Lilly_And_Company>,
        <https://1145.am/db/2597644/Eli_Lilly_And_Company>,
        <https://1145.am/db/2597855/Eli_Lilly_And_Company>,
        <https://1145.am/db/2598317/Eli_Lilly>,
        <https://1145.am/db/264619/Eli_Lilly_And_Co>,
        <https://1145.am/db/385093/Boehringer_Ingelheim>,
        <https://1145.am/db/461671/Eli_Lilly_And_Company>,
        <https://1145.am/db/768105/Eli_Lilly>,
        <https://1145.am/db/86786/Eli_Lilly_And_Co> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2580140/Ipo_Teva_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "ipo" ;
    ns1:documentDate "2012-06-15T02:41:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Teva ($ TEVA) has introduced into the U.K., (Oroeze) Benzydamine 0.15 % w/v Oromucosal spray, an analgesic used in tonsillectomies or dental surgery." ;
    ns1:documentTitle "Valeant nabs OraPharma; GSK get MenHibrix OK'd; Trajenta into India;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/valeant-nabs-orapharma-gsk-get-menhibrix-ok-d-trajenta-into-india> ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2580140/Orapharma> a org:Organization ;
    ns1:basedInLowRaw "Canadian" ;
    ns1:description "oral health" ;
    ns1:documentDate "2012-06-15T02:41:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Valeant nabs OraPharma; GSK get MenHibrix OK'd; Trajenta into India;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/valeant-nabs-orapharma-gsk-get-menhibrix-ok-d-trajenta-into-india> ;
    ns1:foundName "OraPharma" ;
    ns1:industry "drugmaker" ;
    ns1:name "OraPharma" ;
    ns1:sameAsHigh <https://1145.am/db/1764611/Odaia> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2580140/Valeant_Pharmaceuticals_International> a org:Organization ;
    ns1:basedInHighGeoName "Canada" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/6251999/about.rdf> ;
    ns1:basedInHighRaw "Canada" ;
    ns1:buyer <https://1145.am/db/2580140/Orapharma_Acquisition> ;
    ns1:description "drugmaker" ;
    ns1:documentDate "2012-06-15T02:41:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Valeant nabs OraPharma; GSK get MenHibrix OK'd; Trajenta into India;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/valeant-nabs-orapharma-gsk-get-menhibrix-ok-d-trajenta-into-india> ;
    ns1:foundName "Valeant Pharmaceuticals International," ;
    ns1:industry "drugmaker" ;
    ns1:name "Valeant Pharmaceuticals International" ;
    ns1:sameAsHigh <https://1145.am/db/2288428/Valeant>,
        <https://1145.am/db/2294967/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2295456/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2302002/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2302007/Valeant_Canada_Limited>,
        <https://1145.am/db/2302007/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2302826/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2305757/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2305758/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2306724/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2306813/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2308734/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2312215/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2312221/Valeant>,
        <https://1145.am/db/2313272/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2313282/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2313320/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2313365/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2315100/Valeant>,
        <https://1145.am/db/2318350/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2318405/Valeant>,
        <https://1145.am/db/2319331/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2319722/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2322159/Valeant>,
        <https://1145.am/db/2322776/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2323106/Valeant>,
        <https://1145.am/db/2323111/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2324422/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2325692/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2325895/Valeant>,
        <https://1145.am/db/2330074/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2332074/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2335641/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2336083/Valeant>,
        <https://1145.am/db/2336258/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2336278/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2337634/Valeant>,
        <https://1145.am/db/2341518/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2346832/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2346833/Valeant_Canada_Limited>,
        <https://1145.am/db/2346833/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2348864/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2349239/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2349461/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2350907/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2353646/Valeant>,
        <https://1145.am/db/2354801/Valeant>,
        <https://1145.am/db/2354804/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2356945/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2357416/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2360703/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2361172/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2361190/Valeant>,
        <https://1145.am/db/2362893/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2362898/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2362898/Valeant_Pharmaceuticals_North_America_Llc>,
        <https://1145.am/db/2363430/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2365199/Valeant>,
        <https://1145.am/db/2365200/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2366467/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2366468/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2367825/Valeant>,
        <https://1145.am/db/2369037/Valeant>,
        <https://1145.am/db/2369371/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2369374/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2369618/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2538017/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2539802/Valeant>,
        <https://1145.am/db/2540219/Valeant>,
        <https://1145.am/db/2540467/Valeant>,
        <https://1145.am/db/2543893/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2543904/Valeant>,
        <https://1145.am/db/2544888/Valeant>,
        <https://1145.am/db/2545075/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2550867/Valeant>,
        <https://1145.am/db/2556458/Valeant>,
        <https://1145.am/db/2556718/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2556805/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2557472/Valeant>,
        <https://1145.am/db/2560716/Valeant>,
        <https://1145.am/db/2560770/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2566037/Valeant>,
        <https://1145.am/db/2568778/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2568799/Valeant_Canada>,
        <https://1145.am/db/2568808/Valeant_Canada>,
        <https://1145.am/db/2569148/Valeant>,
        <https://1145.am/db/2569149/Valeant>,
        <https://1145.am/db/2570033/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2570121/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2570390/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2571019/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2571068/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2572086/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2572449/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2572450/Valeant>,
        <https://1145.am/db/2572552/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2572553/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2572568/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2572605/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2572612/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2572932/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2573147/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2573199/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2573880/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2574433/Valeant>,
        <https://1145.am/db/2575134/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2575289/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2575552/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2575615/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2575800/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2576039/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2576047/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2576205/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2576478/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2576482/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2576956/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2576962/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2577145/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2577419/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2577770/Valeant>,
        <https://1145.am/db/2577771/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2577774/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2577775/Valeant>,
        <https://1145.am/db/2577846/Valeant>,
        <https://1145.am/db/2577958/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2578188/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2578333/Valeant_Canada>,
        <https://1145.am/db/2578700/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2579147/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2580042/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2580047/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2580122/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2580774/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2580775/Valeant>,
        <https://1145.am/db/2580831/Valeant>,
        <https://1145.am/db/2581225/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2582260/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2582935/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2583270/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2583732/Valeant>,
        <https://1145.am/db/2583843/Valeant_Pharmaceuticals_North_America>,
        <https://1145.am/db/2584209/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2584216/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2584226/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2584644/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2584750/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2584818/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2585746/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2586657/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2586658/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2587640/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2588178/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2589040/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2589223/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2589781/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2590589/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2591690/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2592575/And_Valeant>,
        <https://1145.am/db/2593443/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2593831/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594087/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594236/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594249/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594252/Valeant>,
        <https://1145.am/db/2594253/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2594281/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594413/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594414/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2594557/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2594858/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2595025/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2595150/Valeant>,
        <https://1145.am/db/2595287/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2595706/Valeant>,
        <https://1145.am/db/2595853/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2595929/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2596290/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2596891/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2597119/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597158/Valeant>,
        <https://1145.am/db/2597223/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597433/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597433/Valeant_Pharmaceuticals_North_America_Llc>,
        <https://1145.am/db/2597542/Valeant_Pharmaceuticals_International_Inc>,
        <https://1145.am/db/2597746/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2597769/Valeant>,
        <https://1145.am/db/2598012/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2598032/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2598205/Valeant>,
        <https://1145.am/db/2598261/Valeant_Pharmaceuticals>,
        <https://1145.am/db/2598266/Valeant_Pharmaceuticals_International>,
        <https://1145.am/db/2598558/Valeant_Pharmaceuticals_International> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2588906/Business_Acquisition_Stemgent_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-08-01T13:06:56+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Stemgent Completes Acquisition of Asterand's Human Tissue Business.",
        "Stemgent, Inc. announced today that it has completed the acquisition of Asterand Plc's Human Tissue Business for $ 9 million." ;
    ns1:documentTitle "Stemgent Completes Acquisition of Asterand's Human Tissue Business" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/stemgent-completes-acquisition-asterand-s-human-tissue-business> ;
    ns1:foundName "Acquisition",
        "acquisition" ;
    ns1:name "Acquisition",
        "acquisition" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:targetDetails "Business" ;
    ns1:valueRaw "$ 9 million" ;
    ns1:vendor <https://1145.am/db/2588906/Stemgent> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2595063/Discovery_Science_And_Neotope_Biosciences_Divestment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "divestment",
        "ipo" ;
    ns1:documentDate "2012-08-13T13:08:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders.",
        "Elan Corporation, plc (NYSE: ELN) announced today that its Board of Directors has approved the spin-off of the discovery science and Neotope Biosciences from the company." ;
    ns1:documentTitle "Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/elan-announces-plan-to-spin-off-discovery-science-and-neotope-biosciences-to-shareholders> ;
    ns1:foundName "Spin-Off",
        "spin-off" ;
    ns1:name "Spin-Off",
        "spin-off" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2595063/Discovery_Science_And_Neotope_Biosciences> ;
    ns1:targetName "Discovery Science And Neotope Biosciences",
        "Neotope Biosciences" ;
    ns1:vendor <https://1145.am/db/2595063/Discovery_Science_And_Neotope_Biosciences> .

<https://1145.am/db/2595063/Elan_Corporation> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "investment" ;
    ns1:documentDate "2012-08-13T13:08:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/elan-announces-plan-to-spin-off-discovery-science-and-neotope-biosciences-to-shareholders> ;
    ns1:foundName "Elan Corporation, plc" ;
    ns1:name "Elan Corporation" ;
    ns1:protagonist <https://1145.am/db/2595063/Discovery_Science_And_Neotope_Biosciences_Divestment> ;
    ns1:sameAsHigh <https://1145.am/db/1045846/Amplo>,
        <https://1145.am/db/1173960/Amplo>,
        <https://1145.am/db/1740799/Ecapital>,
        <https://1145.am/db/1746151/Elron>,
        <https://1145.am/db/2346467/Elan_Corporation>,
        <https://1145.am/db/557636/Elad_Gil> ;
    ns1:sameAsMedium <https://1145.am/db/2249118/Elan_Corporation>,
        <https://1145.am/db/2268635/Elan_Corporation>,
        <https://1145.am/db/2308845/Elan>,
        <https://1145.am/db/2308886/Elan>,
        <https://1145.am/db/2308890/Elan_Corporation>,
        <https://1145.am/db/2309137/Elan>,
        <https://1145.am/db/2309970/Elan>,
        <https://1145.am/db/2319399/Elan>,
        <https://1145.am/db/2327327/Elan>,
        <https://1145.am/db/2331746/Elan_Corporation>,
        <https://1145.am/db/2332005/Elan_Corporation>,
        <https://1145.am/db/2335881/Elan>,
        <https://1145.am/db/2335887/Elan>,
        <https://1145.am/db/2336358/Elan>,
        <https://1145.am/db/2336983/Elan>,
        <https://1145.am/db/2339086/Elan_Corporation>,
        <https://1145.am/db/2339096/Elan_Corporation>,
        <https://1145.am/db/2339950/Elan_Corporation>,
        <https://1145.am/db/2340188/Elan>,
        <https://1145.am/db/2340189/Elan_Corporation>,
        <https://1145.am/db/2341772/Elan_Corporation>,
        <https://1145.am/db/2342686/Elan_Corporation>,
        <https://1145.am/db/2343835/Elan>,
        <https://1145.am/db/2345479/Elan_Corporation>,
        <https://1145.am/db/2345992/Elan_Corporation>,
        <https://1145.am/db/2345999/Elan>,
        <https://1145.am/db/2346795/Elan_Corporation>,
        <https://1145.am/db/2346976/Elan_Corporation>,
        <https://1145.am/db/2347453/Elan_Corporation>,
        <https://1145.am/db/2348227/Elan_Corporation>,
        <https://1145.am/db/2349078/Elan_Corporation>,
        <https://1145.am/db/2350115/Elan>,
        <https://1145.am/db/2350116/Elan_Corporation>,
        <https://1145.am/db/2350550/Elan_Corporation>,
        <https://1145.am/db/2351144/Elan>,
        <https://1145.am/db/2351145/Elan_Corporation>,
        <https://1145.am/db/2358431/Elan>,
        <https://1145.am/db/2359529/Elan>,
        <https://1145.am/db/2359600/Elan_Corporation>,
        <https://1145.am/db/2359604/Elan_Corporation>,
        <https://1145.am/db/2360786/Elan_Corporation>,
        <https://1145.am/db/2363656/Elan_Corporation>,
        <https://1145.am/db/2364580/Elan_Corporation>,
        <https://1145.am/db/2364583/Elan>,
        <https://1145.am/db/2364612/Elan_Corporation>,
        <https://1145.am/db/2366961/Elan_Corporation>,
        <https://1145.am/db/2367151/Elan_Corporation>,
        <https://1145.am/db/2537542/Elan>,
        <https://1145.am/db/2554897/Elan>,
        <https://1145.am/db/2560865/Elan>,
        <https://1145.am/db/2573572/Elan>,
        <https://1145.am/db/2575100/Elan_Corporation>,
        <https://1145.am/db/2576104/Elan>,
        <https://1145.am/db/2576144/Elan>,
        <https://1145.am/db/2577010/Elan_Corporation>,
        <https://1145.am/db/2577059/Elan_Corporation>,
        <https://1145.am/db/2580122/Elan>,
        <https://1145.am/db/2583839/Elan>,
        <https://1145.am/db/2584383/Elan>,
        <https://1145.am/db/2584834/Elan>,
        <https://1145.am/db/2584909/Elan>,
        <https://1145.am/db/2585770/Elan>,
        <https://1145.am/db/2586703/Elan>,
        <https://1145.am/db/2589750/Elan>,
        <https://1145.am/db/2590594/Elan>,
        <https://1145.am/db/2590596/Elan_Corporation>,
        <https://1145.am/db/2592543/Elan>,
        <https://1145.am/db/2593465/Elan>,
        <https://1145.am/db/2597331/Elan_Corporation> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2651427/Yammer> a org:Organization ;
    ns1:documentDate "2012-06-26T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Webwire: ITC examines Apple ruling; Microsoft goes social" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/webwire-itc-examines-apple-ruling-microsoft-goes-social> ;
    ns1:foundName "Yammer" ;
    ns1:industry "social network" ;
    ns1:name "Yammer" ;
    ns1:sameAsHigh <https://1145.am/db/1824780/Yammer>,
        <https://1145.am/db/1828648/Yammer>,
        <https://1145.am/db/1834475/Yammer>,
        <https://1145.am/db/1842562/Yammer>,
        <https://1145.am/db/1871784/Yammer>,
        <https://1145.am/db/1893978/Yammer>,
        <https://1145.am/db/2602863/Yammer> ;
    ns1:sameAsMedium <https://1145.am/db/1709371/Yammer>,
        <https://1145.am/db/1827862/Yammer>,
        <https://1145.am/db/1852048/Yammer>,
        <https://1145.am/db/1856090/Yammer>,
        <https://1145.am/db/1874060/Yammer>,
        <https://1145.am/db/1887240/Yammer>,
        <https://1145.am/db/2602130/Yammer> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2651427/Yammer_Joint_Venture> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "joint venture" ;
    ns1:documentDate "2012-06-26T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Microsoft will pay $ 1.2 billion (€959 million) to acquire in-company social network Yammer, which currently has around five million users." ;
    ns1:documentTitle "Webwire: ITC examines Apple ruling; Microsoft goes social" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/webwire-itc-examines-apple-ruling-microsoft-goes-social> ;
    ns1:foundName "acquire" ;
    ns1:name "acquire" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2651427/Yammer> ;
    ns1:targetName "Yammer" ;
    ns1:valueRaw "$ 1.2 billion",
        "€959 million" .

<https://1145.am/db/2653242/Bulgarian_Telecommunications_Company_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-08-08T09:57:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Two banks have reached agreement on the acquisition of Bulgarian fixed and mobile operator Vivacom, quashing any hopes that Turkcell and Telekom Austria may have had of buying the former Bulgarian Telecommunications Company (BTC)." ;
    ns1:documentTitle "Banks agree to buy Bulgaria's Vivacom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/banks-agree-to-buy-bulgaria-s-vivacom> ;
    ns1:foundName "buying" ;
    ns1:name "buying" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "stopped" ;
    ns1:target <https://1145.am/db/2653242/Bulgarian_Telecommunications_Company> ;
    ns1:targetName "Bulgarian Telecommunications Company" ;
    ns1:whereRaw "Bulgarian" .

<https://1145.am/db/2653242/Turkcell_And_Telekom_Austria> a org:Organization ;
    ns1:basedInLowRaw "Austria" ;
    ns1:description "Bulgarian fixed and mobile operator" ;
    ns1:documentDate "2012-08-08T09:57:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Banks agree to buy Bulgaria's Vivacom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/banks-agree-to-buy-bulgaria-s-vivacom> ;
    ns1:foundName "Turkcell and Telekom Austria" ;
    ns1:industry "Telecommunications" ;
    ns1:investor <https://1145.am/db/2653242/Bulgarian_Telecommunications_Company_Investment>,
        <https://1145.am/db/2653242/Vivacom_Acquisition> ;
    ns1:name "Turkcell and Telekom Austria" ;
    ns1:sameAsHigh <https://1145.am/db/2653242/Bulgarian_Telecommunications_Company> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2653242/Vivacom> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Bulgaria" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/732800/about.rdf> ;
    ns1:basedInHighRaw "Bulgaria" ;
    ns1:description "Bulgarian fixed and mobile operator" ;
    ns1:documentDate "2012-08-08T09:57:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Banks agree to buy Bulgaria's Vivacom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/banks-agree-to-buy-bulgaria-s-vivacom> ;
    ns1:foundName "Vivacom" ;
    ns1:industry "Telecommunications" ;
    ns1:name "Vivacom" ;
    ns1:sameAsHigh <https://1145.am/db/2605265/Vivacom>,
        <https://1145.am/db/2661617/Vivacom>,
        <https://1145.am/db/2665174/Vivacom>,
        <https://1145.am/db/2668091/Vivacom> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2671481/Investment_Jp_Morgan_Securities_Telenor_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-06T14:47:43+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Norwegian telco Telenor has boosted shareholding in VimpelCom after exercising an option on shares owned by JP Morgan Securities.",
        "The transaction will see Telenor acquiring 65 million VimpelCom shares from JP Morgan, and increase its shareholding to 35.66 per cent from 31.67 per cent earlier." ;
    ns1:documentTitle "Telenor boosts VimpelCom stake with $715M JP Morgan deal" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-boosts-vimpelcom-stake-715m-jp-morgan-deal> ;
    ns1:foundName "acquiring" ;
    ns1:name "acquiring" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2671481/Jp_Morgan_Securities>,
        <https://1145.am/db/2671481/Vimpelcom> ;
    ns1:targetName "VimpelCom" ;
    ns1:valueRaw "$ 715 million" ;
    ns1:whereGeoName "Russian Federation" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:whereRaw "Russia",
        "Russian" .

<https://1145.am/db/2671481/Jp_Morgan_Securities> a org:Organization ;
    ns1:basedInLowRaw "Norway" ;
    ns1:description "acquiring 65 million VimpelCom shares" ;
    ns1:documentDate "2012-04-06T14:47:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor boosts VimpelCom stake with $715M JP Morgan deal" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-boosts-vimpelcom-stake-715m-jp-morgan-deal> ;
    ns1:foundName "JP Morgan",
        "JP Morgan Securities" ;
    ns1:name "JP Morgan",
        "JP Morgan Securities" ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2672659/The_Federal_Antimonopoly_Service_Of_The_Russian_Federation> a org:Organization ;
    ns1:basedInHighGeoName "Russian Federation" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:basedInHighRaw "Russia" ;
    ns1:documentDate "2012-04-19T10:05:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor faces fresh fight for VimpelCom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-faces-fresh-fight-for-vimpelcom-0> ;
    ns1:foundName "The Federal Antimonopoly Service of the Russian Federation" ;
    ns1:name "The Federal Antimonopoly Service of the Russian Federation" ;
    ns1:participant <https://1145.am/db/2672659/Vimpelcom_Acquisition> ;
    ns1:sameAsMedium <https://1145.am/db/2672667/The_Federal_Antimonopoly_Service_Of_The_Russian_Federation> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2672659/Weather_Investments> a org:Organization ;
    ns1:basedInLowRaw "Russia" ;
    ns1:documentDate "2012-04-19T10:05:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor faces fresh fight for VimpelCom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-faces-fresh-fight-for-vimpelcom-0> ;
    ns1:foundName "Weather Investments" ;
    ns1:investor <https://1145.am/db/2672659/Vimpelcom_Acquisition> ;
    ns1:name "Weather Investments" ;
    ns1:sameAsMedium <https://1145.am/db/2651270/Weather_Investments>,
        <https://1145.am/db/2654657/Weather_Investments>,
        <https://1145.am/db/2662686/Weather_Investments_Ii>,
        <https://1145.am/db/2664571/Weather_Investments>,
        <https://1145.am/db/2672667/Weather_Investments> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2672667/The_Federal_Antimonopoly_Service_Of_The_Russian_Federation> a org:Organization ;
    ns1:basedInHighGeoName "Russian Federation" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:basedInHighRaw "Russia" ;
    ns1:documentDate "2012-04-19T10:26:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor faces fresh fight for VimpelCom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-faces-fresh-fight-for-vimpelcom> ;
    ns1:foundName "The Federal Antimonopoly Service of the Russian Federation" ;
    ns1:name "The Federal Antimonopoly Service of the Russian Federation" ;
    ns1:participant <https://1145.am/db/2672667/Vimpelcom_Acquisition> ;
    ns1:sameAsMedium <https://1145.am/db/2672659/The_Federal_Antimonopoly_Service_Of_The_Russian_Federation> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2672667/Weather_Investments> a org:Organization ;
    ns1:basedInLowRaw "Russia" ;
    ns1:documentDate "2012-04-19T10:26:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor faces fresh fight for VimpelCom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-faces-fresh-fight-for-vimpelcom> ;
    ns1:foundName "Weather Investments" ;
    ns1:investor <https://1145.am/db/2672667/Vimpelcom_Acquisition> ;
    ns1:name "Weather Investments" ;
    ns1:sameAsMedium <https://1145.am/db/2651270/Weather_Investments>,
        <https://1145.am/db/2654657/Weather_Investments>,
        <https://1145.am/db/2662686/Weather_Investments_Ii>,
        <https://1145.am/db/2664571/Weather_Investments>,
        <https://1145.am/db/2672659/Weather_Investments> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2678633/Wavion> a org:Organization ;
    ns1:basedInLowRaw "Israel" ;
    ns1:description "Wimax" ;
    ns1:documentDate "2012-05-30T08:25:36+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alvarion considers ditching Wimax" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/alvarion-considers-ditching-wimax> ;
    ns1:foundName "Wavion" ;
    ns1:industry "Wimax" ;
    ns1:name "Wavion" ;
    ns1:sameAsMedium <https://1145.am/db/2629904/Wavion> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2678633/Wavion_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "divestment" ;
    ns1:documentDate "2012-05-30T08:25:36+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Alvarion, one of the big names of the Wimax bubble, may exit that business, a move which would leave it focused for growth on its recent moves into carrier Wi-Fi with its Wavion acquisition." ;
    ns1:documentTitle "Alvarion considers ditching Wimax" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/alvarion-considers-ditching-wimax> ;
    ns1:foundName "acquisition",
        "exit" ;
    ns1:name "acquisition",
        "exit" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed",
        "stopped" ;
    ns1:target <https://1145.am/db/2678633/Wavion> ;
    ns1:targetName "Wavion" ;
    ns1:whereGeoName "State of Israel" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/294640/about.rdf> ;
    ns1:whereRaw "Israel" .

<https://1145.am/db/2681282/Acquisition_Cox_Communication_Verizon_Wireless_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-04-18T15:23:43+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Separately, Verizon said it will buy Cox Communication's 20 MHz of AWS spectrum covering 28 million POPs for $ 315 million." ;
    ns1:documentTitle "Verizon: We'll sell 700 MHz spectrum to get cable companies' AWS spectrum" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/verizon-we-ll-sell-700-mhz-spectrum-to-get-cable-companies-aws-spectrum> ;
    ns1:foundName "buy" ;
    ns1:name "buy" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:vendor <https://1145.am/db/2681282/Cox_Communication> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "USA" .

<https://1145.am/db/2681282/Acquisition_T-Mobile_Usa_Verizon_Wireless_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-04-18T15:23:43+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Verizon Wireless (NYSE: VZ) said it will sell all of its 700 MHz Lower A and B Block spectrum in exchange for getting regulatory approval to purchase AWS spectrum from a group of cable companies." ;
    ns1:documentTitle "Verizon: We'll sell 700 MHz spectrum to get cable companies' AWS spectrum" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/verizon-we-ll-sell-700-mhz-spectrum-to-get-cable-companies-aws-spectrum> ;
    ns1:foundName "sell" ;
    ns1:name "sell" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:vendor <https://1145.am/db/2681282/Verizon_Wireless> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "USA" .

<https://1145.am/db/2681282/Cox_Communication> a org:Organization ;
    ns1:documentDate "2012-04-18T15:23:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Verizon: We'll sell 700 MHz spectrum to get cable companies' AWS spectrum" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/verizon-we-ll-sell-700-mhz-spectrum-to-get-cable-companies-aws-spectrum> ;
    ns1:foundName "Cox Communication" ;
    ns1:name "Cox Communication" ;
    ns1:sameAsMedium <https://1145.am/db/2679352/Cox_Communication> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2176546/Nds_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-04-04T15:23:44+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> IHS Screen Digest said Cisco's recent purchase of NDS for $ 5 billion gives further support to the notion that the industry is shifting away from hardware set-top boxes toward a software - based system that can better support the deployment of constantly evolving multiscreen devices." ;
    ns1:documentTitle "James Murdoch steps down from BSkyB; Hulu Plus lands on Android tablets" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/james-murdoch-steps-down-from-bskyb-hulu-plus-lands-android-tablets> ;
    ns1:foundName "purchase" ;
    ns1:name "purchase" ;
    ns1:sourceName "StreamTV Insider" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2176546/NDS> ;
    ns1:targetName "NDS" ;
    ns1:valueRaw "$ 5 billion" ;
    ns1:whereGeoName "Republic of Singapore" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/1880251/about.rdf> ;
    ns1:whereRaw "Singapore" .

<https://1145.am/db/2178025/Affectiva> a org:Organization ;
    ns1:description "commercialize emotion technologies for online video content" ;
    ns1:documentDate "2012-08-08T14:37:37+00:00"^^xsd:dateTime ;
    ns1:documentTitle "HBO not talking with Netflix; Affectiva raises an 'emotional' $12 million" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/hbo-not-talking-netflix-affectiva-raises-emotional-12-million> ;
    ns1:foundName "Affectiva" ;
    ns1:investor <https://1145.am/db/2178025/Investment_Affectiva_Rtl_Television_Completed> ;
    ns1:name "Affectiva" ;
    ns1:sameAsMedium <https://1145.am/db/1738400/Affectiva>,
        <https://1145.am/db/1804784/Affectiva>,
        <https://1145.am/db/1848526/Affectiva>,
        <https://1145.am/db/1880330/Affectiva>,
        <https://1145.am/db/575753/Affectiva> ;
    ns1:sourceName "StreamTV Insider" .

<https://1145.am/db/2178025/Investment_Affectiva_Rtl_Television_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-08-08T14:37:37+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Affectiva, a company that plans to commercialize emotion technologies for online video content, said it's raised $ 112 million in financing." ;
    ns1:documentTitle "HBO not talking with Netflix; Affectiva raises an 'emotional' $12 million" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/hbo-not-talking-netflix-affectiva-raises-emotional-12-million> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "StreamTV Insider" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2178025/Affectiva> ;
    ns1:valueRaw "$ 112 million" ;
    ns1:whereRaw "Affectiva" .

<https://1145.am/db/2178025/Joint_Venture_Affectiva_Prosiebensat_1_Media_Ag_Rtl_Television_Stopped> a ns1:CorporateFinanceActivity ;
    ns1:activityType "joint venture" ;
    ns1:documentDate "2012-08-08T14:37:37+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Affectiva, a company that plans to commercialize emotion technologies for online video content, said it's raised $ 112 million in financing." ;
    ns1:documentTitle "HBO not talking with Netflix; Affectiva raises an 'emotional' $12 million" ;
    ns1:documentURL <https://www.streamtvinsider.com/online-video/hbo-not-talking-netflix-affectiva-raises-emotional-12-million> ;
    ns1:foundName "launch" ;
    ns1:name "launch" ;
    ns1:sourceName "StreamTV Insider" ;
    ns1:status "stopped" ;
    ns1:valueRaw "$ 112 million" ;
    ns1:vendor <https://1145.am/db/2178025/Affectiva> ;
    ns1:whereRaw "Affectiva" .

<https://1145.am/db/2224478/Castlight_Health> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:description "health care" ;
    ns1:documentDate "2012-05-01T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Castlight Health Secures $100 Million in Series D Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/castlight-health-secures-100-million-series-d-funding> ;
    ns1:foundName "Castlight Health" ;
    ns1:industry "health care" ;
    ns1:name "Castlight Health" ;
    ns1:sameAsHigh <https://1145.am/db/2201576/Castlight_Health>,
        <https://1145.am/db/2236068/Castlight_Health>,
        <https://1145.am/db/678578/Castlight_Health>,
        <https://1145.am/db/736831/Castlight_Health>,
        <https://1145.am/db/740882/Castlight_Health>,
        <https://1145.am/db/740904/Castlight_Health>,
        <https://1145.am/db/867627/Castlight_Health>,
        <https://1145.am/db/871611/Castlight_Health> ;
    ns1:sameAsMedium <https://1145.am/db/2185708/Castlight_Health>,
        <https://1145.am/db/2187089/Castlight_Health>,
        <https://1145.am/db/2211510/Castlight_Health> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2224478/Investment_Castlight_Health_Redmile_Group_T_Rowe_Price_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-01T13:15:02+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN FRANCISCO- (BUSINESS WIRE) - Castlight Health, the leading provider of health care transparency solutions, today announced it has secured $ 100 million in Series D funding.",
        "The round brings Castlight Health's total funding to $ 181 million and includes participation from two major unnamed mutual funds, as well as T. Rowe Price, Redmile Group and previous investors." ;
    ns1:documentTitle "Castlight Health Secures $100 Million in Series D Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/it/castlight-health-secures-100-million-series-d-funding> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2224478/Castlight_Health> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 100 million",
        "$ 181 million" ;
    ns1:whereGeoName "San Francisco" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:whereRaw "SAN FRANCISCO" .

<https://1145.am/db/2236068/Castlight_Health> a org:Organization ;
    ns1:basedInHighGeoName "San Francisco" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:basedInHighRaw "SAN FRANCISCO" ;
    ns1:description "health care" ;
    ns1:documentDate "2012-05-01T13:13:10+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Castlight Health Secures $100 Million in Series D Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/castlight-health-secures-100-million-series-d-funding> ;
    ns1:foundName "Castlight Health" ;
    ns1:industry "health care" ;
    ns1:name "Castlight Health" ;
    ns1:sameAsHigh <https://1145.am/db/2201576/Castlight_Health>,
        <https://1145.am/db/2224478/Castlight_Health>,
        <https://1145.am/db/678578/Castlight_Health>,
        <https://1145.am/db/736831/Castlight_Health>,
        <https://1145.am/db/740882/Castlight_Health>,
        <https://1145.am/db/740904/Castlight_Health>,
        <https://1145.am/db/867627/Castlight_Health>,
        <https://1145.am/db/871611/Castlight_Health> ;
    ns1:sameAsMedium <https://1145.am/db/2185708/Castlight_Health>,
        <https://1145.am/db/2187089/Castlight_Health>,
        <https://1145.am/db/2211510/Castlight_Health> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2236068/Investment_Castlight_Health_Redmile_Group_T_Rowe_Price_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-01T13:13:10+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN FRANCISCO- (BUSINESS WIRE) - Castlight Health, the leading provider of health care transparency solutions, today announced it has secured $ 100 million in Series D funding.",
        "The round brings Castlight Health's total funding to $ 181 million and includes participation from two major unnamed mutual funds, as well as T. Rowe Price, Redmile Group and previous investors." ;
    ns1:documentTitle "Castlight Health Secures $100 Million in Series D Funding" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/castlight-health-secures-100-million-series-d-funding> ;
    ns1:foundName "funding" ;
    ns1:name "funding" ;
    ns1:sourceName "Fierce Healthcare" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2236068/Castlight_Health> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 100 million",
        "$ 181 million" ;
    ns1:whereGeoName "San Francisco" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:whereRaw "SAN FRANCISCO" .

<https://1145.am/db/2243235/Aerial_Biopharma> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-07-20T01:10:25+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Rex Health Ventures Announces Inaugural Investment in N.C. Firm, Aerial BioPharma" ;
    ns1:documentURL <https://www.fiercehealthcare.com/healthcare/rex-health-ventures-announces-inaugural-investment-n-c-firm-aerial-biopharma> ;
    ns1:foundName "Aerial BioPharma",
        "N.C. Firm, Aerial BioPharma" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Aerial BioPharma" ;
    ns1:sameAsHigh <https://1145.am/db/2338286/Aerial_Biopharma>,
        <https://1145.am/db/2344820/Aerial_Biopharma>,
        <https://1145.am/db/2344821/Tiny_Aerial_Biopharma>,
        <https://1145.am/db/2366403/Aerial_Biopharma> ;
    ns1:sourceName "Fierce Healthcare" .

<https://1145.am/db/2287956/Illumina_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2012-06-22T15:17:51+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Roche ($ RHHBY) , for its part, has moved on from its failed bid for Illumina ($ ILMN) by redoubling its in-house Dx efforts, committing $ 300 million to expand its Indiana diagnostics headquarters." ;
    ns1:documentTitle "Agilent closes $2.2B Dako deal" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/agilent-closes-2-2b-dako-deal> ;
    ns1:foundName "bid",
        "committing" ;
    ns1:name "bid",
        "committing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "stopped" ;
    ns1:target <https://1145.am/db/2287956/Illumina> ;
    ns1:targetName "Illumina" ;
    ns1:valueRaw "$ 300 million" ;
    ns1:whereGeoName "Indiana" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4921868/about.rdf> ;
    ns1:whereRaw "Indiana" .

<https://1145.am/db/2287956/Investment_Genomic_Health_Qiagen_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-22T15:17:51+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Genomic Health and OncoMed Pharmaceuticals have teamed up to develop treatment-specific tests, and Qiagen ($ QGEN) has posted a positive first quarter on the heels of its acquisitions in the companion diagnostics field." ;
    ns1:documentTitle "Agilent closes $2.2B Dako deal" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/agilent-closes-2-2b-dako-deal> ;
    ns1:foundName "acquisitions" ;
    ns1:name "acquisitions" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" .

<https://1145.am/db/2297119/Zoll_Medical_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2012-03-12T11:53:08+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Japan's Asahi Kasei and Zoll Medical ($ ZOLL) have inked a definitive merger agreement through which the former will buy the Chelmsford, MA - based company for $ 2.2 billion." ;
    ns1:documentTitle "Asahi Kasei scoops up Zoll for $2.2B, reflecting Japanese companies' hunger for growth" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/asahi-kasei-scoops-up-zoll-for-2-2b-reflecting-japanese-companies-hunger-for-growth> ;
    ns1:foundName "buy",
        "merger" ;
    ns1:name "buy",
        "merger" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2297119/Zoll_Medical> ;
    ns1:targetName "Zoll" ;
    ns1:valueRaw "$ 2.2 billion" ;
    ns1:whereGeoName "Chelmsford" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4932869/about.rdf> ;
    ns1:whereRaw "Chelmsford, MA" .

<https://1145.am/db/2297604/Molecularmd> a org:Organization ;
    ns1:description "genetic sequencing" ;
    ns1:documentDate "2012-04-02T14:10:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "2 molecular diagnostics companies grab major money" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/2-molecular-diagnostics-companies-grab-major-money> ;
    ns1:foundName "MolecularMD",
        "MolecularMD, of Portland" ;
    ns1:industry "Molecular diagnostics/genetic sequencing" ;
    ns1:name "MolecularMD" ;
    ns1:sameAsMedium <https://1145.am/db/2153692/Molecularmd> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2297604/Sv_Life_Sciences> a org:Organization ;
    ns1:basedInLowRaw "Cambridge, MA" ;
    ns1:description "Investing" ;
    ns1:documentDate "2012-04-02T14:10:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "2 molecular diagnostics companies grab major money" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/2-molecular-diagnostics-companies-grab-major-money> ;
    ns1:foundName "SV Life Sciences" ;
    ns1:investor <https://1145.am/db/2297604/Series_B_Investment_Good_Start_Genetics_Orbimed_Advisors_Sv_Life_Sciences_Safeguard_Scientifics_Completed> ;
    ns1:name "SV Life Sciences" ;
    ns1:sameAsHigh <https://1145.am/db/1386529/Vertis_Sgr>,
        <https://1145.am/db/2302994/Sv_Life_Sciences>,
        <https://1145.am/db/2302995/Sv_Life_Sciences>,
        <https://1145.am/db/2311540/Sv_Life_Sciences>,
        <https://1145.am/db/2313322/Sv_Life_Sciences>,
        <https://1145.am/db/2337166/Sv_Life_Sciences>,
        <https://1145.am/db/2338196/Sv_Life_Sciences>,
        <https://1145.am/db/2358272/Sv_Life_Sciences>,
        <https://1145.am/db/2368572/Sv_Life_Sciences> ;
    ns1:sameAsMedium <https://1145.am/db/2236188/Sv_Life_Sciences>,
        <https://1145.am/db/2246177/Sv_Life_Sciences>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2293765/Sv_Life_Sciences>,
        <https://1145.am/db/2297439/Sv_Life_Sciences>,
        <https://1145.am/db/2298869/Sv_Life_Sciences>,
        <https://1145.am/db/2300322/Sv_Life_Sciences>,
        <https://1145.am/db/2305587/Sv_Life_Sciences>,
        <https://1145.am/db/2310485/Sv_Life_Sciences>,
        <https://1145.am/db/2312831/Sv_Life_Sciences>,
        <https://1145.am/db/2312833/Sv_Life_Sciences>,
        <https://1145.am/db/2313287/Sv_Life_Sciences>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314625/Sv_Life_Sciences>,
        <https://1145.am/db/2316038/Sv_Life_Sciences>,
        <https://1145.am/db/2317635/Sv_Life_Sciences>,
        <https://1145.am/db/2319338/Sv_Life_Sciences>,
        <https://1145.am/db/2321713/Sv_Life_Sciences>,
        <https://1145.am/db/2321861/Sv_Life_Sciences>,
        <https://1145.am/db/2321870/Sv_Life_Sciences>,
        <https://1145.am/db/2327405/Sv_Life_Sciences>,
        <https://1145.am/db/2327677/Sv_Life_Sciences>,
        <https://1145.am/db/2328815/Sv_Life_Sciences>,
        <https://1145.am/db/2329550/Sv_Life_Sciences>,
        <https://1145.am/db/2336313/Sv_Life_Sciences>,
        <https://1145.am/db/2336890/Sv_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2339295/Sv_Life_Sciences>,
        <https://1145.am/db/2342260/Sv_Life_Sciences>,
        <https://1145.am/db/2342261/Sv_Life_Sciences>,
        <https://1145.am/db/2342266/Sv_Life_Sciences>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2342445/Sv_Life_Sciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343467/Sv_Life_Sciences>,
        <https://1145.am/db/2343722/Sv_Life_Sciences>,
        <https://1145.am/db/2343725/Sv_Life_Sciences>,
        <https://1145.am/db/2343737/Sv_Life_Sciences>,
        <https://1145.am/db/2346832/Sv_Life_Sciences>,
        <https://1145.am/db/2347389/Sv_Life_Sciences>,
        <https://1145.am/db/2349406/Sv_Life_Sciences>,
        <https://1145.am/db/2349426/Sv_Life_Sciences>,
        <https://1145.am/db/2350034/Sv_Life_Sciences>,
        <https://1145.am/db/2350720/Sv_Life_Sciences>,
        <https://1145.am/db/2351394/Sv_Life_Sciences>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2352383/Sv_Life_Sciences>,
        <https://1145.am/db/2353098/Sv_Life_Sciences>,
        <https://1145.am/db/2353439/Sv_Life_Sciences>,
        <https://1145.am/db/2355586/Sv_Life_Sciences>,
        <https://1145.am/db/2356861/Sv_Life_Sciences>,
        <https://1145.am/db/2356876/Sv_Life_Sciences>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2359125/Sv_Life_Sciences>,
        <https://1145.am/db/2360756/Sv_Life_Sciences>,
        <https://1145.am/db/2360758/Sv_Life_Sciences>,
        <https://1145.am/db/2361065/Sv_Life_Sciences>,
        <https://1145.am/db/2365315/Sv_Life_Sciences>,
        <https://1145.am/db/2366519/Sv_Life_Sciences>,
        <https://1145.am/db/2366860/Sv_Life_Sciences>,
        <https://1145.am/db/2368251/Sv_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335700/Delphi_Ventures> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:documentDate "2012-07-23T15:59:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $30 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-30-million-financing> ;
    ns1:foundName "Delphi Ventures" ;
    ns1:investor <https://1145.am/db/2335700/Investment_Celgene_Credit_Suisse_First_Boston_Equity_Partners_Delphi_Ventures_Hbm_Bioventures_Novo_A_S_Ptc_Therapeutics_Inc_The_Column_Group_Vulcan_Ventures_Completed> ;
    ns1:name "Delphi Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1124122/Delphi_Ventures>,
        <https://1145.am/db/1718690/Delphi_Ventures>,
        <https://1145.am/db/2290453/Delphi_Ventures>,
        <https://1145.am/db/2291818/Delphi_Ventures>,
        <https://1145.am/db/2292554/Delphi_Ventures>,
        <https://1145.am/db/2294721/Delphi_Ventures>,
        <https://1145.am/db/2299776/Delphi_Ventures>,
        <https://1145.am/db/2300293/Delphi_Ventures>,
        <https://1145.am/db/2300306/Delphi_Ventures>,
        <https://1145.am/db/2300455/Delphi_Ventures>,
        <https://1145.am/db/2302333/Delphi_Ventures>,
        <https://1145.am/db/2304340/Delphi_Ventures>,
        <https://1145.am/db/2306568/Delphi_Ventures>,
        <https://1145.am/db/2308063/Delphi_Ventures>,
        <https://1145.am/db/2310285/Delphi_Ventures>,
        <https://1145.am/db/2317467/Delphi_Ventures>,
        <https://1145.am/db/2317919/Delphi_Ventures>,
        <https://1145.am/db/2319874/Delphi_Ventures>,
        <https://1145.am/db/2326571/Delphi_Ventures>,
        <https://1145.am/db/2333495/Delphi_Ventures>,
        <https://1145.am/db/2333504/Delphi_Ventures>,
        <https://1145.am/db/2343206/Delphi_Ventures>,
        <https://1145.am/db/2352508/Delphi_Ventures>,
        <https://1145.am/db/2359510/Delphi_Ventures>,
        <https://1145.am/db/2360174/Delphi_Ventures>,
        <https://1145.am/db/2362553/Delphi_Ventures>,
        <https://1145.am/db/2365679/Delphi_Ventures>,
        <https://1145.am/db/2367204/Delphi_Ventures>,
        <https://1145.am/db/2443170/Delphi_Ventures>,
        <https://1145.am/db/2575044/Delphi_Ventures>,
        <https://1145.am/db/2584056/Delphi_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2335700/Novo_A_S> a org:Organization ;
    ns1:basedInLowRaw "N.J" ;
    ns1:documentDate "2012-07-23T15:59:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PTC Therapeutics Closes $30 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-30-million-financing> ;
    ns1:foundName "Novo A/S" ;
    ns1:investor <https://1145.am/db/2335700/Investment_Celgene_Credit_Suisse_First_Boston_Equity_Partners_Delphi_Ventures_Hbm_Bioventures_Novo_A_S_Ptc_Therapeutics_Inc_The_Column_Group_Vulcan_Ventures_Completed> ;
    ns1:name "Novo A/S" ;
    ns1:sameAsMedium <https://1145.am/db/1753148/Novo>,
        <https://1145.am/db/1754034/Novo>,
        <https://1145.am/db/2288016/Novo_A_S>,
        <https://1145.am/db/2296606/Novo_A_S>,
        <https://1145.am/db/2298077/Novo_A_S>,
        <https://1145.am/db/2298277/Novo_A_S>,
        <https://1145.am/db/2299423/Novo_As>,
        <https://1145.am/db/2299645/Novo>,
        <https://1145.am/db/2300653/Novo_A_S>,
        <https://1145.am/db/2301290/Novo>,
        <https://1145.am/db/2301494/Novo_A_S>,
        <https://1145.am/db/2302994/Novo_A_S>,
        <https://1145.am/db/2302995/Novo_A_S>,
        <https://1145.am/db/2303767/Novo_A_S>,
        <https://1145.am/db/2304335/Novo_A_S>,
        <https://1145.am/db/2304340/Novo_A_S>,
        <https://1145.am/db/2308758/Novo_A_S>,
        <https://1145.am/db/2309506/Novo_A_S>,
        <https://1145.am/db/2309507/Novo_A_S>,
        <https://1145.am/db/2311133/Novo_A_S>,
        <https://1145.am/db/2311274/Novo>,
        <https://1145.am/db/2312120/Novo_A_S>,
        <https://1145.am/db/2314546/Novo_A_S>,
        <https://1145.am/db/2318733/Novo_A_S>,
        <https://1145.am/db/2319236/Novo_A_S>,
        <https://1145.am/db/2319416/Novo_A_S>,
        <https://1145.am/db/2319433/Novo_A_S>,
        <https://1145.am/db/2319784/Novo_A_S>,
        <https://1145.am/db/2321216/Novo_A_S>,
        <https://1145.am/db/2321861/Novo_A_S>,
        <https://1145.am/db/2321870/Novo_A_S>,
        <https://1145.am/db/2325116/Novo_A_S>,
        <https://1145.am/db/2329010/Novo_A_S>,
        <https://1145.am/db/2329011/Novo_A_S>,
        <https://1145.am/db/2329224/Novo_A_S>,
        <https://1145.am/db/2338817/Novo_A_S>,
        <https://1145.am/db/2339692/Novo_A_S>,
        <https://1145.am/db/2340612/Novo_A_S>,
        <https://1145.am/db/2341934/Novo>,
        <https://1145.am/db/2342284/Novo_A_S>,
        <https://1145.am/db/2345268/Novo_A_S>,
        <https://1145.am/db/2345273/Novo_A_S>,
        <https://1145.am/db/2346452/Novo_A_S>,
        <https://1145.am/db/2349013/Novo_A_S>,
        <https://1145.am/db/2349048/Novo_A_S>,
        <https://1145.am/db/2349050/Novo_A_S>,
        <https://1145.am/db/2349406/Novo_A_S>,
        <https://1145.am/db/2353241/Novo_A_S>,
        <https://1145.am/db/2355183/Novo_A_S>,
        <https://1145.am/db/2356861/Novo_A_S>,
        <https://1145.am/db/2356876/Novo_A_S>,
        <https://1145.am/db/2357109/Novo_A_S>,
        <https://1145.am/db/2358233/Novo_A_S>,
        <https://1145.am/db/2358246/Novo_As>,
        <https://1145.am/db/2358271/Novo_A_S>,
        <https://1145.am/db/2358272/Novo_A_S>,
        <https://1145.am/db/2358459/Novo>,
        <https://1145.am/db/2358464/Novo_A_S>,
        <https://1145.am/db/2358542/Novo_A_S>,
        <https://1145.am/db/2359510/Novo_A_S>,
        <https://1145.am/db/2359683/Novo_A_S>,
        <https://1145.am/db/2360562/Novo>,
        <https://1145.am/db/2361588/Novo_A_S>,
        <https://1145.am/db/2363535/Novo_A_S>,
        <https://1145.am/db/2364505/Novo_A_S>,
        <https://1145.am/db/2364508/Novo_A_S>,
        <https://1145.am/db/2365700/Novo_A_S>,
        <https://1145.am/db/2365701/Novo_A_S>,
        <https://1145.am/db/2366187/Novo_A_S>,
        <https://1145.am/db/2366333/Novo_A_S>,
        <https://1145.am/db/2367275/Novo_A_S>,
        <https://1145.am/db/2367364/Novo_A_S>,
        <https://1145.am/db/2367368/Novo_A_S>,
        <https://1145.am/db/2368297/Novo_A_S>,
        <https://1145.am/db/2368333/Novo_A_S>,
        <https://1145.am/db/2368572/Novo_A_S>,
        <https://1145.am/db/2543793/Novo>,
        <https://1145.am/db/2544115/Novo>,
        <https://1145.am/db/2552947/Novo>,
        <https://1145.am/db/2557027/Novo>,
        <https://1145.am/db/2581901/Novo_A_S>,
        <https://1145.am/db/2581902/Novo_A_S>,
        <https://1145.am/db/2584056/Novo_A_S>,
        <https://1145.am/db/360351/Novo>,
        <https://1145.am/db/751135/Novo> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336098/Prochon_Biotech> a org:Organization ;
    ns1:basedInHighGeoName "State of Israel" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/294640/about.rdf> ;
    ns1:basedInHighRaw "Israel" ;
    ns1:documentDate "2012-07-24T12:13:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics reels in $49M Series A for tissue engineering implants" ;
    ns1:documentURL <https://www.fiercebiotech.com/regulatory/histogenics-reels-49m-series-a-for-tissue-engineering-implants> ;
    ns1:foundName "Prochon BioTech" ;
    ns1:name "Prochon BioTech" ;
    ns1:sameAsMedium <https://1145.am/db/2288967/Prochon_Biotech> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336109/Biomed_Ventures> a org:Organization ;
    ns1:description "financing" ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "BioMed Ventures" ;
    ns1:investor <https://1145.am/db/2336109/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> ;
    ns1:name "BioMed Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1223133/Bioadvance>,
        <https://1145.am/db/1223149/Bioadvance>,
        <https://1145.am/db/1422234/Forbion_Ventures>,
        <https://1145.am/db/1422725/Forbion_Ventures>,
        <https://1145.am/db/1867543/Tpg_Biotech>,
        <https://1145.am/db/1926411/Bioqube_Ventures>,
        <https://1145.am/db/1990861/Bioqube_Ventures>,
        <https://1145.am/db/2060484/Healthtech_Capital>,
        <https://1145.am/db/2155146/Biomatics_Capital_Partners>,
        <https://1145.am/db/2280492/Biovision_Ventures>,
        <https://1145.am/db/2285038/Time_Bioventures>,
        <https://1145.am/db/2286671/Forbion>,
        <https://1145.am/db/2298954/Biossom_Investment_Management>,
        <https://1145.am/db/2298978/Advent_Life_Sciences>,
        <https://1145.am/db/2301741/Bio_*_One_Capital>,
        <https://1145.am/db/2301792/Fonds_Bio-Innovation_Sec>,
        <https://1145.am/db/2302351/Medimmune_Ventures>,
        <https://1145.am/db/2305587/Medimmune_Ventures>,
        <https://1145.am/db/2309840/Bio_Fund>,
        <https://1145.am/db/2310285/Medventure_Associates>,
        <https://1145.am/db/2313322/Biomedinvest>,
        <https://1145.am/db/2313322/Hbm_Bioventures>,
        <https://1145.am/db/2313401/Biogen_Idec_New_Ventures>,
        <https://1145.am/db/2313438/Biomedinvest>,
        <https://1145.am/db/2313438/Hbm_Biocapital>,
        <https://1145.am/db/2313438/Hbm_Bioventures>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314400/Hbm_Biocapital>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314573/Avlar_Bioventures>,
        <https://1145.am/db/2316709/Bioadvance_Ventures>,
        <https://1145.am/db/2317737/Mc_Life_Sciences_Ventures>,
        <https://1145.am/db/2317779/Bio_*_One_Capital>,
        <https://1145.am/db/2319360/Medimmune_Ventures>,
        <https://1145.am/db/2321097/Healthcare_Ventures>,
        <https://1145.am/db/2323785/Medimmune_Ventures>,
        <https://1145.am/db/2324015/Medsciences_Capital>,
        <https://1145.am/db/2324195/Lotus_Bioscience_Ventures>,
        <https://1145.am/db/2325831/Bb_Biotech>,
        <https://1145.am/db/2325831/Hbm_Bioventures>,
        <https://1145.am/db/2338673/Hopen_Life_Science_Ventures>,
        <https://1145.am/db/2339295/Biomedinvest>,
        <https://1145.am/db/2345037/Biomed_Ventures>,
        <https://1145.am/db/2347571/Advent_Life_Sciences>,
        <https://1145.am/db/2352382/Biomedinvest>,
        <https://1145.am/db/2352633/Advanced_Biotechnologies_Venture_Fund>,
        <https://1145.am/db/2354295/Biomed_Ventures>,
        <https://1145.am/db/2359240/Frontline_Bioventures>,
        <https://1145.am/db/2364853/Medimmune_Ventures>,
        <https://1145.am/db/2365171/Healthcare_Ventures>,
        <https://1145.am/db/2366049/Biomed_Ventures>,
        <https://1145.am/db/2366055/Biomed_Ventures>,
        <https://1145.am/db/2366133/Biopacificventures>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2369916/Biomed_Ventures>,
        <https://1145.am/db/363714/Palliare>,
        <https://1145.am/db/564585/Bioqube_Ventures>,
        <https://1145.am/db/566971/Bioqube_Ventures>,
        <https://1145.am/db/684123/Biourja_Ventures>,
        <https://1145.am/db/938108/Bioeconomy_Capital>,
        <https://1145.am/db/971939/I___I_Biotech_Fund>,
        <https://1145.am/db/975114/I___I_Biotech_Fund> ;
    ns1:sameAsMedium <https://1145.am/db/2335675/Biomed_Ventures>,
        <https://1145.am/db/2336102/Biomed_Ventures>,
        <https://1145.am/db/2366046/Biomed_Ventures>,
        <https://1145.am/db/2368333/Biomed_Ventures>,
        <https://1145.am/db/2569522/Biomed_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336125/Series_B_Investment_Coda_Therapeutics_Rusnanomedinvest_Rusnanomedinvest_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-24T21:20:30+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CoDa Therapeutics Completes $ 40 Million Series B Equity Financing.",
        "SAN DIEGO, Jul 24, 2012 - CoDa Therapeutics, Inc. announced today that it raised an additional $ 20M from RusnanoMedInvest (\"RMI\" a subsidiary of RUSNANO) in a second close of its Series B financing round." ;
    ns1:documentTitle "CoDa Therapeutics Completes $40 Million Series B Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/coda-therapeutics-completes-40-million-series-b-equity-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2336125/Coda_Therapeutics> ;
    ns1:targetDetails "Series B",
        "Series B Equity" ;
    ns1:valueRaw "$ 20M",
        "$ 40 Million" ;
    ns1:when "2012-07-24T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2012-Jul-24" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2337971/Mersana_Therapeutics> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2012-07-31T14:27:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates> ;
    ns1:foundName "Mersana Therapeutics",
        "Mersana Therapeutics, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Mersana Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/1374140/Meliora_Therapeutics>,
        <https://1145.am/db/2343802/Mersana_Therapeutics>,
        <https://1145.am/db/2364647/Mersana_Therapeutics>,
        <https://1145.am/db/2365675/Mersana_Therapeutics>,
        <https://1145.am/db/2571149/Mersana_Therapeutics>,
        <https://1145.am/db/2587938/Mersana_Therapeutics>,
        <https://1145.am/db/410053/Mersana_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/2310425/Mersana_Therapeutics>,
        <https://1145.am/db/2317505/Mersana_Therapeutics>,
        <https://1145.am/db/2337681/Mersana_Therapeutics>,
        <https://1145.am/db/2337972/Mersana_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337972/Mersana_Therapeutics> a org:Organization ;
    ns1:description "cancer treatment",
        "fighting cancer" ;
    ns1:documentDate "2012-07-31T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana grabs $27M from Pfizer, NEA and others for muscled cancer drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/mersana-grabs-27m-from-pfizer-nea-and-others-for-muscled-cancer-drugs> ;
    ns1:foundName "Mersana",
        "Mersana Therapeutics" ;
    ns1:industry "biotech" ;
    ns1:name "Mersana",
        "Mersana Therapeutics" ;
    ns1:sameAsHigh <https://1145.am/db/2336324/Sorrento_Therapeutics>,
        <https://1145.am/db/2354367/Sorrento_Therapeutics>,
        <https://1145.am/db/2365675/Mersana_Therapeutics>,
        <https://1145.am/db/2368654/Ocata_Therapeutics>,
        <https://1145.am/db/2369097/Sorrento_Therapeutics>,
        <https://1145.am/db/2579483/Avecia_Biologics> ;
    ns1:sameAsMedium <https://1145.am/db/2310425/Mersana_Therapeutics>,
        <https://1145.am/db/2317505/Mersana_Therapeutics>,
        <https://1145.am/db/2337681/Mersana_Therapeutics>,
        <https://1145.am/db/2337971/Mersana_Therapeutics>,
        <https://1145.am/db/2343802/Mersana_Therapeutics>,
        <https://1145.am/db/2364647/Mersana_Therapeutics>,
        <https://1145.am/db/2571149/Mersana_Therapeutics>,
        <https://1145.am/db/2587938/Mersana_Therapeutics>,
        <https://1145.am/db/410053/Mersana_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2339535/Stemgent> a org:Organization ;
    ns1:buyer <https://1145.am/db/2339535/Business_Acquisition_Stemgent_Completed> ;
    ns1:description "drug and drug target discovery",
        "stem cell research" ;
    ns1:documentDate "2012-08-01T13:01:24+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Stemgent Completes Acquisition of Asterand's Human Tissue Business" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/stemgent-completes-acquisition-asterand-s-human-tissue-business> ;
    ns1:foundName "Asterand",
        "Asterand Plc",
        "Stemgent",
        "Stemgent, Inc." ;
    ns1:name "Asterand",
        "Stemgent" ;
    ns1:sameAsHigh <https://1145.am/db/2588906/Stemgent> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342192/Aragon_Pharmaceuticals> a org:Organization ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-03-05T21:24:31+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Aragon Pharmaceuticals Secures $42 Million in Series C Financing to Advance Pipeline of Therapies Targeting Hormone-Driven Cancers" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aragon-pharmaceuticals-secures-42-million-series-c-financing-to-advance-pipeline-of> ;
    ns1:foundName "Aragon",
        "Aragon Pharmaceuticals" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Aragon Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/101025/Scpharmaceuticals_Inc>,
        <https://1145.am/db/101329/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1031042/Intomics>,
        <https://1145.am/db/1033561/Hs_Pharmaceuticals>,
        <https://1145.am/db/1054457/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/1054503/Hs_Pharmaceuticals>,
        <https://1145.am/db/1061901/Pharmaessentia_Corporation>,
        <https://1145.am/db/1070158/Biognosys>,
        <https://1145.am/db/1079560/Satiogen_Pharmaceuticals>,
        <https://1145.am/db/1080385/Satiogen_Pharmaceuticals>,
        <https://1145.am/db/1092000/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/11010/Progenics_Pharmaceuticals>,
        <https://1145.am/db/1103357/Esperion>,
        <https://1145.am/db/1104169/20045078>,
        <https://1145.am/db/1118439/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1141704/Inmed_Pharmaceuticals>,
        <https://1145.am/db/1174705/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1176480/X4_Pharmaceuticals_Inc>,
        <https://1145.am/db/1183641/Tyme>,
        <https://1145.am/db/1184316/Tyme>,
        <https://1145.am/db/1185008/TDV>,
        <https://1145.am/db/1186876/Cornerstone_Pharmaceuticals>,
        <https://1145.am/db/1198337/Recce_Pharmaceuticals_Ltd>,
        <https://1145.am/db/1213270/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/1216194/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/1216583/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1224125/Ars_Pharmaceuticals>,
        <https://1145.am/db/1224418/Ars_Pharmaceuticals>,
        <https://1145.am/db/1225975/Ars_Pharmaceuticals_Inc>,
        <https://1145.am/db/1226849/Ars_Pharmaceuticals>,
        <https://1145.am/db/1252190/F2g_Ltd>,
        <https://1145.am/db/1265967/Tyme>,
        <https://1145.am/db/1266692/Tyme>,
        <https://1145.am/db/1291286/Vital_Pharmaceuticals_Inc>,
        <https://1145.am/db/1294499/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1294506/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1295948/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1296487/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1307419/X4_Pharmaceuticals>,
        <https://1145.am/db/1322957/Biosion>,
        <https://1145.am/db/1329779/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1334447/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/1339033/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1343020/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/1360048/Alnylam_Pharmaceuticals_Inc>,
        <https://1145.am/db/1361196/Alnylam_Pharmaceuticals_Inc>,
        <https://1145.am/db/1366554/Casi_Pharmaceuticals_Inc>,
        <https://1145.am/db/1370859/Bioivt>,
        <https://1145.am/db/1371279/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1387773/Aspire_Pharma>,
        <https://1145.am/db/1390741/Nexus_Pharmaceuticals_Inc>,
        <https://1145.am/db/1409143/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1417340/Ars_Pharmaceuticals_Inc>,
        <https://1145.am/db/1417348/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1417723/Altasciences>,
        <https://1145.am/db/1418572/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1430057/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1443334/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1443968/Pharmajet®>,
        <https://1145.am/db/1445613/Pharmajet>,
        <https://1145.am/db/1487706/Phathom_Pharmaceuticals_Inc>,
        <https://1145.am/db/1497210/Indivior_Plc>,
        <https://1145.am/db/1497210/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1497218/Indivior>,
        <https://1145.am/db/1497218/Opiant_Pharmaceuticals>,
        <https://1145.am/db/1500616/Indivior_Plc>,
        <https://1145.am/db/1500616/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1502096/Indivior_Plc>,
        <https://1145.am/db/1502096/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1505021/Pharmaceutics_International_Inc>,
        <https://1145.am/db/1505968/Escient_Pharmaceuticals>,
        <https://1145.am/db/1508407/Escient_Pharmaceuticals>,
        <https://1145.am/db/1515279/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1520596/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1520597/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1521624/Scpharmaceuticals>,
        <https://1145.am/db/1521695/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1521941/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/1523220/Scpharmaceuticals_Inc>,
        <https://1145.am/db/1533327/Escient_Pharmaceuticals>,
        <https://1145.am/db/1533685/Escient_Pharmaceuticals>,
        <https://1145.am/db/1537336/Pharmajet®>,
        <https://1145.am/db/1538098/Biocon_Ltd>,
        <https://1145.am/db/1538786/Pharmajet>,
        <https://1145.am/db/1540449/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1541946/Amunix_Pharmaceuticals>,
        <https://1145.am/db/1548955/Amunix_Pharmaceuticals>,
        <https://1145.am/db/1557072/Essential_Pharma>,
        <https://1145.am/db/1559882/X4_Pharmaceuticals_Inc>,
        <https://1145.am/db/1571078/Organon>,
        <https://1145.am/db/1585097/Scpharmaceuticals_Inc>,
        <https://1145.am/db/158742/Biogen_Inc>,
        <https://1145.am/db/1595580/Madrigal_Pharmaceuticals>,
        <https://1145.am/db/160543/Mymd_Pharmaceuticals_Inc>,
        <https://1145.am/db/1606076/Gni_Group_Ltd>,
        <https://1145.am/db/1613688/Pharmalex>,
        <https://1145.am/db/1624479/Indivior_Plc>,
        <https://1145.am/db/1624479/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1625532/Indivior_Plc>,
        <https://1145.am/db/1625532/Opiant_Pharmaceuticals_Inc>,
        <https://1145.am/db/1629605/Biogen>,
        <https://1145.am/db/1629663/Biogen>,
        <https://1145.am/db/1632411/Scipher_Medicine>,
        <https://1145.am/db/1632862/Scipher_Medicine>,
        <https://1145.am/db/1632868/Sovereign_Pharmaceuticals_Llc>,
        <https://1145.am/db/1661035/Biontech>,
        <https://1145.am/db/1680583/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/1685745/Dmk_Pharmaceuticals_Corp>,
        <https://1145.am/db/1687234/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/180589/Servier>,
        <https://1145.am/db/1955684/Eip_Pharma_Inc>,
        <https://1145.am/db/1957460/Pardes_Biosciences_Inc>,
        <https://1145.am/db/1979697/Amphastar_Pharmaceuticals>,
        <https://1145.am/db/2004101/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/2038168/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2039291/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2039678/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2040011/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2045820/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2049603/Inova_Pharmaceuticals>,
        <https://1145.am/db/2054868/Pharmaceuticals_Inc>,
        <https://1145.am/db/2056005/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2056755/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2061803/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2062156/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2066480/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2071248/Biogen>,
        <https://1145.am/db/2074741/Biogen_Inc>,
        <https://1145.am/db/2092442/Leo_Pharma>,
        <https://1145.am/db/2093802/Meitheal_Pharmaceuticals>,
        <https://1145.am/db/2100253/Biogen_Inc>,
        <https://1145.am/db/2101006/Leo_Pharma_A_S>,
        <https://1145.am/db/2138834/Altasciences>,
        <https://1145.am/db/2151781/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2152103/Am-Pharma>,
        <https://1145.am/db/2152434/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2152849/Abide_Therapeutics>,
        <https://1145.am/db/2153295/Curzion_Pharmaceuticals>,
        <https://1145.am/db/2153719/Amag_Pharmaceuticals>,
        <https://1145.am/db/2153727/Amunix_Pharmaceuticals>,
        <https://1145.am/db/2154019/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2154118/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2154527/The_Medicines_Company>,
        <https://1145.am/db/2154871/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2155006/Medicines_Company>,
        <https://1145.am/db/2155312/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2155622/Isa_Pharmaceuticals>,
        <https://1145.am/db/2155792/Ucb_Pharma>,
        <https://1145.am/db/2155798/Ucb_Pharma>,
        <https://1145.am/db/2155994/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2156002/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2198945/Millennium_Pharmaceuticals_Inc>,
        <https://1145.am/db/2201094/Pharmadeals_Ltd>,
        <https://1145.am/db/2204969/Organon_Biosciences>,
        <https://1145.am/db/2207034/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2212420/Cel-Sci_Corporation>,
        <https://1145.am/db/221697/Gw_Pharmaceuticals>,
        <https://1145.am/db/2217819/Pharmacopeia>,
        <https://1145.am/db/221787/Gw_Pharmaceuticals>,
        <https://1145.am/db/2218929/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2224859/Biologics>,
        <https://1145.am/db/2225379/Transdel_Pharmaceuticals_Inc>,
        <https://1145.am/db/2229191/Biologics>,
        <https://1145.am/db/2234316/Intercell_Ag>,
        <https://1145.am/db/2250936/Fera_Pharmaceuticals>,
        <https://1145.am/db/2277669/Pharmerica_Corporation>,
        <https://1145.am/db/2279276/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2279648/Organon>,
        <https://1145.am/db/2280123/Casi_Pharmaceuticals>,
        <https://1145.am/db/2280153/Pharming>,
        <https://1145.am/db/2281547/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2283570/Pherin_Pharmaceuticals>,
        <https://1145.am/db/2284358/Escient_Pharmaceuticals>,
        <https://1145.am/db/2285117/Immedica>,
        <https://1145.am/db/2285495/Bioivt>,
        <https://1145.am/db/2285587/Momenta_Pharmaceuticals>,
        <https://1145.am/db/2286671/Promedior>,
        <https://1145.am/db/2287224/Escient_Pharmaceuticals>,
        <https://1145.am/db/2287505/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2287572/T3_Pharmaceuticals>,
        <https://1145.am/db/2288192/Servier>,
        <https://1145.am/db/2289865/Thar_Pharmaceuticals>,
        <https://1145.am/db/2289873/Thar_Pharmaceuticals>,
        <https://1145.am/db/2290753/Medivir>,
        <https://1145.am/db/2290842/X4_Pharmaceuticals>,
        <https://1145.am/db/2291791/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2291914/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2294547/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2294570/Pharmatek>,
        <https://1145.am/db/2296094/Biogen>,
        <https://1145.am/db/2297534/Bio>,
        <https://1145.am/db/2297691/Ucb>,
        <https://1145.am/db/2298017/Kleo_Pharmaceuticals>,
        <https://1145.am/db/2298037/Ethicon>,
        <https://1145.am/db/2298627/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2299414/Biogen>,
        <https://1145.am/db/2301089/Cerulean_Pharma>,
        <https://1145.am/db/2301346/Pharmaron>,
        <https://1145.am/db/2301718/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2301735/Idera_Pharmaceuticals>,
        <https://1145.am/db/2301764/Map_Pharmaceuticals_Inc>,
        <https://1145.am/db/2301798/Osi_Pharmaceuticals>,
        <https://1145.am/db/2301824/Presidio_Pharmaceuticals_Inc>,
        <https://1145.am/db/2302019/Oscient_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2302275/Map_Pharmaceuticals>,
        <https://1145.am/db/2302426/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2302431/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2302552/Am-Pharma>,
        <https://1145.am/db/2302574/Via_Pharmaceuticals>,
        <https://1145.am/db/2302579/Via_Pharmaceuticals>,
        <https://1145.am/db/2302587/Access_Pharmaceuticals>,
        <https://1145.am/db/2302658/Biotie>,
        <https://1145.am/db/2302707/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2302774/Innovive_Pharmaceuticals>,
        <https://1145.am/db/2302779/Innovive_Pharmaceuticals>,
        <https://1145.am/db/2302890/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2302897/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2303022/Ore_Pharmaceuticals>,
        <https://1145.am/db/2303121/Locus_Pharmaceuticals>,
        <https://1145.am/db/2303131/Locus_Pharmaceuticals>,
        <https://1145.am/db/2303182/Pharmexa>,
        <https://1145.am/db/2303208/Ore_Pharmaceuticals>,
        <https://1145.am/db/2303426/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2303552/Meda>,
        <https://1145.am/db/2303645/Akarx>,
        <https://1145.am/db/2303646/Javelin_Pharmaceuticals>,
        <https://1145.am/db/2303647/Javelin_Pharmaceuticals>,
        <https://1145.am/db/2303674/Cerulean_Pharma>,
        <https://1145.am/db/2303792/Access_Pharmaceuticals>,
        <https://1145.am/db/2303934/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2303956/Prolexys_Pharmaceuticals>,
        <https://1145.am/db/2303974/Actimis_Pharmaceuticals>,
        <https://1145.am/db/2304044/Novamed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2304097/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2304135/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2304342/PTC>,
        <https://1145.am/db/2304610/Pharmos_Corp>,
        <https://1145.am/db/2304745/Critical_Pharmaceuticals>,
        <https://1145.am/db/2304831/Pharmion_Corporation>,
        <https://1145.am/db/2304934/Medicure>,
        <https://1145.am/db/2304985/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2305742/Mh_Pharma_Uk>,
        <https://1145.am/db/2305834/Nps_Pharmaceuticals>,
        <https://1145.am/db/2305927/Entremed>,
        <https://1145.am/db/2305956/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2306115/Aesrx>,
        <https://1145.am/db/2306255/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2306299/Verily>,
        <https://1145.am/db/2306641/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2306962/Pharmaron>,
        <https://1145.am/db/2307239/Pharmaxis_Ltd>,
        <https://1145.am/db/2307246/Pharmaxis>,
        <https://1145.am/db/2307254/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2307651/Organon>,
        <https://1145.am/db/2307834/Savient_Pharmaceuticals>,
        <https://1145.am/db/2307871/Access_Pharmaceuticals>,
        <https://1145.am/db/2307894/Lev_Pharmaceuticals>,
        <https://1145.am/db/2307897/Oramed_Pharmaceuticals>,
        <https://1145.am/db/2308423/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2308429/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/2308446/Pharmathene>,
        <https://1145.am/db/2308922/Lev_Pharmaceuticals>,
        <https://1145.am/db/2308964/Slate_Pharmaceuticals>,
        <https://1145.am/db/2309001/Biocon>,
        <https://1145.am/db/2309301/Inc>,
        <https://1145.am/db/2309923/Diasome_Pharmaceuticals>,
        <https://1145.am/db/2310002/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2310002/Map_Pharmaceuticals>,
        <https://1145.am/db/2310045/Slate_Pharmaceuticals>,
        <https://1145.am/db/2310071/Encysive_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310196/Symbollon_Pharmaceuticals>,
        <https://1145.am/db/2310200/Encysive_Pharmaceuticals>,
        <https://1145.am/db/2310219/Docpharma>,
        <https://1145.am/db/2310232/Genaissance_Pharmaceuticals>,
        <https://1145.am/db/2310471/Cornerstone_Pharmaceuticals>,
        <https://1145.am/db/2310473/Cornerstone_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310476/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2310480/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310568/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2310590/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2310790/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2310989/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310993/Pharmaceutical_Research_And_Manufacturers_Of_America>,
        <https://1145.am/db/2311166/Proprius_Pharmaceuticals>,
        <https://1145.am/db/2311202/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2311217/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2311264/Medicure>,
        <https://1145.am/db/2311359/Jhp_Pharmaceuticals>,
        <https://1145.am/db/2311726/Inc>,
        <https://1145.am/db/2312088/Cerulean_Pharma>,
        <https://1145.am/db/2312088/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2312158/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2312193/Ore_Pharmaceuticals_Inc>,
        <https://1145.am/db/2312257/The_Medicines_Company>,
        <https://1145.am/db/2312344/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2312416/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2312476/Nps_Pharmaceuticals>,
        <https://1145.am/db/2312479/Nps_Pharmaceuticals>,
        <https://1145.am/db/2313181/Pharmeng_International_Inc>,
        <https://1145.am/db/2313305/Tetraphase_Pharmaceuticals_Inc>,
        <https://1145.am/db/2313306/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2313320/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2313320/Ore_Pharmaceuticals>,
        <https://1145.am/db/2313323/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2313324/Ore_Pharmaceuticals_Inc>,
        <https://1145.am/db/2313336/Sound_Pharmaceuticals>,
        <https://1145.am/db/2313487/Symbollon_Pharmaceuticals>,
        <https://1145.am/db/2313501/Bioalliance_Pharma>,
        <https://1145.am/db/2313527/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2313528/Us_Pharmaceutical_Company>,
        <https://1145.am/db/2314217/Sciele_Pharma>,
        <https://1145.am/db/2314271/Biomarck_Pharmaceuticals_Ltd>,
        <https://1145.am/db/2314277/Biomarck_Pharmaceuticals>,
        <https://1145.am/db/2314317/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2314375/Cornerstone_Pharmaceuticals_Inc>,
        <https://1145.am/db/2314474/Pharmion>,
        <https://1145.am/db/2314563/Inex_Pharmaceuticals>,
        <https://1145.am/db/2314680/Pharming>,
        <https://1145.am/db/2314816/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2314837/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2315159/Research_Pharmaceutical_Services_Inc>,
        <https://1145.am/db/2315170/Alan_Copa>,
        <https://1145.am/db/2315192/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2315296/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2315296/Pharmatec_Gmbh>,
        <https://1145.am/db/2315485/Polpharma>,
        <https://1145.am/db/2315571/Sciele_Pharma>,
        <https://1145.am/db/2315624/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2315624/Pharmos>,
        <https://1145.am/db/2315925/Oramed_Pharmaceuticals>,
        <https://1145.am/db/2315941/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2316239/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2316418/Pharmaventures_Ltd>,
        <https://1145.am/db/2316435/Pharmaventures_Ltd>,
        <https://1145.am/db/2316481/Osi_Pharmaceuticals>,
        <https://1145.am/db/2316660/Pharmacopeia>,
        <https://1145.am/db/2316684/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2317337/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2317344/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2317635/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2317762/Pharmathene>,
        <https://1145.am/db/2317826/Anormed>,
        <https://1145.am/db/2317826/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2317842/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2317895/Esprit_Pharma>,
        <https://1145.am/db/2317929/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2317949/Novalar_Pharmaceuticals>,
        <https://1145.am/db/2318104/Pharmaform>,
        <https://1145.am/db/2318105/Pharma_Inc>,
        <https://1145.am/db/2318114/Transdel_Pharmaceuticals_Inc>,
        <https://1145.am/db/2318248/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2318285/Pht_Corporation>,
        <https://1145.am/db/2318469/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2318554/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2318574/Idera_Pharmaceuticals>,
        <https://1145.am/db/2318711/Specialty_Pharmaceuticals>,
        <https://1145.am/db/2318743/Pharmos_Corporation>,
        <https://1145.am/db/2318808/Pharmathene>,
        <https://1145.am/db/2318986/Corgentech>,
        <https://1145.am/db/2318994/Cornerstone_Biopharma>,
        <https://1145.am/db/2319208/Osi_Pharmaceuticals>,
        <https://1145.am/db/2319687/Advisys>,
        <https://1145.am/db/2319790/Pharmacyclics>,
        <https://1145.am/db/2319806/Satori_Pharmaceuticals>,
        <https://1145.am/db/2319809/Satori_Pharmaceuticals_Incorporated>,
        <https://1145.am/db/2319846/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2319938/Del_Pharmaceuticals>,
        <https://1145.am/db/2319939/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2320009/Map_Pharmaceuticals>,
        <https://1145.am/db/2320025/Am-Pharma>,
        <https://1145.am/db/2320025/Esprit_Pharma>,
        <https://1145.am/db/2320461/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2320767/Via_Pharmaceuticals>,
        <https://1145.am/db/2320768/Semafore_Pharmaceuticals>,
        <https://1145.am/db/2320903/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2320949/Medicines_Company>,
        <https://1145.am/db/2321148/Savient_Pharmaceuticals>,
        <https://1145.am/db/2321150/Alinea_Pharmaceuticals>,
        <https://1145.am/db/2321157/Access_Pharmaceuticals>,
        <https://1145.am/db/2321256/Nps_Pharmaceuticals>,
        <https://1145.am/db/2321409/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2321413/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2321565/2009-2010>,
        <https://1145.am/db/2321784/Acceliant>,
        <https://1145.am/db/2321860/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2321861/Astion_Pharma>,
        <https://1145.am/db/2321871/Astion_Pharma>,
        <https://1145.am/db/2321899/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2322135/Millennium_Pharmaceuticals_Inc>,
        <https://1145.am/db/2322159/Pharmaceutical>,
        <https://1145.am/db/2322235/Pharmacopeia>,
        <https://1145.am/db/2322291/Polpharma>,
        <https://1145.am/db/2322481/Cornerstone_Pharmaceuticals_Inc>,
        <https://1145.am/db/2322632/Savient_Pharmaceuticals>,
        <https://1145.am/db/2322850/Clinipace>,
        <https://1145.am/db/2322942/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2322953/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2323173/Pharmacopeia>,
        <https://1145.am/db/2323181/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2323225/Arqule>,
        <https://1145.am/db/2323273/Pharmion_Corporation>,
        <https://1145.am/db/2323278/Pharmion>,
        <https://1145.am/db/2323303/Javelin_Pharmaceuticals>,
        <https://1145.am/db/2323358/Organon_Biosciences>,
        <https://1145.am/db/2324017/Encysive_Pharmaceuticals>,
        <https://1145.am/db/2324024/Presidio_Pharmaceuticals>,
        <https://1145.am/db/2324141/Ucb>,
        <https://1145.am/db/2324243/Arqule>,
        <https://1145.am/db/2324372/Ucb>,
        <https://1145.am/db/2324417/Biomimetic_Pharmaceuticals>,
        <https://1145.am/db/2324753/Biomarin_Pharmaceutical_Inc>,
        <https://1145.am/db/2324838/Biogen>,
        <https://1145.am/db/2325070/The_Medicines_Company>,
        <https://1145.am/db/2325074/The_Medicines_Company>,
        <https://1145.am/db/2325215/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2325259/Pharmacopeia>,
        <https://1145.am/db/2325260/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2325269/Pharmacopeia>,
        <https://1145.am/db/2325394/Pharmion>,
        <https://1145.am/db/2325725/Osi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2326025/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2326148/Encysive_Pharmaceuticals>,
        <https://1145.am/db/2326286/Idera_Pharmaceuticals>,
        <https://1145.am/db/2326361/Apt_Pharmaceuticals>,
        <https://1145.am/db/2326397/Transdel_Pharmaceuticals_Inc>,
        <https://1145.am/db/2326403/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2326466/Macromed>,
        <https://1145.am/db/2326474/Innovive_Pharmaceuticals>,
        <https://1145.am/db/2326541/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2327241/Nps_Pharmaceuticals>,
        <https://1145.am/db/2327258/Biocon_Limited>,
        <https://1145.am/db/2327450/York_Pharma>,
        <https://1145.am/db/2327480/Transdel_Pharmaceuticals>,
        <https://1145.am/db/2327649/Pediamed_Pharmaceuticals>,
        <https://1145.am/db/2327849/Pharmacia_Corporation>,
        <https://1145.am/db/2328017/Calando_Pharmaceuticals>,
        <https://1145.am/db/2328043/Madrigal_Pharmaceuticals>,
        <https://1145.am/db/2328220/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2328222/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2328330/Meda>,
        <https://1145.am/db/2328616/Map_Pharmaceuticals>,
        <https://1145.am/db/2328650/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2328729/Pediamed_Pharmaceuticals>,
        <https://1145.am/db/2328962/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2328988/Cequent_Pharmaceuticals>,
        <https://1145.am/db/2328990/Mdrna>,
        <https://1145.am/db/2328996/Via_Pharmaceuticals>,
        <https://1145.am/db/2329309/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2329643/Pharmaceuticals_Inc>,
        <https://1145.am/db/2329696/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2329756/Provid_Pharmaceuticals>,
        <https://1145.am/db/2329792/Semafore_Pharmaceuticals>,
        <https://1145.am/db/2329814/Map_Pharmaceuticals>,
        <https://1145.am/db/2329816/Map_Pharmaceuticals>,
        <https://1145.am/db/2329848/Idm_Pharma>,
        <https://1145.am/db/2330057/Pharmathene>,
        <https://1145.am/db/2330086/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2330094/Idera_Pharmaceuticals>,
        <https://1145.am/db/2330121/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2330207/Bioxell>,
        <https://1145.am/db/2330207/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2330534/Pharmion>,
        <https://1145.am/db/2330576/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2330667/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2330734/Pharmaceuticals_Group>,
        <https://1145.am/db/2330858/Provid_Pharmaceuticals_Inc>,
        <https://1145.am/db/2330880/Access_Pharmaceuticals>,
        <https://1145.am/db/2330880/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2330882/Proprius_Pharmaceuticals>,
        <https://1145.am/db/2330933/Biocon>,
        <https://1145.am/db/2330949/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2330951/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2330973/Bioxell>,
        <https://1145.am/db/2330989/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2331692/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2331745/Elan_Pharmaceuticals>,
        <https://1145.am/db/2331756/Pro-Pharmaceuticals>,
        <https://1145.am/db/2331795/Ucb>,
        <https://1145.am/db/2331875/Bioalliance_Pharma>,
        <https://1145.am/db/2332028/Donald_Leung>,
        <https://1145.am/db/2332473/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2332596/Esprit_Pharma>,
        <https://1145.am/db/2332777/S_*_Bio>,
        <https://1145.am/db/2332912/Bioscrip>,
        <https://1145.am/db/2332920/Nastech>,
        <https://1145.am/db/2332974/Osi_Pharmaceuticals>,
        <https://1145.am/db/2332980/Pharmos_Corporation>,
        <https://1145.am/db/2333492/Access_Pharmaceuticals>,
        <https://1145.am/db/2333569/Ception>,
        <https://1145.am/db/2333624/Pharmos>,
        <https://1145.am/db/2334034/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2334119/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2334121/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2334183/Idera_Pharmaceuticals>,
        <https://1145.am/db/2335077/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2336040/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2336041/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2336160/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2336175/Forum_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336225/Acorda>,
        <https://1145.am/db/2336293/Aprecia_Pharmaceuticals_Company>,
        <https://1145.am/db/2336378/Oramed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336442/Bionor_Pharma_Asa>,
        <https://1145.am/db/2336452/Pharmaxis_Ltd>,
        <https://1145.am/db/2336503/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336505/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336506/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2336524/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336629/Biota_Pharmaceuticals>,
        <https://1145.am/db/2336934/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336936/Amag_Pharmaceuticals>,
        <https://1145.am/db/2337053/N30_Pharmaceuticals>,
        <https://1145.am/db/2337345/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337348/Cosmo_Pharmaceuticals_Spa>,
        <https://1145.am/db/2337481/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2337547/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337928/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2337986/Pharmagen_Inc>,
        <https://1145.am/db/2338120/The_Medicines_Company>,
        <https://1145.am/db/2338123/The_Medicines_Company>,
        <https://1145.am/db/2338390/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2338401/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2338430/Pharmacyclics>,
        <https://1145.am/db/2338551/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2338735/Map_Pharmaceuticals>,
        <https://1145.am/db/2338877/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2338883/Cerulean_Pharma_Inc>,
        <https://1145.am/db/2339019/Isa_Pharmaceuticals_Bv>,
        <https://1145.am/db/2339127/Kala_Pharmaceuticals>,
        <https://1145.am/db/2339186/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2339570/Map_Pharmaceuticals>,
        <https://1145.am/db/2339718/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2339727/Pharmacyclics_Inc>,
        <https://1145.am/db/2339787/Pharmalink_Ab>,
        <https://1145.am/db/2339830/Ocera>,
        <https://1145.am/db/2339892/Pharmacyclics>,
        <https://1145.am/db/2339907/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2339910/Biomed_Pharmaceuticals>,
        <https://1145.am/db/2339922/Pharmaform>,
        <https://1145.am/db/2339979/Theravance>,
        <https://1145.am/db/2340000/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2340224/Satori_Pharmaceuticals>,
        <https://1145.am/db/2340291/Pharmasset>,
        <https://1145.am/db/2340373/Nps_Pharmaceuticals>,
        <https://1145.am/db/2340431/Savient_Pharmaceuticals>,
        <https://1145.am/db/2341523/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2341742/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2341743/Amag_Pharmaceuticals>,
        <https://1145.am/db/2341752/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/2341998/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2342224/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2342225/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2342469/Pharmadel>,
        <https://1145.am/db/2342687/Bioalliance_Pharma>,
        <https://1145.am/db/2342687/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2342800/Pharmathene>,
        <https://1145.am/db/2342805/Pharmathene>,
        <https://1145.am/db/2342918/Pharmalink_Ab>,
        <https://1145.am/db/2343210/Promedior>,
        <https://1145.am/db/2343264/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2343277/Pharmasset>,
        <https://1145.am/db/2343325/Medivir>,
        <https://1145.am/db/2343497/Fera_Pharmaceuticals>,
        <https://1145.am/db/2343826/The_Medicines_Company>,
        <https://1145.am/db/2343837/Medicines_Co>,
        <https://1145.am/db/2343966/Thesan_Pharmaceuticals>,
        <https://1145.am/db/2344011/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344076/Transdel_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344079/Map_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344131/Pharmascience_Inc>,
        <https://1145.am/db/2344207/Entremed>,
        <https://1145.am/db/2344560/Dmi_Biosciences_Inc>,
        <https://1145.am/db/2344624/Pharmagen_Inc>,
        <https://1145.am/db/2344735/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344739/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2344850/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344939/Theravance>,
        <https://1145.am/db/2344955/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2345106/Map_Pharmaceuticals>,
        <https://1145.am/db/2345474/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2345902/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346138/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2346534/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346542/Conatus_Pharmaceuticals>,
        <https://1145.am/db/2346775/N30_Pharmaceuticals>,
        <https://1145.am/db/2346800/Satori_Pharmaceuticals_Incorporated>,
        <https://1145.am/db/2346807/Satori_Pharmaceuticals_Incorporated>,
        <https://1145.am/db/2346832/Vital_Science_Corp>,
        <https://1145.am/db/2346833/Vital_Science_Corp>,
        <https://1145.am/db/2346951/Biota_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346964/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2347123/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2347125/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2347127/Pharmacyte_Biotech>,
        <https://1145.am/db/2347169/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2347227/Aoxing_Pharmaceutical>,
        <https://1145.am/db/2347272/Pharmascience>,
        <https://1145.am/db/2347519/Pharmadeals_Ltd>,
        <https://1145.am/db/2347644/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2347648/Pharminox_Limited>,
        <https://1145.am/db/2347659/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2347982/Epicept>,
        <https://1145.am/db/2348329/Esperance_Pharmaceuticals>,
        <https://1145.am/db/2348506/Am-Pharma_Bv>,
        <https://1145.am/db/2348523/Am-Pharma_Bv>,
        <https://1145.am/db/2348620/Diartis_Pharmaceuticals_Inc>,
        <https://1145.am/db/2348763/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2348864/Vital_Science_Corp>,
        <https://1145.am/db/2349031/Meda>,
        <https://1145.am/db/2349103/Biota_Pharmaceuticals>,
        <https://1145.am/db/2349111/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349348/R-Pharm>,
        <https://1145.am/db/2349461/Ista_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349573/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349581/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349608/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349965/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2350147/Biota_Pharmaceuticals_Inc>,
        <https://1145.am/db/2350440/Ethicon>,
        <https://1145.am/db/2350852/Isa_Pharmaceuticals>,
        <https://1145.am/db/2350975/Meda>,
        <https://1145.am/db/2351091/Biomotiv>,
        <https://1145.am/db/2351432/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2351471/Mymetics_Corporation>,
        <https://1145.am/db/2351818/Biocon>,
        <https://1145.am/db/2352046/Costim_Pharmaceuticals>,
        <https://1145.am/db/2352165/Bio>,
        <https://1145.am/db/2352177/Theravance_Inc>,
        <https://1145.am/db/2352180/Pharmaceutical_Research_And_Manufacturers_Of_America>,
        <https://1145.am/db/2352333/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2352516/S_*_Bio>,
        <https://1145.am/db/2352538/Biota_Pharmaceuticals>,
        <https://1145.am/db/2352659/Nps_Pharmaceuticals>,
        <https://1145.am/db/2352784/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2352805/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2352808/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353006/Radient_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2353093/Thesan_Pharmaceuticals>,
        <https://1145.am/db/2353098/Thesan_Pharmaceuticals>,
        <https://1145.am/db/2353101/Index_Pharmaceuticals>,
        <https://1145.am/db/2353254/Pharma_Inc>,
        <https://1145.am/db/2353262/Sound_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353279/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353279/Presidio_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353326/Am-Pharma>,
        <https://1145.am/db/2353364/Am-Pharma>,
        <https://1145.am/db/2353651/Pharmathene>,
        <https://1145.am/db/2353668/Biotie>,
        <https://1145.am/db/2354002/N30_Pharmaceuticals>,
        <https://1145.am/db/2354062/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354064/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354083/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354086/Osi_Pharmaceuticals>,
        <https://1145.am/db/2354124/Uk>,
        <https://1145.am/db/2354145/Amag_Pharmaceuticals_Inc>,
        <https://1145.am/db/2354146/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2354376/Aspireo_Pharmaceuticals>,
        <https://1145.am/db/2354380/Pharmaxis>,
        <https://1145.am/db/2354388/Pharmaxis>,
        <https://1145.am/db/2354402/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2354406/Gw_Pharmaceuticals_Plc>,
        <https://1145.am/db/2354779/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2354783/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2354804/Medicis_Pharmaceutical_Corporation>,
        <https://1145.am/db/2354836/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2354913/Bionor_Pharma_Asa>,
        <https://1145.am/db/2355099/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2355102/Addex_Pharmaceuticals_Ltd>,
        <https://1145.am/db/2355109/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2355324/Biota_Pharmaceuticals_Inc>,
        <https://1145.am/db/2355678/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2355721/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2355841/F2g_Ltd>,
        <https://1145.am/db/2355884/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2355885/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2355941/Theratechnologies>,
        <https://1145.am/db/2355974/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2356294/Company>,
        <https://1145.am/db/2356294/Inc>,
        <https://1145.am/db/2356391/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2356410/Ym_Biosciences_Inc>,
        <https://1145.am/db/2356434/The_Medicines_Company>,
        <https://1145.am/db/2356560/Theravance>,
        <https://1145.am/db/2357259/Galmed_Pharmaceuticals>,
        <https://1145.am/db/2357321/K-V_Pharmaceutical_Company>,
        <https://1145.am/db/2357329/Pharmalink_Ab>,
        <https://1145.am/db/2357333/Pharmalink>,
        <https://1145.am/db/2357423/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357456/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357636/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2357905/The_Medicines_Company>,
        <https://1145.am/db/2358047/Entremed>,
        <https://1145.am/db/2358147/Omni_Bio_Pharmaceutical_Inc>,
        <https://1145.am/db/2358405/Pharmagen_Inc>,
        <https://1145.am/db/2358449/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2358479/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2358732/Osi_Pharmaceuticals>,
        <https://1145.am/db/2358877/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/2359266/D-Pharm>,
        <https://1145.am/db/2359380/Amri>,
        <https://1145.am/db/2359401/Scpharmaceuticals_Inc>,
        <https://1145.am/db/2359438/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2359474/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2359517/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2359539/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2359550/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2359668/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2359681/Ucb>,
        <https://1145.am/db/2359882/Biotie>,
        <https://1145.am/db/2359926/Entremed>,
        <https://1145.am/db/2360006/Topica_Pharmaceuticals>,
        <https://1145.am/db/2360155/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2360258/Aldea_Pharmaceuticals>,
        <https://1145.am/db/2360371/Preglem>,
        <https://1145.am/db/2360489/Medac_Pharma>,
        <https://1145.am/db/2360588/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2360596/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2360697/Medgenics>,
        <https://1145.am/db/2360739/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2360945/Entremed>,
        <https://1145.am/db/2361244/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2361516/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/2361646/Biomarin>,
        <https://1145.am/db/2362378/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2362456/Action_Pharma_A_S>,
        <https://1145.am/db/2362525/Horizon_Pharma>,
        <https://1145.am/db/2362593/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/2362609/Amag_Pharmaceuticals>,
        <https://1145.am/db/2363154/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363186/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363248/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2363285/Phenex_Pharmaceuticals_Ag>,
        <https://1145.am/db/2363340/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363387/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2363425/The_Medicines_Company>,
        <https://1145.am/db/2363433/The_Medicines_Company>,
        <https://1145.am/db/2363452/Pharmasum_Therapeutics_As>,
        <https://1145.am/db/2363461/Ucb>,
        <https://1145.am/db/2363530/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363801/Preglem>,
        <https://1145.am/db/2363955/Savient_Pharmaceuticals>,
        <https://1145.am/db/2364093/Biotie>,
        <https://1145.am/db/2364252/Nps_Pharmaceuticals>,
        <https://1145.am/db/2364274/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2364276/S_*_Bio>,
        <https://1145.am/db/2364430/Cipla>,
        <https://1145.am/db/2364494/Bioalliance_Pharma_Sa>,
        <https://1145.am/db/2364495/Bioalliance_Pharma>,
        <https://1145.am/db/2364538/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2364541/K-V_Pharmaceutical_Company>,
        <https://1145.am/db/2364585/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2364593/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2364601/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2364774/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2364884/Entremed_Inc>,
        <https://1145.am/db/2365030/Gw_Pharmaceuticals_Plc>,
        <https://1145.am/db/2365098/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365224/Research_Pharmaceutical_Services>,
        <https://1145.am/db/2365372/Bd>,
        <https://1145.am/db/2365423/Conatus_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365450/Prismic_Pharmaceuticals>,
        <https://1145.am/db/2365724/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365763/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2366139/Prism_Pharmaceuticals>,
        <https://1145.am/db/2366388/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2366521/Novamed_Pharmaceuticals>,
        <https://1145.am/db/2366540/Prism_Pharmaceuticals>,
        <https://1145.am/db/2367021/Biotie>,
        <https://1145.am/db/2367070/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2367182/Biotica>,
        <https://1145.am/db/2367280/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2367438/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2367483/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2367496/Vitae_Pharmaceuticals>,
        <https://1145.am/db/2367951/Prismic_Pharmaceuticals>,
        <https://1145.am/db/2367962/Catalyst_Pharmaceuticals>,
        <https://1145.am/db/2368070/Afferent_Pharmaceuticals>,
        <https://1145.am/db/2368189/Index_Pharmaceuticals>,
        <https://1145.am/db/2368339/Tetraphase_Pharmaceuticals>,
        <https://1145.am/db/2368420/Intec_Pharma>,
        <https://1145.am/db/2368593/Bioquiddity_Incorporated>,
        <https://1145.am/db/2368632/Pharmacyclics>,
        <https://1145.am/db/2368739/Novartis_Pharmaceuticals>,
        <https://1145.am/db/2368826/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2369004/Biogen>,
        <https://1145.am/db/2369037/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2369126/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2369144/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2369233/Biopharmx_Corporation>,
        <https://1145.am/db/2369402/Medicines_Company>,
        <https://1145.am/db/2369617/Amag_Pharmaceuticals_Inc>,
        <https://1145.am/db/2369812/Aoxing_Pharmaceutical_Company>,
        <https://1145.am/db/2369883/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2369931/Biogen>,
        <https://1145.am/db/2369984/Biogaia>,
        <https://1145.am/db/2370022/Apellis_Pharmaceuticals>,
        <https://1145.am/db/2370078/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2370082/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2370089/Abide_Therapeutics>,
        <https://1145.am/db/2370399/Pharmamar>,
        <https://1145.am/db/2370437/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/2370437/MSD>,
        <https://1145.am/db/2370637/Medgenics_Inc>,
        <https://1145.am/db/2370797/Pharmanest>,
        <https://1145.am/db/2370798/Pharmalink_Ab>,
        <https://1145.am/db/2370946/Biogen>,
        <https://1145.am/db/2371015/M_Pharma>,
        <https://1145.am/db/2371016/M_Pharma>,
        <https://1145.am/db/2371279/Biomunex_Pharmaceuticals>,
        <https://1145.am/db/2371320/Pharco_Pharmaceuticals>,
        <https://1145.am/db/2371491/Biopharmx_Corporation>,
        <https://1145.am/db/2371522/Dyax>,
        <https://1145.am/db/238320/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/2536754/Oramed_Pharma>,
        <https://1145.am/db/2536756/Zao>,
        <https://1145.am/db/2537468/Pharmascience_Inc>,
        <https://1145.am/db/2538019/Ucb>,
        <https://1145.am/db/2538171/Biomeda_Group>,
        <https://1145.am/db/2538392/Biocon>,
        <https://1145.am/db/2538422/Idt>,
        <https://1145.am/db/2538567/Upm_Pharmaceuticals>,
        <https://1145.am/db/2538705/PTC>,
        <https://1145.am/db/2538861/Par_Pharmaceuticals>,
        <https://1145.am/db/2538901/The_Harvard_Drug_Group>,
        <https://1145.am/db/2539516/Par_Pharmaceuticals>,
        <https://1145.am/db/2539568/Zao>,
        <https://1145.am/db/2539759/Twi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2540193/Pharmanest>,
        <https://1145.am/db/2540249/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2540449/Biocon>,
        <https://1145.am/db/2540951/Rytary>,
        <https://1145.am/db/2541039/Elan_Pharmaceuticals>,
        <https://1145.am/db/2541239/Pharmstar>,
        <https://1145.am/db/2541326/Advanced_Pharmaceutical>,
        <https://1145.am/db/2541419/Amri>,
        <https://1145.am/db/2541717/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2541810/British_Pharma>,
        <https://1145.am/db/2542071/Ucb>,
        <https://1145.am/db/2542218/Pharmacyclics>,
        <https://1145.am/db/2543839/British_Pharma>,
        <https://1145.am/db/2544054/Cipla>,
        <https://1145.am/db/2544111/Unique_Pharmaceuticals>,
        <https://1145.am/db/2544358/Mundipharma>,
        <https://1145.am/db/2544596/Polpharma>,
        <https://1145.am/db/2544679/Neopharma>,
        <https://1145.am/db/2544783/Citius_Pharmaceuticals>,
        <https://1145.am/db/2545143/Mundipharma>,
        <https://1145.am/db/2545411/Aoxing_Pharmaceutical_Company>,
        <https://1145.am/db/2546441/Intas_Pharmaceuticals>,
        <https://1145.am/db/2546529/Pharma_Tech_Industries>,
        <https://1145.am/db/2546629/Par_Pharmaceutical>,
        <https://1145.am/db/2547068/Alapis>,
        <https://1145.am/db/2547189/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2547319/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2547593/Jhp_Pharmaceuticals>,
        <https://1145.am/db/2547596/Par_Pharmaceuticals>,
        <https://1145.am/db/2548585/Par_Pharmaceuticals>,
        <https://1145.am/db/2548674/Sopharma>,
        <https://1145.am/db/2549477/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2549520/Aoxing_Pharmaceutical_Company>,
        <https://1145.am/db/2549919/Pharmathen>,
        <https://1145.am/db/2550212/Aoxing_Pharmaceutical>,
        <https://1145.am/db/2550232/Cipla>,
        <https://1145.am/db/2550471/Pharmaform>,
        <https://1145.am/db/2550523/Pharmaron>,
        <https://1145.am/db/2550685/Upm_Pharmaceuticals>,
        <https://1145.am/db/2551427/Pharmablock_Sciences>,
        <https://1145.am/db/2551601/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2552169/Alembic_Pharmaceuticals>,
        <https://1145.am/db/2552465/Medis>,
        <https://1145.am/db/2552641/Plethico_Pharmaceuticals>,
        <https://1145.am/db/2552642/Mankind_Pharmaceuticals>,
        <https://1145.am/db/2552746/Supreme_Pharmaceuticals_Inc>,
        <https://1145.am/db/2552794/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2553276/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2553512/Pharmax_Pharmaceuticals>,
        <https://1145.am/db/2553708/Pharmaceutical_Product_Development_Llc>,
        <https://1145.am/db/2554237/Intas_Pharmaceuticals>,
        <https://1145.am/db/2554810/Continuus_Pharmaceuticals>,
        <https://1145.am/db/2554814/Globalpharma>,
        <https://1145.am/db/2554824/Cipla>,
        <https://1145.am/db/2554858/Medicure_Usa_Inc>,
        <https://1145.am/db/2555338/Pharmacore>,
        <https://1145.am/db/2555890/Pharmalucence>,
        <https://1145.am/db/2555896/Pharmalucence>,
        <https://1145.am/db/2555921/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2556805/Medicis_Pharmaceuticals>,
        <https://1145.am/db/2557028/DPX>,
        <https://1145.am/db/2557303/Pharmaron>,
        <https://1145.am/db/2557538/Neopharma>,
        <https://1145.am/db/2558025/Pharmaxis>,
        <https://1145.am/db/2558026/Pharmaxis>,
        <https://1145.am/db/2558071/Cipla>,
        <https://1145.am/db/2558970/Biostar_Pharmaceuticals>,
        <https://1145.am/db/2559783/Polpharma>,
        <https://1145.am/db/2560083/Exemed_Pharmaceuticals>,
        <https://1145.am/db/2561100/Exemed_Pharmaceuticals>,
        <https://1145.am/db/2561312/Oxford_Pharmaceuticals>,
        <https://1145.am/db/2561438/Pharmacia___Upjohn>,
        <https://1145.am/db/2561791/Cipla>,
        <https://1145.am/db/2561978/Biomarin_Pharmaceuticals>,
        <https://1145.am/db/2562199/Novartis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2562446/Specialty_Pharmaceutical>,
        <https://1145.am/db/2562500/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2562552/Ucb>,
        <https://1145.am/db/2562723/Biontech>,
        <https://1145.am/db/2563255/Active_Pharmaceutical_Ingredients>,
        <https://1145.am/db/2563255/MSD>,
        <https://1145.am/db/2563450/Kv_Pharmaceuticals>,
        <https://1145.am/db/2563497/Creo_Pharmaceuticals>,
        <https://1145.am/db/2563497/Polpharma>,
        <https://1145.am/db/2564030/Ucb>,
        <https://1145.am/db/2564196/Pharmaron>,
        <https://1145.am/db/2564713/C2_Pharma>,
        <https://1145.am/db/2566424/Dbl_Pharmaceuticals>,
        <https://1145.am/db/2566946/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2567007/Opiant_Pharmaceuticals>,
        <https://1145.am/db/2567055/Sovereign_Pharmaceuticals>,
        <https://1145.am/db/2567283/The_Pharma_Giant>,
        <https://1145.am/db/2567296/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2567319/PTC>,
        <https://1145.am/db/2567438/Biogen>,
        <https://1145.am/db/2567651/Indivior>,
        <https://1145.am/db/2567651/Opiant_Pharmaceuticals>,
        <https://1145.am/db/2568205/Biogen>,
        <https://1145.am/db/2568375/Biogen>,
        <https://1145.am/db/2569099/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2569102/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2569165/Pharmacyclics>,
        <https://1145.am/db/2569187/Pharmacyclics>,
        <https://1145.am/db/2569370/Co>,
        <https://1145.am/db/2569425/Ucb>,
        <https://1145.am/db/2569679/Pharmaceuticals_Inc>,
        <https://1145.am/db/2569729/The_Medicines_Company>,
        <https://1145.am/db/2569952/Nps_Pharmaceuticals>,
        <https://1145.am/db/2570068/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2570122/Ucb>,
        <https://1145.am/db/2570289/Pharmacyclics>,
        <https://1145.am/db/2570419/Pharmacyclics>,
        <https://1145.am/db/2570449/Biocon>,
        <https://1145.am/db/2570733/Dyax_Corp>,
        <https://1145.am/db/2570741/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2570807/Nps_Pharmaceuticals>,
        <https://1145.am/db/2570807/Pharmacyclics>,
        <https://1145.am/db/2570834/Phrma>,
        <https://1145.am/db/2571136/Kala_Pharmaceuticals>,
        <https://1145.am/db/2571316/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2571723/Amag_Pharmaceuticals>,
        <https://1145.am/db/2572018/Meda>,
        <https://1145.am/db/2572200/The_Medicines_Company>,
        <https://1145.am/db/2572393/Pharmacia_Corporation>,
        <https://1145.am/db/2572870/Hi-Tech_Pharmaceuticals>,
        <https://1145.am/db/2573057/Aprecia_Pharmaceuticals_Company>,
        <https://1145.am/db/2573058/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/2573147/Medicis_Pharmaceutical>,
        <https://1145.am/db/2573271/Physician_Therapeutics>,
        <https://1145.am/db/2573391/Url_Pharma>,
        <https://1145.am/db/2573392/Url_Pharma>,
        <https://1145.am/db/2573593/Biotica>,
        <https://1145.am/db/2573887/Biogen>,
        <https://1145.am/db/2574213/Pharmacia_Corporation>,
        <https://1145.am/db/2574421/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2574679/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/2574891/Pharmacyclics>,
        <https://1145.am/db/2575222/Map_Pharmaceuticals>,
        <https://1145.am/db/2575242/Research_Pharmaceutical_Services_Inc>,
        <https://1145.am/db/2575462/Paras_Pharmaceuticals>,
        <https://1145.am/db/2575567/Fera_Pharmaceuticals>,
        <https://1145.am/db/2575623/Inova_Pharmaceuticals>,
        <https://1145.am/db/2575850/Cipla>,
        <https://1145.am/db/2576205/Medicis_Pharmaceutical_Corporation>,
        <https://1145.am/db/2576967/Insight_Pharmaceuticals>,
        <https://1145.am/db/2577145/Medicis_Pharmaceutical>,
        <https://1145.am/db/2577259/Pharmaceutical_Product_Development>,
        <https://1145.am/db/2577419/Osi_Pharmaceuticals>,
        <https://1145.am/db/2577675/Biogen>,
        <https://1145.am/db/2577684/Biogen>,
        <https://1145.am/db/2577894/Huvepharma_Ad>,
        <https://1145.am/db/2577934/Pharmascience>,
        <https://1145.am/db/2578095/Jhp_Pharmaceuticals>,
        <https://1145.am/db/2578177/Nexus_Pharmaceuticals>,
        <https://1145.am/db/2578209/Ucb>,
        <https://1145.am/db/2578319/Cosmo_Pharmaceuticals>,
        <https://1145.am/db/2578420/Meda_Pharmaceuticals>,
        <https://1145.am/db/2578473/Aa_Pharma>,
        <https://1145.am/db/2578481/Aa_Pharma_Inc>,
        <https://1145.am/db/2578667/Almirall>,
        <https://1145.am/db/2579104/Ucb>,
        <https://1145.am/db/2579147/Medicis_Pharmaceutical>,
        <https://1145.am/db/2579211/Eusa_Pharma>,
        <https://1145.am/db/2579538/Pharmaforce>,
        <https://1145.am/db/2580123/Savient_Pharmaceuticals>,
        <https://1145.am/db/2580479/Pharmaxis>,
        <https://1145.am/db/2581225/Inova_Pharmaceuticals>,
        <https://1145.am/db/2581394/Biocon>,
        <https://1145.am/db/2581552/Imprimis_Pharmaceuticals>,
        <https://1145.am/db/2582110/Savient_Pharmaceuticals>,
        <https://1145.am/db/2582153/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2582174/Pharmasset>,
        <https://1145.am/db/2582283/Amag_Pharmaceuticals>,
        <https://1145.am/db/2582320/Savient_Pharmaceuticals>,
        <https://1145.am/db/2582677/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2582681/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2583013/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2583022/Url_Pharma>,
        <https://1145.am/db/2583220/Cosmo_Pharmaceuticals_Spa>,
        <https://1145.am/db/2583270/Pharmaswiss>,
        <https://1145.am/db/2583291/Savient_Pharmaceuticals>,
        <https://1145.am/db/2583352/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2583352/Mikah>,
        <https://1145.am/db/2583402/Osi_Pharmaceuticals>,
        <https://1145.am/db/2583414/Polpharma>,
        <https://1145.am/db/2583430/Imprimis_Pharmaceuticals>,
        <https://1145.am/db/2583437/Meda>,
        <https://1145.am/db/2583769/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2583783/Biomarin>,
        <https://1145.am/db/2584209/Pharmaswiss_Sa>,
        <https://1145.am/db/2584226/Pharmaswiss_Sa>,
        <https://1145.am/db/2584250/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2584617/Amag_Pharmaceuticals_Inc>,
        <https://1145.am/db/2584750/Meda>,
        <https://1145.am/db/2585281/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2585327/Cipla_Limited>,
        <https://1145.am/db/2585887/Pharma_Inc>,
        <https://1145.am/db/2586547/Ucb>,
        <https://1145.am/db/2586968/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2587155/Millennium_Pharma>,
        <https://1145.am/db/2587292/Javelin_Pharmaceuticals>,
        <https://1145.am/db/2587616/Pharmaq>,
        <https://1145.am/db/2587696/R-Pharm>,
        <https://1145.am/db/2588049/Aegerion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2588718/Pharmacyclics>,
        <https://1145.am/db/2588884/Map_Pharmaceuticals>,
        <https://1145.am/db/2589317/Diartis_Pharmaceuticals>,
        <https://1145.am/db/2589414/Spepharm_Ag>,
        <https://1145.am/db/2589884/Map_Pharmaceuticals>,
        <https://1145.am/db/2590159/Osi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2590195/Nectid>,
        <https://1145.am/db/2590195/Pro-Tect_Pharmaceuticals>,
        <https://1145.am/db/2590409/Biogen>,
        <https://1145.am/db/2590910/Savient_Pharmaceuticals>,
        <https://1145.am/db/2591540/Polpharma>,
        <https://1145.am/db/2591690/Medicis_Pharmaceutical>,
        <https://1145.am/db/2591938/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2592254/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/2592336/Dyax>,
        <https://1145.am/db/2592874/Ucb>,
        <https://1145.am/db/2593048/Meda>,
        <https://1145.am/db/2593142/Access_Pharmaceuticals>,
        <https://1145.am/db/2593573/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594042/Oramed_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594106/Paras_Pharmaceuticals>,
        <https://1145.am/db/2594116/Pharmerica>,
        <https://1145.am/db/2594168/Meda>,
        <https://1145.am/db/2594183/Astex_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594257/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2594262/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2594414/Ista_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594602/Osi_Pharma>,
        <https://1145.am/db/2594798/Pharmerica>,
        <https://1145.am/db/2595190/Nps_Pharmaceuticals>,
        <https://1145.am/db/2595202/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2595210/Nps_Pharmaceuticals>,
        <https://1145.am/db/2595237/Emcure_Pharmaceuticals>,
        <https://1145.am/db/2595326/K-V_Pharmaceutical_Company>,
        <https://1145.am/db/2595413/Osi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596054/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596307/Savient_Pharmaceuticals>,
        <https://1145.am/db/2596356/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596369/Pharmadeals_Ltd>,
        <https://1145.am/db/2596636/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2596818/Pharmasset>,
        <https://1145.am/db/2597158/Nps_Pharmaceuticals>,
        <https://1145.am/db/2597180/Prism_Pharmaceuticals>,
        <https://1145.am/db/2597622/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2597935/Osi_Pharmaceuticals>,
        <https://1145.am/db/2598012/Allos_Therapeutics>,
        <https://1145.am/db/2598027/Nps_Pharmaceuticals>,
        <https://1145.am/db/2598099/Paras_Pharmaceuticals>,
        <https://1145.am/db/2598137/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2598195/Pharmatech>,
        <https://1145.am/db/2598605/Oncomed_Pharmaceuticals>,
        <https://1145.am/db/2765310/Biogen>,
        <https://1145.am/db/281576/Mymd_Pharmaceuticals>,
        <https://1145.am/db/299734/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/307255/Mymd_Pharmaceuticals_Inc>,
        <https://1145.am/db/324642/Mundipharma>,
        <https://1145.am/db/367137/Biomat>,
        <https://1145.am/db/378431/Pharmathen>,
        <https://1145.am/db/378464/Pharmathen>,
        <https://1145.am/db/378839/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/380389/Diamedica_Therapeutics_Inc>,
        <https://1145.am/db/381068/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/401218/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/402158/Puretech>,
        <https://1145.am/db/407888/Quoin_Pharmaceuticals>,
        <https://1145.am/db/410129/Catalyst_Pharmaceuticals_Inc>,
        <https://1145.am/db/427157/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/431169/Pharmablock>,
        <https://1145.am/db/4491/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/452957/Aerie_Pharmaceuticals>,
        <https://1145.am/db/468221/Aerie_Pharmaceuticals>,
        <https://1145.am/db/481129/Biocon_Ltd>,
        <https://1145.am/db/485351/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/486302/Phathom_Pharmaceuticals>,
        <https://1145.am/db/487010/Scipher_Medicine>,
        <https://1145.am/db/488564/Aerie_Pharmaceuticals>,
        <https://1145.am/db/498367/Aspire_Pharma_Limited>,
        <https://1145.am/db/499171/Aspire_Pharma_Limited>,
        <https://1145.am/db/538112/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/538277/Adamas_Pharmaceuticals>,
        <https://1145.am/db/539267/Adamas_Pharmaceuticals>,
        <https://1145.am/db/540865/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/541731/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/541755/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/545583/Citius_Pharmaceuticals>,
        <https://1145.am/db/546391/Inmed_Pharmaceuticals_Inc>,
        <https://1145.am/db/549059/Adamas_Pharmaceuticals>,
        <https://1145.am/db/567789/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/585607/Am-Pharma>,
        <https://1145.am/db/587627/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/592025/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/612466/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/612973/Mingsight_Pharmaceuticals>,
        <https://1145.am/db/614114/Mingsight_Pharmaceuticals>,
        <https://1145.am/db/637582/The_Medicines_Co>,
        <https://1145.am/db/648300/Adamas_Pharmaceuticals>,
        <https://1145.am/db/662016/Prestige_Biopharma_Limited>,
        <https://1145.am/db/668495/Scipher_Medicine>,
        <https://1145.am/db/669775/Scipher_Medicine>,
        <https://1145.am/db/693128/Ascensus_Specialties>,
        <https://1145.am/db/700482/Novartis_Pharmaceuticals>,
        <https://1145.am/db/712037/Amunix_Pharmaceuticals>,
        <https://1145.am/db/712921/Mainpointe_Pharmaceuticals>,
        <https://1145.am/db/713105/Amunix_Pharmaceuticals_Inc>,
        <https://1145.am/db/713736/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/714923/Betterlife_Pharma_Inc>,
        <https://1145.am/db/715385/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/718008/Pharnext_Sa>,
        <https://1145.am/db/723883/Mymd_Pharmaceuticals>,
        <https://1145.am/db/724999/Mymd_Pharmaceuticals_Inc>,
        <https://1145.am/db/724999/Oramed_Pharmaceuticals_Inc>,
        <https://1145.am/db/731944/Aipharma>,
        <https://1145.am/db/734669/Escient_Pharmaceuticals>,
        <https://1145.am/db/739339/Iveric_Bio>,
        <https://1145.am/db/742794/Hr®_Pharmaceuticals_Inc>,
        <https://1145.am/db/744958/Recipharm_Group>,
        <https://1145.am/db/746462/Recipharm_Group>,
        <https://1145.am/db/769779/Ucb_Sa>,
        <https://1145.am/db/769887/Ucb_Sa>,
        <https://1145.am/db/771062/Gw_Pharmaceuticals>,
        <https://1145.am/db/792894/Amt>,
        <https://1145.am/db/793071/Biogen_Inc>,
        <https://1145.am/db/835485/Pharmaessentia_Corporation>,
        <https://1145.am/db/848323/Pharmaceutics_International_Inc>,
        <https://1145.am/db/854026/Aerie_Pharmaceuticals>,
        <https://1145.am/db/854160/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/867644/Aipharma_Group_Ltd>,
        <https://1145.am/db/871621/Aipharma_Group_Ltd>,
        <https://1145.am/db/881631/Pharmcorx>,
        <https://1145.am/db/881719/Pharmcorx>,
        <https://1145.am/db/883896/Biontech>,
        <https://1145.am/db/884665/Pharmaceutical_Institute>,
        <https://1145.am/db/887575/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/889331/Théa_Pharma>,
        <https://1145.am/db/893741/Aipharma_Group_Ltd>,
        <https://1145.am/db/895336/Aipharma_Group_Ltd>,
        <https://1145.am/db/912469/Aerie_Pharmaceuticals>,
        <https://1145.am/db/913730/Aerie_Pharmaceuticals>,
        <https://1145.am/db/922740/Grand_Pharma>,
        <https://1145.am/db/976867/Aprecia_Pharmaceuticals> ;
    ns1:sameAsMedium <https://1145.am/db/2342188/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2352698/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2574227/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2584814/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2592534/Aragon_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342352/5am_Ventures> a org:Organization ;
    ns1:documentDate "2012-08-03T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/atterocor-launches-innovative-company-focused-on-accelerated-development-of-treatment-for> ;
    ns1:foundName "5AM Ventures" ;
    ns1:investor <https://1145.am/db/2342352/Series_A_Investment_5am_Ventures_Atterocor_Atterocor_Frazier_Healthcare_Completed> ;
    ns1:name "5AM Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1157541/5am_Ventures>,
        <https://1145.am/db/1533327/5am_Ventures>,
        <https://1145.am/db/1533685/5am_Ventures>,
        <https://1145.am/db/1608803/5am_Ventures>,
        <https://1145.am/db/1669813/5am_Ventures>,
        <https://1145.am/db/2152422/5am_Ventures>,
        <https://1145.am/db/2153726/5am_Ventures>,
        <https://1145.am/db/2153910/5am_Ventures>,
        <https://1145.am/db/2283394/5am_Ventures>,
        <https://1145.am/db/2286204/5am_Ventures>,
        <https://1145.am/db/2286665/5am_Ventures>,
        <https://1145.am/db/2288016/5am_Ventures>,
        <https://1145.am/db/2298404/5am_Ventures>,
        <https://1145.am/db/2298642/5am_Ventures>,
        <https://1145.am/db/2306549/5am_Ventures>,
        <https://1145.am/db/2306551/5am_Ventures>,
        <https://1145.am/db/2306754/5am_Ventures>,
        <https://1145.am/db/2311595/5am_Ventures>,
        <https://1145.am/db/2313985/5am_Ventures>,
        <https://1145.am/db/2317919/5am_Ventures>,
        <https://1145.am/db/2318733/5am_Ventures>,
        <https://1145.am/db/2319784/5am_Ventures>,
        <https://1145.am/db/2322646/5am_Ventures>,
        <https://1145.am/db/2323210/5am_Ventures>,
        <https://1145.am/db/2323226/5am_Ventures>,
        <https://1145.am/db/2324195/5am_Ventures>,
        <https://1145.am/db/2328146/5am_Ventures>,
        <https://1145.am/db/2328338/5am_Ventures>,
        <https://1145.am/db/2329778/5am_Ventures>,
        <https://1145.am/db/2332322/5am_Ventures>,
        <https://1145.am/db/2339885/5am_Ventures>,
        <https://1145.am/db/2339886/5am_Ventures>,
        <https://1145.am/db/2340344/5am_Ventures>,
        <https://1145.am/db/2340345/5am_Ventures>,
        <https://1145.am/db/2340348/5am_Ventures>,
        <https://1145.am/db/2341003/5am_Ventures>,
        <https://1145.am/db/2347885/5am_Ventures>,
        <https://1145.am/db/2348754/5am_Ventures>,
        <https://1145.am/db/2348857/5am_Ventures>,
        <https://1145.am/db/2349120/5am_Ventures>,
        <https://1145.am/db/2349834/5am_Ventures>,
        <https://1145.am/db/2351316/5am_Ventures>,
        <https://1145.am/db/2351683/5am_Ventures>,
        <https://1145.am/db/2351684/5am_Ventures>,
        <https://1145.am/db/2354296/5am_Ventures>,
        <https://1145.am/db/2355238/5am_Ventures>,
        <https://1145.am/db/2357858/5am_Ventures>,
        <https://1145.am/db/2359401/5am_Ventures>,
        <https://1145.am/db/2359864/5am_Ventures>,
        <https://1145.am/db/2360174/5am_Ventures>,
        <https://1145.am/db/2360415/5am_Ventures>,
        <https://1145.am/db/2362475/5am_Ventures>,
        <https://1145.am/db/2362481/5am_Ventures>,
        <https://1145.am/db/2364492/5am_Ventures>,
        <https://1145.am/db/2367275/5am_Ventures>,
        <https://1145.am/db/2370609/5am_Ventures>,
        <https://1145.am/db/2371160/5am_Ventures>,
        <https://1145.am/db/2371163/5am_Ventures>,
        <https://1145.am/db/2538476/5am_Ventures>,
        <https://1145.am/db/2569220/5am_Ventures>,
        <https://1145.am/db/2572398/5am_Ventures>,
        <https://1145.am/db/2587596/5am_Ventures>,
        <https://1145.am/db/2592685/5am_Ventures>,
        <https://1145.am/db/359190/5am_Ventures>,
        <https://1145.am/db/428737/5am_Ventures>,
        <https://1145.am/db/509733/5am_Ventures>,
        <https://1145.am/db/558016/5am_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342352/Atterocor> a org:Organization ;
    ns1:description "Life Sciences" ;
    ns1:documentDate "2012-08-03T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/atterocor-launches-innovative-company-focused-on-accelerated-development-of-treatment-for> ;
    ns1:foundName "Atterocor",
        "Atterocor, Inc." ;
    ns1:industry "Life Sciences" ;
    ns1:name "Atterocor" ;
    ns1:sameAsHigh <https://1145.am/db/1016355/Esperion>,
        <https://1145.am/db/1087431/Umotif>,
        <https://1145.am/db/1157644/Sc1>,
        <https://1145.am/db/1158946/Sc1>,
        <https://1145.am/db/1320381/RXPX>,
        <https://1145.am/db/1524133/My01_Inc>,
        <https://1145.am/db/1672961/Catalent>,
        <https://1145.am/db/2020041/Benchsci>,
        <https://1145.am/db/2099443/Abcam>,
        <https://1145.am/db/2154080/Abcam>,
        <https://1145.am/db/2154380/Omniome>,
        <https://1145.am/db/2283202/SFL>,
        <https://1145.am/db/2289242/Cri>,
        <https://1145.am/db/2305858/Amri>,
        <https://1145.am/db/2308692/Accelrys>,
        <https://1145.am/db/2309489/Profibrix_Bv>,
        <https://1145.am/db/2313322/Esbatech>,
        <https://1145.am/db/2313438/Esbatech>,
        <https://1145.am/db/2332857/Nitromed>,
        <https://1145.am/db/2343164/Abcam>,
        <https://1145.am/db/2347574/Activaero_Gmbh>,
        <https://1145.am/db/2361717/Obn>,
        <https://1145.am/db/2366385/Primeradx>,
        <https://1145.am/db/2368276/Obn>,
        <https://1145.am/db/2536909/Collbio_Limited>,
        <https://1145.am/db/2561653/Catalent>,
        <https://1145.am/db/2565911/Catalent>,
        <https://1145.am/db/2791820/Graticule>,
        <https://1145.am/db/572381/Cernostics>,
        <https://1145.am/db/607123/Seer_Inc>,
        <https://1145.am/db/660168/Seer_Inc>,
        <https://1145.am/db/879997/SFL>,
        <https://1145.am/db/909528/Seer_Inc>,
        <https://1145.am/db/996648/Escalent> ;
    ns1:sameAsMedium <https://1145.am/db/2345728/Atterocor>,
        <https://1145.am/db/2370807/Atterocor>,
        <https://1145.am/db/2592685/Atterocor> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342352/Frazier_Healthcare> a org:Organization ;
    ns1:description "Venture capital" ;
    ns1:documentDate "2012-08-03T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/atterocor-launches-innovative-company-focused-on-accelerated-development-of-treatment-for> ;
    ns1:foundName "Frazier Healthcare" ;
    ns1:investor <https://1145.am/db/2342352/Series_A_Investment_5am_Ventures_Atterocor_Atterocor_Frazier_Healthcare_Completed> ;
    ns1:name "Frazier Healthcare" ;
    ns1:sameAsHigh <https://1145.am/db/1244886/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1245863/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2152824/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2196903/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2278780/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2307829/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318577/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2330075/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2331784/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2338625/Frazier_Healthcare>,
        <https://1145.am/db/2346532/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2346542/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2351519/Frazier_Healthcare>,
        <https://1145.am/db/2356269/Frazier_Healthcare>,
        <https://1145.am/db/2365700/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2366187/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2553555/Frazier_Healthcare>,
        <https://1145.am/db/2592685/Frazier_Healthcare>,
        <https://1145.am/db/505366/Frazier_Healthcare_Partners>,
        <https://1145.am/db/770024/Frazier_Healthcare_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1329605/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1374146/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1813040/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2154276/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2189855/Frazier_Healthcare>,
        <https://1145.am/db/2245812/Frazier_Healthcare>,
        <https://1145.am/db/2292109/Frazier_Healthcare>,
        <https://1145.am/db/2294202/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2303250/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303251/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303257/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2305524/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2307824/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2308855/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2310795/Frazier_Healthcare>,
        <https://1145.am/db/2310798/Frazier_Healthcare>,
        <https://1145.am/db/2311551/Frazier_Healthcare>,
        <https://1145.am/db/2316391/Frazier_Healthcare>,
        <https://1145.am/db/2318274/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318276/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318635/Frazier_Healthcare>,
        <https://1145.am/db/2321216/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2325326/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2326430/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2327441/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2327442/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2330079/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2334616/Frazier_Healthcare>,
        <https://1145.am/db/2334622/Frazier_Healthcare>,
        <https://1145.am/db/2334624/Frazier_Healthcare>,
        <https://1145.am/db/2335675/Frazier_Healthcare>,
        <https://1145.am/db/2335743/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2336032/Frazier_Healthcare>,
        <https://1145.am/db/2337166/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2338633/Frazier_Healthcare>,
        <https://1145.am/db/2339925/Frazier_Healthcare>,
        <https://1145.am/db/2339926/Frazier_Healthcare>,
        <https://1145.am/db/2340204/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2340207/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2342629/Frazier_Healthcare>,
        <https://1145.am/db/2348754/Frazier_Healthcare>,
        <https://1145.am/db/2351520/Frazier_Healthcare>,
        <https://1145.am/db/2356306/Frazier_Healthcare>,
        <https://1145.am/db/2361549/Frazier_Healthcare>,
        <https://1145.am/db/2361551/Frazier_Healthcare>,
        <https://1145.am/db/2366700/Frazier_Healthcare>,
        <https://1145.am/db/2368333/Frazier_Healthcare>,
        <https://1145.am/db/2370761/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2537423/Frazier_Healthcare>,
        <https://1145.am/db/2584561/Frazier_Healthcare_Partners>,
        <https://1145.am/db/490601/Frazier_Healthcare_Partners>,
        <https://1145.am/db/578056/Frazier_Healthcare_Partners>,
        <https://1145.am/db/578059/Frazier_Healthcare_Partners>,
        <https://1145.am/db/699981/Frazier_Healthcare_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2342352/Series_A_Investment_5am_Ventures_Atterocor_Atterocor_Frazier_Healthcare_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-08-03T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $ 16 Million Series A Financing.",
        "Atterocor, Inc., a company developing an innovative therapy for adrenal cancer, today announced a $ 16 million Series A venture capital financing." ;
    ns1:documentTitle "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/atterocor-launches-innovative-company-focused-on-accelerated-development-of-treatment-for> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2342352/Atterocor> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 16 Million",
        "$ 16 million" .

<https://1145.am/db/2343197/Investment_European_Union_Exonhit_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-07T14:41:47+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Exonhit announced today that it is the beneficiary of a EUR418,000 grant from the European Union through its participation in the RESPONSIFY consortium financed under the 7th Framework Programme for Research and Technological Development (FP7) set up by the European Commission to co-finance research and development projects with grants to research actors." ;
    ns1:documentTitle "Exonhit is Beneficiary of a Grant from the European Union within the Responsify Consortium" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/exonhit-beneficiary-of-a-grant-from-european-union-within-responsify-consortium> ;
    ns1:foundName "grant" ;
    ns1:name "grant" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2343197/Exonhit> ;
    ns1:valueRaw "EUR418,000",
        "approximately EUR6 million" ;
    ns1:whereGeoName "European Union" ;
    ns1:whereRaw "European Union" .

<https://1145.am/db/2343206/Delphi_Ventures> a org:Organization ;
    ns1:basedInLowRaw "ALISO VIEJO, Calif" ;
    ns1:description "Venture capital" ;
    ns1:documentDate "2012-03-07T16:52:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sequent Medical Announces Closing of $26.0 Million Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sequent-medical-announces-closing-of-26-0-million-venture-financing> ;
    ns1:foundName "Delphi Ventures" ;
    ns1:investor <https://1145.am/db/2343206/Series_C_Investment_Delphi_Ventures_Domain_Associates_Sequent_Medical_Us_Venture_Partners_Versant_Ventures_Completed> ;
    ns1:name "Delphi Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1086604/Tdf_Ventures>,
        <https://1145.am/db/1147828/Sixthirty_Ventures>,
        <https://1145.am/db/1199050/Rre_Ventures>,
        <https://1145.am/db/1356216/Trestle_Partners>,
        <https://1145.am/db/1358977/Tlv_Partners>,
        <https://1145.am/db/1427471/Twm_Venture_Co>,
        <https://1145.am/db/1546965/Ttv_Capital>,
        <https://1145.am/db/1569853/Titan_Capital>,
        <https://1145.am/db/168364/Trog_Hawley_Capital>,
        <https://1145.am/db/1693922/Remus_Capital>,
        <https://1145.am/db/1700572/Rre_Ventures>,
        <https://1145.am/db/1703609/Ttv_Capital>,
        <https://1145.am/db/1711383/Knollwood_Capital>,
        <https://1145.am/db/1713710/Remus_Capital>,
        <https://1145.am/db/1717313/Titan_Capital>,
        <https://1145.am/db/1741365/Translink_Capital>,
        <https://1145.am/db/1743285/Redline_Capital>,
        <https://1145.am/db/1746842/Tlcom_Capital>,
        <https://1145.am/db/1750867/Ttv_Capital>,
        <https://1145.am/db/1753054/Tahoma_Ventures>,
        <https://1145.am/db/1757065/Ttv_Capital>,
        <https://1145.am/db/1761607/Trousdale_Capital>,
        <https://1145.am/db/1762653/Tlv_Partners>,
        <https://1145.am/db/1763847/Tq_Ventures>,
        <https://1145.am/db/1788126/Translink_Capital>,
        <https://1145.am/db/1790574/Rre_Ventures>,
        <https://1145.am/db/1790953/T5_Capital>,
        <https://1145.am/db/1794935/Rre_Ventures>,
        <https://1145.am/db/1794935/Translink_Capital>,
        <https://1145.am/db/1805165/Translink_Capital>,
        <https://1145.am/db/1813349/Rre_Ventures>,
        <https://1145.am/db/1820363/Rre_Ventures>,
        <https://1145.am/db/1845022/Translink_Capital>,
        <https://1145.am/db/1849600/Sevenventures>,
        <https://1145.am/db/1851689/Translink_Capital>,
        <https://1145.am/db/1853156/T5_Capital>,
        <https://1145.am/db/1854396/Ttv_Capital>,
        <https://1145.am/db/1882330/Rre_Ventures>,
        <https://1145.am/db/1890000/Rre_Ventures>,
        <https://1145.am/db/1892428/T-Venture_Holding>,
        <https://1145.am/db/1984721/Redmile_Group>,
        <https://1145.am/db/2063249/Tlv_Partners>,
        <https://1145.am/db/2069147/Knollwood_Capital>,
        <https://1145.am/db/2142825/Ttv_Capital>,
        <https://1145.am/db/2291818/Delphi_Ventures>,
        <https://1145.am/db/2300306/Delphi_Ventures>,
        <https://1145.am/db/2302333/Delphi_Ventures>,
        <https://1145.am/db/2306568/Delphi_Ventures>,
        <https://1145.am/db/2315943/Truffle_Capital>,
        <https://1145.am/db/2315957/Truffle_Capital>,
        <https://1145.am/db/2317467/Delphi_Ventures>,
        <https://1145.am/db/2317919/Delphi_Ventures>,
        <https://1145.am/db/2332658/Truffle_Capital>,
        <https://1145.am/db/2332659/Truffle_Capital>,
        <https://1145.am/db/2333504/Delphi_Ventures>,
        <https://1145.am/db/2338059/Teralys_Capital>,
        <https://1145.am/db/2352508/Delphi_Ventures>,
        <https://1145.am/db/2360174/Delphi_Ventures>,
        <https://1145.am/db/2362106/Redmile_Group>,
        <https://1145.am/db/2365679/Delphi_Ventures>,
        <https://1145.am/db/2367204/Delphi_Ventures>,
        <https://1145.am/db/254241/Tkc_Capital>,
        <https://1145.am/db/506560/Tdf_Ventures>,
        <https://1145.am/db/539638/Tdf_Ventures>,
        <https://1145.am/db/601455/Tlv_Partners>,
        <https://1145.am/db/669408/Tdf_Ventures>,
        <https://1145.am/db/759595/Redblue_Capital>,
        <https://1145.am/db/885068/Tt_Capital_Partners>,
        <https://1145.am/db/892831/Ttv_Capital>,
        <https://1145.am/db/904252/Trinity_Capital>,
        <https://1145.am/db/952434/Tdf_Ventures>,
        <https://1145.am/db/991859/Ttv_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1124122/Delphi_Ventures>,
        <https://1145.am/db/1718690/Delphi_Ventures>,
        <https://1145.am/db/2290453/Delphi_Ventures>,
        <https://1145.am/db/2292554/Delphi_Ventures>,
        <https://1145.am/db/2294721/Delphi_Ventures>,
        <https://1145.am/db/2299776/Delphi_Ventures>,
        <https://1145.am/db/2300293/Delphi_Ventures>,
        <https://1145.am/db/2300455/Delphi_Ventures>,
        <https://1145.am/db/2304340/Delphi_Ventures>,
        <https://1145.am/db/2308063/Delphi_Ventures>,
        <https://1145.am/db/2310285/Delphi_Ventures>,
        <https://1145.am/db/2319874/Delphi_Ventures>,
        <https://1145.am/db/2326571/Delphi_Ventures>,
        <https://1145.am/db/2333495/Delphi_Ventures>,
        <https://1145.am/db/2335700/Delphi_Ventures>,
        <https://1145.am/db/2359510/Delphi_Ventures>,
        <https://1145.am/db/2362553/Delphi_Ventures>,
        <https://1145.am/db/2443170/Delphi_Ventures>,
        <https://1145.am/db/2575044/Delphi_Ventures>,
        <https://1145.am/db/2584056/Delphi_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343210/Polaris_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "MALVERN, PA" ;
    ns1:documentDate "2012-03-07T19:32:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promedior-secures-21-5-million-first-closing-of-series-d-financing-to-expand-and-advance> ;
    ns1:foundName "Polaris Venture Partners" ;
    ns1:investor <https://1145.am/db/2343210/Series_D_Investment_Easton_Capital_Investment_Group_Fibrotec_Ventures_Forbion_Capital_Partners_Healthcare_Ventures_Morgenthaler_Ventures_Polaris_Venture_Partners_Promedior_Completed> ;
    ns1:name "Polaris Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1701903/Polaris_Venture_Partners>,
        <https://1145.am/db/1708291/Polaris_Venture_Partners>,
        <https://1145.am/db/1830502/Polaris_Venture_Partners>,
        <https://1145.am/db/1870436/Polaris_Venture_Partners>,
        <https://1145.am/db/1877606/Polaris_Venture_Partners>,
        <https://1145.am/db/1897450/Polaris_Venture_Partners>,
        <https://1145.am/db/1909651/Polaris_Venture_Partners>,
        <https://1145.am/db/2174824/Polaris_Venture_Partners>,
        <https://1145.am/db/2292800/Polaris_Venture_Partners>,
        <https://1145.am/db/2302116/Polaris_Venture_Partners>,
        <https://1145.am/db/2303656/Polaris_Venture_Partners>,
        <https://1145.am/db/2303675/Polaris_Venture_Partners>,
        <https://1145.am/db/2313401/Polaris_Venture_Partners>,
        <https://1145.am/db/2313405/Polaris_Venture_Partners>,
        <https://1145.am/db/2314380/Polaris_Venture_Partners>,
        <https://1145.am/db/2315289/Polaris_Venture_Partners>,
        <https://1145.am/db/2323586/Polaris_Venture_Partners>,
        <https://1145.am/db/2324431/Polaris_Venture_Partners>,
        <https://1145.am/db/2331763/Polaris_Venture_Partners>,
        <https://1145.am/db/2337571/Polaris_Venture_Partners>,
        <https://1145.am/db/2337577/Polaris_Venture_Partners>,
        <https://1145.am/db/2338373/Polaris_Venture_Partners>,
        <https://1145.am/db/2339127/Polaris_Venture_Partners>,
        <https://1145.am/db/2339128/Polaris_Venture_Partners>,
        <https://1145.am/db/2342445/Polaris_Venture_Partners>,
        <https://1145.am/db/2342862/Polaris_Venture_Partners>,
        <https://1145.am/db/2344256/Polaris_Venture_Partners>,
        <https://1145.am/db/2345224/Polaris_Venture_Partners>,
        <https://1145.am/db/2347102/Polaris_Venture_Partners>,
        <https://1145.am/db/2348448/Polaris_Venture_Partners>,
        <https://1145.am/db/2350034/Polaris_Venture_Partners>,
        <https://1145.am/db/2352414/Polaris_Venture_Partners>,
        <https://1145.am/db/2354806/Polaris_Venture_Partners>,
        <https://1145.am/db/2365296/Polaris_Venture_Partners>,
        <https://1145.am/db/2365300/Polaris_Venture_Partners>,
        <https://1145.am/db/2366654/Polaris_Venture_Partners>,
        <https://1145.am/db/2367497/Polaris_Venture_Partners>,
        <https://1145.am/db/2440024/Polaris_Venture_Partners>,
        <https://1145.am/db/2450515/Polaris_Venture_Partners>,
        <https://1145.am/db/2546216/Polaris_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343210/Promedior> a org:Organization ;
    ns1:description "pharmaceuticals" ;
    ns1:documentDate "2012-03-07T19:32:12+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promedior-secures-21-5-million-first-closing-of-series-d-financing-to-expand-and-advance> ;
    ns1:foundName "Promedior",
        "Promedior, Inc." ;
    ns1:industry "biotechnology" ;
    ns1:name "Promedior" ;
    ns1:sameAsHigh <https://1145.am/db/1013406/Moderna>,
        <https://1145.am/db/1042080/Section32>,
        <https://1145.am/db/1060047/Entera_Bio_Ltd>,
        <https://1145.am/db/1062535/20045078>,
        <https://1145.am/db/1086800/Senti_Biosciences>,
        <https://1145.am/db/1087133/Evelo_Biosciences>,
        <https://1145.am/db/1103357/Esperion>,
        <https://1145.am/db/1123329/Senti_Biosciences>,
        <https://1145.am/db/1183641/Tyme>,
        <https://1145.am/db/1184316/Tyme>,
        <https://1145.am/db/1198337/Recce_Pharmaceuticals_Ltd>,
        <https://1145.am/db/1201180/Agomab>,
        <https://1145.am/db/1201808/Agomab>,
        <https://1145.am/db/1202868/Brii_Biosciences_Limited>,
        <https://1145.am/db/1213270/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/1216158/Evelo_Biosciences>,
        <https://1145.am/db/1216194/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/1219346/Section_32>,
        <https://1145.am/db/1219817/Section_32>,
        <https://1145.am/db/1224125/Ars_Pharmaceuticals>,
        <https://1145.am/db/1224418/Ars_Pharmaceuticals>,
        <https://1145.am/db/1225975/Ars_Pharmaceuticals_Inc>,
        <https://1145.am/db/1226849/Ars_Pharmaceuticals>,
        <https://1145.am/db/1252190/F2g_Ltd>,
        <https://1145.am/db/1265967/Tyme>,
        <https://1145.am/db/1266692/Tyme>,
        <https://1145.am/db/1297445/Ansa_Biotechnologies>,
        <https://1145.am/db/1313715/Evelo_Biosciences>,
        <https://1145.am/db/1322957/Biosion>,
        <https://1145.am/db/1334447/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/1360048/Alnylam_Pharmaceuticals_Inc>,
        <https://1145.am/db/1361196/Alnylam_Pharmaceuticals_Inc>,
        <https://1145.am/db/1366554/Casi_Pharmaceuticals_Inc>,
        <https://1145.am/db/1380232/Moderna>,
        <https://1145.am/db/1394919/Morningside>,
        <https://1145.am/db/1417340/Ars_Pharmaceuticals_Inc>,
        <https://1145.am/db/1417348/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1418572/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1430057/Aerie_Pharmaceuticals_Inc>,
        <https://1145.am/db/1476593/Bioatla>,
        <https://1145.am/db/1497210/Indivior_Plc>,
        <https://1145.am/db/1497218/Indivior>,
        <https://1145.am/db/1505021/Pharmaceutics_International_Inc>,
        <https://1145.am/db/1514071/Moderna>,
        <https://1145.am/db/1538098/Biocon_Ltd>,
        <https://1145.am/db/1540449/Aerie_Pharmaceuticals>,
        <https://1145.am/db/1556688/Ron_Alfa>,
        <https://1145.am/db/1563057/Moderna>,
        <https://1145.am/db/1576796/Gri_Bio>,
        <https://1145.am/db/1586050/Evelo_Biosciences>,
        <https://1145.am/db/1596811/Moderna>,
        <https://1145.am/db/159841/Moderna>,
        <https://1145.am/db/160543/Mymd_Pharmaceuticals_Inc>,
        <https://1145.am/db/1606076/Gni_Group_Ltd>,
        <https://1145.am/db/1617793/Moderna>,
        <https://1145.am/db/1632868/Sovereign_Pharmaceuticals_Llc>,
        <https://1145.am/db/1661035/Biontech>,
        <https://1145.am/db/1685745/Dmk_Pharmaceuticals_Corp>,
        <https://1145.am/db/1689320/Innamed>,
        <https://1145.am/db/1690056/Zura>,
        <https://1145.am/db/1940289/Zura>,
        <https://1145.am/db/1957460/Pardes_Biosciences_Inc>,
        <https://1145.am/db/1979697/Amphastar_Pharmaceuticals>,
        <https://1145.am/db/2004101/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/2040011/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2054868/Pharmaceuticals_Inc>,
        <https://1145.am/db/2056005/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2056755/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2061803/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2152103/Am-Pharma>,
        <https://1145.am/db/2152849/Abide_Therapeutics>,
        <https://1145.am/db/2153295/Curzion_Pharmaceuticals>,
        <https://1145.am/db/2153719/Amag_Pharmaceuticals>,
        <https://1145.am/db/2154019/Aerie_Pharmaceuticals>,
        <https://1145.am/db/2154871/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2156002/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2212420/Cel-Sci_Corporation>,
        <https://1145.am/db/2218929/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2225379/Transdel_Pharmaceuticals_Inc>,
        <https://1145.am/db/2234316/Intercell_Ag>,
        <https://1145.am/db/2250936/Fera_Pharmaceuticals>,
        <https://1145.am/db/2277669/Pharmerica_Corporation>,
        <https://1145.am/db/2285587/Momenta_Pharmaceuticals>,
        <https://1145.am/db/2286671/Promedior>,
        <https://1145.am/db/2289865/Thar_Pharmaceuticals>,
        <https://1145.am/db/2289873/Thar_Pharmaceuticals>,
        <https://1145.am/db/2290753/Medivir>,
        <https://1145.am/db/2291914/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2297691/Ucb>,
        <https://1145.am/db/2298017/Kleo_Pharmaceuticals>,
        <https://1145.am/db/2298627/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2301798/Osi_Pharmaceuticals>,
        <https://1145.am/db/2301824/Presidio_Pharmaceuticals_Inc>,
        <https://1145.am/db/2302019/Oscient_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2302552/Am-Pharma>,
        <https://1145.am/db/2302708/Promosome>,
        <https://1145.am/db/2303022/Ore_Pharmaceuticals>,
        <https://1145.am/db/2303426/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2303552/Meda>,
        <https://1145.am/db/2303645/Akarx>,
        <https://1145.am/db/2303646/Javelin_Pharmaceuticals>,
        <https://1145.am/db/2303647/Javelin_Pharmaceuticals>,
        <https://1145.am/db/2303846/Cha_Biotech_Co>,
        <https://1145.am/db/2303956/Prolexys_Pharmaceuticals>,
        <https://1145.am/db/2303974/Actimis_Pharmaceuticals>,
        <https://1145.am/db/2304342/PTC>,
        <https://1145.am/db/2305822/Clal_Biotechnology_Industries>,
        <https://1145.am/db/2305834/Nps_Pharmaceuticals>,
        <https://1145.am/db/2306115/Aesrx>,
        <https://1145.am/db/2306255/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2307834/Savient_Pharmaceuticals>,
        <https://1145.am/db/2307894/Lev_Pharmaceuticals>,
        <https://1145.am/db/2308423/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2308429/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/2310196/Symbollon_Pharmaceuticals>,
        <https://1145.am/db/2310568/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2310590/Adamas_Pharmaceuticals>,
        <https://1145.am/db/2310989/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2311359/Jhp_Pharmaceuticals>,
        <https://1145.am/db/2311730/Bionj>,
        <https://1145.am/db/2312088/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2312158/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2312257/The_Medicines_Company>,
        <https://1145.am/db/2313181/Pharmeng_International_Inc>,
        <https://1145.am/db/2313320/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2313324/Ore_Pharmaceuticals_Inc>,
        <https://1145.am/db/2313487/Symbollon_Pharmaceuticals>,
        <https://1145.am/db/2314317/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2314474/Pharmion>,
        <https://1145.am/db/2314563/Inex_Pharmaceuticals>,
        <https://1145.am/db/2315170/Alan_Copa>,
        <https://1145.am/db/2315296/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2315296/Pharmatec_Gmbh>,
        <https://1145.am/db/2315941/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2316481/Osi_Pharmaceuticals>,
        <https://1145.am/db/2316631/Engene_Inc>,
        <https://1145.am/db/2316660/Pharmacopeia>,
        <https://1145.am/db/2316684/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2317949/Novalar_Pharmaceuticals>,
        <https://1145.am/db/2318104/Pharmaform>,
        <https://1145.am/db/2318711/Specialty_Pharmaceuticals>,
        <https://1145.am/db/2319846/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2319938/Del_Pharmaceuticals>,
        <https://1145.am/db/2319939/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2320759/Ily101>,
        <https://1145.am/db/2320768/Semafore_Pharmaceuticals>,
        <https://1145.am/db/2321150/Alinea_Pharmaceuticals>,
        <https://1145.am/db/2321256/Nps_Pharmaceuticals>,
        <https://1145.am/db/2321409/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2321413/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/2321784/Acceliant>,
        <https://1145.am/db/2322159/Pharmaceutical>,
        <https://1145.am/db/2322850/Clinipace>,
        <https://1145.am/db/2323181/Millennium_Pharmaceuticals>,
        <https://1145.am/db/2323273/Pharmion_Corporation>,
        <https://1145.am/db/2323278/Pharmion>,
        <https://1145.am/db/2323303/Javelin_Pharmaceuticals>,
        <https://1145.am/db/2323586/Promedior>,
        <https://1145.am/db/2324141/Ucb>,
        <https://1145.am/db/2324320/3i>,
        <https://1145.am/db/2324372/Ucb>,
        <https://1145.am/db/2325215/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2325259/Pharmacopeia>,
        <https://1145.am/db/2325260/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2325269/Pharmacopeia>,
        <https://1145.am/db/2325394/Pharmion>,
        <https://1145.am/db/2326361/Apt_Pharmaceuticals>,
        <https://1145.am/db/2326397/Transdel_Pharmaceuticals_Inc>,
        <https://1145.am/db/2326541/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2327241/Nps_Pharmaceuticals>,
        <https://1145.am/db/2327258/Biocon_Limited>,
        <https://1145.am/db/2328017/Calando_Pharmaceuticals>,
        <https://1145.am/db/2328330/Meda>,
        <https://1145.am/db/2328962/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2328996/Via_Pharmaceuticals>,
        <https://1145.am/db/2329696/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2329792/Semafore_Pharmaceuticals>,
        <https://1145.am/db/2329848/Idm_Pharma>,
        <https://1145.am/db/2330121/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2330576/Biocryst_Pharmaceuticals>,
        <https://1145.am/db/2330716/Gpc_Biotech>,
        <https://1145.am/db/2330734/Pharmaceuticals_Group>,
        <https://1145.am/db/2330797/Meridian_Bioscience>,
        <https://1145.am/db/2330858/Provid_Pharmaceuticals_Inc>,
        <https://1145.am/db/2330882/Proprius_Pharmaceuticals>,
        <https://1145.am/db/2330933/Biocon>,
        <https://1145.am/db/2330949/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2330951/Oscient_Pharmaceuticals>,
        <https://1145.am/db/2330973/Bioxell>,
        <https://1145.am/db/2331692/Biosante_Pharmaceuticals>,
        <https://1145.am/db/2331795/Ucb>,
        <https://1145.am/db/2332028/Donald_Leung>,
        <https://1145.am/db/2332912/Bioscrip>,
        <https://1145.am/db/2332920/Nastech>,
        <https://1145.am/db/2336040/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2336041/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2336175/Forum_Pharmaceuticals_Inc>,
        <https://1145.am/db/2336225/Acorda>,
        <https://1145.am/db/2336629/Biota_Pharmaceuticals>,
        <https://1145.am/db/2336936/Amag_Pharmaceuticals>,
        <https://1145.am/db/2337053/N30_Pharmaceuticals>,
        <https://1145.am/db/2337481/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2337928/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2338120/The_Medicines_Company>,
        <https://1145.am/db/2338123/The_Medicines_Company>,
        <https://1145.am/db/2338371/Promedior>,
        <https://1145.am/db/2338373/Promedior>,
        <https://1145.am/db/2339127/Kala_Pharmaceuticals>,
        <https://1145.am/db/2339830/Ocera>,
        <https://1145.am/db/2340408/Biovex_Group>,
        <https://1145.am/db/2340450/Promosome>,
        <https://1145.am/db/2341484/Armo_Biosciences_Inc>,
        <https://1145.am/db/2341743/Amag_Pharmaceuticals>,
        <https://1145.am/db/2342192/Aragon_Pharmaceuticals>,
        <https://1145.am/db/2342224/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2342225/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2342687/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2343325/Medivir>,
        <https://1145.am/db/2343497/Fera_Pharmaceuticals>,
        <https://1145.am/db/2343742/Promedior>,
        <https://1145.am/db/2343749/Promedior>,
        <https://1145.am/db/2343966/Thesan_Pharmaceuticals>,
        <https://1145.am/db/2344560/Dmi_Biosciences_Inc>,
        <https://1145.am/db/2344691/GTX>,
        <https://1145.am/db/2344735/Aragon_Pharmaceuticals_Inc>,
        <https://1145.am/db/2344850/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2346138/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2346775/N30_Pharmaceuticals>,
        <https://1145.am/db/2347123/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2347125/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2347169/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2348001/Ceregene>,
        <https://1145.am/db/2348329/Esperance_Pharmaceuticals>,
        <https://1145.am/db/2348523/Am-Pharma_Bv>,
        <https://1145.am/db/2348620/Diartis_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349031/Meda>,
        <https://1145.am/db/2349111/Idera_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349461/Ista_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349573/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349581/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2349608/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2350147/Biota_Pharmaceuticals_Inc>,
        <https://1145.am/db/2350491/Aviir_Inc>,
        <https://1145.am/db/2350975/Meda>,
        <https://1145.am/db/2351432/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2352516/S_*_Bio>,
        <https://1145.am/db/2352800/Biovex_Group>,
        <https://1145.am/db/2353101/Index_Pharmaceuticals>,
        <https://1145.am/db/2353227/Moderna>,
        <https://1145.am/db/2353279/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353279/Presidio_Pharmaceuticals_Inc>,
        <https://1145.am/db/2353326/Am-Pharma>,
        <https://1145.am/db/2354145/Amag_Pharmaceuticals_Inc>,
        <https://1145.am/db/2354248/Moderna>,
        <https://1145.am/db/2354402/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2354779/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2354783/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2355102/Addex_Pharmaceuticals_Ltd>,
        <https://1145.am/db/2355643/Promedior>,
        <https://1145.am/db/2355841/F2g_Ltd>,
        <https://1145.am/db/2355885/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2356391/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2356410/Ym_Biosciences_Inc>,
        <https://1145.am/db/2356434/The_Medicines_Company>,
        <https://1145.am/db/2356560/Theravance>,
        <https://1145.am/db/2357259/Galmed_Pharmaceuticals>,
        <https://1145.am/db/2357321/K-V_Pharmaceutical_Company>,
        <https://1145.am/db/2357356/Life_Sciences_Fund>,
        <https://1145.am/db/2357423/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357456/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2357505/Regenxbio>,
        <https://1145.am/db/2357905/The_Medicines_Company>,
        <https://1145.am/db/2358147/Omni_Bio_Pharmaceutical_Inc>,
        <https://1145.am/db/2358449/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2358479/Nps_Pharmaceuticals_Inc>,
        <https://1145.am/db/2359227/Regenxbio_Inc>,
        <https://1145.am/db/2359380/Amri>,
        <https://1145.am/db/2359517/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2359539/Omthera_Pharmaceuticals>,
        <https://1145.am/db/2359550/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2359681/Ucb>,
        <https://1145.am/db/2359685/Bioatla_Llc>,
        <https://1145.am/db/2360006/Topica_Pharmaceuticals>,
        <https://1145.am/db/2360258/Aldea_Pharmaceuticals>,
        <https://1145.am/db/2360317/Engene_Inc>,
        <https://1145.am/db/2360371/Preglem>,
        <https://1145.am/db/2360596/Achillion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2361646/Biomarin>,
        <https://1145.am/db/2362378/Ferring_Pharmaceuticals>,
        <https://1145.am/db/2362609/Amag_Pharmaceuticals>,
        <https://1145.am/db/2363154/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2363248/Sagent_Pharmaceuticals>,
        <https://1145.am/db/2363461/Ucb>,
        <https://1145.am/db/2363801/Preglem>,
        <https://1145.am/db/2364274/S_*_Bio_Pte_Ltd>,
        <https://1145.am/db/2364430/Cipla>,
        <https://1145.am/db/2365372/Bd>,
        <https://1145.am/db/2365450/Prismic_Pharmaceuticals>,
        <https://1145.am/db/2366540/Prism_Pharmaceuticals>,
        <https://1145.am/db/2367182/Biotica>,
        <https://1145.am/db/2368189/Index_Pharmaceuticals>,
        <https://1145.am/db/2369126/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2369154/Bioatla>,
        <https://1145.am/db/2369617/Amag_Pharmaceuticals_Inc>,
        <https://1145.am/db/2369883/Achillion_Pharmaceuticals>,
        <https://1145.am/db/2369984/Biogaia>,
        <https://1145.am/db/2370399/Pharmamar>,
        <https://1145.am/db/2370437/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/2370437/MSD>,
        <https://1145.am/db/2371320/Pharco_Pharmaceuticals>,
        <https://1145.am/db/2371522/Dyax>,
        <https://1145.am/db/238320/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/2538019/Ucb>,
        <https://1145.am/db/2538392/Biocon>,
        <https://1145.am/db/2538422/Idt>,
        <https://1145.am/db/2538705/PTC>,
        <https://1145.am/db/2539759/Twi_Pharmaceuticals_Inc>,
        <https://1145.am/db/2540249/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2541326/Advanced_Pharmaceutical>,
        <https://1145.am/db/2541419/Amri>,
        <https://1145.am/db/2542071/Ucb>,
        <https://1145.am/db/2543372/Ocata>,
        <https://1145.am/db/2543375/Ocata>,
        <https://1145.am/db/2544054/Cipla>,
        <https://1145.am/db/2544783/Citius_Pharmaceuticals>,
        <https://1145.am/db/2547068/Alapis>,
        <https://1145.am/db/2547319/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2547593/Jhp_Pharmaceuticals>,
        <https://1145.am/db/2547596/Par_Pharmaceuticals>,
        <https://1145.am/db/2548438/Bioatla>,
        <https://1145.am/db/2550232/Cipla>,
        <https://1145.am/db/2551601/Infinity_Pharmaceuticals>,
        <https://1145.am/db/2552746/Supreme_Pharmaceuticals_Inc>,
        <https://1145.am/db/2554824/Cipla>,
        <https://1145.am/db/2555921/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2557028/DPX>,
        <https://1145.am/db/2558071/Cipla>,
        <https://1145.am/db/2561791/Cipla>,
        <https://1145.am/db/2562317/Bioatla_Llc>,
        <https://1145.am/db/2562446/Specialty_Pharmaceutical>,
        <https://1145.am/db/2562552/Ucb>,
        <https://1145.am/db/2562723/Biontech>,
        <https://1145.am/db/2563255/MSD>,
        <https://1145.am/db/2563450/Kv_Pharmaceuticals>,
        <https://1145.am/db/2564030/Ucb>,
        <https://1145.am/db/2566424/Dbl_Pharmaceuticals>,
        <https://1145.am/db/2566946/Alnylam_Pharmaceuticals>,
        <https://1145.am/db/2567296/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2567319/PTC>,
        <https://1145.am/db/2569099/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2569102/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2569165/Pharmacyclics>,
        <https://1145.am/db/2569425/Ucb>,
        <https://1145.am/db/2569679/Pharmaceuticals_Inc>,
        <https://1145.am/db/2569952/Nps_Pharmaceuticals>,
        <https://1145.am/db/2570122/Ucb>,
        <https://1145.am/db/2570419/Pharmacyclics>,
        <https://1145.am/db/2570733/Dyax_Corp>,
        <https://1145.am/db/2570807/Nps_Pharmaceuticals>,
        <https://1145.am/db/2570834/Phrma>,
        <https://1145.am/db/2571136/Kala_Pharmaceuticals>,
        <https://1145.am/db/2571316/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2571723/Amag_Pharmaceuticals>,
        <https://1145.am/db/2572018/Meda>,
        <https://1145.am/db/2572393/Pharmacia_Corporation>,
        <https://1145.am/db/2573593/Biotica>,
        <https://1145.am/db/2574213/Pharmacia_Corporation>,
        <https://1145.am/db/2574421/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2575567/Fera_Pharmaceuticals>,
        <https://1145.am/db/2575850/Cipla>,
        <https://1145.am/db/2576967/Insight_Pharmaceuticals>,
        <https://1145.am/db/2578095/Jhp_Pharmaceuticals>,
        <https://1145.am/db/2578177/Nexus_Pharmaceuticals>,
        <https://1145.am/db/2578209/Ucb>,
        <https://1145.am/db/2578420/Meda_Pharmaceuticals>,
        <https://1145.am/db/2578667/Almirall>,
        <https://1145.am/db/2579104/Ucb>,
        <https://1145.am/db/2581359/Biovex_Group>,
        <https://1145.am/db/2581394/Biocon>,
        <https://1145.am/db/2581552/Imprimis_Pharmaceuticals>,
        <https://1145.am/db/2582283/Amag_Pharmaceuticals>,
        <https://1145.am/db/2582677/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2582681/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2583291/Savient_Pharmaceuticals>,
        <https://1145.am/db/2583352/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2583352/Mikah>,
        <https://1145.am/db/2583430/Imprimis_Pharmaceuticals>,
        <https://1145.am/db/2583437/Meda>,
        <https://1145.am/db/2583783/Biomarin>,
        <https://1145.am/db/2584250/Progenics_Pharmaceuticals>,
        <https://1145.am/db/2584617/Amag_Pharmaceuticals_Inc>,
        <https://1145.am/db/2584750/Meda>,
        <https://1145.am/db/2585327/Cipla_Limited>,
        <https://1145.am/db/2586547/Ucb>,
        <https://1145.am/db/2586968/Progenics_Pharmaceuticals_Inc>,
        <https://1145.am/db/2587292/Javelin_Pharmaceuticals>,
        <https://1145.am/db/2588049/Aegerion_Pharmaceuticals_Inc>,
        <https://1145.am/db/2589106/Biovex_Group>,
        <https://1145.am/db/2589317/Diartis_Pharmaceuticals>,
        <https://1145.am/db/2589414/Spepharm_Ag>,
        <https://1145.am/db/2590195/Nectid>,
        <https://1145.am/db/2592254/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/2592336/Dyax>,
        <https://1145.am/db/2592874/Ucb>,
        <https://1145.am/db/2593048/Meda>,
        <https://1145.am/db/2593573/Savient_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594106/Paras_Pharmaceuticals>,
        <https://1145.am/db/2594168/Meda>,
        <https://1145.am/db/2594183/Astex_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594257/Hikma_Pharmaceuticals_Plc>,
        <https://1145.am/db/2594262/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2594414/Ista_Pharmaceuticals_Inc>,
        <https://1145.am/db/2594798/Pharmerica>,
        <https://1145.am/db/2595202/Aegerion_Pharmaceuticals>,
        <https://1145.am/db/2595237/Emcure_Pharmaceuticals>,
        <https://1145.am/db/2595326/K-V_Pharmaceutical_Company>,
        <https://1145.am/db/2596054/Elite_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596356/Infinity_Pharmaceuticals_Inc>,
        <https://1145.am/db/2596636/Hikma_Pharmaceuticals>,
        <https://1145.am/db/2597622/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/2598012/Allos_Therapeutics>,
        <https://1145.am/db/2598137/Biosante_Pharmaceuticals_Inc>,
        <https://1145.am/db/299734/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/378431/Pharmathen>,
        <https://1145.am/db/378464/Pharmathen>,
        <https://1145.am/db/378839/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/381068/Adamis_Pharmaceuticals_Corporation>,
        <https://1145.am/db/401218/Biocryst_Pharmaceuticals_Inc>,
        <https://1145.am/db/402158/Puretech>,
        <https://1145.am/db/468723/Abcellera>,
        <https://1145.am/db/487431/Omniome>,
        <https://1145.am/db/498367/Aspire_Pharma_Limited>,
        <https://1145.am/db/499171/Aspire_Pharma_Limited>,
        <https://1145.am/db/506326/Acrigen>,
        <https://1145.am/db/527072/Amplo_Biotechnology>,
        <https://1145.am/db/538277/Adamas_Pharmaceuticals>,
        <https://1145.am/db/539267/Adamas_Pharmaceuticals>,
        <https://1145.am/db/540865/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/541731/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/541755/Adamas_Pharmaceuticals_Inc>,
        <https://1145.am/db/548508/Gv20>,
        <https://1145.am/db/549059/Adamas_Pharmaceuticals>,
        <https://1145.am/db/587627/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/592025/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/611340/Genenta_Science>,
        <https://1145.am/db/612466/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/612973/Mingsight_Pharmaceuticals>,
        <https://1145.am/db/614114/Mingsight_Pharmaceuticals>,
        <https://1145.am/db/637582/The_Medicines_Co>,
        <https://1145.am/db/648300/Adamas_Pharmaceuticals>,
        <https://1145.am/db/693678/Iveric_Bio>,
        <https://1145.am/db/697934/Iveric_Bio>,
        <https://1145.am/db/705474/Senti_Biosciences_Inc>,
        <https://1145.am/db/705671/Genenta_Science_Spa>,
        <https://1145.am/db/706523/Senti_Biosciences_Inc>,
        <https://1145.am/db/710299/Bioatla>,
        <https://1145.am/db/712921/Mainpointe_Pharmaceuticals>,
        <https://1145.am/db/724999/Oramed_Pharmaceuticals_Inc>,
        <https://1145.am/db/731944/Aipharma>,
        <https://1145.am/db/737781/Accro_Bioscience>,
        <https://1145.am/db/739339/Iveric_Bio>,
        <https://1145.am/db/744958/Recipharm_Group>,
        <https://1145.am/db/746462/Recipharm_Group>,
        <https://1145.am/db/769568/Section_32>,
        <https://1145.am/db/769779/Ucb_Sa>,
        <https://1145.am/db/769887/Ucb_Sa>,
        <https://1145.am/db/780157/Explora_Biolabs>,
        <https://1145.am/db/792894/Amt>,
        <https://1145.am/db/848323/Pharmaceutics_International_Inc>,
        <https://1145.am/db/854160/Ani_Pharmaceuticals_Inc>,
        <https://1145.am/db/867644/Aipharma_Group_Ltd>,
        <https://1145.am/db/871621/Aipharma_Group_Ltd>,
        <https://1145.am/db/881631/Pharmcorx>,
        <https://1145.am/db/881719/Pharmcorx>,
        <https://1145.am/db/887924/Avm0703>,
        <https://1145.am/db/893741/Aipharma_Group_Ltd>,
        <https://1145.am/db/895336/Aipharma_Group_Ltd>,
        <https://1145.am/db/906544/Precirix>,
        <https://1145.am/db/913978/Engene_Inc>,
        <https://1145.am/db/976867/Aprecia_Pharmaceuticals>,
        <https://1145.am/db/977143/Moderna> ;
    ns1:sameAsMedium <https://1145.am/db/2319795/Promedior>,
        <https://1145.am/db/2323591/Promedior>,
        <https://1145.am/db/2336372/Promedior>,
        <https://1145.am/db/2343202/Promedior>,
        <https://1145.am/db/2369703/Promedior>,
        <https://1145.am/db/2369708/Promedior>,
        <https://1145.am/db/2369710/Promedior> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344219/Investment_Aastrom_Biosciences_Eastern_Capital_Limited_Mlv___Co_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-09T16:47:01+00:00"^^xsd:dateTime ;
    ns1:documentExtract "ANN ARBOR, Mich., Mar 9, 2012 (GlobeNewswire via COMTEX) - Aastrom Biosciences, Inc., the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has completed a $ 40 million private placement with Eastern Capital Limited in a financing structured and arranged by MLV & Co. Net proceeds to Aastrom, after placement fees and other offering expenses, are approximately $ 38 million.",
        "Aastrom Biosciences Completes $ 40 Million Financing." ;
    ns1:documentTitle "Aastrom Biosciences Completes $40 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/aastrom-biosciences-completes-40-million-financing> ;
    ns1:foundName "Financing",
        "private placement" ;
    ns1:name "Financing",
        "private placement" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2344219/Aastrom_Biosciences> ;
    ns1:valueRaw "$ 40 Million",
        "$ 40 million",
        "approximately $ 38 million" ;
    ns1:when "2012-03-09T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Mar 9, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2344256/Kala_Pharmaceuticals> a org:Organization ;
    ns1:description "developing treatments for diseases that affect mucosal tissues" ;
    ns1:documentDate "2012-03-14T12:43:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing-0> ;
    ns1:foundName "Kala",
        "Kala Pharmaceuticals",
        "Kala Pharmaceuticals, Inc." ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Kala Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1077454/Kala_Pharmaceuticals_Inc>,
        <https://1145.am/db/1078071/Kala_Pharmaceuticals_Inc>,
        <https://1145.am/db/1094206/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/1422341/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/1422954/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/1538298/Kala_Pharmaceuticals_Inc>,
        <https://1145.am/db/1618823/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/1977836/Satsuma_Pharmaceuticals_Inc>,
        <https://1145.am/db/2002431/Satsuma_Pharmaceuticals_Inc>,
        <https://1145.am/db/2067943/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2074565/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2153542/Karuna_Pharmaceuticals>,
        <https://1145.am/db/2154053/Kiadis_Pharma>,
        <https://1145.am/db/2286420/Karuna_Therapeutics>,
        <https://1145.am/db/2291222/Karo_Pharma>,
        <https://1145.am/db/2291678/Karo_Pharma>,
        <https://1145.am/db/2291936/Karuna_Pharmaceuticals>,
        <https://1145.am/db/2292829/Karuna_Pharmaceuticals>,
        <https://1145.am/db/2308413/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2308422/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2308446/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2309368/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2319821/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2324013/Kadmus_Pharmaceuticals>,
        <https://1145.am/db/2324195/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2324214/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2328061/Kala_Pharmaceuticals>,
        <https://1145.am/db/2328338/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2335750/Kala_Pharmaceuticals>,
        <https://1145.am/db/2335755/Kala_Pharmaceuticals>,
        <https://1145.am/db/2336389/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2336546/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2336549/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2339127/Kala_Pharmaceuticals>,
        <https://1145.am/db/2339128/Kala_Pharmaceuticals>,
        <https://1145.am/db/2339953/Kala_Pharmaceuticals>,
        <https://1145.am/db/2342275/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2342284/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2343806/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2344840/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2345224/Kala_Pharmaceuticals>,
        <https://1145.am/db/2351224/Kiadis_Pharma>,
        <https://1145.am/db/2352124/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2352248/Kala_Pharmaceuticals>,
        <https://1145.am/db/2356879/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2356952/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2358210/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2359411/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2361499/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2361510/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2364793/Kala_Pharmaceuticals>,
        <https://1145.am/db/2364794/Kala_Pharmaceuticals>,
        <https://1145.am/db/2365954/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2367880/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2368095/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2368282/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2368384/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2368560/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2368572/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2368798/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2370708/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2571270/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/543141/Satsuma_Pharmaceuticals_Inc>,
        <https://1145.am/db/718170/Karo_Pharma>,
        <https://1145.am/db/718312/Karo_Pharma> ;
    ns1:sameAsMedium <https://1145.am/db/1078074/Kala_Pharmaceuticals>,
        <https://1145.am/db/1196175/Kala_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365944/Guillaume_Pfefer>,
        <https://1145.am/db/2571136/Kala_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344256/Polaris_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "WALTHAM" ;
    ns1:documentDate "2012-03-14T12:43:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing-0> ;
    ns1:foundName "Polaris Venture Partners" ;
    ns1:investor <https://1145.am/db/2344256/Investment_Kala_Pharmaceuticals_Lighthouse_Capital_Partners_Lux_Capital_Polaris_Venture_Partners_Third_Rock_Ventures_Completed> ;
    ns1:name "Polaris Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1701903/Polaris_Venture_Partners>,
        <https://1145.am/db/1708291/Polaris_Venture_Partners>,
        <https://1145.am/db/1830502/Polaris_Venture_Partners>,
        <https://1145.am/db/1870436/Polaris_Venture_Partners>,
        <https://1145.am/db/1877606/Polaris_Venture_Partners>,
        <https://1145.am/db/1897450/Polaris_Venture_Partners>,
        <https://1145.am/db/1909651/Polaris_Venture_Partners>,
        <https://1145.am/db/2174824/Polaris_Venture_Partners>,
        <https://1145.am/db/2292800/Polaris_Venture_Partners>,
        <https://1145.am/db/2302116/Polaris_Venture_Partners>,
        <https://1145.am/db/2303656/Polaris_Venture_Partners>,
        <https://1145.am/db/2303675/Polaris_Venture_Partners>,
        <https://1145.am/db/2313401/Polaris_Venture_Partners>,
        <https://1145.am/db/2313405/Polaris_Venture_Partners>,
        <https://1145.am/db/2314380/Polaris_Venture_Partners>,
        <https://1145.am/db/2315289/Polaris_Venture_Partners>,
        <https://1145.am/db/2323586/Polaris_Venture_Partners>,
        <https://1145.am/db/2324431/Polaris_Venture_Partners>,
        <https://1145.am/db/2331763/Polaris_Venture_Partners>,
        <https://1145.am/db/2337571/Polaris_Venture_Partners>,
        <https://1145.am/db/2337577/Polaris_Venture_Partners>,
        <https://1145.am/db/2338373/Polaris_Venture_Partners>,
        <https://1145.am/db/2339127/Polaris_Venture_Partners>,
        <https://1145.am/db/2339128/Polaris_Venture_Partners>,
        <https://1145.am/db/2342445/Polaris_Venture_Partners>,
        <https://1145.am/db/2342862/Polaris_Venture_Partners>,
        <https://1145.am/db/2343210/Polaris_Venture_Partners>,
        <https://1145.am/db/2345224/Polaris_Venture_Partners>,
        <https://1145.am/db/2347102/Polaris_Venture_Partners>,
        <https://1145.am/db/2348448/Polaris_Venture_Partners>,
        <https://1145.am/db/2350034/Polaris_Venture_Partners>,
        <https://1145.am/db/2352414/Polaris_Venture_Partners>,
        <https://1145.am/db/2354806/Polaris_Venture_Partners>,
        <https://1145.am/db/2365296/Polaris_Venture_Partners>,
        <https://1145.am/db/2365300/Polaris_Venture_Partners>,
        <https://1145.am/db/2366654/Polaris_Venture_Partners>,
        <https://1145.am/db/2367497/Polaris_Venture_Partners>,
        <https://1145.am/db/2440024/Polaris_Venture_Partners>,
        <https://1145.am/db/2450515/Polaris_Venture_Partners>,
        <https://1145.am/db/2546216/Polaris_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345224/Kala_Pharmaceuticals> a org:Organization ;
    ns1:description "developing treatments for diseases that affect mucosal tissues" ;
    ns1:documentDate "2012-03-14T14:02:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing> ;
    ns1:foundName "Kala",
        "Kala Pharmaceuticals",
        "Kala Pharmaceuticals, Inc." ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Kala Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/1077454/Kala_Pharmaceuticals_Inc>,
        <https://1145.am/db/1078071/Kala_Pharmaceuticals_Inc>,
        <https://1145.am/db/1094206/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/1422341/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/1422954/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/1538298/Kala_Pharmaceuticals_Inc>,
        <https://1145.am/db/1618823/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/1977836/Satsuma_Pharmaceuticals_Inc>,
        <https://1145.am/db/2002431/Satsuma_Pharmaceuticals_Inc>,
        <https://1145.am/db/2067943/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2074565/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2153542/Karuna_Pharmaceuticals>,
        <https://1145.am/db/2154053/Kiadis_Pharma>,
        <https://1145.am/db/2286420/Karuna_Therapeutics>,
        <https://1145.am/db/2291222/Karo_Pharma>,
        <https://1145.am/db/2291678/Karo_Pharma>,
        <https://1145.am/db/2291936/Karuna_Pharmaceuticals>,
        <https://1145.am/db/2292829/Karuna_Pharmaceuticals>,
        <https://1145.am/db/2308413/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2308422/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2308446/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2309368/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2319821/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2324013/Kadmus_Pharmaceuticals>,
        <https://1145.am/db/2324195/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2324214/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2328061/Kala_Pharmaceuticals>,
        <https://1145.am/db/2328338/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2335750/Kala_Pharmaceuticals>,
        <https://1145.am/db/2335755/Kala_Pharmaceuticals>,
        <https://1145.am/db/2336389/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2336546/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2336549/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2339127/Kala_Pharmaceuticals>,
        <https://1145.am/db/2339128/Kala_Pharmaceuticals>,
        <https://1145.am/db/2339953/Kala_Pharmaceuticals>,
        <https://1145.am/db/2342275/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2342284/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2343806/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2344256/Kala_Pharmaceuticals>,
        <https://1145.am/db/2344840/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2351224/Kiadis_Pharma>,
        <https://1145.am/db/2352124/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2352248/Kala_Pharmaceuticals>,
        <https://1145.am/db/2356879/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2356952/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2358210/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2359411/Kolltan_Pharmaceuticals>,
        <https://1145.am/db/2361499/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2361510/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2364793/Kala_Pharmaceuticals>,
        <https://1145.am/db/2364794/Kala_Pharmaceuticals>,
        <https://1145.am/db/2365954/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2367880/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2368095/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2368282/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2368384/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2368560/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2368572/Kalvista_Pharmaceuticals>,
        <https://1145.am/db/2368798/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2370708/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/2571270/Kalobios_Pharmaceuticals>,
        <https://1145.am/db/543141/Satsuma_Pharmaceuticals_Inc>,
        <https://1145.am/db/718170/Karo_Pharma>,
        <https://1145.am/db/718312/Karo_Pharma> ;
    ns1:sameAsMedium <https://1145.am/db/1078074/Kala_Pharmaceuticals>,
        <https://1145.am/db/1196175/Kala_Pharmaceuticals_Inc>,
        <https://1145.am/db/2365944/Guillaume_Pfefer>,
        <https://1145.am/db/2571136/Kala_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345224/Polaris_Venture_Partners> a org:Organization ;
    ns1:basedInLowRaw "WALTHAM, Mass" ;
    ns1:documentDate "2012-03-14T14:02:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing> ;
    ns1:foundName "Polaris Venture Partners" ;
    ns1:investor <https://1145.am/db/2345224/Investment_Kala_Pharmaceuticals_Lighthouse_Capital_Partners_Lux_Capital_Polaris_Venture_Partners_Third_Rock_Ventures_Completed> ;
    ns1:name "Polaris Venture Partners" ;
    ns1:sameAsMedium <https://1145.am/db/1701903/Polaris_Venture_Partners>,
        <https://1145.am/db/1708291/Polaris_Venture_Partners>,
        <https://1145.am/db/1830502/Polaris_Venture_Partners>,
        <https://1145.am/db/1870436/Polaris_Venture_Partners>,
        <https://1145.am/db/1877606/Polaris_Venture_Partners>,
        <https://1145.am/db/1897450/Polaris_Venture_Partners>,
        <https://1145.am/db/1909651/Polaris_Venture_Partners>,
        <https://1145.am/db/2174824/Polaris_Venture_Partners>,
        <https://1145.am/db/2292800/Polaris_Venture_Partners>,
        <https://1145.am/db/2302116/Polaris_Venture_Partners>,
        <https://1145.am/db/2303656/Polaris_Venture_Partners>,
        <https://1145.am/db/2303675/Polaris_Venture_Partners>,
        <https://1145.am/db/2313401/Polaris_Venture_Partners>,
        <https://1145.am/db/2313405/Polaris_Venture_Partners>,
        <https://1145.am/db/2314380/Polaris_Venture_Partners>,
        <https://1145.am/db/2315289/Polaris_Venture_Partners>,
        <https://1145.am/db/2323586/Polaris_Venture_Partners>,
        <https://1145.am/db/2324431/Polaris_Venture_Partners>,
        <https://1145.am/db/2331763/Polaris_Venture_Partners>,
        <https://1145.am/db/2337571/Polaris_Venture_Partners>,
        <https://1145.am/db/2337577/Polaris_Venture_Partners>,
        <https://1145.am/db/2338373/Polaris_Venture_Partners>,
        <https://1145.am/db/2339127/Polaris_Venture_Partners>,
        <https://1145.am/db/2339128/Polaris_Venture_Partners>,
        <https://1145.am/db/2342445/Polaris_Venture_Partners>,
        <https://1145.am/db/2342862/Polaris_Venture_Partners>,
        <https://1145.am/db/2343210/Polaris_Venture_Partners>,
        <https://1145.am/db/2344256/Polaris_Venture_Partners>,
        <https://1145.am/db/2347102/Polaris_Venture_Partners>,
        <https://1145.am/db/2348448/Polaris_Venture_Partners>,
        <https://1145.am/db/2350034/Polaris_Venture_Partners>,
        <https://1145.am/db/2352414/Polaris_Venture_Partners>,
        <https://1145.am/db/2354806/Polaris_Venture_Partners>,
        <https://1145.am/db/2365296/Polaris_Venture_Partners>,
        <https://1145.am/db/2365300/Polaris_Venture_Partners>,
        <https://1145.am/db/2366654/Polaris_Venture_Partners>,
        <https://1145.am/db/2367497/Polaris_Venture_Partners>,
        <https://1145.am/db/2440024/Polaris_Venture_Partners>,
        <https://1145.am/db/2450515/Polaris_Venture_Partners>,
        <https://1145.am/db/2546216/Polaris_Venture_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345268/Novo_A_S> a org:Organization ;
    ns1:basedInLowRaw "PHILADELPHIA" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-03-16T13:14:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tarsa-therapeutics-completes-28-million-series-b-financing-to-advance-ostora%E2%84%A2-oral> ;
    ns1:foundName "Novo A/S" ;
    ns1:investor <https://1145.am/db/2345268/Series_B_Investment_Foresite_Capital_Novo_A_S_Tarsa_Therapeutics_Completed> ;
    ns1:name "Novo A/S" ;
    ns1:sameAsHigh <https://1145.am/db/2309507/Novo_A_S>,
        <https://1145.am/db/2313143/Novo_Ventures>,
        <https://1145.am/db/2339295/Novo_Ventures>,
        <https://1145.am/db/2343966/Novo_Ventures>,
        <https://1145.am/db/2354899/Novo_Ventures>,
        <https://1145.am/db/2364505/Novo_A_S>,
        <https://1145.am/db/2570481/Novo_Ventures>,
        <https://1145.am/db/2570483/Novo_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1753148/Novo>,
        <https://1145.am/db/1754034/Novo>,
        <https://1145.am/db/2288016/Novo_A_S>,
        <https://1145.am/db/2296606/Novo_A_S>,
        <https://1145.am/db/2298077/Novo_A_S>,
        <https://1145.am/db/2298277/Novo_A_S>,
        <https://1145.am/db/2299423/Novo_As>,
        <https://1145.am/db/2299645/Novo>,
        <https://1145.am/db/2300653/Novo_A_S>,
        <https://1145.am/db/2301290/Novo>,
        <https://1145.am/db/2301494/Novo_A_S>,
        <https://1145.am/db/2302994/Novo_A_S>,
        <https://1145.am/db/2302995/Novo_A_S>,
        <https://1145.am/db/2303767/Novo_A_S>,
        <https://1145.am/db/2304335/Novo_A_S>,
        <https://1145.am/db/2304340/Novo_A_S>,
        <https://1145.am/db/2308758/Novo_A_S>,
        <https://1145.am/db/2309506/Novo_A_S>,
        <https://1145.am/db/2311133/Novo_A_S>,
        <https://1145.am/db/2311274/Novo>,
        <https://1145.am/db/2312120/Novo_A_S>,
        <https://1145.am/db/2314546/Novo_A_S>,
        <https://1145.am/db/2318733/Novo_A_S>,
        <https://1145.am/db/2319236/Novo_A_S>,
        <https://1145.am/db/2319416/Novo_A_S>,
        <https://1145.am/db/2319433/Novo_A_S>,
        <https://1145.am/db/2319784/Novo_A_S>,
        <https://1145.am/db/2321216/Novo_A_S>,
        <https://1145.am/db/2321861/Novo_A_S>,
        <https://1145.am/db/2321870/Novo_A_S>,
        <https://1145.am/db/2325116/Novo_A_S>,
        <https://1145.am/db/2329010/Novo_A_S>,
        <https://1145.am/db/2329011/Novo_A_S>,
        <https://1145.am/db/2329224/Novo_A_S>,
        <https://1145.am/db/2335700/Novo_A_S>,
        <https://1145.am/db/2338817/Novo_A_S>,
        <https://1145.am/db/2339692/Novo_A_S>,
        <https://1145.am/db/2340612/Novo_A_S>,
        <https://1145.am/db/2341934/Novo>,
        <https://1145.am/db/2342284/Novo_A_S>,
        <https://1145.am/db/2345273/Novo_A_S>,
        <https://1145.am/db/2346452/Novo_A_S>,
        <https://1145.am/db/2349013/Novo_A_S>,
        <https://1145.am/db/2349048/Novo_A_S>,
        <https://1145.am/db/2349050/Novo_A_S>,
        <https://1145.am/db/2349406/Novo_A_S>,
        <https://1145.am/db/2353241/Novo_A_S>,
        <https://1145.am/db/2355183/Novo_A_S>,
        <https://1145.am/db/2356861/Novo_A_S>,
        <https://1145.am/db/2356876/Novo_A_S>,
        <https://1145.am/db/2357109/Novo_A_S>,
        <https://1145.am/db/2358233/Novo_A_S>,
        <https://1145.am/db/2358246/Novo_As>,
        <https://1145.am/db/2358271/Novo_A_S>,
        <https://1145.am/db/2358272/Novo_A_S>,
        <https://1145.am/db/2358459/Novo>,
        <https://1145.am/db/2358464/Novo_A_S>,
        <https://1145.am/db/2358542/Novo_A_S>,
        <https://1145.am/db/2359510/Novo_A_S>,
        <https://1145.am/db/2359683/Novo_A_S>,
        <https://1145.am/db/2360562/Novo>,
        <https://1145.am/db/2361588/Novo_A_S>,
        <https://1145.am/db/2363535/Novo_A_S>,
        <https://1145.am/db/2364508/Novo_A_S>,
        <https://1145.am/db/2365700/Novo_A_S>,
        <https://1145.am/db/2365701/Novo_A_S>,
        <https://1145.am/db/2366187/Novo_A_S>,
        <https://1145.am/db/2366333/Novo_A_S>,
        <https://1145.am/db/2367275/Novo_A_S>,
        <https://1145.am/db/2367364/Novo_A_S>,
        <https://1145.am/db/2367368/Novo_A_S>,
        <https://1145.am/db/2368297/Novo_A_S>,
        <https://1145.am/db/2368333/Novo_A_S>,
        <https://1145.am/db/2368572/Novo_A_S>,
        <https://1145.am/db/2543793/Novo>,
        <https://1145.am/db/2544115/Novo>,
        <https://1145.am/db/2552947/Novo>,
        <https://1145.am/db/2557027/Novo>,
        <https://1145.am/db/2581901/Novo_A_S>,
        <https://1145.am/db/2581902/Novo_A_S>,
        <https://1145.am/db/2584056/Novo_A_S>,
        <https://1145.am/db/360351/Novo>,
        <https://1145.am/db/751135/Novo> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345268/Series_B_Investment_Foresite_Capital_Novo_A_S_Tarsa_Therapeutics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-16T13:14:59+00:00"^^xsd:dateTime ;
    ns1:documentExtract "PHILADELPHIA - Tarsa Therapeutics, Inc. today announced completion of a $ 28 million Series B equity financing led by new investor Foresite Capital.",
        "Tarsa Therapeutics Completes $ 28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin." ;
    ns1:documentTitle "Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/tarsa-therapeutics-completes-28-million-series-b-financing-to-advance-ostora%E2%84%A2-oral> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2345268/Tarsa_Therapeutics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 28 Million",
        "$ 28 million" ;
    ns1:whereGeoName "Philadelphia" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4560349/about.rdf> ;
    ns1:whereRaw "PHILADELPHIA" .

<https://1145.am/db/2346307/Altacor_Stake_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2012-03-21T13:58:49+00:00"^^xsd:dateTime ;
    ns1:documentExtract "France's NicOx ($ NCOX) has decided to play a hot hand with eye drugs and land an agreement to purchase U.K. - based ophthalmology specialist Altacor.",
        "NicOx has already sunk £2 million into Altacor to get an 11.8 % stake in the company, with an exclusive call option to buy the rest of Altacor for an additional £9 million." ;
    ns1:documentTitle "NicOx eyes global status in eye drug game with up to $30.9M buyout of Altacor" ;
    ns1:documentURL <https://www.fiercebiotech.com/financials/nicox-eyes-global-status-eye-drug-game-up-to-30-9m-buyout-of-altacor> ;
    ns1:foundName "buy",
        "purchase" ;
    ns1:name "buy",
        "purchase" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2346307/Altacor> ;
    ns1:targetDetails "stake" ;
    ns1:targetName "Altacor" ;
    ns1:valueRaw "$ 30.9 million",
        "an additional £9 million",
        "up to £19.5 million",
        "£2 million" ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "U.K." .

<https://1145.am/db/2347327/Ruiti> a org:Organization ;
    ns1:basedInHighGeoName "Shanghai" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/1796236/about.rdf> ;
    ns1:basedInHighRaw "Shanghai" ;
    ns1:description "discovering biologics that target G-protein coupled receptors" ;
    ns1:documentDate "2012-03-23T16:13:06+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Anaphore scoops up Chinese biotech; Clovis reveals $75M offering;" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/anaphore-scoops-up-chinese-biotech-clovis-reveals-75m-offering> ;
    ns1:foundName "RuiTi" ;
    ns1:industry "biotech" ;
    ns1:name "RuiTi" ;
    ns1:sameAsHigh <https://1145.am/db/2347327/Anaphore> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349406/Lundbeckfond_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Denmark" ;
    ns1:description "Investing" ;
    ns1:documentDate "2012-04-02T14:49:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "AlloCure Raises $25 Million Series B Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/allocure-raises-25-million-series-b-venture-financing> ;
    ns1:foundName "Lundbeckfond Ventures" ;
    ns1:investor <https://1145.am/db/2349406/Venture_Investment_Allocure_Lundbeckfond_Ventures_Novo_A_S_Sv_Life_Sciences_Completed> ;
    ns1:name "Lundbeckfond Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/2336716/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349050/Lundbeckfond_Ventures>,
        <https://1145.am/db/2352361/Lundbeckfond_Ventures>,
        <https://1145.am/db/2353917/Lundbeckfond_Ventures>,
        <https://1145.am/db/2354401/Lundbeckfond_Ventures>,
        <https://1145.am/db/2362148/Lundbeckfond_Ventures>,
        <https://1145.am/db/2362156/Lundbeckfond_Ventures>,
        <https://1145.am/db/2364492/Lundbeckfond_Ventures>,
        <https://1145.am/db/2366303/Lundbeckfond_Ventures>,
        <https://1145.am/db/281538/Lundbeckfonden_Ventures>,
        <https://1145.am/db/829447/Lundbeck_Foundation> ;
    ns1:sameAsMedium <https://1145.am/db/2296062/Lundbeckfonden_Ventures>,
        <https://1145.am/db/2300680/Lundbeckfond_Ventures>,
        <https://1145.am/db/2301536/Lundbeckfonden_Ventures>,
        <https://1145.am/db/2326981/Lundbeckfond_Ventures>,
        <https://1145.am/db/2338527/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349048/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349405/Lundbeckfond_Ventures>,
        <https://1145.am/db/2352357/Lundbeckfond_Ventures>,
        <https://1145.am/db/2353098/Lundbeckfond_Ventures>,
        <https://1145.am/db/2356402/Lundbeckfond_Ventures>,
        <https://1145.am/db/2356411/Lundbeckfond_Ventures>,
        <https://1145.am/db/2359401/Lundbeckfond_Ventures>,
        <https://1145.am/db/2363947/Lundbeckfond_Ventures>,
        <https://1145.am/db/2363950/Lundbeckfond_Ventures>,
        <https://1145.am/db/2365826/Lundbeckfond_Ventures>,
        <https://1145.am/db/2369169/Lundbeckfond_Ventures>,
        <https://1145.am/db/2369953/Lundbeckfond_Ventures>,
        <https://1145.am/db/2544138/Lundbeckfond_Ventures>,
        <https://1145.am/db/2544140/Lundbeckfond_Ventures>,
        <https://1145.am/db/2573068/Lundbeckfond_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349406/Novo_A_S> a org:Organization ;
    ns1:basedInLowRaw "Denmark" ;
    ns1:description "a clinical stage biotechnology company" ;
    ns1:documentDate "2012-04-02T14:49:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "AlloCure Raises $25 Million Series B Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/allocure-raises-25-million-series-b-venture-financing> ;
    ns1:foundName "Novo A/S" ;
    ns1:investor <https://1145.am/db/2349406/Venture_Investment_Allocure_Lundbeckfond_Ventures_Novo_A_S_Sv_Life_Sciences_Completed> ;
    ns1:name "Novo A/S" ;
    ns1:sameAsMedium <https://1145.am/db/1753148/Novo>,
        <https://1145.am/db/1754034/Novo>,
        <https://1145.am/db/2288016/Novo_A_S>,
        <https://1145.am/db/2296606/Novo_A_S>,
        <https://1145.am/db/2298077/Novo_A_S>,
        <https://1145.am/db/2298277/Novo_A_S>,
        <https://1145.am/db/2299423/Novo_As>,
        <https://1145.am/db/2299645/Novo>,
        <https://1145.am/db/2300653/Novo_A_S>,
        <https://1145.am/db/2301290/Novo>,
        <https://1145.am/db/2301494/Novo_A_S>,
        <https://1145.am/db/2302994/Novo_A_S>,
        <https://1145.am/db/2302995/Novo_A_S>,
        <https://1145.am/db/2303767/Novo_A_S>,
        <https://1145.am/db/2304335/Novo_A_S>,
        <https://1145.am/db/2304340/Novo_A_S>,
        <https://1145.am/db/2308758/Novo_A_S>,
        <https://1145.am/db/2309506/Novo_A_S>,
        <https://1145.am/db/2309507/Novo_A_S>,
        <https://1145.am/db/2311133/Novo_A_S>,
        <https://1145.am/db/2311274/Novo>,
        <https://1145.am/db/2312120/Novo_A_S>,
        <https://1145.am/db/2314546/Novo_A_S>,
        <https://1145.am/db/2318733/Novo_A_S>,
        <https://1145.am/db/2319236/Novo_A_S>,
        <https://1145.am/db/2319416/Novo_A_S>,
        <https://1145.am/db/2319433/Novo_A_S>,
        <https://1145.am/db/2319784/Novo_A_S>,
        <https://1145.am/db/2321216/Novo_A_S>,
        <https://1145.am/db/2321861/Novo_A_S>,
        <https://1145.am/db/2321870/Novo_A_S>,
        <https://1145.am/db/2325116/Novo_A_S>,
        <https://1145.am/db/2329010/Novo_A_S>,
        <https://1145.am/db/2329011/Novo_A_S>,
        <https://1145.am/db/2329224/Novo_A_S>,
        <https://1145.am/db/2335700/Novo_A_S>,
        <https://1145.am/db/2338817/Novo_A_S>,
        <https://1145.am/db/2339692/Novo_A_S>,
        <https://1145.am/db/2340612/Novo_A_S>,
        <https://1145.am/db/2341934/Novo>,
        <https://1145.am/db/2342284/Novo_A_S>,
        <https://1145.am/db/2345268/Novo_A_S>,
        <https://1145.am/db/2345273/Novo_A_S>,
        <https://1145.am/db/2346452/Novo_A_S>,
        <https://1145.am/db/2349013/Novo_A_S>,
        <https://1145.am/db/2349048/Novo_A_S>,
        <https://1145.am/db/2349050/Novo_A_S>,
        <https://1145.am/db/2353241/Novo_A_S>,
        <https://1145.am/db/2355183/Novo_A_S>,
        <https://1145.am/db/2356861/Novo_A_S>,
        <https://1145.am/db/2356876/Novo_A_S>,
        <https://1145.am/db/2357109/Novo_A_S>,
        <https://1145.am/db/2358233/Novo_A_S>,
        <https://1145.am/db/2358246/Novo_As>,
        <https://1145.am/db/2358271/Novo_A_S>,
        <https://1145.am/db/2358272/Novo_A_S>,
        <https://1145.am/db/2358459/Novo>,
        <https://1145.am/db/2358464/Novo_A_S>,
        <https://1145.am/db/2358542/Novo_A_S>,
        <https://1145.am/db/2359510/Novo_A_S>,
        <https://1145.am/db/2359683/Novo_A_S>,
        <https://1145.am/db/2360562/Novo>,
        <https://1145.am/db/2361588/Novo_A_S>,
        <https://1145.am/db/2363535/Novo_A_S>,
        <https://1145.am/db/2364505/Novo_A_S>,
        <https://1145.am/db/2364508/Novo_A_S>,
        <https://1145.am/db/2365700/Novo_A_S>,
        <https://1145.am/db/2365701/Novo_A_S>,
        <https://1145.am/db/2366187/Novo_A_S>,
        <https://1145.am/db/2366333/Novo_A_S>,
        <https://1145.am/db/2367275/Novo_A_S>,
        <https://1145.am/db/2367364/Novo_A_S>,
        <https://1145.am/db/2367368/Novo_A_S>,
        <https://1145.am/db/2368297/Novo_A_S>,
        <https://1145.am/db/2368333/Novo_A_S>,
        <https://1145.am/db/2368572/Novo_A_S>,
        <https://1145.am/db/2543793/Novo>,
        <https://1145.am/db/2544115/Novo>,
        <https://1145.am/db/2552947/Novo>,
        <https://1145.am/db/2557027/Novo>,
        <https://1145.am/db/2581901/Novo_A_S>,
        <https://1145.am/db/2581902/Novo_A_S>,
        <https://1145.am/db/2584056/Novo_A_S>,
        <https://1145.am/db/360351/Novo>,
        <https://1145.am/db/751135/Novo> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349406/Sv_Life_Sciences> a org:Organization ;
    ns1:basedInLowRaw "BURLINGTON, Mass" ;
    ns1:description "biotechnology" ;
    ns1:documentDate "2012-04-02T14:49:32+00:00"^^xsd:dateTime ;
    ns1:documentTitle "AlloCure Raises $25 Million Series B Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/allocure-raises-25-million-series-b-venture-financing> ;
    ns1:foundName "SV Life Sciences" ;
    ns1:investor <https://1145.am/db/2349406/Venture_Investment_Allocure_Lundbeckfond_Ventures_Novo_A_S_Sv_Life_Sciences_Completed> ;
    ns1:name "SV Life Sciences" ;
    ns1:sameAsHigh <https://1145.am/db/2327405/Sv_Life_Sciences>,
        <https://1145.am/db/2328815/Sv_Life_Sciences> ;
    ns1:sameAsMedium <https://1145.am/db/2236188/Sv_Life_Sciences>,
        <https://1145.am/db/2246177/Sv_Life_Sciences>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2293765/Sv_Life_Sciences>,
        <https://1145.am/db/2297439/Sv_Life_Sciences>,
        <https://1145.am/db/2297604/Sv_Life_Sciences>,
        <https://1145.am/db/2298869/Sv_Life_Sciences>,
        <https://1145.am/db/2300322/Sv_Life_Sciences>,
        <https://1145.am/db/2302994/Sv_Life_Sciences>,
        <https://1145.am/db/2302995/Sv_Life_Sciences>,
        <https://1145.am/db/2305587/Sv_Life_Sciences>,
        <https://1145.am/db/2310485/Sv_Life_Sciences>,
        <https://1145.am/db/2311540/Sv_Life_Sciences>,
        <https://1145.am/db/2312831/Sv_Life_Sciences>,
        <https://1145.am/db/2312833/Sv_Life_Sciences>,
        <https://1145.am/db/2313287/Sv_Life_Sciences>,
        <https://1145.am/db/2313322/Sv_Life_Sciences>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314625/Sv_Life_Sciences>,
        <https://1145.am/db/2316038/Sv_Life_Sciences>,
        <https://1145.am/db/2317635/Sv_Life_Sciences>,
        <https://1145.am/db/2319338/Sv_Life_Sciences>,
        <https://1145.am/db/2321713/Sv_Life_Sciences>,
        <https://1145.am/db/2321861/Sv_Life_Sciences>,
        <https://1145.am/db/2321870/Sv_Life_Sciences>,
        <https://1145.am/db/2327677/Sv_Life_Sciences>,
        <https://1145.am/db/2329550/Sv_Life_Sciences>,
        <https://1145.am/db/2336313/Sv_Life_Sciences>,
        <https://1145.am/db/2336890/Sv_Life_Sciences>,
        <https://1145.am/db/2337166/Sv_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338196/Sv_Life_Sciences>,
        <https://1145.am/db/2339295/Sv_Life_Sciences>,
        <https://1145.am/db/2342260/Sv_Life_Sciences>,
        <https://1145.am/db/2342261/Sv_Life_Sciences>,
        <https://1145.am/db/2342266/Sv_Life_Sciences>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2342445/Sv_Life_Sciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343467/Sv_Life_Sciences>,
        <https://1145.am/db/2343722/Sv_Life_Sciences>,
        <https://1145.am/db/2343725/Sv_Life_Sciences>,
        <https://1145.am/db/2343737/Sv_Life_Sciences>,
        <https://1145.am/db/2346832/Sv_Life_Sciences>,
        <https://1145.am/db/2347389/Sv_Life_Sciences>,
        <https://1145.am/db/2349426/Sv_Life_Sciences>,
        <https://1145.am/db/2350034/Sv_Life_Sciences>,
        <https://1145.am/db/2350720/Sv_Life_Sciences>,
        <https://1145.am/db/2351394/Sv_Life_Sciences>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2352383/Sv_Life_Sciences>,
        <https://1145.am/db/2353098/Sv_Life_Sciences>,
        <https://1145.am/db/2353439/Sv_Life_Sciences>,
        <https://1145.am/db/2355586/Sv_Life_Sciences>,
        <https://1145.am/db/2356861/Sv_Life_Sciences>,
        <https://1145.am/db/2356876/Sv_Life_Sciences>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358272/Sv_Life_Sciences>,
        <https://1145.am/db/2359125/Sv_Life_Sciences>,
        <https://1145.am/db/2360756/Sv_Life_Sciences>,
        <https://1145.am/db/2360758/Sv_Life_Sciences>,
        <https://1145.am/db/2361065/Sv_Life_Sciences>,
        <https://1145.am/db/2365315/Sv_Life_Sciences>,
        <https://1145.am/db/2366519/Sv_Life_Sciences>,
        <https://1145.am/db/2366860/Sv_Life_Sciences>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2368572/Sv_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2350465/Kai-4169_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition" ;
    ns1:documentDate "2012-04-10T13:17:14+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Amgen to Acquire Privately Held KAI Pharmaceuticals.",
        "THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 10, 2012 /PRNewswire/ - Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.",
        "Under terms of the agreement, Amgen will pay $ 315 million in cash to acquire KAI." ;
    ns1:documentTitle "Amgen to Acquire Privately Held KAI Pharmaceuticals" ;
    ns1:documentURL <https://www.fiercebiotech.com/financials/amgen-to-acquire-privately-held-kai-pharmaceuticals> ;
    ns1:foundName "Acquire",
        "acquire" ;
    ns1:name "Acquire",
        "acquire" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2350465/Kai-4169> ;
    ns1:targetName "KAI Pharmaceuticals",
        "KAI-4169" ;
    ns1:valueRaw "$ 315 million" ;
    ns1:whereGeoName "South San Francisco",
        "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5397765/about.rdf>,
        <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "South San Francisco",
        "United States" .

<https://1145.am/db/2351519/Frazier_Healthcare> a org:Organization ;
    ns1:description "Venture capital" ;
    ns1:documentDate "2012-04-17T11:22:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alcresta Launches Innovative Enzyme-Based Nutritional Company; Secures $10 Million Series A Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alcresta-launches-innovative-enzyme-based-nutritional-company-secures-10-million-series-a-round> ;
    ns1:foundName "Frazier Healthcare" ;
    ns1:investor <https://1145.am/db/2351519/Series_A_Investment_Alcresta_Alcresta_Allena_Pharmaceuticals_Frazier_Healthcare_Completed> ;
    ns1:name "Frazier Healthcare" ;
    ns1:sameAsHigh <https://1145.am/db/1244886/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1245863/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2152824/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2196903/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2278780/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2307829/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318577/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2330075/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2331784/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2338625/Frazier_Healthcare>,
        <https://1145.am/db/2342352/Frazier_Healthcare>,
        <https://1145.am/db/2346532/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2346542/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2356269/Frazier_Healthcare>,
        <https://1145.am/db/2365700/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2366187/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2553555/Frazier_Healthcare>,
        <https://1145.am/db/2592685/Frazier_Healthcare>,
        <https://1145.am/db/505366/Frazier_Healthcare_Partners>,
        <https://1145.am/db/770024/Frazier_Healthcare_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1329605/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1374146/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1813040/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2154276/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2189855/Frazier_Healthcare>,
        <https://1145.am/db/2245812/Frazier_Healthcare>,
        <https://1145.am/db/2292109/Frazier_Healthcare>,
        <https://1145.am/db/2294202/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2303250/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303251/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303257/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2305524/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2307824/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2308855/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2310795/Frazier_Healthcare>,
        <https://1145.am/db/2310798/Frazier_Healthcare>,
        <https://1145.am/db/2311551/Frazier_Healthcare>,
        <https://1145.am/db/2316391/Frazier_Healthcare>,
        <https://1145.am/db/2318274/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318276/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318635/Frazier_Healthcare>,
        <https://1145.am/db/2321216/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2325326/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2326430/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2327441/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2327442/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2330079/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2334616/Frazier_Healthcare>,
        <https://1145.am/db/2334622/Frazier_Healthcare>,
        <https://1145.am/db/2334624/Frazier_Healthcare>,
        <https://1145.am/db/2335675/Frazier_Healthcare>,
        <https://1145.am/db/2335743/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2336032/Frazier_Healthcare>,
        <https://1145.am/db/2337166/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2338633/Frazier_Healthcare>,
        <https://1145.am/db/2339925/Frazier_Healthcare>,
        <https://1145.am/db/2339926/Frazier_Healthcare>,
        <https://1145.am/db/2340204/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2340207/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2342629/Frazier_Healthcare>,
        <https://1145.am/db/2348754/Frazier_Healthcare>,
        <https://1145.am/db/2351520/Frazier_Healthcare>,
        <https://1145.am/db/2356306/Frazier_Healthcare>,
        <https://1145.am/db/2361549/Frazier_Healthcare>,
        <https://1145.am/db/2361551/Frazier_Healthcare>,
        <https://1145.am/db/2366700/Frazier_Healthcare>,
        <https://1145.am/db/2368333/Frazier_Healthcare>,
        <https://1145.am/db/2370761/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2537423/Frazier_Healthcare>,
        <https://1145.am/db/2584561/Frazier_Healthcare_Partners>,
        <https://1145.am/db/490601/Frazier_Healthcare_Partners>,
        <https://1145.am/db/578056/Frazier_Healthcare_Partners>,
        <https://1145.am/db/578059/Frazier_Healthcare_Partners>,
        <https://1145.am/db/699981/Frazier_Healthcare_Partners> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352489/Series_A_Investment_Borealis_Ventures_Google_Ventures_Wingu_Inc_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-18T13:10:47+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Wingu Announces Funding Led by Google Ventures: Software to Accelerate Distributed Drug Discovery for Pharmaceutical Industry.",
        "Wingu Inc., a developer of software designed to enhance the operational efficiency of pharmaceutical research and discovery, today announced a Series A round of funding led by Google Ventures with additional investment from Borealis Ventures." ;
    ns1:documentTitle "Wingu Announces Funding Led by Google Ventures: Software to Accelerate Distributed Drug Discovery for Pharmaceutical Industry" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/wingu-announces-funding-led-by-google-ventures-software-to-accelerate-distributed-drug> ;
    ns1:foundName "Funding",
        "funding" ;
    ns1:name "Funding",
        "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2352489/Wingu_Inc> ;
    ns1:targetDetails "Series A" ;
    ns1:when "2012-04-17T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "April 17, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2352508/Delphi_Ventures> a org:Organization ;
    ns1:basedInLowRaw "BOTHELL, Wash" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-04-19T12:23:46+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alder-biopharmaceuticals-inc-closes-38-million-series-d-financing-to-accelerate-clinical> ;
    ns1:foundName "Delphi Ventures" ;
    ns1:investor <https://1145.am/db/2352508/Series_D_Investment_Alder_Biopharmaceuticals_Inc_Novo_Ventures_Sevin_Rosen_Funds_Ventures_West_Sevin_Rosen_Funds_Ventures_West_Wrf_Capital_Hig_Ventures_Completed> ;
    ns1:name "Delphi Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1086604/Tdf_Ventures>,
        <https://1145.am/db/1147828/Sixthirty_Ventures>,
        <https://1145.am/db/1199050/Rre_Ventures>,
        <https://1145.am/db/1356216/Trestle_Partners>,
        <https://1145.am/db/1358977/Tlv_Partners>,
        <https://1145.am/db/1427471/Twm_Venture_Co>,
        <https://1145.am/db/1546965/Ttv_Capital>,
        <https://1145.am/db/1569853/Titan_Capital>,
        <https://1145.am/db/168364/Trog_Hawley_Capital>,
        <https://1145.am/db/1693922/Remus_Capital>,
        <https://1145.am/db/1700572/Rre_Ventures>,
        <https://1145.am/db/1703609/Ttv_Capital>,
        <https://1145.am/db/1711383/Knollwood_Capital>,
        <https://1145.am/db/1713710/Remus_Capital>,
        <https://1145.am/db/1717313/Titan_Capital>,
        <https://1145.am/db/1741365/Translink_Capital>,
        <https://1145.am/db/1743285/Redline_Capital>,
        <https://1145.am/db/1746842/Tlcom_Capital>,
        <https://1145.am/db/1750867/Ttv_Capital>,
        <https://1145.am/db/1753054/Tahoma_Ventures>,
        <https://1145.am/db/1757065/Ttv_Capital>,
        <https://1145.am/db/1761607/Trousdale_Capital>,
        <https://1145.am/db/1762653/Tlv_Partners>,
        <https://1145.am/db/1763847/Tq_Ventures>,
        <https://1145.am/db/1788126/Translink_Capital>,
        <https://1145.am/db/1790574/Rre_Ventures>,
        <https://1145.am/db/1790953/T5_Capital>,
        <https://1145.am/db/1794935/Rre_Ventures>,
        <https://1145.am/db/1794935/Translink_Capital>,
        <https://1145.am/db/1805165/Translink_Capital>,
        <https://1145.am/db/1813349/Rre_Ventures>,
        <https://1145.am/db/1820363/Rre_Ventures>,
        <https://1145.am/db/1845022/Translink_Capital>,
        <https://1145.am/db/1849600/Sevenventures>,
        <https://1145.am/db/1851689/Translink_Capital>,
        <https://1145.am/db/1853156/T5_Capital>,
        <https://1145.am/db/1854396/Ttv_Capital>,
        <https://1145.am/db/1882330/Rre_Ventures>,
        <https://1145.am/db/1890000/Rre_Ventures>,
        <https://1145.am/db/1892428/T-Venture_Holding>,
        <https://1145.am/db/1984721/Redmile_Group>,
        <https://1145.am/db/2063249/Tlv_Partners>,
        <https://1145.am/db/2069147/Knollwood_Capital>,
        <https://1145.am/db/2142825/Ttv_Capital>,
        <https://1145.am/db/2291818/Delphi_Ventures>,
        <https://1145.am/db/2300306/Delphi_Ventures>,
        <https://1145.am/db/2302333/Delphi_Ventures>,
        <https://1145.am/db/2306568/Delphi_Ventures>,
        <https://1145.am/db/2315943/Truffle_Capital>,
        <https://1145.am/db/2315957/Truffle_Capital>,
        <https://1145.am/db/2317467/Delphi_Ventures>,
        <https://1145.am/db/2317919/Delphi_Ventures>,
        <https://1145.am/db/2332658/Truffle_Capital>,
        <https://1145.am/db/2332659/Truffle_Capital>,
        <https://1145.am/db/2333504/Delphi_Ventures>,
        <https://1145.am/db/2338059/Teralys_Capital>,
        <https://1145.am/db/2343206/Delphi_Ventures>,
        <https://1145.am/db/2360174/Delphi_Ventures>,
        <https://1145.am/db/2362106/Redmile_Group>,
        <https://1145.am/db/2365679/Delphi_Ventures>,
        <https://1145.am/db/2367204/Delphi_Ventures>,
        <https://1145.am/db/254241/Tkc_Capital>,
        <https://1145.am/db/506560/Tdf_Ventures>,
        <https://1145.am/db/539638/Tdf_Ventures>,
        <https://1145.am/db/601455/Tlv_Partners>,
        <https://1145.am/db/669408/Tdf_Ventures>,
        <https://1145.am/db/759595/Redblue_Capital>,
        <https://1145.am/db/885068/Tt_Capital_Partners>,
        <https://1145.am/db/892831/Ttv_Capital>,
        <https://1145.am/db/904252/Trinity_Capital>,
        <https://1145.am/db/952434/Tdf_Ventures>,
        <https://1145.am/db/991859/Ttv_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/1124122/Delphi_Ventures>,
        <https://1145.am/db/1718690/Delphi_Ventures>,
        <https://1145.am/db/2290453/Delphi_Ventures>,
        <https://1145.am/db/2292554/Delphi_Ventures>,
        <https://1145.am/db/2294721/Delphi_Ventures>,
        <https://1145.am/db/2299776/Delphi_Ventures>,
        <https://1145.am/db/2300293/Delphi_Ventures>,
        <https://1145.am/db/2300455/Delphi_Ventures>,
        <https://1145.am/db/2304340/Delphi_Ventures>,
        <https://1145.am/db/2308063/Delphi_Ventures>,
        <https://1145.am/db/2310285/Delphi_Ventures>,
        <https://1145.am/db/2319874/Delphi_Ventures>,
        <https://1145.am/db/2326571/Delphi_Ventures>,
        <https://1145.am/db/2333495/Delphi_Ventures>,
        <https://1145.am/db/2335700/Delphi_Ventures>,
        <https://1145.am/db/2359510/Delphi_Ventures>,
        <https://1145.am/db/2362553/Delphi_Ventures>,
        <https://1145.am/db/2443170/Delphi_Ventures>,
        <https://1145.am/db/2575044/Delphi_Ventures>,
        <https://1145.am/db/2584056/Delphi_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2352525/Ardea_Biosciences_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "merger" ;
    ns1:documentDate "2012-04-23T12:05:11+00:00"^^xsd:dateTime ;
    ns1:documentExtract "AstraZeneca to Acquire Ardea Biosciences for $ 1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout.",
        "SAN DIEGO, CA, Apr 23, 2012 (MARKETWIRE via COMTEX) -AstraZeneca and Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California - based biotechnology company focused on the development of small-molecule therapeutics.",
        "Under the terms of the agreement, AstraZeneca will acquire Ardea for $ 32 per share which represents a total cash value of approximately $ 1.26 billion." ;
    ns1:documentTitle "AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout" ;
    ns1:documentURL <https://www.fiercebiotech.com/financials/astrazeneca-to-acquire-ardea-biosciences-for-1-26-billion-including-lead-product> ;
    ns1:foundName "acquire",
        "merger" ;
    ns1:name "acquire",
        "merger" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2352525/Ardea_Biosciences> ;
    ns1:targetName "Ardea Biosciences" ;
    ns1:valueRaw "$ 1.26 Billion",
        "approximately $ 1.26 billion" ;
    ns1:whereGeoName "California" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5332921/about.rdf> ;
    ns1:whereRaw "California" .

<https://1145.am/db/2355586/Sv_Life_Sciences> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:description "Investing in biotech companies" ;
    ns1:documentDate "2012-05-08T13:06:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Sutro Closes $16.5 Million Second Tranche of Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sutro-closes-16-5-million-second-tranche-of-series-c-financing> ;
    ns1:foundName "SV Life Sciences" ;
    ns1:industry "Biopharma" ;
    ns1:investor <https://1145.am/db/2355586/Series_C_Investment_Alta_Partners_Amgen_Ventures_Lilly_Ventures_Sv_Life_Sciences_Skyline_Ventures_Sutro_Biopharma_Completed> ;
    ns1:name "SV Life Sciences" ;
    ns1:sameAsHigh <https://1145.am/db/1022241/Kbi_Biopharma>,
        <https://1145.am/db/1025273/Kbi_Biopharma>,
        <https://1145.am/db/1133228/Kbi_Biopharma_Sa>,
        <https://1145.am/db/1171451/Artax_Biopharma>,
        <https://1145.am/db/1582024/Samsara_Biocapital>,
        <https://1145.am/db/1971015/Kbi_Biopharma_Inc>,
        <https://1145.am/db/1978913/Kbi_Biopharma>,
        <https://1145.am/db/2003633/Kbi_Biopharma>,
        <https://1145.am/db/2081748/Kbi_Biopharma>,
        <https://1145.am/db/2152526/Genor_Biopharma>,
        <https://1145.am/db/2310591/Sutro_Biopharma>,
        <https://1145.am/db/2327305/Sr_One>,
        <https://1145.am/db/2327403/C2l>,
        <https://1145.am/db/2336468/Sutro_Biopharma>,
        <https://1145.am/db/2342266/Sv_Life_Sciences>,
        <https://1145.am/db/2345530/Plato_Biopharma>,
        <https://1145.am/db/2353438/Sutro_Biopharma>,
        <https://1145.am/db/2361065/Sv_Life_Sciences>,
        <https://1145.am/db/2536577/Kbi_Biopharma> ;
    ns1:sameAsMedium <https://1145.am/db/2236188/Sv_Life_Sciences>,
        <https://1145.am/db/2246177/Sv_Life_Sciences>,
        <https://1145.am/db/2293662/Sv_Life_Sciences>,
        <https://1145.am/db/2293765/Sv_Life_Sciences>,
        <https://1145.am/db/2297439/Sv_Life_Sciences>,
        <https://1145.am/db/2297604/Sv_Life_Sciences>,
        <https://1145.am/db/2298869/Sv_Life_Sciences>,
        <https://1145.am/db/2300322/Sv_Life_Sciences>,
        <https://1145.am/db/2302994/Sv_Life_Sciences>,
        <https://1145.am/db/2302995/Sv_Life_Sciences>,
        <https://1145.am/db/2305587/Sv_Life_Sciences>,
        <https://1145.am/db/2310485/Sv_Life_Sciences>,
        <https://1145.am/db/2311540/Sv_Life_Sciences>,
        <https://1145.am/db/2312831/Sv_Life_Sciences>,
        <https://1145.am/db/2312833/Sv_Life_Sciences>,
        <https://1145.am/db/2313287/Sv_Life_Sciences>,
        <https://1145.am/db/2313322/Sv_Life_Sciences>,
        <https://1145.am/db/2313438/Sv_Life_Sciences>,
        <https://1145.am/db/2314515/Sv_Life_Sciences>,
        <https://1145.am/db/2314625/Sv_Life_Sciences>,
        <https://1145.am/db/2316038/Sv_Life_Sciences>,
        <https://1145.am/db/2317635/Sv_Life_Sciences>,
        <https://1145.am/db/2319338/Sv_Life_Sciences>,
        <https://1145.am/db/2321713/Sv_Life_Sciences>,
        <https://1145.am/db/2321861/Sv_Life_Sciences>,
        <https://1145.am/db/2321870/Sv_Life_Sciences>,
        <https://1145.am/db/2327405/Sv_Life_Sciences>,
        <https://1145.am/db/2327677/Sv_Life_Sciences>,
        <https://1145.am/db/2328815/Sv_Life_Sciences>,
        <https://1145.am/db/2329550/Sv_Life_Sciences>,
        <https://1145.am/db/2336313/Sv_Life_Sciences>,
        <https://1145.am/db/2336890/Sv_Life_Sciences>,
        <https://1145.am/db/2337166/Sv_Life_Sciences>,
        <https://1145.am/db/2338193/Sv_Life_Sciences>,
        <https://1145.am/db/2338196/Sv_Life_Sciences>,
        <https://1145.am/db/2339295/Sv_Life_Sciences>,
        <https://1145.am/db/2342260/Sv_Life_Sciences>,
        <https://1145.am/db/2342261/Sv_Life_Sciences>,
        <https://1145.am/db/2342284/Sv_Life_Sciences>,
        <https://1145.am/db/2342445/Sv_Life_Sciences>,
        <https://1145.am/db/2342862/Sv_Life_Sciences>,
        <https://1145.am/db/2343467/Sv_Life_Sciences>,
        <https://1145.am/db/2343722/Sv_Life_Sciences>,
        <https://1145.am/db/2343725/Sv_Life_Sciences>,
        <https://1145.am/db/2343737/Sv_Life_Sciences>,
        <https://1145.am/db/2346832/Sv_Life_Sciences>,
        <https://1145.am/db/2347389/Sv_Life_Sciences>,
        <https://1145.am/db/2349406/Sv_Life_Sciences>,
        <https://1145.am/db/2349426/Sv_Life_Sciences>,
        <https://1145.am/db/2350034/Sv_Life_Sciences>,
        <https://1145.am/db/2350720/Sv_Life_Sciences>,
        <https://1145.am/db/2351394/Sv_Life_Sciences>,
        <https://1145.am/db/2351397/Sv_Life_Sciences>,
        <https://1145.am/db/2352382/Sv_Life_Sciences>,
        <https://1145.am/db/2352383/Sv_Life_Sciences>,
        <https://1145.am/db/2353098/Sv_Life_Sciences>,
        <https://1145.am/db/2353439/Sv_Life_Sciences>,
        <https://1145.am/db/2356861/Sv_Life_Sciences>,
        <https://1145.am/db/2356876/Sv_Life_Sciences>,
        <https://1145.am/db/2358271/Sv_Life_Sciences>,
        <https://1145.am/db/2358272/Sv_Life_Sciences>,
        <https://1145.am/db/2359125/Sv_Life_Sciences>,
        <https://1145.am/db/2360756/Sv_Life_Sciences>,
        <https://1145.am/db/2360758/Sv_Life_Sciences>,
        <https://1145.am/db/2365315/Sv_Life_Sciences>,
        <https://1145.am/db/2366519/Sv_Life_Sciences>,
        <https://1145.am/db/2366860/Sv_Life_Sciences>,
        <https://1145.am/db/2368251/Sv_Life_Sciences>,
        <https://1145.am/db/2368572/Sv_Life_Sciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356685/Prosonix> a org:Organization ;
    ns1:description "life science" ;
    ns1:documentDate "2012-05-21T19:58:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Prosonix Extends Series B Financing Round to £17.1M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/prosonix-extends-series-b-financing-round-to-%C2%A317-1m> ;
    ns1:foundName "Prosonix",
        "Prosonix (Oxford, UK)" ;
    ns1:industry "pharmaceutical" ;
    ns1:name "Prosonix" ;
    ns1:sameAsHigh <https://1145.am/db/2310707/Prosonix>,
        <https://1145.am/db/2319890/Proteolix>,
        <https://1145.am/db/2321535/Proteolix>,
        <https://1145.am/db/2321536/Proteolix>,
        <https://1145.am/db/2353373/Prosonix> ;
    ns1:sameAsMedium <https://1145.am/db/2356690/Prosonix>,
        <https://1145.am/db/2358747/Prosonix> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2356690/A_Investment_Baird_Venture_Partners_State_Of_Wisconsin_Investment_Board_Zurex_Pharma_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-22T13:14:33+00:00"^^xsd:dateTime ;
    ns1:documentExtract "In other venture news this morning, Madison, WI - based Zurex Pharma says it has raised $ 6.2 million in its A round, with Baird Venture Partners and the State of Wisconsin Investment Board putting up the cash." ;
    ns1:documentTitle "Biotechs raise new VC rounds to back inhalable drugs, antimicrobials" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotechs-raise-new-vc-rounds-to-back-inhalable-drugs-antimicrobials> ;
    ns1:foundName "raised" ;
    ns1:name "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2356690/Zurex_Pharma> ;
    ns1:targetDetails "A" ;
    ns1:valueRaw "$ 6.2 million" ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "U.K." .

<https://1145.am/db/2356690/Prosonix> a org:Organization ;
    ns1:basedInHighGeoName "Oxford" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2640729/about.rdf> ;
    ns1:basedInHighRaw "Oxford" ;
    ns1:documentDate "2012-05-22T13:14:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biotechs raise new VC rounds to back inhalable drugs, antimicrobials" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotechs-raise-new-vc-rounds-to-back-inhalable-drugs-antimicrobials> ;
    ns1:foundName "Prosonix" ;
    ns1:industry "biotech" ;
    ns1:name "Prosonix" ;
    ns1:sameAsHigh <https://1145.am/db/2358747/Prosonix> ;
    ns1:sameAsMedium <https://1145.am/db/2310707/Prosonix>,
        <https://1145.am/db/2353373/Prosonix>,
        <https://1145.am/db/2356685/Prosonix> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2358812/Fletcher_Spaght_Ventures> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-06-06T15:08:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PhaseBio Pharmaceuticals Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing For Advancement of Metabolic and Cardiovascular Product Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/phasebio-pharmaceuticals-received-an-additional-23-million-completion-of-third-tranche-of-a> ;
    ns1:foundName "Fletcher Spaght Ventures" ;
    ns1:investor <https://1145.am/db/2358812/Series_B_Investment_Fletcher_Spaght_Ventures_Hatteras_Venture_Partners_Johnson___Johnson_Development_Corporation_New_Enterprise_Associates_Osi_Investment_Holdings_Phasebio_Pharmaceuticals_Completed> ;
    ns1:name "Fletcher Spaght Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1006252/Menlo_Ventures>,
        <https://1145.am/db/1006262/Com_Prelude_Ventures>,
        <https://1145.am/db/1006574/Integr8d_Capital>,
        <https://1145.am/db/1006880/Root_Ventures>,
        <https://1145.am/db/1007193/Capital_One_Ventures>,
        <https://1145.am/db/1007527/Integr8d_Capital>,
        <https://1145.am/db/1008085/Root_Ventures>,
        <https://1145.am/db/1008260/Servicenow_Ventures>,
        <https://1145.am/db/1010064/Greatpoint_Ventures>,
        <https://1145.am/db/1010064/Maverick_Ventures>,
        <https://1145.am/db/1010199/One9_Ventures>,
        <https://1145.am/db/102038/Allegion_Ventures>,
        <https://1145.am/db/102038/Pathbreaker_Ventures>,
        <https://1145.am/db/102038/West_Ventures>,
        <https://1145.am/db/1023252/Digitalbridge_Ventures>,
        <https://1145.am/db/1024247/Digitalbridge_Ventures>,
        <https://1145.am/db/1024483/Investbridge_Capital>,
        <https://1145.am/db/1026319/Able_Partners>,
        <https://1145.am/db/1034591/Valia_Ventures>,
        <https://1145.am/db/1041601/Kineo_Finance>,
        <https://1145.am/db/1042250/Kineo_Finance>,
        <https://1145.am/db/1043051/Sequoia_Capital>,
        <https://1145.am/db/1043259/Sequoia_Capital>,
        <https://1145.am/db/1043342/Root_Ventures>,
        <https://1145.am/db/1043516/Kineo_Finance>,
        <https://1145.am/db/1045242/Dipalo_Ventures>,
        <https://1145.am/db/1045384/Sequoia_Capital>,
        <https://1145.am/db/1051115/Dn_Capital>,
        <https://1145.am/db/1051644/Vestigo_Ventures>,
        <https://1145.am/db/1052155/Gate_Ventures>,
        <https://1145.am/db/1059993/Tera_Ventures>,
        <https://1145.am/db/1060146/Ulu_Ventures>,
        <https://1145.am/db/1061824/Bluebird_Ventures>,
        <https://1145.am/db/1061911/Ulu_Ventures>,
        <https://1145.am/db/1065366/Applied_Ventures_Llc>,
        <https://1145.am/db/1065544/Menlo_Ventures>,
        <https://1145.am/db/1066120/Crosslink_Capital>,
        <https://1145.am/db/1081175/Rse_Ventures>,
        <https://1145.am/db/1081490/Vinco_Ventures>,
        <https://1145.am/db/1081888/Ggv_Capital>,
        <https://1145.am/db/1082613/Rse_Ventures>,
        <https://1145.am/db/1082719/Dorilton_Ventures>,
        <https://1145.am/db/1082814/Cathexis_Ventures>,
        <https://1145.am/db/1082814/Promus_Ventures>,
        <https://1145.am/db/1082814/Type_One_Ventures>,
        <https://1145.am/db/1084014/Ret_Ventures>,
        <https://1145.am/db/1085867/Ret_Ventures>,
        <https://1145.am/db/1086604/Alerion_Ventures>,
        <https://1145.am/db/1086673/Wintrust_Ventures>,
        <https://1145.am/db/1089416/Nexo_Ventures>,
        <https://1145.am/db/1090643/Argon_Ventures>,
        <https://1145.am/db/1090643/Glasswing_Ventures>,
        <https://1145.am/db/1101244/Acequia_Capital>,
        <https://1145.am/db/1103270/Acequia_Capital>,
        <https://1145.am/db/1106082/Northpond_Ventures>,
        <https://1145.am/db/1106670/Sequoia_Capital>,
        <https://1145.am/db/1111505/Nissay_Capital>,
        <https://1145.am/db/1111505/Remiges_Ventures>,
        <https://1145.am/db/1112074/Nissay_Capital>,
        <https://1145.am/db/1112074/Remiges_Ventures>,
        <https://1145.am/db/1114979/Catapult_Ventures>,
        <https://1145.am/db/1115103/Northpond_Ventures>,
        <https://1145.am/db/1119456/Truist_Ventures>,
        <https://1145.am/db/1119699/Prelude_Ventures>,
        <https://1145.am/db/1120030/Morpheus_Ventures>,
        <https://1145.am/db/1120030/Point72_Ventures>,
        <https://1145.am/db/1120071/Morpheus_Ventures>,
        <https://1145.am/db/1120071/Point72_Ventures>,
        <https://1145.am/db/1122750/Prelude_Ventures>,
        <https://1145.am/db/1129561/Redbeard_Ventures>,
        <https://1145.am/db/1130744/Redbeard_Ventures>,
        <https://1145.am/db/1133003/Sequoia_Capital>,
        <https://1145.am/db/1134165/Boldstart_Ventures>,
        <https://1145.am/db/1136173/Boldstart_Ventures>,
        <https://1145.am/db/1137178/CRV>,
        <https://1145.am/db/1138154/Ggv_Capital>,
        <https://1145.am/db/1139703/Industry_Ventures>,
        <https://1145.am/db/1140286/Origin_Ventures>,
        <https://1145.am/db/1141736/Redpoint_Ventures>,
        <https://1145.am/db/1150154/Riv_Capital>,
        <https://1145.am/db/1150529/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/1150529/Solasta_Ventures>,
        <https://1145.am/db/1151328/Index_Ventures>,
        <https://1145.am/db/1151736/True_Ventures>,
        <https://1145.am/db/1152929/Aperiamventures>,
        <https://1145.am/db/1153706/Index_Ventures>,
        <https://1145.am/db/1154242/True_Ventures>,
        <https://1145.am/db/1163139/Sentiero_Ventures>,
        <https://1145.am/db/1163139/Skyriver_Ventures>,
        <https://1145.am/db/1164299/Lavrock_Ventures>,
        <https://1145.am/db/1164299/Progress_Ventures>,
        <https://1145.am/db/1164688/Abstract_Ventures>,
        <https://1145.am/db/1164688/Spacecadet_Ventures>,
        <https://1145.am/db/1164845/Lavrock_Ventures>,
        <https://1145.am/db/1164845/Progress_Ventures>,
        <https://1145.am/db/1165515/G2_Group_Ventures>,
        <https://1145.am/db/1166154/Allos_Ventures>,
        <https://1145.am/db/1166957/Seedil_Ventures>,
        <https://1145.am/db/1168757/Accomplice_Ventures>,
        <https://1145.am/db/1169687/Artiman_Ventures>,
        <https://1145.am/db/1169687/J_Ventures>,
        <https://1145.am/db/1169687/Nd_Capital>,
        <https://1145.am/db/1169815/Accomplice_Ventures>,
        <https://1145.am/db/1170971/Equinor_Ventures>,
        <https://1145.am/db/1173428/Equinor_Ventures>,
        <https://1145.am/db/1175576/Divcowest_Ventures>,
        <https://1145.am/db/1175576/Point72_Ventures>,
        <https://1145.am/db/1175576/Signia_Ventures>,
        <https://1145.am/db/1176018/First_Star_Ventures>,
        <https://1145.am/db/1187600/Caymus_Equity_Partners_Llc>,
        <https://1145.am/db/11887/Adv>,
        <https://1145.am/db/1190097/Caymus_Equity_Partners_Llc>,
        <https://1145.am/db/1190127/Animo_Ventures>,
        <https://1145.am/db/1190127/Chaac_Ventures>,
        <https://1145.am/db/1190127/Ulu_Ventures>,
        <https://1145.am/db/1196068/Arthur_Ventures>,
        <https://1145.am/db/1196728/Greatpoint_Ventures>,
        <https://1145.am/db/1199177/Greatpoint_Ventures>,
        <https://1145.am/db/1199182/Boxone_Ventures>,
        <https://1145.am/db/1202673/Basecamp_Ventures>,
        <https://1145.am/db/1203180/Basecamp_Ventures>,
        <https://1145.am/db/1206820/Tenoneten_Ventures>,
        <https://1145.am/db/1208519/Tappanhill_Ventures>,
        <https://1145.am/db/1208749/Industry_Ventures>,
        <https://1145.am/db/1208749/Keshif_Ventures>,
        <https://1145.am/db/1208749/Tenoneten_Ventures>,
        <https://1145.am/db/1213076/Equinor_Ventures>,
        <https://1145.am/db/1213076/Scf_Ventures>,
        <https://1145.am/db/1213119/Nevcaut_Ventures>,
        <https://1145.am/db/1215930/Northpond_Ventures>,
        <https://1145.am/db/1219982/Soma_Ventures>,
        <https://1145.am/db/1221237/C2_Ventures>,
        <https://1145.am/db/1222789/Glasswing_Ventures>,
        <https://1145.am/db/1232497/Droia_Ventures>,
        <https://1145.am/db/1232497/Gv>,
        <https://1145.am/db/1233314/Citta_Capital>,
        <https://1145.am/db/1236549/Adit_Ventures>,
        <https://1145.am/db/1247755/Sinewave_Ventures>,
        <https://1145.am/db/1247761/Clear_Ventures>,
        <https://1145.am/db/1248631/Sinewave_Ventures>,
        <https://1145.am/db/1252447/Gaingels>,
        <https://1145.am/db/1256269/Ampd_Ventures_Inc>,
        <https://1145.am/db/1264028/K3_Ventures>,
        <https://1145.am/db/1264587/Index_Ventures>,
        <https://1145.am/db/1268150/Pender_Ventures>,
        <https://1145.am/db/1269968/Abstract_Ventures>,
        <https://1145.am/db/1272468/Launchpad_Capital>,
        <https://1145.am/db/1279264/Roosh_Ventures>,
        <https://1145.am/db/1281079/Morgenthaler_Ventures>,
        <https://1145.am/db/1281647/Morgenthaler_Ventures>,
        <https://1145.am/db/1282820/Agya_Ventures>,
        <https://1145.am/db/1286872/Morevc>,
        <https://1145.am/db/1287476/Felicis_Ventures>,
        <https://1145.am/db/1297417/Bitkraft_Ventures>,
        <https://1145.am/db/1299578/Seedtob_Capital>,
        <https://1145.am/db/1307620/Inventus_Capital_Partners>,
        <https://1145.am/db/1311917/Avid_Ventures>,
        <https://1145.am/db/1311917/Canapi_Ventures>,
        <https://1145.am/db/1322441/Solana_Ventures>,
        <https://1145.am/db/1326376/Dexcom_Ventures>,
        <https://1145.am/db/1329887/Peter_Nagar>,
        <https://1145.am/db/1331691/Pelion_Ventures>,
        <https://1145.am/db/1332798/Acrobator_Ventures>,
        <https://1145.am/db/1334186/First_Ascent_Ventures>,
        <https://1145.am/db/1334193/Version_One_Ventures>,
        <https://1145.am/db/1334395/Gv>,
        <https://1145.am/db/1334895/Soleus_Capital>,
        <https://1145.am/db/1335073/Yl_Ventures>,
        <https://1145.am/db/1335080/Dorilton_Ventures>,
        <https://1145.am/db/1344240/Neotribe_Ventures>,
        <https://1145.am/db/1352420/Vamos_Ventures>,
        <https://1145.am/db/1353145/Infinity_Ventures>,
        <https://1145.am/db/1362743/Cobalt_Ventures>,
        <https://1145.am/db/1373683/BGV>,
        <https://1145.am/db/1375916/J2_Ventures>,
        <https://1145.am/db/1376353/J2_Ventures>,
        <https://1145.am/db/1378599/Menlo_Ventures>,
        <https://1145.am/db/1381832/Northpond_Ventures>,
        <https://1145.am/db/1382787/Northpond_Ventures>,
        <https://1145.am/db/1383818/Newlin_Ventures>,
        <https://1145.am/db/1387557/Naventures>,
        <https://1145.am/db/138878/Metacartel_Ventures>,
        <https://1145.am/db/1398057/Owen_Van_Natta_Temaris___Associates>,
        <https://1145.am/db/1398917/Trousdale_Ventures>,
        <https://1145.am/db/1407553/Sequoia_Capital>,
        <https://1145.am/db/1407614/C2_Ventures>,
        <https://1145.am/db/1411289/Sequoia_Capital>,
        <https://1145.am/db/1411934/Riptide_Ventures>,
        <https://1145.am/db/1425749/Menlo_Ventures>,
        <https://1145.am/db/1425749/Se_Ventures>,
        <https://1145.am/db/1433429/Crosslink_Capital>,
        <https://1145.am/db/1445378/Mvp_Ventures>,
        <https://1145.am/db/1445935/Verissimo_Ventures>,
        <https://1145.am/db/1449316/+Nd_Capital>,
        <https://1145.am/db/1449740/Mistral_Ventures>,
        <https://1145.am/db/1452107/Abstract_Ventures>,
        <https://1145.am/db/1455216/Engage_Ventures>,
        <https://1145.am/db/1455616/Abstract_Ventures>,
        <https://1145.am/db/1463829/1sharpe_Ventures>,
        <https://1145.am/db/1467693/Preseed_Ventures>,
        <https://1145.am/db/1467892/M_Ventures>,
        <https://1145.am/db/1467932/Sequoia_Capital_Gv>,
        <https://1145.am/db/1468981/Preseed_Ventures>,
        <https://1145.am/db/1476448/Origin_Ventures>,
        <https://1145.am/db/1480152/True_Ventures>,
        <https://1145.am/db/1480651/Glasswing_Ventures>,
        <https://1145.am/db/1480989/Infinity_Ventures>,
        <https://1145.am/db/1481875/Infinity_Ventures>,
        <https://1145.am/db/1482705/Oif_Ventures>,
        <https://1145.am/db/1484103/Boxone_Ventures>,
        <https://1145.am/db/1484857/Iu_Ventures>,
        <https://1145.am/db/1488858/Alkeon_Capital>,
        <https://1145.am/db/1490126/Seedtob_Capital>,
        <https://1145.am/db/1490183/Sofinnova_Partners>,
        <https://1145.am/db/1490978/Seedtob_Capital>,
        <https://1145.am/db/1492889/Future_Ventures>,
        <https://1145.am/db/1492889/Radical_Ventures>,
        <https://1145.am/db/1494028/Alkeon_Capital>,
        <https://1145.am/db/1496360/Realist_Ventures>,
        <https://1145.am/db/1503768/Nevateam_Partners>,
        <https://1145.am/db/1508325/Aramco_Ventures>,
        <https://1145.am/db/1509462/F7_Ventures>,
        <https://1145.am/db/1512891/Acme_Capital>,
        <https://1145.am/db/1515109/Cmfg_Ventures>,
        <https://1145.am/db/1515916/Sequoia_Capital>,
        <https://1145.am/db/1520070/Menlo_Ventures>,
        <https://1145.am/db/1520070/Northpond_Ventures>,
        <https://1145.am/db/1520772/January_Ventures>,
        <https://1145.am/db/1537166/Catalio_Capital_Management>,
        <https://1145.am/db/1537970/Catalio_Capital_Management>,
        <https://1145.am/db/1541308/Panoramic_Ventures>,
        <https://1145.am/db/1541797/G1_Ventures>,
        <https://1145.am/db/1545833/Alerion_Ventures>,
        <https://1145.am/db/1545994/Noemis_Ventures>,
        <https://1145.am/db/1546945/Alerion_Ventures>,
        <https://1145.am/db/1546965/Citi_Ventures>,
        <https://1145.am/db/1546965/Truist_Ventures>,
        <https://1145.am/db/1547281/Noemis_Ventures>,
        <https://1145.am/db/1548592/Gopoint_Ventures>,
        <https://1145.am/db/1556397/Dnx_Ventures>,
        <https://1145.am/db/1556442/C16_Ventures>,
        <https://1145.am/db/1557877/Embark_Ventures>,
        <https://1145.am/db/1559824/Embark_Ventures>,
        <https://1145.am/db/1560704/Breaktrail_Ventures>,
        <https://1145.am/db/1563623/Amex_Ventures>,
        <https://1145.am/db/1564049/Amex_Ventures>,
        <https://1145.am/db/1571330/Seae_Ventures>,
        <https://1145.am/db/1571330/Venturesouth>,
        <https://1145.am/db/1572216/Seae_Ventures>,
        <https://1145.am/db/1572216/Venturesouth>,
        <https://1145.am/db/1574557/True_Ventures>,
        <https://1145.am/db/1574647/Vanterra_Ventures>,
        <https://1145.am/db/1575612/Interlace_Ventures>,
        <https://1145.am/db/1575612/Valia_Ventures>,
        <https://1145.am/db/1578178/N49p>,
        <https://1145.am/db/1578178/Naventures>,
        <https://1145.am/db/1578327/Crit_Ventures>,
        <https://1145.am/db/1578327/Nextview_Ventures>,
        <https://1145.am/db/1579770/Schams_Ventures>,
        <https://1145.am/db/1579792/Crit_Ventures>,
        <https://1145.am/db/1579792/Nextview_Ventures>,
        <https://1145.am/db/1580468/Cohort_Ventures>,
        <https://1145.am/db/1582024/Avalon_Ventures>,
        <https://1145.am/db/1582111/Forepont_Capital_Partners>,
        <https://1145.am/db/1583413/Navigare_Ventures>,
        <https://1145.am/db/1615195/Digitalis_Ventures>,
        <https://1145.am/db/1616990/Digitalis_Ventures>,
        <https://1145.am/db/1632002/Catalio_Capital_Management>,
        <https://1145.am/db/1632028/Catalio_Capital_Management>,
        <https://1145.am/db/1632131/Catalio_Capital_Management>,
        <https://1145.am/db/1632156/Catalio_Capital_Management>,
        <https://1145.am/db/1638640/1digi_Ventures>,
        <https://1145.am/db/1649691/Sequoia_Capital>,
        <https://1145.am/db/1653506/Ascendum_Capital>,
        <https://1145.am/db/1653506/Citta_Capital>,
        <https://1145.am/db/1653506/Morgenthaler_Ventures>,
        <https://1145.am/db/1664837/Civilization_Ventures>,
        <https://1145.am/db/1664948/Dreamit_Ventures>,
        <https://1145.am/db/1669908/Aviso_Ventures>,
        <https://1145.am/db/1670128/Primary_Ventures>,
        <https://1145.am/db/1676513/Connect_Ventures>,
        <https://1145.am/db/1685482/Lavrock_Ventures>,
        <https://1145.am/db/1690703/Arkam_Ventures>,
        <https://1145.am/db/1690703/Prosus_Ventures>,
        <https://1145.am/db/1691060/Veblen_Ventures>,
        <https://1145.am/db/1691364/Ts_Ventures>,
        <https://1145.am/db/1693592/Cventures>,
        <https://1145.am/db/1693668/Sunny_Side_Ventures>,
        <https://1145.am/db/1693981/Boldstart_Ventures>,
        <https://1145.am/db/1694241/True_Ventures>,
        <https://1145.am/db/1694301/Dn_Capital>,
        <https://1145.am/db/1694417/Sequoia_Capital>,
        <https://1145.am/db/1694448/Presidio_Ventures>,
        <https://1145.am/db/1694592/Credo_Ventures>,
        <https://1145.am/db/1694592/Susa_Ventures>,
        <https://1145.am/db/1694798/Udc_Ventures>,
        <https://1145.am/db/1694947/Intersouth_Partners>,
        <https://1145.am/db/1695849/Salesforce_Ventures>,
        <https://1145.am/db/1695885/True_Ventures>,
        <https://1145.am/db/1697044/Palomar_Ventures>,
        <https://1145.am/db/1697044/Sequoia_Capital>,
        <https://1145.am/db/1697373/Lerer_Ventures>,
        <https://1145.am/db/1697910/Entrepia_Ventures>,
        <https://1145.am/db/1697910/Innovacom>,
        <https://1145.am/db/1698516/Engage_Ventures>,
        <https://1145.am/db/1698516/Tyh_Ventures>,
        <https://1145.am/db/1698644/Inovia_Capital>,
        <https://1145.am/db/1699263/Contour_Venture_Partners>,
        <https://1145.am/db/1700565/Sequoia_Capital>,
        <https://1145.am/db/1700572/Contour_Venture_Partners>,
        <https://1145.am/db/1701414/Sequoia_Capital>,
        <https://1145.am/db/1702003/Ventures_West>,
        <https://1145.am/db/1702065/Kreos_Capital>,
        <https://1145.am/db/1702472/Chiratae_Ventures>,
        <https://1145.am/db/1702483/Sure_Ventures_Usvp>,
        <https://1145.am/db/1702517/Prime_Ventures>,
        <https://1145.am/db/1702871/Charles_River_Ventures>,
        <https://1145.am/db/1703120/Point72_Ventures>,
        <https://1145.am/db/1703551/People_Ventures>,
        <https://1145.am/db/1703907/T-Venture>,
        <https://1145.am/db/1704404/True_Ventures>,
        <https://1145.am/db/1704740/T-Venture>,
        <https://1145.am/db/1704842/Se_Ventures>,
        <https://1145.am/db/1704871/Yl_Ventures>,
        <https://1145.am/db/1705825/Ventures_Platform>,
        <https://1145.am/db/1707227/Schams_Ventures>,
        <https://1145.am/db/1707540/Prosus_Ventures>,
        <https://1145.am/db/1707567/Contour_Venture_Partners>,
        <https://1145.am/db/1707567/Reign_Ventures>,
        <https://1145.am/db/1707637/Resolute_Ventures>,
        <https://1145.am/db/1707736/Artiman_Ventures>,
        <https://1145.am/db/1708555/20vc>,
        <https://1145.am/db/1708903/Kaedan_Capital>,
        <https://1145.am/db/1709168/Morgenthaler_Ventures>,
        <https://1145.am/db/1710027/Contour_Venture_Partners>,
        <https://1145.am/db/1711208/Sequoia_Capital>,
        <https://1145.am/db/1711383/Aviso_Ventures>,
        <https://1145.am/db/1711383/Pelion_Ventures>,
        <https://1145.am/db/1711750/Index_Ventures>,
        <https://1145.am/db/1711790/CRV>,
        <https://1145.am/db/1711849/K20_Ventures>,
        <https://1145.am/db/1712471/Cervin_Ventures>,
        <https://1145.am/db/1713712/Grotech_Ventures>,
        <https://1145.am/db/1714098/Charles_River_Ventures>,
        <https://1145.am/db/1714148/Ulu_Ventures>,
        <https://1145.am/db/1714624/Abstract_Ventures>,
        <https://1145.am/db/1714630/January_Ventures>,
        <https://1145.am/db/1716124/Appian_Ventures>,
        <https://1145.am/db/1716168/Onset_Ventures>,
        <https://1145.am/db/1716667/Dag_Ventures>,
        <https://1145.am/db/1717317/Index_Ventures>,
        <https://1145.am/db/1718012/Dag_Ventures>,
        <https://1145.am/db/1718012/Presidio_Ventures>,
        <https://1145.am/db/1718018/Ggv_Capital>,
        <https://1145.am/db/1718081/Jafco_Ventures>,
        <https://1145.am/db/1718748/Truist_Ventures>,
        <https://1145.am/db/1718787/J_Ventures>,
        <https://1145.am/db/1719362/True_Ventures>,
        <https://1145.am/db/1719370/Bv_Capital>,
        <https://1145.am/db/1720145/Bessemer_Ventures>,
        <https://1145.am/db/1720182/Convivialité_Ventures>,
        <https://1145.am/db/1720441/Origin_Ventures>,
        <https://1145.am/db/1721171/Citi_Ventures>,
        <https://1145.am/db/1721392/Redpoint_Ventures>,
        <https://1145.am/db/1721393/Trinity_Ventures>,
        <https://1145.am/db/1721548/Ggv_Capital>,
        <https://1145.am/db/1721548/Menlo_Ventures>,
        <https://1145.am/db/1722252/Onset_Ventures>,
        <https://1145.am/db/1723165/Menlo_Ventures>,
        <https://1145.am/db/1723664/T-Venture>,
        <https://1145.am/db/1723932/Citi_Ventures>,
        <https://1145.am/db/1724979/Jafco_Ventures>,
        <https://1145.am/db/1724979/Sequoia_Capital>,
        <https://1145.am/db/1725680/Index_Ventures>,
        <https://1145.am/db/1726088/Zeev_Ventures>,
        <https://1145.am/db/1726121/Index_Ventures>,
        <https://1145.am/db/1726149/Index_Ventures>,
        <https://1145.am/db/1726544/Ei_Ventures>,
        <https://1145.am/db/1727288/Sozo_Ventures>,
        <https://1145.am/db/1728569/Redpoint_Ventures>,
        <https://1145.am/db/1729186/Catamount_Ventures>,
        <https://1145.am/db/1731187/Rho_Ventures>,
        <https://1145.am/db/1731419/Redpoint_Ventures>,
        <https://1145.am/db/1734104/Alpana_Ventures>,
        <https://1145.am/db/1734104/Highsage_Ventures>,
        <https://1145.am/db/1734728/Talis_Capital>,
        <https://1145.am/db/1735194/Eqt_Ventures>,
        <https://1145.am/db/1735248/Corigin_Ventures>,
        <https://1145.am/db/1735726/Nextview_Ventures>,
        <https://1145.am/db/1735755/Firebolt_Ventures>,
        <https://1145.am/db/1735774/Alpha4_Ventures>,
        <https://1145.am/db/1736136/Ggv_Capital>,
        <https://1145.am/db/1737278/Crosslink_Capital>,
        <https://1145.am/db/1737392/Moxxie_Ventures>,
        <https://1145.am/db/1737979/CRV>,
        <https://1145.am/db/1738162/3one4_Capital>,
        <https://1145.am/db/1738300/Chryscapital>,
        <https://1145.am/db/1738415/Capnamic_Ventures>,
        <https://1145.am/db/1738444/Prosus_Ventures>,
        <https://1145.am/db/1738776/Illuminate_Ventures>,
        <https://1145.am/db/1739022/Eventures>,
        <https://1145.am/db/1739042/Experior_Venture_Fund>,
        <https://1145.am/db/1739064/Jsw_Ventures>,
        <https://1145.am/db/1739106/Sequoia_Capital>,
        <https://1145.am/db/1739120/Sequoia_Capital>,
        <https://1145.am/db/1739285/Sequoia_Capital>,
        <https://1145.am/db/1739630/Redsea_Ventures>,
        <https://1145.am/db/1739719/Seedplus>,
        <https://1145.am/db/1739851/Signum_Capital>,
        <https://1145.am/db/1739909/Root_Ventures>,
        <https://1145.am/db/1739946/Dn_Capital>,
        <https://1145.am/db/1740077/3one4_Capital>,
        <https://1145.am/db/1740665/First_Bridge_Ventures>,
        <https://1145.am/db/1740832/J_Ventures>,
        <https://1145.am/db/1740832/Susa_Ventures>,
        <https://1145.am/db/1740859/Ggv_Capital>,
        <https://1145.am/db/1741357/Dn_Capital>,
        <https://1145.am/db/1741575/Addventure>,
        <https://1145.am/db/1741635/Zeev_Ventures>,
        <https://1145.am/db/1742267/Firebolt_Ventures>,
        <https://1145.am/db/1742267/Point72_Ventures>,
        <https://1145.am/db/1743271/Liil_Ventures>,
        <https://1145.am/db/1743348/Felicis_Ventures>,
        <https://1145.am/db/1743409/Dreamit_Ventures>,
        <https://1145.am/db/1743737/Regah_Ventures>,
        <https://1145.am/db/1744229/R7>,
        <https://1145.am/db/1744775/Point72_Ventures>,
        <https://1145.am/db/1744864/Sequoia_Capital>,
        <https://1145.am/db/1744922/Aglaé_Ventures>,
        <https://1145.am/db/1745326/Eqt_Ventures>,
        <https://1145.am/db/1745326/Lios_Ventures>,
        <https://1145.am/db/1745326/Prime_Ventures>,
        <https://1145.am/db/1745746/Garuda_Ventures>,
        <https://1145.am/db/1745746/Starling_Ventures>,
        <https://1145.am/db/1745920/Sequoia_Capital>,
        <https://1145.am/db/1747252/Citi_Ventures>,
        <https://1145.am/db/1747391/Sequoia_Capital>,
        <https://1145.am/db/1747400/Eqt_Ventures>,
        <https://1145.am/db/1747503/Brighteye_Ventures>,
        <https://1145.am/db/1747722/Shinhan_Capital>,
        <https://1145.am/db/1747943/Altai_Ventures>,
        <https://1145.am/db/1748417/Zeev_Ventures>,
        <https://1145.am/db/1749226/Dn_Capital>,
        <https://1145.am/db/1749425/Ac_Ventures>,
        <https://1145.am/db/1749651/Colle_Capital>,
        <https://1145.am/db/1749911/Khwarizmi_Ventures>,
        <https://1145.am/db/1750942/Celesta_Capital>,
        <https://1145.am/db/1750942/Chiratae_Ventures>,
        <https://1145.am/db/1751135/Inovia_Capital>,
        <https://1145.am/db/1751312/Abstract_Ventures>,
        <https://1145.am/db/1751361/Kreos_Capital>,
        <https://1145.am/db/1751506/Ggv_Capital>,
        <https://1145.am/db/1751551/Gaingels>,
        <https://1145.am/db/1751553/Canapi_Ventures>,
        <https://1145.am/db/1751743/Intudo_Ventures>,
        <https://1145.am/db/1751800/Morpheus_Ventures>,
        <https://1145.am/db/1751954/Novastar_Ventures>,
        <https://1145.am/db/1752102/Origin_Ventures>,
        <https://1145.am/db/1752403/Yl_Ventures>,
        <https://1145.am/db/1752998/Aglaé_Ventures>,
        <https://1145.am/db/1753704/Apex_Ventures>,
        <https://1145.am/db/1753721/Financial_Venture_Studio>,
        <https://1145.am/db/1753721/Resolute_Ventures>,
        <https://1145.am/db/1753745/2i_Ventures>,
        <https://1145.am/db/1754211/Citi_Ventures>,
        <https://1145.am/db/1754211/Menlo_Ventures>,
        <https://1145.am/db/1754242/Gsv_Ventures>,
        <https://1145.am/db/1754595/Global_Ventures>,
        <https://1145.am/db/1754595/Otg_Ventures>,
        <https://1145.am/db/1754751/Menlo_Ventures>,
        <https://1145.am/db/1754787/Letsventure>,
        <https://1145.am/db/1754997/Alkeon_Capital>,
        <https://1145.am/db/1755086/Kollective_Ventures>,
        <https://1145.am/db/1755278/Zeev_Ventures>,
        <https://1145.am/db/1755704/Promus_Ventures>,
        <https://1145.am/db/1755828/Future_Ventures>,
        <https://1145.am/db/1755860/Dg_Ventures>,
        <https://1145.am/db/1755860/Intudo_Ventures>,
        <https://1145.am/db/1756040/Altos_Ventures>,
        <https://1145.am/db/1756094/CRV>,
        <https://1145.am/db/1756141/Index_Ventures>,
        <https://1145.am/db/1756231/Kreos_Capital>,
        <https://1145.am/db/1756326/Neotribe_Ventures>,
        <https://1145.am/db/1756384/Abstract_Ventures>,
        <https://1145.am/db/1756384/Lightspeed_Ventures>,
        <https://1145.am/db/1756599/True_Ventures>,
        <https://1145.am/db/1757035/Vectr_Ventures>,
        <https://1145.am/db/1757365/Will_Ventures>,
        <https://1145.am/db/1757382/Gl_Ventures>,
        <https://1145.am/db/1757590/Kreos_Capital>,
        <https://1145.am/db/1757772/Lorimer_Ventures>,
        <https://1145.am/db/1758193/Tenoneten_Ventures>,
        <https://1145.am/db/1758193/Valia_Ventures>,
        <https://1145.am/db/1758313/Venture_Field>,
        <https://1145.am/db/1758622/Oca_Ventures>,
        <https://1145.am/db/1759048/Avid_Ventures>,
        <https://1145.am/db/1759048/Lightspeed_Ventures>,
        <https://1145.am/db/1759567/J_Ventures>,
        <https://1145.am/db/1759922/Verance_Capital>,
        <https://1145.am/db/1760383/True_Ventures>,
        <https://1145.am/db/1760520/Prologis_Ventures>,
        <https://1145.am/db/1760816/Index_Ventures>,
        <https://1145.am/db/1760984/Index_Ventures>,
        <https://1145.am/db/1760984/Sequoia_Capital>,
        <https://1145.am/db/1760985/Frontier_Ventures>,
        <https://1145.am/db/1761126/Redpoint_Ventures>,
        <https://1145.am/db/1761566/Index_Ventures>,
        <https://1145.am/db/1761607/Menlo_Ventures>,
        <https://1145.am/db/1761607/Sinewave_Ventures>,
        <https://1145.am/db/1761957/Alkeon_Capital>,
        <https://1145.am/db/1761999/Ggv_Capital>,
        <https://1145.am/db/1762031/Menlo_Ventures>,
        <https://1145.am/db/1762055/Altos_Ventures>,
        <https://1145.am/db/1762277/Ac_Ventures>,
        <https://1145.am/db/1762453/Line_Ventures>,
        <https://1145.am/db/1762561/Grotech_Ventures>,
        <https://1145.am/db/1762669/Creandum>,
        <https://1145.am/db/1762844/Signum_Capital>,
        <https://1145.am/db/1763356/Aglaé_Ventures>,
        <https://1145.am/db/1763371/Spacecadet_Ventures>,
        <https://1145.am/db/1763395/Idc_Ventures>,
        <https://1145.am/db/1763565/Felicis_Ventures>,
        <https://1145.am/db/1763774/Ggv_Capital>,
        <https://1145.am/db/1763795/Ventures_Platform>,
        <https://1145.am/db/1763795/Xyz_Ventures>,
        <https://1145.am/db/1763875/Golden_Gate_Ventures>,
        <https://1145.am/db/1764027/Menlo_Ventures>,
        <https://1145.am/db/1764255/Pathbreaker_Ventures>,
        <https://1145.am/db/1764255/Stageone_Ventures>,
        <https://1145.am/db/1764345/Talis_Capital>,
        <https://1145.am/db/1764527/Presidio_Ventures>,
        <https://1145.am/db/1764527/Yl_Ventures>,
        <https://1145.am/db/1765273/Adevinta_Ventures>,
        <https://1145.am/db/1765273/Venturefriends>,
        <https://1145.am/db/1765372/Irobot_Ventures>,
        <https://1145.am/db/1765377/Redpoint_Ventures>,
        <https://1145.am/db/1765550/Sequoia_Capital>,
        <https://1145.am/db/1765646/Amiti_Ventures>,
        <https://1145.am/db/1765673/Salesforce_Ventures>,
        <https://1145.am/db/1766091/Inreach_Ventures>,
        <https://1145.am/db/1766096/Borealis_Ventures>,
        <https://1145.am/db/1766096/Northpond_Ventures>,
        <https://1145.am/db/1766253/Redpoint_Ventures>,
        <https://1145.am/db/1766253/True_Ventures>,
        <https://1145.am/db/1766540/Industry_Ventures>,
        <https://1145.am/db/1766978/Rga_Ventures>,
        <https://1145.am/db/1768099/Eventures>,
        <https://1145.am/db/1768363/Golden_Gate_Ventures>,
        <https://1145.am/db/1768841/Sequoia_Capital>,
        <https://1145.am/db/1769188/Felicis_Ventures>,
        <https://1145.am/db/1770095/Crosslink_Capital>,
        <https://1145.am/db/1770139/Victress_Capital>,
        <https://1145.am/db/1770265/Techstars_Ventures>,
        <https://1145.am/db/1770372/Avalon_Ventures>,
        <https://1145.am/db/1770372/Korelya_Capital>,
        <https://1145.am/db/1770802/Sequoia_Capital>,
        <https://1145.am/db/1770982/Gv>,
        <https://1145.am/db/1770982/Index_Ventures>,
        <https://1145.am/db/1771011/Ggv_Capital>,
        <https://1145.am/db/1771548/Seekdource_Capital>,
        <https://1145.am/db/1771613/Creandum>,
        <https://1145.am/db/1771642/Felicis_Ventures>,
        <https://1145.am/db/1772004/Raed_Ventures>,
        <https://1145.am/db/1772004/Seed_Equity_Venture_Partners>,
        <https://1145.am/db/1772381/Altos_Ventures>,
        <https://1145.am/db/1772452/Connect_Ventures>,
        <https://1145.am/db/1773130/Capnamic_Ventures>,
        <https://1145.am/db/1773143/Venturefriends>,
        <https://1145.am/db/1773323/Crosslink_Capital>,
        <https://1145.am/db/1774348/True_Ventures>,
        <https://1145.am/db/1774535/Felicis_Ventures>,
        <https://1145.am/db/1774535/Susa_Ventures>,
        <https://1145.am/db/1774658/Gv>,
        <https://1145.am/db/1775965/Felicis_Ventures>,
        <https://1145.am/db/1776340/Ggv_Capital>,
        <https://1145.am/db/1776340/Menlo_Ventures>,
        <https://1145.am/db/1776537/Origin_Ventures>,
        <https://1145.am/db/1776537/Tekton_Ventures>,
        <https://1145.am/db/1776621/Redpoint_Ventures>,
        <https://1145.am/db/1777289/Dn_Capital>,
        <https://1145.am/db/1777563/Evolv_Ventures>,
        <https://1145.am/db/1777563/Ggv_Capital>,
        <https://1145.am/db/1777848/Industry_Ventures>,
        <https://1145.am/db/1778935/Oryzn_Capital>,
        <https://1145.am/db/1780024/Partech_Ventures>,
        <https://1145.am/db/1782098/Addventure>,
        <https://1145.am/db/1782221/Point72_Ventures>,
        <https://1145.am/db/1783189/Citi_Ventures>,
        <https://1145.am/db/1784644/Creathor_Ventures>,
        <https://1145.am/db/1784964/Clear_Ventures>,
        <https://1145.am/db/1785361/M_Ventures>,
        <https://1145.am/db/1786249/Redpoint_Ventures>,
        <https://1145.am/db/1786249/Resolute_Ventures>,
        <https://1145.am/db/1786663/Edenred_Capital_Partners>,
        <https://1145.am/db/1786663/Eqt_Ventures>,
        <https://1145.am/db/1787249/Kpn_Ventures>,
        <https://1145.am/db/1787342/Korelya_Capital>,
        <https://1145.am/db/1787536/Point72_Ventures>,
        <https://1145.am/db/1787791/True_Ventures>,
        <https://1145.am/db/1787886/True_Ventures>,
        <https://1145.am/db/1788328/Index_Ventures>,
        <https://1145.am/db/1788570/Sequoia_Capital>,
        <https://1145.am/db/1788726/Redbeat_Capital>,
        <https://1145.am/db/1789460/Eventures>,
        <https://1145.am/db/1789754/Advancit_Capital>,
        <https://1145.am/db/1790280/Arthur_Ventures>,
        <https://1145.am/db/1790399/Capnamic_Ventures>,
        <https://1145.am/db/1790574/Crosslink_Capital>,
        <https://1145.am/db/1790574/Red_Swan_Ventures>,
        <https://1145.am/db/1790574/Sherpa_Ventures>,
        <https://1145.am/db/1790641/Dn_Capital>,
        <https://1145.am/db/1790771/Redpoint_Ventures>,
        <https://1145.am/db/1790777/Connect_Ventures>,
        <https://1145.am/db/1791216/True_Ventures>,
        <https://1145.am/db/1791303/Index_Ventures>,
        <https://1145.am/db/1791628/Industry_Ventures>,
        <https://1145.am/db/1791838/Advancit_Capital>,
        <https://1145.am/db/1792186/Sequoia_Capital>,
        <https://1145.am/db/1792771/Softtechvc>,
        <https://1145.am/db/1792887/Kaedan_Capital>,
        <https://1145.am/db/1792887/Stageone_Ventures>,
        <https://1145.am/db/1794699/Ws_Ventures>,
        <https://1145.am/db/1794935/Intervest_Co_Ltd>,
        <https://1145.am/db/1795020/Redpoint_Ventures>,
        <https://1145.am/db/1795210/Sequoia_Capital>,
        <https://1145.am/db/1795469/Index_Ventures>,
        <https://1145.am/db/1795538/Skystar_Capital>,
        <https://1145.am/db/1796109/Contour_Venture_Partners>,
        <https://1145.am/db/1796593/Tenoneten_Ventures>,
        <https://1145.am/db/1796901/Red_Swan_Ventures>,
        <https://1145.am/db/1796922/Cagni_Ventures>,
        <https://1145.am/db/1797209/Kdwc_Ventures>,
        <https://1145.am/db/1797518/Sequoia_Capital>,
        <https://1145.am/db/1797899/Brave_Ventures>,
        <https://1145.am/db/1797999/Redpoint_Ventures>,
        <https://1145.am/db/1798568/Index_Ventures>,
        <https://1145.am/db/1799099/Inovia_Capital>,
        <https://1145.am/db/1799184/Ggv_Capital>,
        <https://1145.am/db/1800232/Index_Ventures>,
        <https://1145.am/db/1800929/Ventureast>,
        <https://1145.am/db/1802086/High_Line_Ventures>,
        <https://1145.am/db/1802227/Advancit_Capital>,
        <https://1145.am/db/1802288/Sequoia_Capital>,
        <https://1145.am/db/1802336/Capnamic_Ventures>,
        <https://1145.am/db/1804102/True_Ventures>,
        <https://1145.am/db/1804247/Holtzbrinck_Ventures>,
        <https://1145.am/db/1804476/Felicis_Ventures>,
        <https://1145.am/db/1804476/True_Ventures>,
        <https://1145.am/db/1804992/Talis_Capital>,
        <https://1145.am/db/1805389/Industry_Ventures>,
        <https://1145.am/db/1805604/Connect_Ventures>,
        <https://1145.am/db/1805604/Inreach_Ventures>,
        <https://1145.am/db/1806644/Sequoia_Capital>,
        <https://1145.am/db/1806739/Golden_Gate_Ventures>,
        <https://1145.am/db/1808047/Salesforce_Ventures>,
        <https://1145.am/db/1808505/Helion_Ventures>,
        <https://1145.am/db/1808723/Mindworks_Ventures>,
        <https://1145.am/db/1808735/Commonangels_Ventures>,
        <https://1145.am/db/1809007/Sequoia_Capital>,
        <https://1145.am/db/1809844/Real_Ventures>,
        <https://1145.am/db/1809862/Acequia_Capital>,
        <https://1145.am/db/1810384/Starstrike_Ventures>,
        <https://1145.am/db/1810710/Ia_Ventures>,
        <https://1145.am/db/1810714/Catalus_Capital>,
        <https://1145.am/db/1810769/Eventures>,
        <https://1145.am/db/1810769/Sequoia_Capital>,
        <https://1145.am/db/1811357/Index_Ventures>,
        <https://1145.am/db/1812233/Sequoia_Capital>,
        <https://1145.am/db/1812856/Exfinity_Ventures>,
        <https://1145.am/db/1813375/Creandum>,
        <https://1145.am/db/1813575/Ggv_Capital>,
        <https://1145.am/db/1813944/Menlo_Ventures>,
        <https://1145.am/db/1814064/Index_Ventures>,
        <https://1145.am/db/1814643/Corigin_Ventures>,
        <https://1145.am/db/1814643/Launchcapital>,
        <https://1145.am/db/1815038/Plus_Ventures>,
        <https://1145.am/db/1815507/Globis_Capital_Partners>,
        <https://1145.am/db/1815697/Cherubic_Ventures>,
        <https://1145.am/db/1815701/True_Ventures>,
        <https://1145.am/db/1815886/Teneleven_Ventures>,
        <https://1145.am/db/1816491/Grotech_Ventures>,
        <https://1145.am/db/1818174/Advancit_Capital>,
        <https://1145.am/db/1818876/Kreos_Capital>,
        <https://1145.am/db/1818901/Sequoia_Capital>,
        <https://1145.am/db/1819374/Rothenberg_Ventures>,
        <https://1145.am/db/1819387/Index_Ventures>,
        <https://1145.am/db/1820882/Inven_Capital>,
        <https://1145.am/db/1821174/Index_Ventures>,
        <https://1145.am/db/1821711/Winton_Ventures>,
        <https://1145.am/db/1821752/Sequoia_Capital>,
        <https://1145.am/db/1823162/True_Ventures>,
        <https://1145.am/db/1823217/Kdc_Ventures>,
        <https://1145.am/db/1823217/Nbm_Ventures>,
        <https://1145.am/db/1823684/Dcm_Ventures>,
        <https://1145.am/db/1823684/Idg_Ventures>,
        <https://1145.am/db/1824252/Allos_Ventures>,
        <https://1145.am/db/1824253/Trinity_Ventures>,
        <https://1145.am/db/1824944/True_Ventures>,
        <https://1145.am/db/1825465/Ben_Narasin>,
        <https://1145.am/db/1825713/Menlo_Ventures>,
        <https://1145.am/db/1825946/Lerer_Ventures>,
        <https://1145.am/db/1826265/Idg_Ventures>,
        <https://1145.am/db/1826648/True_Ventures>,
        <https://1145.am/db/1826922/Ggv_Capital>,
        <https://1145.am/db/1827021/Dag_Ventures>,
        <https://1145.am/db/1828036/Redpoint_Ventures>,
        <https://1145.am/db/1828092/Eden_Ventures>,
        <https://1145.am/db/1828251/Golden_Gate_Ventures>,
        <https://1145.am/db/1828455/Quotidien_Ventures>,
        <https://1145.am/db/1828658/Focus_Ventures>,
        <https://1145.am/db/1828663/Great_Oaks_Ventures>,
        <https://1145.am/db/1828663/Inovia_Capital>,
        <https://1145.am/db/1829257/Sequoia_Capital>,
        <https://1145.am/db/1829422/Felicis_Ventures>,
        <https://1145.am/db/1829422/Rothenberg_Ventures>,
        <https://1145.am/db/1829612/Lerer_Ventures>,
        <https://1145.am/db/1830502/Frontline_Ventures>,
        <https://1145.am/db/1830613/True_Ventures>,
        <https://1145.am/db/1830809/Numecent>,
        <https://1145.am/db/1830809/T-Ventures>,
        <https://1145.am/db/1830817/Charles_River_Ventures>,
        <https://1145.am/db/1831577/Artiman_Ventures>,
        <https://1145.am/db/1831577/Sofinnova_Ventures>,
        <https://1145.am/db/1831764/Sequoia_Capital>,
        <https://1145.am/db/1832038/True_Ventures>,
        <https://1145.am/db/1832316/Partech_Ventures>,
        <https://1145.am/db/1832316/Scentan_Ventures>,
        <https://1145.am/db/1832316/Startcaps_Ventures>,
        <https://1145.am/db/1832856/Grotech_Ventures>,
        <https://1145.am/db/1834224/Avalon_Ventures>,
        <https://1145.am/db/1834224/Orix_Ventures>,
        <https://1145.am/db/1834305/Charles_River_Ventures>,
        <https://1145.am/db/1834334/Altos_Ventures>,
        <https://1145.am/db/1834334/Baseline_Ventures>,
        <https://1145.am/db/1834334/Firebolt_Ventures>,
        <https://1145.am/db/1834334/Lazerow_Ventures>,
        <https://1145.am/db/1834520/Ben_Horowitz>,
        <https://1145.am/db/1834541/Avalon_Ventures>,
        <https://1145.am/db/1834708/Sherpa_Ventures>,
        <https://1145.am/db/1834965/Lerer_Ventures>,
        <https://1145.am/db/1835229/Lerer_Ventures>,
        <https://1145.am/db/1835229/Trinity_Ventures>,
        <https://1145.am/db/1835229/Xg_Ventures>,
        <https://1145.am/db/1835740/Lerer_Ventures>,
        <https://1145.am/db/1835749/Gree_Ventures>,
        <https://1145.am/db/1835825/Focus_Ventures>,
        <https://1145.am/db/1836984/Siemer_Ventures>,
        <https://1145.am/db/1836984/Tekton_Ventures>,
        <https://1145.am/db/1837741/Menlo_Ventures>,
        <https://1145.am/db/1838026/Plus_Ventures>,
        <https://1145.am/db/1840775/Ggv_Capital>,
        <https://1145.am/db/1840881/Felicis_Ventures>,
        <https://1145.am/db/1840881/Trinity_Ventures>,
        <https://1145.am/db/1841176/Lerer_Ventures>,
        <https://1145.am/db/1841176/True_Ventures>,
        <https://1145.am/db/1842402/Index_Ventures>,
        <https://1145.am/db/1842402/Redpoint_Ventures>,
        <https://1145.am/db/1842898/Grotech_Ventures>,
        <https://1145.am/db/1843003/Eventures>,
        <https://1145.am/db/1843003/Index_Ventures>,
        <https://1145.am/db/1843031/Index_Ventures>,
        <https://1145.am/db/1843449/Redpoint_Ventures>,
        <https://1145.am/db/1843602/Nextview_Ventures>,
        <https://1145.am/db/1843659/Sequoia_Capital>,
        <https://1145.am/db/1844143/Inovia_Capital>,
        <https://1145.am/db/1844472/Sequoia_Capital>,
        <https://1145.am/db/1844737/True_Ventures>,
        <https://1145.am/db/1844931/Charles_River_Ventures>,
        <https://1145.am/db/1845308/Ia_Ventures>,
        <https://1145.am/db/1845960/Lerer_Ventures>,
        <https://1145.am/db/1846254/Index_Ventures>,
        <https://1145.am/db/1846483/Inovia_Capital>,
        <https://1145.am/db/1847463/Prism_Ventureworks>,
        <https://1145.am/db/1847752/T-Venture>,
        <https://1145.am/db/1848523/Trinity_Ventures>,
        <https://1145.am/db/1849673/Inventure_Partners>,
        <https://1145.am/db/1849884/Index_Ventures>,
        <https://1145.am/db/1849949/Holtzbrinck_Ventures>,
        <https://1145.am/db/1850020/Sequoia_Capital>,
        <https://1145.am/db/1850668/True_Ventures>,
        <https://1145.am/db/1850989/Artiman_Ventures>,
        <https://1145.am/db/1850989/Sequoia_Capital>,
        <https://1145.am/db/1851035/Acequia_Capital>,
        <https://1145.am/db/1851035/Index_Ventures>,
        <https://1145.am/db/1851035/Redpoint_Ventures>,
        <https://1145.am/db/1851705/Promus_Ventures>,
        <https://1145.am/db/1851854/Partech_Ventures>,
        <https://1145.am/db/1851923/Dag_Ventures>,
        <https://1145.am/db/1852308/Plus_Ventures>,
        <https://1145.am/db/1852513/Quotidian_Ventures>,
        <https://1145.am/db/1852513/Trestle_Ventures>,
        <https://1145.am/db/1852556/Dave_Morin>,
        <https://1145.am/db/1852806/Redpoint_Ventures>,
        <https://1145.am/db/1852870/Golden_Gate_Ventures>,
        <https://1145.am/db/1852870/Siemer_Ventures>,
        <https://1145.am/db/1853417/Catamount_Ventures>,
        <https://1145.am/db/1853496/T-Ventures>,
        <https://1145.am/db/1854200/Ggv_Capital>,
        <https://1145.am/db/1854201/Charles_River_Ventures>,
        <https://1145.am/db/1854786/Eden_Ventures>,
        <https://1145.am/db/1854874/Crosslink_Capital>,
        <https://1145.am/db/1854874/Sherpa_Ventures>,
        <https://1145.am/db/1854874/Softtech>,
        <https://1145.am/db/1855353/Sequoia_Capital>,
        <https://1145.am/db/1855363/True_Ventures>,
        <https://1145.am/db/1855403/Rho_Ventures>,
        <https://1145.am/db/1855780/Bds_Ventures>,
        <https://1145.am/db/1855780/Ggv_Capital>,
        <https://1145.am/db/1856191/Creandum>,
        <https://1145.am/db/1856380/Softtech>,
        <https://1145.am/db/1856402/Sequoia_Capital>,
        <https://1145.am/db/1856457/Aeris_Capital>,
        <https://1145.am/db/1856616/Redpoint_Ventures>,
        <https://1145.am/db/1856834/Sequoia_Capital>,
        <https://1145.am/db/1857635/Rikard_Steiber>,
        <https://1145.am/db/1857659/Revolution_Ventures>,
        <https://1145.am/db/1857930/Inovia_Capital>,
        <https://1145.am/db/1857930/Version_One_Ventures>,
        <https://1145.am/db/1858323/Avalon_Ventures>,
        <https://1145.am/db/1858545/Sequoia_Capital>,
        <https://1145.am/db/1858592/Apex_Venture_Partners>,
        <https://1145.am/db/1858592/Origin_Ventures>,
        <https://1145.am/db/1858991/Capnamic_Ventures>,
        <https://1145.am/db/1859199/True_Ventures>,
        <https://1145.am/db/1859314/Version_One_Ventures>,
        <https://1145.am/db/1860163/Inovia_Capital>,
        <https://1145.am/db/1860345/Commonangels>,
        <https://1145.am/db/1860345/Launchcapital>,
        <https://1145.am/db/1861054/Sequoia_Capital>,
        <https://1145.am/db/1861355/Rho_Ventures>,
        <https://1145.am/db/1862590/Felicis_Ventures>,
        <https://1145.am/db/1862878/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1863147/Apex_Venture_Partners>,
        <https://1145.am/db/1864601/Trinity_Ventures>,
        <https://1145.am/db/1864646/Inventus_Capital>,
        <https://1145.am/db/1865436/Sequoia_Capital>,
        <https://1145.am/db/1865480/Felicis_Ventures>,
        <https://1145.am/db/1865480/Sequoia_Capital>,
        <https://1145.am/db/1865480/Sherpalo_Ventures>,
        <https://1145.am/db/1866032/Launchcapital>,
        <https://1145.am/db/1866134/Embarcadero_Ventures>,
        <https://1145.am/db/1866134/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1866155/Presidio_Ventures>,
        <https://1145.am/db/1867543/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1867599/Cava_Capital>,
        <https://1145.am/db/1868107/Redpoint_Ventures>,
        <https://1145.am/db/1868109/Charles_River_Ventures>,
        <https://1145.am/db/1868178/True_Ventures>,
        <https://1145.am/db/1870015/Redpoint_Ventures>,
        <https://1145.am/db/1870465/Nextview_Ventures>,
        <https://1145.am/db/1871221/True_Ventures>,
        <https://1145.am/db/1871574/Redpoint_Ventures>,
        <https://1145.am/db/1871777/Charles_River_Ventures>,
        <https://1145.am/db/1871784/Charles_River_Ventures>,
        <https://1145.am/db/1871888/Charles_River_Ventures>,
        <https://1145.am/db/1873191/El_Dorado_Ventures>,
        <https://1145.am/db/1873680/Crosslink_Capital>,
        <https://1145.am/db/1873680/Lerer_Ventures>,
        <https://1145.am/db/1873680/Xg_Ventures>,
        <https://1145.am/db/1874749/True_Ventures>,
        <https://1145.am/db/1874937/Quotidian_Ventures>,
        <https://1145.am/db/1877243/Felicis_Ventures>,
        <https://1145.am/db/1877283/Northzone_Ventures>,
        <https://1145.am/db/1877473/True_Ventures>,
        <https://1145.am/db/1877642/Dag_Ventures>,
        <https://1145.am/db/1878620/Ggv_Capital>,
        <https://1145.am/db/1879279/High_Line_Ventures>,
        <https://1145.am/db/1879759/T-Venture>,
        <https://1145.am/db/1880679/Northzone_Ventures>,
        <https://1145.am/db/1881464/Ggv_Capital>,
        <https://1145.am/db/1881748/Morgenthaler_Ventures>,
        <https://1145.am/db/1882330/New_World_Ventures>,
        <https://1145.am/db/1882727/Charles_River_Ventures>,
        <https://1145.am/db/1882907/Starfish_Ventures>,
        <https://1145.am/db/1883568/Eden_Ventures>,
        <https://1145.am/db/1883572/Astutia_Ventures>,
        <https://1145.am/db/1886402/New_Atlantic_Ventures>,
        <https://1145.am/db/1886566/Sequoia_Capital>,
        <https://1145.am/db/1889394/Focus_Ventures>,
        <https://1145.am/db/1889629/Sequoia_Capital>,
        <https://1145.am/db/1890000/Lerer_Ventures>,
        <https://1145.am/db/1890122/East_Ventures>,
        <https://1145.am/db/1890133/Crosslink_Capital>,
        <https://1145.am/db/1890133/Dag_Ventures>,
        <https://1145.am/db/1890133/Focus_Ventures>,
        <https://1145.am/db/1890157/Morgenthaler_Ventures>,
        <https://1145.am/db/1890208/Menlo_Ventures>,
        <https://1145.am/db/1890619/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1890839/Inovia_Capital>,
        <https://1145.am/db/1890903/Miven_Ventures>,
        <https://1145.am/db/1891615/Holtzbrinck_Ventures>,
        <https://1145.am/db/1891777/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1891913/New_World_Ventures>,
        <https://1145.am/db/1891913/Oca_Ventures>,
        <https://1145.am/db/1891926/New_World_Ventures>,
        <https://1145.am/db/1892050/Charles_River_Ventures>,
        <https://1145.am/db/1892105/Crosscreek_Capital>,
        <https://1145.am/db/1892105/Industry_Ventures>,
        <https://1145.am/db/1892106/Altos_Ventures>,
        <https://1145.am/db/1892106/Illuminate_Ventures>,
        <https://1145.am/db/1892620/True_Ventures>,
        <https://1145.am/db/1892674/Appian_Ventures>,
        <https://1145.am/db/1892902/Crosslink_Capital>,
        <https://1145.am/db/1892955/Guy_Gamzu>,
        <https://1145.am/db/1895072/Nextview_Ventures>,
        <https://1145.am/db/1895951/Windward_Ventures>,
        <https://1145.am/db/1896159/Ia_Ventures>,
        <https://1145.am/db/1896185/Index_Ventures>,
        <https://1145.am/db/1896379/Index_Ventures>,
        <https://1145.am/db/1896379/Redpoint_Ventures>,
        <https://1145.am/db/1896419/True_Ventures>,
        <https://1145.am/db/1902330/Baseline_Ventures>,
        <https://1145.am/db/1905483/Industry_Ventures>,
        <https://1145.am/db/1905858/Index_Ventures>,
        <https://1145.am/db/1907771/Dag_Ventures>,
        <https://1145.am/db/1909430/Menlo_Ventures>,
        <https://1145.am/db/1909651/Revolution_Ventures>,
        <https://1145.am/db/1910694/True_Ventures>,
        <https://1145.am/db/1910922/Charles_River_Ventures>,
        <https://1145.am/db/1912684/Charles_River_Ventures>,
        <https://1145.am/db/1913863/Tl_Ventures>,
        <https://1145.am/db/1913874/Redpoint_Ventures>,
        <https://1145.am/db/1914220/Index_Ventures>,
        <https://1145.am/db/1915393/Mohr_Davidow_Ventures>,
        <https://1145.am/db/1915862/Dag_Ventures>,
        <https://1145.am/db/1915862/Focus_Ventures>,
        <https://1145.am/db/1919724/Dag_Ventures>,
        <https://1145.am/db/1920478/Dawntreader_Ventures>,
        <https://1145.am/db/1920837/Onset_Ventures>,
        <https://1145.am/db/1927817/Trm_Ventures>,
        <https://1145.am/db/1939926/Cobalt_Ventures>,
        <https://1145.am/db/1945479/Crosslink_Capital>,
        <https://1145.am/db/1947303/Cavallo_Ventures>,
        <https://1145.am/db/1947312/Boldstart_Ventures>,
        <https://1145.am/db/1952989/Singularity_Ventures>,
        <https://1145.am/db/1954147/Accomplice_Ventures>,
        <https://1145.am/db/1957179/Sozo_Ventures>,
        <https://1145.am/db/1958963/Prosus_Ventures>,
        <https://1145.am/db/1959001/Capital_Technology_Ventures>,
        <https://1145.am/db/1959001/Glasswing_Ventures>,
        <https://1145.am/db/1962819/Connetic_Ventures>,
        <https://1145.am/db/1967592/Firebolt_Ventures>,
        <https://1145.am/db/1967683/Dig_Ventures_Vine_Ventures>,
        <https://1145.am/db/1975490/Northview_Ventures>,
        <https://1145.am/db/1975547/Nanban_Ventures>,
        <https://1145.am/db/1975547/Sinewave_Ventures>,
        <https://1145.am/db/1986122/Menlo_Ventures>,
        <https://1145.am/db/1995926/Neotribe_Ventures>,
        <https://1145.am/db/1998196/Gni_Group_Ltd>,
        <https://1145.am/db/1999771/Servicenow_Ventures>,
        <https://1145.am/db/2004427/Convivialité_Ventures>,
        <https://1145.am/db/2005131/Wwventures>,
        <https://1145.am/db/2007132/Nventures>,
        <https://1145.am/db/2020041/Inovia_Capital>,
        <https://1145.am/db/2020041/TCV>,
        <https://1145.am/db/2023596/Salesforce_Ventures>,
        <https://1145.am/db/2025081/True_Ventures>,
        <https://1145.am/db/2029648/Sequoia_Capital>,
        <https://1145.am/db/2035454/Gv>,
        <https://1145.am/db/2036021/Clear_Ventures>,
        <https://1145.am/db/2038783/Sequoia_Capital>,
        <https://1145.am/db/2039177/Stellantis_Ventures>,
        <https://1145.am/db/2041480/Brunnur_Ventures>,
        <https://1145.am/db/2042858/Gv>,
        <https://1145.am/db/2044380/20sales>,
        <https://1145.am/db/2045587/Veritec_Ventures>,
        <https://1145.am/db/2050229/Nventures>,
        <https://1145.am/db/2050359/At_One_Ventures>,
        <https://1145.am/db/2051164/Aviso_Ventures>,
        <https://1145.am/db/2053027/Glasswing_Ventures>,
        <https://1145.am/db/2055707/Globis_Capital_Partners>,
        <https://1145.am/db/2056931/We_Ventures>,
        <https://1145.am/db/2060003/Crit_Ventures_100___100_Ventures>,
        <https://1145.am/db/2061278/Incisive_Ventures>,
        <https://1145.am/db/2061278/Volo_Ventures>,
        <https://1145.am/db/2063642/Clear_Bridge_Ventures>,
        <https://1145.am/db/2063967/Vsquared_Ventures>,
        <https://1145.am/db/2069147/Boldstart_Ventures>,
        <https://1145.am/db/2069147/Pelion_Ventures>,
        <https://1145.am/db/2069147/Salesforce_Ventures>,
        <https://1145.am/db/2069495/Intermountain_Ventures>,
        <https://1145.am/db/2069495/Northpond_Ventures>,
        <https://1145.am/db/2073129/Abstract_Ventures>,
        <https://1145.am/db/2073132/Idc_Ventures>,
        <https://1145.am/db/2073480/Astellas_Venture_Management>,
        <https://1145.am/db/2075625/Rocketship_Ventures>,
        <https://1145.am/db/2081180/S4s_Ventures>,
        <https://1145.am/db/2081674/Capital_One_Ventures>,
        <https://1145.am/db/2082068/Arctern_Ventures>,
        <https://1145.am/db/2082068/Prelude_Ventures>,
        <https://1145.am/db/2083987/Vanterra_Ventures>,
        <https://1145.am/db/2087289/Jven_Capital>,
        <https://1145.am/db/2087289/Northpond_Ventures>,
        <https://1145.am/db/2089206/Crescendo_Venture_Partners>,
        <https://1145.am/db/2093427/Yl_Ventures>,
        <https://1145.am/db/2093713/Yl_Ventures>,
        <https://1145.am/db/209861/Crosslink_Capital>,
        <https://1145.am/db/2100116/Epic_Ventures>,
        <https://1145.am/db/2107533/Globis_Capital_Partners>,
        <https://1145.am/db/2109529/Point72_Ventures>,
        <https://1145.am/db/2109799/Sofinnova_Partners>,
        <https://1145.am/db/2109932/Catalio_Capital_Management>,
        <https://1145.am/db/2109932/Epic_Ventures>,
        <https://1145.am/db/2109932/Intermountain_Ventures>,
        <https://1145.am/db/2109932/North_South_Ventures>,
        <https://1145.am/db/2116769/Celesta_Capital>,
        <https://1145.am/db/2116769/Chiratae_Ventures>,
        <https://1145.am/db/2123953/Amex_Ventures>,
        <https://1145.am/db/2123953/Industry_Ventures>,
        <https://1145.am/db/2123953/Infinity_Ventures>,
        <https://1145.am/db/2124766/P1_Ventures>,
        <https://1145.am/db/2125182/Nevcaut_Ventures>,
        <https://1145.am/db/2125182/Ulu_Ventures>,
        <https://1145.am/db/2125927/1984_Ventures>,
        <https://1145.am/db/2127882/Akkadian_Ventures>,
        <https://1145.am/db/2134989/Clear_Ventures>,
        <https://1145.am/db/2134989/Felicis_Ventures>,
        <https://1145.am/db/2141183/S_Ventures>,
        <https://1145.am/db/2141328/Connetic_Ventures>,
        <https://1145.am/db/2143438/Scorpio_Capital>,
        <https://1145.am/db/2147767/Catapult_Ventures>,
        <https://1145.am/db/2147767/Tenoneten_Ventures>,
        <https://1145.am/db/2151983/CRV>,
        <https://1145.am/db/2151983/Greatpoint_Ventures>,
        <https://1145.am/db/2155426/Brighteyes_Ventures>,
        <https://1145.am/db/2155625/Sofinnova_Partners>,
        <https://1145.am/db/2164121/Menlo_Ventures>,
        <https://1145.am/db/2169799/Nwise_Ventures>,
        <https://1145.am/db/217906/Sequoia_Capital>,
        <https://1145.am/db/2181016/Foresite_Capital>,
        <https://1145.am/db/2182443/Global_Ventures>,
        <https://1145.am/db/2183352/Optum_Ventures>,
        <https://1145.am/db/2186568/Frist_Cressey_Ventures>,
        <https://1145.am/db/2186568/Springrock_Ventures>,
        <https://1145.am/db/2186949/Greatpoint_Ventures_And_Cross_Creek>,
        <https://1145.am/db/2186949/Springrock_Ventures>,
        <https://1145.am/db/2190141/Link_Ventures>,
        <https://1145.am/db/2192636/TCV>,
        <https://1145.am/db/219311/Origin_Ventures>,
        <https://1145.am/db/2196875/Sequoia_Capital>,
        <https://1145.am/db/2208603/McKesson_Ventures>,
        <https://1145.am/db/2210557/True_Ventures>,
        <https://1145.am/db/221321/Ggv_Capital>,
        <https://1145.am/db/2214690/Idg_Ventures>,
        <https://1145.am/db/2254568/Felicis_Ventures>,
        <https://1145.am/db/2264763/True_Ventures>,
        <https://1145.am/db/2283006/Catalio_Capital_Management>,
        <https://1145.am/db/2283185/Catalio_Capital_Management>,
        <https://1145.am/db/2283185/Northpond_Ventures>,
        <https://1145.am/db/2284412/Soleus_Capital>,
        <https://1145.am/db/2286665/Shanda_Group>,
        <https://1145.am/db/2288209/Echelon_Ventures>,
        <https://1145.am/db/2288596/Sanderling_Ventures>,
        <https://1145.am/db/2291277/Foresite_Capital>,
        <https://1145.am/db/2293172/Prospect_Ventures>,
        <https://1145.am/db/2294202/Trinitas_Capital>,
        <https://1145.am/db/2294815/Foresite_Capital>,
        <https://1145.am/db/2295253/Arkitekt_Ventures>,
        <https://1145.am/db/2295539/Sofinnova_Ventures>,
        <https://1145.am/db/2296249/Proxima_Ventures>,
        <https://1145.am/db/2296869/Dcm_Ventures>,
        <https://1145.am/db/2297406/Sequoia_Capital>,
        <https://1145.am/db/2298897/Eshelman_Ventures>,
        <https://1145.am/db/2300254/Sequoia_Capital>,
        <https://1145.am/db/2302351/Rho_Ventures>,
        <https://1145.am/db/2302731/Astellas_Venture_Management_Llc>,
        <https://1145.am/db/2302750/Sofinnova_Partners>,
        <https://1145.am/db/2302897/Ventures_West_Capital>,
        <https://1145.am/db/2303098/Seaflower_Ventures>,
        <https://1145.am/db/2303581/Clarus_Ventures>,
        <https://1145.am/db/2304606/Prism_Ventureworks>,
        <https://1145.am/db/2304606/Sofinnova_Ventures>,
        <https://1145.am/db/2305745/Clarus_Ventures>,
        <https://1145.am/db/2305745/Sanderling_Ventures>,
        <https://1145.am/db/2306281/Sanderling_Ventures>,
        <https://1145.am/db/2306568/Cmea_Ventures>,
        <https://1145.am/db/2306568/Sofinnova_Ventures>,
        <https://1145.am/db/2309507/Rho_Ventures>,
        <https://1145.am/db/2309840/Index_Ventures>,
        <https://1145.am/db/2311069/Morgenthaler_Ventures>,
        <https://1145.am/db/2311069/Sofinnova_Ventures>,
        <https://1145.am/db/2312288/Pappas_Ventures>,
        <https://1145.am/db/2312792/Onset_Ventures>,
        <https://1145.am/db/2313322/Clarus_Ventures>,
        <https://1145.am/db/2313438/Clarus_Ventures>,
        <https://1145.am/db/2314380/Puretech_Ventures>,
        <https://1145.am/db/2314397/Pappas_Ventures>,
        <https://1145.am/db/2314397/Sofinnova_Ventures>,
        <https://1145.am/db/2314400/Pappas_Ventures>,
        <https://1145.am/db/2314400/Sofinnova_Ventures>,
        <https://1145.am/db/2314515/Apjohnventures>,
        <https://1145.am/db/2315754/Arcturus_Capital>,
        <https://1145.am/db/2317779/Index_Ventures>,
        <https://1145.am/db/2317779/Sofinnova_Partners>,
        <https://1145.am/db/2319777/Astellas_Venture_Management>,
        <https://1145.am/db/2321856/Ventures_West_Capital_Ltd>,
        <https://1145.am/db/2323785/Eshelman_Ventures>,
        <https://1145.am/db/2324195/Sofinnova_Ventures>,
        <https://1145.am/db/2325015/True_Ventures>,
        <https://1145.am/db/2325140/Index_Ventures>,
        <https://1145.am/db/2325257/Ventures_West>,
        <https://1145.am/db/2325337/Resolvyx>,
        <https://1145.am/db/2326080/Felicis_Ventures>,
        <https://1145.am/db/2326362/Nextech_Venture>,
        <https://1145.am/db/2326404/Intersouth_Partners>,
        <https://1145.am/db/2328585/Cmea_Ventures>,
        <https://1145.am/db/2329870/Sofinnova_Partners>,
        <https://1145.am/db/2330775/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2332748/Clarus_Ventures>,
        <https://1145.am/db/2335587/Sofinnova_Partners>,
        <https://1145.am/db/2338023/Cipla_Ventures>,
        <https://1145.am/db/2338196/Index_Ventures>,
        <https://1145.am/db/2338236/Sanderling_Ventures>,
        <https://1145.am/db/2338703/Wavepoint_Ventures>,
        <https://1145.am/db/2339206/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2340429/Mohr_Davidow_Ventures>,
        <https://1145.am/db/2341896/Sofinnova_Ventures>,
        <https://1145.am/db/2341942/High-Tech_Gründerfonds>,
        <https://1145.am/db/2342998/Sofinnova_Ventures>,
        <https://1145.am/db/2343184/Jven_Capital>,
        <https://1145.am/db/2345017/Venture_Investments>,
        <https://1145.am/db/2345268/Foresite_Capital>,
        <https://1145.am/db/2346300/High-Tech_Gründerfonds>,
        <https://1145.am/db/2346452/Aescap_Venture>,
        <https://1145.am/db/2346532/Pappas_Ventures>,
        <https://1145.am/db/2346978/Ventures_West_Capital>,
        <https://1145.am/db/2347571/Index_Ventures>,
        <https://1145.am/db/2347876/Clarus_Ventures>,
        <https://1145.am/db/2348618/Index_Ventures>,
        <https://1145.am/db/2349096/Sofinnova_Partners>,
        <https://1145.am/db/2349096/Sofinnova_Ventures>,
        <https://1145.am/db/2350004/Clarus_Ventures>,
        <https://1145.am/db/2350044/Avalon_Ventures>,
        <https://1145.am/db/2352436/Forward_Ventures>,
        <https://1145.am/db/2352831/Clarus_Ventures>,
        <https://1145.am/db/2356384/Sofinnova_Partners>,
        <https://1145.am/db/2357487/Savitr_Capital>,
        <https://1145.am/db/2358050/Sofinnova_Ventures>,
        <https://1145.am/db/2358657/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358725/Sofinnova_Ventures>,
        <https://1145.am/db/2358747/Solon_Ventures>,
        <https://1145.am/db/2359562/Pappas_Ventures>,
        <https://1145.am/db/2359960/Sofinnova_Partners>,
        <https://1145.am/db/2362638/Launchpad_Venture_Group>,
        <https://1145.am/db/2363460/Rho_Ventures>,
        <https://1145.am/db/2363854/Chrysalis_Ventures>,
        <https://1145.am/db/2364820/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2365103/Aescap_Venture>,
        <https://1145.am/db/2367675/Avalon_Ventures>,
        <https://1145.am/db/2369967/Foresite_Capital>,
        <https://1145.am/db/2370240/Clarus_Ventures>,
        <https://1145.am/db/2371160/Sofinnova_Ventures>,
        <https://1145.am/db/238282/Carnrite_Ventures>,
        <https://1145.am/db/2400536/Capital_One_Ventures>,
        <https://1145.am/db/2423653/Venturewell>,
        <https://1145.am/db/253438/Esplanade_Ventures>,
        <https://1145.am/db/254357/Ulu_Ventures>,
        <https://1145.am/db/2549491/Ktb_Ventures>,
        <https://1145.am/db/2552636/Morningside_Ventures>,
        <https://1145.am/db/2569491/High-Tech_Gründerfonds>,
        <https://1145.am/db/2570138/Sherpa_Ventures>,
        <https://1145.am/db/2570481/Morgenthaler_Ventures>,
        <https://1145.am/db/2570483/Morgenthaler_Ventures>,
        <https://1145.am/db/2577022/Sofinnova_Partners>,
        <https://1145.am/db/2577022/Sofinnova_Ventures>,
        <https://1145.am/db/2603254/Salesforce_Ventures>,
        <https://1145.am/db/2628424/Verana_Networks>,
        <https://1145.am/db/2628848/Neocarta_Ventures>,
        <https://1145.am/db/2635849/Mohr_Davidow_Ventures>,
        <https://1145.am/db/2638432/Nissay_Capital>,
        <https://1145.am/db/2641337/Promus_Ventures>,
        <https://1145.am/db/2641337/True_Ventures>,
        <https://1145.am/db/2654391/Biggell_Finance>,
        <https://1145.am/db/265532/Ulu_Ventures>,
        <https://1145.am/db/2702871/Inovia_Capital>,
        <https://1145.am/db/274170/G1_Ventures>,
        <https://1145.am/db/2754677/Golden_Gate_Ventures>,
        <https://1145.am/db/2765022/Garuda_Ventures>,
        <https://1145.am/db/2765030/Daniel_Ventures>,
        <https://1145.am/db/2765418/Rw3_Ventures>,
        <https://1145.am/db/2786411/Allegion_Ventures>,
        <https://1145.am/db/2788052/Rx_Ventures>,
        <https://1145.am/db/2790064/Novastar_Ventures>,
        <https://1145.am/db/2794396/Snowpoint_Ventures>,
        <https://1145.am/db/2797562/Menlo_Ventures>,
        <https://1145.am/db/283272/Salesforce_Ventures>,
        <https://1145.am/db/283607/Salesforce_Ventures>,
        <https://1145.am/db/293715/Signum_Capital>,
        <https://1145.am/db/293849/Felicis_Ventures>,
        <https://1145.am/db/293891/Ggv_Capital>,
        <https://1145.am/db/299738/Steadfast_Capital_Ventures>,
        <https://1145.am/db/306236/Index_Ventures>,
        <https://1145.am/db/319155/Bgv_Ventures>,
        <https://1145.am/db/323273/Index_Ventures>,
        <https://1145.am/db/341984/Salesforce_Ventures>,
        <https://1145.am/db/341984/Sequoia_Capital>,
        <https://1145.am/db/341990/Salesforce_Ventures>,
        <https://1145.am/db/341990/Sequoia_Capital>,
        <https://1145.am/db/343459/F7_Ventures>,
        <https://1145.am/db/346598/Salesforce_Ventures>,
        <https://1145.am/db/348442/Triventures>,
        <https://1145.am/db/348659/Launchpad_Capital>,
        <https://1145.am/db/361303/Sequoia_Capital>,
        <https://1145.am/db/364168/Alerion_Ventures>,
        <https://1145.am/db/367592/Gv>,
        <https://1145.am/db/367592/Sequoia_Capital>,
        <https://1145.am/db/388551/Vestigo_Ventures>,
        <https://1145.am/db/396305/Real_Ventures>,
        <https://1145.am/db/402103/1776_Ventures>,
        <https://1145.am/db/402701/January_Ventures>,
        <https://1145.am/db/403810/Riverstone_Ventures>,
        <https://1145.am/db/410322/Gv>,
        <https://1145.am/db/410473/Celesta_Capital>,
        <https://1145.am/db/410473/Lytical_Ventures_And_Nepenthe_Capital>,
        <https://1145.am/db/410529/Goodyear_Ventures>,
        <https://1145.am/db/411539/Zeev_Ventures>,
        <https://1145.am/db/412020/Defi_Ventures_Inc>,
        <https://1145.am/db/415322/CRV>,
        <https://1145.am/db/416041/Akkadian_Ventures>,
        <https://1145.am/db/416041/Signia_Ventures>,
        <https://1145.am/db/416041/Zeev_Ventures>,
        <https://1145.am/db/419489/Point72_Ventures>,
        <https://1145.am/db/424877/North_First_Ventures>,
        <https://1145.am/db/425262/Yl_Ventures>,
        <https://1145.am/db/425423/True_Ventures>,
        <https://1145.am/db/425973/Will_Ventures>,
        <https://1145.am/db/426615/Sequoia_Capital>,
        <https://1145.am/db/429179/C5_Capital>,
        <https://1145.am/db/430986/Cortado_Ventures>,
        <https://1145.am/db/434334/1up_Ventures>,
        <https://1145.am/db/435691/Klick_Ventures>,
        <https://1145.am/db/439819/Cavu_Ventures>,
        <https://1145.am/db/441319/Celesta_Capital>,
        <https://1145.am/db/444105/Exfinity_Ventures>,
        <https://1145.am/db/445365/Revolution_Ventures>,
        <https://1145.am/db/446341/Sinewave_Ventures>,
        <https://1145.am/db/455558/Intudo_Ventures>,
        <https://1145.am/db/457435/Alerce>,
        <https://1145.am/db/457435/Clin>,
        <https://1145.am/db/460454/Index_Ventures>,
        <https://1145.am/db/471253/Gv>,
        <https://1145.am/db/471436/Citi_Ventures>,
        <https://1145.am/db/471504/Canapi_Ventures>,
        <https://1145.am/db/473030/Highsage_Ventures>,
        <https://1145.am/db/474928/Susa_Ventures>,
        <https://1145.am/db/478049/Worldquant_Ventures>,
        <https://1145.am/db/479113/Index_Ventures>,
        <https://1145.am/db/479113/Menlo_Ventures>,
        <https://1145.am/db/485616/K3_Ventures>,
        <https://1145.am/db/486858/Gaingels>,
        <https://1145.am/db/486901/Gaingels>,
        <https://1145.am/db/488743/Salesforce_Ventures>,
        <https://1145.am/db/491130/Raiven_Capital>,
        <https://1145.am/db/491338/Raiven_Capital>,
        <https://1145.am/db/493560/Tyh_Ventures>,
        <https://1145.am/db/495912/Regah_Ventures>,
        <https://1145.am/db/506588/Trinity_Ventures>,
        <https://1145.am/db/508145/Sora_Finance>,
        <https://1145.am/db/508161/Sora_Finance>,
        <https://1145.am/db/510565/Epic_Ventures>,
        <https://1145.am/db/513305/Avid_Ventures>,
        <https://1145.am/db/513305/Canapi_Ventures>,
        <https://1145.am/db/513897/Rlc_Ventures>,
        <https://1145.am/db/514151/Rlc_Ventures>,
        <https://1145.am/db/516396/Acequia_Capital>,
        <https://1145.am/db/517213/Acequia_Capital>,
        <https://1145.am/db/523349/Osf_Ventures>,
        <https://1145.am/db/523776/Root_Ventures>,
        <https://1145.am/db/525285/Inventum_Ventures>,
        <https://1145.am/db/525285/Optima_Ventures>,
        <https://1145.am/db/526109/Ggv_Capital>,
        <https://1145.am/db/526175/Ridgeline_Ventures>,
        <https://1145.am/db/529812/Inventum_Ventures>,
        <https://1145.am/db/529812/Optima_Ventures>,
        <https://1145.am/db/532016/Id_Ventures>,
        <https://1145.am/db/539571/Origin_Ventures>,
        <https://1145.am/db/545843/Capital_One_Ventures>,
        <https://1145.am/db/545852/Boxone_Ventures>,
        <https://1145.am/db/545852/Panache_Ventures>,
        <https://1145.am/db/547770/BGV>,
        <https://1145.am/db/547944/BGV>,
        <https://1145.am/db/554552/Konvoy_Ventures>,
        <https://1145.am/db/555193/Illumina_Ventures>,
        <https://1145.am/db/555193/Technology_Venture_Partners>,
        <https://1145.am/db/556705/Congress_Ave_Ventures>,
        <https://1145.am/db/558005/Illumina_Ventures>,
        <https://1145.am/db/558005/Technology_Venture_Partners>,
        <https://1145.am/db/558877/Falabella_Ventures>,
        <https://1145.am/db/559220/Ulu_Ventures>,
        <https://1145.am/db/561662/Redpoint_Ventures>,
        <https://1145.am/db/561662/Vandelay_Ventures>,
        <https://1145.am/db/562745/Vinmar_Ventures>,
        <https://1145.am/db/563575/Celesta_Capital>,
        <https://1145.am/db/564008/D1_Ventures>,
        <https://1145.am/db/571769/Illumina_Ventures>,
        <https://1145.am/db/571769/M_Ventures>,
        <https://1145.am/db/572097/Menlo_Ventures>,
        <https://1145.am/db/572097/Teneleven_Ventures>,
        <https://1145.am/db/575249/TCV>,
        <https://1145.am/db/576186/Konvoy_Ventures>,
        <https://1145.am/db/577120/Index_Ventures>,
        <https://1145.am/db/586525/Tenoneten_Ventures>,
        <https://1145.am/db/587038/Coparion>,
        <https://1145.am/db/591566/Morningside_Ventures>,
        <https://1145.am/db/596145/Anorak_Ventures>,
        <https://1145.am/db/596564/Anorak_Ventures>,
        <https://1145.am/db/601455/Morningside_Ventures>,
        <https://1145.am/db/603725/Ignitexl_Ventures>,
        <https://1145.am/db/606074/Fiscus_Ventures>,
        <https://1145.am/db/606144/Ggv_Capital>,
        <https://1145.am/db/615337/Companyon_Ventures>,
        <https://1145.am/db/619284/Scf_Ventures>,
        <https://1145.am/db/619366/Capital_One_Ventures>,
        <https://1145.am/db/619736/Lightspeed_Ventures>,
        <https://1145.am/db/623178/Array_Ventures>,
        <https://1145.am/db/625791/Sofinnova_Partners>,
        <https://1145.am/db/626781/Dnx_Ventures>,
        <https://1145.am/db/627030/Launchpad_Capital>,
        <https://1145.am/db/628654/Prologis_Ventures>,
        <https://1145.am/db/633238/True_Ventures>,
        <https://1145.am/db/633869/Skywell_Capital_Partners>,
        <https://1145.am/db/633869/Stageone_Ventures>,
        <https://1145.am/db/640939/Ggv_Capital>,
        <https://1145.am/db/642123/Charles_River_Ventures>,
        <https://1145.am/db/642518/Network_Ventures>,
        <https://1145.am/db/643600/Vinco_Ventures>,
        <https://1145.am/db/648552/True_Ventures>,
        <https://1145.am/db/659010/Index_Ventures>,
        <https://1145.am/db/659675/Gv>,
        <https://1145.am/db/661747/Adit_Ventures>,
        <https://1145.am/db/661818/Index_Ventures>,
        <https://1145.am/db/665129/Ac_Ventures>,
        <https://1145.am/db/665776/Firstime_Ventures>,
        <https://1145.am/db/676217/Steelsky_Ventures>,
        <https://1145.am/db/676869/Ggv_Capital>,
        <https://1145.am/db/678140/Ggv_Capital>,
        <https://1145.am/db/678587/Lightshed_Ventures>,
        <https://1145.am/db/678593/Solana_Ventures>,
        <https://1145.am/db/687538/Kayyak_Ventures>,
        <https://1145.am/db/689460/True_Ventures>,
        <https://1145.am/db/694513/Authentic_Ventures>,
        <https://1145.am/db/694924/Avid_Ventures>,
        <https://1145.am/db/700171/Sequoia_Capital>,
        <https://1145.am/db/700327/Menlo_Ventures>,
        <https://1145.am/db/700877/Gaingels>,
        <https://1145.am/db/703983/Eqventure>,
        <https://1145.am/db/704489/Eqventure>,
        <https://1145.am/db/704753/Felicis_Ventures>,
        <https://1145.am/db/704753/Menlo_Ventures>,
        <https://1145.am/db/704793/Quidnet_Ventures>,
        <https://1145.am/db/704991/Gaingels>,
        <https://1145.am/db/709633/Connetic_Ventures>,
        <https://1145.am/db/726461/Contour_Ventures>,
        <https://1145.am/db/729628/Kyber_Ventures>,
        <https://1145.am/db/729628/Signum_Capital>,
        <https://1145.am/db/738920/Oca_Ventures>,
        <https://1145.am/db/738920/Susa_Ventures>,
        <https://1145.am/db/739538/Morpheus_Ventures>,
        <https://1145.am/db/739538/Oca_Ventures>,
        <https://1145.am/db/739538/Susa_Ventures>,
        <https://1145.am/db/747051/Tenoneten_Ventures>,
        <https://1145.am/db/747771/Ta_Ventures>,
        <https://1145.am/db/749147/1984_Ventures>,
        <https://1145.am/db/749147/Index_Ventures>,
        <https://1145.am/db/749209/1984_Ventures>,
        <https://1145.am/db/749209/Index_Ventures>,
        <https://1145.am/db/750305/Yl_Ventures>,
        <https://1145.am/db/750725/Vestigo_Ventures>,
        <https://1145.am/db/751176/Maverick_Ventures>,
        <https://1145.am/db/751176/Susa_Ventures>,
        <https://1145.am/db/751387/Menlo_Ventures>,
        <https://1145.am/db/753120/Sequoia_Capital>,
        <https://1145.am/db/753251/Savantus_Ventures>,
        <https://1145.am/db/753913/Brunnur_Ventures>,
        <https://1145.am/db/755844/Sequoia_Capital>,
        <https://1145.am/db/758206/Great_North_Ventures>,
        <https://1145.am/db/758206/Grotech_Ventures>,
        <https://1145.am/db/759749/Cava_Capital>,
        <https://1145.am/db/763083/Gaingels>,
        <https://1145.am/db/764875/Rev1_Ventures>,
        <https://1145.am/db/764896/Rev1_Ventures>,
        <https://1145.am/db/765216/True_Ventures>,
        <https://1145.am/db/768172/Gaingels>,
        <https://1145.am/db/768172/Type_One_Ventures>,
        <https://1145.am/db/768349/Salesforce_Ventures>,
        <https://1145.am/db/768852/Felicis_Ventures>,
        <https://1145.am/db/769568/Axon_Ventures>,
        <https://1145.am/db/772099/Array_Ventures>,
        <https://1145.am/db/773235/Prelude_Ventures>,
        <https://1145.am/db/773684/Fulgur_Ventures>,
        <https://1145.am/db/773794/Array_Ventures>,
        <https://1145.am/db/778025/Felicis_Ventures>,
        <https://1145.am/db/778423/Sentiero_Ventures>,
        <https://1145.am/db/779637/Felicis_Ventures>,
        <https://1145.am/db/779867/Genesis_Block_Ventures>,
        <https://1145.am/db/780272/East_Ventures>,
        <https://1145.am/db/780289/East_Ventures>,
        <https://1145.am/db/783431/Cathay_Venture_Inc>,
        <https://1145.am/db/784093/Boldstart_Ventures>,
        <https://1145.am/db/787806/Boldstart_Ventures>,
        <https://1145.am/db/788016/Boldstart_Ventures>,
        <https://1145.am/db/791505/Index_Ventures>,
        <https://1145.am/db/796250/Sp_Ventures>,
        <https://1145.am/db/796629/Index_Ventures>,
        <https://1145.am/db/797597/Lansdowne_Partners>,
        <https://1145.am/db/798095/Index_Ventures>,
        <https://1145.am/db/798753/Sofinnova_Partners>,
        <https://1145.am/db/800093/Sequoia_Capital>,
        <https://1145.am/db/800101/Gaingels>,
        <https://1145.am/db/803541/Credo_Ventures>,
        <https://1145.am/db/803541/Index_Ventures>,
        <https://1145.am/db/803541/Sequoia_Capital>,
        <https://1145.am/db/8045/Greatpoint_Ventures>,
        <https://1145.am/db/806828/Promus_Ventures>,
        <https://1145.am/db/806994/Companyon_Ventures>,
        <https://1145.am/db/807080/K3_Ventures>,
        <https://1145.am/db/808020/Starlight_Ventures>,
        <https://1145.am/db/808020/Valo_Ventures>,
        <https://1145.am/db/8146/Rev1_Ventures>,
        <https://1145.am/db/817162/Orbia_Ventures>,
        <https://1145.am/db/818444/1984_Ventures>,
        <https://1145.am/db/821135/Se_Ventures>,
        <https://1145.am/db/823763/Infinity_Ventures>,
        <https://1145.am/db/828716/Idc_Ventures>,
        <https://1145.am/db/829118/Salesforce_Ventures>,
        <https://1145.am/db/830571/Company_Ventures>,
        <https://1145.am/db/830689/Soleus_Capital>,
        <https://1145.am/db/832264/Salesforce_Ventures>,
        <https://1145.am/db/832573/Solasta_Ventures>,
        <https://1145.am/db/834864/Ggv_Capital>,
        <https://1145.am/db/834864/K3_Ventures>,
        <https://1145.am/db/836848/Technexus_Venture_Collaborative>,
        <https://1145.am/db/836908/Frontier_Ventures>,
        <https://1145.am/db/837034/Redpoint_Ventures>,
        <https://1145.am/db/838138/Root_Ventures>,
        <https://1145.am/db/838181/Sequoia_Capital>,
        <https://1145.am/db/838691/Crosslink_Capital>,
        <https://1145.am/db/847157/Signum_Capital>,
        <https://1145.am/db/847862/Wise_Ventures>,
        <https://1145.am/db/854001/Gv>,
        <https://1145.am/db/854589/Verance_Capital>,
        <https://1145.am/db/854654/Mrtnz_Ventures>,
        <https://1145.am/db/854795/Menlo_Ventures>,
        <https://1145.am/db/867865/Applied_Ventures>,
        <https://1145.am/db/868093/Cobro_Ventures>,
        <https://1145.am/db/869652/Forever_Ventures>,
        <https://1145.am/db/874394/Nextview_Ventures>,
        <https://1145.am/db/874394/True_Ventures>,
        <https://1145.am/db/880050/Crosslink_Capital>,
        <https://1145.am/db/881298/At_One_Ventures>,
        <https://1145.am/db/882723/At_One_Ventures>,
        <https://1145.am/db/884787/Foresite_Capital>,
        <https://1145.am/db/884787/Gv>,
        <https://1145.am/db/884787/Northpond_Ventures>,
        <https://1145.am/db/886445/Gv>,
        <https://1145.am/db/887062/Panoramic_Ventures>,
        <https://1145.am/db/889246/At_One_Ventures>,
        <https://1145.am/db/890271/Panoramic_Ventures>,
        <https://1145.am/db/891162/Emergingvc>,
        <https://1145.am/db/891162/Launchpad_Venture_Group>,
        <https://1145.am/db/903689/Vectr_Ventures>,
        <https://1145.am/db/904276/Nextview_Ventures>,
        <https://1145.am/db/906393/East_Ventures>,
        <https://1145.am/db/907844/Argon_Ventures>,
        <https://1145.am/db/907844/Glasswing_Ventures>,
        <https://1145.am/db/913422/Sequoia_Capital>,
        <https://1145.am/db/913678/Sandbridge_Capital>,
        <https://1145.am/db/919636/Menlo_Ventures>,
        <https://1145.am/db/921704/Scop_Ventures>,
        <https://1145.am/db/92200/Knoll_Ventures>,
        <https://1145.am/db/922066/Irrvrnt_Vc>,
        <https://1145.am/db/922192/Gv>,
        <https://1145.am/db/922498/Sozo_Ventures>,
        <https://1145.am/db/923723/Scop_Ventures>,
        <https://1145.am/db/928711/Frontline_Ventures>,
        <https://1145.am/db/934946/Ggv_Capital>,
        <https://1145.am/db/935046/Origin_Ventures>,
        <https://1145.am/db/935249/Victress_Capital>,
        <https://1145.am/db/935322/Alpana_Ventures>,
        <https://1145.am/db/935322/M_Ventures>,
        <https://1145.am/db/935796/Salesforce_Ventures>,
        <https://1145.am/db/935962/Digitalbridge_Ventures>,
        <https://1145.am/db/936045/Lpc_Ventures>,
        <https://1145.am/db/936057/Noemis_Ventures>,
        <https://1145.am/db/936154/Salesforce_Ventures>,
        <https://1145.am/db/936448/Ggv_Capital>,
        <https://1145.am/db/936862/Lool_Ventures>,
        <https://1145.am/db/936906/Neotribe_Ventures>,
        <https://1145.am/db/937210/Citi_Ventures>,
        <https://1145.am/db/937210/Firebolt_Ventures>,
        <https://1145.am/db/937460/Sequoia_Capital>,
        <https://1145.am/db/938108/Conti_Ventures>,
        <https://1145.am/db/938555/Digitalbridge_Ventures>,
        <https://1145.am/db/938586/Venturesouth>,
        <https://1145.am/db/938921/Redpoint_Ventures>,
        <https://1145.am/db/938975/Ggv_Capital>,
        <https://1145.am/db/939163/Goodyear_Ventures>,
        <https://1145.am/db/940740/Agnc_Ventures>,
        <https://1145.am/db/940913/True_Ventures>,
        <https://1145.am/db/941816/Radical_Ventures>,
        <https://1145.am/db/942825/Argon_Ventures>,
        <https://1145.am/db/946710/Citi_Ventures>,
        <https://1145.am/db/947238/Kyros_Ventures>,
        <https://1145.am/db/952434/Verissimo_Ventures>,
        <https://1145.am/db/955201/Gv>,
        <https://1145.am/db/960022/Verance_Capital>,
        <https://1145.am/db/961837/Sequoia_Capital>,
        <https://1145.am/db/962622/Sequoia_Capital>,
        <https://1145.am/db/970950/Ulu_Ventures>,
        <https://1145.am/db/971415/Altai_Ventures>,
        <https://1145.am/db/971450/Allon_Ventures>,
        <https://1145.am/db/971939/Formic_Ventures>,
        <https://1145.am/db/975114/Formic_Ventures>,
        <https://1145.am/db/979753/Menlo_Ventures>,
        <https://1145.am/db/980678/Menlo_Ventures>,
        <https://1145.am/db/984645/Vinco_Ventures>,
        <https://1145.am/db/987688/Brightspark_Ventures>,
        <https://1145.am/db/987700/Infinityvc>,
        <https://1145.am/db/988084/Abstract_Ventures>,
        <https://1145.am/db/988084/Blank_Ventures>,
        <https://1145.am/db/988318/Arthur_Ventures>,
        <https://1145.am/db/988482/Brightspark_Ventures>,
        <https://1145.am/db/988979/Infinityvc>,
        <https://1145.am/db/989392/Arthur_Ventures>,
        <https://1145.am/db/990085/Radical_Ventures>,
        <https://1145.am/db/995593/Raiven_Capital>,
        <https://1145.am/db/995737/Nuoyan_Capital>,
        <https://1145.am/db/996563/Raiven_Capital> ;
    ns1:sameAsMedium <https://1145.am/db/2289940/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2292313/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2296640/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2306163/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2324756/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358640/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2358658/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2364827/Fletcher_Spaght_Ventures>,
        <https://1145.am/db/2365444/Fletcher_Spaght_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359863/Savara_Pharmaceuticals> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:description "developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions" ;
    ns1:documentDate "2012-06-12T16:30:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Savara Pharmaceuticals Raises $8.6 Million in Series B Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/savara-pharmaceuticals-raises-8-6-million-series-b-financing-round> ;
    ns1:foundName "Savara",
        "Savara Pharmaceuticals" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Savara Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2061393/Savara_Inc>,
        <https://1145.am/db/2309137/Dura_Pharmaceuticals>,
        <https://1145.am/db/2326253/Savara_Pharmaceuticals>,
        <https://1145.am/db/2342892/Savara_Pharmaceuticals>,
        <https://1145.am/db/2342893/Savara_Pharmaceuticals>,
        <https://1145.am/db/2351331/Savara_Inc>,
        <https://1145.am/db/2359865/Savara_Pharmaceuticals>,
        <https://1145.am/db/2370373/Savara_Pharmaceuticals>,
        <https://1145.am/db/2370379/Savara_Pharmaceuticals>,
        <https://1145.am/db/2587367/Savara_Pharmaceuticals>,
        <https://1145.am/db/996844/Savara_Inc>,
        <https://1145.am/db/998845/Savara_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2342894/Savara_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359864/5am_Ventures> a org:Organization ;
    ns1:basedInLowRaw "BURLINGAME, Calif" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-06-12T14:59:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Igenica Closes $33 Million in Series C Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/igenica-closes-33-million-series-c-funding> ;
    ns1:foundName "5AM Ventures" ;
    ns1:investor <https://1145.am/db/2359864/Series_C_Investment_5am_Ventures_Igenica_Orbimed_Advisors_The_Column_Group_Third_Rock_Ventures_Completed> ;
    ns1:name "5AM Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1307620/Z5_Capital>,
        <https://1145.am/db/1765721/5y_Capital>,
        <https://1145.am/db/2153910/5am_Ventures>,
        <https://1145.am/db/2286204/5am_Ventures>,
        <https://1145.am/db/2288016/5am_Ventures>,
        <https://1145.am/db/2318733/5am_Ventures>,
        <https://1145.am/db/2319784/5am_Ventures>,
        <https://1145.am/db/2329778/5am_Ventures>,
        <https://1145.am/db/2339886/5am_Ventures>,
        <https://1145.am/db/2360174/5am_Ventures>,
        <https://1145.am/db/2362475/5am_Ventures>,
        <https://1145.am/db/2592685/5am_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1157541/5am_Ventures>,
        <https://1145.am/db/1533327/5am_Ventures>,
        <https://1145.am/db/1533685/5am_Ventures>,
        <https://1145.am/db/1608803/5am_Ventures>,
        <https://1145.am/db/1669813/5am_Ventures>,
        <https://1145.am/db/2152422/5am_Ventures>,
        <https://1145.am/db/2153726/5am_Ventures>,
        <https://1145.am/db/2283394/5am_Ventures>,
        <https://1145.am/db/2286665/5am_Ventures>,
        <https://1145.am/db/2298404/5am_Ventures>,
        <https://1145.am/db/2298642/5am_Ventures>,
        <https://1145.am/db/2306549/5am_Ventures>,
        <https://1145.am/db/2306551/5am_Ventures>,
        <https://1145.am/db/2306754/5am_Ventures>,
        <https://1145.am/db/2311595/5am_Ventures>,
        <https://1145.am/db/2313985/5am_Ventures>,
        <https://1145.am/db/2317919/5am_Ventures>,
        <https://1145.am/db/2322646/5am_Ventures>,
        <https://1145.am/db/2323210/5am_Ventures>,
        <https://1145.am/db/2323226/5am_Ventures>,
        <https://1145.am/db/2324195/5am_Ventures>,
        <https://1145.am/db/2328146/5am_Ventures>,
        <https://1145.am/db/2328338/5am_Ventures>,
        <https://1145.am/db/2332322/5am_Ventures>,
        <https://1145.am/db/2339885/5am_Ventures>,
        <https://1145.am/db/2340344/5am_Ventures>,
        <https://1145.am/db/2340345/5am_Ventures>,
        <https://1145.am/db/2340348/5am_Ventures>,
        <https://1145.am/db/2341003/5am_Ventures>,
        <https://1145.am/db/2342352/5am_Ventures>,
        <https://1145.am/db/2347885/5am_Ventures>,
        <https://1145.am/db/2348754/5am_Ventures>,
        <https://1145.am/db/2348857/5am_Ventures>,
        <https://1145.am/db/2349120/5am_Ventures>,
        <https://1145.am/db/2349834/5am_Ventures>,
        <https://1145.am/db/2351316/5am_Ventures>,
        <https://1145.am/db/2351683/5am_Ventures>,
        <https://1145.am/db/2351684/5am_Ventures>,
        <https://1145.am/db/2354296/5am_Ventures>,
        <https://1145.am/db/2355238/5am_Ventures>,
        <https://1145.am/db/2357858/5am_Ventures>,
        <https://1145.am/db/2359401/5am_Ventures>,
        <https://1145.am/db/2360415/5am_Ventures>,
        <https://1145.am/db/2362481/5am_Ventures>,
        <https://1145.am/db/2364492/5am_Ventures>,
        <https://1145.am/db/2367275/5am_Ventures>,
        <https://1145.am/db/2370609/5am_Ventures>,
        <https://1145.am/db/2371160/5am_Ventures>,
        <https://1145.am/db/2371163/5am_Ventures>,
        <https://1145.am/db/2538476/5am_Ventures>,
        <https://1145.am/db/2569220/5am_Ventures>,
        <https://1145.am/db/2572398/5am_Ventures>,
        <https://1145.am/db/2587596/5am_Ventures>,
        <https://1145.am/db/359190/5am_Ventures>,
        <https://1145.am/db/428737/5am_Ventures>,
        <https://1145.am/db/509733/5am_Ventures>,
        <https://1145.am/db/558016/5am_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359864/Igenica> a org:Organization ;
    ns1:description "the discovery and development of first-in-class antibodies" ;
    ns1:documentDate "2012-06-12T14:59:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Igenica Closes $33 Million in Series C Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/igenica-closes-33-million-series-c-funding> ;
    ns1:foundName "Igenica",
        "Igenica, Inc." ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Igenica" ;
    ns1:sameAsHigh <https://1145.am/db/1118294/Imago_Biosciences_Inc>,
        <https://1145.am/db/1247997/Idrx>,
        <https://1145.am/db/1382937/Arbutus_Biopharma_Corporation>,
        <https://1145.am/db/1408958/Immatics>,
        <https://1145.am/db/1519366/Imago_Biosciences>,
        <https://1145.am/db/1957094/Appili>,
        <https://1145.am/db/2345833/Alcobra_Ltd>,
        <https://1145.am/db/2348058/Igenica>,
        <https://1145.am/db/2352125/Immusant>,
        <https://1145.am/db/2353064/Alcobra_Ltd>,
        <https://1145.am/db/2353071/Alcobra_Ltd>,
        <https://1145.am/db/2361095/Igenica>,
        <https://1145.am/db/2361127/Igenica_Inc>,
        <https://1145.am/db/2371374/Ait>,
        <https://1145.am/db/631500/Imago_Biosciences_Inc>,
        <https://1145.am/db/636214/Imago_Biosciences_Inc>,
        <https://1145.am/db/721838/Aipharma_Global_Holdings_Llc>,
        <https://1145.am/db/722536/Aipharma_Global_Holdings_Llc>,
        <https://1145.am/db/926281/Imago_Biosciences> ;
    ns1:sameAsMedium <https://1145.am/db/2347885/Igenica>,
        <https://1145.am/db/2359865/Igenica>,
        <https://1145.am/db/2362475/Igenica>,
        <https://1145.am/db/2362481/Igenica_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359865/Igenica> a org:Organization ;
    ns1:description "venture backers" ;
    ns1:documentDate "2012-06-12T14:55:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Third Rock takes lead on $33M C round for antibody upstart Igenica" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/third-rock-takes-lead-on-33m-c-round-for-antibody-upstart-igenica> ;
    ns1:foundName "Igenica",
        "The",
        "biotech" ;
    ns1:industry "biotech" ;
    ns1:name "Igenica" ;
    ns1:sameAsHigh <https://1145.am/db/1422234/Inversago>,
        <https://1145.am/db/1422725/Inversago>,
        <https://1145.am/db/1626385/Inotrem>,
        <https://1145.am/db/1627827/Inotrem>,
        <https://1145.am/db/1629754/Aivita_Biomedical>,
        <https://1145.am/db/1696383/Instadeep>,
        <https://1145.am/db/1697281/Instadeep>,
        <https://1145.am/db/2079910/Sk_Bioscience>,
        <https://1145.am/db/2153375/Imara>,
        <https://1145.am/db/2154835/Insitro>,
        <https://1145.am/db/2154913/Idorsia>,
        <https://1145.am/db/2279310/Senda_Biosciences>,
        <https://1145.am/db/2282558/Vedanta_Biosciences>,
        <https://1145.am/db/2286040/Inotrem>,
        <https://1145.am/db/2290974/Inscripta>,
        <https://1145.am/db/2292367/Acorda>,
        <https://1145.am/db/2300483/Caladrius_Biosciences>,
        <https://1145.am/db/2300532/Inscripta>,
        <https://1145.am/db/2304208/Pra_Health_Sciences>,
        <https://1145.am/db/2320754/Ily101>,
        <https://1145.am/db/2322693/Selecta_Biosciences>,
        <https://1145.am/db/2335908/Athera_Biotechnologies>,
        <https://1145.am/db/2339734/Selecta_Biosciences>,
        <https://1145.am/db/2342629/Imago_Biosciences>,
        <https://1145.am/db/2351883/Immatics>,
        <https://1145.am/db/2357252/Inotrem_Sa>,
        <https://1145.am/db/2357260/Inotrem>,
        <https://1145.am/db/2359440/Immatics>,
        <https://1145.am/db/2359756/Acorda>,
        <https://1145.am/db/2361416/Intarcia>,
        <https://1145.am/db/2363275/Immatics>,
        <https://1145.am/db/2366365/Insmed>,
        <https://1145.am/db/2370223/Ignyta>,
        <https://1145.am/db/2370753/Vedanta_Biosciences>,
        <https://1145.am/db/2562086/Immatics>,
        <https://1145.am/db/2718306/Senda_Biosciences>,
        <https://1145.am/db/2795044/Inotrem>,
        <https://1145.am/db/539018/Interna_Technologies>,
        <https://1145.am/db/602287/Inotrem>,
        <https://1145.am/db/661747/Aanika_Biosciences>,
        <https://1145.am/db/663618/Aanika_Biosciences>,
        <https://1145.am/db/74943/Imago_Biosciences> ;
    ns1:sameAsMedium <https://1145.am/db/2347885/Igenica>,
        <https://1145.am/db/2348058/Igenica>,
        <https://1145.am/db/2359864/Igenica>,
        <https://1145.am/db/2361095/Igenica>,
        <https://1145.am/db/2361127/Igenica_Inc>,
        <https://1145.am/db/2362475/Igenica>,
        <https://1145.am/db/2362481/Igenica_Inc> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359865/Savara_Pharmaceuticals> a org:Organization ;
    ns1:basedInHighGeoName "Austin" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4671654/about.rdf> ;
    ns1:basedInHighRaw "Austin" ;
    ns1:description "VC" ;
    ns1:documentDate "2012-06-12T14:55:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Third Rock takes lead on $33M C round for antibody upstart Igenica" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/third-rock-takes-lead-on-33m-c-round-for-antibody-upstart-igenica> ;
    ns1:foundName "Savara Pharmaceuticals" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Savara Pharmaceuticals" ;
    ns1:sameAsHigh <https://1145.am/db/2061393/Savara_Inc>,
        <https://1145.am/db/2309137/Dura_Pharmaceuticals>,
        <https://1145.am/db/2326253/Savara_Pharmaceuticals>,
        <https://1145.am/db/2342892/Savara_Pharmaceuticals>,
        <https://1145.am/db/2342893/Savara_Pharmaceuticals>,
        <https://1145.am/db/2351331/Savara_Inc>,
        <https://1145.am/db/2359863/Savara_Pharmaceuticals>,
        <https://1145.am/db/2370373/Savara_Pharmaceuticals>,
        <https://1145.am/db/2370379/Savara_Pharmaceuticals>,
        <https://1145.am/db/2587367/Savara_Pharmaceuticals>,
        <https://1145.am/db/996844/Savara_Inc>,
        <https://1145.am/db/998845/Savara_Inc> ;
    ns1:sameAsMedium <https://1145.am/db/2342894/Savara_Pharmaceuticals> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359883/Neuronova_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2012-06-13T14:40:53+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Milan, Italy, June 13, 2012 - Newron Pharmaceuticals S.p.A. (\"Newron\") , announces today that the company has signed an agreement with the key shareholders of Stockholm - based privately - owned NeuroNova AB (\"NeuroNova\") for the acquisition of up to 100 % of the shares of NeuroNova, in an all-share transaction valuing NeuroNova at €15.4m (at closing share price June 11, 2012) .",
        "Milan, Italy, June 13, 2012 - Newron Pharmaceuticals S.p.A. (\"Newron\") , announces today that the company has signed an agreement with the key shareholders of Stockholm - based privately - owned NeuroNova AB (\"NeuroNova\") for the acquisition of up to 100 % of the shares of NeuroNova, in an all-share transaction valuing NeuroNova at €15.4m (at closing share price June 11, 2012).",
        "Newron to acquire Swedish neurogenesis company NeuroNova AB." ;
    ns1:documentTitle "Newron to acquire Swedish neurogenesis company NeuroNova AB" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/newron-to-acquire-swedish-neurogenesis-company-neuronova-ab> ;
    ns1:foundName "acquire",
        "acquisition" ;
    ns1:name "acquire",
        "acquisition" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2359883/Neuronova> ;
    ns1:targetName "NeuroNova" ;
    ns1:valueRaw "€15.4m" ;
    ns1:whereGeoName "Kingdom of Sweden" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2661886/about.rdf> ;
    ns1:whereRaw "Sweden" .

<https://1145.am/db/2363938/Genkyotex> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "NOX inhibitors to treat oxygen-radical mediated diseases" ;
    ns1:documentDate "2012-07-08T20:26:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Genkyotex Raises CHF25 Million in Series C Round Extension" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/genkyotex-raises-chf25-million-series-c-round-extension> ;
    ns1:foundName "Genkyotex" ;
    ns1:name "Genkyotex" ;
    ns1:sameAsMedium <https://1145.am/db/2287415/Genkyotex>,
        <https://1145.am/db/2339245/Genkyotex>,
        <https://1145.am/db/2356043/Genkyotex>,
        <https://1145.am/db/2363941/Genkyotex>,
        <https://1145.am/db/2370822/Genkyotex> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363941/Genkyotex> a org:Organization ;
    ns1:basedInLowRaw "Switzerland" ;
    ns1:description "Biotech" ;
    ns1:documentDate "2012-07-09T04:00:58+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Biotech Genkyotex nails down $26M to fund drug for diabetic kidney disease" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotech-genkyotex-nails-down-26m-to-fund-drug-for-diabetic-kidney-disease> ;
    ns1:foundName "Genkyotex" ;
    ns1:industry "biotech" ;
    ns1:name "Genkyotex" ;
    ns1:sameAsHigh <https://1145.am/db/211062/Genexine_Inc>,
        <https://1145.am/db/2287415/Genkyotex>,
        <https://1145.am/db/2339245/Genkyotex>,
        <https://1145.am/db/2356043/Genkyotex> ;
    ns1:sameAsMedium <https://1145.am/db/2363938/Genkyotex>,
        <https://1145.am/db/2370822/Genkyotex> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363950/Lundbeckfond_Ventures> a org:Organization ;
    ns1:basedInLowRaw "LONDON" ;
    ns1:documentDate "2012-07-09T16:23:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PsiOxus Therapeutics Secures GBP 22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/psioxus-therapeutics-secures-gbp-22-million-34-million-series-b-financing-to-drive-clinical> ;
    ns1:foundName "Lundbeckfond Ventures" ;
    ns1:investor <https://1145.am/db/2363950/Equity_Investment_Imperial_Innovations_Group_Invesco_Perpetual_Lundbeckfond_Ventures_Psioxus_Therapeutics_Ltd_Sr_One_Completed> ;
    ns1:name "Lundbeckfond Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2296062/Lundbeckfonden_Ventures>,
        <https://1145.am/db/2300680/Lundbeckfond_Ventures>,
        <https://1145.am/db/2301536/Lundbeckfonden_Ventures>,
        <https://1145.am/db/2326981/Lundbeckfond_Ventures>,
        <https://1145.am/db/2336716/Lundbeckfond_Ventures>,
        <https://1145.am/db/2338527/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349048/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349050/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349405/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349406/Lundbeckfond_Ventures>,
        <https://1145.am/db/2352357/Lundbeckfond_Ventures>,
        <https://1145.am/db/2352361/Lundbeckfond_Ventures>,
        <https://1145.am/db/2353098/Lundbeckfond_Ventures>,
        <https://1145.am/db/2353917/Lundbeckfond_Ventures>,
        <https://1145.am/db/2354401/Lundbeckfond_Ventures>,
        <https://1145.am/db/2356402/Lundbeckfond_Ventures>,
        <https://1145.am/db/2356411/Lundbeckfond_Ventures>,
        <https://1145.am/db/2359401/Lundbeckfond_Ventures>,
        <https://1145.am/db/2362148/Lundbeckfond_Ventures>,
        <https://1145.am/db/2362156/Lundbeckfond_Ventures>,
        <https://1145.am/db/2363947/Lundbeckfond_Ventures>,
        <https://1145.am/db/2364492/Lundbeckfond_Ventures>,
        <https://1145.am/db/2365826/Lundbeckfond_Ventures>,
        <https://1145.am/db/2366303/Lundbeckfond_Ventures>,
        <https://1145.am/db/2369169/Lundbeckfond_Ventures>,
        <https://1145.am/db/2369953/Lundbeckfond_Ventures>,
        <https://1145.am/db/2544138/Lundbeckfond_Ventures>,
        <https://1145.am/db/2544140/Lundbeckfond_Ventures>,
        <https://1145.am/db/2573068/Lundbeckfond_Ventures>,
        <https://1145.am/db/281538/Lundbeckfonden_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363950/Psioxus_Therapeutics_Ltd> a org:Organization ;
    ns1:basedInHighGeoName "London" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2643743/about.rdf> ;
    ns1:basedInHighRaw "LONDON" ;
    ns1:description "Pharmaceuticals",
        "cancer treatment" ;
    ns1:documentDate "2012-07-09T16:23:02+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PsiOxus Therapeutics Secures GBP 22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/psioxus-therapeutics-secures-gbp-22-million-34-million-series-b-financing-to-drive-clinical> ;
    ns1:foundName "PsiOxus Therapeutics",
        "PsiOxus Therapeutics, Ltd" ;
    ns1:name "PsiOxus Therapeutics",
        "PsiOxus Therapeutics, Ltd" ;
    ns1:sameAsHigh <https://1145.am/db/2363947/Psioxus_Therapeutics>,
        <https://1145.am/db/2544138/Psioxus_Therapeutics> ;
    ns1:sameAsMedium <https://1145.am/db/1272117/Psioxus_Therapeutics>,
        <https://1145.am/db/1273078/Psioxus_Therapeutics>,
        <https://1145.am/db/2153714/Psioxus_Therapeutics>,
        <https://1145.am/db/2346021/Psioxus_Therapeutics>,
        <https://1145.am/db/2354401/Psioxus_Therapeutics_Ltd>,
        <https://1145.am/db/2363801/Psioxus_Therapeutics>,
        <https://1145.am/db/2363802/Psioxus_Therapeutics_Ltd>,
        <https://1145.am/db/2365956/Psioxus_Therapeutics>,
        <https://1145.am/db/2544140/Psioxus_Therapeutics>,
        <https://1145.am/db/2547216/Psioxus_Therapeutics>,
        <https://1145.am/db/2580691/Psioxus_Therapeutics>,
        <https://1145.am/db/2583115/Psioxus_Therapeutics>,
        <https://1145.am/db/2588827/Psioxus_Therapeutics> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366403/Aerial_Biopharma> a org:Organization ;
    ns1:basedInLowRaw "N.C." ;
    ns1:description "Pharmaceuticals" ;
    ns1:documentDate "2012-07-20T01:07:59+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Rex Health Ventures Announces Inaugural Investment in N.C. Firm, Aerial BioPharma" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/rex-health-ventures-announces-inaugural-investment-n-c-firm-aerial-biopharma> ;
    ns1:foundName "Aerial BioPharma",
        "N.C. Firm, Aerial BioPharma" ;
    ns1:industry "biopharmaceutical" ;
    ns1:name "Aerial BioPharma" ;
    ns1:sameAsHigh <https://1145.am/db/2243235/Aerial_Biopharma>,
        <https://1145.am/db/2338286/Aerial_Biopharma>,
        <https://1145.am/db/2344820/Aerial_Biopharma>,
        <https://1145.am/db/2344821/Tiny_Aerial_Biopharma> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366434/Cell_Medica> a org:Organization ;
    ns1:basedInLowRaw "US" ;
    ns1:description "Cell Therapy Development" ;
    ns1:documentDate "2012-07-23T12:18:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Cell Medica Secures £17 million ($26.5 million) Equity Investment to Establish US Operations and Fund Cell Therapy Development" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cell-medica-secures-%C2%A317-million-26-5-million-equity-investment-to-establish-us-operations> ;
    ns1:foundName "Cell Medica" ;
    ns1:name "Cell Medica" ;
    ns1:sameAsHigh <https://1145.am/db/1165421/Cellino_Biotech>,
        <https://1145.am/db/2288967/Prochon_Biotech>,
        <https://1145.am/db/2327996/Cellerix>,
        <https://1145.am/db/2349695/Cellerix>,
        <https://1145.am/db/2555064/Cellular_Biomedicine_Group> ;
    ns1:sameAsMedium <https://1145.am/db/2292846/Cell_Medica>,
        <https://1145.am/db/2297558/Cell_Medica>,
        <https://1145.am/db/2298871/Cell_Medica>,
        <https://1145.am/db/2298902/Cell_Medica>,
        <https://1145.am/db/2301119/Cell_Medica>,
        <https://1145.am/db/2301123/Cell_Medica>,
        <https://1145.am/db/2304353/Cell_Medica>,
        <https://1145.am/db/2340822/Cell_Medica>,
        <https://1145.am/db/2348796/Cell_Medica>,
        <https://1145.am/db/2348797/Cell_Medica>,
        <https://1145.am/db/2348798/Cell_Medica> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2366434/Investment_Cell_Medica_Imperial_Innovations_Invesco_Perpetual_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-23T12:18:01+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Cell Medica Secures £17 million ($ 26.5 million) Equity Investment to Establish US Operations and Fund Cell Therapy Development.",
        "London, UK - 23 July 2012: Cell Medica, a leading cell therapeutics company, today announced it has secured a £17 million ($ 26.5 million) equity investment to launch new operations in Texas focussing on cancer immunotherapy and to continue development of its immune reconstitution cell therapies in Europe." ;
    ns1:documentTitle "Cell Medica Secures £17 million ($26.5 million) Equity Investment to Establish US Operations and Fund Cell Therapy Development" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cell-medica-secures-%C2%A317-million-26-5-million-equity-investment-to-establish-us-operations> ;
    ns1:foundName "investment" ;
    ns1:name "investment" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2366434/Cell_Medica> ;
    ns1:valueRaw "$ 26.5 million",
        "£17 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "US" .

<https://1145.am/db/2544140/Investment_Lundbeckfond_Ventures_Psioxus_Therapeutics_Sr_One_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-09T19:51:57+00:00"^^xsd:dateTime ;
    ns1:documentExtract "And PsiOxus has brought on new investments from GlaxoSmithKline's ($ GSK) venture unit SR One and Lundbeckfond Ventures.",
        "PsiOxus Therapeutics amassed $ 34 million for its Series B." ;
    ns1:documentTitle "PsiOxus lands $34M for cancer vax research" ;
    ns1:documentURL <https://www.fiercepharma.com/r-d/psioxus-lands-34m-for-cancer-vax-research> ;
    ns1:foundName "amassed",
        "investments" ;
    ns1:name "amassed",
        "investments" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2544140/Psioxus_Therapeutics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 34 million" ;
    ns1:whereGeoName "London" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2643743/about.rdf> ;
    ns1:whereRaw "London" .

<https://1145.am/db/2544140/Lundbeckfond_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Denmark" ;
    ns1:documentDate "2012-07-09T19:51:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PsiOxus lands $34M for cancer vax research" ;
    ns1:documentURL <https://www.fiercepharma.com/r-d/psioxus-lands-34m-for-cancer-vax-research> ;
    ns1:foundName "Lundbeckfond Ventures" ;
    ns1:investor <https://1145.am/db/2544140/Investment_Lundbeckfond_Ventures_Psioxus_Therapeutics_Sr_One_Has_Not_Happened> ;
    ns1:name "Lundbeckfond Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/2296062/Lundbeckfonden_Ventures>,
        <https://1145.am/db/2300680/Lundbeckfond_Ventures>,
        <https://1145.am/db/2301536/Lundbeckfonden_Ventures>,
        <https://1145.am/db/2326981/Lundbeckfond_Ventures>,
        <https://1145.am/db/2336716/Lundbeckfond_Ventures>,
        <https://1145.am/db/2338527/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349048/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349050/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349405/Lundbeckfond_Ventures>,
        <https://1145.am/db/2349406/Lundbeckfond_Ventures>,
        <https://1145.am/db/2352357/Lundbeckfond_Ventures>,
        <https://1145.am/db/2352361/Lundbeckfond_Ventures>,
        <https://1145.am/db/2353098/Lundbeckfond_Ventures>,
        <https://1145.am/db/2353917/Lundbeckfond_Ventures>,
        <https://1145.am/db/2354401/Lundbeckfond_Ventures>,
        <https://1145.am/db/2356402/Lundbeckfond_Ventures>,
        <https://1145.am/db/2356411/Lundbeckfond_Ventures>,
        <https://1145.am/db/2359401/Lundbeckfond_Ventures>,
        <https://1145.am/db/2362148/Lundbeckfond_Ventures>,
        <https://1145.am/db/2362156/Lundbeckfond_Ventures>,
        <https://1145.am/db/2363947/Lundbeckfond_Ventures>,
        <https://1145.am/db/2363950/Lundbeckfond_Ventures>,
        <https://1145.am/db/2364492/Lundbeckfond_Ventures>,
        <https://1145.am/db/2365826/Lundbeckfond_Ventures>,
        <https://1145.am/db/2366303/Lundbeckfond_Ventures>,
        <https://1145.am/db/2369169/Lundbeckfond_Ventures>,
        <https://1145.am/db/2369953/Lundbeckfond_Ventures>,
        <https://1145.am/db/2544138/Lundbeckfond_Ventures>,
        <https://1145.am/db/2573068/Lundbeckfond_Ventures>,
        <https://1145.am/db/281538/Lundbeckfonden_Ventures> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2544140/Psioxus_Therapeutics> a org:Organization ;
    ns1:basedInHighGeoName "London" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2643743/about.rdf> ;
    ns1:basedInHighRaw "London" ;
    ns1:basedInLowRaw "Denmark" ;
    ns1:documentDate "2012-07-09T19:51:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PsiOxus lands $34M for cancer vax research" ;
    ns1:documentURL <https://www.fiercepharma.com/r-d/psioxus-lands-34m-for-cancer-vax-research> ;
    ns1:foundName "And PsiOxus",
        "PsiOxus Therapeutics" ;
    ns1:name "PsiOxus",
        "PsiOxus Therapeutics" ;
    ns1:sameAsMedium <https://1145.am/db/1272117/Psioxus_Therapeutics>,
        <https://1145.am/db/1273078/Psioxus_Therapeutics>,
        <https://1145.am/db/2153714/Psioxus_Therapeutics>,
        <https://1145.am/db/2346021/Psioxus_Therapeutics>,
        <https://1145.am/db/2354401/Psioxus_Therapeutics_Ltd>,
        <https://1145.am/db/2363801/Psioxus_Therapeutics>,
        <https://1145.am/db/2363802/Psioxus_Therapeutics_Ltd>,
        <https://1145.am/db/2363947/Psioxus_Therapeutics>,
        <https://1145.am/db/2363950/Psioxus_Therapeutics_Ltd>,
        <https://1145.am/db/2365956/Psioxus_Therapeutics>,
        <https://1145.am/db/2544138/Psioxus_Therapeutics>,
        <https://1145.am/db/2547216/Psioxus_Therapeutics>,
        <https://1145.am/db/2580691/Psioxus_Therapeutics>,
        <https://1145.am/db/2583115/Psioxus_Therapeutics>,
        <https://1145.am/db/2588827/Psioxus_Therapeutics> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2554659/Deltex_Pharmaceuticals_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2012-07-23T19:41:21+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Copanos bought Deltex Pharmaceuticals of Rosenberg, TX, which the FDA in early 2011 closed because of serious manufacturing infractions." ;
    ns1:documentTitle "New Florida drugmaker springs from debacle of another" ;
    ns1:documentURL <https://www.fiercepharma.com/regulatory/new-florida-drugmaker-springs-from-debacle-of-another> ;
    ns1:foundName "bought" ;
    ns1:name "bought" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2554659/Deltex_Pharmaceuticals> ;
    ns1:targetName "Deltex Pharmaceuticals" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2572450/Pele_Nova> a org:Organization ;
    ns1:basedInHighGeoName "Federative Republic of Brazil" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3469034/about.rdf> ;
    ns1:basedInHighRaw "Brazil" ;
    ns1:description "tissue regeneration" ;
    ns1:documentDate "2012-03-26T15:57:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Valeant nabs Russia's Natur Produkt for $175M-plus" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/valeant-nabs-russia-s-natur-produkt-for-175m-plus> ;
    ns1:foundName "Pele Nova" ;
    ns1:name "Pele Nova" ;
    ns1:sameAsMedium <https://1145.am/db/2571019/Pele_Nova> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2580140/Orapharma_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "ipo" ;
    ns1:documentDate "2012-06-15T02:41:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "> Canadian drugmaker Valeant Pharmaceuticals International, has agreed to pay $ 312 million upfront and up to $ 114 million more in constancy payments to buy OraPharma, a specialty oral health company." ;
    ns1:documentTitle "Valeant nabs OraPharma; GSK get MenHibrix OK'd; Trajenta into India;" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/valeant-nabs-orapharma-gsk-get-menhibrix-ok-d-trajenta-into-india> ;
    ns1:foundName "buy" ;
    ns1:name "buy" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2580140/Orapharma> ;
    ns1:targetName "OraPharma" ;
    ns1:valueRaw "$ 312 million",
        "up to $ 114 million" ;
    ns1:whereGeoName "Canada" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6251999/about.rdf> ;
    ns1:whereRaw "Canada" .

<https://1145.am/db/2588906/Stemgent> a org:Organization ;
    ns1:buyer <https://1145.am/db/2588906/Business_Acquisition_Stemgent_Completed> ;
    ns1:description "drug and drug target discovery",
        "stem cell research" ;
    ns1:documentDate "2012-08-01T13:06:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Stemgent Completes Acquisition of Asterand's Human Tissue Business" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/stemgent-completes-acquisition-asterand-s-human-tissue-business> ;
    ns1:foundName "Asterand",
        "Asterand Plc",
        "Stemgent",
        "Stemgent, Inc." ;
    ns1:name "Asterand",
        "Stemgent" ;
    ns1:sameAsHigh <https://1145.am/db/2339535/Stemgent> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2592685/5am_Ventures> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-08-03T13:06:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/atterocor-launches-innovative-company-focused-on-accelerated-development-of-treatment-for> ;
    ns1:foundName "5AM Ventures" ;
    ns1:investor <https://1145.am/db/2592685/Series_A_Investment_5am_Ventures_Atterocor_Frazier_Healthcare_Completed> ;
    ns1:name "5AM Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1307620/Z5_Capital>,
        <https://1145.am/db/1765721/5y_Capital>,
        <https://1145.am/db/2153910/5am_Ventures>,
        <https://1145.am/db/2286204/5am_Ventures>,
        <https://1145.am/db/2288016/5am_Ventures>,
        <https://1145.am/db/2318733/5am_Ventures>,
        <https://1145.am/db/2319784/5am_Ventures>,
        <https://1145.am/db/2329778/5am_Ventures>,
        <https://1145.am/db/2339886/5am_Ventures>,
        <https://1145.am/db/2359864/5am_Ventures>,
        <https://1145.am/db/2360174/5am_Ventures>,
        <https://1145.am/db/2362475/5am_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1157541/5am_Ventures>,
        <https://1145.am/db/1533327/5am_Ventures>,
        <https://1145.am/db/1533685/5am_Ventures>,
        <https://1145.am/db/1608803/5am_Ventures>,
        <https://1145.am/db/1669813/5am_Ventures>,
        <https://1145.am/db/2152422/5am_Ventures>,
        <https://1145.am/db/2153726/5am_Ventures>,
        <https://1145.am/db/2283394/5am_Ventures>,
        <https://1145.am/db/2286665/5am_Ventures>,
        <https://1145.am/db/2298404/5am_Ventures>,
        <https://1145.am/db/2298642/5am_Ventures>,
        <https://1145.am/db/2306549/5am_Ventures>,
        <https://1145.am/db/2306551/5am_Ventures>,
        <https://1145.am/db/2306754/5am_Ventures>,
        <https://1145.am/db/2311595/5am_Ventures>,
        <https://1145.am/db/2313985/5am_Ventures>,
        <https://1145.am/db/2317919/5am_Ventures>,
        <https://1145.am/db/2322646/5am_Ventures>,
        <https://1145.am/db/2323210/5am_Ventures>,
        <https://1145.am/db/2323226/5am_Ventures>,
        <https://1145.am/db/2324195/5am_Ventures>,
        <https://1145.am/db/2328146/5am_Ventures>,
        <https://1145.am/db/2328338/5am_Ventures>,
        <https://1145.am/db/2332322/5am_Ventures>,
        <https://1145.am/db/2339885/5am_Ventures>,
        <https://1145.am/db/2340344/5am_Ventures>,
        <https://1145.am/db/2340345/5am_Ventures>,
        <https://1145.am/db/2340348/5am_Ventures>,
        <https://1145.am/db/2341003/5am_Ventures>,
        <https://1145.am/db/2342352/5am_Ventures>,
        <https://1145.am/db/2347885/5am_Ventures>,
        <https://1145.am/db/2348754/5am_Ventures>,
        <https://1145.am/db/2348857/5am_Ventures>,
        <https://1145.am/db/2349120/5am_Ventures>,
        <https://1145.am/db/2349834/5am_Ventures>,
        <https://1145.am/db/2351316/5am_Ventures>,
        <https://1145.am/db/2351683/5am_Ventures>,
        <https://1145.am/db/2351684/5am_Ventures>,
        <https://1145.am/db/2354296/5am_Ventures>,
        <https://1145.am/db/2355238/5am_Ventures>,
        <https://1145.am/db/2357858/5am_Ventures>,
        <https://1145.am/db/2359401/5am_Ventures>,
        <https://1145.am/db/2360415/5am_Ventures>,
        <https://1145.am/db/2362481/5am_Ventures>,
        <https://1145.am/db/2364492/5am_Ventures>,
        <https://1145.am/db/2367275/5am_Ventures>,
        <https://1145.am/db/2370609/5am_Ventures>,
        <https://1145.am/db/2371160/5am_Ventures>,
        <https://1145.am/db/2371163/5am_Ventures>,
        <https://1145.am/db/2538476/5am_Ventures>,
        <https://1145.am/db/2569220/5am_Ventures>,
        <https://1145.am/db/2572398/5am_Ventures>,
        <https://1145.am/db/2587596/5am_Ventures>,
        <https://1145.am/db/359190/5am_Ventures>,
        <https://1145.am/db/428737/5am_Ventures>,
        <https://1145.am/db/509733/5am_Ventures>,
        <https://1145.am/db/558016/5am_Ventures> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2592685/Atterocor> a org:Organization ;
    ns1:description "Adrenal Cancer" ;
    ns1:documentDate "2012-08-03T13:06:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/atterocor-launches-innovative-company-focused-on-accelerated-development-of-treatment-for> ;
    ns1:foundName "Atterocor",
        "Atterocor, Inc." ;
    ns1:industry "Healthcare" ;
    ns1:name "Atterocor" ;
    ns1:sameAsHigh <https://1145.am/db/1029324/Integracare_Inc>,
        <https://1145.am/db/1060960/Connetics_Usa>,
        <https://1145.am/db/1063801/Connetics_Usa>,
        <https://1145.am/db/1071370/Lrvhealth>,
        <https://1145.am/db/1071776/Exl>,
        <https://1145.am/db/1073166/Hugel>,
        <https://1145.am/db/1084574/Hugel_Inc>,
        <https://1145.am/db/1086114/Hugel_Inc>,
        <https://1145.am/db/1097958/Vizient_Inc>,
        <https://1145.am/db/1131544/Precipio>,
        <https://1145.am/db/1146562/Somed>,
        <https://1145.am/db/1147505/Somed>,
        <https://1145.am/db/1149987/Prolucent>,
        <https://1145.am/db/1149989/Prolucent>,
        <https://1145.am/db/1151652/Prolucent>,
        <https://1145.am/db/1164505/Lrvhealth>,
        <https://1145.am/db/1165813/Lrvhealth>,
        <https://1145.am/db/1178410/Exor>,
        <https://1145.am/db/11887/Adv>,
        <https://1145.am/db/1217219/Medely>,
        <https://1145.am/db/1231536/Cleerly>,
        <https://1145.am/db/1245031/Vizient>,
        <https://1145.am/db/1246028/Vizient>,
        <https://1145.am/db/1247779/Lyniate>,
        <https://1145.am/db/1248702/Lyniate>,
        <https://1145.am/db/1253403/Revecore>,
        <https://1145.am/db/1253946/Z_o_o>,
        <https://1145.am/db/1278636/Careharmony>,
        <https://1145.am/db/1279541/Careharmony>,
        <https://1145.am/db/1294099/Instride>,
        <https://1145.am/db/1295012/Instride>,
        <https://1145.am/db/1326620/Carrum_Health>,
        <https://1145.am/db/1377990/Comar>,
        <https://1145.am/db/1406416/Liine>,
        <https://1145.am/db/1463456/Abiomed>,
        <https://1145.am/db/1490720/Lrvhealth>,
        <https://1145.am/db/1524871/Practicesuite>,
        <https://1145.am/db/1553968/Meduit>,
        <https://1145.am/db/1554054/Clinisupplies>,
        <https://1145.am/db/1555857/Clinisupplies>,
        <https://1145.am/db/1597750/Abiomed>,
        <https://1145.am/db/1598566/Abiomed>,
        <https://1145.am/db/1628699/Qritive>,
        <https://1145.am/db/1631581/Axuall>,
        <https://1145.am/db/1635405/Lrvhealth>,
        <https://1145.am/db/1653432/Knownwell>,
        <https://1145.am/db/1737944/Cred>,
        <https://1145.am/db/1742577/Carrum>,
        <https://1145.am/db/1754984/Recomed>,
        <https://1145.am/db/1762180/Found>,
        <https://1145.am/db/1775902/This_Is_L>,
        <https://1145.am/db/1802991/Credsimple>,
        <https://1145.am/db/1804102/Lumity>,
        <https://1145.am/db/1821186/Clue>,
        <https://1145.am/db/1944061/Thoughtfull>,
        <https://1145.am/db/1962908/Provation>,
        <https://1145.am/db/1963023/Provation>,
        <https://1145.am/db/1965228/Availity>,
        <https://1145.am/db/2010207/Lrvhealth>,
        <https://1145.am/db/2047226/Clariane>,
        <https://1145.am/db/2141061/Plenful>,
        <https://1145.am/db/2180272/Paytient>,
        <https://1145.am/db/2186949/Carrum_Health>,
        <https://1145.am/db/2191705/Alpha_Medical>,
        <https://1145.am/db/2193276/Commure>,
        <https://1145.am/db/2193783/Consensys>,
        <https://1145.am/db/2193804/Carevoyance>,
        <https://1145.am/db/2195913/Select_Medical>,
        <https://1145.am/db/2197584/Docutap>,
        <https://1145.am/db/2200267/Medassets>,
        <https://1145.am/db/2202778/Cadient_Group>,
        <https://1145.am/db/2208415/Apenimed>,
        <https://1145.am/db/2209513/Guidant>,
        <https://1145.am/db/2217745/Inroommd>,
        <https://1145.am/db/2233739/Navigant>,
        <https://1145.am/db/2233787/Cogent_Healthcare>,
        <https://1145.am/db/2233836/Cogent_Healthcare>,
        <https://1145.am/db/2238179/Com_)>,
        <https://1145.am/db/2238216/Accumed>,
        <https://1145.am/db/2240286/Techcomp>,
        <https://1145.am/db/2240682/Cogent_Healthcare>,
        <https://1145.am/db/2246795/Spryance_Inc>,
        <https://1145.am/db/2248736/Cogent_Healthcare>,
        <https://1145.am/db/2249543/(Shp)>,
        <https://1145.am/db/2258277/Curahealth_Llc>,
        <https://1145.am/db/2263381/HCSC>,
        <https://1145.am/db/2277823/(Shp)>,
        <https://1145.am/db/2282491/Mabxience>,
        <https://1145.am/db/2290069/Omniguide>,
        <https://1145.am/db/2295203/Acufocus>,
        <https://1145.am/db/2304313/Chattem_Inc>,
        <https://1145.am/db/2305254/XDX>,
        <https://1145.am/db/2311306/Wyeth>,
        <https://1145.am/db/2320728/Clinquest>,
        <https://1145.am/db/2322509/Chattem>,
        <https://1145.am/db/2361118/Cenduit_Llc>,
        <https://1145.am/db/2560288/Baring>,
        <https://1145.am/db/2562230/Chattem>,
        <https://1145.am/db/2579485/Chattem>,
        <https://1145.am/db/2579503/Chattem>,
        <https://1145.am/db/2594768/Engeneic>,
        <https://1145.am/db/262897/Bizmatics_Inc>,
        <https://1145.am/db/2718916/Prolucent>,
        <https://1145.am/db/2785669/Vizient>,
        <https://1145.am/db/306546/Vizient>,
        <https://1145.am/db/311984/Relatient_Inc>,
        <https://1145.am/db/372259/Availity>,
        <https://1145.am/db/400317/Carevoyance>,
        <https://1145.am/db/402446/Com)>,
        <https://1145.am/db/411367/Avelead>,
        <https://1145.am/db/412775/Currance>,
        <https://1145.am/db/415578/Commure>,
        <https://1145.am/db/427153/Avelead>,
        <https://1145.am/db/446638/Gevity>,
        <https://1145.am/db/447014/Gevity>,
        <https://1145.am/db/456465/Lrvhealth>,
        <https://1145.am/db/488999/Hybrent>,
        <https://1145.am/db/490820/Alpha_Medical>,
        <https://1145.am/db/490899/Hybrent>,
        <https://1145.am/db/506044/Medely>,
        <https://1145.am/db/541625/Medely>,
        <https://1145.am/db/591532/Vizient>,
        <https://1145.am/db/663870/Caresource>,
        <https://1145.am/db/719795/Provation>,
        <https://1145.am/db/720628/Provation>,
        <https://1145.am/db/738729/Com_)>,
        <https://1145.am/db/749590/Lrvhealth>,
        <https://1145.am/db/782649/Alvotech>,
        <https://1145.am/db/802279/Preferral>,
        <https://1145.am/db/803380/Revspring>,
        <https://1145.am/db/847620/Revolugen_Ltd>,
        <https://1145.am/db/850477/Almirall_Sa>,
        <https://1145.am/db/868128/Meduit_Inc>,
        <https://1145.am/db/868162/Sentrics>,
        <https://1145.am/db/888303/Relatient>,
        <https://1145.am/db/890540/Relatient>,
        <https://1145.am/db/903943/Lyniate>,
        <https://1145.am/db/911404/Sycle>,
        <https://1145.am/db/938062/Mabxience>,
        <https://1145.am/db/955357/Revecore>,
        <https://1145.am/db/960265/Cartiheal>,
        <https://1145.am/db/993017/Bonafide> ;
    ns1:sameAsMedium <https://1145.am/db/2342352/Atterocor>,
        <https://1145.am/db/2345728/Atterocor>,
        <https://1145.am/db/2370807/Atterocor> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2592685/Frazier_Healthcare> a org:Organization ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-08-03T13:06:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/atterocor-launches-innovative-company-focused-on-accelerated-development-of-treatment-for> ;
    ns1:foundName "Frazier Healthcare" ;
    ns1:investor <https://1145.am/db/2592685/Series_A_Investment_5am_Ventures_Atterocor_Frazier_Healthcare_Completed> ;
    ns1:name "Frazier Healthcare" ;
    ns1:sameAsHigh <https://1145.am/db/1244886/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1245863/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2152824/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2196903/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2278780/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2307829/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318577/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2330075/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2331784/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2338625/Frazier_Healthcare>,
        <https://1145.am/db/2342352/Frazier_Healthcare>,
        <https://1145.am/db/2346532/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2346542/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2351519/Frazier_Healthcare>,
        <https://1145.am/db/2356269/Frazier_Healthcare>,
        <https://1145.am/db/2365700/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2366187/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2553555/Frazier_Healthcare>,
        <https://1145.am/db/505366/Frazier_Healthcare_Partners>,
        <https://1145.am/db/770024/Frazier_Healthcare_Partners> ;
    ns1:sameAsMedium <https://1145.am/db/1329605/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1374146/Frazier_Healthcare_Partners>,
        <https://1145.am/db/1813040/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2154276/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2189855/Frazier_Healthcare>,
        <https://1145.am/db/2245812/Frazier_Healthcare>,
        <https://1145.am/db/2292109/Frazier_Healthcare>,
        <https://1145.am/db/2294202/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2303250/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303251/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2303257/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2305524/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2307824/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2308855/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2310795/Frazier_Healthcare>,
        <https://1145.am/db/2310798/Frazier_Healthcare>,
        <https://1145.am/db/2311551/Frazier_Healthcare>,
        <https://1145.am/db/2316391/Frazier_Healthcare>,
        <https://1145.am/db/2318274/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318276/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2318635/Frazier_Healthcare>,
        <https://1145.am/db/2321216/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2325326/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2326430/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2327441/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2327442/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2330079/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2334616/Frazier_Healthcare>,
        <https://1145.am/db/2334622/Frazier_Healthcare>,
        <https://1145.am/db/2334624/Frazier_Healthcare>,
        <https://1145.am/db/2335675/Frazier_Healthcare>,
        <https://1145.am/db/2335743/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2336032/Frazier_Healthcare>,
        <https://1145.am/db/2337166/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2338633/Frazier_Healthcare>,
        <https://1145.am/db/2339925/Frazier_Healthcare>,
        <https://1145.am/db/2339926/Frazier_Healthcare>,
        <https://1145.am/db/2340204/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2340207/Frazier_Healthcare_Ventures>,
        <https://1145.am/db/2342629/Frazier_Healthcare>,
        <https://1145.am/db/2348754/Frazier_Healthcare>,
        <https://1145.am/db/2351520/Frazier_Healthcare>,
        <https://1145.am/db/2356306/Frazier_Healthcare>,
        <https://1145.am/db/2361549/Frazier_Healthcare>,
        <https://1145.am/db/2361551/Frazier_Healthcare>,
        <https://1145.am/db/2366700/Frazier_Healthcare>,
        <https://1145.am/db/2368333/Frazier_Healthcare>,
        <https://1145.am/db/2370761/Frazier_Healthcare_Partners>,
        <https://1145.am/db/2537423/Frazier_Healthcare>,
        <https://1145.am/db/2584561/Frazier_Healthcare_Partners>,
        <https://1145.am/db/490601/Frazier_Healthcare_Partners>,
        <https://1145.am/db/578056/Frazier_Healthcare_Partners>,
        <https://1145.am/db/578059/Frazier_Healthcare_Partners>,
        <https://1145.am/db/699981/Frazier_Healthcare_Partners> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2592685/Series_A_Investment_5am_Ventures_Atterocor_Frazier_Healthcare_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-08-03T13:06:01+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $ 16 Million Series A Financing.",
        "Atterocor, Inc., a company developing an innovative therapy for adrenal cancer, today announced a $ 16 million Series A venture capital financing." ;
    ns1:documentTitle "Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/atterocor-launches-innovative-company-focused-on-accelerated-development-of-treatment-for> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Pharma" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2592685/Atterocor> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 16 Million",
        "$ 16 million" .

<https://1145.am/db/2651427/Joint_Venture_Kyivstar_Mts_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "joint venture" ;
    ns1:documentDate "2012-06-26T01:00:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Ukraine's two largest mobile operators - Kyivstar and MTS - have reached a new interconnection agreement, ending a dispute that has been brewing since Kyivstar cancelled their previous arrangement." ;
    ns1:documentTitle "Webwire: ITC examines Apple ruling; Microsoft goes social" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/webwire-itc-examines-apple-ruling-microsoft-goes-social> ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "completed" ;
    ns1:whereGeoName "Ukraine" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/690791/about.rdf> ;
    ns1:whereRaw "Ukraine" .

<https://1145.am/db/2653242/Bulgarian_Telecommunications_Company> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Bulgaria" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/732800/about.rdf> ;
    ns1:basedInHighRaw "Bulgaria" ;
    ns1:description "Bulgarian fixed and mobile operator" ;
    ns1:documentDate "2012-08-08T09:57:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Banks agree to buy Bulgaria's Vivacom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/banks-agree-to-buy-bulgaria-s-vivacom> ;
    ns1:foundName "Bulgarian Telecommunications Company" ;
    ns1:name "Bulgarian Telecommunications Company" ;
    ns1:sameAsHigh <https://1145.am/db/2653242/Turkcell_And_Telekom_Austria> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2671481/Telenor> a org:Organization ;
    ns1:basedInHighGeoName "Kingdom of Norway" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/3144096/about.rdf> ;
    ns1:basedInHighRaw "Norway" ;
    ns1:documentDate "2012-04-06T14:47:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor boosts VimpelCom stake with $715M JP Morgan deal" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-boosts-vimpelcom-stake-715m-jp-morgan-deal> ;
    ns1:foundName "Telenor" ;
    ns1:industry "telco" ;
    ns1:investor <https://1145.am/db/2671481/Investment_Jp_Morgan_Securities_Telenor_Has_Not_Happened> ;
    ns1:name "Telenor" ;
    ns1:sameAsHigh <https://1145.am/db/1346263/Telenor_Asa>,
        <https://1145.am/db/1436432/Telenor_Asa>,
        <https://1145.am/db/1438131/Telenor_Group>,
        <https://1145.am/db/2094378/Telenor>,
        <https://1145.am/db/2650869/Telenor>,
        <https://1145.am/db/2652368/Telenor>,
        <https://1145.am/db/2652904/Telenor>,
        <https://1145.am/db/2654657/Telenor>,
        <https://1145.am/db/2659847/Telenor>,
        <https://1145.am/db/2660899/Telenor>,
        <https://1145.am/db/2663652/Telenor>,
        <https://1145.am/db/2663848/Telenor>,
        <https://1145.am/db/2664724/Telenor>,
        <https://1145.am/db/2666421/Telenor>,
        <https://1145.am/db/2670746/Telenor>,
        <https://1145.am/db/2672659/Telenor>,
        <https://1145.am/db/2672667/Telenor>,
        <https://1145.am/db/2674119/Telenor>,
        <https://1145.am/db/2674480/Telenor>,
        <https://1145.am/db/2674820/Telenor>,
        <https://1145.am/db/2674846/Telenor>,
        <https://1145.am/db/2675034/Telenor>,
        <https://1145.am/db/2675322/Telenor>,
        <https://1145.am/db/2677980/Telenor>,
        <https://1145.am/db/2682600/Telenor>,
        <https://1145.am/db/302649/Telenor_Asa>,
        <https://1145.am/db/303526/Telenor_Asa>,
        <https://1145.am/db/354360/Telenor_Asa>,
        <https://1145.am/db/357674/Telenor_Asa>,
        <https://1145.am/db/367876/Telenor>,
        <https://1145.am/db/367882/Telenor>,
        <https://1145.am/db/373562/Telenor>,
        <https://1145.am/db/383545/Telenor>,
        <https://1145.am/db/476905/Telenor>,
        <https://1145.am/db/602860/Telenor>,
        <https://1145.am/db/638417/Telenor>,
        <https://1145.am/db/643839/Telenor>,
        <https://1145.am/db/649246/Telenor_Asa>,
        <https://1145.am/db/650742/Telenor_Asa>,
        <https://1145.am/db/773044/Telenor>,
        <https://1145.am/db/834341/Telenor>,
        <https://1145.am/db/912047/Telenor>,
        <https://1145.am/db/915710/Telenor_Group>,
        <https://1145.am/db/932342/Telenor> ;
    ns1:sameAsMedium <https://1145.am/db/1170938/Telenor_Asa>,
        <https://1145.am/db/1399415/Telenor>,
        <https://1145.am/db/1796174/Telenor>,
        <https://1145.am/db/1806742/Telenor>,
        <https://1145.am/db/1939108/Telenor>,
        <https://1145.am/db/2607010/Telenor>,
        <https://1145.am/db/2614152/Telenor>,
        <https://1145.am/db/2628991/Telenor>,
        <https://1145.am/db/2636581/Telenor>,
        <https://1145.am/db/2639340/Telenor>,
        <https://1145.am/db/2653163/Telenor>,
        <https://1145.am/db/2653225/Telenor>,
        <https://1145.am/db/2653239/Telenor>,
        <https://1145.am/db/2653265/Telenor>,
        <https://1145.am/db/2654892/Telenor>,
        <https://1145.am/db/2655477/Telenor>,
        <https://1145.am/db/2656915/Telenor>,
        <https://1145.am/db/2659180/Telenor>,
        <https://1145.am/db/2659514/Telenor>,
        <https://1145.am/db/2659801/Telenor>,
        <https://1145.am/db/2660884/Telenor>,
        <https://1145.am/db/2661979/Telenor>,
        <https://1145.am/db/2663852/Telenor>,
        <https://1145.am/db/2663973/Telenor>,
        <https://1145.am/db/2664153/Telenor>,
        <https://1145.am/db/2666299/Telenor>,
        <https://1145.am/db/2667068/Telenor>,
        <https://1145.am/db/2667384/Telenor>,
        <https://1145.am/db/2669581/Telenor>,
        <https://1145.am/db/2672936/Telenor>,
        <https://1145.am/db/2672959/Telenor>,
        <https://1145.am/db/2672967/Telenor>,
        <https://1145.am/db/2673173/Telenor>,
        <https://1145.am/db/2674215/Telenor>,
        <https://1145.am/db/2674464/Telenor>,
        <https://1145.am/db/2677894/Telenor>,
        <https://1145.am/db/2681794/Telenor>,
        <https://1145.am/db/2683657/Telenor>,
        <https://1145.am/db/638291/Telenor_Asa> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2672659/Telenor> a org:Organization ;
    ns1:basedInLowRaw "Norway" ;
    ns1:buyer <https://1145.am/db/2672659/Vimpelcom_Acquisition> ;
    ns1:description "investment" ;
    ns1:documentDate "2012-04-19T10:05:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor faces fresh fight for VimpelCom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-faces-fresh-fight-for-vimpelcom-0> ;
    ns1:foundName "Telenor" ;
    ns1:industry "telco" ;
    ns1:investor <https://1145.am/db/2672659/Vimpelcom_Acquisition> ;
    ns1:name "Telenor" ;
    ns1:sameAsHigh <https://1145.am/db/1346263/Telenor_Asa>,
        <https://1145.am/db/1436432/Telenor_Asa>,
        <https://1145.am/db/1438131/Telenor_Group>,
        <https://1145.am/db/2094378/Telenor>,
        <https://1145.am/db/2650869/Telenor>,
        <https://1145.am/db/2652368/Telenor>,
        <https://1145.am/db/2652904/Telenor>,
        <https://1145.am/db/2654657/Telenor>,
        <https://1145.am/db/2659847/Telenor>,
        <https://1145.am/db/2660899/Telenor>,
        <https://1145.am/db/2663652/Telenor>,
        <https://1145.am/db/2663848/Telenor>,
        <https://1145.am/db/2664724/Telenor>,
        <https://1145.am/db/2666421/Telenor>,
        <https://1145.am/db/2670746/Telenor>,
        <https://1145.am/db/2671481/Telenor>,
        <https://1145.am/db/2672667/Telenor>,
        <https://1145.am/db/2674119/Telenor>,
        <https://1145.am/db/2674480/Telenor>,
        <https://1145.am/db/2674820/Telenor>,
        <https://1145.am/db/2674846/Telenor>,
        <https://1145.am/db/2675034/Telenor>,
        <https://1145.am/db/2675322/Telenor>,
        <https://1145.am/db/2677980/Telenor>,
        <https://1145.am/db/2682600/Telenor>,
        <https://1145.am/db/302649/Telenor_Asa>,
        <https://1145.am/db/303526/Telenor_Asa>,
        <https://1145.am/db/354360/Telenor_Asa>,
        <https://1145.am/db/357674/Telenor_Asa>,
        <https://1145.am/db/367876/Telenor>,
        <https://1145.am/db/367882/Telenor>,
        <https://1145.am/db/373562/Telenor>,
        <https://1145.am/db/383545/Telenor>,
        <https://1145.am/db/476905/Telenor>,
        <https://1145.am/db/602860/Telenor>,
        <https://1145.am/db/638417/Telenor>,
        <https://1145.am/db/643839/Telenor>,
        <https://1145.am/db/649246/Telenor_Asa>,
        <https://1145.am/db/650742/Telenor_Asa>,
        <https://1145.am/db/773044/Telenor>,
        <https://1145.am/db/834341/Telenor>,
        <https://1145.am/db/912047/Telenor>,
        <https://1145.am/db/915710/Telenor_Group>,
        <https://1145.am/db/932342/Telenor> ;
    ns1:sameAsMedium <https://1145.am/db/1170938/Telenor_Asa>,
        <https://1145.am/db/1399415/Telenor>,
        <https://1145.am/db/1796174/Telenor>,
        <https://1145.am/db/1806742/Telenor>,
        <https://1145.am/db/1939108/Telenor>,
        <https://1145.am/db/2607010/Telenor>,
        <https://1145.am/db/2614152/Telenor>,
        <https://1145.am/db/2628991/Telenor>,
        <https://1145.am/db/2636581/Telenor>,
        <https://1145.am/db/2639340/Telenor>,
        <https://1145.am/db/2653163/Telenor>,
        <https://1145.am/db/2653225/Telenor>,
        <https://1145.am/db/2653239/Telenor>,
        <https://1145.am/db/2653265/Telenor>,
        <https://1145.am/db/2654892/Telenor>,
        <https://1145.am/db/2655477/Telenor>,
        <https://1145.am/db/2656915/Telenor>,
        <https://1145.am/db/2659180/Telenor>,
        <https://1145.am/db/2659514/Telenor>,
        <https://1145.am/db/2659801/Telenor>,
        <https://1145.am/db/2660884/Telenor>,
        <https://1145.am/db/2661979/Telenor>,
        <https://1145.am/db/2663852/Telenor>,
        <https://1145.am/db/2663973/Telenor>,
        <https://1145.am/db/2664153/Telenor>,
        <https://1145.am/db/2666299/Telenor>,
        <https://1145.am/db/2667068/Telenor>,
        <https://1145.am/db/2667384/Telenor>,
        <https://1145.am/db/2669581/Telenor>,
        <https://1145.am/db/2672936/Telenor>,
        <https://1145.am/db/2672959/Telenor>,
        <https://1145.am/db/2672967/Telenor>,
        <https://1145.am/db/2673173/Telenor>,
        <https://1145.am/db/2674215/Telenor>,
        <https://1145.am/db/2674464/Telenor>,
        <https://1145.am/db/2677894/Telenor>,
        <https://1145.am/db/2681794/Telenor>,
        <https://1145.am/db/2683657/Telenor>,
        <https://1145.am/db/638291/Telenor_Asa> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2672667/Telenor> a org:Organization ;
    ns1:basedInLowRaw "Norway" ;
    ns1:buyer <https://1145.am/db/2672667/Vimpelcom_Acquisition> ;
    ns1:description "investment" ;
    ns1:documentDate "2012-04-19T10:26:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor faces fresh fight for VimpelCom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-faces-fresh-fight-for-vimpelcom> ;
    ns1:foundName "Telenor" ;
    ns1:industry "telco" ;
    ns1:investor <https://1145.am/db/2672667/Vimpelcom_Acquisition> ;
    ns1:name "Telenor" ;
    ns1:sameAsHigh <https://1145.am/db/1346263/Telenor_Asa>,
        <https://1145.am/db/1436432/Telenor_Asa>,
        <https://1145.am/db/1438131/Telenor_Group>,
        <https://1145.am/db/2094378/Telenor>,
        <https://1145.am/db/2650869/Telenor>,
        <https://1145.am/db/2652368/Telenor>,
        <https://1145.am/db/2652904/Telenor>,
        <https://1145.am/db/2654657/Telenor>,
        <https://1145.am/db/2659847/Telenor>,
        <https://1145.am/db/2660899/Telenor>,
        <https://1145.am/db/2663652/Telenor>,
        <https://1145.am/db/2663848/Telenor>,
        <https://1145.am/db/2664724/Telenor>,
        <https://1145.am/db/2666421/Telenor>,
        <https://1145.am/db/2670746/Telenor>,
        <https://1145.am/db/2671481/Telenor>,
        <https://1145.am/db/2672659/Telenor>,
        <https://1145.am/db/2674119/Telenor>,
        <https://1145.am/db/2674480/Telenor>,
        <https://1145.am/db/2674820/Telenor>,
        <https://1145.am/db/2674846/Telenor>,
        <https://1145.am/db/2675034/Telenor>,
        <https://1145.am/db/2675322/Telenor>,
        <https://1145.am/db/2677980/Telenor>,
        <https://1145.am/db/2682600/Telenor>,
        <https://1145.am/db/302649/Telenor_Asa>,
        <https://1145.am/db/303526/Telenor_Asa>,
        <https://1145.am/db/354360/Telenor_Asa>,
        <https://1145.am/db/357674/Telenor_Asa>,
        <https://1145.am/db/367876/Telenor>,
        <https://1145.am/db/367882/Telenor>,
        <https://1145.am/db/373562/Telenor>,
        <https://1145.am/db/383545/Telenor>,
        <https://1145.am/db/476905/Telenor>,
        <https://1145.am/db/602860/Telenor>,
        <https://1145.am/db/638417/Telenor>,
        <https://1145.am/db/643839/Telenor>,
        <https://1145.am/db/649246/Telenor_Asa>,
        <https://1145.am/db/650742/Telenor_Asa>,
        <https://1145.am/db/773044/Telenor>,
        <https://1145.am/db/834341/Telenor>,
        <https://1145.am/db/912047/Telenor>,
        <https://1145.am/db/915710/Telenor_Group>,
        <https://1145.am/db/932342/Telenor> ;
    ns1:sameAsMedium <https://1145.am/db/1170938/Telenor_Asa>,
        <https://1145.am/db/1399415/Telenor>,
        <https://1145.am/db/1796174/Telenor>,
        <https://1145.am/db/1806742/Telenor>,
        <https://1145.am/db/1939108/Telenor>,
        <https://1145.am/db/2607010/Telenor>,
        <https://1145.am/db/2614152/Telenor>,
        <https://1145.am/db/2628991/Telenor>,
        <https://1145.am/db/2636581/Telenor>,
        <https://1145.am/db/2639340/Telenor>,
        <https://1145.am/db/2653163/Telenor>,
        <https://1145.am/db/2653225/Telenor>,
        <https://1145.am/db/2653239/Telenor>,
        <https://1145.am/db/2653265/Telenor>,
        <https://1145.am/db/2654892/Telenor>,
        <https://1145.am/db/2655477/Telenor>,
        <https://1145.am/db/2656915/Telenor>,
        <https://1145.am/db/2659180/Telenor>,
        <https://1145.am/db/2659514/Telenor>,
        <https://1145.am/db/2659801/Telenor>,
        <https://1145.am/db/2660884/Telenor>,
        <https://1145.am/db/2661979/Telenor>,
        <https://1145.am/db/2663852/Telenor>,
        <https://1145.am/db/2663973/Telenor>,
        <https://1145.am/db/2664153/Telenor>,
        <https://1145.am/db/2666299/Telenor>,
        <https://1145.am/db/2667068/Telenor>,
        <https://1145.am/db/2667384/Telenor>,
        <https://1145.am/db/2669581/Telenor>,
        <https://1145.am/db/2672936/Telenor>,
        <https://1145.am/db/2672959/Telenor>,
        <https://1145.am/db/2672967/Telenor>,
        <https://1145.am/db/2673173/Telenor>,
        <https://1145.am/db/2674215/Telenor>,
        <https://1145.am/db/2674464/Telenor>,
        <https://1145.am/db/2677894/Telenor>,
        <https://1145.am/db/2681794/Telenor>,
        <https://1145.am/db/2683657/Telenor>,
        <https://1145.am/db/638291/Telenor_Asa> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2681282/Verizon_Wireless> a org:Organization ;
    ns1:basedInLowRaw "USA" ;
    ns1:buyer <https://1145.am/db/2681282/Acquisition_Cox_Communication_Verizon_Wireless_Has_Not_Happened> ;
    ns1:description "Wireless",
        "telecommunications" ;
    ns1:documentDate "2012-04-18T15:23:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Verizon: We'll sell 700 MHz spectrum to get cable companies' AWS spectrum" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/verizon-we-ll-sell-700-mhz-spectrum-to-get-cable-companies-aws-spectrum> ;
    ns1:foundName "Verizon",
        "Verizon Wireless" ;
    ns1:industry "Wireless" ;
    ns1:name "Verizon",
        "Verizon Wireless" ;
    ns1:sameAsHigh <https://1145.am/db/1820979/Verizon>,
        <https://1145.am/db/1822834/Verizon>,
        <https://1145.am/db/2168361/Verizon_Communications>,
        <https://1145.am/db/2176727/Verizon>,
        <https://1145.am/db/2177833/Verizon>,
        <https://1145.am/db/2599094/Verizon>,
        <https://1145.am/db/2599594/Verizon>,
        <https://1145.am/db/2599911/Verizon_Communications>,
        <https://1145.am/db/2601763/Verizon_Communications>,
        <https://1145.am/db/2602262/Verizon>,
        <https://1145.am/db/2602271/Verizon>,
        <https://1145.am/db/2602590/Verizon>,
        <https://1145.am/db/2603198/Verizon_Communications>,
        <https://1145.am/db/2603513/Verizon>,
        <https://1145.am/db/2604354/Verizon>,
        <https://1145.am/db/2604587/Verizon>,
        <https://1145.am/db/2604998/Verizon_Communications>,
        <https://1145.am/db/2605637/Verizon>,
        <https://1145.am/db/2605886/Verizon>,
        <https://1145.am/db/2606651/Verizon>,
        <https://1145.am/db/2607119/Verizon_Communications>,
        <https://1145.am/db/2607123/Verizon>,
        <https://1145.am/db/2607214/Verizon>,
        <https://1145.am/db/2607321/Verizon_Communications>,
        <https://1145.am/db/2607321/Verizon_Wireless>,
        <https://1145.am/db/2607417/Verizon>,
        <https://1145.am/db/2607600/Verizon>,
        <https://1145.am/db/2608367/Verizon>,
        <https://1145.am/db/2608379/Verizon>,
        <https://1145.am/db/2608701/Verizon>,
        <https://1145.am/db/2609145/Verizon>,
        <https://1145.am/db/2609727/Verizon>,
        <https://1145.am/db/2609858/Verizon>,
        <https://1145.am/db/2609881/Verizon>,
        <https://1145.am/db/2610099/Verizon>,
        <https://1145.am/db/2610272/Verizon>,
        <https://1145.am/db/2611521/Verizon_Wireless>,
        <https://1145.am/db/2611992/Verizon_Communications>,
        <https://1145.am/db/2612445/Verizon>,
        <https://1145.am/db/2612463/Verizon>,
        <https://1145.am/db/2612867/Verizon>,
        <https://1145.am/db/2613661/Verizon>,
        <https://1145.am/db/2613955/Verizon>,
        <https://1145.am/db/2614713/Verizon>,
        <https://1145.am/db/2614891/Verizon_Communications>,
        <https://1145.am/db/2615051/Verizon>,
        <https://1145.am/db/2617079/Verizon_Communications>,
        <https://1145.am/db/2617606/Verizon>,
        <https://1145.am/db/2617789/Verizon_Communications>,
        <https://1145.am/db/2617844/Verizon_Wireless>,
        <https://1145.am/db/2619083/Verizon>,
        <https://1145.am/db/2619759/Verizon_Communications>,
        <https://1145.am/db/2619999/Verizon>,
        <https://1145.am/db/2621710/Verizon>,
        <https://1145.am/db/2625937/Verizon_Communications>,
        <https://1145.am/db/2627292/Verizon>,
        <https://1145.am/db/2629002/Verizon_Communications>,
        <https://1145.am/db/2629026/Verizon>,
        <https://1145.am/db/2630966/Verizon_Wireless>,
        <https://1145.am/db/2631014/Verizon_Wireless>,
        <https://1145.am/db/2638011/Verizon>,
        <https://1145.am/db/2639565/Verizon_Wireless>,
        <https://1145.am/db/2640950/Verizon>,
        <https://1145.am/db/2642638/Verizon_Wireless>,
        <https://1145.am/db/2642870/Verizon>,
        <https://1145.am/db/2643151/Verizon_Wireless>,
        <https://1145.am/db/2643559/Verizon_Communications>,
        <https://1145.am/db/2643836/Verizon>,
        <https://1145.am/db/2643949/Verizon>,
        <https://1145.am/db/2644793/Verizon>,
        <https://1145.am/db/2646605/Verizon_Wireless>,
        <https://1145.am/db/2646870/Verizon>,
        <https://1145.am/db/2648024/Verizon>,
        <https://1145.am/db/2648450/Verizon_Communications>,
        <https://1145.am/db/2648546/Verizon_Communications>,
        <https://1145.am/db/2649536/Verizon>,
        <https://1145.am/db/2652646/Verizon_Wireless>,
        <https://1145.am/db/2653416/Verizon>,
        <https://1145.am/db/2653676/Verizon>,
        <https://1145.am/db/2654198/Verizon>,
        <https://1145.am/db/2654888/Verizon_Communications>,
        <https://1145.am/db/2658006/Verizon_Communications>,
        <https://1145.am/db/2659280/Verizon_Communications>,
        <https://1145.am/db/2659282/Verizon_Communications>,
        <https://1145.am/db/2659966/Verizon_Wireless>,
        <https://1145.am/db/2664359/Verizon_Wireless>,
        <https://1145.am/db/2665564/Verizon_Communications>,
        <https://1145.am/db/2667132/Verizon_Wireless>,
        <https://1145.am/db/2671406/Verizon_Wireless>,
        <https://1145.am/db/2672472/Verizon_Wireless>,
        <https://1145.am/db/2673622/Verizon_Wireless>,
        <https://1145.am/db/2673958/Verizon_Communications>,
        <https://1145.am/db/2673958/Verizon_Wireless>,
        <https://1145.am/db/2678495/Verizon_Communications>,
        <https://1145.am/db/2678778/Verizon_Communications>,
        <https://1145.am/db/2679163/Verizon_Communications>,
        <https://1145.am/db/2679163/Verizon_Wireless>,
        <https://1145.am/db/2679270/Verizon_Communications>,
        <https://1145.am/db/2679804/Verizon>,
        <https://1145.am/db/2680802/Verizon>,
        <https://1145.am/db/2683349/Verizon_Communications>,
        <https://1145.am/db/2684545/Verizon_Communications>,
        <https://1145.am/db/2684897/Verizon_Wireless>,
        <https://1145.am/db/2789493/Verizon_Communications>,
        <https://1145.am/db/322211/Verizon_Communications_Inc>,
        <https://1145.am/db/633390/Verizon_Communications>,
        <https://1145.am/db/644214/Verizon_Communications_Inc>,
        <https://1145.am/db/839179/Verizon_Communications_Inc>,
        <https://1145.am/db/859213/Verizon>,
        <https://1145.am/db/859301/Verizon> ;
    ns1:sameAsMedium <https://1145.am/db/1698410/Verizon_Wireless>,
        <https://1145.am/db/1709073/Verizon_Wireless>,
        <https://1145.am/db/1713307/Verizon_Wireless>,
        <https://1145.am/db/1854000/Verizon_Wireless>,
        <https://1145.am/db/2175880/Verizon_Wireless>,
        <https://1145.am/db/2603175/Verizon_Wireless>,
        <https://1145.am/db/2615058/Verizon_Wireless>,
        <https://1145.am/db/2623357/Verizon_Wireless>,
        <https://1145.am/db/2625944/Verizon_Wireless>,
        <https://1145.am/db/2626647/Verizon_Wireless>,
        <https://1145.am/db/2629075/Verizon_Wireless>,
        <https://1145.am/db/2630964/Verizon_Wireless>,
        <https://1145.am/db/2633169/Verizon_Wireless>,
        <https://1145.am/db/2636627/Verizon_Wireless>,
        <https://1145.am/db/2636649/Verizon_Wireless>,
        <https://1145.am/db/2637568/Verizon_Wireless>,
        <https://1145.am/db/2638447/Verizon_Wireless>,
        <https://1145.am/db/2638626/Verizon_Wireless>,
        <https://1145.am/db/2640586/Verizon_Wireless>,
        <https://1145.am/db/2640627/Verizon_Wireless>,
        <https://1145.am/db/2640631/Verizon_Wireless>,
        <https://1145.am/db/2641133/Verizon_Wireless>,
        <https://1145.am/db/2641674/Verizon_Wireless>,
        <https://1145.am/db/2643114/Verizon_Wireless>,
        <https://1145.am/db/2644230/Verizon_Wireless>,
        <https://1145.am/db/2647254/Verizon_Wireless>,
        <https://1145.am/db/2648489/Verizon_Wireless>,
        <https://1145.am/db/2648535/Verizon_Wireless>,
        <https://1145.am/db/2653299/Verizon_Wireless>,
        <https://1145.am/db/2654246/Verizon_Wireless>,
        <https://1145.am/db/2655154/Verizon_Wireless>,
        <https://1145.am/db/2655158/Verizon_Wireless>,
        <https://1145.am/db/2658006/Verizon_Wireless>,
        <https://1145.am/db/2658043/Verizon_Wireless>,
        <https://1145.am/db/2659609/Verizon_Wireless>,
        <https://1145.am/db/2660385/Verizon_Wireless>,
        <https://1145.am/db/2661771/Verizon_Wireless>,
        <https://1145.am/db/2663294/Verizon_Wireless>,
        <https://1145.am/db/2665544/Verizon_Wireless>,
        <https://1145.am/db/2665564/Verizon_Wireless>,
        <https://1145.am/db/2666614/Verizon_Wireless>,
        <https://1145.am/db/2667470/Verizon_Wireless>,
        <https://1145.am/db/2669324/Verizon_Wireless>,
        <https://1145.am/db/2669935/Verizon_Wireless>,
        <https://1145.am/db/2669944/Verizon_Wireless>,
        <https://1145.am/db/2671610/Verizon_Wireless>,
        <https://1145.am/db/2672183/Verizon_Wireless>,
        <https://1145.am/db/2672185/Verizon_Wireless>,
        <https://1145.am/db/2672228/Verizon_Wireless>,
        <https://1145.am/db/2672778/Verizon_Wireless>,
        <https://1145.am/db/2672784/Verizon_Wireless>,
        <https://1145.am/db/2673608/Verizon_Wireless>,
        <https://1145.am/db/2673614/Verizon_Wireless>,
        <https://1145.am/db/2673945/Verizon_Wireless>,
        <https://1145.am/db/2676075/Verizon_Wireless>,
        <https://1145.am/db/2676100/Verizon_Wireless>,
        <https://1145.am/db/2680403/Verizon_Wireless>,
        <https://1145.am/db/2680756/Verizon_Wireless>,
        <https://1145.am/db/2681285/Verizon_Wireless>,
        <https://1145.am/db/2682721/Verizon_Wireless>,
        <https://1145.am/db/2683077/Verizon_Wireless>,
        <https://1145.am/db/2683135/Verizon_Wireless>,
        <https://1145.am/db/2683147/Verizon_Wireless>,
        <https://1145.am/db/2683432/Verizon_Wireless>,
        <https://1145.am/db/2683443/Verizon_Wireless>,
        <https://1145.am/db/2684478/Verizon_Wireless>,
        <https://1145.am/db/2684484/Verizon_Wireless>,
        <https://1145.am/db/2684691/Verizon_Wireless>,
        <https://1145.am/db/2685047/Verizon_Wireless>,
        <https://1145.am/db/2685877/Verizon_Wireless>,
        <https://1145.am/db/2686087/Verizon_Wireless>,
        <https://1145.am/db/2686540/Verizon_Wireless> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2288967/Prochon_Biotech> a org:Organization ;
    ns1:basedInHighGeoName "State of Israel" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/294640/about.rdf> ;
    ns1:basedInHighRaw "Israel" ;
    ns1:description "cell therapy" ;
    ns1:documentDate "2012-07-23T23:30:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics reels in $49M Series A for tissue engineering implants" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/histogenics-reels-49m-series-a-for-tissue-engineering-implants> ;
    ns1:foundName "Prochon BioTech" ;
    ns1:name "Prochon BioTech" ;
    ns1:sameAsHigh <https://1145.am/db/1165421/Cellino_Biotech>,
        <https://1145.am/db/2327996/Cellerix>,
        <https://1145.am/db/2349695/Cellerix>,
        <https://1145.am/db/2366434/Cell_Medica>,
        <https://1145.am/db/2555064/Cellular_Biomedicine_Group> ;
    ns1:sameAsMedium <https://1145.am/db/2336098/Prochon_Biotech> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2297604/Series_B_Investment_Good_Start_Genetics_Orbimed_Advisors_Sv_Life_Sciences_Safeguard_Scientifics_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-02T14:10:43+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Good Start Genetics in Cambridge, MA, closed a $ 14 million Series B round by way of a Series B Preferred Stock financing.",
        "Molecular diagnostics/genetic sequencing startups Good Start Genetics and MolecularMD have nailed down new rounds of cash to advance clinical and commercial development of their products." ;
    ns1:documentTitle "2 molecular diagnostics companies grab major money" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/2-molecular-diagnostics-companies-grab-major-money> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2297604/Good_Start_Genetics>,
        <https://1145.am/db/2297604/Molecularmd> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 14 million" ;
    ns1:whereGeoName "Cambridge" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4931972/about.rdf> ;
    ns1:whereRaw "Cambridge, MA" .

<https://1145.am/db/2337971/New_Enterprise_Associates> a org:Organization ;
    ns1:basedInLowRaw "CAMBRIDGE" ;
    ns1:documentDate "2012-07-31T14:27:00+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates> ;
    ns1:foundName "New Enterprise Associates" ;
    ns1:investor <https://1145.am/db/2337971/Series_A_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_New_Enterprise_Associates_Pfizer_Venture_Investments_Proquest_Investments_Rho_Ventures_Completed> ;
    ns1:name "New Enterprise Associates" ;
    ns1:sameAsMedium <https://1145.am/db/1031040/New_Enterprise_Associates>,
        <https://1145.am/db/1091201/New_Enterprise_Associates>,
        <https://1145.am/db/1115103/New_Enterprise_Associates>,
        <https://1145.am/db/1115600/New_Enterprise_Associates>,
        <https://1145.am/db/1116035/New_Enterprise_Associates>,
        <https://1145.am/db/1116076/New_Enterprise_Associates>,
        <https://1145.am/db/1127410/New_Enterprise_Associates>,
        <https://1145.am/db/1169121/New_Enterprise_Associates>,
        <https://1145.am/db/1230022/New_Enterprise_Associates>,
        <https://1145.am/db/1233430/New_Enterprise_Associates>,
        <https://1145.am/db/1279264/New_Enterprise_Associates>,
        <https://1145.am/db/1281079/New_Enterprise_Associates>,
        <https://1145.am/db/1281647/New_Enterprise_Associates>,
        <https://1145.am/db/1371086/New_Enterprise_Associates>,
        <https://1145.am/db/1422234/New_Enterprise_Associates>,
        <https://1145.am/db/1422725/New_Enterprise_Associates>,
        <https://1145.am/db/1427471/New_Enterprise_Associates>,
        <https://1145.am/db/1469165/New_Enterprise_Associates>,
        <https://1145.am/db/1571794/New_Enterprise_Associates>,
        <https://1145.am/db/1606686/New_Enterprise_Associates>,
        <https://1145.am/db/1653132/New_Enterprise_Associates>,
        <https://1145.am/db/1653506/New_Enterprise_Associates>,
        <https://1145.am/db/1654515/New_Enterprise_Associates>,
        <https://1145.am/db/1694448/New_Enterprise_Associates>,
        <https://1145.am/db/1696213/New_Enterprise_Associates>,
        <https://1145.am/db/1699877/New_Enterprise_Associates>,
        <https://1145.am/db/1701285/New_Enterprise_Associates>,
        <https://1145.am/db/1701411/New_Enterprise_Associates>,
        <https://1145.am/db/1701589/New_Enterprise_Associates>,
        <https://1145.am/db/1715860/New_Enterprise_Associates>,
        <https://1145.am/db/1717498/New_Enterprise_Associates>,
        <https://1145.am/db/1717968/New_Enterprise_Associates>,
        <https://1145.am/db/1718000/New_Enterprise_Associates>,
        <https://1145.am/db/1718018/New_Enterprise_Associates>,
        <https://1145.am/db/1719370/New_Enterprise_Associates>,
        <https://1145.am/db/1719408/New_Enterprise_Associates>,
        <https://1145.am/db/1720645/New_Enterprise_Associates>,
        <https://1145.am/db/1721392/New_Enterprise_Associates>,
        <https://1145.am/db/1731944/New_Enterprise_Associates>,
        <https://1145.am/db/1738986/New_Enterprise_Associates>,
        <https://1145.am/db/1743570/New_Enterprise_Associates>,
        <https://1145.am/db/1743999/New_Enterprise_Associates>,
        <https://1145.am/db/1751207/New_Enterprise_Associates>,
        <https://1145.am/db/1753526/New_Enterprise_Associates>,
        <https://1145.am/db/1760464/New_Enterprise_Associates>,
        <https://1145.am/db/1761607/New_Enterprise_Associates>,
        <https://1145.am/db/1772584/New_Enterprise_Associates>,
        <https://1145.am/db/1777442/New_Enterprise_Associates>,
        <https://1145.am/db/1777542/New_Enterprise_Associates>,
        <https://1145.am/db/1783236/New_Enterprise_Associates>,
        <https://1145.am/db/1788268/New_Enterprise_Associates>,
        <https://1145.am/db/1788746/New_Enterprise_Associates>,
        <https://1145.am/db/1790370/New_Enterprise_Associates>,
        <https://1145.am/db/1790675/New_Enterprise_Associates>,
        <https://1145.am/db/1791343/New_Enterprise_Associates>,
        <https://1145.am/db/1792086/New_Enterprise_Associates>,
        <https://1145.am/db/1794202/New_Enterprise_Associates>,
        <https://1145.am/db/1796249/New_Enterprise_Associates>,
        <https://1145.am/db/1798548/New_Enterprise_Associates>,
        <https://1145.am/db/1798774/New_Enterprise_Associates>,
        <https://1145.am/db/1801088/New_Enterprise_Associates>,
        <https://1145.am/db/1801934/New_Enterprise_Associates>,
        <https://1145.am/db/1804355/New_Enterprise_Associates>,
        <https://1145.am/db/1811114/New_Enterprise_Associates>,
        <https://1145.am/db/1811472/New_Enterprise_Associates>,
        <https://1145.am/db/1813288/New_Enterprise_Associates>,
        <https://1145.am/db/1816928/New_Enterprise_Associates>,
        <https://1145.am/db/1818535/New_Enterprise_Associates>,
        <https://1145.am/db/1819637/New_Enterprise_Associates>,
        <https://1145.am/db/1823697/New_Enterprise_Associates>,
        <https://1145.am/db/1823742/New_Enterprise_Associates>,
        <https://1145.am/db/1824558/New_Enterprise_Associates>,
        <https://1145.am/db/1825681/New_Enterprise_Associates>,
        <https://1145.am/db/1826221/New_Enterprise_Associates>,
        <https://1145.am/db/1826275/New_Enterprise_Associates>,
        <https://1145.am/db/1826446/New_Enterprise_Associates>,
        <https://1145.am/db/1827724/New_Enterprise_Associates>,
        <https://1145.am/db/1828072/New_Enterprise_Associates>,
        <https://1145.am/db/1828658/New_Enterprise_Associates>,
        <https://1145.am/db/1828979/New_Enterprise_Associates>,
        <https://1145.am/db/1829581/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/1830382/New_Enterprise_Associates>,
        <https://1145.am/db/1830408/New_Enterprise_Associates>,
        <https://1145.am/db/1830873/New_Enterprise_Associates>,
        <https://1145.am/db/1831689/New_Enterprise_Associates>,
        <https://1145.am/db/1832186/New_Enterprise_Associates>,
        <https://1145.am/db/1835229/New_Enterprise_Associates>,
        <https://1145.am/db/1837877/New_Enterprise_Associates>,
        <https://1145.am/db/1838611/New_Enterprise_Associates>,
        <https://1145.am/db/1842035/New_Enterprise_Associates>,
        <https://1145.am/db/1845066/New_Enterprise_Associates>,
        <https://1145.am/db/1845590/New_Enterprise_Associates>,
        <https://1145.am/db/1846607/New_Enterprise_Associates>,
        <https://1145.am/db/1848728/New_Enterprise_Associates>,
        <https://1145.am/db/1849310/New_Enterprise_Associates>,
        <https://1145.am/db/1849986/New_Enterprise_Associates>,
        <https://1145.am/db/1851923/New_Enterprise_Associates>,
        <https://1145.am/db/1852048/New_Enterprise_Associates>,
        <https://1145.am/db/1853875/New_Enterprise_Associates>,
        <https://1145.am/db/1854098/New_Enterprise_Associates>,
        <https://1145.am/db/1859858/New_Enterprise_Associates>,
        <https://1145.am/db/1860644/New_Enterprise_Associates>,
        <https://1145.am/db/1860804/New_Enterprise_Associates>,
        <https://1145.am/db/1869421/New_Enterprise_Associates>,
        <https://1145.am/db/1875228/New_Enterprise_Associates>,
        <https://1145.am/db/1879023/New_Enterprise_Associates>,
        <https://1145.am/db/1879085/New_Enterprise_Associates>,
        <https://1145.am/db/1880677/New_Enterprise_Associates>,
        <https://1145.am/db/1883008/New_Enterprise_Associates>,
        <https://1145.am/db/1885336/New_Enterprise_Associates>,
        <https://1145.am/db/1887711/New_Enterprise_Associates>,
        <https://1145.am/db/1889764/New_Enterprise_Associates>,
        <https://1145.am/db/1889877/New_Enterprise_Associates>,
        <https://1145.am/db/1889935/New_Enterprise_Associates>,
        <https://1145.am/db/1890000/New_Enterprise_Associates>,
        <https://1145.am/db/1891539/New_Enterprise_Associates>,
        <https://1145.am/db/1891961/New_Enterprise_Associates>,
        <https://1145.am/db/1893324/New_Enterprise_Associates>,
        <https://1145.am/db/1893352/New_Enterprise_Associates>,
        <https://1145.am/db/1894602/New_Enterprise_Associates>,
        <https://1145.am/db/1910957/New_Enterprise_Associates>,
        <https://1145.am/db/1917393/New_Enterprise_Associates>,
        <https://1145.am/db/1919425/New_Enterprise_Associates>,
        <https://1145.am/db/1958068/New_Enterprise_Associates>,
        <https://1145.am/db/2028610/New_Enterprise_Associates>,
        <https://1145.am/db/2069394/New_Enterprise_Associates>,
        <https://1145.am/db/2151964/New_Enterprise_Associates>,
        <https://1145.am/db/2152126/New_Enterprise_Associates>,
        <https://1145.am/db/2152422/New_Enterprise_Associates>,
        <https://1145.am/db/2153373/New_Enterprise_Associates>,
        <https://1145.am/db/2153726/New_Enterprise_Associates>,
        <https://1145.am/db/2155273/New_Enterprise_Associates>,
        <https://1145.am/db/217906/New_Enterprise_Associates>,
        <https://1145.am/db/2185936/New_Enterprise_Associates>,
        <https://1145.am/db/2195351/New_Enterprise_Associates>,
        <https://1145.am/db/2196440/New_Enterprise_Associates>,
        <https://1145.am/db/2207324/New_Enterprise_Associates>,
        <https://1145.am/db/2233715/New_Enterprise_Associates>,
        <https://1145.am/db/2239029/New_Enterprise_Associates>,
        <https://1145.am/db/2280770/New_Enterprise_Associates>,
        <https://1145.am/db/2282600/New_Enterprise_Associates>,
        <https://1145.am/db/2284358/New_Enterprise_Associates>,
        <https://1145.am/db/2287244/New_Enterprise_Associates>,
        <https://1145.am/db/2288979/New_Enterprise_Associates>,
        <https://1145.am/db/2291315/New_Enterprise_Associates>,
        <https://1145.am/db/2292554/New_Enterprise_Associates>,
        <https://1145.am/db/2293793/New_Enterprise_Associates>,
        <https://1145.am/db/2294677/New_Enterprise_Associates>,
        <https://1145.am/db/2295964/New_Enterprise_Associates>,
        <https://1145.am/db/2296696/New_Enterprise_Associates>,
        <https://1145.am/db/2296810/New_Enterprise_Associates>,
        <https://1145.am/db/2297280/New_Enterprise_Associates>,
        <https://1145.am/db/2297471/New_Enterprise_Associates>,
        <https://1145.am/db/2297592/New_Enterprise_Associates>,
        <https://1145.am/db/2298167/New_Enterprise_Associates>,
        <https://1145.am/db/2298437/New_Enterprise_Associates>,
        <https://1145.am/db/2299411/New_Enterprise_Associates>,
        <https://1145.am/db/2300340/New_Enterprise_Associates>,
        <https://1145.am/db/2301461/New_Enterprise_Associates>,
        <https://1145.am/db/2301790/New_Enterprise_Associates>,
        <https://1145.am/db/2302449/New_Enterprise_Associates>,
        <https://1145.am/db/2303391/New_Enterprise_Associates>,
        <https://1145.am/db/2305256/New_Enterprise_Associates>,
        <https://1145.am/db/2305507/New_Enterprise_Associates>,
        <https://1145.am/db/2305514/New_Enterprise_Associates>,
        <https://1145.am/db/2305610/New_Enterprise_Associates>,
        <https://1145.am/db/2305611/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2305656/New_Enterprise_Associates>,
        <https://1145.am/db/2306163/New_Enterprise_Associates>,
        <https://1145.am/db/2306167/New_Enterprise_Associates>,
        <https://1145.am/db/2306705/New_Enterprise_Associates>,
        <https://1145.am/db/2307682/New_Enterprise_Associates>,
        <https://1145.am/db/2307691/New_Enterprise_Associates>,
        <https://1145.am/db/2309059/New_Enterprise_Associates>,
        <https://1145.am/db/2313401/New_Enterprise_Associates>,
        <https://1145.am/db/2313405/New_Enterprise_Associates>,
        <https://1145.am/db/2315049/New_Enterprise_Associates>,
        <https://1145.am/db/2316601/New_Enterprise_Associates>,
        <https://1145.am/db/2316605/New_Enterprise_Associates>,
        <https://1145.am/db/2317951/New_Enterprise_Associates>,
        <https://1145.am/db/2319399/New_Enterprise_Associates>,
        <https://1145.am/db/2319809/New_Enterprise_Associates>,
        <https://1145.am/db/2323138/New_Enterprise_Associates>,
        <https://1145.am/db/2323563/New_Enterprise_Associates>,
        <https://1145.am/db/2323568/New_Enterprise_Associates>,
        <https://1145.am/db/2323682/New_Enterprise_Associates>,
        <https://1145.am/db/2323683/New_Enterprise_Associates>,
        <https://1145.am/db/2323845/New_Enterprise_Associates>,
        <https://1145.am/db/2324289/New_Enterprise_Associates>,
        <https://1145.am/db/2326447/New_Enterprise_Associates>,
        <https://1145.am/db/2326455/New_Enterprise_Associates>,
        <https://1145.am/db/2326571/New_Enterprise_Associates>,
        <https://1145.am/db/2326893/New_Enterprise_Associates>,
        <https://1145.am/db/2328700/New_Enterprise_Associates>,
        <https://1145.am/db/2329246/New_Enterprise_Associates>,
        <https://1145.am/db/2331784/New_Enterprise_Associates>,
        <https://1145.am/db/2331852/New_Enterprise_Associates>,
        <https://1145.am/db/2331858/New_Enterprise_Associates>,
        <https://1145.am/db/2332445/New_Enterprise_Associates>,
        <https://1145.am/db/2332982/New_Enterprise_Associates>,
        <https://1145.am/db/2333119/New_Enterprise_Associates>,
        <https://1145.am/db/2334847/New_Enterprise_Associates>,
        <https://1145.am/db/2335837/New_Enterprise_Associates>,
        <https://1145.am/db/2336052/New_Enterprise_Associates>,
        <https://1145.am/db/2336391/New_Enterprise_Associates>,
        <https://1145.am/db/2336634/New_Enterprise_Associates>,
        <https://1145.am/db/2337250/New_Enterprise_Associates>,
        <https://1145.am/db/2337254/New_Enterprise_Associates>,
        <https://1145.am/db/2337972/New_Enterprise_Associates>,
        <https://1145.am/db/2338086/New_Enterprise_Associates>,
        <https://1145.am/db/2339041/New_Enterprise_Associates>,
        <https://1145.am/db/2339206/New_Enterprise_Associates>,
        <https://1145.am/db/2340224/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2340888/New_Enterprise_Associates>,
        <https://1145.am/db/2340890/New_Enterprise_Associates>,
        <https://1145.am/db/2341792/New_Enterprise_Associates>,
        <https://1145.am/db/2341800/New_Enterprise_Associates>,
        <https://1145.am/db/2341896/New_Enterprise_Associates>,
        <https://1145.am/db/2343773/New_Enterprise_Associates>,
        <https://1145.am/db/2344507/New_Enterprise_Associates>,
        <https://1145.am/db/2346094/New_Enterprise_Associates>,
        <https://1145.am/db/2348024/New_Enterprise_Associates>,
        <https://1145.am/db/2348029/New_Enterprise_Associates>,
        <https://1145.am/db/2348042/New_Enterprise_Associates>,
        <https://1145.am/db/2348057/New_Enterprise_Associates>,
        <https://1145.am/db/2348066/New_Enterprise_Associates>,
        <https://1145.am/db/2348956/New_Enterprise_Associates>,
        <https://1145.am/db/2348967/New_Enterprise_Associates>,
        <https://1145.am/db/2349234/New_Enterprise_Associates>,
        <https://1145.am/db/2350164/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2350167/New_Enterprise_Associates>,
        <https://1145.am/db/2350231/New_Enterprise_Associates>,
        <https://1145.am/db/2350327/New_Enterprise_Associates>,
        <https://1145.am/db/2352899/New_Enterprise_Associates>,
        <https://1145.am/db/2355048/New_Enterprise_Associates>,
        <https://1145.am/db/2355531/New_Enterprise_Associates>,
        <https://1145.am/db/2355543/New_Enterprise_Associates>,
        <https://1145.am/db/2355754/New_Enterprise_Associates>,
        <https://1145.am/db/2355885/New_Enterprise_Associates>,
        <https://1145.am/db/2356048/New_Enterprise_Associates>,
        <https://1145.am/db/2356216/New_Enterprise_Associates>,
        <https://1145.am/db/2356391/New_Enterprise_Associates>,
        <https://1145.am/db/2356393/New_Enterprise_Associates>,
        <https://1145.am/db/2356395/New_Enterprise_Associates>,
        <https://1145.am/db/2356396/New_Enterprise_Associates>,
        <https://1145.am/db/2357144/New_Enterprise_Associates>,
        <https://1145.am/db/2357566/New_Enterprise_Associates>,
        <https://1145.am/db/2358225/New_Enterprise_Associates>,
        <https://1145.am/db/2358242/New_Enterprise_Associates>,
        <https://1145.am/db/2358506/New_Enterprise_Associates>,
        <https://1145.am/db/2358529/New_Enterprise_Associates>,
        <https://1145.am/db/2358640/New_Enterprise_Associates>,
        <https://1145.am/db/2358657/New_Enterprise_Associates>,
        <https://1145.am/db/2358658/New_Enterprise_Associates>,
        <https://1145.am/db/2358812/New_Enterprise_Associates>,
        <https://1145.am/db/2358883/New_Enterprise_Associates>,
        <https://1145.am/db/2359185/New_Enterprise_Associates>,
        <https://1145.am/db/2359873/New_Enterprise_Associates>,
        <https://1145.am/db/2359875/New_Enterprise_Associates>,
        <https://1145.am/db/2360682/New_Enterprise_Associates>,
        <https://1145.am/db/2360979/New_Enterprise_Associates>,
        <https://1145.am/db/2361004/New_Enterprise_Associates>,
        <https://1145.am/db/2361005/New_Enterprise_Associates>,
        <https://1145.am/db/2364422/New_Enterprise_Associates>,
        <https://1145.am/db/2365868/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2366775/New_Enterprise_Associates>,
        <https://1145.am/db/2366984/New_Enterprise_Associates>,
        <https://1145.am/db/2367497/New_Enterprise_Associates>,
        <https://1145.am/db/2367678/New_Enterprise_Associates>,
        <https://1145.am/db/2367711/New_Enterprise_Associates>,
        <https://1145.am/db/2367714/New_Enterprise_Associates>,
        <https://1145.am/db/2369202/New_Enterprise_Associates>,
        <https://1145.am/db/2369785/New_Enterprise_Associates>,
        <https://1145.am/db/2369916/New_Enterprise_Associates>,
        <https://1145.am/db/2370094/New_Enterprise_Associates>,
        <https://1145.am/db/2370436/New_Enterprise_Associates>,
        <https://1145.am/db/2370782/New_Enterprise_Associates>,
        <https://1145.am/db/2370799/New_Enterprise_Associates>,
        <https://1145.am/db/2371165/New_Enterprise_Associates>,
        <https://1145.am/db/2371166/New_Enterprise_Associates>,
        <https://1145.am/db/2438933/New_Enterprise_Associates>,
        <https://1145.am/db/2443170/New_Enterprise_Associates>,
        <https://1145.am/db/2450551/New_Enterprise_Associates>,
        <https://1145.am/db/2454491/New_Enterprise_Associates>,
        <https://1145.am/db/2541350/New_Enterprise_Associates>,
        <https://1145.am/db/2552598/New_Enterprise_Associates>,
        <https://1145.am/db/2570481/New_Enterprise_Associates>,
        <https://1145.am/db/2570483/New_Enterprise_Associates>,
        <https://1145.am/db/2571149/New_Enterprise_Associates>,
        <https://1145.am/db/2580133/New_Enterprise_Associates>,
        <https://1145.am/db/2587938/New_Enterprise_Associates>,
        <https://1145.am/db/2636760/New_Enterprise_Associates>,
        <https://1145.am/db/301469/New_Enterprise_Associates>,
        <https://1145.am/db/303111/New_Enterprise_Associates>,
        <https://1145.am/db/522665/New_Enterprise_Associates>,
        <https://1145.am/db/525766/New_Enterprise_Associates>,
        <https://1145.am/db/563438/New_Enterprise_Associates>,
        <https://1145.am/db/580082/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/661958/New_Enterprise_Associates>,
        <https://1145.am/db/676316/New_Enterprise_Associates>,
        <https://1145.am/db/680751/New_Enterprise_Associates>,
        <https://1145.am/db/714395/New_Enterprise_Associates>,
        <https://1145.am/db/849950/New_Enterprise_Associates>,
        <https://1145.am/db/893810/New_Enterprise_Associates>,
        <https://1145.am/db/918706/New_Enterprise_Associates>,
        <https://1145.am/db/961672/New_Enterprise_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337972/New_Enterprise_Associates> a org:Organization ;
    ns1:documentDate "2012-07-31T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Mersana grabs $27M from Pfizer, NEA and others for muscled cancer drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/mersana-grabs-27m-from-pfizer-nea-and-others-for-muscled-cancer-drugs> ;
    ns1:foundName "New Enterprise Associates" ;
    ns1:investor <https://1145.am/db/2337972/Series_A-1_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_Nea_Proquest_Investments_Rho_Ventures_Venture_Investments_Completed> ;
    ns1:name "New Enterprise Associates" ;
    ns1:sameAsMedium <https://1145.am/db/1031040/New_Enterprise_Associates>,
        <https://1145.am/db/1091201/New_Enterprise_Associates>,
        <https://1145.am/db/1115103/New_Enterprise_Associates>,
        <https://1145.am/db/1115600/New_Enterprise_Associates>,
        <https://1145.am/db/1116035/New_Enterprise_Associates>,
        <https://1145.am/db/1116076/New_Enterprise_Associates>,
        <https://1145.am/db/1127410/New_Enterprise_Associates>,
        <https://1145.am/db/1169121/New_Enterprise_Associates>,
        <https://1145.am/db/1230022/New_Enterprise_Associates>,
        <https://1145.am/db/1233430/New_Enterprise_Associates>,
        <https://1145.am/db/1279264/New_Enterprise_Associates>,
        <https://1145.am/db/1281079/New_Enterprise_Associates>,
        <https://1145.am/db/1281647/New_Enterprise_Associates>,
        <https://1145.am/db/1371086/New_Enterprise_Associates>,
        <https://1145.am/db/1422234/New_Enterprise_Associates>,
        <https://1145.am/db/1422725/New_Enterprise_Associates>,
        <https://1145.am/db/1427471/New_Enterprise_Associates>,
        <https://1145.am/db/1469165/New_Enterprise_Associates>,
        <https://1145.am/db/1571794/New_Enterprise_Associates>,
        <https://1145.am/db/1606686/New_Enterprise_Associates>,
        <https://1145.am/db/1653132/New_Enterprise_Associates>,
        <https://1145.am/db/1653506/New_Enterprise_Associates>,
        <https://1145.am/db/1654515/New_Enterprise_Associates>,
        <https://1145.am/db/1694448/New_Enterprise_Associates>,
        <https://1145.am/db/1696213/New_Enterprise_Associates>,
        <https://1145.am/db/1699877/New_Enterprise_Associates>,
        <https://1145.am/db/1701285/New_Enterprise_Associates>,
        <https://1145.am/db/1701411/New_Enterprise_Associates>,
        <https://1145.am/db/1701589/New_Enterprise_Associates>,
        <https://1145.am/db/1715860/New_Enterprise_Associates>,
        <https://1145.am/db/1717498/New_Enterprise_Associates>,
        <https://1145.am/db/1717968/New_Enterprise_Associates>,
        <https://1145.am/db/1718000/New_Enterprise_Associates>,
        <https://1145.am/db/1718018/New_Enterprise_Associates>,
        <https://1145.am/db/1719370/New_Enterprise_Associates>,
        <https://1145.am/db/1719408/New_Enterprise_Associates>,
        <https://1145.am/db/1720645/New_Enterprise_Associates>,
        <https://1145.am/db/1721392/New_Enterprise_Associates>,
        <https://1145.am/db/1731944/New_Enterprise_Associates>,
        <https://1145.am/db/1738986/New_Enterprise_Associates>,
        <https://1145.am/db/1743570/New_Enterprise_Associates>,
        <https://1145.am/db/1743999/New_Enterprise_Associates>,
        <https://1145.am/db/1751207/New_Enterprise_Associates>,
        <https://1145.am/db/1753526/New_Enterprise_Associates>,
        <https://1145.am/db/1760464/New_Enterprise_Associates>,
        <https://1145.am/db/1761607/New_Enterprise_Associates>,
        <https://1145.am/db/1772584/New_Enterprise_Associates>,
        <https://1145.am/db/1777442/New_Enterprise_Associates>,
        <https://1145.am/db/1777542/New_Enterprise_Associates>,
        <https://1145.am/db/1783236/New_Enterprise_Associates>,
        <https://1145.am/db/1788268/New_Enterprise_Associates>,
        <https://1145.am/db/1788746/New_Enterprise_Associates>,
        <https://1145.am/db/1790370/New_Enterprise_Associates>,
        <https://1145.am/db/1790675/New_Enterprise_Associates>,
        <https://1145.am/db/1791343/New_Enterprise_Associates>,
        <https://1145.am/db/1792086/New_Enterprise_Associates>,
        <https://1145.am/db/1794202/New_Enterprise_Associates>,
        <https://1145.am/db/1796249/New_Enterprise_Associates>,
        <https://1145.am/db/1798548/New_Enterprise_Associates>,
        <https://1145.am/db/1798774/New_Enterprise_Associates>,
        <https://1145.am/db/1801088/New_Enterprise_Associates>,
        <https://1145.am/db/1801934/New_Enterprise_Associates>,
        <https://1145.am/db/1804355/New_Enterprise_Associates>,
        <https://1145.am/db/1811114/New_Enterprise_Associates>,
        <https://1145.am/db/1811472/New_Enterprise_Associates>,
        <https://1145.am/db/1813288/New_Enterprise_Associates>,
        <https://1145.am/db/1816928/New_Enterprise_Associates>,
        <https://1145.am/db/1818535/New_Enterprise_Associates>,
        <https://1145.am/db/1819637/New_Enterprise_Associates>,
        <https://1145.am/db/1823697/New_Enterprise_Associates>,
        <https://1145.am/db/1823742/New_Enterprise_Associates>,
        <https://1145.am/db/1824558/New_Enterprise_Associates>,
        <https://1145.am/db/1825681/New_Enterprise_Associates>,
        <https://1145.am/db/1826221/New_Enterprise_Associates>,
        <https://1145.am/db/1826275/New_Enterprise_Associates>,
        <https://1145.am/db/1826446/New_Enterprise_Associates>,
        <https://1145.am/db/1827724/New_Enterprise_Associates>,
        <https://1145.am/db/1828072/New_Enterprise_Associates>,
        <https://1145.am/db/1828658/New_Enterprise_Associates>,
        <https://1145.am/db/1828979/New_Enterprise_Associates>,
        <https://1145.am/db/1829581/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/1830382/New_Enterprise_Associates>,
        <https://1145.am/db/1830408/New_Enterprise_Associates>,
        <https://1145.am/db/1830873/New_Enterprise_Associates>,
        <https://1145.am/db/1831689/New_Enterprise_Associates>,
        <https://1145.am/db/1832186/New_Enterprise_Associates>,
        <https://1145.am/db/1835229/New_Enterprise_Associates>,
        <https://1145.am/db/1837877/New_Enterprise_Associates>,
        <https://1145.am/db/1838611/New_Enterprise_Associates>,
        <https://1145.am/db/1842035/New_Enterprise_Associates>,
        <https://1145.am/db/1845066/New_Enterprise_Associates>,
        <https://1145.am/db/1845590/New_Enterprise_Associates>,
        <https://1145.am/db/1846607/New_Enterprise_Associates>,
        <https://1145.am/db/1848728/New_Enterprise_Associates>,
        <https://1145.am/db/1849310/New_Enterprise_Associates>,
        <https://1145.am/db/1849986/New_Enterprise_Associates>,
        <https://1145.am/db/1851923/New_Enterprise_Associates>,
        <https://1145.am/db/1852048/New_Enterprise_Associates>,
        <https://1145.am/db/1853875/New_Enterprise_Associates>,
        <https://1145.am/db/1854098/New_Enterprise_Associates>,
        <https://1145.am/db/1859858/New_Enterprise_Associates>,
        <https://1145.am/db/1860644/New_Enterprise_Associates>,
        <https://1145.am/db/1860804/New_Enterprise_Associates>,
        <https://1145.am/db/1869421/New_Enterprise_Associates>,
        <https://1145.am/db/1875228/New_Enterprise_Associates>,
        <https://1145.am/db/1879023/New_Enterprise_Associates>,
        <https://1145.am/db/1879085/New_Enterprise_Associates>,
        <https://1145.am/db/1880677/New_Enterprise_Associates>,
        <https://1145.am/db/1883008/New_Enterprise_Associates>,
        <https://1145.am/db/1885336/New_Enterprise_Associates>,
        <https://1145.am/db/1887711/New_Enterprise_Associates>,
        <https://1145.am/db/1889764/New_Enterprise_Associates>,
        <https://1145.am/db/1889877/New_Enterprise_Associates>,
        <https://1145.am/db/1889935/New_Enterprise_Associates>,
        <https://1145.am/db/1890000/New_Enterprise_Associates>,
        <https://1145.am/db/1891539/New_Enterprise_Associates>,
        <https://1145.am/db/1891961/New_Enterprise_Associates>,
        <https://1145.am/db/1893324/New_Enterprise_Associates>,
        <https://1145.am/db/1893352/New_Enterprise_Associates>,
        <https://1145.am/db/1894602/New_Enterprise_Associates>,
        <https://1145.am/db/1910957/New_Enterprise_Associates>,
        <https://1145.am/db/1917393/New_Enterprise_Associates>,
        <https://1145.am/db/1919425/New_Enterprise_Associates>,
        <https://1145.am/db/1958068/New_Enterprise_Associates>,
        <https://1145.am/db/2028610/New_Enterprise_Associates>,
        <https://1145.am/db/2069394/New_Enterprise_Associates>,
        <https://1145.am/db/2151964/New_Enterprise_Associates>,
        <https://1145.am/db/2152126/New_Enterprise_Associates>,
        <https://1145.am/db/2152422/New_Enterprise_Associates>,
        <https://1145.am/db/2153373/New_Enterprise_Associates>,
        <https://1145.am/db/2153726/New_Enterprise_Associates>,
        <https://1145.am/db/2155273/New_Enterprise_Associates>,
        <https://1145.am/db/217906/New_Enterprise_Associates>,
        <https://1145.am/db/2185936/New_Enterprise_Associates>,
        <https://1145.am/db/2195351/New_Enterprise_Associates>,
        <https://1145.am/db/2196440/New_Enterprise_Associates>,
        <https://1145.am/db/2207324/New_Enterprise_Associates>,
        <https://1145.am/db/2233715/New_Enterprise_Associates>,
        <https://1145.am/db/2239029/New_Enterprise_Associates>,
        <https://1145.am/db/2280770/New_Enterprise_Associates>,
        <https://1145.am/db/2282600/New_Enterprise_Associates>,
        <https://1145.am/db/2284358/New_Enterprise_Associates>,
        <https://1145.am/db/2287244/New_Enterprise_Associates>,
        <https://1145.am/db/2288979/New_Enterprise_Associates>,
        <https://1145.am/db/2291315/New_Enterprise_Associates>,
        <https://1145.am/db/2292554/New_Enterprise_Associates>,
        <https://1145.am/db/2293793/New_Enterprise_Associates>,
        <https://1145.am/db/2294677/New_Enterprise_Associates>,
        <https://1145.am/db/2295964/New_Enterprise_Associates>,
        <https://1145.am/db/2296696/New_Enterprise_Associates>,
        <https://1145.am/db/2296810/New_Enterprise_Associates>,
        <https://1145.am/db/2297280/New_Enterprise_Associates>,
        <https://1145.am/db/2297471/New_Enterprise_Associates>,
        <https://1145.am/db/2297592/New_Enterprise_Associates>,
        <https://1145.am/db/2298167/New_Enterprise_Associates>,
        <https://1145.am/db/2298437/New_Enterprise_Associates>,
        <https://1145.am/db/2299411/New_Enterprise_Associates>,
        <https://1145.am/db/2300340/New_Enterprise_Associates>,
        <https://1145.am/db/2301461/New_Enterprise_Associates>,
        <https://1145.am/db/2301790/New_Enterprise_Associates>,
        <https://1145.am/db/2302449/New_Enterprise_Associates>,
        <https://1145.am/db/2303391/New_Enterprise_Associates>,
        <https://1145.am/db/2305256/New_Enterprise_Associates>,
        <https://1145.am/db/2305507/New_Enterprise_Associates>,
        <https://1145.am/db/2305514/New_Enterprise_Associates>,
        <https://1145.am/db/2305610/New_Enterprise_Associates>,
        <https://1145.am/db/2305611/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2305656/New_Enterprise_Associates>,
        <https://1145.am/db/2306163/New_Enterprise_Associates>,
        <https://1145.am/db/2306167/New_Enterprise_Associates>,
        <https://1145.am/db/2306705/New_Enterprise_Associates>,
        <https://1145.am/db/2307682/New_Enterprise_Associates>,
        <https://1145.am/db/2307691/New_Enterprise_Associates>,
        <https://1145.am/db/2309059/New_Enterprise_Associates>,
        <https://1145.am/db/2313401/New_Enterprise_Associates>,
        <https://1145.am/db/2313405/New_Enterprise_Associates>,
        <https://1145.am/db/2315049/New_Enterprise_Associates>,
        <https://1145.am/db/2316601/New_Enterprise_Associates>,
        <https://1145.am/db/2316605/New_Enterprise_Associates>,
        <https://1145.am/db/2317951/New_Enterprise_Associates>,
        <https://1145.am/db/2319399/New_Enterprise_Associates>,
        <https://1145.am/db/2319809/New_Enterprise_Associates>,
        <https://1145.am/db/2323138/New_Enterprise_Associates>,
        <https://1145.am/db/2323563/New_Enterprise_Associates>,
        <https://1145.am/db/2323568/New_Enterprise_Associates>,
        <https://1145.am/db/2323682/New_Enterprise_Associates>,
        <https://1145.am/db/2323683/New_Enterprise_Associates>,
        <https://1145.am/db/2323845/New_Enterprise_Associates>,
        <https://1145.am/db/2324289/New_Enterprise_Associates>,
        <https://1145.am/db/2326447/New_Enterprise_Associates>,
        <https://1145.am/db/2326455/New_Enterprise_Associates>,
        <https://1145.am/db/2326571/New_Enterprise_Associates>,
        <https://1145.am/db/2326893/New_Enterprise_Associates>,
        <https://1145.am/db/2328700/New_Enterprise_Associates>,
        <https://1145.am/db/2329246/New_Enterprise_Associates>,
        <https://1145.am/db/2331784/New_Enterprise_Associates>,
        <https://1145.am/db/2331852/New_Enterprise_Associates>,
        <https://1145.am/db/2331858/New_Enterprise_Associates>,
        <https://1145.am/db/2332445/New_Enterprise_Associates>,
        <https://1145.am/db/2332982/New_Enterprise_Associates>,
        <https://1145.am/db/2333119/New_Enterprise_Associates>,
        <https://1145.am/db/2334847/New_Enterprise_Associates>,
        <https://1145.am/db/2335837/New_Enterprise_Associates>,
        <https://1145.am/db/2336052/New_Enterprise_Associates>,
        <https://1145.am/db/2336391/New_Enterprise_Associates>,
        <https://1145.am/db/2336634/New_Enterprise_Associates>,
        <https://1145.am/db/2337250/New_Enterprise_Associates>,
        <https://1145.am/db/2337254/New_Enterprise_Associates>,
        <https://1145.am/db/2337971/New_Enterprise_Associates>,
        <https://1145.am/db/2338086/New_Enterprise_Associates>,
        <https://1145.am/db/2339041/New_Enterprise_Associates>,
        <https://1145.am/db/2339206/New_Enterprise_Associates>,
        <https://1145.am/db/2340224/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2340888/New_Enterprise_Associates>,
        <https://1145.am/db/2340890/New_Enterprise_Associates>,
        <https://1145.am/db/2341792/New_Enterprise_Associates>,
        <https://1145.am/db/2341800/New_Enterprise_Associates>,
        <https://1145.am/db/2341896/New_Enterprise_Associates>,
        <https://1145.am/db/2343773/New_Enterprise_Associates>,
        <https://1145.am/db/2344507/New_Enterprise_Associates>,
        <https://1145.am/db/2346094/New_Enterprise_Associates>,
        <https://1145.am/db/2348024/New_Enterprise_Associates>,
        <https://1145.am/db/2348029/New_Enterprise_Associates>,
        <https://1145.am/db/2348042/New_Enterprise_Associates>,
        <https://1145.am/db/2348057/New_Enterprise_Associates>,
        <https://1145.am/db/2348066/New_Enterprise_Associates>,
        <https://1145.am/db/2348956/New_Enterprise_Associates>,
        <https://1145.am/db/2348967/New_Enterprise_Associates>,
        <https://1145.am/db/2349234/New_Enterprise_Associates>,
        <https://1145.am/db/2350164/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2350167/New_Enterprise_Associates>,
        <https://1145.am/db/2350231/New_Enterprise_Associates>,
        <https://1145.am/db/2350327/New_Enterprise_Associates>,
        <https://1145.am/db/2352899/New_Enterprise_Associates>,
        <https://1145.am/db/2355048/New_Enterprise_Associates>,
        <https://1145.am/db/2355531/New_Enterprise_Associates>,
        <https://1145.am/db/2355543/New_Enterprise_Associates>,
        <https://1145.am/db/2355754/New_Enterprise_Associates>,
        <https://1145.am/db/2355885/New_Enterprise_Associates>,
        <https://1145.am/db/2356048/New_Enterprise_Associates>,
        <https://1145.am/db/2356216/New_Enterprise_Associates>,
        <https://1145.am/db/2356391/New_Enterprise_Associates>,
        <https://1145.am/db/2356393/New_Enterprise_Associates>,
        <https://1145.am/db/2356395/New_Enterprise_Associates>,
        <https://1145.am/db/2356396/New_Enterprise_Associates>,
        <https://1145.am/db/2357144/New_Enterprise_Associates>,
        <https://1145.am/db/2357566/New_Enterprise_Associates>,
        <https://1145.am/db/2358225/New_Enterprise_Associates>,
        <https://1145.am/db/2358242/New_Enterprise_Associates>,
        <https://1145.am/db/2358506/New_Enterprise_Associates>,
        <https://1145.am/db/2358529/New_Enterprise_Associates>,
        <https://1145.am/db/2358640/New_Enterprise_Associates>,
        <https://1145.am/db/2358657/New_Enterprise_Associates>,
        <https://1145.am/db/2358658/New_Enterprise_Associates>,
        <https://1145.am/db/2358812/New_Enterprise_Associates>,
        <https://1145.am/db/2358883/New_Enterprise_Associates>,
        <https://1145.am/db/2359185/New_Enterprise_Associates>,
        <https://1145.am/db/2359873/New_Enterprise_Associates>,
        <https://1145.am/db/2359875/New_Enterprise_Associates>,
        <https://1145.am/db/2360682/New_Enterprise_Associates>,
        <https://1145.am/db/2360979/New_Enterprise_Associates>,
        <https://1145.am/db/2361004/New_Enterprise_Associates>,
        <https://1145.am/db/2361005/New_Enterprise_Associates>,
        <https://1145.am/db/2364422/New_Enterprise_Associates>,
        <https://1145.am/db/2365868/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2366775/New_Enterprise_Associates>,
        <https://1145.am/db/2366984/New_Enterprise_Associates>,
        <https://1145.am/db/2367497/New_Enterprise_Associates>,
        <https://1145.am/db/2367678/New_Enterprise_Associates>,
        <https://1145.am/db/2367711/New_Enterprise_Associates>,
        <https://1145.am/db/2367714/New_Enterprise_Associates>,
        <https://1145.am/db/2369202/New_Enterprise_Associates>,
        <https://1145.am/db/2369785/New_Enterprise_Associates>,
        <https://1145.am/db/2369916/New_Enterprise_Associates>,
        <https://1145.am/db/2370094/New_Enterprise_Associates>,
        <https://1145.am/db/2370436/New_Enterprise_Associates>,
        <https://1145.am/db/2370782/New_Enterprise_Associates>,
        <https://1145.am/db/2370799/New_Enterprise_Associates>,
        <https://1145.am/db/2371165/New_Enterprise_Associates>,
        <https://1145.am/db/2371166/New_Enterprise_Associates>,
        <https://1145.am/db/2438933/New_Enterprise_Associates>,
        <https://1145.am/db/2443170/New_Enterprise_Associates>,
        <https://1145.am/db/2450551/New_Enterprise_Associates>,
        <https://1145.am/db/2454491/New_Enterprise_Associates>,
        <https://1145.am/db/2541350/New_Enterprise_Associates>,
        <https://1145.am/db/2552598/New_Enterprise_Associates>,
        <https://1145.am/db/2570481/New_Enterprise_Associates>,
        <https://1145.am/db/2570483/New_Enterprise_Associates>,
        <https://1145.am/db/2571149/New_Enterprise_Associates>,
        <https://1145.am/db/2580133/New_Enterprise_Associates>,
        <https://1145.am/db/2587938/New_Enterprise_Associates>,
        <https://1145.am/db/2636760/New_Enterprise_Associates>,
        <https://1145.am/db/301469/New_Enterprise_Associates>,
        <https://1145.am/db/303111/New_Enterprise_Associates>,
        <https://1145.am/db/522665/New_Enterprise_Associates>,
        <https://1145.am/db/525766/New_Enterprise_Associates>,
        <https://1145.am/db/563438/New_Enterprise_Associates>,
        <https://1145.am/db/580082/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/661958/New_Enterprise_Associates>,
        <https://1145.am/db/676316/New_Enterprise_Associates>,
        <https://1145.am/db/680751/New_Enterprise_Associates>,
        <https://1145.am/db/714395/New_Enterprise_Associates>,
        <https://1145.am/db/849950/New_Enterprise_Associates>,
        <https://1145.am/db/893810/New_Enterprise_Associates>,
        <https://1145.am/db/918706/New_Enterprise_Associates>,
        <https://1145.am/db/961672/New_Enterprise_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337974/Series_B_Investment_Canaan_Partners_Cytomx_Therapeutics_Roche_Venture_Fund_Third_Rock_Ventures_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-31T14:27:45+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CytomX Therapeutics Expands Series B Financing; Canaan Partners Joins Syndicate.",
        "SAN FRANCISCO, Jul 31, 2012 (BUSINESS WIRE) - CytomX Therapeutics, Inc., a biotechnology company creating a new generation of highly targeted antibody therapeutics, today announced that the company has expanded its Series B financing, bringing the total size of the round to $ 41 million." ;
    ns1:documentTitle "CytomX Therapeutics Expands Series B Financing; Canaan Partners Joins Syndicate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-expands-series-b-financing-canaan-partners-joins-syndicate> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2337974/Cytomx_Therapeutics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 41 million" ;
    ns1:when "2012-07-31T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2012-Jul-31" ;
    ns1:whereGeoName "San Francisco" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:whereRaw "SAN FRANCISCO" .

<https://1145.am/db/2346467/Discovery_Science_And_Neotope_Biosciences> a org:Organization ;
    ns1:basedInLowRaw "NYSE" ;
    ns1:description "Biosciences",
        "research" ;
    ns1:documentDate "2012-08-13T13:01:55+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/elan-announces-plan-to-spin-off-discovery-science-and-neotope-biosciences-to-shareholders> ;
    ns1:foundName "Discovery Science And Neotope Biosciences",
        "Elan",
        "Neotope Biosciences",
        "the discovery science and Neotope Biosciences" ;
    ns1:name "Discovery Science",
        "Discovery Science And Neotope Biosciences",
        "Neotope Biosciences" ;
    ns1:sameAsHigh <https://1145.am/db/2345479/Neotope_Biosciences>,
        <https://1145.am/db/2595063/Discovery_Science_And_Neotope_Biosciences> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2349406/Venture_Investment_Allocure_Lundbeckfond_Ventures_Novo_A_S_Sv_Life_Sciences_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-02T14:49:32+00:00"^^xsd:dateTime ;
    ns1:documentExtract "AlloCure Raises $ 25 Million Series B Venture Financing.",
        "BURLINGTON, Mass., Apr 02, 2012 (BUSINESS WIRE) - AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced the closing of a $ 25 million Series B venture financing." ;
    ns1:documentTitle "AlloCure Raises $25 Million Series B Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/allocure-raises-25-million-series-b-venture-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2349406/Allocure> ;
    ns1:targetDetails "Series B Venture",
        "venture" ;
    ns1:valueRaw "$ 25 Million",
        "$ 25 million" ;
    ns1:when "2012-04-02T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Apr 02, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2354608/Series_A_Investment_Eleven_Biotherapeutics_Flagship_Ventures_Jafco_Third_Rock_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-08T10:07:18+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Cambridge, MA - May 8, 2012 - Eleven Biotherapeutics, Inc., a biopharmaceutical company designing and engineering novel and differentiated protein - based biotherapeutics, announced today that it has secured $ 20 million dollars in series A equity financing, expanding the total Series A investment to $ 45M.",
        "Eleven Biotherapeutics Secures $ 20 Million and Expands Series A Financing- Company to Advance its lead Drug Candidate, EBI-005, into Clinic Development for Dry Eye Disease -" ;
    ns1:documentTitle "Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing- Company to Advance its lead Drug Candidate, EBI-005, into Clinic Development for Dry Eye Disease -" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/eleven-biotherapeutics-secures-20-million-and-expands-series-a-financing-company-to-advance> ;
    ns1:foundName "Secures",
        "financing" ;
    ns1:name "Secures",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2354608/Eleven_Biotherapeutics> ;
    ns1:targetDetails "equity",
        "series A" ;
    ns1:valueRaw "$ 10 million",
        "$ 20 Million",
        "$ 20 million dollars",
        "$ 45M" ;
    ns1:when "2012-05-08T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "May 8" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2358812/New_Enterprise_Associates> a org:Organization ;
    ns1:basedInLowRaw "Pa" ;
    ns1:documentDate "2012-06-06T15:08:33+00:00"^^xsd:dateTime ;
    ns1:documentTitle "PhaseBio Pharmaceuticals Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing For Advancement of Metabolic and Cardiovascular Product Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/phasebio-pharmaceuticals-received-an-additional-23-million-completion-of-third-tranche-of-a> ;
    ns1:foundName "New Enterprise Associates" ;
    ns1:investor <https://1145.am/db/2358812/Series_B_Investment_Fletcher_Spaght_Ventures_Hatteras_Venture_Partners_Johnson___Johnson_Development_Corporation_New_Enterprise_Associates_Osi_Investment_Holdings_Phasebio_Pharmaceuticals_Completed> ;
    ns1:name "New Enterprise Associates" ;
    ns1:sameAsMedium <https://1145.am/db/1031040/New_Enterprise_Associates>,
        <https://1145.am/db/1091201/New_Enterprise_Associates>,
        <https://1145.am/db/1115103/New_Enterprise_Associates>,
        <https://1145.am/db/1115600/New_Enterprise_Associates>,
        <https://1145.am/db/1116035/New_Enterprise_Associates>,
        <https://1145.am/db/1116076/New_Enterprise_Associates>,
        <https://1145.am/db/1127410/New_Enterprise_Associates>,
        <https://1145.am/db/1169121/New_Enterprise_Associates>,
        <https://1145.am/db/1230022/New_Enterprise_Associates>,
        <https://1145.am/db/1233430/New_Enterprise_Associates>,
        <https://1145.am/db/1279264/New_Enterprise_Associates>,
        <https://1145.am/db/1281079/New_Enterprise_Associates>,
        <https://1145.am/db/1281647/New_Enterprise_Associates>,
        <https://1145.am/db/1371086/New_Enterprise_Associates>,
        <https://1145.am/db/1422234/New_Enterprise_Associates>,
        <https://1145.am/db/1422725/New_Enterprise_Associates>,
        <https://1145.am/db/1427471/New_Enterprise_Associates>,
        <https://1145.am/db/1469165/New_Enterprise_Associates>,
        <https://1145.am/db/1571794/New_Enterprise_Associates>,
        <https://1145.am/db/1606686/New_Enterprise_Associates>,
        <https://1145.am/db/1653132/New_Enterprise_Associates>,
        <https://1145.am/db/1653506/New_Enterprise_Associates>,
        <https://1145.am/db/1654515/New_Enterprise_Associates>,
        <https://1145.am/db/1694448/New_Enterprise_Associates>,
        <https://1145.am/db/1696213/New_Enterprise_Associates>,
        <https://1145.am/db/1699877/New_Enterprise_Associates>,
        <https://1145.am/db/1701285/New_Enterprise_Associates>,
        <https://1145.am/db/1701411/New_Enterprise_Associates>,
        <https://1145.am/db/1701589/New_Enterprise_Associates>,
        <https://1145.am/db/1715860/New_Enterprise_Associates>,
        <https://1145.am/db/1717498/New_Enterprise_Associates>,
        <https://1145.am/db/1717968/New_Enterprise_Associates>,
        <https://1145.am/db/1718000/New_Enterprise_Associates>,
        <https://1145.am/db/1718018/New_Enterprise_Associates>,
        <https://1145.am/db/1719370/New_Enterprise_Associates>,
        <https://1145.am/db/1719408/New_Enterprise_Associates>,
        <https://1145.am/db/1720645/New_Enterprise_Associates>,
        <https://1145.am/db/1721392/New_Enterprise_Associates>,
        <https://1145.am/db/1731944/New_Enterprise_Associates>,
        <https://1145.am/db/1738986/New_Enterprise_Associates>,
        <https://1145.am/db/1743570/New_Enterprise_Associates>,
        <https://1145.am/db/1743999/New_Enterprise_Associates>,
        <https://1145.am/db/1751207/New_Enterprise_Associates>,
        <https://1145.am/db/1753526/New_Enterprise_Associates>,
        <https://1145.am/db/1760464/New_Enterprise_Associates>,
        <https://1145.am/db/1761607/New_Enterprise_Associates>,
        <https://1145.am/db/1772584/New_Enterprise_Associates>,
        <https://1145.am/db/1777442/New_Enterprise_Associates>,
        <https://1145.am/db/1777542/New_Enterprise_Associates>,
        <https://1145.am/db/1783236/New_Enterprise_Associates>,
        <https://1145.am/db/1788268/New_Enterprise_Associates>,
        <https://1145.am/db/1788746/New_Enterprise_Associates>,
        <https://1145.am/db/1790370/New_Enterprise_Associates>,
        <https://1145.am/db/1790675/New_Enterprise_Associates>,
        <https://1145.am/db/1791343/New_Enterprise_Associates>,
        <https://1145.am/db/1792086/New_Enterprise_Associates>,
        <https://1145.am/db/1794202/New_Enterprise_Associates>,
        <https://1145.am/db/1796249/New_Enterprise_Associates>,
        <https://1145.am/db/1798548/New_Enterprise_Associates>,
        <https://1145.am/db/1798774/New_Enterprise_Associates>,
        <https://1145.am/db/1801088/New_Enterprise_Associates>,
        <https://1145.am/db/1801934/New_Enterprise_Associates>,
        <https://1145.am/db/1804355/New_Enterprise_Associates>,
        <https://1145.am/db/1811114/New_Enterprise_Associates>,
        <https://1145.am/db/1811472/New_Enterprise_Associates>,
        <https://1145.am/db/1813288/New_Enterprise_Associates>,
        <https://1145.am/db/1816928/New_Enterprise_Associates>,
        <https://1145.am/db/1818535/New_Enterprise_Associates>,
        <https://1145.am/db/1819637/New_Enterprise_Associates>,
        <https://1145.am/db/1823697/New_Enterprise_Associates>,
        <https://1145.am/db/1823742/New_Enterprise_Associates>,
        <https://1145.am/db/1824558/New_Enterprise_Associates>,
        <https://1145.am/db/1825681/New_Enterprise_Associates>,
        <https://1145.am/db/1826221/New_Enterprise_Associates>,
        <https://1145.am/db/1826275/New_Enterprise_Associates>,
        <https://1145.am/db/1826446/New_Enterprise_Associates>,
        <https://1145.am/db/1827724/New_Enterprise_Associates>,
        <https://1145.am/db/1828072/New_Enterprise_Associates>,
        <https://1145.am/db/1828658/New_Enterprise_Associates>,
        <https://1145.am/db/1828979/New_Enterprise_Associates>,
        <https://1145.am/db/1829581/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/1830382/New_Enterprise_Associates>,
        <https://1145.am/db/1830408/New_Enterprise_Associates>,
        <https://1145.am/db/1830873/New_Enterprise_Associates>,
        <https://1145.am/db/1831689/New_Enterprise_Associates>,
        <https://1145.am/db/1832186/New_Enterprise_Associates>,
        <https://1145.am/db/1835229/New_Enterprise_Associates>,
        <https://1145.am/db/1837877/New_Enterprise_Associates>,
        <https://1145.am/db/1838611/New_Enterprise_Associates>,
        <https://1145.am/db/1842035/New_Enterprise_Associates>,
        <https://1145.am/db/1845066/New_Enterprise_Associates>,
        <https://1145.am/db/1845590/New_Enterprise_Associates>,
        <https://1145.am/db/1846607/New_Enterprise_Associates>,
        <https://1145.am/db/1848728/New_Enterprise_Associates>,
        <https://1145.am/db/1849310/New_Enterprise_Associates>,
        <https://1145.am/db/1849986/New_Enterprise_Associates>,
        <https://1145.am/db/1851923/New_Enterprise_Associates>,
        <https://1145.am/db/1852048/New_Enterprise_Associates>,
        <https://1145.am/db/1853875/New_Enterprise_Associates>,
        <https://1145.am/db/1854098/New_Enterprise_Associates>,
        <https://1145.am/db/1859858/New_Enterprise_Associates>,
        <https://1145.am/db/1860644/New_Enterprise_Associates>,
        <https://1145.am/db/1860804/New_Enterprise_Associates>,
        <https://1145.am/db/1869421/New_Enterprise_Associates>,
        <https://1145.am/db/1875228/New_Enterprise_Associates>,
        <https://1145.am/db/1879023/New_Enterprise_Associates>,
        <https://1145.am/db/1879085/New_Enterprise_Associates>,
        <https://1145.am/db/1880677/New_Enterprise_Associates>,
        <https://1145.am/db/1883008/New_Enterprise_Associates>,
        <https://1145.am/db/1885336/New_Enterprise_Associates>,
        <https://1145.am/db/1887711/New_Enterprise_Associates>,
        <https://1145.am/db/1889764/New_Enterprise_Associates>,
        <https://1145.am/db/1889877/New_Enterprise_Associates>,
        <https://1145.am/db/1889935/New_Enterprise_Associates>,
        <https://1145.am/db/1890000/New_Enterprise_Associates>,
        <https://1145.am/db/1891539/New_Enterprise_Associates>,
        <https://1145.am/db/1891961/New_Enterprise_Associates>,
        <https://1145.am/db/1893324/New_Enterprise_Associates>,
        <https://1145.am/db/1893352/New_Enterprise_Associates>,
        <https://1145.am/db/1894602/New_Enterprise_Associates>,
        <https://1145.am/db/1910957/New_Enterprise_Associates>,
        <https://1145.am/db/1917393/New_Enterprise_Associates>,
        <https://1145.am/db/1919425/New_Enterprise_Associates>,
        <https://1145.am/db/1958068/New_Enterprise_Associates>,
        <https://1145.am/db/2028610/New_Enterprise_Associates>,
        <https://1145.am/db/2069394/New_Enterprise_Associates>,
        <https://1145.am/db/2151964/New_Enterprise_Associates>,
        <https://1145.am/db/2152126/New_Enterprise_Associates>,
        <https://1145.am/db/2152422/New_Enterprise_Associates>,
        <https://1145.am/db/2153373/New_Enterprise_Associates>,
        <https://1145.am/db/2153726/New_Enterprise_Associates>,
        <https://1145.am/db/2155273/New_Enterprise_Associates>,
        <https://1145.am/db/217906/New_Enterprise_Associates>,
        <https://1145.am/db/2185936/New_Enterprise_Associates>,
        <https://1145.am/db/2195351/New_Enterprise_Associates>,
        <https://1145.am/db/2196440/New_Enterprise_Associates>,
        <https://1145.am/db/2207324/New_Enterprise_Associates>,
        <https://1145.am/db/2233715/New_Enterprise_Associates>,
        <https://1145.am/db/2239029/New_Enterprise_Associates>,
        <https://1145.am/db/2280770/New_Enterprise_Associates>,
        <https://1145.am/db/2282600/New_Enterprise_Associates>,
        <https://1145.am/db/2284358/New_Enterprise_Associates>,
        <https://1145.am/db/2287244/New_Enterprise_Associates>,
        <https://1145.am/db/2288979/New_Enterprise_Associates>,
        <https://1145.am/db/2291315/New_Enterprise_Associates>,
        <https://1145.am/db/2292554/New_Enterprise_Associates>,
        <https://1145.am/db/2293793/New_Enterprise_Associates>,
        <https://1145.am/db/2294677/New_Enterprise_Associates>,
        <https://1145.am/db/2295964/New_Enterprise_Associates>,
        <https://1145.am/db/2296696/New_Enterprise_Associates>,
        <https://1145.am/db/2296810/New_Enterprise_Associates>,
        <https://1145.am/db/2297280/New_Enterprise_Associates>,
        <https://1145.am/db/2297471/New_Enterprise_Associates>,
        <https://1145.am/db/2297592/New_Enterprise_Associates>,
        <https://1145.am/db/2298167/New_Enterprise_Associates>,
        <https://1145.am/db/2298437/New_Enterprise_Associates>,
        <https://1145.am/db/2299411/New_Enterprise_Associates>,
        <https://1145.am/db/2300340/New_Enterprise_Associates>,
        <https://1145.am/db/2301461/New_Enterprise_Associates>,
        <https://1145.am/db/2301790/New_Enterprise_Associates>,
        <https://1145.am/db/2302449/New_Enterprise_Associates>,
        <https://1145.am/db/2303391/New_Enterprise_Associates>,
        <https://1145.am/db/2305256/New_Enterprise_Associates>,
        <https://1145.am/db/2305507/New_Enterprise_Associates>,
        <https://1145.am/db/2305514/New_Enterprise_Associates>,
        <https://1145.am/db/2305610/New_Enterprise_Associates>,
        <https://1145.am/db/2305611/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2305656/New_Enterprise_Associates>,
        <https://1145.am/db/2306163/New_Enterprise_Associates>,
        <https://1145.am/db/2306167/New_Enterprise_Associates>,
        <https://1145.am/db/2306705/New_Enterprise_Associates>,
        <https://1145.am/db/2307682/New_Enterprise_Associates>,
        <https://1145.am/db/2307691/New_Enterprise_Associates>,
        <https://1145.am/db/2309059/New_Enterprise_Associates>,
        <https://1145.am/db/2313401/New_Enterprise_Associates>,
        <https://1145.am/db/2313405/New_Enterprise_Associates>,
        <https://1145.am/db/2315049/New_Enterprise_Associates>,
        <https://1145.am/db/2316601/New_Enterprise_Associates>,
        <https://1145.am/db/2316605/New_Enterprise_Associates>,
        <https://1145.am/db/2317951/New_Enterprise_Associates>,
        <https://1145.am/db/2319399/New_Enterprise_Associates>,
        <https://1145.am/db/2319809/New_Enterprise_Associates>,
        <https://1145.am/db/2323138/New_Enterprise_Associates>,
        <https://1145.am/db/2323563/New_Enterprise_Associates>,
        <https://1145.am/db/2323568/New_Enterprise_Associates>,
        <https://1145.am/db/2323682/New_Enterprise_Associates>,
        <https://1145.am/db/2323683/New_Enterprise_Associates>,
        <https://1145.am/db/2323845/New_Enterprise_Associates>,
        <https://1145.am/db/2324289/New_Enterprise_Associates>,
        <https://1145.am/db/2326447/New_Enterprise_Associates>,
        <https://1145.am/db/2326455/New_Enterprise_Associates>,
        <https://1145.am/db/2326571/New_Enterprise_Associates>,
        <https://1145.am/db/2326893/New_Enterprise_Associates>,
        <https://1145.am/db/2328700/New_Enterprise_Associates>,
        <https://1145.am/db/2329246/New_Enterprise_Associates>,
        <https://1145.am/db/2331784/New_Enterprise_Associates>,
        <https://1145.am/db/2331852/New_Enterprise_Associates>,
        <https://1145.am/db/2331858/New_Enterprise_Associates>,
        <https://1145.am/db/2332445/New_Enterprise_Associates>,
        <https://1145.am/db/2332982/New_Enterprise_Associates>,
        <https://1145.am/db/2333119/New_Enterprise_Associates>,
        <https://1145.am/db/2334847/New_Enterprise_Associates>,
        <https://1145.am/db/2335837/New_Enterprise_Associates>,
        <https://1145.am/db/2336052/New_Enterprise_Associates>,
        <https://1145.am/db/2336391/New_Enterprise_Associates>,
        <https://1145.am/db/2336634/New_Enterprise_Associates>,
        <https://1145.am/db/2337250/New_Enterprise_Associates>,
        <https://1145.am/db/2337254/New_Enterprise_Associates>,
        <https://1145.am/db/2337971/New_Enterprise_Associates>,
        <https://1145.am/db/2337972/New_Enterprise_Associates>,
        <https://1145.am/db/2338086/New_Enterprise_Associates>,
        <https://1145.am/db/2339041/New_Enterprise_Associates>,
        <https://1145.am/db/2339206/New_Enterprise_Associates>,
        <https://1145.am/db/2340224/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2340888/New_Enterprise_Associates>,
        <https://1145.am/db/2340890/New_Enterprise_Associates>,
        <https://1145.am/db/2341792/New_Enterprise_Associates>,
        <https://1145.am/db/2341800/New_Enterprise_Associates>,
        <https://1145.am/db/2341896/New_Enterprise_Associates>,
        <https://1145.am/db/2343773/New_Enterprise_Associates>,
        <https://1145.am/db/2344507/New_Enterprise_Associates>,
        <https://1145.am/db/2346094/New_Enterprise_Associates>,
        <https://1145.am/db/2348024/New_Enterprise_Associates>,
        <https://1145.am/db/2348029/New_Enterprise_Associates>,
        <https://1145.am/db/2348042/New_Enterprise_Associates>,
        <https://1145.am/db/2348057/New_Enterprise_Associates>,
        <https://1145.am/db/2348066/New_Enterprise_Associates>,
        <https://1145.am/db/2348956/New_Enterprise_Associates>,
        <https://1145.am/db/2348967/New_Enterprise_Associates>,
        <https://1145.am/db/2349234/New_Enterprise_Associates>,
        <https://1145.am/db/2350164/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2350167/New_Enterprise_Associates>,
        <https://1145.am/db/2350231/New_Enterprise_Associates>,
        <https://1145.am/db/2350327/New_Enterprise_Associates>,
        <https://1145.am/db/2352899/New_Enterprise_Associates>,
        <https://1145.am/db/2355048/New_Enterprise_Associates>,
        <https://1145.am/db/2355531/New_Enterprise_Associates>,
        <https://1145.am/db/2355543/New_Enterprise_Associates>,
        <https://1145.am/db/2355754/New_Enterprise_Associates>,
        <https://1145.am/db/2355885/New_Enterprise_Associates>,
        <https://1145.am/db/2356048/New_Enterprise_Associates>,
        <https://1145.am/db/2356216/New_Enterprise_Associates>,
        <https://1145.am/db/2356391/New_Enterprise_Associates>,
        <https://1145.am/db/2356393/New_Enterprise_Associates>,
        <https://1145.am/db/2356395/New_Enterprise_Associates>,
        <https://1145.am/db/2356396/New_Enterprise_Associates>,
        <https://1145.am/db/2357144/New_Enterprise_Associates>,
        <https://1145.am/db/2357566/New_Enterprise_Associates>,
        <https://1145.am/db/2358225/New_Enterprise_Associates>,
        <https://1145.am/db/2358242/New_Enterprise_Associates>,
        <https://1145.am/db/2358506/New_Enterprise_Associates>,
        <https://1145.am/db/2358529/New_Enterprise_Associates>,
        <https://1145.am/db/2358640/New_Enterprise_Associates>,
        <https://1145.am/db/2358657/New_Enterprise_Associates>,
        <https://1145.am/db/2358658/New_Enterprise_Associates>,
        <https://1145.am/db/2358883/New_Enterprise_Associates>,
        <https://1145.am/db/2359185/New_Enterprise_Associates>,
        <https://1145.am/db/2359873/New_Enterprise_Associates>,
        <https://1145.am/db/2359875/New_Enterprise_Associates>,
        <https://1145.am/db/2360682/New_Enterprise_Associates>,
        <https://1145.am/db/2360979/New_Enterprise_Associates>,
        <https://1145.am/db/2361004/New_Enterprise_Associates>,
        <https://1145.am/db/2361005/New_Enterprise_Associates>,
        <https://1145.am/db/2364422/New_Enterprise_Associates>,
        <https://1145.am/db/2365868/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2366775/New_Enterprise_Associates>,
        <https://1145.am/db/2366984/New_Enterprise_Associates>,
        <https://1145.am/db/2367497/New_Enterprise_Associates>,
        <https://1145.am/db/2367678/New_Enterprise_Associates>,
        <https://1145.am/db/2367711/New_Enterprise_Associates>,
        <https://1145.am/db/2367714/New_Enterprise_Associates>,
        <https://1145.am/db/2369202/New_Enterprise_Associates>,
        <https://1145.am/db/2369785/New_Enterprise_Associates>,
        <https://1145.am/db/2369916/New_Enterprise_Associates>,
        <https://1145.am/db/2370094/New_Enterprise_Associates>,
        <https://1145.am/db/2370436/New_Enterprise_Associates>,
        <https://1145.am/db/2370782/New_Enterprise_Associates>,
        <https://1145.am/db/2370799/New_Enterprise_Associates>,
        <https://1145.am/db/2371165/New_Enterprise_Associates>,
        <https://1145.am/db/2371166/New_Enterprise_Associates>,
        <https://1145.am/db/2438933/New_Enterprise_Associates>,
        <https://1145.am/db/2443170/New_Enterprise_Associates>,
        <https://1145.am/db/2450551/New_Enterprise_Associates>,
        <https://1145.am/db/2454491/New_Enterprise_Associates>,
        <https://1145.am/db/2541350/New_Enterprise_Associates>,
        <https://1145.am/db/2552598/New_Enterprise_Associates>,
        <https://1145.am/db/2570481/New_Enterprise_Associates>,
        <https://1145.am/db/2570483/New_Enterprise_Associates>,
        <https://1145.am/db/2571149/New_Enterprise_Associates>,
        <https://1145.am/db/2580133/New_Enterprise_Associates>,
        <https://1145.am/db/2587938/New_Enterprise_Associates>,
        <https://1145.am/db/2636760/New_Enterprise_Associates>,
        <https://1145.am/db/301469/New_Enterprise_Associates>,
        <https://1145.am/db/303111/New_Enterprise_Associates>,
        <https://1145.am/db/522665/New_Enterprise_Associates>,
        <https://1145.am/db/525766/New_Enterprise_Associates>,
        <https://1145.am/db/563438/New_Enterprise_Associates>,
        <https://1145.am/db/580082/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/661958/New_Enterprise_Associates>,
        <https://1145.am/db/676316/New_Enterprise_Associates>,
        <https://1145.am/db/680751/New_Enterprise_Associates>,
        <https://1145.am/db/714395/New_Enterprise_Associates>,
        <https://1145.am/db/849950/New_Enterprise_Associates>,
        <https://1145.am/db/893810/New_Enterprise_Associates>,
        <https://1145.am/db/918706/New_Enterprise_Associates>,
        <https://1145.am/db/961672/New_Enterprise_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359830/Investment_Fluorinov_Pharma_Inc_The_Ontario_Institute_For_Cancer_Research_Has_Not_Happened> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-07T16:06:40+00:00"^^xsd:dateTime ;
    ns1:documentExtract "OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers.",
        "TORONTO, June 7, 2012 /PRNewswire via COMTEX/ - The Ontario Institute for Cancer Research (OICR) today announced $ 1.5 million in funding over three years for the development of a new drug by Toronto - based Fluorinov Pharma, Inc." ;
    ns1:documentTitle "OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/oicr-funds-fluorinov-pharma-inc-to-further-develop-its-novel-drug-for-treatment-of-blood> ;
    ns1:foundName "development",
        "funding" ;
    ns1:name "development",
        "funding" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2359830/Fluorinov_Pharma_Inc> ;
    ns1:valueRaw "$ 1.5 million" ;
    ns1:whereRaw "Fluorinov Pharma Inc." .

<https://1145.am/db/2359873/New_Enterprise_Associates> a org:Organization ;
    ns1:basedInLowRaw "BOSTON" ;
    ns1:documentDate "2012-06-13T11:26:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/rhythm-raises-25m-series-b-financing-for-diabetes-and-obesity-therapeutics> ;
    ns1:foundName "New Enterprise Associates" ;
    ns1:investor <https://1145.am/db/2359873/Series_B_Investment_Ipsen_Mpm_Capital_New_Enterprise_Associates_Rhythm_Third_Rock_Ventures_Completed> ;
    ns1:name "New Enterprise Associates" ;
    ns1:sameAsMedium <https://1145.am/db/1031040/New_Enterprise_Associates>,
        <https://1145.am/db/1091201/New_Enterprise_Associates>,
        <https://1145.am/db/1115103/New_Enterprise_Associates>,
        <https://1145.am/db/1115600/New_Enterprise_Associates>,
        <https://1145.am/db/1116035/New_Enterprise_Associates>,
        <https://1145.am/db/1116076/New_Enterprise_Associates>,
        <https://1145.am/db/1127410/New_Enterprise_Associates>,
        <https://1145.am/db/1169121/New_Enterprise_Associates>,
        <https://1145.am/db/1230022/New_Enterprise_Associates>,
        <https://1145.am/db/1233430/New_Enterprise_Associates>,
        <https://1145.am/db/1279264/New_Enterprise_Associates>,
        <https://1145.am/db/1281079/New_Enterprise_Associates>,
        <https://1145.am/db/1281647/New_Enterprise_Associates>,
        <https://1145.am/db/1371086/New_Enterprise_Associates>,
        <https://1145.am/db/1422234/New_Enterprise_Associates>,
        <https://1145.am/db/1422725/New_Enterprise_Associates>,
        <https://1145.am/db/1427471/New_Enterprise_Associates>,
        <https://1145.am/db/1469165/New_Enterprise_Associates>,
        <https://1145.am/db/1571794/New_Enterprise_Associates>,
        <https://1145.am/db/1606686/New_Enterprise_Associates>,
        <https://1145.am/db/1653132/New_Enterprise_Associates>,
        <https://1145.am/db/1653506/New_Enterprise_Associates>,
        <https://1145.am/db/1654515/New_Enterprise_Associates>,
        <https://1145.am/db/1694448/New_Enterprise_Associates>,
        <https://1145.am/db/1696213/New_Enterprise_Associates>,
        <https://1145.am/db/1699877/New_Enterprise_Associates>,
        <https://1145.am/db/1701285/New_Enterprise_Associates>,
        <https://1145.am/db/1701411/New_Enterprise_Associates>,
        <https://1145.am/db/1701589/New_Enterprise_Associates>,
        <https://1145.am/db/1715860/New_Enterprise_Associates>,
        <https://1145.am/db/1717498/New_Enterprise_Associates>,
        <https://1145.am/db/1717968/New_Enterprise_Associates>,
        <https://1145.am/db/1718000/New_Enterprise_Associates>,
        <https://1145.am/db/1718018/New_Enterprise_Associates>,
        <https://1145.am/db/1719370/New_Enterprise_Associates>,
        <https://1145.am/db/1719408/New_Enterprise_Associates>,
        <https://1145.am/db/1720645/New_Enterprise_Associates>,
        <https://1145.am/db/1721392/New_Enterprise_Associates>,
        <https://1145.am/db/1731944/New_Enterprise_Associates>,
        <https://1145.am/db/1738986/New_Enterprise_Associates>,
        <https://1145.am/db/1743570/New_Enterprise_Associates>,
        <https://1145.am/db/1743999/New_Enterprise_Associates>,
        <https://1145.am/db/1751207/New_Enterprise_Associates>,
        <https://1145.am/db/1753526/New_Enterprise_Associates>,
        <https://1145.am/db/1760464/New_Enterprise_Associates>,
        <https://1145.am/db/1761607/New_Enterprise_Associates>,
        <https://1145.am/db/1772584/New_Enterprise_Associates>,
        <https://1145.am/db/1777442/New_Enterprise_Associates>,
        <https://1145.am/db/1777542/New_Enterprise_Associates>,
        <https://1145.am/db/1783236/New_Enterprise_Associates>,
        <https://1145.am/db/1788268/New_Enterprise_Associates>,
        <https://1145.am/db/1788746/New_Enterprise_Associates>,
        <https://1145.am/db/1790370/New_Enterprise_Associates>,
        <https://1145.am/db/1790675/New_Enterprise_Associates>,
        <https://1145.am/db/1791343/New_Enterprise_Associates>,
        <https://1145.am/db/1792086/New_Enterprise_Associates>,
        <https://1145.am/db/1794202/New_Enterprise_Associates>,
        <https://1145.am/db/1796249/New_Enterprise_Associates>,
        <https://1145.am/db/1798548/New_Enterprise_Associates>,
        <https://1145.am/db/1798774/New_Enterprise_Associates>,
        <https://1145.am/db/1801088/New_Enterprise_Associates>,
        <https://1145.am/db/1801934/New_Enterprise_Associates>,
        <https://1145.am/db/1804355/New_Enterprise_Associates>,
        <https://1145.am/db/1811114/New_Enterprise_Associates>,
        <https://1145.am/db/1811472/New_Enterprise_Associates>,
        <https://1145.am/db/1813288/New_Enterprise_Associates>,
        <https://1145.am/db/1816928/New_Enterprise_Associates>,
        <https://1145.am/db/1818535/New_Enterprise_Associates>,
        <https://1145.am/db/1819637/New_Enterprise_Associates>,
        <https://1145.am/db/1823697/New_Enterprise_Associates>,
        <https://1145.am/db/1823742/New_Enterprise_Associates>,
        <https://1145.am/db/1824558/New_Enterprise_Associates>,
        <https://1145.am/db/1825681/New_Enterprise_Associates>,
        <https://1145.am/db/1826221/New_Enterprise_Associates>,
        <https://1145.am/db/1826275/New_Enterprise_Associates>,
        <https://1145.am/db/1826446/New_Enterprise_Associates>,
        <https://1145.am/db/1827724/New_Enterprise_Associates>,
        <https://1145.am/db/1828072/New_Enterprise_Associates>,
        <https://1145.am/db/1828658/New_Enterprise_Associates>,
        <https://1145.am/db/1828979/New_Enterprise_Associates>,
        <https://1145.am/db/1829581/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/1830382/New_Enterprise_Associates>,
        <https://1145.am/db/1830408/New_Enterprise_Associates>,
        <https://1145.am/db/1830873/New_Enterprise_Associates>,
        <https://1145.am/db/1831689/New_Enterprise_Associates>,
        <https://1145.am/db/1832186/New_Enterprise_Associates>,
        <https://1145.am/db/1835229/New_Enterprise_Associates>,
        <https://1145.am/db/1837877/New_Enterprise_Associates>,
        <https://1145.am/db/1838611/New_Enterprise_Associates>,
        <https://1145.am/db/1842035/New_Enterprise_Associates>,
        <https://1145.am/db/1845066/New_Enterprise_Associates>,
        <https://1145.am/db/1845590/New_Enterprise_Associates>,
        <https://1145.am/db/1846607/New_Enterprise_Associates>,
        <https://1145.am/db/1848728/New_Enterprise_Associates>,
        <https://1145.am/db/1849310/New_Enterprise_Associates>,
        <https://1145.am/db/1849986/New_Enterprise_Associates>,
        <https://1145.am/db/1851923/New_Enterprise_Associates>,
        <https://1145.am/db/1852048/New_Enterprise_Associates>,
        <https://1145.am/db/1853875/New_Enterprise_Associates>,
        <https://1145.am/db/1854098/New_Enterprise_Associates>,
        <https://1145.am/db/1859858/New_Enterprise_Associates>,
        <https://1145.am/db/1860644/New_Enterprise_Associates>,
        <https://1145.am/db/1860804/New_Enterprise_Associates>,
        <https://1145.am/db/1869421/New_Enterprise_Associates>,
        <https://1145.am/db/1875228/New_Enterprise_Associates>,
        <https://1145.am/db/1879023/New_Enterprise_Associates>,
        <https://1145.am/db/1879085/New_Enterprise_Associates>,
        <https://1145.am/db/1880677/New_Enterprise_Associates>,
        <https://1145.am/db/1883008/New_Enterprise_Associates>,
        <https://1145.am/db/1885336/New_Enterprise_Associates>,
        <https://1145.am/db/1887711/New_Enterprise_Associates>,
        <https://1145.am/db/1889764/New_Enterprise_Associates>,
        <https://1145.am/db/1889877/New_Enterprise_Associates>,
        <https://1145.am/db/1889935/New_Enterprise_Associates>,
        <https://1145.am/db/1890000/New_Enterprise_Associates>,
        <https://1145.am/db/1891539/New_Enterprise_Associates>,
        <https://1145.am/db/1891961/New_Enterprise_Associates>,
        <https://1145.am/db/1893324/New_Enterprise_Associates>,
        <https://1145.am/db/1893352/New_Enterprise_Associates>,
        <https://1145.am/db/1894602/New_Enterprise_Associates>,
        <https://1145.am/db/1910957/New_Enterprise_Associates>,
        <https://1145.am/db/1917393/New_Enterprise_Associates>,
        <https://1145.am/db/1919425/New_Enterprise_Associates>,
        <https://1145.am/db/1958068/New_Enterprise_Associates>,
        <https://1145.am/db/2028610/New_Enterprise_Associates>,
        <https://1145.am/db/2069394/New_Enterprise_Associates>,
        <https://1145.am/db/2151964/New_Enterprise_Associates>,
        <https://1145.am/db/2152126/New_Enterprise_Associates>,
        <https://1145.am/db/2152422/New_Enterprise_Associates>,
        <https://1145.am/db/2153373/New_Enterprise_Associates>,
        <https://1145.am/db/2153726/New_Enterprise_Associates>,
        <https://1145.am/db/2155273/New_Enterprise_Associates>,
        <https://1145.am/db/217906/New_Enterprise_Associates>,
        <https://1145.am/db/2185936/New_Enterprise_Associates>,
        <https://1145.am/db/2195351/New_Enterprise_Associates>,
        <https://1145.am/db/2196440/New_Enterprise_Associates>,
        <https://1145.am/db/2207324/New_Enterprise_Associates>,
        <https://1145.am/db/2233715/New_Enterprise_Associates>,
        <https://1145.am/db/2239029/New_Enterprise_Associates>,
        <https://1145.am/db/2280770/New_Enterprise_Associates>,
        <https://1145.am/db/2282600/New_Enterprise_Associates>,
        <https://1145.am/db/2284358/New_Enterprise_Associates>,
        <https://1145.am/db/2287244/New_Enterprise_Associates>,
        <https://1145.am/db/2288979/New_Enterprise_Associates>,
        <https://1145.am/db/2291315/New_Enterprise_Associates>,
        <https://1145.am/db/2292554/New_Enterprise_Associates>,
        <https://1145.am/db/2293793/New_Enterprise_Associates>,
        <https://1145.am/db/2294677/New_Enterprise_Associates>,
        <https://1145.am/db/2295964/New_Enterprise_Associates>,
        <https://1145.am/db/2296696/New_Enterprise_Associates>,
        <https://1145.am/db/2296810/New_Enterprise_Associates>,
        <https://1145.am/db/2297280/New_Enterprise_Associates>,
        <https://1145.am/db/2297471/New_Enterprise_Associates>,
        <https://1145.am/db/2297592/New_Enterprise_Associates>,
        <https://1145.am/db/2298167/New_Enterprise_Associates>,
        <https://1145.am/db/2298437/New_Enterprise_Associates>,
        <https://1145.am/db/2299411/New_Enterprise_Associates>,
        <https://1145.am/db/2300340/New_Enterprise_Associates>,
        <https://1145.am/db/2301461/New_Enterprise_Associates>,
        <https://1145.am/db/2301790/New_Enterprise_Associates>,
        <https://1145.am/db/2302449/New_Enterprise_Associates>,
        <https://1145.am/db/2303391/New_Enterprise_Associates>,
        <https://1145.am/db/2305256/New_Enterprise_Associates>,
        <https://1145.am/db/2305507/New_Enterprise_Associates>,
        <https://1145.am/db/2305514/New_Enterprise_Associates>,
        <https://1145.am/db/2305610/New_Enterprise_Associates>,
        <https://1145.am/db/2305611/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2305656/New_Enterprise_Associates>,
        <https://1145.am/db/2306163/New_Enterprise_Associates>,
        <https://1145.am/db/2306167/New_Enterprise_Associates>,
        <https://1145.am/db/2306705/New_Enterprise_Associates>,
        <https://1145.am/db/2307682/New_Enterprise_Associates>,
        <https://1145.am/db/2307691/New_Enterprise_Associates>,
        <https://1145.am/db/2309059/New_Enterprise_Associates>,
        <https://1145.am/db/2313401/New_Enterprise_Associates>,
        <https://1145.am/db/2313405/New_Enterprise_Associates>,
        <https://1145.am/db/2315049/New_Enterprise_Associates>,
        <https://1145.am/db/2316601/New_Enterprise_Associates>,
        <https://1145.am/db/2316605/New_Enterprise_Associates>,
        <https://1145.am/db/2317951/New_Enterprise_Associates>,
        <https://1145.am/db/2319399/New_Enterprise_Associates>,
        <https://1145.am/db/2319809/New_Enterprise_Associates>,
        <https://1145.am/db/2323138/New_Enterprise_Associates>,
        <https://1145.am/db/2323563/New_Enterprise_Associates>,
        <https://1145.am/db/2323568/New_Enterprise_Associates>,
        <https://1145.am/db/2323682/New_Enterprise_Associates>,
        <https://1145.am/db/2323683/New_Enterprise_Associates>,
        <https://1145.am/db/2323845/New_Enterprise_Associates>,
        <https://1145.am/db/2324289/New_Enterprise_Associates>,
        <https://1145.am/db/2326447/New_Enterprise_Associates>,
        <https://1145.am/db/2326455/New_Enterprise_Associates>,
        <https://1145.am/db/2326571/New_Enterprise_Associates>,
        <https://1145.am/db/2326893/New_Enterprise_Associates>,
        <https://1145.am/db/2328700/New_Enterprise_Associates>,
        <https://1145.am/db/2329246/New_Enterprise_Associates>,
        <https://1145.am/db/2331784/New_Enterprise_Associates>,
        <https://1145.am/db/2331852/New_Enterprise_Associates>,
        <https://1145.am/db/2331858/New_Enterprise_Associates>,
        <https://1145.am/db/2332445/New_Enterprise_Associates>,
        <https://1145.am/db/2332982/New_Enterprise_Associates>,
        <https://1145.am/db/2333119/New_Enterprise_Associates>,
        <https://1145.am/db/2334847/New_Enterprise_Associates>,
        <https://1145.am/db/2335837/New_Enterprise_Associates>,
        <https://1145.am/db/2336052/New_Enterprise_Associates>,
        <https://1145.am/db/2336391/New_Enterprise_Associates>,
        <https://1145.am/db/2336634/New_Enterprise_Associates>,
        <https://1145.am/db/2337250/New_Enterprise_Associates>,
        <https://1145.am/db/2337254/New_Enterprise_Associates>,
        <https://1145.am/db/2337971/New_Enterprise_Associates>,
        <https://1145.am/db/2337972/New_Enterprise_Associates>,
        <https://1145.am/db/2338086/New_Enterprise_Associates>,
        <https://1145.am/db/2339041/New_Enterprise_Associates>,
        <https://1145.am/db/2339206/New_Enterprise_Associates>,
        <https://1145.am/db/2340224/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2340888/New_Enterprise_Associates>,
        <https://1145.am/db/2340890/New_Enterprise_Associates>,
        <https://1145.am/db/2341792/New_Enterprise_Associates>,
        <https://1145.am/db/2341800/New_Enterprise_Associates>,
        <https://1145.am/db/2341896/New_Enterprise_Associates>,
        <https://1145.am/db/2343773/New_Enterprise_Associates>,
        <https://1145.am/db/2344507/New_Enterprise_Associates>,
        <https://1145.am/db/2346094/New_Enterprise_Associates>,
        <https://1145.am/db/2348024/New_Enterprise_Associates>,
        <https://1145.am/db/2348029/New_Enterprise_Associates>,
        <https://1145.am/db/2348042/New_Enterprise_Associates>,
        <https://1145.am/db/2348057/New_Enterprise_Associates>,
        <https://1145.am/db/2348066/New_Enterprise_Associates>,
        <https://1145.am/db/2348956/New_Enterprise_Associates>,
        <https://1145.am/db/2348967/New_Enterprise_Associates>,
        <https://1145.am/db/2349234/New_Enterprise_Associates>,
        <https://1145.am/db/2350164/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2350167/New_Enterprise_Associates>,
        <https://1145.am/db/2350231/New_Enterprise_Associates>,
        <https://1145.am/db/2350327/New_Enterprise_Associates>,
        <https://1145.am/db/2352899/New_Enterprise_Associates>,
        <https://1145.am/db/2355048/New_Enterprise_Associates>,
        <https://1145.am/db/2355531/New_Enterprise_Associates>,
        <https://1145.am/db/2355543/New_Enterprise_Associates>,
        <https://1145.am/db/2355754/New_Enterprise_Associates>,
        <https://1145.am/db/2355885/New_Enterprise_Associates>,
        <https://1145.am/db/2356048/New_Enterprise_Associates>,
        <https://1145.am/db/2356216/New_Enterprise_Associates>,
        <https://1145.am/db/2356391/New_Enterprise_Associates>,
        <https://1145.am/db/2356393/New_Enterprise_Associates>,
        <https://1145.am/db/2356395/New_Enterprise_Associates>,
        <https://1145.am/db/2356396/New_Enterprise_Associates>,
        <https://1145.am/db/2357144/New_Enterprise_Associates>,
        <https://1145.am/db/2357566/New_Enterprise_Associates>,
        <https://1145.am/db/2358225/New_Enterprise_Associates>,
        <https://1145.am/db/2358242/New_Enterprise_Associates>,
        <https://1145.am/db/2358506/New_Enterprise_Associates>,
        <https://1145.am/db/2358529/New_Enterprise_Associates>,
        <https://1145.am/db/2358640/New_Enterprise_Associates>,
        <https://1145.am/db/2358657/New_Enterprise_Associates>,
        <https://1145.am/db/2358658/New_Enterprise_Associates>,
        <https://1145.am/db/2358812/New_Enterprise_Associates>,
        <https://1145.am/db/2358883/New_Enterprise_Associates>,
        <https://1145.am/db/2359185/New_Enterprise_Associates>,
        <https://1145.am/db/2359875/New_Enterprise_Associates>,
        <https://1145.am/db/2360682/New_Enterprise_Associates>,
        <https://1145.am/db/2360979/New_Enterprise_Associates>,
        <https://1145.am/db/2361004/New_Enterprise_Associates>,
        <https://1145.am/db/2361005/New_Enterprise_Associates>,
        <https://1145.am/db/2364422/New_Enterprise_Associates>,
        <https://1145.am/db/2365868/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/2366775/New_Enterprise_Associates>,
        <https://1145.am/db/2366984/New_Enterprise_Associates>,
        <https://1145.am/db/2367497/New_Enterprise_Associates>,
        <https://1145.am/db/2367678/New_Enterprise_Associates>,
        <https://1145.am/db/2367711/New_Enterprise_Associates>,
        <https://1145.am/db/2367714/New_Enterprise_Associates>,
        <https://1145.am/db/2369202/New_Enterprise_Associates>,
        <https://1145.am/db/2369785/New_Enterprise_Associates>,
        <https://1145.am/db/2369916/New_Enterprise_Associates>,
        <https://1145.am/db/2370094/New_Enterprise_Associates>,
        <https://1145.am/db/2370436/New_Enterprise_Associates>,
        <https://1145.am/db/2370782/New_Enterprise_Associates>,
        <https://1145.am/db/2370799/New_Enterprise_Associates>,
        <https://1145.am/db/2371165/New_Enterprise_Associates>,
        <https://1145.am/db/2371166/New_Enterprise_Associates>,
        <https://1145.am/db/2438933/New_Enterprise_Associates>,
        <https://1145.am/db/2443170/New_Enterprise_Associates>,
        <https://1145.am/db/2450551/New_Enterprise_Associates>,
        <https://1145.am/db/2454491/New_Enterprise_Associates>,
        <https://1145.am/db/2541350/New_Enterprise_Associates>,
        <https://1145.am/db/2552598/New_Enterprise_Associates>,
        <https://1145.am/db/2570481/New_Enterprise_Associates>,
        <https://1145.am/db/2570483/New_Enterprise_Associates>,
        <https://1145.am/db/2571149/New_Enterprise_Associates>,
        <https://1145.am/db/2580133/New_Enterprise_Associates>,
        <https://1145.am/db/2587938/New_Enterprise_Associates>,
        <https://1145.am/db/2636760/New_Enterprise_Associates>,
        <https://1145.am/db/301469/New_Enterprise_Associates>,
        <https://1145.am/db/303111/New_Enterprise_Associates>,
        <https://1145.am/db/522665/New_Enterprise_Associates>,
        <https://1145.am/db/525766/New_Enterprise_Associates>,
        <https://1145.am/db/563438/New_Enterprise_Associates>,
        <https://1145.am/db/580082/New_Enterprise_Associates_Inc>,
        <https://1145.am/db/661958/New_Enterprise_Associates>,
        <https://1145.am/db/676316/New_Enterprise_Associates>,
        <https://1145.am/db/680751/New_Enterprise_Associates>,
        <https://1145.am/db/714395/New_Enterprise_Associates>,
        <https://1145.am/db/849950/New_Enterprise_Associates>,
        <https://1145.am/db/893810/New_Enterprise_Associates>,
        <https://1145.am/db/918706/New_Enterprise_Associates>,
        <https://1145.am/db/961672/New_Enterprise_Associates> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2572450/Gerot_Lannach> a org:Organization ;
    ns1:basedInHighGeoName "Republic of Austria" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2782113/about.rdf> ;
    ns1:basedInHighRaw "Austria" ;
    ns1:description "branded-generics maker" ;
    ns1:documentDate "2012-03-26T15:57:29+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Valeant nabs Russia's Natur Produkt for $175M-plus" ;
    ns1:documentURL <https://www.fiercepharma.com/m-a/valeant-nabs-russia-s-natur-produkt-for-175m-plus> ;
    ns1:foundName "Gerot Lannach" ;
    ns1:industry "Pharmaceuticals" ;
    ns1:name "Gerot Lannach" ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2595063/Discovery_Science_And_Neotope_Biosciences> a org:Organization ;
    ns1:basedInLowRaw "NYSE" ;
    ns1:description "Biosciences",
        "research" ;
    ns1:documentDate "2012-08-13T13:08:09+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders" ;
    ns1:documentURL <https://www.fiercepharma.com/pharma/elan-announces-plan-to-spin-off-discovery-science-and-neotope-biosciences-to-shareholders> ;
    ns1:foundName "Discovery Science And Neotope Biosciences",
        "Elan",
        "Neotope Biosciences",
        "the discovery science and Neotope Biosciences" ;
    ns1:name "Discovery Science",
        "Discovery Science And Neotope Biosciences",
        "Neotope Biosciences" ;
    ns1:sameAsHigh <https://1145.am/db/2345479/Neotope_Biosciences>,
        <https://1145.am/db/2346467/Discovery_Science_And_Neotope_Biosciences> ;
    ns1:sourceName "Fierce Pharma" .

<https://1145.am/db/2653242/Vivacom_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2012-08-08T09:57:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Reuters reported that VTB Capital, a unit of Russia's VTB Bank, and Bulgarian lender Corporate Commercial Bank (CCBank) have agreed to take over Vivacom, which carried debt of €1.65 billion.",
        "Two banks have reached agreement on the acquisition of Bulgarian fixed and mobile operator Vivacom, quashing any hopes that Turkcell and Telekom Austria may have had of buying the former Bulgarian Telecommunications Company (BTC)." ;
    ns1:documentTitle "Banks agree to buy Bulgaria's Vivacom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/banks-agree-to-buy-bulgaria-s-vivacom> ;
    ns1:foundName "acquisition",
        "take over" ;
    ns1:name "acquisition",
        "take over" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "has not happened" ;
    ns1:target <https://1145.am/db/2653242/Vivacom> ;
    ns1:targetName "Vivacom" ;
    ns1:valueRaw "€1.65 billion" ;
    ns1:whereRaw "Bulgarian" .

<https://1145.am/db/2671481/Vimpelcom> a org:Organization ;
    ns1:basedInHighGeoName "Russian Federation" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:basedInHighRaw "Russia" ;
    ns1:documentDate "2012-04-06T14:47:43+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor boosts VimpelCom stake with $715M JP Morgan deal" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-boosts-vimpelcom-stake-715m-jp-morgan-deal> ;
    ns1:foundName "VimpelCom" ;
    ns1:industry "telco" ;
    ns1:name "VimpelCom" ;
    ns1:sameAsHigh <https://1145.am/db/1530772/Vimpelcom>,
        <https://1145.am/db/1659276/Vimpelcom>,
        <https://1145.am/db/2141019/Vimpelcom>,
        <https://1145.am/db/2602370/Vimpelcom>,
        <https://1145.am/db/2626593/Vimpelcom>,
        <https://1145.am/db/2652974/Vimpelcom>,
        <https://1145.am/db/2653311/Vimpelcom>,
        <https://1145.am/db/2654657/Vimpelcom>,
        <https://1145.am/db/2659847/Vimpelcom>,
        <https://1145.am/db/2662999/Vimpelcom>,
        <https://1145.am/db/2664167/Vimpelcom>,
        <https://1145.am/db/2664571/Vimpelcom>,
        <https://1145.am/db/2665211/Vimpelcom>,
        <https://1145.am/db/2666405/Vimpelcom>,
        <https://1145.am/db/2666410/Vimpelcom>,
        <https://1145.am/db/2667105/Vimpelcom>,
        <https://1145.am/db/2671088/Vimpelcom>,
        <https://1145.am/db/2671104/Vimpelcom>,
        <https://1145.am/db/2672659/Vimpelcom>,
        <https://1145.am/db/2672667/Vimpelcom>,
        <https://1145.am/db/2674298/Vimpelcom>,
        <https://1145.am/db/2679855/Vimpelcom>,
        <https://1145.am/db/2680662/Vimpelcom>,
        <https://1145.am/db/2723235/Vimpelcom> ;
    ns1:sameAsMedium <https://1145.am/db/1529511/Vimpelcom>,
        <https://1145.am/db/1656234/Vimpelcom>,
        <https://1145.am/db/1668852/Vimpelcom>,
        <https://1145.am/db/2600327/Vimpelcom>,
        <https://1145.am/db/2602398/Vimpelcom>,
        <https://1145.am/db/2607010/Vimpelcom>,
        <https://1145.am/db/2611520/Vimpelcom>,
        <https://1145.am/db/2625867/Vimpelcom>,
        <https://1145.am/db/2628046/Vimpelcom>,
        <https://1145.am/db/2646871/Vimpelcom>,
        <https://1145.am/db/2646907/Vimpelcom>,
        <https://1145.am/db/2651270/Vimpelcom>,
        <https://1145.am/db/2652389/Vimpelcom>,
        <https://1145.am/db/2652985/Vimpelcom>,
        <https://1145.am/db/2653167/Vimpelcom>,
        <https://1145.am/db/2653171/Vimpelcom>,
        <https://1145.am/db/2653186/Vimpelcom>,
        <https://1145.am/db/2653225/Vimpelcom>,
        <https://1145.am/db/2654675/Vimpelcom>,
        <https://1145.am/db/2655477/Vimpelcom>,
        <https://1145.am/db/2655754/Vimpelcom>,
        <https://1145.am/db/2658492/Vimpelcom>,
        <https://1145.am/db/2659767/Vimpelcom>,
        <https://1145.am/db/2659780/Vimpelcom>,
        <https://1145.am/db/2660593/Vimpelcom>,
        <https://1145.am/db/2661700/Vimpelcom>,
        <https://1145.am/db/2661979/Vimpelcom>,
        <https://1145.am/db/2663844/Vimpelcom>,
        <https://1145.am/db/2663852/Vimpelcom>,
        <https://1145.am/db/2664956/Vimpelcom>,
        <https://1145.am/db/2665182/Vimpelcom>,
        <https://1145.am/db/2665345/Vimpelcom>,
        <https://1145.am/db/2665678/Vimpelcom>,
        <https://1145.am/db/2666025/Vimpelcom>,
        <https://1145.am/db/2666299/Vimpelcom>,
        <https://1145.am/db/2667506/Vimpelcom>,
        <https://1145.am/db/2668411/Vimpelcom>,
        <https://1145.am/db/2668429/Vimpelcom>,
        <https://1145.am/db/2669505/Vimpelcom>,
        <https://1145.am/db/2669683/Vimpelcom>,
        <https://1145.am/db/2670639/Vimpelcom>,
        <https://1145.am/db/2670685/Vimpelcom>,
        <https://1145.am/db/2670712/Vimpelcom>,
        <https://1145.am/db/2671812/Vimpelcom>,
        <https://1145.am/db/2671929/Vimpelcom>,
        <https://1145.am/db/2671975/Vimpelcom>,
        <https://1145.am/db/2672959/Vimpelcom>,
        <https://1145.am/db/2673845/Vimpelcom>,
        <https://1145.am/db/2676518/Vimpelcom>,
        <https://1145.am/db/2676527/Vimpelcom>,
        <https://1145.am/db/2676659/Vimpelcom>,
        <https://1145.am/db/2678839/Vimpelcom>,
        <https://1145.am/db/2678849/Vimpelcom>,
        <https://1145.am/db/2683657/Vimpelcom> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2672659/Vimpelcom> a org:Organization ;
    ns1:basedInHighGeoName "Russian Federation" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:basedInHighRaw "Russia" ;
    ns1:description "domestic carrier" ;
    ns1:documentDate "2012-04-19T10:05:01+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor faces fresh fight for VimpelCom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-faces-fresh-fight-for-vimpelcom-0> ;
    ns1:foundName "VimpelCom" ;
    ns1:industry "domestic carrier" ;
    ns1:name "VimpelCom" ;
    ns1:sameAsHigh <https://1145.am/db/1530772/Vimpelcom>,
        <https://1145.am/db/1659276/Vimpelcom>,
        <https://1145.am/db/2141019/Vimpelcom>,
        <https://1145.am/db/2602370/Vimpelcom>,
        <https://1145.am/db/2626593/Vimpelcom>,
        <https://1145.am/db/2652974/Vimpelcom>,
        <https://1145.am/db/2653311/Vimpelcom>,
        <https://1145.am/db/2654657/Vimpelcom>,
        <https://1145.am/db/2659847/Vimpelcom>,
        <https://1145.am/db/2662999/Vimpelcom>,
        <https://1145.am/db/2664167/Vimpelcom>,
        <https://1145.am/db/2664571/Vimpelcom>,
        <https://1145.am/db/2665211/Vimpelcom>,
        <https://1145.am/db/2666405/Vimpelcom>,
        <https://1145.am/db/2666410/Vimpelcom>,
        <https://1145.am/db/2667105/Vimpelcom>,
        <https://1145.am/db/2668411/Vimpelcom>,
        <https://1145.am/db/2671088/Vimpelcom>,
        <https://1145.am/db/2671104/Vimpelcom>,
        <https://1145.am/db/2671481/Vimpelcom>,
        <https://1145.am/db/2672667/Vimpelcom>,
        <https://1145.am/db/2674298/Vimpelcom>,
        <https://1145.am/db/2679855/Vimpelcom>,
        <https://1145.am/db/2680662/Vimpelcom>,
        <https://1145.am/db/2723235/Vimpelcom> ;
    ns1:sameAsMedium <https://1145.am/db/1529511/Vimpelcom>,
        <https://1145.am/db/1656234/Vimpelcom>,
        <https://1145.am/db/1668852/Vimpelcom>,
        <https://1145.am/db/2600327/Vimpelcom>,
        <https://1145.am/db/2602398/Vimpelcom>,
        <https://1145.am/db/2607010/Vimpelcom>,
        <https://1145.am/db/2611520/Vimpelcom>,
        <https://1145.am/db/2625867/Vimpelcom>,
        <https://1145.am/db/2628046/Vimpelcom>,
        <https://1145.am/db/2646871/Vimpelcom>,
        <https://1145.am/db/2646907/Vimpelcom>,
        <https://1145.am/db/2651270/Vimpelcom>,
        <https://1145.am/db/2652389/Vimpelcom>,
        <https://1145.am/db/2652985/Vimpelcom>,
        <https://1145.am/db/2653167/Vimpelcom>,
        <https://1145.am/db/2653171/Vimpelcom>,
        <https://1145.am/db/2653186/Vimpelcom>,
        <https://1145.am/db/2653225/Vimpelcom>,
        <https://1145.am/db/2654675/Vimpelcom>,
        <https://1145.am/db/2655477/Vimpelcom>,
        <https://1145.am/db/2655754/Vimpelcom>,
        <https://1145.am/db/2658492/Vimpelcom>,
        <https://1145.am/db/2659767/Vimpelcom>,
        <https://1145.am/db/2659780/Vimpelcom>,
        <https://1145.am/db/2660593/Vimpelcom>,
        <https://1145.am/db/2661700/Vimpelcom>,
        <https://1145.am/db/2661979/Vimpelcom>,
        <https://1145.am/db/2663844/Vimpelcom>,
        <https://1145.am/db/2663852/Vimpelcom>,
        <https://1145.am/db/2664956/Vimpelcom>,
        <https://1145.am/db/2665182/Vimpelcom>,
        <https://1145.am/db/2665345/Vimpelcom>,
        <https://1145.am/db/2665678/Vimpelcom>,
        <https://1145.am/db/2666025/Vimpelcom>,
        <https://1145.am/db/2666299/Vimpelcom>,
        <https://1145.am/db/2667506/Vimpelcom>,
        <https://1145.am/db/2668429/Vimpelcom>,
        <https://1145.am/db/2669505/Vimpelcom>,
        <https://1145.am/db/2669683/Vimpelcom>,
        <https://1145.am/db/2670639/Vimpelcom>,
        <https://1145.am/db/2670685/Vimpelcom>,
        <https://1145.am/db/2670712/Vimpelcom>,
        <https://1145.am/db/2671812/Vimpelcom>,
        <https://1145.am/db/2671929/Vimpelcom>,
        <https://1145.am/db/2671975/Vimpelcom>,
        <https://1145.am/db/2672959/Vimpelcom>,
        <https://1145.am/db/2673845/Vimpelcom>,
        <https://1145.am/db/2676518/Vimpelcom>,
        <https://1145.am/db/2676527/Vimpelcom>,
        <https://1145.am/db/2676659/Vimpelcom>,
        <https://1145.am/db/2678839/Vimpelcom>,
        <https://1145.am/db/2678849/Vimpelcom>,
        <https://1145.am/db/2683657/Vimpelcom> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2672667/Vimpelcom> a org:Organization ;
    ns1:basedInHighGeoName "Russian Federation" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:basedInHighRaw "Russia" ;
    ns1:description "domestic carrier" ;
    ns1:documentDate "2012-04-19T10:26:52+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Telenor faces fresh fight for VimpelCom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-faces-fresh-fight-for-vimpelcom> ;
    ns1:foundName "VimpelCom" ;
    ns1:industry "domestic carrier" ;
    ns1:name "VimpelCom" ;
    ns1:sameAsHigh <https://1145.am/db/1530772/Vimpelcom>,
        <https://1145.am/db/1659276/Vimpelcom>,
        <https://1145.am/db/2141019/Vimpelcom>,
        <https://1145.am/db/2602370/Vimpelcom>,
        <https://1145.am/db/2626593/Vimpelcom>,
        <https://1145.am/db/2652974/Vimpelcom>,
        <https://1145.am/db/2653311/Vimpelcom>,
        <https://1145.am/db/2654657/Vimpelcom>,
        <https://1145.am/db/2659847/Vimpelcom>,
        <https://1145.am/db/2662999/Vimpelcom>,
        <https://1145.am/db/2664167/Vimpelcom>,
        <https://1145.am/db/2664571/Vimpelcom>,
        <https://1145.am/db/2665211/Vimpelcom>,
        <https://1145.am/db/2666405/Vimpelcom>,
        <https://1145.am/db/2666410/Vimpelcom>,
        <https://1145.am/db/2667105/Vimpelcom>,
        <https://1145.am/db/2668411/Vimpelcom>,
        <https://1145.am/db/2671088/Vimpelcom>,
        <https://1145.am/db/2671104/Vimpelcom>,
        <https://1145.am/db/2671481/Vimpelcom>,
        <https://1145.am/db/2672659/Vimpelcom>,
        <https://1145.am/db/2674298/Vimpelcom>,
        <https://1145.am/db/2679855/Vimpelcom>,
        <https://1145.am/db/2680662/Vimpelcom>,
        <https://1145.am/db/2723235/Vimpelcom> ;
    ns1:sameAsMedium <https://1145.am/db/1529511/Vimpelcom>,
        <https://1145.am/db/1656234/Vimpelcom>,
        <https://1145.am/db/1668852/Vimpelcom>,
        <https://1145.am/db/2600327/Vimpelcom>,
        <https://1145.am/db/2602398/Vimpelcom>,
        <https://1145.am/db/2607010/Vimpelcom>,
        <https://1145.am/db/2611520/Vimpelcom>,
        <https://1145.am/db/2625867/Vimpelcom>,
        <https://1145.am/db/2628046/Vimpelcom>,
        <https://1145.am/db/2646871/Vimpelcom>,
        <https://1145.am/db/2646907/Vimpelcom>,
        <https://1145.am/db/2651270/Vimpelcom>,
        <https://1145.am/db/2652389/Vimpelcom>,
        <https://1145.am/db/2652985/Vimpelcom>,
        <https://1145.am/db/2653167/Vimpelcom>,
        <https://1145.am/db/2653171/Vimpelcom>,
        <https://1145.am/db/2653186/Vimpelcom>,
        <https://1145.am/db/2653225/Vimpelcom>,
        <https://1145.am/db/2654675/Vimpelcom>,
        <https://1145.am/db/2655477/Vimpelcom>,
        <https://1145.am/db/2655754/Vimpelcom>,
        <https://1145.am/db/2658492/Vimpelcom>,
        <https://1145.am/db/2659767/Vimpelcom>,
        <https://1145.am/db/2659780/Vimpelcom>,
        <https://1145.am/db/2660593/Vimpelcom>,
        <https://1145.am/db/2661700/Vimpelcom>,
        <https://1145.am/db/2661979/Vimpelcom>,
        <https://1145.am/db/2663844/Vimpelcom>,
        <https://1145.am/db/2663852/Vimpelcom>,
        <https://1145.am/db/2664956/Vimpelcom>,
        <https://1145.am/db/2665182/Vimpelcom>,
        <https://1145.am/db/2665345/Vimpelcom>,
        <https://1145.am/db/2665678/Vimpelcom>,
        <https://1145.am/db/2666025/Vimpelcom>,
        <https://1145.am/db/2666299/Vimpelcom>,
        <https://1145.am/db/2667506/Vimpelcom>,
        <https://1145.am/db/2668429/Vimpelcom>,
        <https://1145.am/db/2669505/Vimpelcom>,
        <https://1145.am/db/2669683/Vimpelcom>,
        <https://1145.am/db/2670639/Vimpelcom>,
        <https://1145.am/db/2670685/Vimpelcom>,
        <https://1145.am/db/2670712/Vimpelcom>,
        <https://1145.am/db/2671812/Vimpelcom>,
        <https://1145.am/db/2671929/Vimpelcom>,
        <https://1145.am/db/2671975/Vimpelcom>,
        <https://1145.am/db/2672959/Vimpelcom>,
        <https://1145.am/db/2673845/Vimpelcom>,
        <https://1145.am/db/2676518/Vimpelcom>,
        <https://1145.am/db/2676527/Vimpelcom>,
        <https://1145.am/db/2676659/Vimpelcom>,
        <https://1145.am/db/2678839/Vimpelcom>,
        <https://1145.am/db/2678849/Vimpelcom>,
        <https://1145.am/db/2683657/Vimpelcom> ;
    ns1:sourceName "Fierce Wireless" .

<https://1145.am/db/2681282/Investment_Leap_Wireless_Metropcs_T-Mobile_Usa_Verizon_Wireless_Stopped> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-18T15:23:43+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Verizon Wireless (NYSE: VZ) said it will sell all of its 700 MHz Lower A and B Block spectrum in exchange for getting regulatory approval to purchase AWS spectrum from a group of cable companies." ;
    ns1:documentTitle "Verizon: We'll sell 700 MHz spectrum to get cable companies' AWS spectrum" ;
    ns1:documentURL <https://www.fiercewireless.com/wireless/verizon-we-ll-sell-700-mhz-spectrum-to-get-cable-companies-aws-spectrum> ;
    ns1:foundName "purchase",
        "purchasing" ;
    ns1:name "purchase",
        "purchasing" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "stopped" ;
    ns1:target <https://1145.am/db/2681282/Verizon_Wireless> ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "USA" .

<https://1145.am/db/2288967/Histogenics> a org:Organization ;
    ns1:description "tissue engineering" ;
    ns1:documentDate "2012-07-23T23:30:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics reels in $49M Series A for tissue engineering implants" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/histogenics-reels-49m-series-a-for-tissue-engineering-implants> ;
    ns1:foundName "Histogenics" ;
    ns1:industry "tissue engineering" ;
    ns1:name "Histogenics" ;
    ns1:sameAsHigh <https://1145.am/db/2336098/Histogenics> ;
    ns1:sameAsMedium <https://1145.am/db/2292194/Histogenics>,
        <https://1145.am/db/2295860/Histogenics>,
        <https://1145.am/db/2318779/Histogenics_Corporation>,
        <https://1145.am/db/2318807/Histogenics>,
        <https://1145.am/db/2336102/Histogenics_Corporation>,
        <https://1145.am/db/2336109/Histogenics_Corporation>,
        <https://1145.am/db/2336311/Histogenics_Corporation>,
        <https://1145.am/db/2346967/Histogenics_Corp>,
        <https://1145.am/db/2349778/Histogenics_Corporation>,
        <https://1145.am/db/2354294/Histogenics_Corp>,
        <https://1145.am/db/2362578/Histogenics_Corp>,
        <https://1145.am/db/2363710/Histogenics_Corporation>,
        <https://1145.am/db/2364581/Histogenics>,
        <https://1145.am/db/2368340/Histogenics_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336102/Histogenics_Corporation> a org:Organization ;
    ns1:basedInHighGeoName "Waltham" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4954380/about.rdf> ;
    ns1:basedInHighRaw "WALTHAM, Mass." ;
    ns1:description "Regenerative medicine" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "Histogenics",
        "Histogenics Corporation" ;
    ns1:industry "Regenerative medicine" ;
    ns1:name "Histogenics",
        "Histogenics Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/2292194/Histogenics>,
        <https://1145.am/db/2295860/Histogenics>,
        <https://1145.am/db/2336109/Histogenics_Corporation>,
        <https://1145.am/db/2336311/Histogenics_Corporation>,
        <https://1145.am/db/2357626/Histogen>,
        <https://1145.am/db/2357628/Histogen>,
        <https://1145.am/db/2363710/Histogenics_Corporation>,
        <https://1145.am/db/2364581/Histogenics>,
        <https://1145.am/db/2368340/Histogenics_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/2288967/Histogenics>,
        <https://1145.am/db/2318779/Histogenics_Corporation>,
        <https://1145.am/db/2318807/Histogenics>,
        <https://1145.am/db/2336098/Histogenics>,
        <https://1145.am/db/2346967/Histogenics_Corp>,
        <https://1145.am/db/2349778/Histogenics_Corporation>,
        <https://1145.am/db/2354294/Histogenics_Corp>,
        <https://1145.am/db/2362578/Histogenics_Corp> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2336109/Histogenics_Corporation> a org:Organization ;
    ns1:description "Biomedical",
        "Regenerative medicine" ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "Histogenics",
        "Histogenics Corporation" ;
    ns1:industry "Biomedical",
        "Regenerative medicine" ;
    ns1:name "Histogenics",
        "Histogenics Corporation" ;
    ns1:sameAsHigh <https://1145.am/db/2292194/Histogenics>,
        <https://1145.am/db/2295860/Histogenics>,
        <https://1145.am/db/2336102/Histogenics_Corporation>,
        <https://1145.am/db/2336311/Histogenics_Corporation>,
        <https://1145.am/db/2357626/Histogen>,
        <https://1145.am/db/2357628/Histogen>,
        <https://1145.am/db/2363710/Histogenics_Corporation>,
        <https://1145.am/db/2364581/Histogenics>,
        <https://1145.am/db/2368340/Histogenics_Corporation> ;
    ns1:sameAsMedium <https://1145.am/db/2288967/Histogenics>,
        <https://1145.am/db/2318779/Histogenics_Corporation>,
        <https://1145.am/db/2318807/Histogenics>,
        <https://1145.am/db/2336098/Histogenics>,
        <https://1145.am/db/2346967/Histogenics_Corp>,
        <https://1145.am/db/2349778/Histogenics_Corporation>,
        <https://1145.am/db/2354294/Histogenics_Corp>,
        <https://1145.am/db/2362578/Histogenics_Corp> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2343206/Series_C_Investment_Delphi_Ventures_Domain_Associates_Sequent_Medical_Us_Venture_Partners_Versant_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-07T16:52:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "ALISO VIEJO, Calif., March 6, 2012 /PRNewswire/ - Sequent Medical, Inc. announced today that it has closed a $ 26.0 million Series C venture capital financing.",
        "Sequent Medical Announces Closing of $ 26.0 Million Venture Financing." ;
    ns1:documentTitle "Sequent Medical Announces Closing of $26.0 Million Venture Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sequent-medical-announces-closing-of-26-0-million-venture-financing> ;
    ns1:foundName "capital",
        "financing" ;
    ns1:name "capital",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2343206/Sequent_Medical> ;
    ns1:targetDetails "Series C",
        "Venture" ;
    ns1:valueRaw "$ 26.0 Million",
        "$ 26.0 million" ;
    ns1:when "2012-03-06T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "March 6, 2012" ;
    ns1:whereGeoName "Aliso Viejo" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5323163/about.rdf> ;
    ns1:whereRaw "ALISO VIEJO" .

<https://1145.am/db/2344256/Investment_Kala_Pharmaceuticals_Lighthouse_Capital_Partners_Lux_Capital_Polaris_Venture_Partners_Third_Rock_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-14T12:43:49+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Kala Pharmaceuticals Secures $ 6.2 Million in Additional Equity Financing.",
        "WALTHAM, Mass.- (BUSINESS WIRE) -Kala Pharmaceuticals, Inc., developer of treatments for diseases that affect mucosal tissues, announced today that it raised $ 6.2M in additional equity financing from existing venture investors Lux Capital, Polaris Venture Partners, Third Rock Ventures, and Lighthouse Capital Partners." ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing-0> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2344256/Kala_Pharmaceuticals> ;
    ns1:valueRaw "$ 6.2 Million",
        "$ 6.2M" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2345224/Investment_Kala_Pharmaceuticals_Lighthouse_Capital_Partners_Lux_Capital_Polaris_Venture_Partners_Third_Rock_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-14T14:02:53+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Kala Pharmaceuticals Secures $ 6.2 Million in Additional Equity Financing.",
        "WALTHAM, Mass., Mar 14, 2012 (BUSINESS WIRE) - Kala Pharmaceuticals, Inc., developer of treatments for diseases that affect mucosal tissues, announced today that it raised $ 6.2M in additional equity financing from existing venture investors Lux Capital, Polaris Venture Partners, Third Rock Ventures, and Lighthouse Capital Partners." ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing> ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2345224/Kala_Pharmaceuticals> ;
    ns1:valueRaw "$ 11.2M",
        "$ 6.2 Million",
        "$ 6.2M" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2348356/Series_B_Investment_Atmi_Boehringer_Ingelheim_Mitsui_Global_Investment_Promethera_Biosciences_Sambrinvest_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-28T15:57:09+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Belgian cell therapy company Promethera Biosciences, has raised 23.6 million euros ($ 31.4 million) in Series B round of investment.",
        "Promethera Biosciences Raises $ 31.4m in Series B.",
        "Promethera Biosciences, the Belgian cell therapy company operating in the field of liver diseases, completed today an exceptional fundraising round that generated 23.6 million euros ($ 31.4 million) , including 17 million euros in capital." ;
    ns1:documentTitle "Promethera Biosciences Raises $31.4m in Series B" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promethera-biosciences-raises-31-4m-series-b> ;
    ns1:foundName "Raises",
        "fundraising",
        "investment" ;
    ns1:name "Raises",
        "fundraising",
        "investment" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2348356/Promethera_Biosciences> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 31.4 million",
        "$ 31.4m",
        "17 million euros",
        "23.6 million euros" ;
    ns1:whereRaw "Belgian" .

<https://1145.am/db/2359864/Series_C_Investment_5am_Ventures_Igenica_Orbimed_Advisors_The_Column_Group_Third_Rock_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-12T14:59:53+00:00"^^xsd:dateTime ;
    ns1:documentExtract "BURLINGAME, Calif., June 12, 2012 /PRNewswire via COMTEX/ - Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $ 33 million in a Series C round of funding.",
        "Igenica Closes $ 33 Million in Series C Funding." ;
    ns1:documentTitle "Igenica Closes $33 Million in Series C Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/igenica-closes-33-million-series-c-funding> ;
    ns1:foundName "Funding",
        "funding",
        "raised" ;
    ns1:name "Funding",
        "funding",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2359864/Igenica> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 33 Million",
        "$ 33 million" ;
    ns1:when "2012-06-12T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "June 12, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2359873/Series_B_Investment_Ipsen_Mpm_Capital_New_Enterprise_Associates_Rhythm_Third_Rock_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-13T11:26:04+00:00"^^xsd:dateTime ;
    ns1:documentExtract "BOSTON, June 13, 2012- Rhythm announced today that it has raised $ 25 million in a Series B financing round.",
        "Rhythm Raises $ 25M in Series B Financing for Diabetes and Obesity Therapeutics." ;
    ns1:documentTitle "Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/rhythm-raises-25m-series-b-financing-for-diabetes-and-obesity-therapeutics> ;
    ns1:foundName "financing",
        "raised" ;
    ns1:name "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2359873/Rhythm> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 25 million",
        "$ 25M",
        "$ 65 million" ;
    ns1:when "2012-06-13T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "June 13, 2012" ;
    ns1:whereGeoName "Boston" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/4930956/about.rdf> ;
    ns1:whereRaw "BOSTON" .

<https://1145.am/db/2360922/Investment_Industrifonden_Nuevolution_A_S_Seb_Utvecklingsstiftelse_Seb_Venture_Capital_Sunstone_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-19T12:13:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Copenhagen, Denmark, June 19, 2012 / B3C newswire / - Nuevolution A/S, a leading small molecule lead discovery company, today announced that the company has raised DKK 80.5 million in a new financing round.",
        "Nuevolution A/S Raises € 11 Million in New Financing Round." ;
    ns1:documentTitle "Nuevolution A/S Raises € 11 Million in New Financing Round" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/nuevolution-a-s-raises-%E2%82%AC-11-million-new-financing-round> ;
    ns1:foundName "Raises",
        "financing",
        "raised" ;
    ns1:name "Raises",
        "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2360922/Nuevolution_A_S> ;
    ns1:valueRaw "DKK 80.5 million",
        "€ 11 Million" ;
    ns1:when "2012-06-19T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "19 June 2012",
        "June 19, 2012" ;
    ns1:whereGeoName "Kingdom of Denmark" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2623032/about.rdf> ;
    ns1:whereRaw "Denmark" .

<https://1145.am/db/2363938/Series_C_Investment_Eclosion_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Vesalius_Biocapital_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-08T20:26:55+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Geneva, Switzerland and Archamps, France, July 9, 2012 - Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the closing of a CHF25 million (USD26 million) extension to its Series C financing.",
        "Genkyotex Raises CHF25 Million in Series C Round Extension." ;
    ns1:documentTitle "Genkyotex Raises CHF25 Million in Series C Round Extension" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/genkyotex-raises-chf25-million-series-c-round-extension> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2363938/Genkyotex> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "CHF25 Million",
        "CHF25 million",
        "USD26 million" ;
    ns1:whereGeoName "Switzerland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:whereRaw "Switzerland" .

<https://1145.am/db/2363950/Equity_Investment_Imperial_Innovations_Group_Invesco_Perpetual_Lundbeckfond_Ventures_Psioxus_Therapeutics_Ltd_Sr_One_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-09T16:23:02+00:00"^^xsd:dateTime ;
    ns1:documentExtract "LONDON, Jul 09, 2012 (BUSINESS WIRE) - PsiOxus Therapeutics, Ltd. (PsiOxus) announced that it has closed a Series B round of equity financing totaling GBP 22 million ($ 34 million) .",
        "PsiOxus Therapeutics Secures GBP 22 Million ($ 34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine." ;
    ns1:documentTitle "PsiOxus Therapeutics Secures GBP 22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/psioxus-therapeutics-secures-gbp-22-million-34-million-series-b-financing-to-drive-clinical> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2363950/Psioxus_Therapeutics_Ltd> ;
    ns1:targetDetails "Series B",
        "equity" ;
    ns1:valueRaw "$ 34 Million",
        "$ 34 million",
        "GBP 22 Million",
        "GBP 22 million" ;
    ns1:when "2012-07-09T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2012-Jul-09" ;
    ns1:whereGeoName "London" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2643743/about.rdf> ;
    ns1:whereRaw "LONDON" .

<https://1145.am/db/2364853/Series_B_Investment_Ascent_Biomedical_Ventures_Coferon_Inc_Hatteras_Venture_Partners_Medimmune_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-18T15:46:32+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Coferon, Inc. Announces $ 12 Million Series B Financing.",
        "STONY BROOK, NY, Jul 16, 2012 (MARKETWIRE via COMTEX) - Coferon Inc., a privately held, New York - based biotechnology company, today announced that it has closed on a $ 12 million Series B financing round led by a trio of new venture investors: Hatteras Venture Partners of Durham, N.C.; MedImmune Ventures of Gaithersburg, MD (the corporate venture arm of AstraZeneca Ltd) ; and Ascent Biomedical Ventures of New York, N.Y." ;
    ns1:documentTitle "Coferon, Inc. Announces $12 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/coferon-inc-announces-12-million-series-b-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2364853/Coferon_Inc> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 12 Million",
        "$ 12 million" ;
    ns1:when "2012-07-16T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "2012-Jul-16" ;
    ns1:whereGeoName "New York City" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5128581/about.rdf> ;
    ns1:whereRaw "New York" .

<https://1145.am/db/2672659/Vimpelcom_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2012-04-19T10:05:01+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Russia's competition authority is challenging Telenor's acquisition of a leading stake in domestic carrier VimpelCom, filing a claim in Moscow's commercial court against the move.",
        "The Federal Antimonopoly Service of the Russian Federation (FAS) is seeking to invalidate the sale of VimpelCom shares to Telenor by Weather Investments in February, claiming the deal violates Russia's Strategic Investment Law." ;
    ns1:documentTitle "Telenor faces fresh fight for VimpelCom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-faces-fresh-fight-for-vimpelcom-0> ;
    ns1:foundName "acquisition",
        "sale" ;
    ns1:name "acquisition",
        "sale" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "stopped" ;
    ns1:target <https://1145.am/db/2672659/Vimpelcom> ;
    ns1:targetName "VimpelCom" ;
    ns1:whenRaw "February" ;
    ns1:whereGeoName "Russian Federation" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:whereRaw "Russia" .

<https://1145.am/db/2672667/Vimpelcom_Acquisition> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2012-04-19T10:26:52+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Russia's competition authority is challenging Telenor's acquisition of a leading stake in domestic carrier VimpelCom, filing a claim in Moscow's commercial court against the move.",
        "The Federal Antimonopoly Service of the Russian Federation (FAS) is seeking to invalidate the sale of VimpelCom shares to Telenor by Weather Investments in February, claiming the deal violates Russia's Strategic Investment Law." ;
    ns1:documentTitle "Telenor faces fresh fight for VimpelCom" ;
    ns1:documentURL <https://www.fiercewireless.com/europe/telenor-faces-fresh-fight-for-vimpelcom> ;
    ns1:foundName "acquisition",
        "sale" ;
    ns1:name "acquisition",
        "sale" ;
    ns1:sourceName "Fierce Wireless" ;
    ns1:status "stopped" ;
    ns1:target <https://1145.am/db/2672667/Vimpelcom> ;
    ns1:targetName "VimpelCom" ;
    ns1:whenRaw "February" ;
    ns1:whereGeoName "Russian Federation" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2017370/about.rdf> ;
    ns1:whereRaw "Russia" .

<https://1145.am/db/2336098/Histogenics> a org:Organization ;
    ns1:basedInHighGeoName "Waltham" ;
    ns1:basedInHighGeoNameRDF <https://sws.geonames.org/4954380/about.rdf> ;
    ns1:basedInHighRaw "Waltham, MA" ;
    ns1:description "tissue engineering" ;
    ns1:documentDate "2012-07-24T12:13:57+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Histogenics reels in $49M Series A for tissue engineering implants" ;
    ns1:documentURL <https://www.fiercebiotech.com/regulatory/histogenics-reels-49m-series-a-for-tissue-engineering-implants> ;
    ns1:foundName "Histogenics" ;
    ns1:industry "tissue engineering" ;
    ns1:name "Histogenics" ;
    ns1:sameAsHigh <https://1145.am/db/2288967/Histogenics> ;
    ns1:sameAsMedium <https://1145.am/db/2292194/Histogenics>,
        <https://1145.am/db/2295860/Histogenics>,
        <https://1145.am/db/2318779/Histogenics_Corporation>,
        <https://1145.am/db/2318807/Histogenics>,
        <https://1145.am/db/2336102/Histogenics_Corporation>,
        <https://1145.am/db/2336109/Histogenics_Corporation>,
        <https://1145.am/db/2336311/Histogenics_Corporation>,
        <https://1145.am/db/2346967/Histogenics_Corp>,
        <https://1145.am/db/2349778/Histogenics_Corporation>,
        <https://1145.am/db/2354294/Histogenics_Corp>,
        <https://1145.am/db/2362578/Histogenics_Corp>,
        <https://1145.am/db/2363710/Histogenics_Corporation>,
        <https://1145.am/db/2364581/Histogenics>,
        <https://1145.am/db/2368340/Histogenics_Corporation> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2337974/Third_Rock_Ventures> a org:Organization ;
    ns1:basedInLowRaw "SAN FRANCISCO" ;
    ns1:description "venture capital" ;
    ns1:documentDate "2012-07-31T14:27:45+00:00"^^xsd:dateTime ;
    ns1:documentTitle "CytomX Therapeutics Expands Series B Financing; Canaan Partners Joins Syndicate" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/cytomx-therapeutics-expands-series-b-financing-canaan-partners-joins-syndicate> ;
    ns1:foundName "Third Rock Ventures" ;
    ns1:investor <https://1145.am/db/2337974/Series_B_Investment_Canaan_Partners_Cytomx_Therapeutics_Roche_Venture_Fund_Third_Rock_Ventures_Has_Not_Happened> ;
    ns1:name "Third Rock Ventures" ;
    ns1:sameAsHigh <https://1145.am/db/1042269/Third_Rock_Ventures>,
        <https://1145.am/db/1352190/Third_Prime_Ventures>,
        <https://1145.am/db/1412391/Third_Point_Ventures>,
        <https://1145.am/db/1739929/K3_Ventures>,
        <https://1145.am/db/1753054/Third_Point_Ventures>,
        <https://1145.am/db/1765385/K3_Ventures>,
        <https://1145.am/db/1928208/Third_Rock_Ventures>,
        <https://1145.am/db/2303251/Third_Rock_Ventures>,
        <https://1145.am/db/2303257/Third_Rock_Ventures>,
        <https://1145.am/db/2311551/Third_Rock_Ventures>,
        <https://1145.am/db/2335750/Third_Rock_Ventures>,
        <https://1145.am/db/2337555/Third_Rock_Ventures>,
        <https://1145.am/db/2337559/Third_Rock_Ventures>,
        <https://1145.am/db/2338625/Third_Rock_Ventures>,
        <https://1145.am/db/2341792/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2355043/Third_Rock_Ventures>,
        <https://1145.am/db/2359334/Third_Rock_Ventures>,
        <https://1145.am/db/2362102/Third_Rock_Ventures>,
        <https://1145.am/db/2362128/Third_Rock_Ventures>,
        <https://1145.am/db/2580088/Third_Rock_Ventures>,
        <https://1145.am/db/441151/Third_Rock_Ventures>,
        <https://1145.am/db/620653/K3_Ventures>,
        <https://1145.am/db/633929/Trilogy_Equity_Partners>,
        <https://1145.am/db/773235/Third_Point_Ventures>,
        <https://1145.am/db/866101/Third_Point_Ventures> ;
    ns1:sameAsMedium <https://1145.am/db/1086582/Third_Rock_Ventures>,
        <https://1145.am/db/1089269/Third_Rock_Ventures>,
        <https://1145.am/db/1325987/Third_Rock_Ventures>,
        <https://1145.am/db/1326547/Third_Rock_Ventures>,
        <https://1145.am/db/1503058/Third_Rock_Ventures>,
        <https://1145.am/db/159801/Third_Rock_Ventures>,
        <https://1145.am/db/2095032/Third_Rock_Ventures>,
        <https://1145.am/db/2152566/Third_Rock_Ventures>,
        <https://1145.am/db/2153763/Third_Rock_Ventures>,
        <https://1145.am/db/2281272/Third_Rock_Ventures>,
        <https://1145.am/db/2291199/Third_Rock_Ventures>,
        <https://1145.am/db/2291940/Third_Rock_Ventures>,
        <https://1145.am/db/2294789/Third_Rock_Ventures>,
        <https://1145.am/db/2298193/Third_Rock_Ventures>,
        <https://1145.am/db/2298844/Third_Rock_Ventures>,
        <https://1145.am/db/2300971/Third_Rock_Ventures>,
        <https://1145.am/db/2303250/Third_Rock_Ventures>,
        <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2315931/Third_Rock_Ventures>,
        <https://1145.am/db/2315933/Third_Rock_Ventures>,
        <https://1145.am/db/2322522/Third_Rock_Ventures>,
        <https://1145.am/db/2322531/Third_Rock_Ventures>,
        <https://1145.am/db/2327474/Third_Rock_Ventures>,
        <https://1145.am/db/2335531/Third_Rock_Ventures>,
        <https://1145.am/db/2335755/Third_Rock_Ventures>,
        <https://1145.am/db/2336126/Third_Rock_Ventures>,
        <https://1145.am/db/2337889/Third_Rock_Ventures>,
        <https://1145.am/db/2337958/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2339127/Third_Rock_Ventures>,
        <https://1145.am/db/2339128/Third_Rock_Ventures>,
        <https://1145.am/db/2339413/Third_Rock_Ventures>,
        <https://1145.am/db/2339704/Third_Rock_Ventures>,
        <https://1145.am/db/2339925/Third_Rock_Ventures>,
        <https://1145.am/db/2339926/Third_Rock_Ventures>,
        <https://1145.am/db/2341662/Third_Rock_Ventures>,
        <https://1145.am/db/2342754/Third_Rock_Ventures>,
        <https://1145.am/db/2342768/Third_Rock_Ventures>,
        <https://1145.am/db/2342771/Third_Rock_Ventures>,
        <https://1145.am/db/2344256/Third_Rock_Ventures>,
        <https://1145.am/db/2344912/Third_Rock_Ventures>,
        <https://1145.am/db/2344918/Third_Rock_Ventures>,
        <https://1145.am/db/2345224/Third_Rock_Ventures>,
        <https://1145.am/db/2346212/Third_Rock_Ventures>,
        <https://1145.am/db/2346216/Third_Rock_Ventures>,
        <https://1145.am/db/2346988/Third_Rock_Ventures>,
        <https://1145.am/db/2347885/Third_Rock_Ventures>,
        <https://1145.am/db/2350364/Third_Rock_Ventures>,
        <https://1145.am/db/2351009/Third_Rock_Ventures>,
        <https://1145.am/db/2351011/Third_Rock_Ventures>,
        <https://1145.am/db/2351348/Third_Rock_Ventures>,
        <https://1145.am/db/2351372/Third_Rock_Ventures>,
        <https://1145.am/db/2351520/Third_Rock_Ventures>,
        <https://1145.am/db/2351644/Third_Rock_Ventures>,
        <https://1145.am/db/2354307/Third_Rock_Ventures>,
        <https://1145.am/db/2354314/Third_Rock_Ventures>,
        <https://1145.am/db/2354608/Third_Rock_Ventures>,
        <https://1145.am/db/2354613/Third_Rock_Ventures>,
        <https://1145.am/db/2357253/Third_Rock_Ventures>,
        <https://1145.am/db/2357256/Third_Rock_Ventures>,
        <https://1145.am/db/2357722/Third_Rock_Ventures>,
        <https://1145.am/db/2358551/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2359321/Third_Rock_Ventures>,
        <https://1145.am/db/2359447/Third_Rock_Ventures>,
        <https://1145.am/db/2359575/Third_Rock_Ventures>,
        <https://1145.am/db/2359818/Third_Rock_Ventures>,
        <https://1145.am/db/2359864/Third_Rock_Ventures>,
        <https://1145.am/db/2359873/Third_Rock_Ventures>,
        <https://1145.am/db/2359875/Third_Rock_Ventures>,
        <https://1145.am/db/2359887/Third_Rock_Ventures>,
        <https://1145.am/db/2359984/Third_Rock_Ventures>,
        <https://1145.am/db/2359987/Third_Rock_Ventures>,
        <https://1145.am/db/2360006/Third_Rock_Ventures>,
        <https://1145.am/db/2360169/Third_Rock_Ventures>,
        <https://1145.am/db/2360814/Third_Rock_Ventures>,
        <https://1145.am/db/2360877/Third_Rock_Ventures>,
        <https://1145.am/db/2362109/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2364240/Third_Rock_Ventures>,
        <https://1145.am/db/2364249/Third_Rock_Ventures>,
        <https://1145.am/db/2364255/Third_Rock_Ventures>,
        <https://1145.am/db/2364283/Third_Rock_Ventures>,
        <https://1145.am/db/2364481/Third_Rock_Ventures>,
        <https://1145.am/db/2365109/Third_Rock_Ventures>,
        <https://1145.am/db/2365111/Third_Rock_Ventures>,
        <https://1145.am/db/2365315/Third_Rock_Ventures>,
        <https://1145.am/db/2366539/Third_Rock_Ventures>,
        <https://1145.am/db/2366641/Third_Rock_Ventures>,
        <https://1145.am/db/2367442/Third_Rock_Ventures>,
        <https://1145.am/db/2367448/Third_Rock_Ventures>,
        <https://1145.am/db/2368166/Third_Rock_Ventures>,
        <https://1145.am/db/2368501/Third_Rock_Ventures>,
        <https://1145.am/db/2369130/Third_Rock_Ventures>,
        <https://1145.am/db/2369202/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2371191/Third_Rock_Ventures>,
        <https://1145.am/db/2584533/Third_Rock_Ventures>,
        <https://1145.am/db/572554/Third_Rock_Ventures>,
        <https://1145.am/db/768794/Third_Rock_Ventures>,
        <https://1145.am/db/769408/Third_Rock_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2344256/Third_Rock_Ventures> a org:Organization ;
    ns1:basedInLowRaw "WALTHAM" ;
    ns1:documentDate "2012-03-14T12:43:49+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing-0> ;
    ns1:foundName "Third Rock Ventures" ;
    ns1:investor <https://1145.am/db/2344256/Investment_Kala_Pharmaceuticals_Lighthouse_Capital_Partners_Lux_Capital_Polaris_Venture_Partners_Third_Rock_Ventures_Completed> ;
    ns1:name "Third Rock Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Third_Rock_Ventures>,
        <https://1145.am/db/1086582/Third_Rock_Ventures>,
        <https://1145.am/db/1089269/Third_Rock_Ventures>,
        <https://1145.am/db/1325987/Third_Rock_Ventures>,
        <https://1145.am/db/1326547/Third_Rock_Ventures>,
        <https://1145.am/db/1503058/Third_Rock_Ventures>,
        <https://1145.am/db/159801/Third_Rock_Ventures>,
        <https://1145.am/db/1928208/Third_Rock_Ventures>,
        <https://1145.am/db/2095032/Third_Rock_Ventures>,
        <https://1145.am/db/2152566/Third_Rock_Ventures>,
        <https://1145.am/db/2153763/Third_Rock_Ventures>,
        <https://1145.am/db/2281272/Third_Rock_Ventures>,
        <https://1145.am/db/2291199/Third_Rock_Ventures>,
        <https://1145.am/db/2291940/Third_Rock_Ventures>,
        <https://1145.am/db/2294789/Third_Rock_Ventures>,
        <https://1145.am/db/2298193/Third_Rock_Ventures>,
        <https://1145.am/db/2298844/Third_Rock_Ventures>,
        <https://1145.am/db/2300971/Third_Rock_Ventures>,
        <https://1145.am/db/2303250/Third_Rock_Ventures>,
        <https://1145.am/db/2303251/Third_Rock_Ventures>,
        <https://1145.am/db/2303257/Third_Rock_Ventures>,
        <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2311551/Third_Rock_Ventures>,
        <https://1145.am/db/2315931/Third_Rock_Ventures>,
        <https://1145.am/db/2315933/Third_Rock_Ventures>,
        <https://1145.am/db/2322522/Third_Rock_Ventures>,
        <https://1145.am/db/2322531/Third_Rock_Ventures>,
        <https://1145.am/db/2327474/Third_Rock_Ventures>,
        <https://1145.am/db/2335531/Third_Rock_Ventures>,
        <https://1145.am/db/2335750/Third_Rock_Ventures>,
        <https://1145.am/db/2335755/Third_Rock_Ventures>,
        <https://1145.am/db/2336126/Third_Rock_Ventures>,
        <https://1145.am/db/2337555/Third_Rock_Ventures>,
        <https://1145.am/db/2337559/Third_Rock_Ventures>,
        <https://1145.am/db/2337889/Third_Rock_Ventures>,
        <https://1145.am/db/2337958/Third_Rock_Ventures>,
        <https://1145.am/db/2337974/Third_Rock_Ventures>,
        <https://1145.am/db/2338625/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2339127/Third_Rock_Ventures>,
        <https://1145.am/db/2339128/Third_Rock_Ventures>,
        <https://1145.am/db/2339413/Third_Rock_Ventures>,
        <https://1145.am/db/2339704/Third_Rock_Ventures>,
        <https://1145.am/db/2339925/Third_Rock_Ventures>,
        <https://1145.am/db/2339926/Third_Rock_Ventures>,
        <https://1145.am/db/2341662/Third_Rock_Ventures>,
        <https://1145.am/db/2341792/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2342754/Third_Rock_Ventures>,
        <https://1145.am/db/2342768/Third_Rock_Ventures>,
        <https://1145.am/db/2342771/Third_Rock_Ventures>,
        <https://1145.am/db/2344912/Third_Rock_Ventures>,
        <https://1145.am/db/2344918/Third_Rock_Ventures>,
        <https://1145.am/db/2345224/Third_Rock_Ventures>,
        <https://1145.am/db/2346212/Third_Rock_Ventures>,
        <https://1145.am/db/2346216/Third_Rock_Ventures>,
        <https://1145.am/db/2346988/Third_Rock_Ventures>,
        <https://1145.am/db/2347885/Third_Rock_Ventures>,
        <https://1145.am/db/2350364/Third_Rock_Ventures>,
        <https://1145.am/db/2351009/Third_Rock_Ventures>,
        <https://1145.am/db/2351011/Third_Rock_Ventures>,
        <https://1145.am/db/2351348/Third_Rock_Ventures>,
        <https://1145.am/db/2351372/Third_Rock_Ventures>,
        <https://1145.am/db/2351520/Third_Rock_Ventures>,
        <https://1145.am/db/2351644/Third_Rock_Ventures>,
        <https://1145.am/db/2354307/Third_Rock_Ventures>,
        <https://1145.am/db/2354314/Third_Rock_Ventures>,
        <https://1145.am/db/2354608/Third_Rock_Ventures>,
        <https://1145.am/db/2354613/Third_Rock_Ventures>,
        <https://1145.am/db/2355043/Third_Rock_Ventures>,
        <https://1145.am/db/2357253/Third_Rock_Ventures>,
        <https://1145.am/db/2357256/Third_Rock_Ventures>,
        <https://1145.am/db/2357722/Third_Rock_Ventures>,
        <https://1145.am/db/2358551/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2359321/Third_Rock_Ventures>,
        <https://1145.am/db/2359334/Third_Rock_Ventures>,
        <https://1145.am/db/2359447/Third_Rock_Ventures>,
        <https://1145.am/db/2359575/Third_Rock_Ventures>,
        <https://1145.am/db/2359818/Third_Rock_Ventures>,
        <https://1145.am/db/2359864/Third_Rock_Ventures>,
        <https://1145.am/db/2359873/Third_Rock_Ventures>,
        <https://1145.am/db/2359875/Third_Rock_Ventures>,
        <https://1145.am/db/2359887/Third_Rock_Ventures>,
        <https://1145.am/db/2359984/Third_Rock_Ventures>,
        <https://1145.am/db/2359987/Third_Rock_Ventures>,
        <https://1145.am/db/2360006/Third_Rock_Ventures>,
        <https://1145.am/db/2360169/Third_Rock_Ventures>,
        <https://1145.am/db/2360814/Third_Rock_Ventures>,
        <https://1145.am/db/2360877/Third_Rock_Ventures>,
        <https://1145.am/db/2362102/Third_Rock_Ventures>,
        <https://1145.am/db/2362109/Third_Rock_Ventures>,
        <https://1145.am/db/2362128/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2364240/Third_Rock_Ventures>,
        <https://1145.am/db/2364249/Third_Rock_Ventures>,
        <https://1145.am/db/2364255/Third_Rock_Ventures>,
        <https://1145.am/db/2364283/Third_Rock_Ventures>,
        <https://1145.am/db/2364481/Third_Rock_Ventures>,
        <https://1145.am/db/2365109/Third_Rock_Ventures>,
        <https://1145.am/db/2365111/Third_Rock_Ventures>,
        <https://1145.am/db/2365315/Third_Rock_Ventures>,
        <https://1145.am/db/2366539/Third_Rock_Ventures>,
        <https://1145.am/db/2366641/Third_Rock_Ventures>,
        <https://1145.am/db/2367442/Third_Rock_Ventures>,
        <https://1145.am/db/2367448/Third_Rock_Ventures>,
        <https://1145.am/db/2368166/Third_Rock_Ventures>,
        <https://1145.am/db/2368501/Third_Rock_Ventures>,
        <https://1145.am/db/2369130/Third_Rock_Ventures>,
        <https://1145.am/db/2369202/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2371191/Third_Rock_Ventures>,
        <https://1145.am/db/2580088/Third_Rock_Ventures>,
        <https://1145.am/db/2584533/Third_Rock_Ventures>,
        <https://1145.am/db/441151/Third_Rock_Ventures>,
        <https://1145.am/db/572554/Third_Rock_Ventures>,
        <https://1145.am/db/768794/Third_Rock_Ventures>,
        <https://1145.am/db/769408/Third_Rock_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2345224/Third_Rock_Ventures> a org:Organization ;
    ns1:basedInLowRaw "WALTHAM" ;
    ns1:documentDate "2012-03-14T14:02:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Kala Pharmaceuticals Secures $6.2 Million in Additional Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/kala-pharmaceuticals-secures-6-2-million-additional-equity-financing> ;
    ns1:foundName "Third Rock Ventures" ;
    ns1:investor <https://1145.am/db/2345224/Investment_Kala_Pharmaceuticals_Lighthouse_Capital_Partners_Lux_Capital_Polaris_Venture_Partners_Third_Rock_Ventures_Completed> ;
    ns1:name "Third Rock Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Third_Rock_Ventures>,
        <https://1145.am/db/1086582/Third_Rock_Ventures>,
        <https://1145.am/db/1089269/Third_Rock_Ventures>,
        <https://1145.am/db/1325987/Third_Rock_Ventures>,
        <https://1145.am/db/1326547/Third_Rock_Ventures>,
        <https://1145.am/db/1503058/Third_Rock_Ventures>,
        <https://1145.am/db/159801/Third_Rock_Ventures>,
        <https://1145.am/db/1928208/Third_Rock_Ventures>,
        <https://1145.am/db/2095032/Third_Rock_Ventures>,
        <https://1145.am/db/2152566/Third_Rock_Ventures>,
        <https://1145.am/db/2153763/Third_Rock_Ventures>,
        <https://1145.am/db/2281272/Third_Rock_Ventures>,
        <https://1145.am/db/2291199/Third_Rock_Ventures>,
        <https://1145.am/db/2291940/Third_Rock_Ventures>,
        <https://1145.am/db/2294789/Third_Rock_Ventures>,
        <https://1145.am/db/2298193/Third_Rock_Ventures>,
        <https://1145.am/db/2298844/Third_Rock_Ventures>,
        <https://1145.am/db/2300971/Third_Rock_Ventures>,
        <https://1145.am/db/2303250/Third_Rock_Ventures>,
        <https://1145.am/db/2303251/Third_Rock_Ventures>,
        <https://1145.am/db/2303257/Third_Rock_Ventures>,
        <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2311551/Third_Rock_Ventures>,
        <https://1145.am/db/2315931/Third_Rock_Ventures>,
        <https://1145.am/db/2315933/Third_Rock_Ventures>,
        <https://1145.am/db/2322522/Third_Rock_Ventures>,
        <https://1145.am/db/2322531/Third_Rock_Ventures>,
        <https://1145.am/db/2327474/Third_Rock_Ventures>,
        <https://1145.am/db/2335531/Third_Rock_Ventures>,
        <https://1145.am/db/2335750/Third_Rock_Ventures>,
        <https://1145.am/db/2335755/Third_Rock_Ventures>,
        <https://1145.am/db/2336126/Third_Rock_Ventures>,
        <https://1145.am/db/2337555/Third_Rock_Ventures>,
        <https://1145.am/db/2337559/Third_Rock_Ventures>,
        <https://1145.am/db/2337889/Third_Rock_Ventures>,
        <https://1145.am/db/2337958/Third_Rock_Ventures>,
        <https://1145.am/db/2337974/Third_Rock_Ventures>,
        <https://1145.am/db/2338625/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2339127/Third_Rock_Ventures>,
        <https://1145.am/db/2339128/Third_Rock_Ventures>,
        <https://1145.am/db/2339413/Third_Rock_Ventures>,
        <https://1145.am/db/2339704/Third_Rock_Ventures>,
        <https://1145.am/db/2339925/Third_Rock_Ventures>,
        <https://1145.am/db/2339926/Third_Rock_Ventures>,
        <https://1145.am/db/2341662/Third_Rock_Ventures>,
        <https://1145.am/db/2341792/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2342754/Third_Rock_Ventures>,
        <https://1145.am/db/2342768/Third_Rock_Ventures>,
        <https://1145.am/db/2342771/Third_Rock_Ventures>,
        <https://1145.am/db/2344256/Third_Rock_Ventures>,
        <https://1145.am/db/2344912/Third_Rock_Ventures>,
        <https://1145.am/db/2344918/Third_Rock_Ventures>,
        <https://1145.am/db/2346212/Third_Rock_Ventures>,
        <https://1145.am/db/2346216/Third_Rock_Ventures>,
        <https://1145.am/db/2346988/Third_Rock_Ventures>,
        <https://1145.am/db/2347885/Third_Rock_Ventures>,
        <https://1145.am/db/2350364/Third_Rock_Ventures>,
        <https://1145.am/db/2351009/Third_Rock_Ventures>,
        <https://1145.am/db/2351011/Third_Rock_Ventures>,
        <https://1145.am/db/2351348/Third_Rock_Ventures>,
        <https://1145.am/db/2351372/Third_Rock_Ventures>,
        <https://1145.am/db/2351520/Third_Rock_Ventures>,
        <https://1145.am/db/2351644/Third_Rock_Ventures>,
        <https://1145.am/db/2354307/Third_Rock_Ventures>,
        <https://1145.am/db/2354314/Third_Rock_Ventures>,
        <https://1145.am/db/2354608/Third_Rock_Ventures>,
        <https://1145.am/db/2354613/Third_Rock_Ventures>,
        <https://1145.am/db/2355043/Third_Rock_Ventures>,
        <https://1145.am/db/2357253/Third_Rock_Ventures>,
        <https://1145.am/db/2357256/Third_Rock_Ventures>,
        <https://1145.am/db/2357722/Third_Rock_Ventures>,
        <https://1145.am/db/2358551/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2359321/Third_Rock_Ventures>,
        <https://1145.am/db/2359334/Third_Rock_Ventures>,
        <https://1145.am/db/2359447/Third_Rock_Ventures>,
        <https://1145.am/db/2359575/Third_Rock_Ventures>,
        <https://1145.am/db/2359818/Third_Rock_Ventures>,
        <https://1145.am/db/2359864/Third_Rock_Ventures>,
        <https://1145.am/db/2359873/Third_Rock_Ventures>,
        <https://1145.am/db/2359875/Third_Rock_Ventures>,
        <https://1145.am/db/2359887/Third_Rock_Ventures>,
        <https://1145.am/db/2359984/Third_Rock_Ventures>,
        <https://1145.am/db/2359987/Third_Rock_Ventures>,
        <https://1145.am/db/2360006/Third_Rock_Ventures>,
        <https://1145.am/db/2360169/Third_Rock_Ventures>,
        <https://1145.am/db/2360814/Third_Rock_Ventures>,
        <https://1145.am/db/2360877/Third_Rock_Ventures>,
        <https://1145.am/db/2362102/Third_Rock_Ventures>,
        <https://1145.am/db/2362109/Third_Rock_Ventures>,
        <https://1145.am/db/2362128/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2364240/Third_Rock_Ventures>,
        <https://1145.am/db/2364249/Third_Rock_Ventures>,
        <https://1145.am/db/2364255/Third_Rock_Ventures>,
        <https://1145.am/db/2364283/Third_Rock_Ventures>,
        <https://1145.am/db/2364481/Third_Rock_Ventures>,
        <https://1145.am/db/2365109/Third_Rock_Ventures>,
        <https://1145.am/db/2365111/Third_Rock_Ventures>,
        <https://1145.am/db/2365315/Third_Rock_Ventures>,
        <https://1145.am/db/2366539/Third_Rock_Ventures>,
        <https://1145.am/db/2366641/Third_Rock_Ventures>,
        <https://1145.am/db/2367442/Third_Rock_Ventures>,
        <https://1145.am/db/2367448/Third_Rock_Ventures>,
        <https://1145.am/db/2368166/Third_Rock_Ventures>,
        <https://1145.am/db/2368501/Third_Rock_Ventures>,
        <https://1145.am/db/2369130/Third_Rock_Ventures>,
        <https://1145.am/db/2369202/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2371191/Third_Rock_Ventures>,
        <https://1145.am/db/2580088/Third_Rock_Ventures>,
        <https://1145.am/db/2584533/Third_Rock_Ventures>,
        <https://1145.am/db/441151/Third_Rock_Ventures>,
        <https://1145.am/db/572554/Third_Rock_Ventures>,
        <https://1145.am/db/768794/Third_Rock_Ventures>,
        <https://1145.am/db/769408/Third_Rock_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2348350/Series_A_Investment_Cycad_Group_Imaginab_Merieux_Developpement_Momentum_Biosciences_Nextech_Invest_Novartis_Venture_Funds_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-28T14:04:39+00:00"^^xsd:dateTime ;
    ns1:documentExtract "ImaginAb Concludes $ 12.5m Series A Financing.",
        "LOS ANGELES, March 26, 2012 /PRNewswire/ - ImaginAb, Inc. a clinical-stage company developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology, today announced the completion of a Series A financing - led by Novartis Venture Funds." ;
    ns1:documentTitle "ImaginAb Concludes $12.5m Series A Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/imaginab-concludes-12-5m-series-a-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2348350/Imaginab> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 12.5m" ;
    ns1:when "2012-03-26T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "March 26, 2012" ;
    ns1:whereGeoName "Los Angeles County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5368381/about.rdf> ;
    ns1:whereRaw "LOS ANGELES" .

<https://1145.am/db/2352508/Series_D_Investment_Alder_Biopharmaceuticals_Inc_Novo_Ventures_Sevin_Rosen_Funds_Ventures_West_Sevin_Rosen_Funds_Ventures_West_Wrf_Capital_Hig_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-19T12:23:46+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Alder BioPharmaceuticals Inc. Closes $ 38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics.",
        "BOTHELL, Wash., April 19, 2012 /PRNewswire via COMTEX/ - Alder BioPharmaceuticals Inc. today announced the closing of a $ 38 million Series D financing to support the development of the company's clinical stage pipeline." ;
    ns1:documentTitle "Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/alder-biopharmaceuticals-inc-closes-38-million-series-d-financing-to-accelerate-clinical> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2352508/Alder_Biopharmaceuticals_Inc> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 38 Million",
        "$ 38 million" ;
    ns1:when "2012-04-19T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "April 19, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2353524/Series_B_Investment_Amgen_Ventures_Atlas_Venture_Boulder_Ventures_Ltd_Broadview_Ventures_Miragen_Therapeutics_Miragen_Therapeutics_Remeditex_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-24T14:20:32+00:00"^^xsd:dateTime ;
    ns1:documentExtract "BOULDER, Colo. - MiRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA) -based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, announced today the completion of a $ 20 million Series B financing.",
        "miRagen Therapeutics Secures $ 20 Million Series B Financing." ;
    ns1:documentTitle "miRagen Therapeutics Secures $20 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/miragen-therapeutics-secures-20-million-series-b-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2353524/Miragen_Therapeutics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 20 Million",
        "$ 20 million" ;
    ns1:whereGeoName "Boulder County" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5574999/about.rdf> ;
    ns1:whereRaw "BOULDER" .

<https://1145.am/db/2354608/Third_Rock_Ventures> a org:Organization ;
    ns1:basedInLowRaw "Cambridge, MA" ;
    ns1:documentDate "2012-05-08T10:07:18+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing- Company to Advance its lead Drug Candidate, EBI-005, into Clinic Development for Dry Eye Disease -" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/eleven-biotherapeutics-secures-20-million-and-expands-series-a-financing-company-to-advance> ;
    ns1:foundName "Third Rock Ventures" ;
    ns1:investor <https://1145.am/db/2354608/Series_A_Investment_Eleven_Biotherapeutics_Flagship_Ventures_Jafco_Third_Rock_Ventures_Completed> ;
    ns1:name "Third Rock Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Third_Rock_Ventures>,
        <https://1145.am/db/1086582/Third_Rock_Ventures>,
        <https://1145.am/db/1089269/Third_Rock_Ventures>,
        <https://1145.am/db/1325987/Third_Rock_Ventures>,
        <https://1145.am/db/1326547/Third_Rock_Ventures>,
        <https://1145.am/db/1503058/Third_Rock_Ventures>,
        <https://1145.am/db/159801/Third_Rock_Ventures>,
        <https://1145.am/db/1928208/Third_Rock_Ventures>,
        <https://1145.am/db/2095032/Third_Rock_Ventures>,
        <https://1145.am/db/2152566/Third_Rock_Ventures>,
        <https://1145.am/db/2153763/Third_Rock_Ventures>,
        <https://1145.am/db/2281272/Third_Rock_Ventures>,
        <https://1145.am/db/2291199/Third_Rock_Ventures>,
        <https://1145.am/db/2291940/Third_Rock_Ventures>,
        <https://1145.am/db/2294789/Third_Rock_Ventures>,
        <https://1145.am/db/2298193/Third_Rock_Ventures>,
        <https://1145.am/db/2298844/Third_Rock_Ventures>,
        <https://1145.am/db/2300971/Third_Rock_Ventures>,
        <https://1145.am/db/2303250/Third_Rock_Ventures>,
        <https://1145.am/db/2303251/Third_Rock_Ventures>,
        <https://1145.am/db/2303257/Third_Rock_Ventures>,
        <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2311551/Third_Rock_Ventures>,
        <https://1145.am/db/2315931/Third_Rock_Ventures>,
        <https://1145.am/db/2315933/Third_Rock_Ventures>,
        <https://1145.am/db/2322522/Third_Rock_Ventures>,
        <https://1145.am/db/2322531/Third_Rock_Ventures>,
        <https://1145.am/db/2327474/Third_Rock_Ventures>,
        <https://1145.am/db/2335531/Third_Rock_Ventures>,
        <https://1145.am/db/2335750/Third_Rock_Ventures>,
        <https://1145.am/db/2335755/Third_Rock_Ventures>,
        <https://1145.am/db/2336126/Third_Rock_Ventures>,
        <https://1145.am/db/2337555/Third_Rock_Ventures>,
        <https://1145.am/db/2337559/Third_Rock_Ventures>,
        <https://1145.am/db/2337889/Third_Rock_Ventures>,
        <https://1145.am/db/2337958/Third_Rock_Ventures>,
        <https://1145.am/db/2337974/Third_Rock_Ventures>,
        <https://1145.am/db/2338625/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2339127/Third_Rock_Ventures>,
        <https://1145.am/db/2339128/Third_Rock_Ventures>,
        <https://1145.am/db/2339413/Third_Rock_Ventures>,
        <https://1145.am/db/2339704/Third_Rock_Ventures>,
        <https://1145.am/db/2339925/Third_Rock_Ventures>,
        <https://1145.am/db/2339926/Third_Rock_Ventures>,
        <https://1145.am/db/2341662/Third_Rock_Ventures>,
        <https://1145.am/db/2341792/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2342754/Third_Rock_Ventures>,
        <https://1145.am/db/2342768/Third_Rock_Ventures>,
        <https://1145.am/db/2342771/Third_Rock_Ventures>,
        <https://1145.am/db/2344256/Third_Rock_Ventures>,
        <https://1145.am/db/2344912/Third_Rock_Ventures>,
        <https://1145.am/db/2344918/Third_Rock_Ventures>,
        <https://1145.am/db/2345224/Third_Rock_Ventures>,
        <https://1145.am/db/2346212/Third_Rock_Ventures>,
        <https://1145.am/db/2346216/Third_Rock_Ventures>,
        <https://1145.am/db/2346988/Third_Rock_Ventures>,
        <https://1145.am/db/2347885/Third_Rock_Ventures>,
        <https://1145.am/db/2350364/Third_Rock_Ventures>,
        <https://1145.am/db/2351009/Third_Rock_Ventures>,
        <https://1145.am/db/2351011/Third_Rock_Ventures>,
        <https://1145.am/db/2351348/Third_Rock_Ventures>,
        <https://1145.am/db/2351372/Third_Rock_Ventures>,
        <https://1145.am/db/2351520/Third_Rock_Ventures>,
        <https://1145.am/db/2351644/Third_Rock_Ventures>,
        <https://1145.am/db/2354307/Third_Rock_Ventures>,
        <https://1145.am/db/2354314/Third_Rock_Ventures>,
        <https://1145.am/db/2354613/Third_Rock_Ventures>,
        <https://1145.am/db/2355043/Third_Rock_Ventures>,
        <https://1145.am/db/2357253/Third_Rock_Ventures>,
        <https://1145.am/db/2357256/Third_Rock_Ventures>,
        <https://1145.am/db/2357722/Third_Rock_Ventures>,
        <https://1145.am/db/2358551/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2359321/Third_Rock_Ventures>,
        <https://1145.am/db/2359334/Third_Rock_Ventures>,
        <https://1145.am/db/2359447/Third_Rock_Ventures>,
        <https://1145.am/db/2359575/Third_Rock_Ventures>,
        <https://1145.am/db/2359818/Third_Rock_Ventures>,
        <https://1145.am/db/2359864/Third_Rock_Ventures>,
        <https://1145.am/db/2359873/Third_Rock_Ventures>,
        <https://1145.am/db/2359875/Third_Rock_Ventures>,
        <https://1145.am/db/2359887/Third_Rock_Ventures>,
        <https://1145.am/db/2359984/Third_Rock_Ventures>,
        <https://1145.am/db/2359987/Third_Rock_Ventures>,
        <https://1145.am/db/2360006/Third_Rock_Ventures>,
        <https://1145.am/db/2360169/Third_Rock_Ventures>,
        <https://1145.am/db/2360814/Third_Rock_Ventures>,
        <https://1145.am/db/2360877/Third_Rock_Ventures>,
        <https://1145.am/db/2362102/Third_Rock_Ventures>,
        <https://1145.am/db/2362109/Third_Rock_Ventures>,
        <https://1145.am/db/2362128/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2364240/Third_Rock_Ventures>,
        <https://1145.am/db/2364249/Third_Rock_Ventures>,
        <https://1145.am/db/2364255/Third_Rock_Ventures>,
        <https://1145.am/db/2364283/Third_Rock_Ventures>,
        <https://1145.am/db/2364481/Third_Rock_Ventures>,
        <https://1145.am/db/2365109/Third_Rock_Ventures>,
        <https://1145.am/db/2365111/Third_Rock_Ventures>,
        <https://1145.am/db/2365315/Third_Rock_Ventures>,
        <https://1145.am/db/2366539/Third_Rock_Ventures>,
        <https://1145.am/db/2366641/Third_Rock_Ventures>,
        <https://1145.am/db/2367442/Third_Rock_Ventures>,
        <https://1145.am/db/2367448/Third_Rock_Ventures>,
        <https://1145.am/db/2368166/Third_Rock_Ventures>,
        <https://1145.am/db/2368501/Third_Rock_Ventures>,
        <https://1145.am/db/2369130/Third_Rock_Ventures>,
        <https://1145.am/db/2369202/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2371191/Third_Rock_Ventures>,
        <https://1145.am/db/2580088/Third_Rock_Ventures>,
        <https://1145.am/db/2584533/Third_Rock_Ventures>,
        <https://1145.am/db/441151/Third_Rock_Ventures>,
        <https://1145.am/db/572554/Third_Rock_Ventures>,
        <https://1145.am/db/768794/Third_Rock_Ventures>,
        <https://1145.am/db/769408/Third_Rock_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2355586/Series_C_Investment_Alta_Partners_Amgen_Ventures_Lilly_Ventures_Sv_Life_Sciences_Skyline_Ventures_Sutro_Biopharma_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-08T13:06:35+00:00"^^xsd:dateTime ;
    ns1:documentExtract "SAN FRANCISCO, May 8, 2012 /PRNewswire/ - Sutro Biopharma today announced the closing of the $ 16.5 million second tranche of its Series C financing.",
        "Sutro Closes $ 16.5 Million Second Tranche of Series C Financing." ;
    ns1:documentTitle "Sutro Closes $16.5 Million Second Tranche of Series C Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/sutro-closes-16-5-million-second-tranche-of-series-c-financing> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2355586/Sutro_Biopharma> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 16.5 Million",
        "$ 16.5 million" ;
    ns1:when "2012-05-08T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "May 8" ;
    ns1:whereGeoName "San Francisco" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5391959/about.rdf> ;
    ns1:whereRaw "SAN FRANCISCO" .

<https://1145.am/db/2355609/Series_B_Investment_Atlas_Venture_Cls_Capital_Egalet_Ltd_Index_Ventures_Omega_Funds_Sunstone_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-10T14:51:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Egalet Announces Series B Financing and Names Bob Radie Chief Executive Officer.",
        "MALVERN, Pa., May 7, 2012 /PRNewswire/ - Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-resistant medications, announced today that it has raised $ 14.3 million in a Series B financing round adding CLS Capital to the existing group of investors that includes Atlas Venture, Omega Funds, Sunstone Capital and Index Ventures." ;
    ns1:documentTitle "Egalet Announces Series B Financing and Names Bob Radie Chief Executive Officer" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/egalet-announces-series-b-financing-and-names-bob-radie-chief-executive-officer> ;
    ns1:foundName "financing",
        "raised" ;
    ns1:name "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2355609/Egalet_Ltd> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 14.3 million" ;
    ns1:when "2012-05-07T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "May 7, 2012" ;
    ns1:whereRaw "Egalet Announces Series B Financing and Names Bob Radie Chief Executive" .

<https://1145.am/db/2358812/Series_B_Investment_Fletcher_Spaght_Ventures_Hatteras_Venture_Partners_Johnson___Johnson_Development_Corporation_New_Enterprise_Associates_Osi_Investment_Holdings_Phasebio_Pharmaceuticals_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-06T15:08:33+00:00"^^xsd:dateTime ;
    ns1:documentExtract "In December 2009, PhaseBio raised $ 25M in a Series B financing led by New Enterprise Associates, with participation by OSI Investment Holdings (now Astellas Venture Management) and previous investors Johnson & Johnson Development Corporation, Hatteras Venture Partners and Fletcher Spaght Ventures.",
        "MALVERN, Pa.-PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has raised a total of $ 48.4 million from its Series B financing following receipt of the third tranche to advance the company's product development programs." ;
    ns1:documentTitle "PhaseBio Pharmaceuticals Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing For Advancement of Metabolic and Cardiovascular Product Portfolio" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/phasebio-pharmaceuticals-received-an-additional-23-million-completion-of-third-tranche-of-a> ;
    ns1:foundName "financing",
        "raised" ;
    ns1:name "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2358812/Malvern>,
        <https://1145.am/db/2358812/Phasebio_Pharmaceuticals> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 25M",
        "$ 48.4 million" ;
    ns1:whereGeoName "Malvern" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5199600/about.rdf> ;
    ns1:whereRaw "MALVERN, Pa." .

<https://1145.am/db/2359864/Third_Rock_Ventures> a org:Organization ;
    ns1:basedInLowRaw "United States" ;
    ns1:documentDate "2012-06-12T14:59:53+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Igenica Closes $33 Million in Series C Funding" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/igenica-closes-33-million-series-c-funding> ;
    ns1:foundName "Third Rock Ventures" ;
    ns1:investor <https://1145.am/db/2359864/Investment_Third_Rock_Ventures_Has_Not_Happened>,
        <https://1145.am/db/2359864/Series_C_Investment_5am_Ventures_Igenica_Orbimed_Advisors_The_Column_Group_Third_Rock_Ventures_Completed> ;
    ns1:name "Third Rock Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Third_Rock_Ventures>,
        <https://1145.am/db/1086582/Third_Rock_Ventures>,
        <https://1145.am/db/1089269/Third_Rock_Ventures>,
        <https://1145.am/db/1325987/Third_Rock_Ventures>,
        <https://1145.am/db/1326547/Third_Rock_Ventures>,
        <https://1145.am/db/1503058/Third_Rock_Ventures>,
        <https://1145.am/db/159801/Third_Rock_Ventures>,
        <https://1145.am/db/1928208/Third_Rock_Ventures>,
        <https://1145.am/db/2095032/Third_Rock_Ventures>,
        <https://1145.am/db/2152566/Third_Rock_Ventures>,
        <https://1145.am/db/2153763/Third_Rock_Ventures>,
        <https://1145.am/db/2281272/Third_Rock_Ventures>,
        <https://1145.am/db/2291199/Third_Rock_Ventures>,
        <https://1145.am/db/2291940/Third_Rock_Ventures>,
        <https://1145.am/db/2294789/Third_Rock_Ventures>,
        <https://1145.am/db/2298193/Third_Rock_Ventures>,
        <https://1145.am/db/2298844/Third_Rock_Ventures>,
        <https://1145.am/db/2300971/Third_Rock_Ventures>,
        <https://1145.am/db/2303250/Third_Rock_Ventures>,
        <https://1145.am/db/2303251/Third_Rock_Ventures>,
        <https://1145.am/db/2303257/Third_Rock_Ventures>,
        <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2311551/Third_Rock_Ventures>,
        <https://1145.am/db/2315931/Third_Rock_Ventures>,
        <https://1145.am/db/2315933/Third_Rock_Ventures>,
        <https://1145.am/db/2322522/Third_Rock_Ventures>,
        <https://1145.am/db/2322531/Third_Rock_Ventures>,
        <https://1145.am/db/2327474/Third_Rock_Ventures>,
        <https://1145.am/db/2335531/Third_Rock_Ventures>,
        <https://1145.am/db/2335750/Third_Rock_Ventures>,
        <https://1145.am/db/2335755/Third_Rock_Ventures>,
        <https://1145.am/db/2336126/Third_Rock_Ventures>,
        <https://1145.am/db/2337555/Third_Rock_Ventures>,
        <https://1145.am/db/2337559/Third_Rock_Ventures>,
        <https://1145.am/db/2337889/Third_Rock_Ventures>,
        <https://1145.am/db/2337958/Third_Rock_Ventures>,
        <https://1145.am/db/2337974/Third_Rock_Ventures>,
        <https://1145.am/db/2338625/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2339127/Third_Rock_Ventures>,
        <https://1145.am/db/2339128/Third_Rock_Ventures>,
        <https://1145.am/db/2339413/Third_Rock_Ventures>,
        <https://1145.am/db/2339704/Third_Rock_Ventures>,
        <https://1145.am/db/2339925/Third_Rock_Ventures>,
        <https://1145.am/db/2339926/Third_Rock_Ventures>,
        <https://1145.am/db/2341662/Third_Rock_Ventures>,
        <https://1145.am/db/2341792/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2342754/Third_Rock_Ventures>,
        <https://1145.am/db/2342768/Third_Rock_Ventures>,
        <https://1145.am/db/2342771/Third_Rock_Ventures>,
        <https://1145.am/db/2344256/Third_Rock_Ventures>,
        <https://1145.am/db/2344912/Third_Rock_Ventures>,
        <https://1145.am/db/2344918/Third_Rock_Ventures>,
        <https://1145.am/db/2345224/Third_Rock_Ventures>,
        <https://1145.am/db/2346212/Third_Rock_Ventures>,
        <https://1145.am/db/2346216/Third_Rock_Ventures>,
        <https://1145.am/db/2346988/Third_Rock_Ventures>,
        <https://1145.am/db/2347885/Third_Rock_Ventures>,
        <https://1145.am/db/2350364/Third_Rock_Ventures>,
        <https://1145.am/db/2351009/Third_Rock_Ventures>,
        <https://1145.am/db/2351011/Third_Rock_Ventures>,
        <https://1145.am/db/2351348/Third_Rock_Ventures>,
        <https://1145.am/db/2351372/Third_Rock_Ventures>,
        <https://1145.am/db/2351520/Third_Rock_Ventures>,
        <https://1145.am/db/2351644/Third_Rock_Ventures>,
        <https://1145.am/db/2354307/Third_Rock_Ventures>,
        <https://1145.am/db/2354314/Third_Rock_Ventures>,
        <https://1145.am/db/2354608/Third_Rock_Ventures>,
        <https://1145.am/db/2354613/Third_Rock_Ventures>,
        <https://1145.am/db/2355043/Third_Rock_Ventures>,
        <https://1145.am/db/2357253/Third_Rock_Ventures>,
        <https://1145.am/db/2357256/Third_Rock_Ventures>,
        <https://1145.am/db/2357722/Third_Rock_Ventures>,
        <https://1145.am/db/2358551/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2359321/Third_Rock_Ventures>,
        <https://1145.am/db/2359334/Third_Rock_Ventures>,
        <https://1145.am/db/2359447/Third_Rock_Ventures>,
        <https://1145.am/db/2359575/Third_Rock_Ventures>,
        <https://1145.am/db/2359818/Third_Rock_Ventures>,
        <https://1145.am/db/2359873/Third_Rock_Ventures>,
        <https://1145.am/db/2359875/Third_Rock_Ventures>,
        <https://1145.am/db/2359887/Third_Rock_Ventures>,
        <https://1145.am/db/2359984/Third_Rock_Ventures>,
        <https://1145.am/db/2359987/Third_Rock_Ventures>,
        <https://1145.am/db/2360006/Third_Rock_Ventures>,
        <https://1145.am/db/2360169/Third_Rock_Ventures>,
        <https://1145.am/db/2360814/Third_Rock_Ventures>,
        <https://1145.am/db/2360877/Third_Rock_Ventures>,
        <https://1145.am/db/2362102/Third_Rock_Ventures>,
        <https://1145.am/db/2362109/Third_Rock_Ventures>,
        <https://1145.am/db/2362128/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2364240/Third_Rock_Ventures>,
        <https://1145.am/db/2364249/Third_Rock_Ventures>,
        <https://1145.am/db/2364255/Third_Rock_Ventures>,
        <https://1145.am/db/2364283/Third_Rock_Ventures>,
        <https://1145.am/db/2364481/Third_Rock_Ventures>,
        <https://1145.am/db/2365109/Third_Rock_Ventures>,
        <https://1145.am/db/2365111/Third_Rock_Ventures>,
        <https://1145.am/db/2365315/Third_Rock_Ventures>,
        <https://1145.am/db/2366539/Third_Rock_Ventures>,
        <https://1145.am/db/2366641/Third_Rock_Ventures>,
        <https://1145.am/db/2367442/Third_Rock_Ventures>,
        <https://1145.am/db/2367448/Third_Rock_Ventures>,
        <https://1145.am/db/2368166/Third_Rock_Ventures>,
        <https://1145.am/db/2368501/Third_Rock_Ventures>,
        <https://1145.am/db/2369130/Third_Rock_Ventures>,
        <https://1145.am/db/2369202/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2371191/Third_Rock_Ventures>,
        <https://1145.am/db/2580088/Third_Rock_Ventures>,
        <https://1145.am/db/2584533/Third_Rock_Ventures>,
        <https://1145.am/db/441151/Third_Rock_Ventures>,
        <https://1145.am/db/572554/Third_Rock_Ventures>,
        <https://1145.am/db/768794/Third_Rock_Ventures>,
        <https://1145.am/db/769408/Third_Rock_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2359873/Third_Rock_Ventures> a org:Organization ;
    ns1:basedInLowRaw "BOSTON" ;
    ns1:documentDate "2012-06-13T11:26:04+00:00"^^xsd:dateTime ;
    ns1:documentTitle "Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/rhythm-raises-25m-series-b-financing-for-diabetes-and-obesity-therapeutics> ;
    ns1:foundName "Third Rock Ventures" ;
    ns1:investor <https://1145.am/db/2359873/Series_B_Investment_Ipsen_Mpm_Capital_New_Enterprise_Associates_Rhythm_Third_Rock_Ventures_Completed> ;
    ns1:name "Third Rock Ventures" ;
    ns1:sameAsMedium <https://1145.am/db/1042269/Third_Rock_Ventures>,
        <https://1145.am/db/1086582/Third_Rock_Ventures>,
        <https://1145.am/db/1089269/Third_Rock_Ventures>,
        <https://1145.am/db/1325987/Third_Rock_Ventures>,
        <https://1145.am/db/1326547/Third_Rock_Ventures>,
        <https://1145.am/db/1503058/Third_Rock_Ventures>,
        <https://1145.am/db/159801/Third_Rock_Ventures>,
        <https://1145.am/db/1928208/Third_Rock_Ventures>,
        <https://1145.am/db/2095032/Third_Rock_Ventures>,
        <https://1145.am/db/2152566/Third_Rock_Ventures>,
        <https://1145.am/db/2153763/Third_Rock_Ventures>,
        <https://1145.am/db/2281272/Third_Rock_Ventures>,
        <https://1145.am/db/2291199/Third_Rock_Ventures>,
        <https://1145.am/db/2291940/Third_Rock_Ventures>,
        <https://1145.am/db/2294789/Third_Rock_Ventures>,
        <https://1145.am/db/2298193/Third_Rock_Ventures>,
        <https://1145.am/db/2298844/Third_Rock_Ventures>,
        <https://1145.am/db/2300971/Third_Rock_Ventures>,
        <https://1145.am/db/2303250/Third_Rock_Ventures>,
        <https://1145.am/db/2303251/Third_Rock_Ventures>,
        <https://1145.am/db/2303257/Third_Rock_Ventures>,
        <https://1145.am/db/2303294/Third_Rock_Ventures>,
        <https://1145.am/db/2311551/Third_Rock_Ventures>,
        <https://1145.am/db/2315931/Third_Rock_Ventures>,
        <https://1145.am/db/2315933/Third_Rock_Ventures>,
        <https://1145.am/db/2322522/Third_Rock_Ventures>,
        <https://1145.am/db/2322531/Third_Rock_Ventures>,
        <https://1145.am/db/2327474/Third_Rock_Ventures>,
        <https://1145.am/db/2335531/Third_Rock_Ventures>,
        <https://1145.am/db/2335750/Third_Rock_Ventures>,
        <https://1145.am/db/2335755/Third_Rock_Ventures>,
        <https://1145.am/db/2336126/Third_Rock_Ventures>,
        <https://1145.am/db/2337555/Third_Rock_Ventures>,
        <https://1145.am/db/2337559/Third_Rock_Ventures>,
        <https://1145.am/db/2337889/Third_Rock_Ventures>,
        <https://1145.am/db/2337958/Third_Rock_Ventures>,
        <https://1145.am/db/2337974/Third_Rock_Ventures>,
        <https://1145.am/db/2338625/Third_Rock_Ventures>,
        <https://1145.am/db/2338633/Third_Rock_Ventures>,
        <https://1145.am/db/2339127/Third_Rock_Ventures>,
        <https://1145.am/db/2339128/Third_Rock_Ventures>,
        <https://1145.am/db/2339413/Third_Rock_Ventures>,
        <https://1145.am/db/2339704/Third_Rock_Ventures>,
        <https://1145.am/db/2339925/Third_Rock_Ventures>,
        <https://1145.am/db/2339926/Third_Rock_Ventures>,
        <https://1145.am/db/2341662/Third_Rock_Ventures>,
        <https://1145.am/db/2341792/Third_Rock_Ventures>,
        <https://1145.am/db/2341800/Third_Rock_Ventures>,
        <https://1145.am/db/2342754/Third_Rock_Ventures>,
        <https://1145.am/db/2342768/Third_Rock_Ventures>,
        <https://1145.am/db/2342771/Third_Rock_Ventures>,
        <https://1145.am/db/2344256/Third_Rock_Ventures>,
        <https://1145.am/db/2344912/Third_Rock_Ventures>,
        <https://1145.am/db/2344918/Third_Rock_Ventures>,
        <https://1145.am/db/2345224/Third_Rock_Ventures>,
        <https://1145.am/db/2346212/Third_Rock_Ventures>,
        <https://1145.am/db/2346216/Third_Rock_Ventures>,
        <https://1145.am/db/2346988/Third_Rock_Ventures>,
        <https://1145.am/db/2347885/Third_Rock_Ventures>,
        <https://1145.am/db/2350364/Third_Rock_Ventures>,
        <https://1145.am/db/2351009/Third_Rock_Ventures>,
        <https://1145.am/db/2351011/Third_Rock_Ventures>,
        <https://1145.am/db/2351348/Third_Rock_Ventures>,
        <https://1145.am/db/2351372/Third_Rock_Ventures>,
        <https://1145.am/db/2351520/Third_Rock_Ventures>,
        <https://1145.am/db/2351644/Third_Rock_Ventures>,
        <https://1145.am/db/2354307/Third_Rock_Ventures>,
        <https://1145.am/db/2354314/Third_Rock_Ventures>,
        <https://1145.am/db/2354608/Third_Rock_Ventures>,
        <https://1145.am/db/2354613/Third_Rock_Ventures>,
        <https://1145.am/db/2355043/Third_Rock_Ventures>,
        <https://1145.am/db/2357253/Third_Rock_Ventures>,
        <https://1145.am/db/2357256/Third_Rock_Ventures>,
        <https://1145.am/db/2357722/Third_Rock_Ventures>,
        <https://1145.am/db/2358551/Third_Rock_Ventures>,
        <https://1145.am/db/2358737/Third_Rock_Ventures>,
        <https://1145.am/db/2359321/Third_Rock_Ventures>,
        <https://1145.am/db/2359334/Third_Rock_Ventures>,
        <https://1145.am/db/2359447/Third_Rock_Ventures>,
        <https://1145.am/db/2359575/Third_Rock_Ventures>,
        <https://1145.am/db/2359818/Third_Rock_Ventures>,
        <https://1145.am/db/2359864/Third_Rock_Ventures>,
        <https://1145.am/db/2359875/Third_Rock_Ventures>,
        <https://1145.am/db/2359887/Third_Rock_Ventures>,
        <https://1145.am/db/2359984/Third_Rock_Ventures>,
        <https://1145.am/db/2359987/Third_Rock_Ventures>,
        <https://1145.am/db/2360006/Third_Rock_Ventures>,
        <https://1145.am/db/2360169/Third_Rock_Ventures>,
        <https://1145.am/db/2360814/Third_Rock_Ventures>,
        <https://1145.am/db/2360877/Third_Rock_Ventures>,
        <https://1145.am/db/2362102/Third_Rock_Ventures>,
        <https://1145.am/db/2362109/Third_Rock_Ventures>,
        <https://1145.am/db/2362128/Third_Rock_Ventures>,
        <https://1145.am/db/2363422/Third_Rock_Ventures>,
        <https://1145.am/db/2364240/Third_Rock_Ventures>,
        <https://1145.am/db/2364249/Third_Rock_Ventures>,
        <https://1145.am/db/2364255/Third_Rock_Ventures>,
        <https://1145.am/db/2364283/Third_Rock_Ventures>,
        <https://1145.am/db/2364481/Third_Rock_Ventures>,
        <https://1145.am/db/2365109/Third_Rock_Ventures>,
        <https://1145.am/db/2365111/Third_Rock_Ventures>,
        <https://1145.am/db/2365315/Third_Rock_Ventures>,
        <https://1145.am/db/2366539/Third_Rock_Ventures>,
        <https://1145.am/db/2366641/Third_Rock_Ventures>,
        <https://1145.am/db/2367442/Third_Rock_Ventures>,
        <https://1145.am/db/2367448/Third_Rock_Ventures>,
        <https://1145.am/db/2368166/Third_Rock_Ventures>,
        <https://1145.am/db/2368501/Third_Rock_Ventures>,
        <https://1145.am/db/2369130/Third_Rock_Ventures>,
        <https://1145.am/db/2369202/Third_Rock_Ventures>,
        <https://1145.am/db/2370105/Third_Rock_Ventures_Llc>,
        <https://1145.am/db/2371191/Third_Rock_Ventures>,
        <https://1145.am/db/2580088/Third_Rock_Ventures>,
        <https://1145.am/db/2584533/Third_Rock_Ventures>,
        <https://1145.am/db/441151/Third_Rock_Ventures>,
        <https://1145.am/db/572554/Third_Rock_Ventures>,
        <https://1145.am/db/768794/Third_Rock_Ventures>,
        <https://1145.am/db/769408/Third_Rock_Ventures> ;
    ns1:sourceName "Fierce Biotech" .

<https://1145.am/db/2363941/Investment_Edmond_De_Rothschild_Investment_Partners_Genkyotex_Mp_Healthcare_Venture_Mitsubishi_Tanabe_Pharma_Group_Vesalius_Biocapital_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-09T04:00:58+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Geneva - based Genkyotex has now raised $ 44 million (CHF 43 million) in the third-round financing, with backing from Swiss incubator Eclosion, France's Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners in Luxembourg and MP Healthcare Venture, the VC arm of Japan's Mitsubishi Tanabe Pharma Group.",
        "With big plans to advance a first-in-class compound for diabetic nephropathy, the startup Genkyotex has rallied its existing backers to extend its Series C round by $ 26 million (CHF 25 million) ." ;
    ns1:documentTitle "Biotech Genkyotex nails down $26M to fund drug for diabetic kidney disease" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/biotech-genkyotex-nails-down-26m-to-fund-drug-for-diabetic-kidney-disease> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2363941/Genkyotex> ;
    ns1:targetDetails "Series C" ;
    ns1:valueRaw "$ 26 million",
        "$ 44 million",
        "CHF 25 million",
        "CHF 43 million" ;
    ns1:whereGeoName "Switzerland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2658434/about.rdf> ;
    ns1:whereRaw "Switzerland" .

<https://1145.am/db/2288613/Rhoen_Share_Stake_Investment> a ns1:CorporateFinanceActivity ;
    ns1:activityType "acquisition",
        "investment" ;
    ns1:documentDate "2012-07-13T12:25:39+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Devicemaker B. Braun has acquired options to buy a stake in hospital operator Rhoen-Klinikum, Reuters reports, a move that throws dirt on Fresenius' efforts to buy the company.",
        "Four German firms-Braun, Fresenius, Sana and Asklepios-are in a bidding battle for Rhoen, and the latest development forces a stalemate among the rival companies, Reuters reports.",
        "Fresenius announced in April a plan to acquire Rhoen for €3.1 billion ($ 3.8 billion) , but that deal needed the OK from 90 % of shareholders, which was blocked after Asklepios bought a 5 % share in the hospital operator." ;
    ns1:documentTitle "Report: B. Braun moves to block Fresenius' bid for Rhoen" ;
    ns1:documentURL <https://www.fiercebiotech.com/medical-devices/report-b-braun-moves-to-block-fresenius-bid-for-rhoen> ;
    ns1:foundName "acquire",
        "bidding",
        "bought",
        "buy",
        "purchase" ;
    ns1:name "acquire",
        "bidding",
        "bought",
        "buy",
        "purchase" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "stopped" ;
    ns1:target <https://1145.am/db/2288613/Rhoen> ;
    ns1:targetDetails "share",
        "stake" ;
    ns1:targetName "Rhoen" ;
    ns1:valueRaw "$ 3.8 billion",
        "€3.1 billion" ;
    ns1:whereGeoName "Federal Republic of Germany" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:whereRaw "Germany" .

<https://1145.am/db/2335701/Investment_7_Med_Health_Ventures_Arch_Venture_Partners_Abingworth_Chiasma_F3_Ventures_Fredric_Price_Mpm_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-23T16:25:40+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Chiasma Closes $ 38.5 Million Equity Financing.",
        "NEW YORK and JERUSALEM, July 23, 2012 /PRNewswire via COMTEX/ - Chiasma (pronounced key-azma) , Inc., a privately held biopharma company, announced that it closed a $ 38.5 million equity financing co - led by new investor Abingworth and current investor MPM Capital that also included investments from existing shareholders 7 Med Health Ventures, ARCH Venture Partners, F3 Ventures and Fredric Price, Chiasma's Chairman & CEO." ;
    ns1:documentTitle "Chiasma Closes $38.5 Million Equity Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/chiasma-closes-38-5-million-equity-financing-0> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2335701/Chiasma> ;
    ns1:valueRaw "$ 38.5 Million",
        "$ 38.5 million" ;
    ns1:when "2012-07-23T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "July 23, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2337971/Series_A_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_New_Enterprise_Associates_Pfizer_Venture_Investments_Proquest_Investments_Rho_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-31T14:27:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CAMBRIDGE, Mass., July 31, 2012 /PRNewswire via COMTEX/ - Mersana Therapeutics, Inc., a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, announced today that it has closed a $ 27 million Series A-1 financing led by new investor New Enterprise Associates (NEA) .",
        "Mersana Therapeutics Raises $ 27M to Advance Fleximer® Antibody-drug Conjugates." ;
    ns1:documentTitle "Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/mersana-therapeutics-raises-27m-to-advance-fleximer%C2%AE-antibody-drug-conjugates> ;
    ns1:foundName "Raises",
        "financing" ;
    ns1:name "Raises",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2337971/Mersana_Therapeutics> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 27 million",
        "$ 27M" ;
    ns1:when "2012-07-31T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "July 31, 2012" ;
    ns1:whereRaw "Mersana Therapeutics" .

<https://1145.am/db/2343210/Series_D_Investment_Easton_Capital_Investment_Group_Fibrotec_Ventures_Forbion_Capital_Partners_Healthcare_Ventures_Morgenthaler_Ventures_Polaris_Venture_Partners_Promedior_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-03-07T19:32:12+00:00"^^xsd:dateTime ;
    ns1:documentExtract "MALVERN, PA - March 7, 2012 - Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that it has raised $ 21.5 million in a first closing of a Series D financing round.",
        "Promedior Secures $ 21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases." ;
    ns1:documentTitle "Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/promedior-secures-21-5-million-first-closing-of-series-d-financing-to-expand-and-advance> ;
    ns1:foundName "Financing",
        "financing",
        "raised" ;
    ns1:name "Financing",
        "financing",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2343210/Promedior> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 21.5 Million",
        "$ 21.5 million" ;
    ns1:when "2012-03-07T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "March 7, 2012" ;
    ns1:whereGeoName "Malvern" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/5199600/about.rdf> ;
    ns1:whereRaw "MALVERN, PA" .

<https://1145.am/db/2353522/Series_D_Investment_Argos_Therapeutics_Inc_Aurora_Funds_Forbion_Capital_Intersouth_Partners_Caisse_De_Depot_Et_Placement_Du_Quebec_Lumira_Capital_Morningside_Group_Tvm_Capital_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-04-24T14:18:25+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Argos Therapeutics Secures $ 25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012.",
        "DURHAM, N.C., April 24, 2012 /PRNewswire via COMTEX/ - Argos Therapeutics Inc. today announced that it has secured a $ 25 million Series D financing to support the commencement of its Phase 3 ADAPT study in patients with newly diagnosed, metastatic renal cell carcinoma (mRCC) in mid-2012." ;
    ns1:documentTitle "Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/argos-therapeutics-secures-25-million-series-d-financing-to-commence-phase-3-adapt-study> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2353522/Argos_Therapeutics_Inc> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 25 million" ;
    ns1:when "2012-04-24T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "April 24, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "U.S." .

<https://1145.am/db/2356685/Series_B_Investment_Entrepreneurs_Fund_Gilde_Healthcare_Partners_Gimv_Prosonix_Quest_For_Growth_Solon_Ventures_Ventech_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-21T19:58:04+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Prosonix (Oxford, UK) , a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its unique particle engineering technology, today announced the second closing of its Series B equity financing round.",
        "Prosonix Extends Series B Financing Round to £17.1M." ;
    ns1:documentTitle "Prosonix Extends Series B Financing Round to £17.1M" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/prosonix-extends-series-b-financing-round-to-%C2%A317-1m> ;
    ns1:foundName "equity",
        "financing" ;
    ns1:name "equity",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2356685/Prosonix> ;
    ns1:targetDetails "Series B",
        "equity" ;
    ns1:valueRaw "£17.1M",
        "£5.7M" ;
    ns1:whenRaw "June 2011" ;
    ns1:whereGeoName "United Kingdom of Great Britain and Northern Ireland" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2635167/about.rdf> ;
    ns1:whereRaw "UK" .

<https://1145.am/db/2358806/Series_D_Investment_Aperture_Venture_Partners_Bioadvance_Ceptaris_Therapeutics_Osage_Palo_Alto_Investors_Burrill___Company_Third_Point_Llc_Vivo_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-06-05T14:30:23+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Ceptaris Secures $ 10 Million in Series D-1 Financing.",
        "MALVERN, Pa.- (BUSINESS WIRE) -Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that it has raised $ 10 million through a Series D-1 private placement of preferred stock." ;
    ns1:documentTitle "Ceptaris Secures $10 Million in Series D-1 Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ceptaris-secures-10-million-series-d-1-financing> ;
    ns1:foundName "private placement",
        "raised" ;
    ns1:name "private placement",
        "raised" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2358806/Ceptaris_Therapeutics> ;
    ns1:targetDetails "Series D" ;
    ns1:valueRaw "$ 10 Million",
        "$ 10 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2440017/Investment_Fund_Of_Mitsubishi_Ufj_Capital_Ibg___Goodvent_Kfw_L-Bank_Ludgate_Environmental_Fund_Micropelt_Shs_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-05-03T05:00:00+00:00"^^xsd:dateTime ;
    ns1:documentExtract "FREIBURG, Germany - (BUSINESS WIRE) - Micropelt has raised 6' 5 Mio EURO for the roll-out and global expansion of its thin-film thermoelectric energy harvesting technology." ;
    ns1:documentTitle "Micropelt Raises 6'5 Mio EURO" ;
    ns1:documentURL <https://www.fierceelectronics.com/embedded/micropelt-raises-6-5-mio-euro> ;
    ns1:foundName "investment",
        "raised" ;
    ns1:name "investment",
        "raised" ;
    ns1:sourceName "Fierce Electronics" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2440017/Micropelt> ;
    ns1:valueRaw "0' 5 Mio EURO",
        "1 Mio EURO",
        "5 Mio EURO",
        "6' 5 Mio EURO" ;
    ns1:whereGeoName "Federal Republic of Germany" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/2921044/about.rdf> ;
    ns1:whereRaw "Germany" .

<https://1145.am/db/2335700/Investment_Celgene_Credit_Suisse_First_Boston_Equity_Partners_Delphi_Ventures_Hbm_Bioventures_Novo_A_S_Ptc_Therapeutics_Inc_The_Column_Group_Vulcan_Ventures_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-23T15:59:14+00:00"^^xsd:dateTime ;
    ns1:documentExtract "PTC Therapeutics Closes $ 30 Million Financing.",
        "SOUTH PLAINFIELD, N.J., July 23, 2012 /PRNewswire via COMTEX/ - PTC Therapeutics, Inc. (PTC) today announced the completion of a $ 30 million financing." ;
    ns1:documentTitle "PTC Therapeutics Closes $30 Million Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/ptc-therapeutics-closes-30-million-financing> ;
    ns1:foundName "Financing",
        "financing" ;
    ns1:name "Financing",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2335700/Ptc_Therapeutics_Inc> ;
    ns1:valueRaw "$ 30 Million",
        "$ 30 million" ;
    ns1:when "2012-07-23T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "July 23, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2337972/Series_A-1_Investment_Fidelity_Biosciences_Harris_And_Harris_Group_Mersana_Therapeutics_Nea_Proquest_Investments_Rho_Ventures_Venture_Investments_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-31T14:22:14+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Fresh from revealing a $ 2.6 billion fund last week, New Enterprise Associates (NEA) has jumped aboard as a lead backer of Mersana Therapeutics' next-gen antibody drug conjugates-one of the hottest areas of cancer treatment.",
        "Mersana plans to use the $ 27 million Series A-1 round of financing-which was led by NEA and includes funds from Pfizer Venture Investments, Fidelity Biosciences, ProQuest Investments, Rho Ventures as well as Harris and Harris Group-to build out its own pipeline of antibody-drug conjugates (ADCs) for fighting cancer and advance its enabling technology for the treatments." ;
    ns1:documentTitle "Mersana grabs $27M from Pfizer, NEA and others for muscled cancer drugs" ;
    ns1:documentURL <https://www.fiercebiotech.com/r-d/mersana-grabs-27m-from-pfizer-nea-and-others-for-muscled-cancer-drugs> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed",
        "has not happened" ;
    ns1:target <https://1145.am/db/2337972/Mersana_Therapeutics> ;
    ns1:targetDetails "Series A-1" ;
    ns1:valueRaw "$ 2.6 billion",
        "$ 27 million" .

<https://1145.am/db/2336102/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-24T12:16:56+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Histogenics Closes $ 49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products.",
        "WALTHAM, Mass., Jul 24, 2012 (BUSINESS WIRE) - Regenerative medicine company Histogenics Corporation, announced today the completion of a $ 49 million round of financing." ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of-0> ;
    ns1:foundName "Fundraising",
        "financing" ;
    ns1:name "Fundraising",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2336102/Histogenics_Corporation> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 49 Million",
        "$ 49 million" ;
    ns1:when "2012-07-24T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "Jul 24, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2336109/Investment_Altima_Partners_Biomed_Ventures_Boston_Millennia_Partners_Fintech_Gimv_Fund_Foundation_Medical_Partners_Histogenics_Corporation_Inflection_Point_Capital_Prochon_Holdings_Bv_Sofinnova_Ventures_Split_Rock_Partners_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-24T13:01:35+00:00"^^xsd:dateTime ;
    ns1:documentExtract "Histogenics Closes $ 49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products.",
        "Regenerative medicine company Histogenics Corporation, announced today the completion of a $ 49 million round of financing." ;
    ns1:documentTitle "Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/histogenics-closes-49-million-series-a-fundraising-to-support-commercial-development-of> ;
    ns1:foundName "Fundraising",
        "financing" ;
    ns1:name "Fundraising",
        "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2336109/Histogenics_Corporation> ;
    ns1:targetDetails "Series A" ;
    ns1:valueRaw "$ 49 Million",
        "$ 49 million" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

<https://1145.am/db/2364827/Series_B_Investment_Early_Stage_Partners_Fletcher_Spaght_Ventures_Glengary_Global_Cardiovascular_Innovation_Center_Juventas_Therapeutics_New_Science_Ventures_Reservoir_Venture_Partners_Takeda_Ventures_Tri-State_Growth_Fund_Triathlon_Medical_Venture_Partners_Venture_Investors_Completed> a ns1:CorporateFinanceActivity ;
    ns1:activityType "investment" ;
    ns1:documentDate "2012-07-16T15:17:30+00:00"^^xsd:dateTime ;
    ns1:documentExtract "CLEVELAND, July 16, 2012 /PRNewswire/ - Juventas Therapeutics, a clinical-stage regenerative medicine company, announced today that it has closed a $ 22.2 million Series B financing that was co - led by Triathlon Medical Venture Partners and New Science Ventures.",
        "Juventas Therapeutics Raises $ 22.2 Million Series B Financing." ;
    ns1:documentTitle "Juventas Therapeutics Raises $22.2 Million Series B Financing" ;
    ns1:documentURL <https://www.fiercebiotech.com/biotech/juventas-therapeutics-raises-22-2-million-series-b-financing-0> ;
    ns1:foundName "financing" ;
    ns1:name "financing" ;
    ns1:sourceName "Fierce Biotech" ;
    ns1:status "completed" ;
    ns1:target <https://1145.am/db/2364827/Juventas_Therapeutics> ;
    ns1:targetDetails "Series B" ;
    ns1:valueRaw "$ 22.2 Million",
        "$ 22.2 million" ;
    ns1:when "2012-07-16T00:00:00"^^xsd:dateTime ;
    ns1:whenRaw "July 16, 2012" ;
    ns1:whereGeoName "United States" ;
    ns1:whereGeoNameRDF <https://sws.geonames.org/6252001/about.rdf> ;
    ns1:whereRaw "United States" .

